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 C   vADMIUM 
FOREWORD
	  
This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic
Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA).  The
original guidelines were published in the Federal Register on April 17, 1987.  Each profile will be revised 
and republished as necessary.
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for the toxic substances each profile describes.  Each peer-reviewed profile identifies and
reviews the key literature that describes a substance's toxicologic properties.  Other pertinent literature is
also presented but is described in less detail than the key studies.  The profile is not intended to be an 
exhaustive document; however, more comprehensive sources of specialty information are referenced.
The profiles focus on health and toxicologic information; therefore, each toxicological profile begins with 
a public health statement that describes, in nontechnical language, a substance's relevant toxicological
properties.  Following the public health statement is information concerning levels of significant human 
exposure and, where known, significant health effects. A health effects summary describes the adequacy
of information to determine a substance's health effects. ATSDR identifies data needs that are significant
to protection of public health. 
Each profile:
(A) Examines, summarizes, and interprets available toxicologic information and
epidemiologic evaluations on a toxic substance to ascertain the levels of significant human 
exposure for the substance and the associated acute, subacute, and chronic health effects;
(B) Determines whether adequate information on the health effects of each substance is
available or being developed to determine levels of exposure that present a significant risk to
human health of acute, subacute, and chronic health effects; and
(C) Where appropriate, identifies toxicologic testing needed to identify the types or levels of
exposure that may present significant risk of adverse health effects in humans.
The principal audiences for the toxicological profiles are federal, state, and local health professionals;
interested private sector organizations and groups; and members of the public.  
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been
peer-reviewed.  Staff of the Centers for Disease Control and Prevention and other federal scientists also 
have reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel
and was made available for public review.  Final responsibility for the contents and views expressed in
this toxicological profile resides with ATSDR. 
Christopher J. Portier, Ph.D. 
Assistant Administrator
Agency for Toxic Substances and Disease Registry
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 C  vADMIUM 
*Legislative Background
The toxicological profiles are developed under the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund).  CERCLA section 
104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related 
authorities” of the statute.  This includes the preparation of toxicological profiles for hazardous 
substances most commonly found at facilities on the CERCLA National Priorities List and that pose the
most significant potential threat to human health, as determined by ATSDR and the EPA. Section 
104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile
for each substance on the list.  In addition, ATSDR has the authority to prepare toxicological profiles for
substances not found at sites on the National Priorities List, in an effort to “…establish and maintain 
inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA
Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise
necessary to support the site-specific response actions conducted by ATSDR. 
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QUICK REFERENCE FOR HEALTH CARE PROVIDERS 
 
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance.  Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance.  Health care providers treating 
patients potentially exposed to hazardous substances will find the following information helpful for fast 
answers to often-asked questions. 
 
 
Primary Chapters/Sections of Interest 
 
Chapter 1:  Public Health Statement: The Public Health Statement can be a useful tool for educating 
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant 
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of 
the general health effects observed following exposure. 
 
Chapter 2:  Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, 
and assesses the significance of toxicity data to human health. 
 
Chapter 3:  Health Effects: Specific health effects of a given hazardous compound are reported by type 
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic).  In addition, both human and animal studies are 
reported in this section.  
 NOTE: Not all health effects reported in this section are necessarily observed in the clinical 
setting.  Please refer to the Public Health Statement to identify general health effects observed 
following exposure. 
 
Pediatrics:  Four new sections have been added to each Toxicological Profile to address child health 
issues: 
 Section 1.6 How Can (Chemical X) Affect Children? 
 Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)? 
 Section 3.7 Children’s Susceptibility 
 Section 6.6 Exposures of Children 
 
Other Sections of Interest: 
 Section 3.8  Biomarkers of Exposure and Effect 
 Section 3.11  Methods for Reducing Toxic Effects 
 
 
ATSDR Information Center  
 Phone:   1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY)   Fax:   (770) 488-4178 
 E-mail:   cdcinfo@cdc.gov  Internet:   http://www.atsdr.cdc.gov 
 
The following additional material can be ordered through the ATSDR Information Center: 
 
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an 
exposure history and how to conduct one are described, and an example of a thorough exposure 
history is provided.  Other case studies of interest include Reproductive and Developmental 
Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide 
Toxicity; and numerous chemical-specific case studies. 
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Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident.  Volumes I and II are planning guides to assist first responders and hospital emergency 
department personnel in planning for incidents that involve hazardous materials.  Volume III—
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials. 
 
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances. 
 
 
Other Agencies and Organizations 
 
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the 
workplace.  Contact:  NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, 
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015. 
 
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health.  Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 
• Phone: 800-35-NIOSH. 
 
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for 
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212. 
 
 
Referrals 
 
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact:  
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone:  202-347-4976 
• FAX:  202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/. 
 
The American College of Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact:  ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk 
Grove Village, IL 60007-1030 • Phone:  847-818-1800 • FAX:  847-818-9266. 
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THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS: 
 
 
1. Health Effects Review.  The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and classifying 
end points. 
 
2. Minimal Risk Level Review.  The Minimal Risk Level Workgroup considers issues relevant to 
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each 
profile, and makes recommendations for derivation of MRLs. 
 
3. Data Needs Review.  The Environmental Toxicology Branch (proposed) reviews data needs 
sections to assure consistency across profiles and adherence to instructions in the Guidance. 
 
4. Green Border Review.  Green Border review assures the consistency with ATSDR policy. 
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PEER REVIEW 
 
 
A peer review panel was assembled for cadmium.  The panel consisted of the following members:  
 
1. Maryka H. Bhattacharyya, Ph.D., Senior Biochemist, Biosciences Division (BIO), Argonne 
National Laboratory, Lemont, Illinois 60439,  
 
2. Masayuki Ikeda, Ph.D., M.D., Professor, Kyoto Industrial Health Association, Kyoto, Japan 
604-8472, and  
 
3. Zahir A Shaikh, Ph.D., Professor of Pharmacology and Toxicology, Director of the Center for 
Molecular Toxicology, University of Rhode Island, Kingston, Rhode Island 02881. 
 
These experts collectively have knowledge of cadmium’s physical and chemical properties, 
toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and 
quantification of risk to humans.  All reviewers were selected in conformity with the conditions for peer 
review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, 
and Liability Act, as amended. 
 
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer 
reviewers' comments and determined which comments will be included in the profile.  A listing of the 
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their 
exclusion, exists as part of the administrative record for this compound.   
 
The citation of the peer review panel should not be understood to imply its approval of the profile's final 
content.  The responsibility for the content of this profile lies with the ATSDR. 
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1.  PUBLIC HEALTH STATEMENT 
 
This public health statement tells you about cadmium and the effects of exposure to it. 
 
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the 
nation.  These sites are then placed on the National Priorities List (NPL) and are targeted for long-term 
federal clean-up activities.  Cadmium has been found in at least 1,014 of the 1,669 current or former NPL 
sites.  Although the total number of NPL sites evaluated for this substance is not known, the possibility 
exists that the number of sites at which cadmium is found may increase in the future as more sites are 
evaluated.  This information is important because these sites may be sources of exposure and exposure to 
this substance may be harmful. 
 
When a substance is released either from a large area, such as an industrial plant, or from a container, 
such as a drum or bottle, it enters the environment.  Such a release does not always lead to exposure.  You 
can be exposed to a substance only when you come in contact with it.  You may be exposed by breathing, 
eating, or drinking the substance, or by skin contact. 
 
If you are exposed to cadmium or cadmium compounds, many factors will determine whether you will be 
harmed.  These factors include the dose (how much), the duration (how long), and how you come in 
contact with it.  You must also consider any other chemicals you are exposed to and your age, sex, diet, 
family traits, lifestyle, and state of health. 
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1.1   WHAT IS CADMIUM? 
 
Description Metal found in the earth’s crust, associated with zinc, lead, and copper 
ores.  
 
Pure cadmium is a soft, silver-white metal.  Cadmium chloride and 
cadmium sulfate are soluble in water. 
 
Uses 
 • Manufacturing 
 
 
 
 • Consumer 
products 
 
Most cadmium used in the United States is extracted as a byproduct 
during the production of other metals such as zinc, lead, or copper.  
Cadmium is also recovered from used batteries.  
 
Cadmium is used for the following:  
 • batteries (83%) 
 • pigments (8%) 
 • coatings and platings (7%) 
 • stabilizers for plastics (1.2%) 
 • nonferrous alloys, photovoltaic devices, and other uses (0.8%) 
 
 
For more information on the properties and uses of cadmium, see Chapters 4 and 5. 
 
1.2   WHAT HAPPENS TO CADMIUM WHEN IT ENTERS THE ENVIRONMENT? 
 
Sources Cadmium is emitted to soil, water, and air by non-ferrous metal mining 
and refining, manufacture and application of phosphate fertilizers, fossil 
fuel combustion, and waste incineration and disposal.  
 
Cadmium can accumulate in aquatic organisms and agricultural crops. 
 
Fate 
 • Air 
 
 
 
 
 • Soil 
 
 
 
 
 
 • Water 
 
Cadmium (as oxide, chloride, and sulfate) will exist in air as particles or 
vapors (from high temperature processes).  It can be transported long 
distances in the atmosphere, where it will deposit (wet or dry) onto soils 
and water surfaces.   
 
Cadmium and its compounds may travel through soil, but its mobility 
depends on several factors such as pH and amount of organic matter, 
which will vary depending on the local environment.  Generally, 
cadmium binds strongly to organic matter where it will be immobile in 
soil and be taken up by plant life, eventually, entering the food supply.  
 
Cadmium exists as the hydrated ion or as ionic complexes with other 
inorganic or organic substances.  Soluble forms migrate in water.  
Insoluble forms of cadmium are immobile and will deposit and absorb 
to sediments. 
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1.3   HOW MIGHT I BE EXPOSED TO CADMIUM? 
 
Food and 
smoking—primary 
sources of 
exposure 
In the United States, for nonsmokers the primary source of cadmium 
exposure is from the food supply.  In general, leafy vegetables such as 
lettuce and spinach, potatoes and grains, peanuts, soybeans, and 
sunflower seeds contain high levels of cadmium, approximately 0.05–
0.12 mg cadmium/kg. 
 
Tobacco leaves accumulate high levels of cadmium from the soil.   
 
The national geometric mean blood cadmium level for adults is 
0.38 μg/L.  A geometric mean blood cadmium level of 1.58 μg/L for New 
York City smokers has been reported.  The amount of cadmium 
absorbed from smoking one pack of cigarettes per day is about 1–
3 μg/day.  Direct measurement of cadmium levels in body tissues 
confirms that smoking roughly doubles cadmium body burden in 
comparison to not smoking.  
 
Air Except for people living near cadmium-emitting industries, 
cadmium is not expected to be a major concern. 
 
inhalation of 
Water  Elevated cadmium levels in water sources in the vicinity of cadmium-
emitting industries (historical and current) have been reported.  Aquatic 
organisms will accumulate cadmium, possibly entering the food supply.  
People who fish in local waters as a means of food should be cautious 
and abide by any advisories. 
 
Occupational 
exposure 
Highest risk of exposure from processes involving heating cadmium-
containing materials such as smelting and electroplating.  Risk will vary 
depending on the workplace.  
 
Major route of exposure is through inhalation of dust and fumes or 
incidental ingestion from contaminated hands, food, or cigarettes.  
 
Exposure can be controlled through personal protective equipment, 
good industrial hygiene practices, and control and reduction of cadmium 
emissions. 
 
 
In Chapter 6, you can find more information on how you might be exposed to cadmium. 
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1.4   HOW CAN CADMIUM ENTER AND LEAVE MY BODY? 
 
Enter your body  
 • Inhalation About 5–50% of the cadmium you breathe will enter your body through 
 your lungs.   
  
 • Ingestion A small amount of the cadmium in food and water (about 1–10%) will 
 enter your body through the digestive tract.  If you do not have enough 
 iron or other nutrients in your diet, you are likely to take up more 
 cadmium from your food than usual.   
  
 • Dermal contact Virtually no cadmium enters your body through your skin.   
 
Leave your body  Most of the cadmium that enters your body goes to your kidney and liver 
and can remain there for many years.  A small portion of the cadmium 
that enters your body leaves slowly in urine and feces.   
 
Your body can change most cadmium to a form that is not harmful, but 
too much cadmium can overload the ability of your liver and kidney to 
change the cadmium to a harmless form. 
 
 
More information on how cadmium enters and leaves the body is found in Chapter 3. 
 
1.5   HOW CAN CADMIUM AFFECT MY HEALTH? 
 
This section looks at studies concerning potential health effects in animal and human studies. 
 
Workers  
 • Inhalation Breathing air with very high levels of cadmium can severely damage the 
 lungs and may cause death.   
 
Breathing air with lower levels of cadmium over long periods of time (for 
years) results in a build-up of cadmium in the kidney, and if sufficiently 
high, may result in kidney disease. 
 
Laboratory animals   
 • Inhalation  Damage to the lungs and nasal cavity has been observed in animals 
exposed to cadmium. 
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Humans  
 • Oral 
 
 
Eating food or drinking water with very high cadmium levels severely 
irritates the stomach, leading to vomiting and diarrhea, and sometimes 
death. 
 
Eating lower levels of cadmium over a long period of time can lead to a 
build-up of cadmium in the kidneys.  If the build-up of cadmium is high 
enough, it will damage the kidneys. 
 
Exposure to lower levels of cadmium for a long time can also cause bones 
to become fragile and break easily. 
 
Laboratory animals  
 • Oral 
 
Kidney and bone effects have also been observed in laboratory animals 
ingesting cadmium. 
 
Anemia, liver disease, and nerve or brain damage have been observed in 
animals eating or drinking cadmium.  We have no good information on 
people to indicate what cadmium levels people would need to eat or drink 
to result in these diseases, or if they would occur at all. 
 
Cancer Lung cancer has been found in some studies of workers exposed to 
cadmium in the air and studies of rats that breathed in cadmium.   
 
The U.S. Department of Health and Human Services (DHHS) has 
determined that cadmium and cadmium compounds are known human 
carcinogens.  The International Agency for Research on Cancer (IARC) 
has determined that cadmium is carcinogenic to humans.  The EPA has 
determined that cadmium is a probable human carcinogen. 
 
 
More information on how cadmium can affect your health is found in Chapters 2 and 3. 
 
1.6   HOW CAN CADMIUM AFFECT CHILDREN? 
 
This section discusses potential health effects in humans from exposures during the period from 
conception to maturity at 18 years of age. 
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Effects in children  The health effects seen in children from exposure to toxic levels of 
cadmium are expected to be similar to the effects seen in adults (kidney 
and lung damage).   
 
Harmful effects on child development or behavior have not generally been 
seen in populations exposed to cadmium, but more research is needed.   
 
A few studies in animals indicate that younger animals absorb more 
cadmium than adults.  Animal studies also indicate that the young are 
more susceptible than adults to a loss of bone and decreased bone 
strength from exposure to cadmium.   
 
Cadmium is found in breast milk and a small amount will enter the infant’s 
body through breastfeeding.  The amount of cadmium that can pass to the 
infant depends on how much exposure the mother may have had. 
 
Birth defects We do not know whether cadmium can cause birth defects in people.   
 
Studies in animals exposed to high enough levels of cadmium during 
pregnancy have resulted in harmful effects in the young.  The nervous 
system appears to be the most sensitive target.  Young animals exposed 
to cadmium before birth have shown effects on behavior and learning.  
There is also some information from animal studies that high enough 
exposures to cadmium before birth can reduce body weights and affect 
the skeleton in the developing young. 
 
 
1.7   HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO CADMIUM? 
 
Do not smoke Cadmium accumulates in tobacco leaves.  The national geometric mean 
tobacco products blood cadmium level for adults is 0.376 μg/L.  Mean blood cadmium levels 
for heavy smokers have been reported as high as 1.58 μg/L. 
 
Good occupational 
hygiene 
Occupational exposure can be controlled through personal protective 
equipment, good industrial hygiene practices, and control and reduction of 
cadmium emissions. 
 
Children can be exposed to cadmium through parents who work in 
cadmium-emitting industries.  Therefore, good hygiene practices such as 
bathing and changing clothes before returning home may help reduce the 
cadmium transported from the job to the home. 
 
Avoid cadmium Check and obey local fishing advisories before consuming fish or shellfish 
contaminated areas from local waterways.  
and food  
Avoid hazardous waste sites. 
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Proper disposal of 
cadmium-
containing products 
Dispose of nickel-cadmium batteries properly.  Many states have laws in 
effect that ban the disposal of batteries as municipal waste.  Recycle old 
batteries whenever possible.  
 
Contact your local waste and recycling authority on how to properly 
dispose of paints and coatings. 
 
Handle properly Do not allow children to play with batteries.  If mishandled, batteries could 
rupture.  
 
Children may also swallow small nickel-cadmium batteries. 
 
 
If your doctor finds that you have been exposed to significant amounts of cadmium, ask whether your 
children might also be exposed.  Your doctor might need to ask you state health department to investigate. 
 
1.8   IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO 
CADMIUM? 
 
Detecting exposure  
 
Cadmium can be measured in blood, urine, hair, or nails.  Urinary 
cadmium has been shown to accurately reflect the amount of cadmium in 
the body.   
 
Measuring exposure The amount of cadmium in your blood shows your recent exposure to 
cadmium.  The amount of cadmium in your urine shows both your recent 
and your past exposure.   
 
Cadmium levels in hair or nails are not as useful as an indication of when 
or how much cadmium you may have taken in, partly because cadmium 
from outside of your body may attach to the hair or nails.   
 
Tests are also available to measure the amount of cadmium inside your 
liver and kidneys. 
 
 
More information on how cadmium can be measured in exposed humans is presented in Chapters 3 and 7. 
 
1.9   WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 
PROTECT HUMAN HEALTH? 
 
The federal government develops regulations and recommendations to protect public health.  Regulations 
can be enforced by law.  The EPA, the Occupational Safety and Health Administration (OSHA), and the 
Food and Drug Administration (FDA) are some federal agencies that develop regulations for toxic 
substances.  Recommendations provide valuable guidelines to protect public health, but cannot be 
enforced by law.  The Agency for Toxic Substances and Disease Registry (ATSDR) and the National 
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Institute for Occupational Safety and Health (NIOSH) are two federal organizations that develop 
recommendations for toxic substances. 
 
Regulations and recommendations can be expressed as “not-to-exceed” levels.  These are levels of a toxic 
substance in air, water, soil, or food that do not exceed a critical value.  This critical value is usually based 
on levels that affect animals; they are then adjusted to levels that will help protect humans.  Sometimes 
these not-to-exceed levels differ among federal organizations because they used different exposure times 
(an 8-hour workday or a 24-hour day), different animal studies, or other factors. 
 
Recommendations and regulations are also updated periodically as more information becomes available.  
For the most current information, check with the federal agency or organization that provides it. 
 
Recommendations and regulations are also updated periodically as more information becomes available.  
For the most current information, check with the federal agency or organization that provides it.  Some 
regulations and recommendations for cadmium include the following: 
 
Drinking water  The EPA has determined that exposure to cadmium in drinking water at a 
concentration of 0.04 mg/L for up to 10 days is not expected to cause any 
adverse effects in a child. 
 
The EPA has determined that lifetime exposure to 0.005 mg/L cadmium in 
drinking water is not expected to cause any adverse effects.   
 
Consumer products  The FDA has determined that cadmium levels in bottled water should not 
exceed 0.005 mg/L.   
 
Workplace air  OSHA set a legal limit of 5 μg/m3 cadmium in air averaged over an 8-hour 
work day. 
 
 
More information on governmental rules regarding cadmium can be found in Chapter 8. 
 
1.10   WHERE CAN I GET MORE INFORMATION? 
 
If you have any more questions or concerns, please contact your community or state health or 
environmental quality department, or contact ATSDR at the address and phone number below. 
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ATSDR can also tell you the location of occupational and environmental health clinics.  These clinics 
specialize in recognizing, evaluating, and treating illnesses that result from exposure to hazardous 
substances. 
 
Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM.  You may 
request a copy of the ATSDR ToxProfilesTM CD-ROM by calling the toll-free information and technical 
assistance number at 1-800-CDCINFO (1-800-232-4636), by e-mail at cdcinfo@cdc.gov, or by writing 
to:  
 
  
  
  
  
  
  
 
Agency for Toxic Substances and Disease Registry 
Division of Toxicology and Human Health Sciences (proposed) 
1600 Clifton Road NE 
Mailstop F-62 
Atlanta, GA 30333 
Fax: 1-770-488-4178 
Organizations for-profit may request copies of final Toxicological Profiles from the following: 
 
  National Technical Information Service (NTIS) 
  5285 Port Royal Road 
  Springfield, VA 22161 
  Phone: 1-800-553-6847 or 1-703-605-6000 
  Web site:  http://www.ntis.gov/ 
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2.  RELEVANCE TO PUBLIC HEALTH  
 
2.1   BACKGROUND AND ENVIRONMENTAL EXPOSURES TO CADMIUM IN THE UNITED 
STATES  
 
Cadmium occurs in the earth’s crust at a concentration of 0.1–0.5 ppm and is commonly associated with 
zinc, lead, and copper ores.  It is also a natural constituent of ocean water with average levels between 
<5 and 110 ng/L, with higher levels reported near coastal areas and in marine phosphates and 
phosphorites.  The cadmium concentration of natural surface water and groundwater is usually <1 μg/L.  
Surface soil concentrations will depend on several factors such as its mobility, natural geochemistry, and 
magnitude of contamination from sources such as fertilizers and atmospheric deposition.  Natural 
emissions of cadmium to the environment can result from volcanic eruptions, forest fires, generation of 
sea salt aerosols, or other natural phenomena. 
 
In the environment, cadmium exists in only one oxidation state (+2) and does not undergo oxidation-
reduction reactions.  In surface water and groundwater, cadmium can exist as the hydrated ion or as ionic 
complexes with other inorganic or organic substances.  Soluble forms of cadmium can migrate in water.  
Insoluble forms of cadmium will settle and adsorb to sediments.  Cadmium’s fate in soil depends on 
several factors such as pH of the soil and the availability of organic matter.  Generally, cadmium will bind 
strongly to organic matter and this will, for the most part, immobilize it.  However, cadmium’s behavior 
in soil will vary depending on the environmental conditions.  It is not likely that cadmium will undergo 
significant transformation in the atmosphere.  It will exist in particulate form and sometimes vapor form 
(emitted from high temperature processes) where it will undergo atmospheric transport and eventually 
deposit onto soils and surface waters.  
 
Non-ferrous metal mining and refining, manufacture and application of phosphate fertilizers, fossil fuel 
combustion, and waste incineration and disposal are the main anthropogenic sources of cadmium in the 
environment.  Except for those who live near cadmium-emitting industries, inhalation of cadmium in the 
ambient air may occur, but is not a major source of exposure.  Water sources near cadmium-emitting 
industries, both with historic and current operations, have shown a marked elevation of cadmium in water 
sediments and aquatic organisms.  Concentrations of cadmium in these polluted waters have ranged from 
<1.0 to 77 μg/L.  For the U.S. population, cadmium exposure through the drinking water supply is of 
minor concern.  Cadmium from polluted soil and water can accumulate in plants and organisms, thus 
entering the food supply.  
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In the United States, the largest source of cadmium exposure for nonsmoking adults and children is 
through dietary intake.  The estimated daily intakes of cadmium in nonsmoking adult males and females 
living in the United States are 0.35 and 0.30 μg Cd/kg/day, respectively.  Females generally absorb 
greater amounts of cadmium in the gastrointestinal tract.  In general, leafy vegetables such as lettuce and 
spinach and staples such as potatoes and grains contain relatively high values of cadmium.  Peanuts, 
soybeans, and sunflower seeds have naturally high levels of cadmium.  People who regularly consume 
shellfish and organ meats (liver and kidney) have increased cadmium exposure.   
 
Mean values of cadmium in the blood and urine of the U.S. population were reported in the National 
Health and Nutrition Examination Survey (NHANES) 1999–2008.  Blood cadmium tends to reflect recent 
exposures and urinary cadmium reflects cumulative cadmium exposure and body burden (particularly, 
kidney cadmium levels).  The 20 years or older age group had geometric mean levels of blood and urine 
cadmium that were slightly higher than the younger age groups (0.376 µg/L in blood and 0.232 μg/L in 
urine).  Females (0.331 μg/L in blood and 0.191 μg/L in urine) had slightly higher blood and urine 
cadmium levels than males (0.299 μg/L in blood and 0.179 μg/L in urine).   
 
Smoking greatly increases exposure to cadmium, as tobacco leaves naturally accumulate high amounts of 
cadmium.  It has been estimated that tobacco smokers are exposed to 1.7 μg cadmium per cigarette, and 
about 10% is inhaled when smoked.  A geometric mean blood cadmium level for a heavy smoker has 
been reported as high as 1.58 μg/L, compared to the estimated national mean of 0.38 μg/L for all adults.  
Nonsmokers may also be exposed to cadmium in cigarettes via second-hand smoke. 
 
2.2   SUMMARY OF HEALTH EFFECTS  
 
Since the early 1950s, when the hazards of occupational cadmium exposure were recognized, a large 
amount of information has been generated concerning the toxic effects of cadmium exposure in humans 
and laboratory animals.  Toxicological properties of cadmium are similar for the several different salts 
and oxides of cadmium that have been investigated, although differences in absorption and distribution 
lead to different effect levels.  For inhalation exposure, particle size and solubility in biological fluids (in 
contrast to solubility in water) appear to be the more important determinants of the toxicokinetics.  For 
oral exposure, most experimental studies have used soluble cadmium, which exists as the Cd+2 ion 
regardless of the initial salt.  Absorption appears to be similar for cadmium ion and cadmium complexed 
with proteins in food, except for a few specific types of foods such as Bluff oysters and seal meat.  Also, 
poorly soluble cadmium pigments may be absorbed to a lesser extent than soluble cadmium ion.  For the 
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general population, dietary exposure to cadmium is the most likely route of exposure.  There is an 
extensive database on the toxicity of cadmium in environmentally exposed populations and in cadmium 
workers; however, most of these studies were focused on the presumed sensitive targets.  These sensitive 
targets of cadmium toxicity are the kidney and bone following oral exposure and kidney and lung 
following inhalation exposure.  Studies in animals support the identification of these sensitive targets and 
provide some suggestive evidence that the developing organisms may also be a sensitive target.  There is 
also evidence to suggest that cadmium is a human carcinogen.  Other effects that have been observed in 
humans and/or animals include reproductive toxicity, hepatic effects, hematological effects, and 
immunological effects. 
 
The earliest indication of kidney damage in humans is an increased excretion of low molecular weight 
proteins, particularly β2-microglobulin, human complex forming glycoprotein (pHC) (also referred to as 
α1-microglobulin), and retinol binding protein; increased urinary levels of intracellular enzymes such as 
N-acetyl-β-glucosaminidase (NAG); and increased excretion of calcium and metallothione.  Numerous 
studies of cadmium workers and populations living in areas with low, moderate, or high cadmium 
pollution have found significant associations between urinary cadmium levels and biomarker levels or 
significant increases in the prevalence of abnormal biomarker levels.  At higher exposure levels, 
decreases in glomerular filtration rate, increased risk of renal replacement therapy (dialysis or kidney 
transplantation), and significant increases in the risk of deaths from renal disease  have been observed.  
The sensitivity of the kidney to cadmium is related to its distribution in the body and de novo synthesis of 
metallothionein in the kidney.  In the blood, cadmium is bound to metallothionein and is readily filtered at 
the glomerulus and reabsorbed in the proximal tubule.  Within the tubular cells, the metallothionein is 
degraded in lysosomes and free cadmium is released; the synthesis of endogenous metallothionein by the 
tubular cells is then stimulated.  However, when the total cadmium content in the renal cortex reaches 
between 50 and 300 μg/g wet weight, the amount of cadmium not bound to metallothionein becomes 
sufficiently high to cause tubular damage.  Free cadmium ions may inactivate metal-dependent enzymes, 
activate calmodulin, and/or damage cell membranes through activation of oxygen species.  Because the 
toxicity of cadmium is dependent on its concentration in the kidney, adverse effects in humans are 
typically not observed after shorter durations.   
 
Acute inhalation exposure to cadmium at concentrations above about 5 mg/m3 may cause destruction of 
lung epithelial cells, resulting in pulmonary edema, tracheobronchitis, and pneumonitis in both humans 
and animals.  A single, high-level cadmium exposure can result in long-term impairment of lung function.  
At the cellular level, catalase, superoxide dismutase, non-protein sulfhydryl, glucose-6-phosphate 
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dehydrogenase, and glutathione peroxidase are decreased in response to cadmium lung insults.  The 
respiratory response to cadmium is similar to the response seen with other agents that produce oxidative 
damage.  There typically is an alveolar pneumocyte type 2 cell hyperplasia in response to type 1 cell 
damage and necrosis.  Longer-term inhalation exposure at lower levels also leads to decreased lung 
function and emphysema in cadmium workers.  Some tolerance to cadmium-induced lung irritation 
develops in exposed humans and animals, and respiratory function may recover after cessation of 
cadmium exposure.  Another effect of long-term inhalation cadmium exposure is damage to the olfactory 
function and nasal epithelium.  Lung damage has also been seen in a few studies of oral cadmium 
exposure in rats, but the lung effects are likely to be related to liver or kidney damage and subsequent 
changes in cellular metabolism.   
 
Prolonged inhalation or ingestion exposure of humans to cadmium at levels causing renal dysfunction can 
lead to painful and debilitating bone disease in individuals with risk factors such as poor nutrition; the 
occurrence of these bone effects in elderly Japanese women exposed to high levels of cadmium in rice 
and water was referred to as Itai-Itai disease.  Decreases in bone mineral density, increases in the risk of 
fractures, and increases in the risk of osteoporosis have also been observed in populations living in 
cadmium-polluted areas.  An association between bone effects and cadmium exposure has also been 
observed in populations exposed to higher levels of cadmium, but not living in cadmium polluted areas.  
Similar effects have also been observed in young rats orally exposed to cadmium.  Animal data strongly 
suggest that cadmium exposure results in increases in bone turnover and decreases in mineralization 
during the period of rapid bone growth.  Although animal studies suggest that these effects are due to 
direct damage to the bone, it is likely that renal damage resulting in the loss of calcium and phosphate and 
alteration in renal metabolism of vitamin D would compound these effects.     
 
There are few human data on developmental effects from exposure to cadmium.  Some studies indicate 
that maternal cadmium exposure may cause decreased birth weight in humans, but most of these studies 
are of limited use because of weaknesses in the study design and lack of control for confounding factors.  
A number of other studies did not find a significant relationship between maternal cadmium levels and 
newborn body weight.  In animals, cadmium has been shown to be a developmental toxin by the 
inhalation, oral, and parenteral routes.  Decreased fetal weight, skeletal malformations, and delayed 
ossification are produced by relatively high maternal doses (1–20 mg/kg/day) due to placental toxicity, 
interference with fetal metabolism, and damage to the maternal liver.  Neurodevelopmental effects have 
been observed at lower doses.  Impaired performance on neurobehavioral tests were observed in the 
offspring of rats exposed to 0.02 mg/m3 or ≥0.04 mg/kg/day. 
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The results of occupational exposure studies examining the possible association between cadmium 
exposure and an increased risk of lung cancer are inconsistent, with some studies finding significant 
increases in lung cancer deaths and other studies not finding increases.  Interpretation of the results of 
many of the studies is complicated by inadequate controls for confounding factors such as co-exposure 
with other metal carcinogens and smoking, small number of lung cancer deaths, and the lack of 
significant relationships between cadmium exposure and duration.  For prostate cancer, initial studies in 
European workers indicated an elevation in prostate cancer, but subsequent investigations found either no 
increases in prostate cancer or increases that were not statistically significant.  Strong evidence from 
animal studies exists that cadmium inhalation can cause lung cancer, but only in rats.  Most oral studies in 
laboratory animals have not found significant increases in cancer incidence.  The Department of Health 
and Human Services concluded that there were sufficient human and animal data to conclude that 
cadmium is a known human carcinogen; likewise, IARC classified cadmium as carcinogenic to humans 
(Group 1).  The EPA has classified cadmium as a probable human carcinogen by inhalation (Group B1), 
based on its assessment of limited evidence of an increase in lung cancer in humans and sufficient 
evidence of lung cancer in rats.   
 
2.3   MINIMAL RISK LEVELS (MRLs) 
 
Estimates of exposure levels posing minimal risk to humans (MRLs) have been made for cadmium.  An 
MRL is defined as an estimate of daily human exposure to a substance that is likely to be without an 
appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure.  MRLs are 
derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive 
health effect(s) for a specific duration within a given route of exposure.  MRLs are based on 
noncancerous health effects only and do not consider carcinogenic effects.  MRLs can be derived for 
acute, intermediate, and chronic duration exposures for inhalation and oral routes.  Appropriate 
methodology does not exist to develop MRLs for dermal exposure. 
 
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990d), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional 
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in development 
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
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bronchitis.  As these kinds of health effects data become available and methods to assess levels of 
significant human exposure improve, these MRLs will be revised. 
 
The database on the toxicity of cadmium in humans and animals following inhalation or oral exposure is 
extensive.  Target organs are similar among species and, in general, toxicokinetic properties after oral and 
inhalation exposures are similar.  Most of the human data involve chronic inhalation exposure of workers 
or chronic dietary exposure of the general population or populations living in cadmium-polluted areas.  
Several approaches for characterizing cadmium exposure have been used in these studies.  Occupational 
exposure studies have used current air concentrations or have estimated cumulative exposure based on 
historical and current monitoring data.  Some epidemiology studies have estimated cumulative intake 
based on the levels of cadmium in rice, in populations where rice has been the dominant source of oral 
exposure to cadmium.  However, most studies (particularly oral studies) have used urinary cadmium 
levels as a biomarker of exposure.  As discussed in greater detail in Section 3.8.1, urinary cadmium levels 
correlate with cadmium body burden and cadmium concentration in kidney (a critical target organ for 
chronic exposure).  The relationship between renal and urinary cadmium appears to be nearly linear at 
chronic intakes and kidney burdens that do not produce nephrotoxicity (i.e., elimination half-time is 
independent of dose).  However, at high kidney cadmium burdens, associated with renal damage (>50 μg 
Cd/g cortex), the elimination half-time increases with increasing severity of renal damage.  Linearity in 
the dose-urinary excretion relationship also does not appear to apply following an acute high exposure to 
cadmium.  The Nordberg-Kjellström model (described in detail in Section 3.4.5.3) is a multicompartment 
pharmacokinetic model that can be used to estimate cadmium intakes (inhalation and oral exposure) 
associated with a given urinary cadmium level and/or kidney cadmium burden.  The model has been 
extensively evaluated for predicting dose-kidney-urinary cadmium relationships within the linear range of 
the dose-urinary cadmium relationship. 
 
Inhalation MRLs 
 
Acute-Duration Inhalation MRL 
 
• An MRL of 3x10-5 mg Cd/m3 (0.03 μg Cd/m3) has been derived for acute-duration inhalation 
exposure (<14 days) to cadmium. 
 
The acute toxicity of airborne cadmium, particularly cadmium oxide fumes, was first recognized in the 
early 1920s and there have been numerous case reports of cadmium workers dying after brief exposures 
to presumably high concentrations of cadmium fumes (European Chemicals Bureau 2007).  The initial 
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symptoms, similar to those observed in metal fume fever, are usually mild but rapidly progress to severe 
pulmonary edema and chemical pneumonitis.  Persistent respiratory effects (often lasting years after the 
exposure) have been reported in workers surviving these initial effects.  There are limited monitoring data 
for these human reports; however, Elinder (1986b) estimated that an 8-hour exposure to 1–5 mg/m3 would 
be immediately dangerous.    
 
Animal studies support the findings in humans that acute exposure to cadmium results in lung damage.  
Single exposures to approximately 1–10 mg Cd/m3 as cadmium chloride or cadmium oxide resulted in 
interstitial pneumonitis, diffuse alveolitis with hemorrhage, focal interstitial thickening, and edema 
(Boudreau et al. 1989; Buckley and Bassett 1987b; Bus et al. 1978; Grose et al. 1987; Hart 1986; 
Henderson et al. 1979; Palmer et al. 1986).  Repeated exposure to 6.1 mg Cd/m3 1 hour/day for 5, 10, or 
15 days resulted in emphysema in rats (Snider et al. 1973).  Lower concentrations of 0.4–0.5 mg Cd/m3 as 
cadmium oxide for 2–3 hours (Buckley and Bassett 1987b; Grose et al. 1987) or 0.17 mg Cd/m3 as 
cadmium chloride 6 hours/day for 10 days (Klimisch 1993) resulted in mild hypercellularity and increases 
in lung weight.  Alveolar histiocytic infiltration and focal inflammation and minimal fibrosis in alveolar 
septa were observed in rats exposed to 0.088 mg Cd/m3 as cadmium oxide 6.2 hours/day, 5 days/week for 
2 weeks (NTP 1995); in similarly exposed mice, histiocytic infiltration was observed at 0.088 mg Cd/m3 
(NTP 1995).  At similar concentrations (0.19 or 0.88 mg Cd/m3as cadmium chloride), decreases in 
humoral immune response were observed in mice exposed for 1–2 hours (Graham et al. 1978; 
Krzystyniak et al. 1987).  Other effects that have been reported in animals acutely exposed to cadmium 
include erosion of the stomach, decreased body weight gain, and tremors in rats exposed to 132 mg Cd/m3 
as cadmium carbonate for 2 hours (Rusch et al. 1986) and weight loss and reduced activity in rats exposed 
to 112 mg Cd/m3 as cadmium oxide for 2 hours (Rusch et al. 1986). 
 
The NTP (1995) study was selected as the basis of an acute duration inhalation MRL.  In this study, 
groups of five male and five female F344 rats were exposed to 0, 0.1, 0.3, 1, 3, or 10 mg cadmium 
oxide/m3 (0, 0.088, 0.26, 0.88, 2.6, or 8.8 mg Cd/m3) 6.2 hours/day, 5 days/week for 2 weeks.  The mean 
median aerodynamic diameter (MMAD) of the cadmium oxide particles was 1.5 μm with a geometric 
standard deviation of 1.6–1.8.  The animals were observed twice daily and weighed on days 1, 8, and at 
termination.  Other parameters used to assess toxicity included organ weights (heart, kidney, liver, lungs, 
spleen, testis, and thymus) and histopathological examination (gross lesions, heart, kidney, liver, lungs, 
tracheobronchial lymph nodes, and nasal cavity and turbinates).  All rats in the 8.8 mg Cd/m3 group died 
by day 6; no other deaths occurred.  A slight decrease in terminal body weights was observed at 2.6 mg 
Cd/m3; however, the body weights were within 10% of control weights.  Significant increases in relative 
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and absolute lung weights were observed at 0.26 (males only), 0.88, and 2.6 mg Cd/m3.  Histological 
alterations were limited to the respiratory tract and consisted of alveolar histiocytic infiltrate and focal 
inflammation and minimal fibrosis in alveolar septa at ≥0.088 mg Cd/m3, necrosis of the epithelium lining 
alveolar ducts at ≥0.26 mg Cd/m3, tracheobronchial lymph node inflammation at ≥0.88 mg Cd/m3, 
degeneration of the nasal olfactory epithelium at 0.88 mg Cd/m3, and inflammation and metaplasia of the 
nasal respiratory epithelium at 2.6 mg Cd/m3. 
 
The lowest-observed-adverse-effect level (LOAEL) of 0.088 mg Cd/m3 was selected as the point of 
departure for derivation of the MRL; benchmark dose analysis was considered; however, the data were 
not suitable for benchmark dose analysis because the data do not provide sufficient information about the 
shape of the dose-response relationship below the 100% response level.  The LOAELHEC was calculated 
using the equations below.   
 
LOAELHEC = LOAELADJ x RDDR 
 
The duration-adjusted LOAEL (LOAELADJ) was calculated as follows: 
 
LOAELADJ = 0.088 mg Cd/m
3 x 6.2 hours/24 hours x 5 days/7 days 
LOAELADJ = 0.016 mg Cd/m
3 
 
The regional deposited dose ratio (RDDR) for the pulmonary region of 0.617 was calculated with EPA’s 
RDDR calculator (EPA 1994a) using the final body weight of 0.194 kg for the male rats exposed to 
0.088 mg Cd/m3, the reported MMAD of 1.5 μm and the midpoint of the reported range of geometric 
standard deviations (1.7). 
 
LOAELHEC = 0.016 mg Cd/m
3 x 0.617 
LOAELHEC = 0.01 mg Cd/m
3 
 
The LOAELHEC was divided by an uncertainty factor of 300 (10 for the use of a LOAEL, 3 for 
extrapolation from animals to humans with dosimetric adjustments, and 10 for human variability) 
resulting in an acute-duration inhalation MRL of 3x10-5 mg Cd/m3 (0.03 μg Cd/m3).  
 
CADMIUM  19 
 
2.  RELEVANCE TO PUBLIC HEALTH 
 
 
 
 
 
 
 
Intermediate-Duration Inhalation MRL 
 
There are no studies examining the intermediate-duration toxicity of inhaled cadmium in humans; 
however, numerous animal studies have identified several targets of cadmium toxicity.  Increases in the 
number of bronchioalveolar macrophages, alveolar histiocytic infiltration, degeneration or metaplasia in 
the larynx, and proliferations have been observed in rats and mice exposed to 0.022 mg Cd/m3 as 
cadmium oxide or cadmium chloride (Glaser et al. 1986; NTP 1995; Prigge 1978a).  At higher 
concentrations (>0.88 mg Cd/m3), marked inflammation and fibrosis was observed in lungs of rats 
(Kutzman et al. 1986; NTP 1995).  In general, these studies did not identify no-observed-adverse-effect 
levels (NOAELs) for lung effects.  The NTP (1995) study also found significant increases in the 
incidence of inflammation of the nasal respiratory epithelium in rats exposed to 0.22 mg Cd/m3 and 
degeneration of the nasal olfactory epithelium in mice exposed to 0.088 mg Cd/m3.  The NTP (1995) 
study did not find any histological alterations in non-respiratory tract tissues, alterations in urinalysis 
parameters, or changes in blood pressure (rats only) in rats or mice.  Prigge (1978a, 1978b) reported 
increases in hemoglobin and hematocrit levels in rats continuously exposed to ≥0.052 mg Cd/m3; 
however, this effect was not observed in the NTP (1995) studies.  Reproductive effects (increased 
duration of estrous cycle and decreased spermatid counts) have also been observed at higher 
concentrations (0.88–1 mg Cd/m3) (Baranski and Sitarek 1987; NTP 1995). 
 
The studies by Baranski (1984, 1985) provide suggestive evidence that the developing organism is also a 
sensitive target of cadmium toxicity.  Significant alterations in performance on neurobehavioral tests were 
observed in the offspring of rats exposed to 0.02 mg Cd/m3 as cadmium oxide 5 hours/day, 5 days/week 
for 5 months prior to mating, during a 3-week mating period, and during gestation days 1–20.  No other 
studies examined neurodevelopmental end points following inhalation exposure.  However, the 
identification of neurodevelopmental effects as a sensitive target of cadmium toxicity is supported by 
several intermediate-duration animal studies finding neurodevelopmental effects including alterations in 
motor activity and delays in the development of sensory motor coordination reflexes (Ali et al. 1986; 
Baranski 1985; Desi et al. 1998; Nagymajtenyi et al. 1997).  Other developmental effects observed in the 
inhalation studies included decreases in fetal body weight in the fetuses of rats exposed to 1.7 or 0.581 mg 
Cd/m3 (NTP 1995; Prigge 1978b) and mice exposed to 0.4 mg Cd/m3 (NTP 1995).   
 
Based on the available animal data, the LOAEL of 0.022 mg Cd/m3 for lung and larynx effects in mice 
(NTP 1995) and the LOAEL of 0.02 mg Cd/m3 for neurodevelopmental effects (Baranski 1984, 1985) 
were evaluated as possible points of departure for the intermediate-duration inhalation MRL for cadmium.  
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The LOAEL of 0.022 mg Cd/m3 identified in the NTP (1995) mouse study was considered as the point of 
departure for the MRL because the NTP study provided more study details and information on particle 
size distribution.  Because an MRL based on this LOAEL (LOAELHEC of 1 μg Cd/m
3) would be lower 
than the chronic-duration inhalation MRL based on human data, an intermediate-duration inhalation MRL 
was not derived. 
 
Chronic-Duration Inhalation MRL 
 
• An MRL of 0.01 μg Cd/m3 has been derived for chronic-duration inhalation exposure (≥1 year) to 
cadmium. 
 
Numerous studies examining the toxicity of cadmium in workers have identified the respiratory tract and 
the kidney as sensitive targets of toxicity.  A variety of respiratory tract effects have been observed in 
cadmium workers including respiratory symptoms (e.g., dyspnea, coughing, wheezing), emphysema, and 
impaired lung function.  However, many of these studies did not control for smoking, and thus, the role of 
cadmium in the induction of these effects is difficult to determine.  Impaired lung function was reported 
in several studies that controlled for smoking (Chan et al. 1988; Cortona et al. 1992; Davison et al. 1988; 
Smith et al. 1976); other studies have not found significant alterations (Edling et al. 1986).  The observed 
alterations included an increase in residual volume in workers exposed to air concentrations of cadmium 
fumes ranging from 0.008 (in 1990) to 1.53 mg/m3 (in 1975) (mean urinary cadmium level in the workers 
was 4.3 μg/L) (Cortona et al. 1992); alterations in several lung function parameters (e.g., forced 
expiratory volume, transfer factor, transfer coefficient) in workers exposed to 0.034–0.156 mg/m3 
(Davison et al. 1988); and decreased force vital capacity in workers exposed to >0.2 mg/m3 (Smith et al. 
1976).  Additionally, Chan et al. (1988) found significant improvements in several parameters of lung 
function of workers following reduction or cessation of cadmium exposure. 
 
The renal toxicity of cadmium in workers chronically exposed to high levels of cadmium is well 
established.  Observed effects include tubular proteinuria (increased excretion of low molecular weight 
proteins), decreased resorption of other solutes (increased excretion of enzymes such as NAG, amino 
acids, glucose, calcium, inorganic phosphate), evidence of increased glomerular permeability (increased 
excretion of albumin), increased kidney stone formation, and decreased glomerular filtration rate (GFR).  
The earliest sign of cadmium-induced kidney damage is an increase in urinary levels of low molecular 
weight proteins (particularly, β2-microglobulin, retinol binding protein, and pHC) in cadmium workers, 
as compared to levels found in a reference group of workers or the general population (Bernard et al. 
1990; Chen et al. 2006a, 2006b; Chia et al. 1992; Elinder et al. 1985a; Falck et al. 1983; Jakubowski et al. 
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1987, 1992; Järup and Elinder 1994; Järup et al. 1988; Shaikh et al. 1987; Toffoletto et al. 1992; 
Verschoor et al. 1987).  Although increases in the excretion of low molecular weight proteins are not 
diagnostic of renal damage (Bernard et al. 1997; Järup et al. 1998b), tubular proteinuria is considered an 
adverse effect because it is an early change in a sequence of events which ultimately may result in 
compromised renal function (Bernard et al. 1997).  Most investigators consider a 10% cadmium-
associated increase in the prevalence of abnormal levels of renal biomarkers (urinary β2-microglobulin, 
retinol binding protein, pHC) to be indicative of cadmium-induced renal disease in the population.  
However, there is less consensus on the low molecular protein level regarded as elevated or abnormal 
(cut-off point). 
 
Several biomarkers of tubular damage have been used in occupational exposure studies; these include 
β2-microglobulin, retinol binding protein, NAG, and pHC.  Of these biomarkers, which differ in their 
sensitivities to detect tubular damage, β2-microglobulin is the most widely used in occupational exposure 
studies.  In healthy humans, urinary β2-microglobulin levels are <300 μg/24 hours (approximately 
300 μg/g creatinine).  Four studies have estimated the prevalence of abnormal urinary β2-microglobulin 
levels among cadmium workers using cut-off levels of 187–380 μg/g creatinine (Chen et al. 2006a; 
Elinder et al. 1985a; Jakubowski et al. 1987; Järup and Elinder 1994).  The prevalence of abnormal 
urinary β2-microglobin levels was 10% among workers with urinary cadmium levels of 1.5 (≥60 years of 
age) or 5 (<60 years of age) μg/g creatinine (β2-microglobulin cut-off level of 220 μg/g creatinine) (Järup 
and Elinder 1994), 25% among workers with urinary cadmium levels of 2–5 μg/g creatinine (cut-off level 
of 300 μg/g creatinine) (Elinder et al. 1985a), 40% among workers with urinary cadmium levels of 5–
10 μg/g creatinine (cut-off level of 187 μg/g creatinine) (Chen et al. 2006a), and 10% among workers 
with urinary cadmium levels of 10–15 μg/g creatinine (cut-off level of 380 μg/g creatinine (Jakubowski et 
al. 1987).  A 10% prevalence of abnormal β2-microglobulin levels (cut-off level of 300 μg/g creatinine) 
was also observed in workers with a cumulative blood cadmium level of 300 μg-years/L (30 years of 
10 μg/L) (Jakubowski et al. 1992) or blood cadmium level of 5.6 μg/L (cumulative exposure of 
691 μg-years/m3) (Järup et al. 1988). 
 
Most of the studies reporting respiratory effects expressed cadmium exposure as air concentrations; 
however, these air concentrations may not be indicative of cadmium exposure over time.  For example, in 
the Cortona et al. (1992) study, cadmium levels of 0.030 mg/m3 were measured in 1990 in one foundry; in 
1976, the cadmium levels in this foundry were 1.53 mg/m3.  Cortona et al. (1992) also reported cadmium 
body burden data; the mean urinary cadmium level in the workers was 4.3 μg/L (roughly equivalent to 
4 μg/g creatinine).  Renal effects have been observed at similar cadmium burdens.  Most studies have 
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reported renal effects in workers with urinary cadmium levels of ≥5 μg/g creatinine; Järup and Elinder 
(1994) found an increased prevalence of low molecular weight proteinuria in workers ≥60 years of age 
with mean urinary cadmium of 1.5 μg/g creatinine.  The air concentration that would result in this urinary 
cadmium level would be considered a LOAEL.  However, cadmium in the workplace air was not the only 
source of cadmium.  The workers were also exposed to other sources of cadmium (e.g., cadmium in the 
diet); both sources contributed to the renal cadmium burden.  Thus, in order to calculate a chronic-
duration inhalation MRL from the LOAEL identified in the Järup and Elinder (1994) study, the workers’ 
other sources of cadmium need to be taken into consideration; this information was not reported in the 
study.   
 
An alternative approach would be to use environmental exposure studies to establish a point of departure 
for the urinary cadmium-renal response relationship and pharmacokinetic models (ICRP 1994; Kjellström 
and Nordberg 1978) to predict cadmium air concentrations.  As described in greater detail in the chronic 
oral MRL section, a meta-analysis of available environmental exposure studies was conducted to estimate 
an internal dose (urinary cadmium expressed as μg/g creatinine) corresponding to a 10% excess risk of 
low molecular weight proteinuria (urinary cadmium dose, UCD10).  For the inhalation MRL, the meta-
analysis also included dose-response data from three occupational exposure studies (Chen et al. 2006a, 
2006b; Järup and Elinder 1994; Roels et al. 1993).  Analysis of the environmental exposure studies 
resulted in an estimation of a urinary cadmium level that would result in a 10% increase in the prevalence 
of β2-microglobulin proteinuria (1.34 μg/g creatinine); the 95% lower confidence limit on this value was 
0.5 μg/g creatinine.  The UCD10 values from the occupational exposure studies were 7.50 μg/g creatinine 
for the European cohorts (Järup and Elinder 1994; Roels et al. 1993) and 4.58 μg/g creatinine for the 
Chinese cohort (Chen et al. 2006a, 2006b).  Because the dose-response analysis using the European 
environmental exposure studies provided the lowest UCD10, it was selected for derivation of the chronic-
duration inhalation MRL; the 95% lower confidence limit on this value (UCDL10) of 0.5 μg/g creatinine 
was used as the point of departure for the MRL. 
 
Deposition and clearance of inhaled cadmium oxide and cadmium sulfide particles were modeled using 
the ICRP Human Respiratory Tract Model (ICRP 1994).  The ICRP model simulates deposition, 
retention, and absorption of inhaled cadmium particles of specific aerodynamic diameters, when specific 
parameters for cadmium clearance are used in the model (ICRP 1980).  Cadmium-specific parameters 
represent categories of solubility and dissolution kinetics in the respiratory tract (e.g., slow, S; moderate, 
M; or fast, F).  Cadmium compounds are classified as follows: oxides and hydroxides, S; sulfides, halides 
and nitrates, M; all other, including chloride salts, F.   
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Inhalation exposures (μg/m3) to cadmium oxide or cadmium sulfide aerosols having particle diameters of 
1, 5, or 10 μg (AMAD) were simulated using the ICRP model.  Predicted mass transfers of cadmium from 
the respiratory tract to the gastrointestinal tract (i.e., mucociliary transport) and to blood (i.e., absorption) 
were used as inputs to the gastrointestinal and blood compartments of the Nordberg-Kjellström 
pharmacokinetic model (Kjellström and Nordberg 1978) to simulate the kidney and urinary cadmium 
levels that correspond to a given inhalation exposure.   
 
As illustrated in Figure 2-1, an airborne cadmium concentration of 1.8–2.4 μg/m3 as cadmium oxide or 
1.2–1.4 μg/m3 as cadmium sulfide would result in a urinary cadmium level of 0.5 μg/g creatinine, 
assuming that there was no dietary source of cadmium.  This assumption is not accurate because the diet 
is a significant contributor to the cadmium body burden.  Thus, inhalation exposures were combined with 
ingestion intakes to estimate an internal dose in terms of urinary cadmium.  The age-weighted average 
intakes of cadmium in non smoking males and females in the United States are 0.35 and 0.30 μg 
Cd/kg/day, respectively (0.32 μg/kg/day for males and females combined) (estimated from data in 
Choudhury et al. 2001).  Based on the relationship predicted between chronic inhalation exposures to 
cadmium sulfide (activity median aerodynamic diameter [AMAD]=1 μm) and oral intakes that yield the 
same urinary cadmium level (Figure 2-1), exposure to an airborne cadmium concentration of 0.1 μg/m3 
and a dietary intake of 0.3 μg/kg/day would result in a urinary cadmium level of 0.5 μg/g creatinine.  
Dividing this cadmium air concentration (0.1 μg Cd/m3) by an uncertainty factor of 3 for human 
variability and a modifying factor of 3 results in chronic-duration inhalation MRL of 0.01 μg Cd/m3.  The 
uncertainty factor of 3 for human variability was used to account for the possible increased sensitivity of 
diabetics (Åkesson et al. 2005; Buchet et al. 1990) and the modifying factor of 3 was used to account for 
the lack of adequate human data, which could be used to compare the relative sensitivities of the 
respiratory tract and kidneys.  Although based on exposure to cadmium sulfide, the MRL would be 
protective of exposure to cadmium oxide; the pharmacokinetic models predict that exposure to 0.1 μg/m3 
as cadmium oxide (AMAD=1 μm) in combination with a dietary intake of 0.3 μg/kg/day would result in a 
urinary cadmium level of 0.4 μg/g creatinine. 
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Figure 2-1.  Combined Chronic Oral Cadmium Intakes (μg/kg/day) and Inhalation 
Cadmium Exposures (μg/m3) that Achieve a Urinary Cadmium Excretion of 
0.5 μg/g Creatinine at Age 55 Years Predicted by the Cadmium  
Pharmacokinetic Model and the International Commission on  
Radiological Protection (ICRP) Human Respiratory  
Tract Model*   
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*The upper panel shows simulations of inhalation exposures to cadmium oxide (AMAD=1, 5, or 10 μm); the lower 
panel shows simulations of inhalation cadmium sulfide aerosols. 
 
 
CADMIUM  25 
 
2.  RELEVANCE TO PUBLIC HEALTH 
 
 
 
 
 
 
 
 
Oral MRLs 
 
Acute-Duration Oral MRL 
 
There are no reliable studies on the acute toxicity of cadmium in humans; animal studies have identified 
several targets of toxicity.  High exposures (>10 mg Cd/kg/day) to cadmium chloride administered via 
gavage or drinking water resulted in increases in hematological (increased hemoglobin, hematocrit, and 
erythrocytes, anemia), liver (focal necrosis and degeneration), kidney (focal necrosis of tubular 
epithelium), intestine (necrosis, hemorrhage, ulcers), stomach (gastritis, necrosis), neurological 
(decreased motor activity), and testicular (atrophy and necrosis, loss of spermatogenic elements) effects 
and decreases in body weight in rats and mice (Andersen et al. 1988; Basinger et al. 1988; Bomhard et al. 
1987; Borzelleca et al. 1989; Dixon et al. 1976; Kotsonis and Klaassen 1977; Machemer and Lorke 1981; 
Sakata et al. 1988; Shimizu and Morita 1990).  The NOAELs for these effects ranged from 1.12 to 
65.6 mg Cd/kg/day. 
 
 
Developmental effects have been observed at lower cadmium doses.  Delayed ossification of the sternum 
and ribs was observed in the offspring of rats administered 2 mg Cd/kg/day via gavage on gestation 
days 7–16; at 40 mg Cd/kg/day, fused lower limbs, decreased number of live fetuses, and increased 
resorptions were observed (Baranski 1985).  A significant increase in malformations was observed in the 
offspring of rats administered 18.39 mg Cd/kg/day on gestation days 6–15 (Machemer and Lorke 1981); 
no developmental effects were observed in the offspring of rats administered 12.5 mg Cd/kg/day via 
drinking water on gestation days 6–15 (Machemer and Lorke 1981).   
Although the Baranski (1985) study identified the lowest LOAEL (2 mg Cd/kg/day) following acute-
duration exposure, this study was not considered suitable for derivation of an MRL.  The investigators 
noted that “a retarded process of ossification of the sternum and ribs was observed after exposure to 
cadmium at any of the doses used.”  However, the data were not shown and the statistical significance of 
the finding was not reported.  Additionally, an intermediate-duration study conducted earlier by this 
investigator (Baranski et al. 1983) did not find delays in ossification in the offspring of rats administered 
up to 4 mg Cd/kg/day for 5 weeks prior to mating, during the 3-week mating period, and throughout 
gestation. 
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Because of the amount of uncertainty associated with the most sensitive end point, an acute-duration oral 
MRL was not derived. 
 
Intermediate-Duration Oral MRL 
 
• An MRL of 0.5 μg Cd/kg/day has been derived for intermediate-duration oral exposure (15–
364 days) to cadmium. 
 
There are limited data on the toxicity of cadmium in humans following intermediate-duration exposure.  
Numerous animal studies have examined the systemic, immunological, neurological, reproductive, and 
developmental toxicity of cadmium.  The most sensitive systemic effect following intermediate-duration 
oral exposure to cadmium appears to be damage to growing bone.  Exposure to 0.2 mg Cd/kg/day as 
cadmium chloride in drinking water for 3–12 months resulted in decreases in bone mineral density, 
impaired mechanical strength of the lumbar spine, tibia, and femur bones, increased bone turnover, and 
increased incidence of deformed or fractured lumbar spine bone in young female rats (3 weeks of age at 
study initiation) (Brzóska and Moniuszko-Jakoniuk 2005d; Brzóska et al. 2004b, 2005a, 2005b, 2005c, 
2010); similar findings were observed in young male rats exposed to 0.5 mg Cd/kg/day for up to 
12 months (Brzóska and Moniuszko-Jakoniuk 2005a, 2005b).  Decreases in bone strength were also 
observed in young rats exposed to 0.8 mg Cd/kg/day as cadmium chloride in drinking water for 4 weeks 
(Ogoshi et al. 1989); however, no skeletal effects were observed in adult or elderly female rats exposed to 
doses >20 mg Cd/kg/day for 4 weeks (Ogoshi et al. 1989).  Decreases in bone calcium were observed in 
mice undergoing repeated pregnancy/lactation periods (Bhattacharyya et al. 1988b) or ovariectomized 
mice (Bhaattacharyya et al. 1988c); these changes were not observed in groups not under physiological 
stress. 
 
Renal effects have been observed at higher doses than the skeletal effects.  Vesiculation of the proximal 
tubules was observed in rats exposed to 1.18 mg Cd/kg/day as cadmium chloride in drinking water for 
40 weeks (Gatta et al. 1989).  At approximately 3–8 mg Cd/kg/day, proteinuria, tubular necrosis, and 
decreased renal clearance were observed in rats (Cha 1987; Itokawa et al. 1974; Kawamura et al. 1978; 
Kotsonis and Klaassen 1978; Prigge 1978a).  Liver necrosis and anemia (Cha 1987; Groten et al. 1990; 
Kawamura et al. 1978) were observed at similar cadmium doses. 
 
Immunological effects have been observed in studies of monkeys, rats, and mice.  The observed effects 
include increases in cell-mediated immune response in monkeys exposed to 5 mg Cd/kg/day as cadmium 
chloride in the diet for 10 weeks (Chopra et al. 1984), decreased humoral immune response in mice 
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exposed to 2.8 mg Cd/kg/day as cadmium chloride in drinking water for 3 weeks (Blakley 1985), and 
greater susceptibility to lymphocytic leukemia virus in mice exposed to 1.9 mg Cd/kg/day as cadmium 
chloride in drinking water for 280 days (Blakley 1986).   
 
 
 
Neurological effects observed in rats include decreases in motor activity at 3.1 or 9 mg Cd/kg/day 
(Kotsonis and Klaassen 1978; Nation et al. 1990) and increased passive avoidance at 5 mg Cd/kg/day 
(Nation et al. 1984).  Reproductive effects (necrosis and atrophy of seminiferous tubules, decreased sperm 
count and motility) were observed in rats exposed to 8–12 mg Cd/kg/day (Cha 1987; Saxena et al. 1989). 
A number of developmental effects have been observed in the offspring of rats exposed to cadmium 
during gestation and lactation.  Decreases in glomerular filtration rates and increases in urinary fractional 
excretion of phosphate, magnesium, potassium, sodium, and calcium were observed in 60-day-old 
offspring of rats administered via gavage 0.5 mg Cd/kg/day on gestation days 1–21 (Jacquillet et al. 
2007).  Neurodevelopmental alterations have also been observed at the low maternal doses.  Delays in the 
development of sensory motor coordination reflexes and increased motor activity were observed at 
0.706 mg Cd/kg/day (gestation days 1–21) (Ali et al. 1986), decreased motor activity at 0.04 mg 
Cd/kg/day (5–8 weeks of pre-gestation exposure, gestation days 1–21) (Baranski et al. 1983), decreased 
ambulation and rearing activity and altered ECG at 14 mg Cd/kg/day (gestation days 5–15, lactation days 
2–28, postnatal days 1–56) (Desi et al. 1998) or 7 mg Cd/kg/day (F2 and F3 generations) (Nagymajtenyi et 
al. 1997) have been observed.  Decreases in pup body weight were observed at ≥5 mg Cd/kg/day 
(Baranski 1987; Gupta et al. 1993; Kostial et al. 1993; Pond and Walker 1975) and decreases in fetal body 
weight or birth weight were observed at ≥2.4 mg Cd/kg/day (Petering et al. 1979; Sorell and Graziano 
1990; Webster 1978; Sutou et al. 1980).  Another commonly reported developmental effect was 
alterations in hematocrit levels or anemia in the offspring of animals exposed to ≥1.5 mg Cd/kg/day 
(Baranski 1987; Kelman et al. 1978; Webster 1978).  Increases in the occurrence of malformations or 
anomalies is limited to a study by Sutou et al. (1980), which reported a significant delay in ossification in 
rats exposed to 10 mg Cd/kg/day. 
The animal studies identify several sensitive targets of toxicity following intermediate-duration exposure 
to cadmium; these include skeletal mineralization in young female rats exposed for at least 3 months to 
0.2 mg Cd/kg/day (Brzóska and Moniuszko-Jakoniuk 2005d; Brzóska et al. 2004b, 2005a, 2005b, 2005c), 
decreased glomerular filtration in young rats exposed during gestation to maternal doses of 0.5 mg 
Cd/kg/day (Jacquillet et al. 2007), and neurodevelopmental effects following gestational exposure to 
0.04 mg Cd/kg/day (Baranski et al. 1983).  Although the Baranski et al. (1983) study reported the lowest 
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LOAEL, it was not selected as the principal study for derivation of an intermediate-duration MRL.  For 
locomotor activity, a significant decrease in activity was observed in female offspring exposed to 0.04, 
0.4, and 4 mg Cd/kg/day, as compared to controls; however, no significant differences were found 
between the cadmium groups despite the 100-fold difference in doses.  Locomotor activity was also 
decreased in males exposed to 0.4 or 4 mg Cd/kg/day.  For the rotorod test, a significant decrease in the 
length of time the rat stayed on the rotorod was observed in males exposed to 0.04 and 0.4 mg Cd/kg/day, 
but not to 4 mg Cd/kg/day and in females exposed to 0.4 and 4 mg Cd/kg/day; no differences between the 
cadmium groups were observed in the males and females.  The results were not well described and the 
investigators did not explain the lack of dose-response of the effects or the discrepancy between genders. 
 
 
The skeletal effects observed in young rats exposed to cadmium during the period of rapid skeletal growth 
and mineralization was selected as the critical effect.  The Brzóska and associate study (Brzóska and 
Moniuszko-Jakoniuk 2005d; Brzóska et al. 2005a, 2005c) was selected as the principal study.  In this 
study, groups of 40 3-week-old female Wistar rats were exposed to 0, 1, 5, or 50 mg Cd/L as cadmium 
chloride in drinking water for 12 months.  The investigators noted that cadmium intakes were 0.059–
0.219, 0.236–1.005, and 2.247–9.649 mg Cd/kg/day in the 1, 5, and 50 mg/L groups, respectively.  Using 
cadmium intake data presented in a figure, cadmium intakes of 0.2, 0.5, and 4 mg Cd/kg/day were 
estimated.  Bone mineral density, bone mineral concentration, and mineralization area of the lumbar 
spine, femur, and total skeleton (bone mineral density only) were assessed after 3, 6, 9, or 12 months of 
exposure.  The mechanical properties of the femur and tibia were evaluated after 12 months of exposure.  
Markers for bone resorption (urinary and serum levels of C-terminal cross-linking telopeptide of type I 
collagen [CTX]) and bone formation (serum osteocalcin, total alkaline phosphatase, and cortical bone and 
trabecular bone alkaline phosphatase), and serum and urinary levels of calcium were also measured at 3, 
6, 9, and 12 months.   
No significant alterations in body weight gain or food and water consumption were observed.  Significant 
decreases in total skeletal bone mineral density was observed at ≥0.2 mg Cd/kg/day; the decrease was 
significant after 3 months in the 4 mg Cd/kg/day group, after 6 months in the 0.5 mg Cd/kg/day group, 
and after 9 months in the 0.2 mg Cd/kg/day group.  Significant decreases in whole tibia and diaphysis 
bone mineral density were observed at ≥0.2 mg Cd/kg/day after 12 months of exposure.  At 0.2 mg 
Cd/kg/day, bone mineral density was decreased at the proximal and distal ends of the femur after 
6 months of exposure; diaphysis bone mineral density was not affected.  At 0.5 mg Cd/kg/day, bone 
mineral density was decreased at the femur proximal and distal ends after 3 months of exposure and 
diaphysis bone mineral density after 6 months of exposure.  At 4 mg Cd/kg/day decreases in femoral 
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proximal, distal, and diaphysis bone mineral density were decreased after 3 months of exposure.  
Similarly, bone mineral density was significantly decreased in the lumbar spine in the 0.2 and 0.5 mg 
Cd/kg/day groups beginning at 6 months and at 3 months in the 4 mg Cd/kg/day group.  Significant 
decreases in the mineralization area were observed in the femur and lumbar spine of rats exposed to 4 mg 
Cd/kg/day; lumbar spine bone mineral area was also affected at 0.5 mg Cd/kg/day.  Significant decreases 
in tibia weight and length were observed at 4 mg Cd/kg/day.  In tests of the mechanical properties of the 
tibia diaphysis, significant alterations in ultimate load, yield load, and displacement at load were observed 
at ≥0.2 mg Cd/kg/day; work to fracture was also significantly altered at 4 mg Cd/kg/day.  In the 
mechanical properties compression tests of the tibia, significant alterations were observed in ultimate 
load, ultimate load, and stiffness at 0.2 mg Cd/kg/day; displacement at yield and work to fracture at 
≥0.5 mg Cd/kg/day; and displacement at ultimate at 4 mg Cd/kg/day.  Multiple regression analysis 
showed that the cadmium-induced weakness in bone mechanical properties of the tibia was primarily due 
to its effects on bone composition, particularly the non-organic components, organic components, and the 
ratio of ash weight to organic weight.  The mechanical properties of the femur were strongly influenced 
by the bone mineral density (at the whole bone and diaphysis).  A significant decrease in femur length 
was observed at 6 months of exposure to ≥0.2 mg Cd/kg/day; however, decreases in length were not 
observed at other time points in the 0.2 or 0.5 mg Cd/kg/day groups.  Femur weight was significantly 
decreased at 4 mg Cd/kg/day.  In tests of mechanical properties of the femur (neck and distal portions), 
decreases in yield load, ultimate load, displacement at ultimate, work to fracture (neck only), and stiffness 
(distal only) were observed at ≥0.2 mg Cd/kg/day.  For the femoral diaphysis, significant alterations were 
observed for yield load, displacement at yield, and stiffness at ≥0.2 mg Cd/kg/day.  Significant decreases 
in osteocalcin concentrations were observed in all cadmium groups during the first 6 months of exposure, 
but not during the last 6 months.  Decreases in total alkaline phosphatase levels at 4 mg Cd/kg/day, 
trabecular bone alkaline phosphatase at 0.2 mg Cd/kg/day, and cortical bone alkaline phosphatase at 4 mg 
Cd/kg/day were observed.  CTX was decreased at ≥0.2 mg Cd/kg/day.  Total urinary calcium and 
fractional excretion of calcium were increased at ≥0.2 mg Cd/kg/day. 
 
At the lowest dose tested, 0.2 mg Cd/kg/day, a number of skeletal alterations were observed including 
decreases in bone mineral density in the lumbar spine, femur, and tibia, alterations in the mechanical 
properties of the femur and tibia, decreases in osteocalcin levels, decreases in trabecular bone alkaline 
phosphatase, and decreases in CTX.  Of these skeletal end points, the decrease in bone mineral density 
was selected as the critical effect because Brzóska et al. (2005a, 2005c) demonstrated that the bone 
mineral density was a stronger predictor of femur and tibia strength and the risk of fractures.  As 
discussed in greater detail in Appendix A, available continuous models in the EPA Benchmark Dose 
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Software (version 1.4.1c) were fit to data for changes in bone mineral density of the femur and lumbar 
spine in female rats resulting from exposure to cadmium in the drinking water for 6, 9, or 12 months 
(Brzóska and Moniuszko-Jakoniuk 2005d).  The benchmark dose (BMD) and the 95% lower confidence 
limit (BMDL) is an estimate of the doses associated with a change of 1 standard deviation from the 
control.  The BMDLsd1 derived from the best fitting models for each dataset ranged from 0.05 to 0.17 mg 
Cd/kg/day.  The BMDLsd1 of 0.05 mg Cd/kg/day estimated from the 9-month lumbar spine data set was 
selected as the point of departure for the MRL.  In young female rats, the process of intense bone 
formation occurs during the first 7 months of life (the first 6 months of exposure in this study); thereafter, 
the increase in bone mineral density slows.  In the lumbar spine of the control group, the changes in bone 
mineral density at 3–6 months, 6–9 months, and 9–12 months were 15, 4, and 1%, respectively.  Thus, the 
9-month data may best reflect the effect of cadmium on bone mineral density during the period of rapid 
skeletal growth.  The lumbar spine data was selected over the femur data set because trabecular bone, 
which is abundant in the spine, appears to be more susceptible to cadmium toxicity than cortical bone.  
The BMDLsd1 was divided by an uncertainty factor of 100 (10 for extrapolation from animals to humans 
and 10 for human variability) resulting in an intermediate-duration oral MRL of 0.5 μg Cd/kg/day. 
 
Chronic-Duration Oral MRL 
 
• An MRL of 0.1 μg/kg/day has been derived for chronic-duration oral exposure (≥1 year) to 
cadmium. 
 
The database examining the chronic toxicity of cadmium following oral exposure is extensive.  Although 
there are some chronic studies in animals, the majority of the studies in the chronic database examine the 
relationship between urinary cadmium levels (or cumulative cadmium intake) and adverse health effects 
in the general population or in populations living in cadmium polluted areas.  A variety of health effects 
have been observed including skeletal defects (osteoporosis, increased bone fractures, decreased bone 
mineral density), kidney dysfunction, and alterations in reproductive hormone levels.  These 
environmental exposure studies strongly support the identification of bone and kidney as the most 
sensitive targets of chronic cadmium toxicity.   
 
Bone effects, particularly osteomalacia and/or osteoporosis and increased bone fractures, were first 
reported in Japanese women living in areas with heavy cadmium contamination.  Chronic cadmium 
exposure has been shown to play a role in this disorder, referred to as Itai-Itai disease; however, other 
factors such as multiple pregnancies, poor nutrition (low calories, calcium, protein, vitamin D, and iron 
intakes), and low zinc levels in food also play important roles in the etiology.  Although a conclusive role 
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of cadmium in Itai-Itai has not been established, several other studies have found bone defects.  Observed 
bone effects include increased risk of bone fractures in postmenopausal women with urinary cadmium 
levels of >1 μg/day (approximately >0.7 μg Cd/g creatinine; Staessen et al. 1999), individuals (>50 years 
of age) with urinary cadmium levels of >2 μg/g creatinine (Alfvén et al. 2004), and men and women 
(>40 years of age) with urinary cadmium levels of 9.20 and 12.86 μg/g creatinine, respectively (Wang et 
al. 2003); increased risk of osteoporosis in men (>60 years of age) with urinary cadmium levels of 
≥1.5 μg/g creatinine (Alfvén et al. 2000), in males and females with urinary cadmium levels of ≥10 μg/g 
creatinine (Jin et al. 2004b), in males and females (>40 years of age) with urinary cadmium levels of 
9.20 and 12.86 μg/g creatinine, respectively (Wang et al. 2003), and women with renal tubular damage 
(urinary NAG ≥12 IU/g creatinine) (Chen et al. 2011); and decreased bone mineral density in women 
with urinary cadmium levels of >0.6 μg/g creatinine (Schutte et al. 2008), postmenopausal women with 
urinary cadmium levels of >20 μg/g creatinine (Nordberg et al. 2002), postmenopausal women with 
median urinary cadmium levels of 1.1 µg/g creatinine (Engström et al. 2009), and men with urinary 
cadmium levels of ≥2 µg/g creatinine (Trzcinka-Ochocka et al. 2010).   
 
Evidence of renal dysfunction in environmentally exposed populations include increases in deaths from 
renal dysfunction in residents living in cadmium polluted areas of Japan (Arisawa et al. 2001, 2007b; 
Iwata et al. 1991a, 1991b; Matsuda et al. 2002; Nakagawa et al. 1993; Nishijo et al. 1995, 2004a, 2006), 
increases in renal replacement therapy which is indicative of severe renal dysfunction (Hellström et al. 
2001), and increases in the excretion of biomarkers of renal dysfunction in association with increased 
cadmium intake, increased renal cadmium concentrations, increased blood cadmium levels, and/or 
increased urinary cadmium concentrations (Bandara et al. 2010; Buchet et al. 1990; Cai et al. 1990, 1992, 
1998, 2001; Ferraro et al. 2010; Hayano et al. 1996; Honda et al. 2010; Horiguchi et al. 2004, 2010; 
Hwangbo et al. 2011; Ishizaki et al. 1989; Izuno et al. 2000; Järup et al. 2000; Jin et al. 2002, 2004a, 
2004c; Kawada et al. 1992; Kido and Nogawa 1993; Kobayashi et al. 2002a, 2009b; Monzawa et al. 
1998; Nakadaira and Nishi 2003; Nakashima et al. 1997; Nogawa et al. 1989; Noonan et al. 2002; 
Nordberg et al. 1997; Olsson et al. 2002; Oo et al. 2000; Osawa et al. 2001; Roels et al. 1981b; Suwazono 
et al. 2006; Teeyakasem et al. 2007; Trzcinka-Ochocka et al. 2004; Uno et al. 2005; Yamanaka et al. 
1998; Wu et al. 2001).  The urinary excretion of several biomarkers have been shown to increase due to 
cadmium-related alterations in kidney function; these biomarkers include low molecular weight proteins 
(e.g., β2-microglobulin, pHC, retinol binding protein), intracellular tubular enzymes (e.g., NAG), amino 
acids, high molecular weight proteins (e.g., albumin), metallothionein, and electrolytes (e.g., potassium, 
sodium, calcium).  Although the more severe renal effects have been observed in populations living in 
highly contaminated areas (e.g., decreased glomerular filtration rate), alterations in the above biomarkers 
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have been observed in areas not considered to be cadmium polluted.  Alterations in these biomarker levels 
appear to be the most sensitive indicator of cadmium toxicity.  Many of the studies examining biomarkers 
have reported significant correlations between urinary cadmium levels and biomarker levels.  However, 
these correlations do not provide insight into exposure levels associated with renal dysfunction.  In this 
MRL analysis, attention was given to dose-response studies examining the derived quantitative 
relationships between cadmium exposure and the prevalence of abnormal biomarker levels.  As discussed 
in the inhalation MRL section, a 10% increase in the prevalence of abnormal biomarker levels 
(particularly β2-microglobulin, pHC, or retinol binding protein) in association with increasing cadmium 
exposure is generally considered to be indicative of cadmium-associated renal dysfunction in populations.  
However, when examining the prevalence of abnormal levels, careful consideration should be given to the 
response criterion (cut-off level) used in the study.  A wide range of cut-off levels have been used in the 
environmental exposure studies.  For β2-microglobulin, the most commonly used biomarker, the cut-off 
values ranged from 283 to 1,129 μg/g creatinine.  A summary of environmental studies finding significant 
dose-response associations between urinary cadmium (or cumulative cadmium intake) and the prevalence 
of abnormal levels of urinary biomarkers of renal dysfunction is presented in Table 2-1.  The adverse 
effect levels range from urinary cadmium levels of 1 μg/g creatinine (Järup et al. 2000) to 9.51 μg/g 
creatinine (Jin et al. 2004a). 
 
 
The adverse effect levels for renal effects were similar to those observed for skeletal effects.  Because the 
renal effects database is stronger, it was used for derivation of a chronic-duration oral MRL for cadmium.  
Several approaches were considered for derivation of the MRL:  (1) NOAEL/LOAEL approach using a 
single environmental exposure study finding an increased prevalence of abnormal renal effect biomarker 
levels, (2) selection of a point of departure from a published benchmark dose analysis, or (3) selection of 
a point of departure based on an analysis of the dose-response functions from a number of environmental 
exposure studies. 
In the first approach, all studies in which individual internal doses for subjects were estimated based on 
urinary cadmium were considered.  The Järup et al. (2000) study is selected as the principal study because 
it identified the lowest adverse effect level (Table 2-1).  In this study, 1,021 individuals living near a 
nickel-cadmium battery factory (n=799) or employed at the factory (n=222) were examined.  The mean 
urinary cadmium concentrations were 0.81 μg/g creatinine in men and 0.65 μg/g creatinine in women.  A 
significant association was found between urinary cadmium concentrations and urinary pHC levels, after 
adjustment for age; the association remained statistically significant after removal of the cadmium 
workers from the analysis.  The investigators estimated that a urinary cadmium level of 1 μg/g creatinine  
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Table 2-1.  Summary of Human Studies Finding Dose-Response Relationships 
Between Biomarkers of Renal Dysfunction and Cadmium Exposure 
 
Population  
Effect 
biomarker Response criterion 
Adverse 
effect level 
(urinary 
cadmium) Reference 
General population (Japan) 
 
General population 
(Belgium) 
 
Residents in cadmium-
polluted area (China) 
Residents in cadmium-
polluted area (China)  
Residents in cadmium-
polluted area (China) 
Residents in cadmium-
polluted area (China)  
Residents in cadmium-
polluted area (Japan) 
Residents in cadmium-
polluted area (Japan) 
 
Residents in cadmium-
polluted area (Japan) 
 
Total prt 
 
β2M 
 
NAG 
β2M 
RBP 
NAG 
amino acid 
calcium 
β2M 
β2M  
RBP 
albumin 
β2M  
NAG 
albumin 
β2M  
 
β2M 
β2M  
 
β2M  
 
157.4 μg/g creat. (M) 
158.5 μg/g creat. (F) 
507 μg/g creat. (M) 
400 μg/g creat. (F) 
8.2 μg/g creat. (M) 
8.5 μg/g creat. (F) 
283 μg/24 hours 
338 μg/24 hours 
3-6 IU/24 hours 
357 mg α-N/24 hours 
4-9 mmol/24 hours 
355 μg/g creat. (M <45 years) 
>2,500 μg/g creat. (M ≥45 years) 
500 μg/g creat. (F) 
300 μg/g creat. 
300 μg/g creat. 
15 mg/g creat. 
800 μg/g creat. 
15 U/g creat. 
20 mg/g creat. 
800 μg/g creat. 
1,000 μg/g creat. 
1,000 μg/g creat. (M,F) 
 
1,129 μg/g creat. (M) 
1,059 μg/g creat. (F) 
 
a2.4 μg/g creat.  
1.92 μg/g 
bcreat.  
4–7.99 μg/g 
ccreat.  
≥5 μg/g creat. 
9.51 μg/g 
creat. 
2–4 μg/g 
ccreat.  
6.9 μg/g creat. 
Cadmium 
intake: 
150 μg/day 
 
4–4.9 μg/g 
ccreat.  
 Suwazono et 
 al. 2006
Buchet et al. 
1990 
Cai et al. 
1998 
Jin et al. 
2002 
Jin et al. 
2004a 
Nordberg et 
al. 1997 
Cai et al. 
2001 
Nogawa et 
al. 1989; 
Kido and 
Nogawa 
1993 
Ishizaki et al. 
1989; 
Hayano et al. 
1996 
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Table 2-1.  Summary of Human Studies Finding Dose-Response Relationships 
Between Biomarkers of Renal Dysfunction and Cadmium Exposure 
 
Population  
Effect 
biomarker Response criterion 
Adverse 
effect level 
(urinary 
cadmium) Reference 
Residents in cadmium-
polluted area (Thailand) 
β2M  
 
400 μg/g creat. 6–10 μg/g 
creat. 
Teeyakasem 
et al. 2007 
Residents in cadmium-
polluted area (includes 
occupationally exposed 
subjects (Sweden) 
pHC 7.1 mg/g creat. (M) 
5.3 mg/g creat. (F) 
1 μg/g creat.d Järup et al. 
2000 
 
aMean urinary cadmium level  
b>10% prevalence of abnormal β2-microglobulin, retinal binding protein, amino acid, and calcium values at 3.05, 
2.87, 2.74, 4.29, or 1.92 μg/24 hours, respectively. 
cUrinary cadmium level associated with an approximate doubling of prevalence of abnormal β2-microglobulin levels 
dThe European Chemicals Bureau (2007) recalculated this value (using raw data from Järup et al. 2000) to account 
for differences in age of the reference population and study population; based on these recalculations, a doubling of 
the probability of abnormal pHC values would occur at 2.62 μg/g creatinine for the total population and a 0.5 μg/g 
creatinine for the environmentally exposed population. 
 
AAP = alanine aminopeptidase; β2M = β2-microglobulin; creat. = creatinine; F = female; M = male; NAG = N-acetyl-
β-glucosaminidase; pHC = human complex-forming glycoprotein, also referred to as α1M; RBP = retinol binding 
protein 
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would be associated with a 10% increase in the prevalence of abnormal pHC levels above background 
prevalence (approximately a 10% added risk).  However, the European Chemicals Bureau (2007) 
recalculated the probability of HC proteinuria because the reference population and the study population 
were not matched for age (40 versus 53 years, respectively).  They estimated that the probability of HC 
proteinuria (13%) would be twice as high as the reference population at a urinary cadmium concentration 
of 0.5 μg/g creatinine.   
 
 
The second approach involves the evaluation of eight published benchmark dose analyses.  The 
benchmark doses and the lower 95% confidence interval of the benchmark dose (BMDL) for low 
molecular weight proteinuria are presented in Table 2-2 (benchmark doses and BMDLs for all effect 
parameters are presented in Table 3-8 in the toxicological profile).  The BMDL values corresponding to a 
10% increase in the prevalence of low molecular weight proteinuria above background (excess risk) 
ranged from 0.7 μg/g creatinine (Uno et al. 2005) to 9.9 μg/g creatinine (Kobayashi et al. 2006).  Both 
studies examined populations living in non-cadmium polluted areas of Japan and used β2-microglobulin 
as the effect biomarker.  The large difference in cut-off values (233 versus 784 μg/g creatinine) likely 
contributed to the order of magnitude difference in BMDLs.  The BMDL10 of 0.7 μg/g creatinine is 
supported by the Suwazono et al. (2006) benchmark dose analysis, which found a similar BMDL10 
(0.81 μg/g creatinine) using pHC as the effect biomarker.  The Uno et al. (2005) study examined 410 men 
and 418 women (aged 40–59 years) living in three areas of Japan without any known environmental 
cadmium pollution.  Mean urinary cadmium concentrations were 1.3 and 1.6 μg/g creatinine in men and 
women, respectively.  Cut-off levels for β2-microglobulin were 233 and 274 μg/g creatinine in males and 
females; these values represent the 84% upper limit values calculated from the target population assuming 
a log normal distribution. 
The third approach involved a meta-analysis of selected environmental exposure dose-response studies.  
Studies were selected for inclusion in this analysis based on the following qualitative criteria:  (1) the 
study measured urinary cadmium as indicator of internal dose; (2) the study measured reliable indicators 
of low molecular weight (LMW) proteinuria; (3) a dose-response relationship was reported in sufficient 
detail so that the dose-response function could be reproduced independently; (4) the study was of 
reasonable size to have provided statistical strength to the estimates of dose-response model parameters 
(i.e., most studies selected included several hundred to several thousand subjects); and (5) major co-
variables that might affect the dose-response relationship (e.g., age, gender) were measured or constrained 
by design and included in the dose-response analysis.  No attempt was made to weight selected studies for 
quality, statistical power, or statistical uncertainty in dose-response parameters.  Studies using a cut-off  
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Table 2-2.  Selected Benchmark Dose Estimations of Urinary Cadmium  
Levels Associated with Increases in the Prevalence of  
Low Molecular Weight Proteinuria 
 
Study 
population 
Effect 
biomarker 
Response 
criterion 
BMD 
model 
5% BMR 10% BMR 
Reference BMD BMDL BMD BMDL 
General 
population 
(Sweden) 
pHC 6.8 mg/g creat. 
(95% cut-off)a 
Profile 
likelihood 
method 
0.63 (F) 0.49 (F) 1.05 (F) 0.81 (F) Suwazono 
et al. 2006 
Residents in 
cadmium-
polluted and 
non-polluted 
areas (Japan) 
 
β2M 507 μg/g creat. (M) 
400 μg/g creat. (F) 
(84% cut-off)b 
Quantal 
linear 
model 
1.5 (M) 
1.4 (F) 
1.2 (M) 
1.1 (F) 
3.1 (M) 
2.9 (F) 
2.5 (M) 
2.3 (F) 
Shimizu et 
al. 2006 
994 μg/g creat. (M) 
784 μg/g creat. (F) 
(95% cut-off)c 
2.3 (M) 
1.7 (F) 
1.8 (M) 
1.4 (F) 
4.7 (M) 
3.5 (F) 
3.7 (M) 
2.9 (F) 
Residents in 
cadmium-
pollutedd and 
nonpolluted 
areas (Japan) 
β2M 915.5 µg/g creat. 
(M) 
897.1 µg/g creat. 
(F) 
(95% cut-off)e 
Profile 
likelihood 
method 
4.0 (M) 
4.0 (F) 
3.5 (M) 
(3.7 )F) 
Not calculated Suwazono 
et al. 2011b 
General 
population 
(Japan) 
 
β2M 507 μg/g creat. (M) 
400 μg/g creat. (F) 
(84% cut-off)f 
Log-
logistic 
model 
2.9 (M) 
3.8 (F) 
2.4 (M) 
3.3 (F) 
5.0 (M) 
6.6 (F) 
4.0 (M) 
5.5 (F) 
Kobayashi 
et al. 2006 
994 μg/g creat. (M) 
784 μg/g creat. (F) 
(95% cut-off)g 
6.4 (M) 
8.7 (F) 
4.5 (M) 
7.3 (F) 
10.2 (M) 
12.0 (F) 
7.1 (M) 
9.9 (F) 
General 
population 
(Japan) 
β2M 492 µg/g creat. (M) 
407 µg/g creat. (F) 
(84% cut-off)h 
Multiple 
logistic 
model 
3.0 (M) 
3.4 (F) 
2.7 (M) 
3.2 (F) 
5.0 (M) 
5.7 (F) 
4.6 (M) 
5.4 (F) 
Kobayashi 
et al. 2008a 
965 µg/g creat. (M) 
798 µg/g creat. (F) 
(97.5% cut-off)i 
4.9 (M) 
5.9 (F) 
4.5 (M) 
5.6 (F) 
 
7.4 (M) 
8.6 (F) 
6.8 (M) 
8.1 (F) 
General 
population 
(Japan) 
 
β2M 708 µg/g creat. (M) 
415 µg/g creat. (F) 
(95% cut-off)j 
Profile 
likelihood 
method 
3.4 (M) 
1.7 (F) 
2.6 (M) 
1.4 (F) 
Not calculated Suwazono 
et al. 2011c 
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Table 2-2.  Selected Benchmark Dose Estimations of Urinary Cadmium  
Levels Associated with Increases in the Prevalence of  
Low Molecular Weight Proteinuria 
 
Study 
population 
Effect 
biomarker 
Response 
criterion 
BMD 
model 
5% BMR 10% BMR 
Reference BMD BMDL BMD BMDL 
General 
population 
(Japan) 
β2M 233 μg/g creat. (M) 
274 μg/g creat. (F) 
(84% cut-off)k 
Quantal 
linear 
model 
0.5 (M) 
0.9 (F) 
0.4 (M) 
0.8 (F) 
1.0 (M) 
1.8 (F) 
0.7 (M) 
1.3 (F) 
Uno et al. 
2005 
Residents in 
cadmium 
highly, or 
moderately 
polluted area 
(China) 
β2M 800 μg/g creat. 
(95% cut-off)l 
Quantal 
linear 
logistic 
regression 
model 
5.86 (M) 
9.98 (F) 
4.74 (M) 
8.47 (F) 
  Jin et al. 
2004c 
RBP 0.300 mg/g creat. 
(95% cut-off)l 
5.99 (M) 
9.03 (F) 
4.87 (M) 
7.63 (F) 
  
 
a95th percentile of effect biomarkers on the “hypothetical” control distribution at a urinary cadmium level of zero. 
b84% upper limit values from a group of 424 males and 1,611 females who did not smoke and lived in three different 
cadmium nonpolluted areas. 
c95% upper limit values from a group of 424 males and 1,611 females who did not smoke and lived in three different 
cadmium nonpolluted areas. 
dSame population of residents living in polluted area as Shimizu et al. (2006). 
e95th percentile calculated by benchmark model at no cadmium exposure (urinary cadmium equal to zero), adjusted 
to mean age. 
f84% upper limit value of the target population of people who have not smoked. 
g95% upper limit value of the target population of people who have not smoked. 
h84th percentile level in subjects from nonpolluted areas. 
i97.5th percentile level in subjects from nonpolluted areas. 
j95th percentile calculated by benchmark model at no cadmium exposure (urinary cadmium equal to zero), adjusted 
to mean age. 
k84% upper limit value of the target population.   
l95% upper limit value from a control group 98 males and 155 females living in a cadmium nonpolluted area. 
 
BMD = benchmark dose; BMDL = benchmark dose low; BMR = benchmark response; β2M = β2-microglobulin; 
creat. = creatinine; F = female; M = male; NAG = N-acetyl-β-D-glucosaminidase; 
NAG-B = N-acetyl-β-D-glucosaminidase’s isoform B; RBP = retinol binding protein 
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value for β2-microglobulin of ≥1,000 μg/g creatinine were eliminated from the analysis based on the 
conclusions of Bernard et al. (1997) that urinary β2-microglobulin levels of 1,000–10,000 μg/g creatinine 
were indicative of irreversible tubular proteinuria, which may lead to an age-related decline in GFR.  
Additionally, an attempt was made to avoid using multiple analyses of the same study population. 
 
The individual dose-response functions from each study were implemented to arrive at estimates of the 
internal dose (urinary cadmium expressed as μg/g creatinine) corresponding to probabilities of 10% 
excess risk of low molecular weight proteinuria (urinary cadmium dose, UCD10).  Estimates were derived 
from the seven environmental exposure studies listed in Table 2-3.  When available, male and female data 
were treated separately; thus, 11 dose-response relationships were analyzed.  For studies that did not 
report the UCD10, the value was estimated by iteration of the reported dose response relationship for 
varying values of urinary cadmium, until an excess risk of 10% was achieved: 
 
)0(1
)0()(
P
PdPER
−
−
=  
 
where ER is the excess risk, P(d) is the probability of low molecular weight proteinuria associated with a 
given internal (i.e., urinary cadmium) dose, and P(0) is the background probability (i.e., the probability 
predicted by the dose-response model when urinary cadmium was zero).  For studies that reported the 
dose-response relationship graphically, but did not report the actual dose-response function, a function 
was derived by least squares fitting based on data from a digitization of the graphic. 
 
 
Aggregate UCD10 estimates and the estimates stratified by location (i.e., Europe, Japan, China) are 
presented in Figure 2-2.  The lowest UCD10 (1.34 μg/g creatinine) was estimated from the European 
database and the 95% lower confidence limit on this UCD10 (UCDL10) of 0.5 μg/g creatinine was 
considered as a potential point of departure for the MRL.   
Points of departure selected using the three different approaches are similar:  0.5 μg/g creatinine from the 
Järup et al. (2000) study (using the European Chemicals Bureau 2007 recalculation), 0.7 μg/g creatinine 
from the Uno et al. (2005) benchmark dose analysis, and 0.5 μg/g creatinine from the dose-response 
analysis.  The third approach (meta-analysis of environmental exposure studies) was selected for the 
derivation of the MRL because it uses the whole dose-response curves from several studies rather than 
data from a single study.   
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Table 2-3.  Selected Studies of Dose-Response Relationship for Cadmium-
Induced Low Molecular Weight Proteinuria  
 
Reference Population Number 
Effect 
biomarker 
Response 
criterion 
Dose-
response 
model  
UCD10 
(μg/g 
creat.) 
Buchet et al. 
1990 
General population 
(Belgium) 
1,699 M 
2,080 F 
β2M 283 μg/24 hours 
 
Logistica 2.51 M 
1.44 F 
Suwazono et al. 
2006 
General population 
(Sweden) 
790 F pHC 3.6 U/g creat. Logistic 0.81 
Järup et al. 2000 Residents in 
cadmium polluted 
area (Sweden) 
1,465 
M,F 
pHC 7.1 mg/g creat. M 
5.3 mg/g creat. F 
Logistic 0.6 
Kobayashi et al. 
2006 
General population 
(Japan) 
1,114 M 
1,664 F 
β2M 507 μg/g creat. M 
400 μg/g creat. F 
Log-logistic 5.0 M 
6.6 F 
Shimizu et al. 
2006 
Residents in 
cadmium polluted 
and non-polluted 
areas (Japan) 
1,865 M 
1,527 F 
β2M 507 μg/g creat. M 
400 μg/g creat. F 
Log-logistic 5.1 M 
4.2 F 
Jin et al. 2004c Residents in 
cadmium polluted 
or non-polluted 
area (China) 
790 M,F β2M 800 μg/g creat. Logistic 9.5 M 
15.4 F 
Wu et al. 2001 Residents in 
cadmium polluted 
area (China) 
247 M,F β2M 800 μg/g creat. M 
900 μg/g creat. F 
 
Linearb 3.75 
 
aDigitized from Figure 2 in Lauwerys et al. 1991 
bDigitized from Figure 2 in Wu et al. 2001 
 
β2M = β2-microglobulin; creat. = creatinine; F = female; M = male; pHC = human complex-forming glycoprotein (also 
referred to as α1-microglobulin); UCD10 = urinary cadmium level corresponding to a probability of 10% excess risk of 
low molecular weight proteinuria 
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Figure 2-2.  Estimates of the UCD10 from Environmental Exposure Dose-Response 
Studies*  
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*Estimates of urinary cadmium concentrations (μg/g creatinine) associated with a 10% excess risk of urinary 
β2-microglobulin (UCD10) using data from European, Japanese, and Chinese studies.  For the aggregate of studies 
(plot #4), the mean (-), median (▪), and 95% confidence intervals (CI) on the median are shown.  All other plots show 
the mean and 95% CI on the mean.  Numbers in parenthesis are the number of estimates of the UCD10. 
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The UCDL10 of 0.5 μg/g creatinine was transformed into estimates of chronic cadmium intake (expressed 
as μg Cd/kg/day) that would result in the UCDL10 at age 55 (approximate age of peak cadmium 
concentration in the renal cortex associated with a constant chronic intake; Figure 2-3).  The dose 
transformations were achieved by simulation using a modification of the Nordberg-Kjellström model 
(Kjellström and Nordberg 1978).  The following modifications (Choudhury et al. 2001; Diamond et al. 
2003) were made to the model:  (1) the equations describing intercompartmental transfers of cadmium 
were implemented as differential equations in Advanced Computer Simulation Language (acslXtreme, 
version 2.4.0.9); (2) growth algorithms for males and females and corresponding organ weights 
(O’Flaherty 1993) were used to calculate age-specific cadmium concentrations from tissue cadmium 
masses; (3) the cadmium concentration in renal cortex (RC, μg/g) was calculated as follows: 
 
KW
KRC ⋅= 5.1  
 
where K is the age-specific renal cadmium burden (μg) and KW is the age-specific kidney wet weight (g) 
(Friberg et al. 1974). 
 
(4) the rate of creatinine excretion (e.g., Crur, g creatinine/day) was calculated from the relationship 
between lean body mass (LBM) and Crur; and (5) absorption of ingested cadmium was assumed to be 
5% in males and 10% in females.  The rate of creatinine excretion (e.g., Crur, g creatinine/day) was 
estimated from the relationship between LBM (kg) and Crur: 
 
58.82.27 +⋅= urCrLBM  
 
 
 
where the constants 27.2 and 8.58 are the sample size-weighted arithmetic mean of estimates of these 
variables from eight studies reported in (Forbes and Bruining 1976).  Lean body mass was estimated as 
follows (ICRP 1981): 
 
femalesadultBWLBM ,85.0⋅=
malesadultBWLBM ,88.0⋅=
 
where the central tendency for adult body weight for males and females were assumed to be 70 and 58 kg 
for adult European/American males and females, respectively. 
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Figure 2-3.  Urinary Cadmium (µg/g creatinine) and Renal Cortex Cadmium 
Concentration (µg/g wet tissue) Predicted by the Cadmium  
Pharmacokinetic Model* 
 
 
 
*Shown is a simulation of peak renal cadmium concentration (at age 55) in females based on a chronic intake of 
0.33 µg Cd/kg/day. 
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Dose units expressed as cadmium intake (μg/kg/day), urinary cadmium excretion (μg/g creatinine), or 
kidney tissue cadmium (μg/g cortex) were interconverted by iterative pharmacokinetic model simulations 
of constant intakes for the life-time to age 55 years, the age at which renal cortex cadmium concentrations 
are predicted to reach their peak when the rate of intake (μg/kg/day) is constant.  
 
 
 
 
The dietary cadmium intakes which would result in urinary cadmium levels of 1.34 and 0.5 μg/g 
creatinine (UCD10 and UCDL10) are 0.97 and 0.33 μg/kg/day in females and 2.24 and 0.70 μg/kg/day in 
males.  The dietary concentration associated with the UCDL10 in females (0.33 μg/kg/day) was divided by 
an uncertainty factor of 3 for human variability resulting in a chronic-duration oral MRL of 0.1 μg/kg/day 
(1x10-4 mg Cd/kg/day).  The UCD is based on several large-scale environmental exposure studies that 
likely included sensitive subpopulations; however, there is concern that individuals with diabetes may be 
especially sensitive to the renal toxicity of cadmium (Åkesson et al. 2005; Buchet et al. 1990) and 
diabetics were excluded from a number of the human studies, and thus, an uncertainty factor of 3 was 
used.   
The urinary cadmium point of departure used as the basis of the MRL (0.5 μg/g creatinine) is 
approximately 2-fold higher than the geometric mean urinary cadmium concentrations in the United 
States, which is 0.247 μg/g creatinine for adults 20 years and older (CDC 2011).  The MRL of 
0.1 μg/kg/day is lower than the estimated age-weighted cadmium intake of 0.3 μg/kg/day (estimated from 
data in Choudhury et al. 2001).  Because this intake is derived from the cadmium dietary exposure model 
which estimates food cadmium concentrations from national survey data and food consumption patterns, 
it should not be considered a precise value.  A better comparison would be between the mean urinary 
cadmium concentration in adults living in the United States (0.247 μg/g creatinine) and the MRL 
expressed as a urinary cadmium concentration (0.2 μg/g creatinine).   
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3.  HEALTH EFFECTS 
 
3.1   INTRODUCTION  
 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of cadmium.  It 
contains descriptions and evaluations of toxicological studies and epidemiological investigations and 
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health. 
 
 
 
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 
The form of cadmium and the route of exposure can greatly affect the absorption and distribution of 
cadmium to various target sites, and therefore, the concentration at the target site and the severity of the 
observed effect.  The mechanism of action, however, involves the cadmium cation’s effect on the target 
site, and the cation is the same regardless of the anionic species.  For inhaled cadmium compounds, the 
size of the cadmium particle (i.e., fume or aerosol) can also affect the absorption and distribution.  For 
oral exposures, cadmium chloride is most often tested in animal studies because of its high water 
solubility and the resulting high concentrations of cadmium delivered to target sites.  Studies on cadmium 
bound to metallothionein are also of interest because cadmium-metallothionein complexes may have 
different toxic profiles and are found in relatively high levels in organ meats (e.g., liver and kidney).  
Cadmium oxide and cadmium carbonate, which are relatively insoluble in water (but may dissolve at 
gastric pH), appear to be similar in absorption and toxicity to soluble cadmium.  There are fewer studies 
available on other forms of cadmium including insoluble forms in water such as cadmium sulfide (a 
yellow pigment) and cadmium selenium sulfide (a red pigment), and a soluble form, cadmium sulfate, 
which is less soluble in a closed air system where there is a limited amount of dissolved carbon dioxide.  
Chapter 4 lists the chemical and physical properties of several cadmium compounds. 
3.2   DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE  
 
To help public health professionals and others address the needs of persons living or working near 
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects).  These data are discussed in terms of three exposure 
periods:  acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more). 
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Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures.  The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies.  
LOAELs have been classified into "less serious" or "serious" effects.  "Serious" effects are those that 
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death).  "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be 
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these end points.  ATSDR 
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 
"less serious" and "serious" effects.  The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which 
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not 
the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health.   
 
 
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike. 
Levels of exposure associated with carcinogenic effects (Cancer Effect Levels, CELs) of cadmium are 
indicated in Tables 3-1 and 3-6 and Figures 3-1 and 3-2.  Because cancer effects could occur at lower 
exposure levels, Figure 3-1 also shows a range for the upper bound of estimated excess risks, ranging 
from a risk of 1 in 10,000 to 1 in 10,000,000 (10-4 to 10-7), as developed by EPA. 
 
 
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs. 
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3.2.1   Inhalation Exposure  
 
The information in this section on health effects of inhalation exposure to cadmium in humans is derived 
from studies of workers exposed to cadmium fume or dusts in industries such as smelting, battery 
manufacturing, soldering, and pigment production.  Adverse effects of human exposure to cadmium were 
first established among workers in a cadmium battery factory (Friberg 1950).  Workers are exposed 
occupationally to cadmium primarily by inhalation of fumes or dust.  Some gastrointestinal tract exposure 
may also occur when dust is removed from the lungs by mucociliary clearance and subsequently 
swallowed, or by ingestion of dust on hands, cigarettes, or food (Adamsson et al. 1979).  In experiments 
with animals, some ingestion may also occur from inhalation exposures by mucociliary clearance or from 
animal grooming.  The primary form of cadmium in occupational exposures is cadmium oxide.  
Experimental studies in laboratory animals have used cadmium oxide, cadmium chloride, and 
occasionally other forms of cadmium such as cadmium sulfide and cadmium sulfate.  In general, the 
different forms of cadmium have similar toxicological effects by the inhalation route, although 
quantitative differences may exist from different absorption and distribution characteristics, particularly 
for the less soluble cadmium pigments such as cadmium sulfide and cadmium selenium sulfide (Buckley 
and Bassett 1987b; Klimisch 1993; Oldiges and Glaser 1986; Oldiges et al. 1989; Rusch et al. 1986).  
 
Smokers inhale cadmium, but studies of cadmium exposure in the general population are considered in 
Section 3.2.2 because the primary route of exposure for the general population is through the diet.  Also, 
the many other toxic compounds in cigarette smoke make it difficult to attribute specific adverse effects 
of smoking to the inhalation of cadmium. 
 
3.2.1.1   Death  
 
Numerous studies have shown that acute inhalation exposure to cadmium can cause death in humans and 
animals.  In humans, several fatal inhalation exposures have occurred in occupational accidents.  During 
the acute exposure, the general symptoms are relatively mild but, within a few days following exposure, 
severe pulmonary edema and chemical pneumonitis develop, leading to death due to respiratory failure 
(Beton et al. 1966; Lucas et al. 1980; Patwardhan and Finckh 1976; Seidal et al. 1993).  The cadmium 
concentration in air was not measured in these cases of accidental death in humans.  However, the lung 
concentrations of cadmium in the men who died from these accidental acute exposures were measured.  
In micrograms of cadmium per gram wet weight (w/w) of lung tissue (μg/g), Patwardhan and Finckh 
(1976) reported 1.5 μg/g, Beton et al. (1966) reported 2.5 μg/g, Barrett et al. (1947) reported 3.5 μg/g, and 
Lucas et al. (1980) reported 4.7 μg/g.  Based upon estimates of the percentage of inhaled cadmium fume 
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that would be retained in the lungs, Barrett et al. (1947) calculated an exposure of 2,500 minutes x mg/m3 
in air would be fatal to humans.  Beton et al. (1966) used a similar technique to estimate that an exposure 
to cadmium oxide in air of 8.63 mg/m3 for 5 hours led to the fatal deaths of the five workers with 
cadmium lung burdens of 2.5 μg/g.  The lower lung concentrations reported by Patwardhan and Finckh 
(1976) prompted Elinder (1986b) to estimate that an exposure of 1–5 mg/m3 for 8 hours could be 
immediately dangerous.  These estimates of air concentrations, however, are based on a number of 
uncertain assumptions concerning the duration of exposure and the retention of cadmium in the human 
lung being similar to that found in animal studies (Barrett et al. 1947; Elinder 1986b).  No studies on 
deaths in humans from intermediate inhalation exposures were found.  In a study on chronic exposures, 
Friberg (1950) attributes the deaths of 2 workers to exposure to cadmium dust in the air averaging 6.8 mg 
Cd/m3 (range 3–15 mg/m3).  One worker was 57 years old at death (after 14 years of exposure to the dust) 
and the other was 60 years old at death (after 25 years of exposure to the dust).  A detailed postmortem 
evaluation for the 60-year-old worker showed the presence of emphysema and the occurrence of hyaline 
casts in renal tubules, as well as slight nephrotic changes.  Pneumonia was the direct cause of death as an 
acute complication of chronic bronchitis and pulmonary emphysema.  The exposure estimate of 6.8 mg 
Cd/m3 is from only six samples taken in 1946.  The conditions in earlier years were thought to be similar, 
but this exposure value is, at best, a very rough approximation of the actual exposures spanning 34 years. 
 
Acute inhalation of cadmium oxide fumes has also led to death in rats, mice, rabbits, guinea pigs, dogs, 
and monkeys, with the mortality rate apparently being directly proportional to the product of the duration 
of exposure and the concentration of inhaled cadmium (Barrett et al. 1947).  The most reliable LC50 
(lethal concentration, 50% kill) (at 7 days) established by this study was 500 minute-mg cadmium 
oxide/m3 for rats, equivalent to a 15-minute exposure to 30 mg Cd/m3 (Barrett et al. 1947).  Rusch et al. 
(1986) demonstrated high mortality rates in the Sprague-Dawley rat from a 2-hour exposure to cadmium 
fumes at 112 mg Cd/m3 (25 of 32 died within 1 week).  A 2-hour exposure to a different form of 
cadmium, cadmium carbonate, at 132 mg Cd/m3 resulted in considerably lower mortality (3 of 22 died by 
day 30).  No deaths resulted from a 2-hour exposure to cadmium sulfide at 99 mg Cd/m3 or cadmium 
selenium sulfide (cadmium red pigment) at 97 mg Cd/m3.  Grose et al. (1987) reported 2 out of 36 rats 
died from a 2-hour, nose-only inhalation exposure to only 0.45 mg Cd/m3 of cadmium oxide dusts, but the 
statistical significance of this low rate of mortality was not reported.  A 3-day, 1-hour/day exposure to 
cadmium chloride aerosol at 61 mg Cd/m3 resulted in the death of 17 of 18 rats exposed (Snider et al. 
1973).  In another study, no deaths were observed in rats from a cadmium yellow (cadmium sulfide) 
pigment exposure 6 hours/day for 10 days at 6.29 mg Cd/m3 (Klimisch 1993).  Thus, it appears that in 
acute exposures, the relatively more soluble cadmium chloride, cadmium oxide fume, and cadmium 
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carbonate compounds are more toxic than the relatively less soluble cadmium sulfide compounds 
(Klimisch 1993; Rusch et al. 1986).  Rusch et al. (1986) attribute this difference to higher lung absorption 
and retention times for the more soluble compounds, and greater mucociliary clearance for the less-
soluble pigments.  Glaser et al. (1986), however, demonstrated that toxicity does not strictly correlate 
with solubility, and that solubility of cadmium oxide in biological fluids may be greater than its solubility 
in water.  In hamsters, Henderson et al. (1979) reported that a 30-minute exposure to 10.1 mg Cd/m3 from 
cadmium chloride resulted in the death of 3 of 30 animals by day 6 postexposure.  In rabbits, Friberg 
(1950) reported an LC50 (by day 14) from a 4-hour exposure to cadmium metal dusts at 28.4 mg Cd/m
3.  
Barrett et al. (1947) also reported LC50 values for cadmium oxide fume of 940 mg Cd/m
3 for a 14-minute 
exposure in the monkey, 46.7 mg/m3 for a 15-minute exposure in the mouse, 204 mg Cd/m3 for a 
15-minute exposure in the guinea pig, and 230 mg Cd/m3 for a 15-minute exposure in the dog.  However, 
the authors report that these LC50 values are only approximations because of insufficiencies in the data or 
the small numbers of animals used. 
 
 
At longer durations of exposure, lower concentrations cause lethality in rats.  Cadmium oxide dust 
resulted in the deaths of 100% of the females at 1 mg Cd/m3 for 5 hours/day, 5 days/week for 20 weeks, 
(Baranski and Sitarek 1987), and of 5 of 12 female rats at only 0.105 mg Cd/m3 22 hours/day, 
7 days/week for 63 days (Oldiges and Glaser 1986).  Continuous inhalation exposure to cadmium oxide 
dust at 0.105 mg Cd/m3 (i.e., 24 hours/day) for 63 days resulted in 5 of 12 deaths in female rats (Prigge 
1978a).  Five of 54 males died from a cadmium chloride exposure to 1.06 mg Cd/m3 for 62 days, 
5 days/week, 6 hours/day (Kutzman et al. 1986).  Kutzman et al. (1986) determined that the concentration 
times hours of exposure to produce 50% mortality in rats was 390 mg-hour/m3 (males) and 489 mg-
hour/m3 (females).  Takenaka et al. (1983) reported that cadmium chloride at 0.0508 mg Cd/m3 
23 hours/day, 7 days/week for 18 months resulted in the death of 5 of 40 male rats.   
Oldiges et al. (1989) evaluated the long-term effects in rats of inhaling cadmium as either cadmium 
chloride, cadmium sulfate, cadmium sulfide, or cadmium oxide.  Rats were exposed to aerosols in nearly 
continuous exposures of 22 hours/day, 7 days/week for 18 months.  An observation period of 12 months 
followed the exposure period.  Oldiges et al. (1989) recorded mortality as exceeding 25% of the test 
animals during the exposure period or 75% of the test animals during the observation period.  If either 
25 or 75% mortality occurred, the exposure period or the observation period, respectively, was 
terminated.  The results showed that cadmium chloride at 0.030 mg Cd/m3 was lethal to >75% of the male 
and female rats by 12 months of exposure; cadmium oxide dusts at 0.090 mg Cd/m3 were lethal for >25% 
of the males by 7 months and 25% of the females by 11 months of exposure; cadmium oxide fume at the 
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highest dose of 0.03 mg Cd/m3 did not result in >25% mortality during exposure or 75% during the 
postexposure period; cadmium sulfate at 0.090 mg Cd/m3 was lethal for >25% of the males during the 
exposure and for >75% of the females by 14 months following exposure; and cadmium sulfide at 
0.090 mg Cd/m3 was not lethal during the exposure period but was lethal to >75% of the males and 
females by 12 months postexposure.  In these chronic studies, cadmium's lethal effects differed among the 
chemical forms in the following order from most to least toxic:  cadmium chloride>cadmium sulfate ≈ 
cadmium oxide dust>cadmium sulfide, but lethality still occurred from all forms of cadmium.  Oldiges 
and Glaser (1986) report that in their chronic studies and at the doses tested, cadmium toxicity appeared 
to be more related to the long-term lung retention of the bioavailable amounts of cadmium than to a 
simple function of solubility in water.  Representative LOAEL and LC50 values for lethality in each 
species and duration category are recorded in Table 3-1 and are plotted in Figure 3-1. 
 
 
3.2.1.2   Systemic Effects  
 
The highest NOAEL values and all LOAEL values from each reliable study for systemic effects in each 
species and duration category are recorded in Table 3-1 and plotted in Figure 3-1. 
Respiratory Effects.    In humans, inhalation exposure to high levels of cadmium oxide fumes or dust 
is intensely irritating to respiratory tissue, but symptoms can be delayed.  During and immediately after 
(up to 2 hours) an acute exposure for 5 hours of 8.63 mg/m3, Beton et al. (1966) reported that there were 
few symptoms of toxicity limited to coughing and slight irritation of the throat and mucosa.  From 4 to 
10 hours postexposure, influenza-like symptoms began to appear, including cough, tight chest, pain in 
chest on coughing, dyspnea, malaise, ache, chilling, sweating, shivering, and aching pain in back and 
limbs.  From 8 hours to 7 days postexposure, more advanced stages of pulmonary response included 
severe dyspnea and wheezing, chest pain and precordial constriction, persistent cough, weakness and 
malaise, anorexia, nausea, diarrhea, nocturia, abdominal pain, hemoptysis, and prostration.  Acute, 
high-level exposures can be fatal (see Section 3.2.1.1), and those who survive may have impaired lung 
function for years after a single acute exposure.  A 34-year-old worker exposed to cadmium fume from 
soldering for 1 hour (dose not determined) had persistent impaired lung function when examined 4 years 
following the exposure (Barnhart and Rosenstock 1984).  Initial symptoms were dyspnea, cough, 
myalgia, and fever.  An initial chest X-ray revealed infiltrates.  Townshend (1982) reports the case of a 
male welder who developed acute cadmium pneumonitis from a single exposure (dose not determined).  
Nine years after the exposure, this worker continued to show signs of progressive pulmonary fibrosis and  
a
Key to
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Table 3-1  Levels of Significant Exposure to Cadmium  -  Inhalation
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/m³)
Less Serious
(mg/m³)
Serious
(mg/m³)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
ACUTE EXPOSURE
Death
1
2
Beton et al. 1966
CdO fume
M8.63 (5 male workers died
after a 5 hour exposure)
8.63
Human 5 hr
(occup)
2
7
Barrett et al. 1947
CdO fume
30 (LC50 at 7 days)
30
Rat
(NS)
10-15 min
3
1020
NTP 1995
CdO
8.8 (100% mortality by day 6)
8.8
Rat
(Fischer- 344)
6.2 hr/d
5 d/wk
2 wk
4
13
Rusch et al. 1986
CdO fume
112 (25/32 died within 1
week)
112
Rat
(Sprague-
Dawley)
2 hr
5
17
Snider et al. 1973
CdCl2
M61 (17/18 died within 3
days)
61
Rat
(Sprague-
Dawley)
3 d
1 hr/d
6
1023
NTP 1995
CdO
8.8 (100% mortality by day 7)
8.8
Mouse
(B6C3F1)
6.2 hr/d
5 d/wk
2 wk
7
24
Friberg 1950
Cd metal dust
28.4 (LC50 at 14 days)
28.4
Rabbit
(NS)
4 hr
3.  H
E
A
LTH
 E
FFE
C
TS
C
A
D
M
IU
M
51
a
Key to
Figure
(continued)Table 3-1  Levels of Significant Exposure to Cadmium  -  Inhalation
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/m³)
Less Serious
(mg/m³)
Serious
(mg/m³)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
Systemic
8
28
Boudreau et al. 1989
CdCl2
Resp M5 (pulmonary edema,
enzyme changes
associated with type 2
cell hyperplasia)
5
Rat
(Long- Evans)
1 hr
9
29
Buckley and Bassett 1987b
CdO dust
Resp M0.4 (mild hypercellularity at
the bronchoalveolar
junction and in adjacent
alveoli)
0.4
M4.6 (persistent focal
interstitial thickening,
increased collagen,
general hypercellularity)
4.6
Rat
(Wistar)
3 hr
Bd Wt M0.4
0.4
M4.6 (15% decreased body
weight)
4.6
10
30
Bus et al. 1978
CdCl2
Resp M6.5 (severe pneumonitis)
6.5
Rat
(Sprague-
Dawley)
1 hr
Bd Wt M6.5 (10.8% decreased body
weight)
6.5
11
34
Grose et al. 1987
CdCl2
Resp M0.45
0.45
M4.5 (moderate to severe
pneumonitis,
hemorrhage, edema)
4.5
Rat
(Sprague-
Dawley)
2 hr
Bd Wt M4.5 (20% decreased body
weight)
4.5
3.  H
E
A
LTH
 E
FFE
C
TS
C
A
D
M
IU
M
52
a
Key to
Figure
(continued)Table 3-1  Levels of Significant Exposure to Cadmium  -  Inhalation
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/m³)
Less Serious
(mg/m³)
Serious
(mg/m³)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
12
35
Grose et al. 1987
CdO dust
Resp M0.45 (significant increased
absolute  and relative
lung weight)
0.45
M4.5 (severe pneumonitis,
hyperplasia of type 2
cells and fibroblasts)
4.5
Rat
(Sprague-
Dawley)
2 hr
Bd Wt M0.45
0.45
13
36
Hart 1986
CdO dust
Resp M1.6 (interstitial pneumonitis)
1.6
Rat
(Lewis)
1-6 wk
5 d/wk
3 hr/d
14
38
No histopathological
examination.
Klimisch 1993
CdCl2
Bd Wt M0.17
0.17
Rat
(Wistar)
10 d
6 hr/d
15
39
No histopathological
examination.
Klimisch 1993
CdS
Bd Wt M6.29
6.29
Rat
(Wistar)
10 d
6 hr/d
16
1017
NTP 1995
CdO
Resp F0.88 (degeneration of nasal
olfactory epithelium)
0.88
b
0.088 (alveolar histiocytic
infiltrate and focal
inflammation in alveolar
septa)
0.088
8.8 (marked necrosis of
alveolar ducts)
8.8
Rat
(Fischer- 344)
6.2 hr/d
5 d/wk
2 wk
Hepatic 2.6
2.6
Renal 2.6
2.6
3.  H
E
A
LTH
 E
FFE
C
TS
C
A
D
M
IU
M
53
a
Key to
Figure
(continued)Table 3-1  Levels of Significant Exposure to Cadmium  -  Inhalation
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/m³)
Less Serious
(mg/m³)
Serious
(mg/m³)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
17
40
Palmer et al. 1986
CdCl2
Resp M6 (alveolar type 1 cell
damage and necrosis)
6
Rat
(Sprague-
Dawley)
2 hr
Endocr M6
6
Bd Wt M6
6
18
41
Rusch et al. 1986
CdCO3
Gastro 132 (erosions of the stomach)
132
Rat
(Sprague-
Dawley)
2 hr
19
45
Snider et al. 1973
CdCl2
Resp M6.1 (emphysema)
6.1
Rat
(Sprague-
Dawley)
5, 10, or
15 d
1 hr/d
20
46
Snider et al. 1973
CdCl2
Resp M61 (pulmonary hemorrhage)
61
Rat
(Sprague-
Dawley)
3 d
1 hr/d
21
1022
NTP 1995
CdO
Resp 0.88 (fibrosis and
inflammation around the
alveolar ducts, necrosis
of the alveolar duct
epithelium)
0.88
0.088 (histiocytic infiltrates)
0.088
Mouse
(B6C3F1)
6.2 hr/d
5 d/wk
2 wk
Hepatic 2.6
2.6
Renal 2.6
2.6
3.  H
E
A
LTH
 E
FFE
C
TS
C
A
D
M
IU
M
54
a
Key to
Figure
(continued)Table 3-1  Levels of Significant Exposure to Cadmium  -  Inhalation
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/m³)
Less Serious
(mg/m³)
Serious
(mg/m³)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
22
47
Henderson et al. 1979
CdCl2
Resp 1.1 (moderate increase in
PMN, 2-fold increase in
acid phosphatase)
1.1
10.1 (severe pneumonitis)
10.1
Hamster
(Golden
Syrian)
30 min
23
48
Grose et al. 1987
CdCl2
Resp M4.5 (mild, multifocal
interstitial pneumonitis)
4.5
Rabbit
(New
Zealand)
2 hr
24
49
Grose et al. 1987
CdO dust
Resp M0.45 (increase in alveolar
macrophages)
0.45
M4.5 (multifocal interstitial
pneumonitis)
4.5
Rabbit
(New
Zealand)
2 hr
Bd Wt M0.45 (unspecified decrease in
body weight)
0.45
Immuno/ Lymphoret
25
53
Graham et al. 1978
CdCl2
F0.11
0.11
F0.19 (decreased humoral
immune response)
0.19
Mouse
(Swiss)
2 hr
26
54
Krzystyniak et al. 1987
CdCl2
F0.88 (reduction in spleen
lymphocyte viability
[35%], numbers, and
humoral response (75%)]
0.88
Mouse
(C57BI/6)
60 min
INTERMEDIATE EXPOSURE
Death
27
58
Baranski and Sitarek 1987
CdO dusts
F1 (13/13 died by week 20)
1
Rat
(Wistar)
20 wk
5 d/wk
5 hr/d
3.  H
E
A
LTH
 E
FFE
C
TS
C
A
D
M
IU
M
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a
Key to
Figure
(continued)Table 3-1  Levels of Significant Exposure to Cadmium  -  Inhalation
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/m³)
Less Serious
(mg/m³)
Serious
(mg/m³)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
28
62
Kutzman et al. 1986
CdCl2
M2.13 (100% mortality by day
45)
2.13
Rat
(Fischer 344)
62 d
5 d/wk
6 hr/d
29
65
Oldiges et al. 1989
CdCl2
0.09 (> 75% mortality by
11-12 months
postexposure)
0.09
Rat
(Wistar)
6 mo
40 hr/wk
30
67
Oldiges et al. 1989
CdS
0.27 (> 75% mortality by
21-23 months
postexposure)
0.27
Rat
(Wistar)
6 mo
40 hr/wk
31
68
Prigge 1978a
CdO dust
F0.105 (5/12 died)
0.105
Rat
(Wistar)
63d
24 hr/d
Systemic
32
71
Baranski and Sitarek 1987
CdO dusts
Bd Wt F0.16
0.16
F1 (30-50% decreased body
weight gain)
1
Rat
(Wistar)
20 wk
5 d/wk
5 hr/d
33
72
No histopathology
examination.
Glaser et al. 1986
CdCl2
Resp M0.105 (increased total
bronchoalvelolar
macrophage numbers,
leukocytes, and
macrophage cytotoxicity)
0.105
Rat
(Wistar)
30 d
7 d/wk
22 hr/d
Hemato M0.105 (45% increase in WBC)
0.105
3.  H
E
A
LTH
 E
FFE
C
TS
C
A
D
M
IU
M
56
a
Key to
Figure
(continued)Table 3-1  Levels of Significant Exposure to Cadmium  -  Inhalation
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/m³)
Less Serious
(mg/m³)
Serious
(mg/m³)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
34
73
No histopathology
examination.
Glaser et al. 1986
CdO dust
Resp M0.098 (increased total
bronchoalvelolar
macrophage numbers,
leukocytes, and
macrophage cytotoxicity)
0.098
Rat
(Wistar)
30 d
7 d/wk
22 hr/d
Hemato M0.098 (45% increase in WBC)
0.098
35
74
No histopathological
examination.
Glaser et al. 1986
CdS
Resp M1.034 (increased total
bronchoalvelolar
macrophage numbers,
leukocytes, and
macrophage cytotoxicity)
1.034
Rat
(Wistar)
30 d
7 d/wk
22 hr/d
Hemato M1.034
1.034
Bd Wt M1.034
1.034
36
78
Kutzman et al. 1986
CdCl2
Resp M1.06 (marked fibrosis with
significant increase in
collagen)
1.06
Rat
(Fischer 344)
62 d
5 d/wk
6 hr/d
Bd Wt 0.33
0.33
1.06 (14% decreased body
weight)
1.06
2.13 (42-51% decreased body
weight)
2.13
3.  H
E
A
LTH
 E
FFE
C
TS
C
A
D
M
IU
M
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a
Key to
Figure
(continued)Table 3-1  Levels of Significant Exposure to Cadmium  -  Inhalation
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/m³)
Less Serious
(mg/m³)
Serious
(mg/m³)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
37
1018
NTP 1995
CdO
Resp F0.022 (epithelial degeneration
in the larynx)
0.022
0.22 (Inflammation of nasal
respiratory epithelium)
0.22
0.88 (marked inflammation
and moderate fibrosis in
interstitium around
alveolar ducts and
terminal bronchioles)
0.88
Rat
(Fischer- 344)
6.33 hr/d
5 d/wk
13 wk
Cardio 0.88
0.88
Gastro 0.88
0.88
Hemato 0.88
0.88
Hepatic 0.88
0.88
Renal 0.88
0.88
Bd Wt 0.88
0.88
38
79
Oberdorster et al. 1994
CdCl2
Resp M0.1
0.1
Rat
(Fischer 344)
4 wks
5 d/wk
6 hr/d
3.  H
E
A
LTH
 E
FFE
C
TS
C
A
D
M
IU
M
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Key to
Figure
(continued)Table 3-1  Levels of Significant Exposure to Cadmium  -  Inhalation
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/m³)
Less Serious
(mg/m³)
Serious
(mg/m³)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
39
82
Prigge 1978a
CdO dust
Resp F0.025 (proliferations, histiocytic
cell granulomas)
0.025
Rat
(Wistar)
63 or 90 d
24 hr/d
Hemato F0.052 (increased hemoglobin
and hematocrit)
0.052
Hepatic F0.105
0.105
Renal F0.105
0.105
Bd Wt F0.105 (11% decrease in body
weight)
0.105
Metab F0.105 (decreased blood pH and
pO2, increased pCO2)
0.105
40
83
Prigge 1978b
CdCl2
Resp F0.204 (77% increased lung
relative weight)
0.204
Rat
(Wistar)
21 d
Gd 1-21
24 hr/d
Hemato F0.204 (8% increased
hemoglobin, 5%
increased hematocrit )
0.204
Hepatic F0.581
0.581
Renal F0.581
0.581
Bd Wt F0.394
0.394
3.  H
E
A
LTH
 E
FFE
C
TS
C
A
D
M
IU
M
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a
Key to
Figure
(continued)Table 3-1  Levels of Significant Exposure to Cadmium  -  Inhalation
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/m³)
Less Serious
(mg/m³)
Serious
(mg/m³)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
41
84
Prigge 1978b
CdCl2
Resp F0.204 (70% increased lung
relative weight)
0.204
Rat
(Wistar)
21 d
Gd 1-21
24 hr/d
Hemato F0.581 (increased hemoglobin
[12%], hematocrit [12%],
total biliurin [2-fold])
0.581
Hepatic F0.581
0.581
Renal F0.581
0.581
Bd Wt F0.394 (12% decreased
maternal weight gain)
0.394
42
1024
NTP 1995
CdO
Resp M0.088 (Degeneration of nasal
olfactory epithelium)
0.088
0.022 (alveolar histiocytic
infiltrates and squamous
metaplasia of the larynx)
0.022
Mouse
(B6C3F1)
6.33 hr/d
5 d/wk
13 wk
Cardio 0.88
0.88
Gastro 0.88
0.88
Hepatic 0.88
0.88
Renal 0.88
0.88
Bd Wt 0.88
0.88
3.  H
E
A
LTH
 E
FFE
C
TS
C
A
D
M
IU
M
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a
Key to
Figure
(continued)Table 3-1  Levels of Significant Exposure to Cadmium  -  Inhalation
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/m³)
Less Serious
(mg/m³)
Serious
(mg/m³)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
43
86
Oberdorster et al. 1994
CdCl2
Resp M0.1 (increased neutrophils,
LDH and
beta-glucuronidase;
pulmonary inflammation)
0.1
Mouse
(BALB/c)
4 wks
5 d/wk
6 hr/d
44
87
Friberg 1950
Cd metal dust
Resp 4 (chronic pneumonia,
emphysema)
4
Rabbit
(NS)
9 mo
21 d/mo
3 hr/d
Hemato 4 (eosinophilia, lower
hemoglobin)
4
Renal 4 (proteinuria)
4
45
88
Friberg 1950
Cd metal dust
Resp 5.6 (emphysema)
5.6
Rabbit
(NS)
7 mo
23 d/mo
3 hr/d
Renal 5.6 (proteinuria in 6/10
surviving to the end of
exposure)
5.6
46
89
Johansson et al. 1984
CdCl2
Resp M0.4 (lung interstitial
inflammation, type 2 cell
hyperplasia)
0.4
Rabbit
(NS)
4-6 wk
5 d/wk
6 hr/d
3.  H
E
A
LTH
 E
FFE
C
TS
C
A
D
M
IU
M
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a
Key to
Figure
(continued)Table 3-1  Levels of Significant Exposure to Cadmium  -  Inhalation
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/m³)
Less Serious
(mg/m³)
Serious
(mg/m³)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
Reproductive
47
1026
Baranski 1984
CdO
F0.16
0.16
Rat
(Wistar)
5 hr/d
5 d/wk
5 mo
premating,
mating, Gd
1-20
48
97
Baranski and Sitarek 1987
CdO dusts
F1 (increased duration of
estrous cycle)
1
Rat
(Wistar)
20 wk
5 d/wk
5 hr/d
49
98
Kutzman et al. 1986
CdCl2
M1.06 (
t
1.06
Rat
(Fischer 344)
62 d
5 d/wk
6 hr/d
50
1019
NTP 1995
CdO
M0.22
0.22
F0.22
0.22
M0.88 (decreased spermatid
counts
0.88
F0.88 (increased estrous cycle
length)
0.88
Rat
(Fischer- 344)
6.33 hr/d
5 d/wk
13 wk
Developmental
51
1027
Baranski 1984
CdO
F0.02 (altered performance on
neurobehavioral tests)
0.02
Rat
(Wistar)
5 hr/d
5 d/wk
5 mo
premating,
mating, Gd
1-20
3.  H
E
A
LTH
 E
FFE
C
TS
C
A
D
M
IU
M
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Key to
Figure
(continued)Table 3-1  Levels of Significant Exposure to Cadmium  -  Inhalation
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/m³)
Less Serious
(mg/m³)
Serious
(mg/m³)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
52
100
Baranski 1985
CdO dusts
0.02 (altered performance on
neurobehavioral tests)
0.02
0.16 (decreased pup viability)
0.16
Rat
(Wistar)
4-5 mo
5 d/wk
5 hr/d
53
1021
NTP 1995
CdO
F0.4
0.4
F1.7 (decreased fetal body
weight and reduced
ossification)
1.7
Rat
(Sprague-
Dawley)
6.27 hr/d
7 d/wk
Gd 4-19
54
101
Prigge 1978b
CdCl2
0.581 (9% decreased fetal body
weight, 12% increase in
fetal alkaline
phosphatase)
0.581
Rat
(Wistar)
21 d
Gd 1-21
24 hr/d
55
1025
NTP 1995
CdO
F0.04
0.04
F0.4 (decreased fetal body
weight)
0.4
Mouse
(Swiss)
6.27 hr/d
7 d/wk
Gd 4-17
Cancer
56
103
Oldiges et al. 1989
CdCl2
0.09 (CEL: lung
bronchioalveolar
adenomas,
adenocarcinomas, and
squamous cell
carcinomas)
0.09
Rat
(Wistar)
6 mo
40 hr/wk
CHRONIC EXPOSURE
Death
57
106
Friberg 1950
Cd dust
M6.8 (2 fatalities from 14 years
or 25 years of exposure
to Cd dust)
6.8
Human 1-34 yr
5 d/wk
8 hr/d
(occup)
3.  H
E
A
LTH
 E
FFE
C
TS
C
A
D
M
IU
M
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a
Key to
Figure
(continued)Table 3-1  Levels of Significant Exposure to Cadmium  -  Inhalation
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/m³)
Less Serious
(mg/m³)
Serious
(mg/m³)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
58
108
Oldiges and Glaser 1986
CdSO4
M0.095 (6/20 died)
0.095
Rat
(Wistar)
413-455 d
7 d/wk
22 hr/d
59
109
Oldiges et al. 1989
CdCl2
M0.03 (>75% mortality by 12
months postexposure)
0.03
Rat
(Wistar)
18 mo
7 d/wk
22 hr/d
60
110
Oldiges et al. 1989
CdO dust
0.09 (more than 25% died
after 7 months [M] and
11 months [F] of
exposure)
0.09
Rat
(Wistar)
18 mo
7 d/wk
22 hr/d
61
112
Oldiges et al. 1989
CdS
0.09 (>75% mortality after 12
months postexposure)
0.09
Rat
(Wistar)
18 mo
7 d/wk
22 hr/d
62
113
Oldiges et al. 1989
CdSO4
M0.09 (>25% mortality by 14
months of exposure)
0.09
F0.09 (>75% by 11 months
postexposure)
0.09
Rat
(Wistar)
18 mo
7 d/wk
22 hr/d
Systemic
63
1035
Buchet et al. 1990; Jarup et al.
2000; Suwazono et al. 2006
form not specified
Renal
c
F0.0001
0.0001
Human
3.  H
E
A
LTH
 E
FFE
C
TS
C
A
D
M
IU
M
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a
Key to
Figure
(continued)Table 3-1  Levels of Significant Exposure to Cadmium  -  Inhalation
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/m³)
Less Serious
(mg/m³)
Serious
(mg/m³)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
64
129
Edling et al. 1986
CdO fume
Resp 0.025
0.025
Human 4-24 yr
5 d/wk
8 hr/d
(occup)
65
131
Elinder et al. 1985b
CdO fume
Renal 0.033
0.033
0.067 (pronounced proteinuria)
0.067
Human 30 yr
5 d/wk
8 hr/d
(occup)
66
132
Falck et al. 1983
CdO fume
Renal M0.0153
0.0153
M0.0379 (100% incidence of
proteinuria in the cohort
exposed to this level for
21 years)
0.0379
Human 30 yr
5 d/wk
8 hr/d
(occup)
67
138
Jarup et al. 1988
CdO dust
Renal 0.017
0.017
0.023 (9.2% incidence of
proteinuria)
0.023
Human 30 yr
5 d/wk
8 hr/d
(occup)
68
150
Mason et al. 1988
form not specified
Renal M0.0367
0.0367
Human 30 yr
5 d/wk
8 hr/d
(occup)
69
169
Thun et al. 1989
CdO dust  or fume
Renal 0.027
0.027
Human 30 yr
5 d/wk
8 hr/d
(occup)
3.  H
E
A
LTH
 E
FFE
C
TS
C
A
D
M
IU
M
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a
Key to
Figure
(continued)Table 3-1  Levels of Significant Exposure to Cadmium  -  Inhalation
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/m³)
Less Serious
(mg/m³)
Serious
(mg/m³)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
70
174
Takenaka et al. 1983
CdCl2
Resp M0.0134 (adenomatous
hyperplasia in the
bronchoalveolar area)
0.0134
Rat
(Wistar)
18 mo
7 d/wk
23 hr/d
Bd Wt M0.0508
0.0508
Cancer
71
209
Stayner et al. 1992
CdO dust or fumes
M0.1 (CEL: 50-111 lung
cancer deaths per 1000
workers; 45 year
exposure)
0.1
Human 6 mo - 43 yr
7 d/wk
8 hr/d
(occup)
72
210
Oldiges et al. 1989
CdCl2
0.03 (CEL: lung
bronchioalveolar
adenomas,
adenocarcinomas, and
squamous cell
carcinomas)
0.03
Rat
(Wistar)
18 mo
7 d/wk
22 hr/d
73
211
Oldiges et al. 1989
CdO dust
0.03 (CEL: lung
bronchioalveolar
adenomas,
adenocarcinomas, and
squamous cell
carcinomas)
0.03
Rat
(Wistar)
18 mo
7 d/wk
22 hr/d
3.  H
E
A
LTH
 E
FFE
C
TS
C
A
D
M
IU
M
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Key to
Figure
(continued)Table 3-1  Levels of Significant Exposure to Cadmium  -  Inhalation
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/m³)
Less Serious
(mg/m³)
Serious
(mg/m³)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
74
212
Oldiges et al. 1989
CdO fume
0.03 (CEL: lung
bronchioalveolar
adenomas,
adenocarcinomas)
0.03
Rat
(Wistar)
18 mo
7 d/wk
22 hr/d
75
213
Oldiges et al. 1989
CdS
0.09 (CEL: lung
bronchioalveolar
adenomas,
adenocarcinomas, and
squamous cell
carcinomas)
0.09
Rat
(Wistar)
18 mo
7 d/wk
22 hr/d
76
214
Oldiges et al. 1989
CdSO4
0.09 (CEL: lung
bronchio-alveolar
adenomas,
adenocarcinomas,
squamous cell
carcinomas)
0.09
Rat
(Wistar)
18 mo
7 d/wk
22 hr/d
3.  H
E
A
LTH
 E
FFE
C
TS
C
A
D
M
IU
M
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Key to
Figure
(continued)Table 3-1  Levels of Significant Exposure to Cadmium  -  Inhalation
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/m³)
Less Serious
(mg/m³)
Serious
(mg/m³)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
77
215
Takenaka et al. 1983
CdCl2
M0.0134 (CEL: lung epidermoid
carcinomas,
adenocarcinomas, and
mucoepidermoid
carcinomas)
0.0134
Rat
(Wistar)
18 mo
7 d/wk
23 hr/d
a The number corresponds to entries in Figure 3-1.
b  Used to derive an acute-duration inhalation minimal risk level (MRL) of 0.00003 mg Cd/m3 (0.03 ug Cd/m3); concentration was adjusted for intermittent exposure (6.2 hours/day, 5
days/week) and divided by an uncertainty factor of 300 (10 for use of a LOAEL, 3 for extrapolation from animals to humans with dosimetric adjustment, and 10 for human variability).
c The chronic-duration inhalation MRL of 0.00001 mg Cd/m3 (0.01 ug Cd/m3) was calculated from the 95% lower confidence limit of the urinary cadmium level associated with a 10%
increased risk of low molecular weight proteinuria (0.5 ug/g creatinine) estimated from a meta-analysis of select environmental exposure studies.  An air concentration (together with
an assumed dietary intake of 0.3 ug Cd/kg/day) which would result in this urinary cadmium concentration was estimated using the ICRP human respiratory tract model and a
modification of the Nordberg-Kjellström pharmacokinetic model (see Appendix A for details on the meta-analysis and extrapolation to air concentration).  This air concentration of 0.1
ug Cd/m3 was divided by an uncertainty factor of 3 for human variability and a modifying factor of 3.
Bd Wt = body weight; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); Endocr = endocrine; F = Female; Gastro = gastrointestinal; Gd = gestational day; Hemato =
hematological; hr = hour(s); Immuno/Lymphoret = immunological/lymphoreticular; LC50 = lethal concentration, 50% kill; LDH = lactate dehydrogenase; LOAEL =
lowest-observed-adverse-effect level; M = male; min = minute(s); Metab =  metabolic; mo = month(s); NOAEL = no-observed-adverse-effect level; NS = not specified; occup =
occupational; PMN = polymorphonuclear leukocyte; Resp = respiratory; WBC = white blood cells; wk = week(s); yr = year(s)
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Figure 3-1  Levels of Significant Exposure to Cadmium - Inhalation (Continued)
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Figure 3-1  Levels of Significant Exposure to Cadmium - Inhalation (Continued)
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Figure 3-1  Levels of Significant Exposure to Cadmium - Inhalation (Continued)
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had no improvement in respiratory function.  Precise estimates of cadmium concentrations leading to 
acute respiratory effects in humans are not currently available. 
 
 
 
 
The initial symptoms of respiratory distress observed in the higher acute exposures do not occur 
following lower-level, longer-term inhalation exposures (Friberg 1950).  Longer-term occupational 
exposure to levels of cadmium below those causing lung inflammation, however, have been reported to 
cause emphysema and dyspnea in humans (Bonnell 1955; Friberg 1950; Lane and Campbell 1954; Smith 
et al. 1960).  Kjellström et al. (1979) reported a significant increase in deaths due to respiratory diseases 
in cadmium-exposed battery factory workers exposed for >5 years. 
A significant, dose-dependent excess in the ratio of observed to expected deaths from bronchitis (i.e., 
standardized mortality ratio [SMR]=434) but not emphysema was found among 6,995 men occupationally 
exposed to cadmium for an average of 11 years (Armstrong and Kazantzis 1983).  The dose level was not 
determined. 
The earlier occupational studies did not control for the health effects of cigarette smoking.  There is some 
evidence that cadmium may accelerate the development of emphysema in smokers.  Leduc et al. (1993) 
report a case history of a 59-year-old male worker who smoked a pack of cigarettes per day since age 16, 
but had no prior history of respiratory disease in 1975 until developing emphysema in 1979 after inhaling 
various concentrations of cadmium (range of 0.0164–1.192 mg/m3, mean of 0.446 mg/m3, about nine 
times the threshold value of 0.050 mg/m3) for 4 years as a furnace operator.  Very high levels of cadmium 
in air samples at the workplace and in the patient’s blood, urine, and lung tissue confirmed massive 
exposures.  Lung-function tests declined rapidly, with a faster than usual onset of emphysema compared 
to other smokers.  The mean concentration of cadmium in a removed section of lung was 580 μg/g dry 
tissue, compared to 14 μg/g in three unexposed controls matched for age, sex, and smoking habit who had 
also undergone resection of a bronchial carcinoma.  The authors state that this case supports the 
hypothesis for an etiological role of cadmium fume inhalation in the development of emphysema.   
More recent studies that controlled for smoking report lung impairment in cadmium-exposed workers 
(Chan et al. 1988; Cortona et al. 1992; Davison et al. 1988; Smith et al. 1976).  Cortona et al. (1992) 
measured respiratory function parameters in 69 smoking and nonsmoking male subjects (average age 45) 
who were exposed to concentrations of 0.008–1.53 mg/m3 of cadmium fumes over a period of 
several years in a factory that produced cadmium alloys (silver-cadmium-copper).  Forced Expiratory 
Volume (FEV), Forced Vital Capacity (FVC), Residual Volume (RV), Transfer Factor by the carbon 
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monoxide method (TLCO), and Transfer Coefficient (KCO) were measured in these exposed individuals.  
The study found that there were no significant differences in the FVC, FEV, TLCO, and KCO between 
the workers exposed to cadmium fumes and control (non-exposed) individuals.  There was a significant 
increase in RV of >8% in exposed workers; this effect was notably greater in those with higher 
cumulative exposures to cadmium (>10%).  It is uncertain how much of a factor on the increased RV was 
due to the tendency of smokers to develop an initial emphysematous alteration in lung tissue due to 
smoking. 
 
Davison et al. (1988) evaluated lung function in 101 men who had manufactured copper-cadmium alloy 
in a plant in England for ≥1 years since 1926.  The exposed men were compared to controls from the 
factory’s other seven divisions matched for age and employment status.  Smoking in exposed and control 
men was similar.  Between 1951 and 1983, 933 measurements of airborne cadmium had been made, 
697 with static samplers and 236 with personal samplers.  The various sampling methods used before 
1964 are no longer considered to be reliable, so estimates of air concentrations were made based on 
changes in production techniques, ventilation, levels of production, and discussions with occupational 
health physicians, industrial hygienist, the management, and the workers.  Cadmium concentrations in air 
from 1926 to 1972 were determined to have declined from 0.6 to 0.156 mg/m3.  In 1973, concentrations 
were 0.085 mg/m3; from 1974 to 1983, concentrations ranged from 0.034 to 0.058 mg/m3.  The lung 
function of 77 of the men occupationally exposed to cadmium was significantly impaired compared to the 
unexposed controls, with the greatest abnormalities in the highest-dose group.  Forced expiratory volume 
in one second, ratio of forced expiratory volume to forced vital capacity, transfer factor, or transfer 
coefficient were significantly lower than expected and radiographic total lung capacity, residual volume, 
and the ratio of these two were significantly higher than expected.  The greatest abnormalities were 
observed in workers with the highest cumulative exposure and the highest liver cadmium levels.  
Regression of the lung transfer coefficient versus cadmium exposure indicated a linear relationship with 
no apparent threshold. 
 
Smith et al. (1976) studied the pulmonary function of 17 high-exposure workers, 12 low-exposure 
workers, and 17 controls.  Cadmium air concentrations where high-exposure subjects worked were 
>0.2 mg/m3.  High-exposure subjects had worked at the plant a median of 26.4 years, with a maximum of 
40.2 years, and low-exposure subjects had worked a median of 27.1 years, with a maximum of 34.8 years.  
Workers with high exposure to cadmium had significantly decreased the FVC compared to low-exposure 
workers and controls.  Chest X-rays indicated mild or moderate interstitial fibrosis in 29% of high 
exposure workers.  A dose-response relationship was found between FVC and urinary cadmium, and 
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with months of exposure to cadmium fume, but not cadmium sulfate aerosol.  In an analysis of the 
smoking habits, there was no significant difference between the two cadmium-exposed groups with 
respect to the proportion of present or past cigarette smokers, the intensity or duration of cigarette 
smoking, or cigar or pipe smoking habits.  The control subjects, however, had a significantly (p<0.05) 
“higher” exposure to cigarette smoke than the cadmium exposed workers with substantially greater 
numbers of pack-years, cigarettes smoked per day, and years smoked.  A step-down and multiple 
regression analyses with a dependent variable of FVC (as percent of predicted), and the independent 
variables, age-height, cigarette pack-years, and urinary cadmium, resulted in no indication that an 
interaction between the independent variables led to the observed relationship between FVC and 
cadmium excretion. 
 
Other studies, however, have not shown a cadmium-related increase in impaired respiratory function.  
Edling et al. (1986) studied Swedish workers occupationally exposed to cadmium oxide fume from 
cadmium-containing solders.  Cadmium-containing solder had been used at the plant from 1955 to 1978.  
The results from the lung-function analysis showed no significant difference in symptoms or lung 
function between the cadmium-exposed and the reference group.  The exposed and the reference groups 
were similar with respect to sex, age, and height.  There was a higher percentage of smokers in the 
reference group (52%) than in the exposed group (42%), but the difference was not statistically 
significant.  The authors could not explain why significant differences in effects were not seen in these 
workers since other studies have shown significant effects at comparable cadmium exposure levels.  The 
authors suggest that a possible bias could have been introduced if people who had worked for >5 years in 
the plant had changed their occupation because of lung disease, so that only “healthy” workers remained.  
Significant effects may also have been found if the reference group included workers other than those 
who worked with solder, but the purpose of the study was to resolve the effects of cadmium exposure 
among workers with similar occupations.  Evaluating the data from smokers and nonsmokers separately 
also showed no significant impairment in lung function between smoking exposed and smoking 
unexposed or nonsmoking exposed and nonsmoking unexposed.  The lung impairment due to smoking 
was observed in that smokers in both the exposed and unexposed groups had a somewhat deteriorated 
closing volume and other lung function indicators in accordance with previous studies on the effects of 
smoking.  These results support the hypothesis that the response to occupational dust exposure differs 
from the response to tobacco smoking. 
 
Another possible reason for differing results is that lung injury caused by high-level cadmium exposure 
may be partially reversible (Bonnell 1955; Chan et al. 1988), with a return towards normal several years 
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after exposures have been significantly reduced.  Chan et al. (1988) studied a cohort of 36 female and 
8 male workers at a Singapore cadmium battery factory exposed to cadmium oxide dust.  Cadmium 
concentrations in air were 0.03–0.09 mg/m3 (geometric means).  Lung function was measured using 
spirometry, helium dilution, tidal sampling, X-ray, and respiratory symptoms.  The recovery of lung 
function after reduction or cessation of occupational exposure to cadmium dusts was assessed.  Total lung 
capacity increased following reduction of exposure and, following cessation of exposure, vital capacity, 
FEV, and prevalence of respiratory symptoms all improved.  Blood and urine cadmium concentrations 
were considerably lower with the reduction or cessation of exposure and were consistent with a decrease 
in the cadmium air levels. 
 
Additional respiratory symptoms less frequently reported in workers occupationally exposed to cadmium 
are chronic rhinitis and impairment or loss of the sense of smell (Adams et al. 1969; Bonnell 1955; 
Friberg 1950; Liu et al. 1985; Rose et al. 1992).  The cause of these effects may be chronic irritation or 
necrosis of the nasal membranes, as they are generally found only in individuals with high-level exposure.  
An increased prevalence of abnormal parasinus radiographic findings in cadmium-exposed workers 
compared to other published reports on non-exposed populations was reported by Shaham et al. (1993). 
 
Studies in animals confirm that inhalation exposure to cadmium can lead to respiratory injury.  Single 
acute exposures in rats to 5–10 mg Cd/m3 as cadmium oxide dust, cadmium oxide fume, or cadmium 
chloride for 1–5 hours resulted in moderate to severe, multifocal interstitial pneumonitis, diffuse alveolitis 
with hemorrhage, increased lung weight, inhibition of macrophages, focal interstitial thickening, edema, 
and necrosis of alveolar type 1 cells leading to type 2 cell hyperplasia and fibroblasts (Boudreau et al. 
1989; Buckley and Bassett 1987b; Bus et al. 1978; Grose et al. 1987; Hart et al. 1989a; NTP 1995; 
Palmer et al. 1986).  Similar results (i.e., severe pneumonitis) were seen in hamsters exposed to cadmium 
chloride at 10 mg/m3 for 30 minutes (Henderson et al. 1979) and in rabbits exposed to cadmium oxide 
dusts at 4.5 mg/m3 for 2 hours (Grose et al. 1987).  Exposures in rats to cadmium chloride at 6.1 mg 
Cd/m3 1 hour/day for 5, 10, or 15 days resulted in emphysema; a 3-day exposure to 61 mg Cd/m3 for 
1 hour/day resulted in pulmonary hemorrhage (Snider et al. 1973).  Repeated exposure to 0.088 mg Cd/m3 
as cadmium oxide for 2 weeks resulted in minimal to mild alveolar histiocytic (macrophage) infiltration 
in rats and mice, focal inflammation surrounding alveolar ducts and extending into the adjacent alveolar 
septa in rats, and hyperplasia in tracheobronchial lymph nodes in mice (NTP 1995).  At higher 
concentrations, the severity of these lesions increased (the severity of the lung lesions was scored as 
moderate at ≥0.88 mg Cd/m3) and necrosis of the epithelial lining of the alveolar ducts was observed at 
≥0.26 mg Cd/m3 in rats and 0.88 mg Cd/m3 in mice.  The NTP (1995) study also found significant 
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increases in the incidence of lesions in the nasal cavity; minimal-to-mild degeneration of the olfactory 
epithelium was observed in rats and mice exposed to 0.88 mg Cd/m3 and hyperplasia and inflammation of 
respiratory epithelium were observed in rats at 2.6 mg Cd/m3. 
 
Persistent damage has been reported in an animal model following a single intratracheal exposure to 25, 
100, or 400 μg cadmium chloride/kg body weight (Driscoll et al. 1992).  Although most BALF 
biochemical (lactate dehydrogenase, total protein, and N-acetylglucosaminidase) and cellular (neutrophils 
and lymphocyte numbers) parameters returned to control levels 28 days after exposure, histopathological 
alterations including inflammation and fibrosis were still present 90 days post-exposure and the incidence 
and severity of the lesions were greater at 90 days compared to 28 days. 
 
Intermediate-duration exposure to cadmium results in similar respiratory effects as seen in the acute 
exposures.  Concentration-related increases in the severity and types of respiratory lesions have been 
observed.  Because the intermediate-duration studies used different exposure protocols, intermittent 
exposure studies were duration-adjusted to continuous exposure (Table 3-2) to facilitate comparisons 
across these studies.  The lowest adverse effect level for lung effects was 0.004 mg Cd/m3 for alveolar 
epithelial hyperplasia in mice (NTP 1995).  At 0.008–0.07 mg Cd/m3, inflammation and minimal fibrosis 
were observed in rats, mice, and rabbits (Johansson et al. 1984; NTP 1995; Oberdörster et al. 1994) and 
marked inflammation and moderate fibrosis were observed in rats at 0.17 mg Cd/m3 (NTP 1995).  At 
≥0.34 mg Cd/m3, emphysema and chronic pneumonia were observed in rats and rabbits (Friberg 1950; 
Prigge 1978b).  In addition to the widely reported effects in the lungs, NTP (1995) reported minimal 
lesions in the larynx of rats (epithelial degeneration) and mice (squamous metaplasia) exposed to 
0.022 mg Cd/m3 and minimal lesions in the nasal cavity in rats (inflammation of respiratory epithelium) 
and mice (degeneration of olfactory epithelium) exposed to 0.088 mg Cd/m3.  The toxicity of cadmium to 
the respiratory tract following intermediate-duration exposure is highlighted by the NTP (1995) rat and 
mouse studies.  As summarized in Table 3-3, rats and mice were exposed to five concentrations (0.022, 
0.044, 0.088, 0.22, and 0.88 mg Cd/m3 as cadmium oxide) 6.33 hours/day, 5 days/week for 13 weeks.  
The earliest effects observed were alveolar histiocytic infiltrates, alveolar epithelial hyperplasia, and 
tracheal epithelial hyperplasia or squamous metaplasia; these lesions were all graded as minimal.  With 
increasing concentrations, the severity of most lesions increased as did the type of lesion. 
 
There are fewer chronic-inhalation exposure studies that specifically reported systemic respiratory effects.  
Oldiges and Glaser (1986) report increased lung weights (amount unspecified) in rats from exposure to 
either cadmium sulfate at 0.092 mg Cd/m3 or cadmium sulfide at 0.254 mg Cd/m3 for 22 hours/day,  
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Table 3-2.  Comparison of Lung Effects Across Intermediate-Duration Inhalation 
Studies 
 
Species 
Exposure 
frequency/duration 
Adverse 
effect level 
(mg Cd/m3) 
Duration-
adjusted 
adverse 
effect level 
(mg Cd/m3) Effect Reference  
Mouse 6.33 hours/day, 
5 days/week, 13 weeks 
0.022 0.004 Alveolar 
hyperplasia 
NTP 1995 
Rat 6.33 hours/day, 
5 days/week, 13 weeks 
0.044 0.008 Alveolar 
histiocytic 
infiltrates and 
hyperplasia 
NTP 1995 
Mouse 6.33 hours/day, 
5 days/week, 13 weeks 
0.044 0.008 Minimal 
fibrosis 
NTP 1995 
Mouse 6.33 hours/day, 
5 days/week, 13 weeks 
0.088 0.017 Moderate 
inflammation 
NTP 1995 
Rat 6.33 hours/day, 
5 days/week, 13 weeks 
0.22 0.017 Minimal 
fibrosis 
NTP 1995 
Mouse 6 hours/day, 
5 days/week, 4 weeks 
0.1 0.02 Inflammation Oberdörster 
et al. 1994 
Rat 24 hours/day, 
7 days/week, 90 days 
0.025 0.025 Proliferations Prigge 1978a 
Rat 6.33 hours/day, 
5 days/week, 13 weeks 
0.22 0.04 Inflammation NTP 1995 
Rat 6.33 hours/day, 
5 days/week, 13 weeks 
0.88 0.17 Marked 
inflammation 
and 
moderate 
fibrosis 
NTP 1995 
Mouse 6.33 hours/day, 
5 days/week, 13 weeks 
0.88 0.17 Moderate 
fibrosis 
NTP 1995 
Rat 6 hours/day, 
5 days/week, 62 days 
0.33 0.06 Fibrosis Kutzman et 
al. 1986 
Rabbit 6 hours/day, 
5 days/week 4–6 weeks 
0.4 0.07 Inflammation Johansson et 
al. 1984 
Rabbit 3 hours/day, 
21 days/month, 9 months 
4 0.34 Pneumonia/ 
emphysema 
Friberg 1950 
Rabbit 3 hours/day, 
23 days/month, 7 months 
5.6 0.53 Emphysema Friberg 1950 
Rat 24 hours/day, 
7 days/week 
   Prigge 1978b 
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Table 3-3.  Severity of Respiratory Effects in Rats and Mice Exposed to 
Cadmium Oxide for 13 Weeksa 
 
   
   0 
3)Concentration (mg Cd/m  
0.022 0.044 0.088 0.22 0.88 
Male rats       
 Lung       
  Alveolar histiocytic infiltrate — b—   1.0c 2.0 3.0 3.0 
  Alveolar epithelial hyperplasia — — 1.0 1.0 2.0 2.1 
  Inflammation — — — — 2.6 4.0 
  Fibrosis — — — 1.0 2.0 2.7 
 Mediastinal lymph node       
  inflammation — — — 1.3 3.2 3.3 
 Larynx       
  Epithelial degeneration  1.0 1.0 1.0 1.0 1.0 
 Nose       
  Olfactory epithelium — — —  1.0 3.0 
degeneration 
  Olfactory epithelium — — — — — 1.3 
respiratory metaplasia 
  Olfactory epithelium — — — — — 1.9 
squamous metaplasia 
  Respiratory epithelium — — — — 1.0 2.6 
inflammation 
  Respiratory epithelium — — — — — 1.5 
degeneration 
Female rats       
 Lung       
  Alveolar histiocytic infiltrate — — 1.0 2.1 3.0 3.0 
  Alveolar epithelial hyperplasia — — 1.0 1.0 2.0 2.1 
  Inflammation — — —  1.6 3.5 
  Fibrosis — — — 1.0 2.0 2.1 
 Mediastinal lymph node       
  inflammation — — 1.0 1.5 3.6 4.0 
 Larynx       
  Epithelial degeneration — 1.0 1.0 1.0 1.0 1.0 
 Nose       
  Olfactory epithelium — — — — 1.0 2.8 
degeneration 
  Olfactory epithelium — — — — 1.0 1.0 
respiratory metaplasia 
  Olfactory epithelium — — — — — 1.4 
squamous metaplasia 
  Respiratory epithelium — — — 1.0 1.8 1.8 
inflammation 
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Table 3-3.  Severity of Respiratory Effects in Rats and Mice Exposed to 
Cadmium Oxide for 13 Weeksa 
 
   
   0 
3)Concentration (mg Cd/m  
0.022 0.044 0.088 0.22 0.88 
Male mice       
 Lung       
  Alveolar epithelial hyperplasia — 1.0 1.0 1.8 1.7 2.0 
  Inflammation — — — 3.0 2.2 2.7 
  Fibrosis — — 1.0 1.0 1.0 1.0 
 Tracheobronchial lymph node       
  hyperplasia — — 1.0 2.3 2.4 2.7 
 Larynx       
  Squamous metaplasia — 1.0 1.0 1.0 1.0 1.1 
 Nose       
  Olfactory epithelium — — — 1.0 1.7 2.0 
degeneration 
  Olfactory epithelium — — — — 1.0 1.5 
respiratory metaplasia 
  Olfactory epithelium — — — —  1.0 
squamous metaplasia 
  Respiratory epithelium — — — — 1.0 1.0 
hyaline droplets 
Female mice       
 Lung       
  Alveolar histiocytic infiltrate — 1.0 1.0 2.0 2.0 3.0 
  Alveolar epithelial hyperplasia — — — 1.4 2.0 2.0 
  Inflammation — — — 2.3 2.1 2.9 
  Fibrosis — — 1.0 1.0 1.0 1.0 
 Tracheobronchial lymph node       
  hyperplasia — — 1.0 1.5 2.0 2.4 
 Larynx       
  Squamous metaplasia — 1.0 1.0 1.0 1.0 1.0 
 Nose       
  Olfactory epithelium — — — 1.0 1.0 2.0 
degeneration 
  Olfactory epithelium — — — — — 1.0 
respiratory metaplasia 
  Respiratory epithelium — — — — 1.0 1.0 
hyaline droplets 
 
aAnimals were exposed for 6.33 hours/day, 5 days/week. 
bNo lesions present or not significantly different from control group. 
cSeverity score:  1 = minimal, 2 = mild, 3 = moderate, 4 = marked 
 
Source:  NTP 1995 
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7 days/week for 413–455 days.  Takenaka et al. (1983) observed adenomatous hyperplasia in the 
bronchoalveolar region in rats from exposure to cadmium chloride at 0.0134 mg Cd/m
3 for 23 hours/day, 
7 days/week for 18 months.   
 
 
 
 
The available data suggest that there may be species differences in the respiratory toxicity of cadmium.  
In a comparison of the pulmonary response to exposure to 0.1 mg Cd/m3 as cadmium chloride 
6 hours/day, 5 days/week for 4 weeks, Oberdörster et al. (1994) found that the inflammatory response in 
the lungs of mice was greater than that of rats exposed to the same cadmium concentration.  However, the 
cadmium lung burden in mice was twice as high as the rat’s lung burden.  In the NTP (1995) study, 
adverse lung effects were observed at lower concentrations in mice compared to rats, but at the higher 
concentrations, the severity of the lung effects were greater in the rats.  Although these data suggest 
species differences in the pulmonary toxicity of cadmium, more information is needed to evaluate if there 
are differences at given lung burdens. 
Based on differences in the pharmacokinetic properties of various cadmium compounds, it is expected 
that differences in toxicity would be observed.  As discussed in Oberdörster (1992), cadmium chloride 
and cadmium oxide elicited similar responses following a single intratracheal dose, whereas no response 
was observed for cadmium sulfide.  However, Glaser et al. (1990) found similar responses following 
repeated exposures to various cadmium compounds. 
Hart and colleagues (Hart 1986; Hart et al. 1989a, 2001) demonstrated that repeated low-concentration 
exposure to cadmium results in the development of adaptive survival response.  In rats exposed to 1.6 mg 
Cd/m3 as cadmium acetate 3 hours/day, 5 days/week, thickening of the alveolar septa and mononuclear 
cell and polymorphonuclear leukocyte aggregates were observed after 2 weeks of exposure (Hart 1986).  
However, the inflammatory response was decreased after 3 weeks of exposure and no significant 
histopathological alteration were observed in rats exposed for 4, 5, or 6 weeks.  After 5 weeks of 
cadmium exposure, a single high concentration (8.4 mg Cd/m3) resulted in less pulmonary damage 
compared to non-pretreated animals (Hart et al. 1989a).  Multiple pulmonary resistance factors appear to 
contribute to this resistance/tolerance.  These factors include increased levels of metallothionein, 
glutathione, and γ-glutamylcysteinesynthetase (Hart et al. 2001).  However, as suggested by Hart et al. 
(2001), cadmium-adapted alveolar epithelial cells have a reduced ability to repair DNA damage and 
apoptotic cell death is attenuated in these cells; thus, cadmium adapted animals may be more susceptible 
to tumor formation. 
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Cardiovascular Effects.    Inhalation exposure to cadmium does not appear to have significant effects 
on the cardiovascular system.  Most studies of workers occupationally exposed to cadmium have not 
found cadmium-related cardiovascular toxicity.  In some studies, the mortality from cardiovascular 
disease was lower in the cadmium-exposed population.  Armstrong and Kazantzis (1983) reported that a 
cohort of 6,995 British men occupationally exposed to cadmium for an average duration of 11 years had a 
significantly lower mortality from vascular disease.  
 
 
 
 
 
Fifty-three male workers exposed to cadmium and lead and 52 male controls were examined for 
correlations in urine levels and blood pressure.  The average duration of exposure was 12.5 years.  
Correlations between blood pressure and urinary cadmium in exposed workers were not significant after 
controlling for age or age and heart rate.  Exposure to lead was a significant confounding factor (de Kort 
et al. 1987). 
Friberg (1950) investigated the health of workers in a manufacturing plant that made cadmium-containing 
electrodes used in the production of batteries.  Fifty-eight workers (30–50 years of age) were divided into 
two groups based on number of years at the plant.  Workers were clinically examined for subjective 
symptoms and corresponding morphological or functional changes of the respiratory, cardiovascular, and 
excretory systems.  The cardiovascular exam was largely unremarkable.  Only a slight rise in blood 
pressure in a few cases was observed in Group 1.  Electrocardiograms (EKG) were not significantly 
different from a matched control group in Group 1.  Group 2 had neither increased blood pressure nor 
altered EKGs.  
Kazantzis et al. (1988) studied mortality in a cohort of 6,958 cadmium-exposed male workers with 
average occupational exposures of 12 years.  This was a follow-up study to the work of Armstrong and 
Kazantzis (1983).  There was a significant deficit in deaths from cerebrovascular disease among men 
occupationally exposed to cadmium.  There was no significant excess risk from hypertensive or renal 
disease. 
Smith et al. (1980) studied 16 male high-exposure production workers and 11 male low-exposure office 
and supervisory workers for renal function.  Average duration of exposure was 25 years.  High-exposure 
workers were exposed to cadmium oxide concentrations of 0.23–45.2 mg/m3 and cadmium sulfide 
concentrations of 0.04–1.27 mg/m3.  No difference was found in hypertension between high- and low-
exposure workers, adjusted for age and weight or cigarette smoking. 
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Sorahan and Waterhouse (1983) examined mortality rates in a cohort of 3,025 nickel-cadmium battery 
workers (2,559 males and 466 females).  Cadmium levels in air ranged from 0.05 to 2.8 mg/m3, primarily 
as cadmium oxide.  Duration of exposure ranged from 1 to >6 years.  No increase in mortality from 
diseases of the circulatory system (e.g., hypertension) was seen in cadmium-exposed workers. 
 
 
 
 
 
Staessen and Lauwerys (1993), in a study known as the Cadmibel Study (a cross-sectional population 
study), evaluated 2,327 people from a random sample of the population of four Belgian districts chosen to 
provide a wide range of environmental exposure to cadmium.  Participants completed a questionnaire 
regarding their medical history, current and past occupations, smoking habits, alcohol consumption, and 
intake of medications.  Urine and blood samples were taken, and pulse rate, blood pressure, height, and 
weight were recorded.  Exposure to cadmium was considered to be by both the oral and inhalation routes.  
Cadmium levels in blood and urine were significantly increased in the high-exposure areas compared to 
the low-exposure areas (p<0.001).  Blood pressure was not correlated with the urine or blood cadmium 
levels.  The prevalence of hypertension or other cardiovascular diseases was similar in all four districts, 
and was not correlated with urine or blood cadmium levels.  A follow-up investigation of 692 participants 
of this study also showed no correlation with urine or blood calcium levels and the prevalence of 
hypertension after 5 years (Staessen et al. 2000).  These results do not support a hypothesis that cadmium 
increases blood pressure, prevalence of hypertension, or other cardiovascular diseases. 
One study found a statistically significant increase in blood pressure in exposed workers compared to 
controls (Thun et al. 1989), but mortality in this cohort was lower than expected (Thun et al. 1985). 
There are limited data on the cardiotoxicity of cadmium in animals.  No significant alterations in systolic 
blood pressure or histological alterations in the heart were observed in rats exposed to cadmium oxide 
concentrations as high as 0.88 mg Cd/m3 for 13 weeks (NTP 1995).   
Gastrointestinal Effects.    In the cohort he studied, Friberg (1950) found no association between 
inhalation cadmium exposure in workers and symptoms of gastrointestinal toxicity.  Symptoms that had 
been reported in case histories from the 1920s included pain or tenderness at the epigastrium associated 
with nausea and some constipation.  No other human studies report any cadmium associated gastro-
intestinal toxicity from inhalation exposure.   
In the only animal study located, Rusch et al. (1986) observed erosion of the stomach in rats from 
exposure to cadmium carbonate at 132 mg Cd/m3 for 2 hours.  Postmortem evaluation was performed at 
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1, 3, 7, and 30 days postexposure.  After the inhalation exposure in a whole-body chamber, rats were 
vacuumed to remove any cadmium carbonate dust adhering to the ventral and dorsal fur.  The 132 mg 
Cd/m3 dose is relatively high.  Three of the 10 test animals died during the 2-hour exposure so the 
significance of the gastrointestinal effect in this study is unclear. 
 
 
 
 
Hematological Effects.    The evidence concerning hematological effects following inhalation 
exposure to cadmium is conflicting.  Lowered hemoglobin concentrations and decreased packed cell 
volumes have been observed in some studies of workers occupationally exposed to cadmium (Bernard et 
al. 1979; Friberg 1950; Kagamimori et al. 1986), but not in others (Bonnell 1955; Chan et al. 1988; 
Davison et al. 1988).  The changes that were found often were not statistically significant (Bernard et al. 
1979; Friberg 1950), and examination of bone marrow of some workers with lowered hemoglobin 
revealed no detectable abnormalities (Friberg 1950). 
Conflicting results on the hematologic effect of cadmium after inhalation exposure have also been 
obtained with animal studies.  Rabbits exposed to cadmium oxide dust at 4 mg/m3 for 3 hours/day, 
21 days/month for 9 months developed eosinophilia and a slightly lower hemoglobin (Friberg 1950).  In 
contrast, rats exposed to cadmium oxide dust at 0.052 mg Cd/m3 for 24 hours/day for 90 days had 
increased hemoglobin and hematocrit that were attributed to decreased lung function (Prigge 1978a).  
Prigge (1978b) also reported increased hemoglobin and hematocrit in rats continuously exposed to 
cadmium chloride at 0.204 mg Cd/m3 and higher for 21 days.  Other studies report no Cd-related 
hematological effects.  A nearly continuous 30-day exposure in rats to cadmium sulfide at 1.034 mg 
Cd/m3 had no effect on red blood cell counts (Glaser et al. 1986).  A nearly continuous 218-day exposure 
in rats to cadmium oxide dust or fume at 0.090 mg Cd/m3 had no effect on a routine hematological 
evaluation (specific tests not reported) (Oldiges and Glaser 1986).  A partial explanation for these 
conflicting results may be that Cd-induced anemia primarily results from impaired absorption of iron 
from the diet following gastrointestinal exposure to cadmium (see Section 3.2.2.2), and the amount of 
gastrointestinal exposure following cadmium inhalation is variable depending on the form and dose. 
Musculoskeletal Effects.    Case studies indicate that calcium deficiency, osteoporosis, or 
osteomalacia can develop in some workers after long-term occupational exposure to high levels of 
cadmium (Adams et al. 1969; Blainey et al. 1980; Bonnell 1955; Kazantzis 1979; Scott et al. 1980).  
Effects on bone generally arise only after kidney damage has occurred and are likely to be secondary to 
resulting changes in calcium, phosphorus, and vitamin D metabolism (Blainey et al. 1980).   
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No studies were located regarding musculoskeletal effects in animals after inhalation exposure to 
cadmium. 
 
 
 
Hepatic Effects.    Liver effects are not usually associated with inhalation exposure to cadmium.  
Friberg (1950) reported some nonspecific signs of liver disease in some workers from a group exposed to 
cadmium in the air for 20 years.  Test results included increased serum gamma-globulin, and other 
indicators of abnormal serum globulins, including the flocculation test results of a positive Takata 
reaction and/or an elevated thymol values.  These tests (the latter of which are not used today) were 
nonspecific indicators of cirrhosis or hepatitis.  The significance of these test results with respect to 
cadmium exposure is questionable.  Subsequent studies on workers exposed to cadmium in the air have 
not reported adverse liver effects (Adams et al. 1969; Bonnell 1955). 
Liver effects have occasionally been found in animal studies.  Cats examined within one day of inhalation 
exposure to an unspecified concentration of cadmium oxide fume had a variety of hepatic lesions, and 
liver changes from cell granulation at low doses to fatty infiltration at high doses (Prodan 1932).  
Increased serum alanine aminotransferase activity, indicative of liver damage, was seen in rats exposed 
for 30 days to 0.1 mg/m3 cadmium, but activity had returned to normal 2 months after exposure (Glaser et 
al. 1986).  Kutzman et al. (1986) reported an increased liver relative weight in rats from a cadmium 
chloride exposure at 1.06 mg Cd/m3 for 6 hours/day, 5 days/week, for 62 days.  Increased liver weight 
was not observed from a continuous cadmium chloride exposure at 0.029 mg Cd/m3 for 255 days, from a 
continuous cadmium oxide exposure at 0.090 mg Cd/m3 for 218 days, or from a continuous cadmium 
sulfate exposure at 0.095 mg Cd/m3 for 413 days (Oldiges and Glaser 1986).  Similar negative results 
were reported by Prigge (1978a, 1978b) for a 21-day exposure to cadmium chloride at 0.581 mg Cd/m3, 
and for a 63-day exposure to cadmium oxide at 0.105 mg Cd/m3 (a dose that was very toxic to the lungs).  
A continuous high-dose exposure to cadmium sulfide at 2.247 mg Cd/m3 for 105 days did result in an 
unspecified increase in liver weight in surviving rats (Oldiges and Glaser 1986).  Cadmium accumulates 
in the liver as well as the kidney, the main target organ for cadmium toxicity.  The resistance of the liver 
to toxic effects from cadmium may be related to a higher capacity of the liver to produce metallothionein 
that would bind to cadmium and would lower the concentrations of free cadmium ions (see Section 3.4.3). 
Renal Effects.    There is very strong evidence that the kidney is one of the main target organ of 
cadmium toxicity following extended inhalation exposure.  The sensitivity of the kidney to cadmium was 
recognized in an early investigation of workers exposed to cadmium oxide dust and cadmium fumes in a 
factory producing nickel-cadmium batteries (Friberg 1950).  These workers suffered from a high 
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incidence of abnormal renal function, indicated by proteinuria and a decrease in glomerular filtration rate.  
Many studies examining cadmium workers have reported various effects on the kidneys.  Similar signs of 
renal damage have been observed in many other studies of workers occupationally exposed to cadmium 
(Adams et al. 1969; Bernard et al. 1979; Beton et al. 1966; Bonnell 1955; Bustueva et al. 1994; Chia et al. 
1989; Elinder et al. 1985a, 1985b; Falck et al. 1983; Gompertz et al. 1983; Iwata et al. 1993; Jakubowski 
et al. 1987; Järup and Elinder 1993; Järup et al. 1988; Kjellström et al. 1977a; Liu et al. 1985; Mason et 
al. 1988; Piscator 1966; Roels et al. 1981b; Rose et al. 1992; Smith et al. 1980; Thun et al. 1989).  Most 
of these studies did not report cadmium exposure levels; rather, urinary cadmium, blood cadmium, or 
cumulative exposures were used as biomarkers of exposure.  Thus, these studies are not presented in the 
LSE table (Table 3-1).  Selected occupational exposure studies are summarized in Table 3-4. 
 
 
 
One of the first signs of kidney effects is tubular dysfunction characterized by an increased urinary 
excretion of low-molecular-weight proteins such as β2-microglobulin, human complex-forming 
glycoprotein (pHC) (also referred to as α1-microglobulin), and retinol binding protein or increased 
urinary levels of intracellular enzymes such as N-acetyl-β-glucosaminidase (NAG) (European Chemicals 
Bureau 2007; Järup et al. 1998b).  Numerous occupational exposure studies have reported increases in 
urinary levels of these biomarkers (Bernard et al. 1990; Chen et al. 2006a, 2006b; Chia et al. 1992; 
Elinder et al. 1985b; Falck et al. 1983; Jakubowski et al. 1987, 1992; Järup and Elinder 1994; Järup et al. 
1988; Kawada et al. 1989; Roels et al. 1993; Shaikh et al. 1987; Thun et al. 1989; Toffoletto et al. 1992; 
Verschoor et al. 1987).  At higher exposure levels, increased urinary levels of high-molecular-weight 
proteins such as albumin have been reported (Bernard et al. 1979, 1990; Chen et al. 2006a, 2006b; Elinder 
et al. 1985b; Mason et al. 1988; Roels et al. 1989, 1993; Thun et al. 1989), but there is some debate as to 
whether this represents glomerular damage (Bernard et al. 1979; Roels et al. 1989) or severe tubular 
damage (Elinder et al. 1985a; Mason et al. 1988; Piscator 1984).   
Chronic exposure to very high cadmium levels can result in glomerular damage resulting in decreases in 
glomerular filtration rate (GFR) (Friberg 1950; Järup et al. 1995b; Roels et al. 1991).  Järup et al. (1995b) 
found a dose-response relationship between blood cadmium levels and GFR in cadmium workers.  At 
blood cadmium levels of 5.6 to <8.4 μg/L, 33.3% of the workers had decreased GFR (defined as <80% of 
referents); whereas all subjects with blood cadmium levels of ≥8.4 μg/L exhibited a decreased GFR.   
Another study did not find alterations in GFR in workers with urinary cadmium levels of approximately 
11 μg/g creatinine; however, an exacerbation of the age-related decline in maximal GFR was observed  
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Table 3-4.  Summary of Occupational Exposure Studies Examining Renal Effects 
 
 
 
Population Effect Adverse effect level Reference 
Zinc-cadmium smelter Age-related decline in maximal U-Cd:  11.1 μg/g Roels et al. 1991 
workers (n=87) GFR was exacerbated in workers creatinine 
with cadmium-induced 
microproteinuria. 
Workers using Significant increase in urinary β2M U-Cd:  5 μg/g Verschoor et al. 
cadmium pigments in and NAG levels. creatinine 1987 
plastic production or 
using cadmium in 
welding (n=27) 
Cadmium alloy workers Higher incidence of increased U-Cd:  10 μg/g Toffoletto et al. 1992 
(n=164) urinary β2M levels (>250 μg/L cut- creatinine 
off) when urinary cadmium levels 
exceeded 10 μg/g creatinine on 
one or more occasions, as 
compared to workers who never 
exceeded the 10 μg/g creatinine 
level. 
Cadmium smelter Significant increase in urinary U-Cd:  13.3 μg/g Shaikh et al. 1987 
workers (n=53) protein and β2M levels. creatinine 
Non-ferrous smelter Significant increase in urinary U-Cd:  >10 μg/g Bernard et al. 1990 
workers (n=58) β2M, RBP protein, pHC, albumin, creatinine 
and transferrin levels. 
Workers exposed to Significant correlation between U-Cd:  1.1–1.4 μg/g Kawada et al. 1989 
cadmium pigment dust urinary cadmium and NAG levels; creatinine 
(n=58) significant correlation with β2M at 
one of the two time points. 
Zinc-cadmium smelter Significant association between U-Cd:  4 μg/g Roels et al. 1993 
workers (n=50) urinary cadmium levels and creatinine 
urinary levels of NAG, albumin, 
and transferrin.  At higher urinary 
cadmium levels (10 μg/g 
creatinine), there were significant 
associations with RBP and β2M. 
Battery workers 10% prevalence of abnormal β2M U-Cd:  1.5 μg/g Järup and Elinder 
(n=561) levels (220 μg/g creatinine cut-off). creatinine for 1994 
≥60 years of age 
U-Cd:  5 μg/g 
creatinine for 
<60 years of age 
Alkaline battery factory 10% prevalence of renal U-Cd:  10–15 μg/g Jakubowski et al. 
workers (n=102) dysfunction (β2M >380 μg/g creatinine 1987 
creatinine; RBP >130 μg/g 
creatinine). 
Workers at a factory 25% prevalence of abnormal β2M U-Cd:  2–5 μg/g Elinder et al. 1985a 
using cadmium- levels (300 μg/g creatinine cut-off). creatinine 
containing solders 
(n=60) 
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Table 3-4.  Summary of Occupational Exposure Studies Examining Renal Effects 
 
Population Effect Adverse effect level Reference 
Workers at nickel- Significant increase in pHC and U-Cd:  5–10 μg/g Chia et al. 1992 
cadmium battery factory NAG levels (after adjustment for creatinine 
(n=92) age, gender, and race). 
Cadmium smelter Significant increases in levels β2M U-Cd:  5–10 μg/g Chen et al. 2006a, 
workers (n=85) and NAG levels and increased creatinine 2006b 
prevalence of abnormal levels of 
these biomarkers.  
Alkaline battery factory 10% prevalence of renal B-Cd:  300 μg-years/L Jakubowski et al. 
workers (n=141) dysfunction (β2M >300 μg/L; RBP (30 years of 10 μg/L) 1992 
>300 μg/L). 
Battery workers Approximately 10% prevalence of B-Cd:  5.6 μg/L Järup et al. 1988 
(n=440) abnormal β2M levels (35 μg/mmol 
creatinine cut-off). 
Cumulative exposure:  
3691 μg-years/m  
Cadmium recovery 
plant workers (n=45) 
Significant association between 
cumulative exposure and urinary 
Cumulative exposure:  
3300 mg/m  
Thun et al. 1989 
β2M, RBP, phosphate, and 
calcium and serum creatinine 
levels. 
Workers exposed to 
cadmium fumes (n=33) 
Increased urinary β2M and protein 
levels (mean 6,375 μg/g creatinine 
Cumulative exposure: 
1,137 μg/m3/years 
Falck et al. 1983 
and 246 mg/g creatinine, 
respectively) in 7 workers (mean 
in remaining 23 workers 53 μg/g 
creatinine and 34 mg/g creatinine). 
 
U-Cd = urinary cadmium, B-Cd = blood cadmium; GFR = glomerular filtration rate; pHC = human complex-forming 
glycoprotein (also referred to as α1-microglobulin); NAG = N-acetyl-β-glucosaminidase; β2M = β2-microglobulin; 
prt = protein; RBP = retinol binding protein 
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(Roels et al. 1991).  Other studies reported increases in serum creatinine levels, which are suggestive of 
impaired GFR (Roels et al. 1989; Thun et al. 1989). 
 
Depressed tubular resorption of other solutes such as enzymes, amino acids, glucose, calcium, copper, 
and inorganic phosphate have been reported in workers with signs of tubular proteinuria (Elinder et al. 
1985a, 1985b; Falck et al. 1983; Gompertz et al. 1983; Mason et al. 1988).  An increased frequency of 
kidney stone formation has also been reported in cadmium workers (Elinder et al. 1985a; Falck et al. 
1983; Järup and Elinder 1993; Kazantzis 1979; Scott et al. 1978; Thun et al. 1989; Trevisan and Gardin 
2005).  This effect is likely to be secondary to disruption of calcium metabolism due to kidney damage.  
Järup and Elinder (1993) calculated an incidence rate ratio (IRR) (after adjustment for age and calendar 
time) of 3.0 (95% CI 1.3–6.8) for the occurrence of kidney stones among workers with a cumulative 
exposure of ≥5000 μg/m3 years; the IRR was not significantly elevated at lower cumulative exposure 
levels.  Significant increases in kidney stone formation were observed in workers with increased urinary 
cadmium (median of 3.7 μg/g creatinine), blood cadmium (median of 7 μg/L), and urinary 
β2-microglobulin (median of 155 μg/g creatinine).  The increased kidney stone formation may be 
secondary to the cadmium-induced kidney damage disruption of calcium metabolism. 
 
Hellström et al. (2001) evaluated the association between occupational cadmium exposure and end stage 
renal disease among cadmium workers and residents living near a cadmium facility; renal replacement 
therapy was used as a surrogate for renal disease.  The standardized rate ratios (SRRs) (95% CI) were 
2.1 (0.6–5.3) and 2.5 (0.7–6.5) in male workers aged 20–79 or 40–79 years, respectively.  Although the 
SRRs were not statistically significant, the ratios were significantly elevated in residents presumably 
exposed to lower cadmium levels (see Section 3.2.2.2 for more information on these results).  Studies 
examining the cause of death among cadmium workers have not found significant increases in the 
standardized mortality ratios (SMRs) for nephritis or nephrosis (Armstrong and Kazantzis 1983; Järup et 
al. 1998a) or nonmalignant renal disease (Thun et al. 1985).   
 
The data from studies of cadmium workers provide strong, clear evidence that the kidney is a sensitive 
target following chronic exposure, but the data do not clearly identify a threshold of toxicity.  The earliest 
indication of an effect on the kidney is an increase in urinary levels of low molecular weight proteins 
particularly β2-microglobulin, retinol binding protein, and pHC.  However, there is some question as to 
the adversity of these early indicators because increased excretion of low molecular weight proteins 
precede the clinical manifestations (Bernard et al. 1997; Järup et al. 1998b).  As noted by Bernard et al. 
(1997), the assessment of the health significance of changes affecting a biomarker involves localizing the 
CADMIUM  90 
 
3.  HEALTH EFFECTS 
 
 
 
 
 
 
 
changes in the sequence of events that ultimately results in compromised renal function and appreciating 
the probability that these changes may lead to a deterioration of renal function.  Their guidelines for 
interpreting β2-microglobulin levels in cadmium workers are presented in Table 3-5. 
 
Another aspect of interpreting alterations in renal biomarkers and assessing risk is the issue of the 
reversibility of cadmium-induced tubular dysfunction and impaired glomerular filtration rate.  In workers 
exposed to high levels of cadmium, cessation of exposure does not generally result in a reversibility of 
kidney damage.  Increases in urinary levels of β2-microglobulin, retinol binding protein, or total protein 
(Elinder et al. 1985b; Järup et al. 1993; Mason et al. 1999; Piscator 1984; Roels et al. 1989; Thun et al. 
1989) or a decrease in glomerular filtration rate (Järup et al. 1993; Piscator 1984; Roels et al. 1989) have 
been observed in workers years after cadmium exposure cessation.  However, in workers exposed to low 
levels of cadmium, cessation of exposure resulted in decreased or no change in urinary β2-microglobulin 
levels (McDiarmid et al. 1997; van Sittert et al. 1993).  In studies by Roels et al. (1997) and Trzcinka-
Ochocka et al. (2002), former cadmium workers were divided into groups based on historical cadmium 
levels and urinary β2-microglobulin or retinol binding protein levels.  Both studies found that the 
reversibility of tubular dysfunction was dependent on the cadmium body burden and the severity of 
microproteinuria at the time cadmium exposure was reduced or ceased.  In the Roels study, significant 
decreases in retinol binding protein levels and no change in β2-microglobulin levels were observed in 
workers whose urinary cadmium levels never exceeded 10 μg/g creatinine.  Decreases in 
β2-microglobulin and retinol binding protein levels were also observed in workers whose 
β2-microglobulin levels were <300 μg/g creatinine or between 300 and 1,500 μg/g creatinine and urinary 
cadmium levels were >10 μg/g creatinine, but were never >20 μg/g creatinine.  However, a progression of 
microproteinuria (increased urinary levels of β2-microglobulin and retinol binding protein levels) was 
observed in workers who had initial β2-microglobulin levels >1,500 μg/g creatinine and urinary cadmium 
levels >20 μg/g creatinine.  In contrast, Trzcinka-Ochocka et al. (2002) found decreases in 
β2-microglobulin and retinol binding protein levels in groups of workers with initial β2-microglobulin 
and retinol binding protein levels of ≤300, >300, ≤1,500, or ≥1,500 μg/g creatinine; in all groups, the 
initial mean urinary cadmium levels were >20 μg/g creatinine.  However, the risk of increased excretion 
of retinol binding protein was higher in the groups of workers with initial retinol binding protein levels of 
>300 μg/g creatinine.  Logistic regression analysis demonstrated that the initial level of retinol binding 
protein was the most important determinant in reversibility of tubular proteinuria and that the influence of 
urinary cadmium level or length of time since exposure cessation was not statistically significant. 
 
CADMIUM  91 
 
3.  HEALTH EFFECTS 
 
 
 
 
 
 
 
 
Table 3-5.  Guidelines for Interpreting β2-microglobulin Levels 
 
β2-Microglobulin level Significance 
<300 μg/g creatinine Normal value. 
300–1,000 μg/g creatinine Incipient cadmium tubulopathy (possibility of 
reversibility after removal from exposure).  No 
change in GFR. 
1,000–10,000 μg/g creatinine Irreversible tubular proteinuria which may lead to 
accelerated decline in the GFR with age.  GFR 
normal or slightly altered. 
>10,000 μg/g creatinine Overt cadmium nephropathy usually associated 
with decreased GFR. 
 
GFR = glomerular filtration rate 
 
Source:  Bernard et al. 1997 
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The available occupational exposure data suggest that tubular dysfunction generally develops only after 
cadmium reaches a threshold concentration in the renal cortex.  However, a number of factors can 
influence urinary levels of β2-microglobulin or retinol binding protein and direct relationship between 
urinary levels of these proteins and a kidney cadmium concentration has not been established.  Based on 
the findings of early occupational exposure studies, a number of investigators estimated that the “critical 
concentration” of cadmium in the renal cortex associated with increased incidence of renal dysfunction in 
an occupational setting was about 200 μg/g wet weight (Friberg et al. 1974; Kjellström et al. 1977a; Roels 
et al. 1983); this corresponds to a urinary cadmium levels of 5–10 μg/g creatinine (European Chemicals 
Bureau 2007).  Although 10 μg/g creatinine was initially established as a threshold urinary cadmium 
concentration, there is sufficient evidence to suggest that adverse effects occur at lower urinary cadmium 
levels (Chen et al. 2006a, 2006b; Chia et al. 1992; Elinder et al. 1985b; Järup and Elinder 1994; Kawada 
et al. 1989; Roels et al. 1993; Verschoor et al. 1987). 
 
 
Indications of renal dysfunction associated with airborne cadmium exposure has also been observed in 
residents living near a lead/zinc smelter in the United Kingdom with high cadmium stack emissions 
(Thomas et al. 2009) and a zinc smelter in Norway (Bråtveit et al. 2011).  In both studies, the subjects 
were exposed to airborne cadmium and elevated cadmium levels in the soil.  The Thomas et al. (2009) 
study found a significant association between urinary cadmium levels and modeled atmospheric cadmium 
concentrations.  The mean urinary cadmium concentrations were 0.22 and 0.34 nmol/mmol creatinine 
(approximately 0.22 and 0.34 µg/g creatinine) in males and females, respectively, in the Thomas et al. 
(2009) study and 0.44 and 0.42 µg/g creatinine in males and females, respectively, in the Bråtveit et al. 
(2011) study; Bråtveit et al. (2011) also measured urinary cadmium levels in the residents living in a 
nonpolluted area and found no significant differences in urinary cadmium levels between the two groups.  
Thomas et al. (2009) found significant correlations between urinary cadmium levels and urinary NAG 
levels in males and females and pHC in females.  Additionally, the study found a significant dose-
response relationship between urinary cadmium levels and NAG levels above the reference level of 
1.25 IU/mmol creatinine.  Bråtveit et al. (2011) also found a significant association between urinary pHC 
levels and urinary cadmium levels; however, there were no significant differences in pHC levels between 
residents living in the polluted areas and the control area. 
Early animal studies confirmed that renal damage occurs following inhalation exposure to cadmium.  
Rabbits developed proteinuria after a 4-month inhalation exposure to cadmium metal dust at 4 mg/m3 for 
3 hours/day, 21 days/month; histologic lesions were found after an additional 3–4 months of exposure 
(Friberg 1950).  Friberg (1950) noted that the degree of proteinuria was not especially pronounced.  Most 
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subsequent studies using inhalation exposure have not found proteinuria (Glaser et al. 1986; Kutzman et 
al. 1986; Prigge 1978a, 1978b), primarily because the levels of exposure and durations of follow up (e.g., 
1–5 mg/m3 for intermediate exposures; 0.2–2 mg/m3 for chronic exposures) that produce serious 
respiratory effects have not been sufficient to produce a critical concentration of cadmium in the kidney. 
 
 
 
 
 
Dermal Effects.    Dermal toxicity does not appear to be a significant effect of inhalation exposure to 
cadmium.  Studies of workers occupationally exposed to cadmium have not reported dermal effects 
following acute or chronic exposure (Barnhart and Rosenstock 1984; Bonnell 1955; Friberg 1950).  No 
study was located that specifically examined dermal toxicity in humans or animals following inhalation 
exposure to cadmium.   
Ocular Effects.    Ocular toxicity does not appear to be a significant effect of inhalation exposure to 
cadmium.  Studies of workers occupationally exposed to cadmium have not reported ocular effects 
following acute or chronic exposure (Barnhart and Rosenstock 1984; Bonnell 1955; Friberg 1950).  No 
study was located that specifically examined ocular toxicity in humans following inhalation exposure to 
cadmium.   
Rats exposed to a single 2-hour inhalation exposure to about 100 mg Cd/m3 as cadmium pigments had 
excessive lacrimation 4 hours after exposure (Rusch et al. 1986), but this was likely due to a direct 
irritation of the eyes rather than a systemic effect. 
Body Weight Effects.    No data were found regarding the effects of inhaled cadmium on human body 
weights.   
In animals, cadmium has been shown to significantly reduce body weights.  An acute exposure to 
cadmium oxide fumes at 112 mg Cd/m3 for 2 hours (Rusch et al. 1986) and cadmium oxide dust at 4.6 mg 
Cd/m3 for 3 hours (Buckley and Bassett 1987b) resulted in a significant reduction of body weight in male 
rats.  Cadmium chloride at 6.5 mg Cd/m3 for 1 hour or 4.5 mg Cd/m3 for 2 hours produced significant 
reductions in male rat body weights (Bus et al. 1978; Grose et al. 1987).  Cadmium carbonate at 132 mg 
Cd/m3 for 2 hours slowed rat body weight gains (Rusch et al. 1986).  NOAELs for acute cadmium 
chloride exposure have been reported at 0.45 mg Cd/m3 for 2 hours (Grose et al. 1987); 0.17 mg Cd/m3 
for 6 hours/day for 10 days (Klimisch 1993); and 6 mg Cd/m3 for 2 hours (Palmer et al. 1986).  NOAELs 
for cadmium sulfide and cadmium selenium sulfide were much higher at 99 mg Cd/m3 for 2 hours and 
97 mg Cd/m3 for 2 hours, respectively (Rusch et al. 1986).  The effect of cadmium on body weight gain 
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appears to compound-related, with cadmium chloride the most toxic and cadmium sulfide the least toxic.  
These compound-related differences are probably related to difference in absorption. 
 
 
 
The body weight response also appears to be duration-related; lower NOAELs and LOAELs have been 
identified for intermediate-duration exposure.  Levels of cadmium that significantly reduce rat body 
weights when administered for an intermediate exposure duration have been reported for cadmium 
chloride at around 1 mg Cd/m3 for female and male rats (Baranski and Sitarek 1987; Kutzman et al. 
1986), for cadmium chloride at around 0.394 mg Cd/m3 for pregnant female rats (Prigge 1978a), and for 
cadmium dusts at 0.1 mg Cd/m3 for female rats (Prigge 1978a).  NOAELs have been reported for 
intermediate exposures to cadmium chloride at 0.394 mg Cd/m3 for female nonpregnant rats (Prigge 
1978a), 0.33 mg Cd/m3 for rats (Kutzman et al. 1986), and 0.0508 mg Cd/m3 for male rats (Takenaka et 
al. 1983).  NOAELs have been reported for intermediate exposures to cadmium oxide dust at 0.16 mg 
Cd/m3 for female rats (Baranski and Sitarek 1987) and 0.45 mg Cd/m3 for male rabbits (Grose et al. 
1987); and for cadmium sulfide at 1.034 mg Cd/m3 for male rats (Glaser et al. 1986).  A NOAEL for 
chronic exposure in rats to cadmium sulfate has been reported as 0.95 mg Cd/m3 (Oldiges and Glaser 
1986).   
Other Systemic Effects.    Yellow discoloration of the teeth has occasionally been reported in 
workers occupationally exposed to high levels of cadmium (Friberg 1950; Liu et al. 1985).  No data were 
located to indicate that this was related to any functional impairment. 
3.2.1.3   Immunological and Lymphoreticular Effects  
 
There is limited evidence for immunological effects following inhalation exposure to cadmium.  The 
blood of workers exposed to cadmium for 1–14 years had a slight but statistically significant decrease in 
the generation of reactive oxygen species by leukocytes compared to unexposed controls (Guillard and 
Lauwerys 1989).  The toxicological significance of this effect is unclear.   
 
Karakaya et al. (1994) measured blood and urine concentrations of cadmium, and serum IgG, IgM, and 
IgA in a group of 37 males employed in zinc/cadmium smelters and a small Cd-electroplating plant.  
Blood cadmium concentrations were significantly higher in exposed workers compared to controls in both 
the urine (2.39 versus 0.69 μg/100 mL, p<0.001) and the blood (5.55 versus 2.01 μg/g creatinine, p<0.05).  
No differences between the exposed and control serum concentrations of IgG, IgM, and IgA populations 
were observed.  No changes in blood counts of white blood cells (lymphocyte, neutrophil, and eosinophil) 
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were found between exposed and control populations, except for significantly increased monocyte counts.  
No other studies were located regarding immunological effects in humans following inhalation exposure 
to cadmium. 
 
 
 
Acute inhalation exposure to cadmium chloride in mice at 0.190 mg Cd/m3 for 2 hours can affect immune 
function, causing suppression of the primary humoral immune response (Graham et al. 1978).  The 
NOAEL for immunological effects from the study by Graham et al. (1978) was 0.11 mg Cd/m3.  
Krzystyniak et al. (1987) reported spleen lymphocyte cytotoxicity at 0.88 mg Cd/m3 for 1 hour.   
At intermediate-duration exposures, Kutzman et al. (1986) observed increased spleen relative weights and 
lymphoid hyperplasia from inhalation of cadmium chloride aerosols at 1.06 mg Cd/m3 6 hours/day, 
5 days/week for 62 days.  Prigge (1978b) also observed increased relative spleen weights in pregnant 
females at 0.394 mg Cd/m3 for an exposure of 24 hours/day for 21 days during gestation.  Oldiges and 
Glaser (1986) observed enlarged thoracic lymph nodes in dead animals in a chronic-exposure study with 
cadmium sulfate at 0.092 mg Cd/m3 for 22 hours/day, 7 days/week for 413–455 days; and in an 
intermediate study with cadmium oxide dust at 0.090 mg Cd/m3 for 22 hours/day, 7 days/week for 
218 days.  However, other studies have found no effect on natural killer cell activity or viral induction of 
interferon in mice (Daniels et al. 1987).  Evidence concerning the effect of inhalation exposure to 
cadmium on resistance to infection is conflicting, because the same exposure decreases resistance to 
bacterial infection while increasing resistance to viral infection (Bouley et al. 1982).  The highest NOAEL 
values and all LOAEL values from each reliable study for immunological effects in each species and 
duration category are recorded in Table 3-1 and plotted in Figure 3-1. 
3.2.1.4   Neurological Effects  
 
Neurotoxicity is not generally associated with inhalation exposure to cadmium, although a few studies 
have specifically looked for neurological effects.  Hart et al. (1989b) reported that in a group of 31 men 
occupationally exposed to cadmium in a refrigerator coil manufacturing plant (average 
exposure=14.5 years) there was a modest correlation between cadmium exposure and decreased 
performance on neuropsychologic tests for attention, psychomotor speed, and memory.  The limited 
number of men studied makes it difficult to evaluate the significance of this effect.   
 
Rose et al. (1992) studied the presence and severity of olfactory impairment in workers chronically 
exposed to cadmium fumes generated during a brazing operation.  Detailed occupational history, medical 
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history, and smoking history, and symptoms were collected for 55 workers.  Body burden was estimated 
using urinary cadmium levels, and renal damage was assessed by urinary β2-microglobulin levels.  
Olfactory test scores from these workers were compared to a reference group of 16 male subjects that 
were selected according to the following criteria:  (1) no history of taste or smell complaints, (2) no 
history of surgery to the upper respiratory tract, (3) no upper respiratory tract infection within 2 days of 
testing, and (4) no history of having been tested.  The dose of the cadmium oxide fume received by the 
workers being evaluated in this study was not reported or estimated.  For both the exposed workers and 
the reference group, 38% were smokers.  A significant olfactory impairment was observed in the workers 
compared to the reference group (p<0.003).  Thirteen percent of the workers were either moderately or 
severely hyposmic compared to none in the reference group, 44% of the workers were mildly hyposmic 
compared to 31% of the reference group, and only 44% of workers were normosmic.  Although the 
odor-identification test findings for workers were similar to those of the reference group, butanol 
detection threshold scores were significantly lower in the worker population (p<0.005).  The workers with 
both higher urinary cadmium levels and tubular proteinuria had the most significant olfactory 
dysfunction, with a selective defect in odor threshold.  The results suggest that chronic occupational 
cadmium exposure sufficient to cause renal damage is also associated with impairment in olfactory 
function.  Some limitations of the study are that historical exposure to other confounders cannot be ruled 
out, the classification for nephrotoxicity is based on a single 24-hour urine β2-microglobulin level, and 
the smoking history of the reference group was unknown.  No other human neurological studies from 
inhaled cadmium were found. 
 
In rats, cadmium carbonate produced tremors from exposure to 132 mg Cd/m3 for 2 hours, and cadmium 
fumes produced reduced activity at 112 mg Cd/m3 for 2 hours (Rusch et al. 1986).  Studies on continuous 
exposure to cadmium for 30 days have shown no neurological effects at 0.105 mg Cd/m3 for cadmium 
chloride, 0.098 mg Cd/m3 for cadmium dusts, or 1.034 mg Cd/m3 for cadmium sulfide (Glaser et al. 
1986).  Cadmium chloride had no neurological effects at 0.33 mg Cd/m3 for 5 days/week, 6 hours/day for 
a total of 62 daily exposures, but did significantly increase relative brain weight at 1.034 mg Cd/m3 
(Kutzman et al. 1986).  No other studies were located regarding neurological effects in adult animals after 
inhalation exposure to cadmium.  Neurological effects in offspring of rats exposed to cadmium by 
inhalation during gestation are discussed in Section 3.2.1.5.  The highest NOAEL values and all LOAEL 
values from each reliable study for neurological effects in each species and duration category are recorded 
in Table 3-1 and plotted in Figure 3-1. 
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3.2.1.5   Reproductive Effects  
 
Evidence is insufficient to determine an association between inhalation exposure to cadmium and 
reproductive effects.   
 
 
 
Gennart et al. (1992) studied male reproductive effects of cadmium in 83 occupationally exposed blue-
collar Belgian workers in two smelting operations.  The workers were exposed to cadmium in dust and 
fumes.  Information was recorded on age, residence, education, occupational and health history, actual 
and previous occupations, smoking habits, and coffee and alcohol consumption.  Fertility parameters 
included dates of birth of wife and husband, date of marriage, and number of children born alive and their 
dates of birth.  Blood and urine samples were also collected from each worker.  Some cadmium workers 
had been excessively exposed; 25% of them already had signs of kidney dysfunction as evidenced by 
microproteinuria and/or a serum creatinine level >13 mg/L.  No effects were observed on male fertility as 
evidenced by no significant influence of cadmium on the probability of a live birth.  The limitation of this 
study, as described by the authors, included the fact that the wives were not interviewed and, therefore, 
factors that could have influenced their reproductive ability were not considered. 
Men occupationally exposed to cadmium at levels causing renal damage had no change in testicular 
endocrine function, as measured by serum levels of testosterone, luteinizing hormone, and follicle-
stimulating hormone (Mason 1990). 
Noack-Fuller et al. (1993) measured concentrations of cadmium, lead, selenium, and zinc in whole semen 
and seminal fluid of 22 unexposed men (13 were smokers) to evaluate intra-individual variability and to 
examine the statistical association between element concentrations and semen characteristics and sperm 
motion parameters.  None of the men had any known occupational exposure to cadmium.  
Concentrations of cadmium were similar in semen and seminal plasma (0.40±0.23 and 0.34±0.19 μg/L, 
respectively).  Sperm motility (p<0.02), linear velocity (p<0.001), and curvilinear velocity (CV) 
(p<0.002) were significantly correlated with semen cadmium levels.  Intra-individual coefficients of 
variation for sperm count (CV=46±4%) and sperm concentration (CV=37±6%) showed the highest 
variability.  No positive correlation was found between cadmium concentration in semen and sperm 
density.  The smokers had slightly elevated levels of cadmium.  The concentrations of cadmium in semen 
of these volunteers were very low.  Additional studies are needed (preferably with larger sample sizes) to 
evaluate the robustness of this association between cadmium (at the low levels detected) and sperm 
motion parameters.  Saaranen et al. (1989) measured cadmium, selenium, and zinc in seminal fluid and 
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serum in 64 men, half of whom were smokers.  Smokers had significantly higher serum cadmium 
concentration than nonsmokers.  Seminal fluid cadmium was also elevated in smokers, and was higher 
than serum cadmium in smokers consuming >20 cigarettes daily.  Semen quality was measured for 
volume, sperm density, morphology, motility, and number of immature germ cells.  No differences were 
found in semen quality or fertility between smokers and nonsmokers.  There was no significant 
correlation between seminal fluid cadmium levels and semen quality or fertility. 
 
 
 
 
Xu et al. (1993a) measured trace elements in blood and seminal plasma and their relationship to sperm 
quality in 221 Singapore men (age range 24–54; mean 34.8) who were undergoing initial screening for 
infertility.  Men with significant past medical history and those who had been occupationally exposed 
were excluded.  Parameters monitored included semen volume and sperm density, motility, morphology, 
and viability.  Graphite furnace atomic absorption was used to determine cadmium concentration in blood 
and semen.  No differences were observed in sperm quality (density, motility, morphology, volume, and 
viability) of the 221 men compared to a cohort of 38 fertility proven men (wives had recently conceived).  
Cadmium levels in blood did have a significant inverse relationship with sperm density (r=-0.15, p<0.05) 
in oligospermic men (sperm density <20 million/mL), but not in normospermic men.  There was a 
significant reduction in sperm count in men with blood cadmium of >1.5 μg/L.  Also, there was a weak 
negative correlation between defective sperm and concentration of cadmium in semen (r=-0.21, p<0.05).  
The volume of semen was inversely proportional to the cadmium concentration in semen (r=-0.29, 
p<0.05).  These findings suggest that cadmium may have an effect on the male reproductive system.  
Limitations of the study include lack of control for potential confounding factors such as the lower levels 
of zinc in seminal plasma, and the validity of using infertile men as the study group (i.e., again because of 
confounding factors that may be affecting both cadmium levels and sperm levels). 
A postmortem study of men occupationally exposed to cadmium who died from emphysema found high 
levels of cadmium in their testes, but no histologic lesions other than those attributable to terminal illness 
(Smith et al. 1960)  
Russian women occupationally exposed to cadmium concentrations up to 35 mg/m3 had no irregularities 
in their menstrual cycles (Tsvetkova 1970).  Fertility and other indices of reproductive function were not 
measured.  No studies were located that showed reproductive effects in women following inhalation 
exposure to cadmium. 
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In rats, exposure to cadmium oxide dusts at 1 mg Cd/m3 for 5 hours/day, 5 days/week for 20 weeks, 
increased the duration of the estrous cycle (Baranski and Sitarek 1987).  Male and female rats exposed to 
cadmium concentrations of 1.06 mg/m3 as cadmium chloride for 6 hours/day, 5 days/week for 62 days 
and subsequently mated with unexposed controls showed no loss in reproductive success measured by 
viable embryos and preimplantation losses, but males did have an increased relative testes weight 
(Kutzman et al. 1986).  Similarly, no alterations in fertility in female rats exposed to 0.16 mg Cd/m3 as 
cadmium oxide for 5 months prior to mating with unexposed males and during the mating and gestation 
periods (Baranski 1984).  Tsvetkova (1970) studied rats exposed to cadmium sulfate aerosols at 2.8 mg 
Cd/m3 before and during pregnancy.  A lengthening of the estrous cycle was observed 2 months after the 
start of exposure in one-half of the exposed animals.  By the fourth month, diestrus was 6.2 days in the 
exposed group compared to 1.2 days in controls.  An increased in estrous cycle length was also observed 
in rats exposed to 0.88 mg Cd/m3 as cadmium oxide for 13 weeks (NTP 1995); this study also reported a 
significant decrease in spermatid counts in males exposed to the same cadmium concentration.  No other 
studies were found on reproductive effects in animals.  The highest NOAEL values and all LOAEL 
values from each reliable study for reproductive effects in each species and duration category are 
recorded in Table 3-1 and plotted in Figure 3-1. 
 
3.2.1.6   Developmental Effects  
 
Russian women occupationally exposed to cadmium at concentrations ranging from 0.02 to 35 mg/m3 had 
offspring with decreased birth weights compared to unexposed controls, but without congenital 
malformations (Tsvetkova 1970).  No association was found between birth weights of offspring and 
length of maternal cadmium exposure.  Moreover, no control was made for parity, maternal weight, 
gestational age, or other factors known to influence birth weight (Tsvetkova 1970).  A nonsignificant 
decrease in birth weight was found in offspring of women with some occupational exposure to cadmium 
in France; however, no adverse effects were documented in these newborns (Huel et al. 1984).  Huel et al. 
(1984) used hair samples to estimate exposure, and this method is limited without controls to distinguish 
between exogenous and endogenous sources.  No other studies were located regarding developmental 
effects in humans after inhalation exposure to cadmium. 
 
In utero exposure to cadmium results in significant decreases in pup viability, fetal body weight, pup 
body weight gain, delays in ossification, and impaired performance on neurobehavioral tests.  Decreases 
in pup viability (percentage of pups born alive that survived until postnatal day 4) were observed in the 
offspring of rats exposed to 0.16 mg Cd/m3 as cadmium oxide for 5 months prior to mating and during 
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mating and gestation day 1–20 (Baranski 1984).  Decreases in fetal body weight were observed in the 
offspring of rats exposed to ≥0.581 mg Cd/m3 as cadmium chloride (Prigge 1978b) or cadmium oxide 
(NTP 1995) and mice exposed ≥0.4 mg Cd/m3 as cadmium oxide (NTP 1995); maternal toxicity 
(decreased body weight gain and/or hypoactivity and dyspnea) were also observed at these exposure 
levels.  Although Baranski (1984) did not find significant alterations in birth weight, a decrease in pup 
body weight gain was observed in the offspring of rats exposed to 0.16 mg Cd/m3 as cadmium oxide.  
Delays in skeletal ossification have also been observed in the offspring of rats and mice exposed to 
1.7 mg Cd/m3 as cadmium oxide (NTP 1995); although Baranski (1985) also reported a delay in 
ossification in the offspring of rats, it is unclear whether the effect was observed at 0.02 mg Cd/m3, 
0.16 mg Cd/m3, or both.   
 
Baranski (1984, 1985) evaluated the potential of cadmium to induce neurobehavioral effects in the 
offspring of rats exposed to 0.02 or 0.16 mg Cd/m3 as cadmium oxide for 5 months prior to mating, 
during mating and gestation day 1–20; the studies reported similar effects and it is unclear whether the 
papers are reporting the results from separate experiments.  The neurobehavioral alterations included 
decreased exploratory motor activity and avoidance acquisition in 3 month old male and female offspring, 
respectively, exposed to 0.02 mg Cd/m3.  At 0.16 mg Cd/m3, decreased avoidance acquisition in 3 month 
old female offspring, exploratory motor activity in 3 month old male and female offspring, ambulations in 
open field test in 5 month old male offspring, and spontaneous mobility in male offspring and 
prolongation of latency in negative geotaxis test. 
 
3.2.1.7   Cancer  
 
The relationship between occupational exposure to cadmium and increased risk of cancer (particularly 
lung and prostate cancer) has been explored in a number of occupational exposure studies.  The results of 
these studies are conflicting and the carcinogenicity of cadmium has not been unequivocally established.  
Overall, the results provide suggestive evidence of an increased risk of lung cancer in humans following 
prolonged inhalation exposure to cadmium.  Initial studies indicated an elevation in prostate cancer 
among men occupationally exposed to cadmium (Kipling and Waterhouse 1967; Kjellström et al. 1979; 
Lemen et al. 1976), but subsequent investigations found either no increases in prostate cancer or increases 
that were not statistically significant (Elinder et al. 1985c; Kazantzis et al. 1988; Sorahan 1987; Sorahan 
and Esmen 2004; Thun et al. 1985).  Based on an analysis of the mortality data from a 5-year update of 
the cohort from 17 plants in England and a review of the other epidemiological evidence, Kazantzis et al. 
(1992) concluded that cadmium does not appear to act as a prostatic carcinogen. 
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Significant increases in mortality from lung cancer have been reported in workers employed at a U.S. 
cadmium recovery facility (Stayner et al. 1992a; Thun et al. 1985), nickel-cadmium battery facilities in 
England (Sorahan 1987) and Sweden (Järup et al. 1998a), and in a cohort of workers at cadmium 
processing facilities and/or smelters (Ades and Kazantzis 1988; Kazantzis et al. 1988).  However, no clear 
relationships between level and duration of cadmium exposure and lung cancer risk have been established 
and many of these studies did not account for confounding exposure to other carcinogenic metals 
(particularly arsenic and nickel) and cigarette smoking. 
 
The possible association between occupational exposure to cadmium and lung cancer was investigated in 
several studies of a cohort of workers employed at a U.S. cadmium recovery facility.  The cohort was 
initially examined by Lemen et al. (1976) who found a significant increase in deaths from malignant 
neoplasms of the respiratory tract among hourly workers employed for at least 2 years between 1940 and 
1969.  A re-examination of the cohort (deaths through 1978) also found statistically significant 
standardized mortality rates (SMRs) for malignant neoplasms in the respiratory tract (Thun et al. 1985).  
To adjust for possible arsenic exposure (between 1918 and 1925, the facility functioned as an arsenic 
smelter), workers were divided based on year of hire.  Mortality from lung cancer was significantly 
elevated in workers hired prior to 1926 and among workers hired after 1926 with 2 or more years of 
employment.  Dividing the workers into three exposure groups based on estimated cumulative exposure 
resulted in a significant dose-related trend for lung cancer deaths; in the highest exposure group 
(cumulative exposures >8 years-mg/m3), a 2- to 8-fold increase in the risk of lung cancer deaths was 
observed (Thun et al. 1985).  A subsequent analysis of these data (workers followed through 1985) used 
comparisons of rates with the cohort rather than the U.S. population (Stayner et al. 1992a).  Lung cancer 
mortality was significantly increased among non-Hispanic whites, among workers with the highest 
cumulative exposure (>2,291 days-mg/m3), and among workers with the longest time since first exposure 
(>20 years).  Lamm et al. (1992, 1994) used nearly the same data set for the U.S. cohort as Stayner et al. 
(1992a) in a nested case-control analysis that used the period of hire as a surrogate for arsenic exposure.  
Based on this analysis as a means to control for the confounding factor of arsenic exposure, Lamm et al. 
(1992, 1994) reported no residual association of lung cancer with cadmium.  They also reported that cases 
were eight times more likely to have been cigarette smokers than were controls.  Lamm et al. (1992, 
1994) conclude that arsenic exposure and cigarette smoking were the major determinants of lung cancer 
risk, not cadmium exposure.   
 
CADMIUM  102 
 
3.  HEALTH EFFECTS 
 
 
 
 
 
 
 
The reasons for these conflicting conclusions based on the same cohort data are unclear.  Doll (1992) 
suggested some possible reasons including: (1) that the total number of cases was small (n=25) and that 
only 21 of these cases were included in both studies (i.e., each study included some cases that were not 
included in the other study); (2) that Stayner et al. (1992a) used national rather than regional mortality 
rates; (3) that the Lamm et al. (1992, 1994) control series was overmatched, although the matching by 
date of hire was necessary to control for arsenic exposure; and (4) that there are some concerns about the 
validity (i.e., biological relevance) of the dose-response-models used by Stayner et al. (1992a).  In a 
response to Doll (1992), Stayner et al. (1993) reported that use of regional mortality rates would increase 
rather than decrease support for their conclusion, and that the nested case-control analysis of Lamm et al. 
(1992) used overmatched controls.  Stayner et al. (1993) provided additional analyses including the use of 
the Armitage-Doll multistage model to support the conclusion of an increased risk of cancer from 
cadmium exposure.  Sorahan and Lancashire (1994) subsequently raised concerns about inconsistencies 
and inaccuracies in the NIOSH job history data used in these studies on the U.S. cohort.  Sorahan and 
Lancashire (1997) then conducted further analyses, based on detailed job histories extracted from time 
sheet records, to better resolve the potential confounding affects of arsenic.  Poisson regression was used 
to investigate risks of mortality from lung cancer in relation to four concentrations of accumulative 
exposure to cadmium (<400, 400–999, 1,000–1,999, and >2,000 mg-days/m3).  After adjustment for age 
attained, year of hire, and Hispanic ethnicity; Sorahan and Lancashire (1997) report a significant positive 
trend (p<0.05) between cumulative exposure to cadmium and risks of mortality from lung cancer.  
However, when the exposure to cadmium was evaluated with or without concurrent exposure to arsenic, a 
significant trend for lung cancer was only found for exposure to cadmium received in the presence of 
arsenic trioxide.  Since there were only 21 deaths from lung cancer, Sorahan and Lancashire (1997) state 
that it is impossible to determine which of the following three hypotheses is the correct one: (1) cadmium 
oxide in the presence of arsenic trioxide is a human lung carcinogen, (2) cadmium oxide and arsenic 
trioxide are human lung carcinogens and cadmium sulphate and cadmium sulphide are not (i.e., cadmium 
sulphate and cadmium sulphide were the main cadmium compounds of exposure when arsenic was not 
present), or (3) arsenic trioxide is a human carcinogen and the three cadmium compounds are not 
carcinogenic.  
 
The carcinogenicity of cadmium has also been examined in European alloy, battery, smelter, and process 
workers.  A study of workers at two copper-cadmium alloy facilities in the United Kingdom found no 
significant increase in lung cancer mortality (Sorahan et al. 1995).  Dividing the workers into groups 
based on cumulative cadmium exposure or time since first exposure did not result in significant increases 
in lung cancer deaths in the alloy workers.  An initial study of workers at nickel-cadmium battery 
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manufacturing facilities in the United Kingdom found a significant increase in cancer of the respiratory 
tract (Sorahan and Waterhouse 1983).  A subsequent study (Sorahan 1987) found an increase in lung 
cancer deaths among workers with the highest exposure first employed between 1926 and 1946; no 
association was found in workers employed after 1946.  Another study of nickel-cadmium battery 
workers in the United Kingdom did not find significant increases in lung cancer deaths (Sorahan and 
Esmen 2004), although a significant increase in pharyngeal cancer deaths was observed.  A study of 
nickel cadmium battery workers in Sweden found an increase in lung cancer mortality, but the increase 
was not statistically significant (Elinder et al. 1985c).  An update of this study, which includes additional 
workers, found a significant increase in lung cancer deaths (Järup et al. 1998a).  However, there was no 
exposure-response relationship between cumulative exposure to cadmium (or nickel) and the risk of lung 
cancer.  A significant increase in lung cancer mortality was observed in workers employed at a zinc-lead-
cadmium smelter (Ades and Kazantzis 1988).  However, no relationship between cumulative cadmium 
exposure and lung cancer deaths was found, suggesting that cadmium was not the causative agent.  
Another study of workers in 19 facilities in the United Kingdom that process cadmium did not find a 
statistically significant increase in lung cancer deaths (Armstrong and Kazantzis 1983).  An update of this 
study found a significant increase in lung cancer deaths (Kazantzis et al. 1988).  However, >60% of the 
lung cancer deaths were workers at the zinc-lead-cadmium smelter examined by Ades and Kazantzis 
(1988). 
 
Studies in rats provide strong evidence of the lung carcinogenic potential of chronically inhaled cadmium.  
Oldiges et al. (1989) reported a clear dose response increase in lung tumors in male and female rats from 
an 18-month continuous exposure to either cadmium chloride, cadmium oxide dusts, cadmium oxide 
fume, cadmium sulfate, or cadmium sulfide.  In the cadmium chloride study at 30 μg/m3, the observation 
period in the males had to be shortened to 30 months (rather than 31) because of mortality in excess of 
75%.  No lung tumors were observed in control rats after 31 months of observation.  A high incidence of 
nodules and tumors was seen in 30 μg/m3 exposures to cadmium chloride in both males and females.  
Results showed lung nodules in 18 of 20 males and 15 of 18 females and primary lung tumors in 15 of 
20 males and 13 of 18 females.  Tumor incidence as bronchioalveolar adenomas, adenocarcinomas, 
squamous cell carcinomas, or combined epidermoid carcinoma and adenocarcinoma were 2, 12, 0, and 
1 for males; and 4, 7, 0, and 2 for females, respectively.  Increased lung tumors in males and females were 
also observed with chronic exposures to cadmium oxide dust or fume at 30 μg/m3, to cadmium sulfate at 
90 μg/m3, and to cadmium sulfide at 90 μg/m3 (Oldiges et al. 1989).  Cadmium sulfate produced by 
photolysis of cadmium sulfide under the experimental conditions may have contributed to some of the 
response observed with cadmium sulfide (Konig et al. 1992).   
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Takenaka et al. (1983) also demonstrated cadmium carcinogenicity in male rats exposed to cadmium 
chloride aerosols at 0.0134, 0.0257, and 0.0508 mg Cd/m3 for 18 months.  The exposure produced a dose-
related increase in lung epidermoid carcinomas, adenocarcinomas, and mucoepidermoid carcinomas 
starting at 20 months.  No other type of tumor was observed to increase with increasing dose.  
 
 
 
In a protocol similar to the studies by Oldiges et al. (1989), Heinrich et al. (1989) did not observe an 
increase in lung tumors in male or female Syrian golden hamsters from chronic inhalation exposure to 
either cadmium oxide dust or fumes, cadmium chloride, cadmium sulfate, or cadmium sulfide.  In female 
mice, lung tumor incidence increased at all dose levels, but incidence in the controls was also high, and 
the cadmium-induced increases were not statistically significant.  Lung tumors in the cadmium-treated 
mice also did not increase in a dose-responsive manner except for a weak increase from exposure to the 
cadmium oxide fumes (Heinrich et al. 1989).   
The available data provide inconclusive evidence on the potential of cadmium to induce lung cancer in 
humans.  The strongest evidence comes from early studies of workers at a U.S. cadmium recovery facility 
(Stayner et al. 1992a; Thun et al. 1985), but later examinations of this cohort did not find conclusive 
evidence (Lamm et al. 1992, 1994; Sorahan and Lancashire 1997).  The inconsistent results may be due to 
the small number of lung cancer cases and adjustments for possible early exposure to arsenic.  Some 
studies of European cadmium workers have found significant increases in lung cancer (Ades and 
Kazantzis 1988; Järup et al. 1998a; Kazantzis et al. 1988; Sorahan 1987; Sorahan and Waterhouse 1983), 
but lung cancer deaths were not significantly associated with cumulative cadmium levels or duration of 
exposure and the investigators concluded that the effects may not have been related to cadmium exposure.  
Based on an early 1990s analysis of the available human and animal data, IARC (1993) classified 
cadmium as carcinogenic to humans (Group 1), based on sufficient evidence for carcinogenicity in both 
human and animal studies.  Similarly, the DHHS (NTP 2011) classified cadmium and certain cadmium 
compounds as substances known to be human carcinogens.  EPA classified cadmium as a probable human 
carcinogen by inhalation (Group B1), based on limited evidence of an increase in lung cancer in humans 
and sufficient evidence of lung cancer in rats (IRIS 2012).  EPA estimated an inhalation unit risk (the risk 
corresponding to lifetime exposure to 1 μg/m3) of 1.8x10-3 based on the Thun et al. (1985) study (IRIS 
2012).  A range of concentrations that correspond to upper bound lifetime excess risks of 10-4–10-7 is 
shown in Figure 3-1.   
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3.2.2   Oral Exposure  
 
Information on health effects of oral exposure to cadmium in humans is derived mainly from studies of 
residents living in cadmium-polluted areas.  Cadmium exposure in these populations is often estimated by 
blood or urinary cadmium levels (see Section 3.8.1).  Exposure in these cases occurs primarily through 
the diet, but smokers in these cohorts are also exposed to cadmium by inhalation.  When evaluating oral 
exposure studies, smoking was treated as a confounding variable rather than an exposure route because of 
the large number of toxic compounds (in addition to cadmium) present in cigarette smoke, and because 
the primary concern is effects attributable to cadmium.  Cadmium is more readily found in the free ionic 
form in water, while in food, the cadmium ion generally exists in a complex with a variety of ligands, 
including proteins such as metallothionein (Crews et al. 1989; Groten et al. 1990; Nordberg et al. 1986).  
Experimental studies in animals have generally used soluble salts of cadmium (such as cadmium chloride) 
for food, drinking water, and gavage exposures.  The toxicological properties of the cadmium ion do not 
appear to depend on the counter ion, although absorption may be significantly affected by protein 
complexes (see Section 3.3.1.2). 
 
3.2.2.1   Death  
 
Intentional ingestion of cadmium has been used as a means of suicide, causing death due to massive fluid 
loss, edema, and widespread organ destruction (Buckler et al. 1986; Wisniewska-Knypl et al. 1971).  The 
doses ingested in two known fatal cases were estimated to be 25 mg Cd/kg from cadmium iodide 
(Wisniewska-Knypl et al. 1971) and 1,840 mg Cd/kg from cadmium chloride (Buckler et al. 1986).  Time 
to death after cadmium iodide ingestion was 7 days (Wisniewska-Knypl et al. 1971) and 33 hours after 
ingestion of the cadmium chloride (Buckler et al. 1986). 
 
 
In rats and mice, acute oral LD50 (lethal dose, 50% kill) values for cadmium range from about 100 to 
300 mg/kg (Baer and Benson 1987; Basinger et al. 1988; Kostial et al. 1978; Kotsonis and Klaassen 1978; 
Shimizu and Morita 1990).  The lowest dose causing death (2 of 20 animals) was 15.3 mg/kg in Sprague-
Dawley rats (Borzelleca et al. 1989).  Very young animals have lower LD50 values than adult animals 
(Kostial et al. 1978, 1989); this effect may be related to the greater fractional absorption of ingested 
cadmium in the immature organism (see Section 3.4.1.2).  For example, the LD50 values in rats aged 2, 3, 
6, 18, and 54 week are 47, 240, 216, 170, and 109 mg/kg, respectively (Kostial et al. 1978). 
Deaths related to cadmium exposure have been reported in only two of the intermediate exposure studies 
found.  In a study in Wistar rats exposed to cadmium chloride by gavage at 40 mg Cd/kg/day, 
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5 days/week for up to 14 weeks; 4 of 13 female Wistar rats died by 8 weeks (Baranski and Sitarek 1987).  
In mice, Blakley (1986) studied the effect of cadmium on chemical- and viral-induced tumor production.  
Female albino Swiss mice (8 weeks old, n=41) were administered cadmium chloride in the drinking water 
for 280 days at doses of 0, 5, 10, or 50 ppm.  These mice have a high incidence of spontaneous 
lymphocytic leukemia of thymic origin.  A significant 33% increase (p=0.0228, chi-square analysis) in 
deaths from virally induced leukemia was observed from exposure to 1.9 or 9.5 mg Cd/kg/day.  The 
deaths were attributed to cadmium-impaired immunosurveillance mechanisms that control expression of 
the murine lymphocytic leukemia virus. 
 
 
 
 
The LOAEL values from each reliable study for lethality in each species and duration category are 
recorded in Table 3-6 and plotted in Figure 3-2. 
3.2.2.2   Systemic Effects  
 
The highest NOAEL values and all LOAEL values from each reliable study for systemic effects in each 
species and duration category are recorded in Table 3-6 and plotted in Figure 3-2. 
Respiratory Effects.    No studies were located regarding respiratory effects in humans after oral 
exposure to cadmium.   
No respiratory effects were observed in Rhesus monkeys from 4 mg/kg/day of cadmium chloride in the 
food for 9 years (Masaoka et al. 1994).  Intermediate-duration oral exposure caused fibrosis in lungs of 
rats exposed to 2.4 mg Cd/kg/day of cadmium chloride after 6 and 16 weeks (Miller et al. 1974b).  
Petering et al. (1979) observed a reduced static compliance and lung lesions (not specified) in male 
Sprague-Dawley rats exposed to 1.2 mg Cd/kg/day in water for 200 days.  Zinc-deficient rats were more 
susceptible to lung lesions from exposure to cadmium chloride (Petering et al. 1979).  Rats exposed to 
cadmium chloride at 3.62 mg Cd/kg/day in the drinking water for 120 days developed emphysema 
(Petering et al. 1979).  No histopathologic lesions of the lung were found in male Sprague-Dawley rats 
after 24 weeks of exposure to cadmium in drinking water at a maximum dose of 8 mg/kg/day (Kotsonis 
and Klaassen 1978).  Lung weight was unchanged in Wistar rats after 90 days of exposure in drinking 
water at 16 mg/kg/day (Prigge 1978a).  Effects on the lung following oral exposure to cadmium may be 
secondary to systemic changes (Petering et al. 1979); however, the studies that found lung effects did not 
examine other systemic effects in the exposed rats (Miller et al. 1974b; Petering et al. 1979). 
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Table 3-6  Levels of Significant Exposure to Cadmium  -  Oral
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/kg/day)
Less Serious
(mg/kg/day)
Serious
(mg/kg/day)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
ACUTE EXPOSURE
Death
1
230
Kostial et al. 1978
CdCl2
29 (LD50 at 8 days; 2 weeks
old)
29
F129 (LD50 at 8 days; 6 weeks
old)
129
F104 (LD50 at 8 days; 18
weeks old)
104
Rat
(NS)
once
(G)
2
232
Kotsonis and Klaassen 1977
CdCl2
M225 (LD50 at 14 days)
225
Rat
(Sprague-
Dawley)
once
(GW)
3
233
Kotsonis and Klaassen 1978
CdCl2
M42 (7/9 died within 2 weeks)
42
Rat
(Sprague-
Dawley)
2 wk
(W)
4
236
Shimizu and Morita 1990
CdCl2
M327 (LD50 at 24 hours; fed
rats)
327
M107 (LD50 at 24 hours; fasted
rats)
107
Rat
(Sprague-
Dawley)
once
(GW)
5
238
Baer and Benson 1987
CdCl2
M95.5 (LD50 at 96 hours)
95.5
Mouse
(Swiss-
Webster)
once
(GW)
6
239
Basinger et al. 1988
CdCl2
M112 (5/10 died within 8 days)
112
Mouse
(ICR)
once
(GW)
3.  H
E
A
LTH
 E
FFE
C
TS
C
A
D
M
IU
M
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(continued)Table 3-6  Levels of Significant Exposure to Cadmium  -  Oral
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/kg/day)
Less Serious
(mg/kg/day)
Serious
(mg/kg/day)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
Systemic
7
245
Baranski 1985
CdCl2
Bd Wt F2
2
F12 (14% decreased
maternal body weight)
12
Rat
(Wistar)
10 d
Gd 7-16
once
(GW)
8
246
Borzelleca et al. 1989
CdCl2
Hemato M31.3
31.3
F138
138
M65.6 (increased hemoglobin,
hematocrit, erythrocytes)
65.6
Rat
(Sprague-
Dawley)
10 d
1 x/d
(GW)
Hepatic M65.6
65.6
M138 (focal necrosis of
hepatocytes)
138
Renal 15.3 (focal necrosis of tubular
epithelium)
15.3
Bd Wt M15.3 (18% decreased body
weight)
15.3
M31.3 (23% decreased body
weight)
31.3
F31.3
31.3
F65.6 (18% decreased body
weight)
65.6
9
247
Borzelleca et al. 1989
CdCl2
Hepatic 13.9
13.9
Rat
(Sprague-
Dawley)
10 d
(W)
Renal 13.9
13.9
Bd Wt 13.9
13.9
M1.1
1.1
M7.8 (14% decreased body
weight)
7.8
M11.2 (25% decreased body
weight)
11.2
3.  H
E
A
LTH
 E
FFE
C
TS
C
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D
M
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(continued)Table 3-6  Levels of Significant Exposure to Cadmium  -  Oral
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/kg/day)
Less Serious
(mg/kg/day)
Serious
(mg/kg/day)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
10
248
Kotsonis and Klaassen 1977
CdCl2
Cardio M150
150
Rat
(Sprague-
Dawley)
once
(GW)
Hemato M150
150
Hepatic M150
150
Renal M25 (50% decrease in urine
flow for first 2 days)
25
Bd Wt 100
100
M150 (initial 12% decreased
body weight)
150
11
249
Machemer and Lorke 1981
CdCl2
Gastro F6.13
6.13
F61.32 (intestinal necrosis,
hemorrhage, ulcers)
61.32
Rat
(Long- Evans)
Gd 6-15
(GW)
Bd Wt F1.84
1.84
F6.13 (27% decrease in body
weight gain during
treatment)
6.13
F18.39 (persistent 50% decrease
in maternal body weight
gain)
18.39
12
250
Machemer and Lorke 1981
CdCl2
Gastro F12.5
12.5
Rat
(Long- Evans)
Gd 6-15
(F)
Bd Wt F3.5
3.5
F12.5 (transient 19% decrease
in maternal body weight
gain during treatment)
12.5
13
251
Sakata et al. 1988
CdCl2
Hemato M12 (anemia)
12
Rat
(Wistar)
12 d
(W)
3.  H
E
A
LTH
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(continued)Table 3-6  Levels of Significant Exposure to Cadmium  -  Oral
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/kg/day)
Less Serious
(mg/kg/day)
Serious
(mg/kg/day)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
14
252
Shimizu and Morita 1990
CdCl2
Hepatic M75 (focal degeneration and
necrosis of parenchymal
cells)
75
Rat
(Sprague-
Dawley)
once
(GW)
15
253
Andersen et al. 1988
CdCl2
Gastro M15.7
15.7
M30.4 (gastritis and enteritis)
30.4
M88.8 (severe gastric necrosis)
88.8
Mouse
(CBA/Bom)
once
(GW)
Hepatic M15.7
15.7
M30.4 (fatty infiltration of liver
cells, occasional
hepatocellular necrosis)
30.4
Renal 59.6
59.6
M88.8 (tubular necrosis and
casts)
88.8
16
254
Basinger et al. 1988
CdCl2
Gastro M112 (glandular stomach
epithelial necrosis)
112
Mouse
(ICR)
once
(GW)
Hepatic M112 (extensive hepatocellular
coagulative necrosis)
112
Renal M112
112
Immuno/ Lymphoret
17
255
Borzelleca et al. 1989
CdCl2
M65.6
65.6
F31.3
31.3
F65.6 (increased leukocyte
counts)
65.6
Rat
(Sprague-
Dawley)
10 d
1 x/d
(GW)
Neurological
18
256
Kotsonis and Klaassen 1977
CdCl2
M25
25
M50 (decreased motor
activity)
50
Rat
(Sprague-
Dawley)
once
(GW)
3.  H
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(continued)Table 3-6  Levels of Significant Exposure to Cadmium  -  Oral
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/kg/day)
Less Serious
(mg/kg/day)
Serious
(mg/kg/day)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
Reproductive
19
257
Bomhard et al. 1987
CdCl2
M50
50
M100 (testicular necrosis)
100
Rat
(Wistar)
once
(GW)
20
258
Borzelleca et al. 1989
CdCl2
F138
138
M65.6 (testicular atrophy and
loss of spermatogenic
elements)
65.6
Rat
(Sprague-
Dawley)
10 d
1 x/d
(GW)
21
259
Dixon et al. 1976
CdCl2
M25
25
Rat
(Sprague-
Dawley)
once
(GW)
22
260
Kotsonis and Klaassen 1977
CdCl2
M50
50
M100 (testicular necrosis;
decreased
spermatogenesis;
decreased number
females producing pups)
100
Rat
(Sprague-
Dawley)
once
(GW)
23
263
Andersen et al. 1988
CdCl2
M30.3
30.3
M59.6 (testicular necrosis)
59.6
Mouse
(CBM/ Bom)
once
(GW)
Developmental
24
264
Baranski 1985
CdCl2
F2 (delayed ossification of
the sternum and ribs)
2
40 (fused lower limbs,
absent limbs, decreased
number of live fetuses,
increased number of
resorptions)
40
Rat
(Wistar)
10 d
Gd 7-16
once
(GW)
3.  H
E
A
LTH
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(continued)Table 3-6  Levels of Significant Exposure to Cadmium  -  Oral
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/kg/day)
Less Serious
(mg/kg/day)
Serious
(mg/kg/day)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
25
265
Machemer and Lorke 1981
CdCl2
6.13
6.13
18.39 (increased number of
fetuses with
malformations)
18.39
Rat
(Long- Evans)
1 x/d
Gd 6-15
(GW)
26
266
Machemer and Lorke 1981
CdCl2
12.5
12.5
Rat
(Long- Evans)
10 d
Gd 6-15
(F)
INTERMEDIATE EXPOSURE
Death
27
269
Baranski and Sitarek 1987
CdCl2
F40 (4/13 died by week 8;
7/13 by week 14)
40
Rat
(Wistar)
14 wk
5 d/wk
(GW)
28
273
Blakley 1986
CdCl2
F1.9 (24/41 died by 280 days)
1.9
Mouse
(Swiss)
280 d
(W)
Systemic
29
276
Chopra et al. 1984
CdCl2
Bd Wt M5
5
Monkey
(Rhesus)
10 wk
(F)
30
280
Baranski and Sitarek 1987
CdCl2
Bd Wt F4
4
F40 (29% decreased
maternal body weight)
40
Rat
(Wistar)
14 wk
5 d/wk
(GW)
31
282
Bernard et al. 1988a
CdCl2
Renal F30 (B2-microglobulinuria)
30
Rat
(Sprague-
Dawley)
2-10 mo
(W)
3.  H
E
A
LTH
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(continued)Table 3-6  Levels of Significant Exposure to Cadmium  -  Oral
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/kg/day)
Less Serious
(mg/kg/day)
Serious
(mg/kg/day)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
32
1031
Brzoska and
Moniuszko-Jakoniuk 2005a,
2005b; Brzoska et al. 2010
CdCl2
Musc/skel M0.2
0.2
M0.5 (increased lumbar spine
deformities, decreased in
lumbar spine and femur
mineralization, altered
bone turnover
parameters)
0.5
Rat
(Wistar)
daily
12 mo
(W)
33
1030
Brzoska and
Moniuszko-Jakoniuk 2005d;
Brzoska et al. 2005a, 2005c
CdCl2
Musc/skel
b
F0.2 (decreased bone
mineralization,
mechanical properties of
tibia and femur, and
altered bone turnover
parameters)
0.2
Rat
(Wistar)
daily
12 mo
(W)
34
1029
Brzoska et al. 2004b, 2005b
CdCl2
Musc/skel F0.3 (alterations in bone
mineral content and
density and mechanical
properties of lumbar
vertebral and femoral
bones)
0.3
Rat
(Wistar)
daily
12 mo
(W)
35
283
Cardenas et al. 1992a
CdCl2
Renal F15.2 (albuminuria,
transferrinuria,
B2-microglobulinuria)
15.2
Rat
(Sprague-
Dawley)
4 or 7 mo
(W)
36
284
Carmignanti and Boscolo 1984
Cd acetate
Cardio M1.4 (20% increase in diastolic
blood pressure)
1.4
Rat
(Sprague-
Dawley)
190 d
(W)
Bd Wt M2.8
2.8
3.  H
E
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(continued)Table 3-6  Levels of Significant Exposure to Cadmium  -  Oral
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/kg/day)
Less Serious
(mg/kg/day)
Serious
(mg/kg/day)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
37
285
Cha 1987
CdCl2
Hepatic M8.58 (necrosis of central
lobules)
8.58
Rat
(Sprague-
Dawley)
12 wk
(W)
Renal M8.58 (necrosis of proximal
tubular epithelial cells
and cloudy swelling)
8.58
Bd Wt M8.58 (23% decreased in body
weight gain; 9% total
body weight decrease)
8.58
38
286
Cifone et al. 1989a
CdCl2
Bd Wt F56
56
Rat
(Wistar)
170 d
(W)
39
287
Decker et al. 1958
CdCl2
Hemato 2 (anemia)
2
Rat
(Sprague-
Dawley)
3 mo
(W)
Bd Wt F2 (15% decreased body
weight)
2
M2 (25% decreased body
weight)
2
40
288
Gatta et al. 1989
CdCl2
Renal 1.18 (vesiculation of proximal
tubules)
1.18
Rat
(Wistar)
4-60 wk
(W)
41
290
Groten et al. 1990
CdCl2
Hemato M2.5 (anemia)
2.5
Rat 4 wk
(F)
Renal M2.5
2.5
3.  H
E
A
LTH
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(continued)Table 3-6  Levels of Significant Exposure to Cadmium  -  Oral
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/kg/day)
Less Serious
(mg/kg/day)
Serious
(mg/kg/day)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
42
292
Itokawa et al. 1974
CdCl2
Hemato M3.6 (anemia)
3.6
Rat
(Wistar)
120 d
(W)
Renal M3.6 (tubular necrosis and
casts, glomerular
adhesions)
3.6
43
293
Jamall et al. 1989
CdCl2
Cardio M2.5 (congested myocardium,
separation of muscle
fibers)
2.5
Rat
(Sprague-
Dawley)
7 wk
(F)
Renal M2.5
2.5
Bd Wt M2.5
2.5
44
294
Kawamura et al. 1978
CdCl2
Hemato F8 (anemia)
8
Rat
(Wistar)
90 d
(W)
Musc/skel F8 (osteomalacia changes)
8
Renal F8 (decreased renal
clearance)
8
Endocr F8
8
Bd Wt F8 (12% decreased body
weight)
8
45
295
Kelman et al. 1978
form not specified
Hemato F1.5 (slight anemia)
1.5
Rat
(Sprague-
Dawley)
22 d
Gd 0-21
(W)
Musc/skel F3.8
3.8
3.  H
E
A
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(continued)Table 3-6  Levels of Significant Exposure to Cadmium  -  Oral
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/kg/day)
Less Serious
(mg/kg/day)
Serious
(mg/kg/day)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
46
297
Kotsonis and Klaassen 1978
CdCl2
Resp M8
8
Rat
(Sprague-
Dawley)
24 wk
(W)
Cardio M8
8
Gastro M8
8
Hemato M8
8
Musc/skel M8
8
Hepatic M8
8
Renal M1.2
1.2
M3.1 (proteinuria, slight focal
tubular necrosis)
3.1
Endocr M8
8
Bd Wt M8
8
47
1039
Larregle et al. 2008
CdCl2
Hepatic M18 (increased serum and
liver triglyceride levels;
increased serum
cholesterol levels)
18
Rat
(Wistar)
8 weeks
daily
(W)
48
302
Loeser and Lorke 1977a
CdCl2
Cardio 3
3
Rat
(Wistar)
3 mo
(F)
Hemato 3
3
Hepatic 3
3
Renal 3
3
Endocr 3
3
Bd Wt 3
3
3.  H
E
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Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/kg/day)
Less Serious
(mg/kg/day)
Serious
(mg/kg/day)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
49
304
Miller et al. 1974b
CdCl2
Resp 2.4 (lung fibrosis)
2.4
Rat
(Sprague-
Dawley)
6-16 wk
(W)
50
306
Muller et al. 1988
Cd acetate
Hepatic M0.25
0.25
Rat
(Sprague-
Dawley)
6 wk
5 d/wk
1 x/d
(GW)
Bd Wt M0.25
0.25
51
307
Ogoshi et al. 1989
CdCl2
Hemato F0.8 (decreased hematocrit
and hemoglobin)
0.8
Rat
(NS)
4 wk
(W)
Musc/skel F0.8 (decreased bone
strength in young
animals)
0.8
Bd Wt 0.8
0.8
F1.6 (10% decreased body
weight gain)
1.6
52
309
Petering et al. 1979
CdCl2
Resp M0.6
0.6
M1.2 (reduced static
compliance, lung lesions)
1.2
Rat
(NS)
200 d
(W)
53
310
Petering et al. 1979
CdCl2
Resp M3.62 (emphysema)
3.62
Rat
(Sprague-
Dawley)
120 d
(W)
3.  H
E
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Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/kg/day)
Less Serious
(mg/kg/day)
Serious
(mg/kg/day)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
54
311
Petering et al. 1979
CdCl2
Hemato F5.23
5.23
Rat
(Sprague-
Dawley)
111 d
(90 d prior to
Gd 1-21)
(W)
55
315
Pond and Walker 1975
CdCl2
Bd Wt F19.7 (77-80% decreased
maternal weight gain)
19.7
Rat
(Sprague-
Dawley)
Gd 1- Ld 1
(F)
56
316
Prigge 1978a
CdCl2
Resp F16
16
Rat
(Wistar)
90 d
(W)
Hemato F4 (23% decreased serum
iron)
4
Renal F4
4
F8 (35% increase in urine
protein)
8
Bd Wt F8
8
57
317
Sakata et al. 1988
CdCl2
Hemato M12 (iron deficient anemia)
12
Rat
(Wistar)
12, 26, 50, or
100 d
(W)
58
324
Viau et al. 1984
CdCl2
Renal F13
13
Rat
(Sprague-
Dawley)
7-12 mo
(W)
Bd Wt F13
13
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(continued)Table 3-6  Levels of Significant Exposure to Cadmium  -  Oral
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/kg/day)
Less Serious
(mg/kg/day)
Serious
(mg/kg/day)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
59
327
Bhattacharyya et al. 1988a,
1988b
Musc/skel F0.65 (decrease in femur
calcium content in mice
undergoing repeated
pregnancy/lactation
periods)
0.65
Mouse
(CF1)
252 d
(F)
60
356
Malave and de Ruffino 1984
CdCl2
Bd Wt M12.5 (63% decreased body
weight gain)
12.5
Mouse
(C57BL/6)
3-11 wk
(W)
61
331
Waalkes et al. 1993
CdCl2
Bd Wt M232 (45% decreased body
weight)
232
Mouse
(B6C3F1)
16-46 wk
(W)
62
332
Webster 1978
CdCl2
Hemato F4.8
4.8
F9.6 (anemia)
9.6
Mouse
(QS/CH)
Gd 1-19
(W)
Bd Wt F4.8
4.8
F9.6 (14% decrease in
maternal weight gain)
9.6
63
335
Loeser and Lorke 1977b
CdCl2
Cardio 0.75
0.75
Dog
(Beagle)
3 mo
(F)
Hemato 0.75
0.75
Hepatic 0.75
0.75
Renal 0.75
0.75
Bd Wt 0.75
0.75
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(continued)Table 3-6  Levels of Significant Exposure to Cadmium  -  Oral
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/kg/day)
Less Serious
(mg/kg/day)
Serious
(mg/kg/day)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
64
336
Boscolo and Carmignani 1986
CdCl2
Cardio M1.6 (increased aortic
resistance, reduced
contractility)
1.6
Rabbit
(New
Zealand)
9 mo
(W)
Renal M1.6
1.6
Bd Wt M1.6
1.6
65
338
Stowe et al. 1972
CdCl2
Hemato M14.9 (anemia)
14.9
Rabbit
(New Zealand
and Belgian
Giant)
200 d
(W)
Hepatic M14.9 (focal hepatic fibrosis and
biliary hyperplasia)
14.9
Renal M14.9 (tubular necrosis,
glomerular and interstitial
fibrosis)
14.9
Endocr 14.9
14.9
Bd Wt M14.9 (11% decrease in body
weight)
14.9
Immuno/ Lymphoret
66
341
Chopra et al. 1984
CdCl2
M5 (increased cell-mediated
immune response)
5
Monkey
(Rhesus)
10 wk
(F)
67
343
Cifone et al. 1989a
CdCl2
F28 (biphasic decrease then
increase in natural killer
cell activity)
28
Rat
(Wistar)
170 d
(W)
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Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/kg/day)
Less Serious
(mg/kg/day)
Serious
(mg/kg/day)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
68
344
Loeser and Lorke 1977a
CdCl2
3
3
Rat
(Wistar)
3 mo
(F)
69
349
Blakley 1985
CdCl2
F1.4
1.4
F2.8 (decreased humoral
immune response)
2.8
Mouse
(BDF1)
3 wk
(W)
70
350
Blakley 1986
CdCl2
F1.9 (greater susceptibility to
murine lymphocytic
leukemia virus)
1.9
Mouse
(Swiss)
280 d
(W)
71
351
Blakley 1988
CdCl2
F12.5
12.5
Mouse
(BDF1)
26 d
(W)
72
353
Bouley et al.  1984
Cd acetate
M22
22
Mouse
(Swiss-
Webster)
30 d
(W)
73
354
Exon et al. 1986
CdCl2, Cd acetate, or Cd
sulfate
M57
57
Mouse
(Swiss-
Webster)
10 wk
(W)
74
355
Krzystyniak et al. 1987
CdCl2
F19
19
F57 (reduced number of
SRBC-activated,
plaque-forming cells)
57
Mouse
(C57BL/6N)
12-16 wk
(W)
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(continued)Table 3-6  Levels of Significant Exposure to Cadmium  -  Oral
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/kg/day)
Less Serious
(mg/kg/day)
Serious
(mg/kg/day)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
75
356
Malave and de Ruffino 1984
CdCl2
M12.5 (decreased suppressor
cell activity)
12.5
Mouse
(C57BL/6)
3-11 wk
(W)
76
357
Ohsawa et al. 1988
CdCl2
M0.75 (induction of anti-nuclear
autoantibodies)
0.75
Mouse
(ICR)
10 wk
(W)
Neurological
77
358
Baranski and Sitarek 1987
CdCl2
F4
4
F40 (aggressive behavior)
40
Rat
(Wistar)
14 wk
5 d/wk
(GW)
78
359
Kotsonis and Klaassen 1978
CdCl2
M1.2
1.2
M3.1 (decreased motor
activity)
3.1
Rat
(Sprague-
Dawley)
3-24 wk
(W)
79
361
Nation et al. 1984
CdCl2
M1
1
M5 (increased passive
avoidance)
5
Rat
(Sprague-
Dawley)
55 d
(F)
80
363
Nation et al. 1990
CdCl2
M9 (decreased motor
activity)
9
Rat
(Sprague-
Dawley)
60 d
(F)
Reproductive
81
367
Baranski and Sitarek 1987
CdCl2
F4
4
F40 (increased duration of
estrus cycle)
40
Rat
(Wistar)
14 wk
5 d/wk
(GW)
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Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/kg/day)
Less Serious
(mg/kg/day)
Serious
(mg/kg/day)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
82
368
Baranski et al. 1983
CdCl2
F4
4
Rat
(Wistar)
11 wk
5 d/wk
(GW)
83
370
Histopathology only.Bomhard et al. 1987
CdCl2
M5
5
Rat
(Wistar)
10 wk
1 x/wk
(GW)
84
372
Cha 1987
CdCl2
M8.58 (necrosis and atrophy of
seminiferous tubule
epithelium)
8.58
Rat
(Sprague-
Dawley)
12 wk
(W)
85
374
Histopathology only.Groten et al. 1990
CdCl2
M2.5
2.5
Rat 4 wk
(F)
86
376
Kostial et al. 1993
CdCl2
F4.8
4.8
Rat
(albino)
4 wk
(W)
87
377
Kotsonis and Klaassen 1978
CdCl2
M8
8
Rat
(Sprague-
Dawley)
24 wk
(W)
88
379
Histopathology only.Loeser and Lorke 1977a
CdCl2
3
3
Rat
(Wistar)
3 mo
(F)
89
384
Saxena et al. 1989
Cd acetate
M12.6 (decreased sperm count
and motility, seminiferous
tubular damage)
12.6
Rat
(NS)
120 d
(W)
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Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/kg/day)
Less Serious
(mg/kg/day)
Serious
(mg/kg/day)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
90
387
Zenick et al. 1982
CdCl2
M4.64
4.64
Rat
(Long- Evans)
70-80 d
(W)
91
390
Loeser and Lorke 1977b
CdCl2
0.75
0.75
Dog
(Beagle)
3 mo
(F)
Developmental
92
391
Ali et al. 1986
Cd acetate
0.706 (delayed development of
sensory motor
coordination reflexes;
increased motor activity)
0.706
Rat
(Wistar)
21 d
Gd 1-21
(W)
93
392
Decreased maternal
water and food
consumption.
Baranski 1987
CdCl2
9.6 (decreased fetal body
weight  [12%], body
length [7%], and
hematocrit [13%])
9.6
Rat
(Wistar)
20 d
Gd 1-20
(W)
94
393
Baranski et al. 1983
CdCl2
0.04 (pup behavioral
alterations)
0.04
Rat
(Wistar)
11 wk
5 d/wk
1 x/d
(GW)
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Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/kg)
Less Serious
(mg/kg)
Serious
(mg/kg)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
95
1002
Desi et al. 1998
CdCl2
M14 (decreased horizontal
ambulation and rearing
activity; increased
frequency of
somatosensory, visual,
and auditory
electrocorticogram;
prolonged latency and
duration of evoked
potentials)
14
Rat
(Wistar)
11-94 d
Gd 5-15
Ld 2-28
1 x/d
ppd 1-56
5 d/wk
1 x/d
(GW)
96
394
Gupta et al 1993
Cd acetate
5 (decreased pup brain
and body weight at 7, 14,
and 21 days)
5
Rat
(Druckery)
Gd 0- Ld 21
(W)
97
395
Kelman et al. 1978
form not specified
1.5 (12% decreased
hematocrit)
1.5
Rat
(Sprague-
Dawley)
Gd 0-20
(W)
98
396
Kostial et al. 1993
CdCl2
4.8 (12% decrease in pup
body weight at weaning)
4.8
Rat
(albino)
10 wk
(W)
99
1016
Nagymajtenyi  et al. 1997
CdCl2
M7 (alterations in ambulation
behavior;  prolonged
latency and duration of
somatosensory evoked
potentials)
7
Rat
(Wistar)
approx. 49 d
4 wk old through
mating
7 d/wk
1 x/d
(GO)
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(continued)Table 3-6  Levels of Significant Exposure to Cadmium  -  Oral
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/kg/day)
Less Serious
(mg/kg/day)
Serious
(mg/kg/day)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
100
397
Petering et al. 1979
CdCl2
2.61 (decreased live birth
weight)
2.61
Rat
(Sprague-
Dawley)
60 d prior to Gd
1
or
Gd 1-21
(W)
101
399
Pond and Walker 1975
CdCl2
19.7 (13-19% decreased pup
birth weight)
19.7
Rat
(Sprague-
Dawley)
Gd 1- Ld 1
(F)
102
400
Saxena et al. 1986
Cd acetate
21
21
Rat
(ITRC)
21 d
Gd 0-20
(W)
103
401
Sorell and Graziano 1990
CdCl2
0.63
0.63
4.7 (8% decreased fetal body
weight)
4.7
Rat
(Sprague-
Dawley)
15 d
Gd 6-20
(W)
104
402
Sutou et al. 1980
form not specified
1
1
10 (delayed ossification,
decreased body weight)
10
Rat
(Sprague-
Dawley)
9 wk
1 x/d
(GW)
105
404
Webster 1978
CdCl2
2.4 (decreased fetal body
weight; severe anemia)
2.4
Mouse
(QS/CH)
19 d
Gd 1-19
(W)
CHRONIC EXPOSURE
Systemic
106
1036
Buchet et al. 1990; Jarup et al.
2000; Suwazono et al. 2006
form not specified
Renal
c
F0.0003
0.0003
Human
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(continued)Table 3-6  Levels of Significant Exposure to Cadmium  -  Oral
Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/kg/day)
Less Serious
(mg/kg/day)
Serious
(mg/kg/day)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
107
437
Nogawa et al. 1989
form not specified
Renal 0.0021
0.0021
Human NS
lifetime
(F)
108
441
Shiwen et al. 1990
Cd metal
Hemato 0.0078
0.0078
Human >25 yr
lifetime
(environ)
Musc/skel 0.0078
0.0078
Renal 0.0078 (increased excretion of
low molecular weight
proteins)
0.0078
109
448
Akahori et al. 1994
CdCl2
Cardio M0.53
0.53
M1.71 (increased blood
pressure during the first
1.5 years)
1.71
Monkey
(Rhesus)
9 yr
(F)
110
451
Bernard et al. 1992
CdCl2
Renal F13 (loss of glomerular
polyanion charge barrier,
proteinuria)
13
Rat
(Sprague-
Dawley)
18 mo
(W)
111
452
Bomhard et al. 1984
CdCl2
Renal 3.5
3.5
17.5 (8 to 9-fold increase in
LDH and GST starting at
13 weeks)
17.5
Rat
(Wistar)
72 wk
(F)
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Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/kg/day)
Less Serious
(mg/kg/day)
Serious
(mg/kg/day)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
112
1032
Brzoska and
Moniuszko-Jakoniuk 2004a,
2004b; Brzoska 2011
CdCl2
Musc/skel F0.08 (decreases in bone
mineral content and
density of lumbar spine,
altered bone turnover
paramters, increases in
deformed and fractured
vertebral bodies)
0.08
Rat
(Wistar)
daily
24 mo
(W)
113
453
Decker et al. 1958
CdCl2
Hemato 0.79
0.79
Rat
(Sprague-
Dawley)
12 mo
(W)
Bd Wt 0.79
0.79
114
454
Fingerle et al. 1982
CdCl2
Cardio 4.01
4.01
Rat
(Sprague-
Dawley)
M: 92 wk
F: 84 wk
(W)
Renal 0.8
0.8
1.51 (proximal tubule lesions)
1.51
Bd Wt 4.01
4.01
115
456
Mangler et al 1988
CdCl2
Cardio F2.281
2.281
Rat
(Sprague-
Dawley)
6, 12, or 18 mo
(W)
Hepatic F2.281
2.281
Renal F2.337 (cloudy swelling of
tubular cells)
2.337
Bd Wt F2.281
2.281
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Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/kg/day)
Less Serious
(mg/kg/day)
Serious
(mg/kg/day)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
116
458
Sato et al. 1978
CdCl2
Musc/skel 3.6 (muscle atrophy)
3.6
Rat
(Wistar)
31 mo
(W)
Bd Wt 3.6
3.6
117
460
Shaikh et al. 1989
CdCl2
Renal M2.6
2.6
Rat
(Wistar)
2 yr
(W)
118
461
Waalkes and Rehm 1992
CdCl2
Bd Wt M3.5
3.5
M7 (10% decreased body
weight)
7
Rat
(Wistar)
77 wk
(F)
119
1038
Bhattacharyya et al. 1988cMusc/skel F0.65
0.65
F6.5 (loss of bone calcium in
ovariectomized mice)
6.5
Mouse
(CF1)
18 months
(F)
120
464
Hays and Margaretten 1985
form not specified
Hemato 57 (anemia and bone
marrow hypoplasia)
57
Mouse
(CBA/H)
12 mo
(W)
Renal 57
57
Bd Wt 57 (21% decreased terminal
body weight)
57
Neurological
121
469
Sato et al. 1978
CdCl2
3.6 (peripheral neuropathy)
3.6
Rat
(Wistar)
31 mo
(W)
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Species
(Strain)
LOAEL
CommentsSystem
NOAEL
(mg/kg/day)
Less Serious
(mg/kg/day)
Serious
(mg/kg/day)
Reference
Chemical Form
Exposure/
Duration/
Frequency
(Route)
Cancer
122
a The number corresponds to entries in Figure 3-2.
488
3.5
Rat 77 wk Waalkes and Rehm 1992
CdCl2
M3.5 (CEL: increased rates of
prostatic adenomas)(Wistar) (F)
b The intermediate-duration oral MRL of 0.0005 mg Cd/kg/day (0.5 ug Cd/kg/day) was calculated using a benchmark dose analysis.  The BMDL1std of 0.05 mg Cd/kg/day was
divided by an uncertainty factor of 100 (10 to account for extrapolation from animals to humans and 10 for human variability).
c The chronic-duration oral MRL of 0.0001 mg Cd/kg/day (0.1 ug Cd/kg/day) was calculated from the 95% lower confidence limit of the urinary cadmium level associated with a 10%
increased risk of low molecular weight proteinuria (0.5 ug/g creatinine) estimated from a meta-analysis of select environmental exposure studies.  An intake which would result in this
urinary cadmium concentration was estimated using a modification of the Nordberg-Kjellström pharmacokinetic model (see Appendix A for details on the meta-analysis and
extrapolation to dietary intake).  This dose of 0.3 ug/kg/day was divided by an uncertainty factor of 3 for human variability.
Bd Wt = body weight; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); Endocr = endocrine; (F) = feed; F = Female; (G) = gavage; Gastro = gastrointestinal; Gd =
gestational day; (GO) = gavage in oil; GST = glutathione-S-transferase; (GW) = gavage in water; Hemato = hematological; Immuno/Lymphoret = immunological/lymphoreticular; LD50
= lethal dose, 50% kill; LDH = Lactate dehydrogenase; LOAEL = lowest-observed-adverse-effect level; M = male; mo = month(s); Musc/skel = musculoskeletal; NOAEL =
no-observed-adverse-effect level; NS = not specified; ppd = post-parturition day; Resp = respiratory; SRBC = sheep red blood cells; (W) = drinking water; wk = week(s); x = time(s); yr
= year(s)
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Figure 3-2  Levels of Significant Exposure to Cadmium - Oral
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Figure 3-2  Levels of Significant Exposure to Cadmium - Oral (Continued)
Intermediate (15-364 days)
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Figure 3-2  Levels of Significant Exposure to Cadmium - Oral (Continued)
Intermediate (15-364 days)
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Figure 3-2  Levels of Significant Exposure to Cadmium - Oral (Continued)
Intermediate (15-364 days)
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Figure 3-2  Levels of Significant Exposure to Cadmium - Oral (Continued)
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Cardiovascular Effects.    Studies regarding cardiovascular effects in humans after oral exposure to 
cadmium have primarily investigated relationships between blood pressure and biomarkers of cadmium 
exposure such as cadmium levels in blood, urine, or other tissues.  Smoking is an important confounding 
factor, because of the higher blood, urine, and tissue cadmium levels of smokers (see Section 3.4) and the 
known cardiovascular toxicity of cigarette smoking.  Case-control and cohort epidemiologic studies that 
adequately control for smoking have typically found no association between body cadmium levels 
(primarily reflecting dietary exposure) and hypertension (Beevers et al. 1980; Cummins et al. 1980; 
Ewers et al. 1985; Lazebnik et al. 1989; Satarug et al. 2005; Shiwen et al. 1990); however, some studies 
have found positive correlations (Geiger et al. 1989; Swaddiwuhipong et al. 2010; Tulley and Lehmann 
1982) or negative correlations (Kagamimori et al. 1986; Staessen et al. 1984).  Similar conflicting 
findings have been reported in studies analyzing death rates from cardiovascular disease among 
populations with dietary cadmium exposure (Inskip et al. 1982; Shigematsu 1984).  Disorders of the 
cardiac conduction system, lower blood pressure, and decreased frequency of cardiac ischemic changes 
were found among elderly women with past high dietary exposure to cadmium (Kagamimori et al. 1986).  
Rhythmic disturbances, including ventricular fibrillation, were seen in an individual who had ingested 
25 mg/kg cadmium as cadmium iodide (Wisniewska-Knypl et al. 1971). 
 
Several studies conducting cross-sectional analysis on data from the National Health and Nutrition 
Examination Surveys (NHANES), investigated associations between blood and urine cadmium levels and 
cardiovascular effects (Agarwal et al. 2011; Eguogu et al. 2009; Everett and Frithsen 2008; Menke et al. 
2009; Navas-Acien et al. 2005; Peters et al. 2010; Tellez-Plaza et al. 2008, 2010).  Among adult 
participants in the NHANES 1988–1994 survey followed for mortality through 2000, the multivariable 
(including smoking)-adjusted hazard ratios of cardiovascular mortality associated with a 2-fold increase 
in creatinine-corrected urinary cadmium were 1.21 (95% CI of 1.07–1.36) in men and 0.93 (95% CI of 
0.84–1.04) in women (Menke et al. 2009).  The hazard ratios for coronary heart disease mortality were 
1.36 (95% CI of 1.11–1.66) and 0.82 (95% CI of 0.76–0.89).  Thus, the study suggests an association 
between elevated cadmium exposure and increased risk of cardiovascular mortality in men, but not in 
women.  Urinary cadmium levels were found to be strongly associated with peripheral arterial disease 
(PAD, defined as blood pressure ankle brachial index <0.0 in at least one leg) in analysis conducted on 
728 participants (at least 40 years of age) in the NHANES 1999–2000 study (Navas-Acien et al. 2005) 
and approximately 6,500 participants (≥40 years of age) in the NHANES 1999–2004 survey (Tellez-Plaza 
et al. 2010).  Navas-Acien et al. (2005) reported that individuals with PAD had a 36% higher mean urine 
cadmium level than individuals without PAD; this study also found that individuals with PAD had 49% 
CADMIUM  137 
 
3.  HEALTH EFFECTS 
 
 
 
 
 
 
 
higher urinary tungsten levels and urinary antimony levels exceeding 0.1 μg/L.  In the Tellez-Plaza et al. 
(2010) analysis, the odds ratio for PAD comparing men with urinary cadmium levels in the highest 
quartile (≥0.69 µg/g creatinine) with the lowest quartile (<0.20 µg/g creatinine) was 4.90 (95% CI of 
1.55–15.54), after adjustment for age, race/ethnicity, education, smoking habits, and a variety of 
cardiovascular risk factors.  In contrast, the odds ratio in women was 0.56 (95% CI of 0.18–1.71).  When 
the women were divided by smoking habit, there was a positive progressive dose-response relationship 
and the odds ratio for PAD comparing the 80th with the 20th percentile for urinary cadmium was 1.46 
(95% CI of 0.75–2.85) and for blood cadmium was 2.88 (95% CI of 1.10–7.50).  Another study found a 
modest increase in systolic or diastolic blood pressure associated with increasing blood cadmium levels 
(geometric mean blood cadmium levels among all participants was 0.4 μg/L); no associations with blood 
pressure and urinary cadmium levels were found (Tellez-Plaza et al. 2008).  The association between 
blood cadmium levels and blood pressure was stronger in participants who never smoked than in former 
smokers or current smokers.  There were no associations between hypertension and cadmium levels in 
blood or urine.  In the third study, analysis on 4,912 participants (45–79 years old) in the NHANES 1988–
1994 survey found a significant association between urinary cadmium levels and myocardial infarction in 
women, but not men (Everett and Frithsen 2008).  After adjusting for numerous risk factors including 
smoking, race, and family history, a significant increase in the risk of myocardial infarction was observed 
in women with urinary cadmium levels of ≥0.88 μg/g creatinine.  Agarwal et al. (2011) found 
significantly higher blood cadmium levels among participants with cardiovascular and cerebrovascular 
disease in the NHANES 1999–2006 survey, as compared to participants without disease.  The odds ratio 
of cardiovascular and cerebrovascular disease comparing the lowest blood cadmium quartile to the 
highest quartile was 1.44 (95% CI of 1.07–1.95) after adjusting for age, gender, race, education, 
hypertension, diabetes, hypercholesterolemia, BMI, c-reactive protein, and smoking.  Peters et al. (2010) 
found that a 50% increase in blood or urinary cadmium levels resulted in a significant increase in the risk 
of stroke and congestive heart failure among participants in the NHANES survey.  After adjusting for age, 
gender, race/ethnicity, education, BMI, poverty income ratio, alcohol consumption, smoking status, and 
disease (diabetes, hypertension, hypercholesterolemia, and chronic kidney disease), the odds ratios (95% 
CI) for stroke were 1.38 (1.14–1.67) and 1.10 (1.00–1.20) for 50% increases in blood and urinary 
cadmium levels, respectively; 50% increases in blood and urinary cadmium levels resulted in odds ratios 
(95% CI) for congestive heart failure of 1.48 (1.17–1.87) and 1.12 (1.04–1.21), respectively.  A 
significant negative correlation between urinary cadmium levels and volume of oxygen consumed at sub-
maximum activity (VO2 max) among white males or Mexican American females (Egwuogu et al. 2009); 
however, no significant associations were found in black or Mexican American males and white and 
black females.  Using a similar approach, Eum et al. (2008) and Lee et al. (2011) used data from the 
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Korean National Health and Nutrition Examination Survey (KNHANES) to assess the possible 
associations between cadmium exposure and cardiovascular effects.  Eum et al. (2008) found a positive 
association (adjusted for age, gender, education, smoking status, alcohol intake, BMI, self-reported 
hypertension, family history of hypertension, and blood lead level) between blood cadmium levels and 
systolic, diastolic, and mean arterial blood pressure among adults.  When comparing participants with the 
highest tertile of blood cadmium (1.87–5.52 µg/L) to those in the lowest tertile (0.18–1.28 µg/L), the 
multivariable adjusted odds ratio was 1.521 (95% CI of 1.129–2.049).  In a similar analysis, Lee et al. 
(2011) divided the subjects by gender and found that an interquartile range increase (0.91 µg/L) in blood 
cadmium was associated with an elevated risk of hypertension (odds ratio of 1.4; 95% CI of 1.1–1.8) only 
in men.  Lee et al. (2011) also found significant associations between an interquartile range increase in 
blood cadmium and the risk of ischemic heart disease in women (odds ratio of 2.28; 95% CI of 1.26–
4.15).  No significant associations between blood cadmium and risk of stroke were found. 
In a study of children enrolled in the Treatment of Lead-Exposed Children trial, no significant 
associations between blood cadmium levels and blood pressure in 5 and 7 years olds following treatment 
for elevated blood lead levels (Cao et al. 2009). 
A single gavage dose of 150 mg/kg cadmium in male Sprague-Dawley rats had no effect on blood 
pressure (Kotsonis and Klaassen 1977).  Oral exposure of rats, rabbits, and monkeys to cadmium over 
intermediate and chronic durations has been found to increase blood pressure in some studies (Akahori et 
al. 1994; Boscolo and Carmignani 1986; Carmignani and Boscolo 1984; Kopp et al. 1982; Perry et al. 
1989; Tomera and Harakal 1988), but not in others (Fingerle et al. 1982; Kotsonis and Klaassen 1978; 
Loeser and Lorke 1977a, 1977b; Mangler et al. 1988; Wills et al. 1981).  In general, studies showing an 
effect on blood pressure have had control groups with lower blood pressure than studies showing no 
effect, and observed increases in blood pressure are generally small.  At least in rats, the effect on blood 
pressure appears to be biphasic, reaching a maximum effect (an increase of 12–14 mm Hg in average 
systolic pressure) at intakes of 0.07 mg/kg/day, but decreasing to normal or even below normal at intakes 
10–100 times higher (Kopp et al. 1982).  Enlarged and arteriosclerotic hearts have been found in rats 
orally exposed to 0.35 mg Cd/kg/day for 3 years (Schroeder et al. 1965) or to 2.79 mg Cd/kg/day for 
100 days (Wilson et al. 1941), but this effect is likely to be secondary to cadmium-induced anemia 
(Wilson et al. 1941).  Histopathologic lesions of heart tissues (congestion, separation of muscle fibers) 
and decreased activity of antioxidant enzymes, but no increase in peroxidation, were found among rats 
given 2.5 mg/kg/day of cadmium in the diet for 7 weeks (Jamall et al. 1989).   
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Gastrointestinal Effects.    Numerous human and animal studies indicate that oral exposure to 
cadmium in high concentrations causes severe irritation to the gastrointestinal epithelium (Andersen et al. 
1988; Frant and Kleeman 1941).  Common symptoms in humans following ingestion of food or 
beverages containing high concentrations of cadmium include nausea, vomiting, salivation, abdominal 
pain, cramps, and diarrhea (Baker and Hafner 1961; Buckler et al. 1986; Frant and Kleeman 1941; 
Nordberg et al. 1973; Shipman 1986; Wisniewska-Knypl et al. 1971).  Although exact doses have not 
been measured, gastrointestinal symptoms have been caused in children by 16 mg/L cadmium in soft 
drinks (Nordberg et al. 1973) and 13 mg/L cadmium in popsicles (Frant and Kleeman 1941).  Assuming 
an intake of 0.15 L (Nordberg et al. 1973) and a body weight of 35 kg, the emetic dose is 0.07 mg/kg.  
Although few studies have specifically examined gastrointestinal effects of longer-term cadmium 
exposure, no surveys of environmentally exposed populations have reported gastrointestinal symptoms 
(Morgan and Simms 1988; Roels et al. 1981a; Shigematsu 1984). 
 
 
 
In rats and mice, histopathologic lesions (e.g., severe necrosis, hemorrhage, ulcers) in the gastrointestinal 
epithelium have been observed after high (>30 mg/kg/day) acute-duration oral cadmium exposure by 
gavage (Andersen et al. 1988; Basinger et al. 1988; Machemer and Lorke 1981), but not after lower levels 
(8 mg/kg/day in drinking water) for 24 weeks (Kotsonis and Klaassen 1978).  
Hematological Effects.    Oral cadmium exposure reduces gastrointestinal uptake of iron, which can 
result in anemia if dietary intake of iron is low.  Anemia has been found in some instances among humans 
with chronic dietary exposure to cadmium (Kagamimori et al. 1986), but other studies have found no 
significant relationship between dietary cadmium exposure and anemia in humans (Roels et al. 1981a; 
Shiwen et al. 1990).  Hypoproteinemia and hypoalbuminemia were reported in a male who ingested 
25 mg/kg cadmium as cadmium iodide (Wisniewska-Knypl et al. 1971). 
A number of studies have demonstrated that oral exposure to cadmium frequently produces anemia in 
laboratory animals, and that additional iron prevents anemia (Decker et al. 1958; Groten et al. 1990; Hays 
and Margaretten 1985; Itokawa et al. 1974; Kawamura et al. 1978; Kelman et al. 1978; Kozlowska et al. 
1993; Ogoshi et al. 1989; Pleasants et al. 1992, 1993; Pond and Walker 1972; Sakata et al. 1988; Sorell 
and Graziano 1990; Stowe et al. 1972; Watanabe et al. 1986; Webster 1978; Wilson et al. 1941).  
Decreases in serum iron have also been reported (Prigge 1978a).  Borzelleca et al. (1989) reported slight 
but statistically significant increases in hemoglobin, hematocrit, and erythrocytes in male rats at 
65.6 mg/kg/day once a day for 10 days, but no change in females.  Male Sprague-Dawley rats receiving a 
single gavage dose of 150 mg/kg cadmium showed no signs of anemia 14 days later (Kotsonis and 
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Klaassen 1977), but anemia was produced in male Wistar rats after 12 days of drinking-water exposure to 
12 mg/kg/day (Sakata et al. 1988).  Most intermediate-duration exposure studies in rats have shown 
evidence of anemia at doses of 2–14 mg/kg day (Decker et al. 1958; Groten et al. 1990; Itokawa et al. 
1974; Kawamura et al. 1978; Pleasants et al. 1993; Pond and Walker 1972; Sakata et al. 1988; Wilson et 
al. 1941).  However, some intermediate-duration studies have found no change in hemoglobin (Kotsonis 
and Klaassen 1978; Loeser and Lorke 1977a; Petering et al. 1979; Prigge 1978a) in rats treated at similar 
doses.  Anemia has also been seen in intermediate-duration studies in mice (Webster 1978) and rabbits 
(Stowe et al. 1972), but not in dogs (Loeser and Lorke 1977b).  The result in dogs may be due to the 
relatively low dose of cadmium (0.75 mg/kg/day) used in this study.  Hematological effects following 
chronic-duration oral exposure to cadmium are less well characterized.  In monkeys maintained on 
4 mg/kg/day cadmium in food, pale feces, and clinical signs of anemia occurred after 90 weeks, but the 
anemia was associated with a decreased food intake rather than an increase in reticulocytes (Masaoka et 
al. 1994).  Anemia was not present in rats exposed via drinking water for 12 months to the relatively low 
dose of 0.79 mg/kg/day (Decker et al. 1958).  The number of erythroid progenitor cells in bone marrow is 
decreased in mice exposed to 57 mg/kg/day of cadmium in drinking water for 12 months (Hays and 
Margaretten 1985), but is increased in rats exposed to 12 mg/kg/day of cadmium in drinking water for up 
to 100 days (Sakata et al. 1988).  Thus, the question remains open whether factors, in addition to reduced 
gastrointestinal absorption of iron, such as direct cytotoxicity to marrow or inhibition of heme synthesis 
may contribute to anemia.  
 
Musculoskeletal Effects.    Osteomalacia, osteoporosis, bone fractures, and decreased bone mineral 
density have been observed in several populations exposed to elevated levels of cadmium in the diet.  
Bone effects were first reported in residents in the Jinzu River Basin, a cadmium-contaminated area in 
Japan.  The disease termed Itai-Itai or "ouch-ouch" disease most often affected women with several risk 
factors such as poor nutrition, multiparity, and postmenopausal status (Shigematsu 1984).  The disease 
was characterized by multiple fractures of the long bones, osteomalacia, and osteoporosis in combination 
with proteinuria (Järup et al. 1998b; Nordberg et al. 1997).  Other Japanese populations with dietary 
cadmium exposure have also been found to have elevated osteoporosis and osteomalacia in both men and 
women (Kido et al. 1989b).  Kagamimori et al. (1986) evaluated elderly Japanese women with heavy 
cadmium exposure from ingesting polluted drinking water, rice, and fish during World Wars I and II; and 
continued low-grade cadmium exposure from agricultural produce.  Of 56 cases of Itai-Itai disease, 
26 were accompanied by osteomalacia and 26 were without osteomalacia.  Another study found that the 
degree of loss of bone density is correlated with urinary excretion of β2-microglobulin, an index of renal 
injury (see Section 3.5.2) (Kido et al. 1990a).  The bone effects observed in Itai-Itai disease and in other 
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studies of Japanese populations exposed to high levels of cadmium in rice are primarily due to kidney 
damage, which results from a progressive disturbance in renal metabolism of vitamin D to its biologically 
active form (Nogawa et al. 1987, 1990) and an increased urinary excretion of calcium (Buchet et al. 
1990).  These results suggest that bone changes may be secondary to disruption in kidney of vitamin D 
metabolism and resulting imbalances in calcium absorption and excretion.  A recent study of women 
living in the Jinzu River basin found that bone turnover, particularly bone formation, was influenced by 
renal tubular function (Aoshima et al. 2003).  However, it is possible that some bone effects are not 
mediated via the kidney.   
 
Bone effects have also been observed in communities outside of Japan and in populations exposed to low 
levels of cadmium.  In a study of Swedish women environmentally exposed to cadmium, a significant 
negative relationship between urinary cadmium levels and bone mineral density was observed (Åkesson 
et al. 2005); the mean urinary cadmium level of the population was 0.52 μg/L.  In Swedish residents 
living in an area with known cadmium pollution from battery manufacturing facilities, significant 
associations were noted between blood cadmium levels and bone mineral density and between urinary 
cadmium levels and risk of fractures and osteoporosis.  There were significant decreases in bone mineral 
density in environmentally exposed subjects older than 60 years of age with blood cadmium levels of 
≥0.56 μg/L (Alfvén et al. 2002a).  Increases in the risk of bone fractures were observed in subjects 
(approximately 10% of all subjects examined had environmental and occupational exposure to cadmium) 
older than 50 years of age with urinary cadmium levels >2 μg/g creatinine; no significant associations 
were found in subjects under 50 years of age (Alfvén et al. 2004).  Another study of this population found 
significant increases in the risk of osteoporosis among men >60 years of age with urinary cadmium levels 
≥5 μg/g creatinine; however, an increased risk of osteoporosis was not observed in women (Alfvén et al. 
2000).  A Belgian study in which residents living near zinc smelters found a 2-fold increase in cadmium 
exposure (as assessed via urinary cadmium levels) was associated with a decrease in proximal and distal 
forearm bone density of approximately 0.1 g/cm2 among postmenopausal women (Staessen et al. 1999).  
For women with urinary cadmium levels >1 μg/day, the incidence of bone fracture was 13.5 per 
1,000 person-years.  Another study of a subset of the women living near a zinc smelters (Schutte et al. 
2008) provides suggestive evidence that cadmium has a direct osteotoxic effect.  Significant associations 
between urinary cadmium levels and the levels of two pyridinium crosslinks of collagen (urinary levels of 
hydroxylysylpyridinoline and lysylpyridinoline), proximal forearm bone mineral density, and serum 
parathyroid hormone levels were found.  In almost all of the examined women, urinary levels of retinol 
binding protein were below the cut-off level of 338 μg/day, suggesting no cadmium-induced effect on 
renal tubular function.  Several biomarkers of bone damage were examined in a subsequent follow-up 
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study of some of the women (Schutte et al. 2008) only 1 of the 294 women examined had evidence of 
renal dysfunction (increased retinol binding protein).  Significant associations between urinary cadmium 
excretion and two biomarkers of bone resorption (urinary hydroxylysylpyridinoline and lysylpyridinoline) 
were found.  Although significant associations between urinary cadmium levels and biomarkers of renal 
dysfunction were observed in Polish adults living in a cadmium-polluted area, the only association 
between urinary cadmium and bone biomarkers was a significant decrease in bone mineral density among 
males with urinary cadmium levels of ≥2 µg/g creatinine (Trzcinka-Ochocka et al. 2010).  Similar results 
have been observed in several studies of residents living in areas of China with moderate or high 
cadmium pollution levels (Jin et al. 2004b; Nordberg et al. 2002; Wang et al. 2003; Zhu et al. 2004).  
There were significant increases in the prevalence of low forearm bone mineral density in 
postmenopausal women with urinary cadmium levels >20 μg/g creatinine and in men, premenopausal 
women, and postmenopausal women with blood cadmium levels >20 μg/L (Nordberg et al. 2002).  An 
increase in bone fractures was observed in males and females over the age of 40 years living in the area of 
high cadmium exposure (mean urinary cadmium levels in the area were 9.20 and 12.86 μg/g creatinine in 
the males and females, respectively) (Wang et al. 2003).  A significant dose-response relationship 
between urinary cadmium levels and the prevalence of osteoporosis was observed (Jin et al. 2004b; Wang 
et al. 2003; Zhu et al. 2004); the Jin et al. (2004b) study found that 23 of the 31 subjects with osteoporosis 
also exhibited signs of renal dysfunction.  A subsequent study by this group examined 316 male and 
female residents living in areas with moderate or heavy cadmium pollution 10 years after the source of 
rice was switched to commercially available rice from nonpolluted areas (Chen et al. 2009).  As in the 
earlier studies, significant decreases in forearm bone mineral density were observed in the women living 
in the moderately polluted area and in the men and women living in the heavily polluted areas.  When the 
subjects were divided by age, decreases in bone mineral density were observed in women 60–69 or 
≥70 years old in both cadmium polluted areas and in men ≥70 years living in the heavily polluted area.  A 
significantly higher prevalence of osteoporosis was also observed in women living in the polluted areas 
and the prevalence increased with increasing urinary cadmium levels.  In another study of this population, 
Chen et al. (2011) found a higher prevalence of osteoporosis (assessed in 2006) among women with renal 
dysfunction (urinary albumin >15 mg/g creatinine and urinary NAG ≥12 IU/g creatinine; renal 
biomarkers assessed in 1998) or tubular damage (urinary NAG ≥12 IU/g creatinine); no significant 
association was found for glomerular damage (urinary albumin ≥15 mg/g creatinine).  Significantly lower 
bone mineral density levels were also found in women with tubular damage, as compared to those without 
tubular damage.  In men, no significant associations between the prevalence of osteoporosis or bone 
mineral density and alterations in renal biomarkers were found.  Chen et al. (2011) also compared the 
change in bone mineral damage from 1998 to 2006 in subjects with and without evidence of kidney 
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damage and found a significantly greater decrease in bone mineral damage among women with tubular 
damage.  In a study of adults living near an industrial complex in Korea, significant associations between 
high urinary cadmium levels (≥1.0 µg/g creatinine) and osteopenia were observed in males and females 
(Shin et al. 2011).  Bone mineral density was also negatively associated with urinary cadmium levels. 
 
 
In a substudy of a population-based health survey in Sweden (Engström et al. 2009), a significantly lower 
bone mineral density was observed in postmenopausal women with elevated urinary cadmium levels 
(median of 1.1 µg/g creatinine, 5–95th percentile of 0.69–1.7 µg/g creatinine) as compared to women with 
low urinary cadmium levels (median of 0.36 µg/g creatinine; 5–95th percentile of 0.18–0.73 µg/g 
creatinine).  Significant decreases in serum parathyroid hormone levels and increases in urinary 
deoxypyridinoline levels (indicative of increased bone resorption) were also found in the high urinary 
cadmium group; however, there were no significant alterations in serum 1,25-dihydroxyvitamin D levels 
Significant elevations in biomarkers of renal dysfunction (urinary NAG and pHC and estimated 
glomerular filtration rate) were also in the high urinary cadmium group.  In the U.S. general population 
(using data collected during NHANES III, 1988–1994), a significant association was found between 
urinary cadmium levels and osteopenia and osteoporosis among adults with urinary cadmium levels of 
>1 µg/g creatinine (Wu et al. 2010).  Using the same NHANES data set, Gallagher et al. (2008) found a 
43% increased risk of osteoporosis (hip bone mineral density defined) (odds ratio of 1.43; 95% CI of 
1.02–2.00) among women ≥50 years of age with urinary cadmium levels of 0.50–1.00 µg/g creatinine, as 
compared to women with urinary cadmium levels of <0.50 µg/g creatinine. 
Using data collected during NHANES III (1988–1994), Arora et al. (2008, 2008) examined the possible 
association between urinary cadmium levels and dental health in children and adults.  In children aged 6–
12 years, a significant association (adjusted for age, gender, ethnicity, education level, poverty status, log-
transformed blood lead, log-transformed serum cotinine, and dietary sucrose intake) between urinary 
cadmium levels and dental caries in deciduous teeth among children with low external tobacco smoke 
exposure; no significant associations were found in permanent teeth (Arora et al. 2008).  A significant 
association (after adjustment for gender, age, education level of household head, race/ethnicity, household 
poverty status, time since last visit to dentist, missing teeth, serum cotinine, smoking habits, exposure to 
external tobacco smoke, blood lead, diabetes, renal dysfunction, and bone mineral density) between 
urinary cadmium and periodontal disease (presence of attachment loss of at least 4 mm in >10% of sites 
examined) in adults (≥18 years of age) (Arora et al. 2009).  A logistic regression model predicted a 56% 
increase in the prevalence of periodontal disease associated with a 3-fold increase in urinary cadmium 
levels (0.18–0.63 µg/g creatinine). 
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A number of animal studies confirm the findings of the epidemiology data suggesting that the bone is a 
sensitive target of cadmium toxicity.  Decreases in bone mineralization and bone mineral density have 
been observed in female rats exposed to ≥0.2 mg Cd/kg/day in the lumbar spine, femur, and tibia 
(Brzóska et al. 2004b, 2005a, 2005b, 2005c) and in male rats exposed to ≥0.5 mg Cd/kg/day (Brzóska and 
Moniuszko-Jakoniuk 2005a, 2005b; Brzóska et al. 2010; Yokota and Tonami 2008) for an intermediate 
duration and in female rats chronically exposed to 0.08 mg Cd/kg/day (Brzóska 2012; Brzóska and 
Moniuszko-Jakoniuk 2004a, 2004b).  In the series of studies conducted by Brzóska and associates, the 
occurrence of osteopenia and osteoporosis was evaluated using data for bone mineral density of the 
cadmium-exposed rats, control rats, and healthy adult rats.  Osteopenia was observed in male rats exposed 
to 0.5 mg Cd/kg/day for 12 months (Brzóska and Moniuszko-Jakoniuk 2005a, 2005b) and in female rats 
exposed to 0.08 mg Cd/kg/day for 12 or 18 months (Brzóska and Moniuszko-Jakoniuk 2004a, 2004b); 
osteoporosis was observed in male rats exposed to 4 mg Cd/kg/day for 12 months (Brzóska and 
Moniuszko-Jakoniuk 2005a, 2005b) and in female rats exposed to 0.08 mg Cd/kg/day for 24 months 
(Brzóska and Moniuszko-Jakoniuk 2004a, 2004b). 
 
 
The decreases in bone mineralization resulted in altered mechanical properties (e.g., stiffness, load, 
displacement at load) of the vertebral body, femur, and tibia and increases in the number of animals with 
deformed or fractured lumbar spinal bone in female rats exposed to ≥0.2 mg Cd/kg/day for an 
intermediate duration (Brzóska and Moniuszko-Jakoniuk 2005d; Brzóska et al. 2004b, 2005b, 2005a, 
2005c, 2010; Ogoshi et al. 1989); increases in lumbar spine deformities were also observed in male rats 
exposed to 0.5 mg Cd/kg/day for 12 months (Brzóska and Moniuszko-Jakoniuk 2005a, 2005b) and in 
female rats exposed to 0.08 mg Cd/kg/day for 24 months (Brzóska 2012; Brzóska and Moniuszko-
Jakoniuk 2004a, 2004b). 
The studies by Brzóska and associates reported significant alterations in biochemical markers of bone 
turnover.  During the first 6 months of a 1-year study, significant decreases in osteocalcin concentrations 
were observed in female rats exposed to ≥0.2 mg Cd/kg/day; no alterations were observed during the last 
6 months of the study (Brzóska and Moniuszko-Jakoniuk 2005d).  Observed changes in alkaline 
phosphatase levels included decreases in total serum levels in the 4 mg Cd/kg/day group after 6, 9, or 
12 months of exposure, decreases in trabecular bone levels at ≥0.2 mg Cd/kg/day after 3, 6, or 9 months 
of exposure and at 0.5 mg Cd/kg/day at 12 months, decreases in cortical bone levels at 4 mg Cd/kg/day 
after 3 months of exposure, and increases in trabecular bone and cortical bone alkaline phosphatase at 
4 mg Cd/kg/day after 12 months (Brzóska and Moniuszko-Jakoniuk 2005d).  Serum C-terminal 
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telopeptides of type I collagen concentration (CTX) was significantly decreased after 3 or 6 months of 
exposure or increased after 9 or 12 months in rats exposed to ≥0.2 mg Cd/kg/day (Brzóska and 
Moniuszko-Jakoniuk 2005d).  As noted by Brzóska and Moniuszko-Jakoniuk (2005d), these alterations in 
bone turnover markers indicate that cadmium exposure at the stage of intensive skeletal development 
leads to low bone turnover and induces high bone turnover due to enhanced resorption at the stage of 
consolidation of bone mass and at skeletal maturity. 
 
 
 
Decreased calcium content of bone and increased urinary calcium excretion are common findings in 
intermediate- and chronic-duration studies in the 0.2–8 mg Cd/kg/day range (Brzóska and Moniuszko-
Jakoniuk 2005d; Kawamura et al. 1978; Nogawa et al. 1981b; Pleasants et al. 1992; Watanabe et al. 
1986).  In contrast, Kotsonis and Klaassen (1978) reported no change in bone calcification after a 
24-week exposure via drinking water at 8 mg/kg/day, and Kelman et al. (1978) reported no significant 
change in stable or radiolabeled calcium in any maternal rat tissues from a 3.8 mg/kg/day in drinking 
water for 22 days during gestation.   
Gender, age, and nutritional state appear to influence cadmium toxicity on bone.  In the series of 
experiments conducted by Brzóska and associates, alterations in bone mineral density and the mechanical 
strength of the lumbar spine and femur were observed in female rats exposed to ≥0.2 mg Cd/kg/day and 
in male rats at 0.5 mg Cd/kg/day (Brzóska and Moniuszko-Jakoniuk 2005a, 2005b, 2005d; Brzoska et al. 
2005a, 2005c); no adverse bone effects were observed in males exposed to 0.2 mg Cd/kg/day.  In the 
Ogoshi et al. (1989) study, decreases in the mechanical strength of the femur bone were observed in 
young rats (21 days of age) exposed to 0.8 mg Cd/kg/day for 4 weeks; however, no alterations in bone 
strength were observed in adult (24 weeks of age) or elderly (1.5 years of age) rats exposed to cadmium 
doses as high as 25.6 mg Cd/kg/day for 4 weeks.  Adverse effects on bone are exacerbated by a calcium-
deficient diet (Itokawa et al. 1974; Kimura et al. 1974; Larsson and Piscator 1971; Wang and 
Bhattacharyya 1993; Wang et al. 1994), by ovariectomy (Bhattacharyya et al. 1988c), or by multiple 
rounds of gestation and lactation (Bhattacharyya et al. 1988b).  
Hepatic Effects.    Liver damage is not usually associated with oral cadmium exposure, except at very 
high levels of exposure.  In humans, a fatal dose of cadmium can cause pronounced liver damage 
(Buckler et al. 1986; Wisniewska-Knypl et al. 1971).  Nishino et al. (1988) reported increased serum 
concentrations of the urea-cycle amino acids among individuals exposed to cadmium in the diet, and that 
these levels reflected liver as well as kidney damage.  No cadmium-related alterations in liver biomarkers 
including serum levels of alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, 
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lactate dehydrogenase, and γ-glutamyl transpeptidase were observed in women living in cadmium 
nonpolluted areas in Japan (Ikeda et al. 1997, 2000).  No other studies were located regarding hepatic 
effects in humans after oral exposure to cadmium. 
 
 
 
 
Hepatic effects have been found in rats, mice, and rabbits after oral cadmium exposure.  Acute exposure 
via gavage at doses of 30–138 mg/kg/day causes liver necrosis in most studies (Andersen et al. 1988; 
Basinger et al. 1988; Borzelleca et al. 1989; Shimizu and Morita 1990), although histopathologic 
evidence of liver damage was not seen in one study at a gavage dose of 150 mg/kg (Kotsonis and 
Klaassen 1977).  Exposure of rats for 10 days to drinking water containing 13.9 mg Cd/kg/day was 
without effect on the liver (Borzelleca et al. 1989).  Depletion of liver glutathione by fasting increases the 
liver necrosis following acute oral exposure to cadmium in rats (Shimizu and Morita 1990). 
In a 10-week study, male Rhesus monkeys exposed to 4 mg/kg/day cadmium chloride via gavage, had a 
significant decrease in glutathione peroxidase in liver, kidney, heart, and lung in the following order: 
liver>kidney>heart>lung; a significant decrease in glutathione S-transferase (GST) activity towards 
1-chloro-2,4-dinitrobenzene in all four organs in the following order:  liver>lung>kidney>heart; and a 
significant increase in GST activity towards ethacrynic acid in all four organs in the following order: 
heart>lung>kidney>liver (Sidhu et al. 1993).  Intermediate-duration exposure causes histopathologic 
changes in the liver (e.g., necrosis of central lobules, focal hepatic fibrosis, biliary hyperplasia) at doses of 
1.6–15 mg/kg/day (Cha 1987; Gill et al. 1989b; Miller et al. 1974a; Renugadevi and Prabu 2010; 
Schroeder et al. 1965; Stowe et al. 1972; Wilson et al. 1941), and metabolic alterations (e.g., decreased 
cytochrome c oxidase activity in mitochondria, increased ALT and AST activities) at doses of 0.05–
10 mg/kg/day (Groten et al. 1990; Muller and Stacey 1988; Muller et al. 1988; Renugadevi and Prabu 
2010; Sporn et al. 1970; Steibert et al. 1984; Tewari et al. 1986b).  Decreased relative liver weight to 
body weight has also been reported in male rats fed 5.95 mg/kg/day for 6 weeks (Kozlowska et al. 1993).   
Hypertriglyceridemia was observed in male rats exposed to 18 mg Cd/kg/day as cadmium chloride in the 
drinking water for 8 weeks (Larregle et al. 2008); the increase in plasma triglycerides was likely due to a 
decrease in lipoprotein lipase activity (key enzyme in triglyceride hydrolysis).  A significant increase in 
liver triglyceride level was also observed; this increase was attributed to increased triglyceride synthesis.   
Other intermediate and chronic duration studies have not found liver effects in animals following oral 
exposure.  These studies include a daily gavage exposure of 14 mg/kg/day for 6 weeks in rats (Hopf et al. 
1990), a 3-month exposure to cadmium in food at 3 mg/kg/day in rats (Loeser and Lorke 1977a), a 
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24-week exposure to cadmium in water at 8 mg/kg/day in rats (Kotsonis and Klaassen 1978), and a 
3-month exposure in food at 0.75 mg/kg/day in dogs (Loeser and Lorke 1977b).  Kopp et al. (1982) report 
no hepatic effects from a chronic exposure of 18 months to cadmium in water at 0.65 mg/kg/day in rats. 
 
 
 
Renal Effects.    Numerous studies indicate that the kidney is the primary target organ of cadmium 
toxicity following extended oral exposure, with effects similar to those seen following inhalation 
exposure (see Section 3.2.1.2).  Most of the data involves chronic exposure to cadmium; two case reports 
involving acute exposure to large doses of cadmium also found kidney effects.  In two fatal cases of oral 
cadmium poisoning, anuria was present in one individual who ingested 25 mg/kg cadmium as cadmium 
iodide.  Damage to the kidneys was reported at autopsy, but was not further specified (Wisniewska-Knypl 
et al. 1971).  The kidneys were reported as normal at autopsy in an individual who died 2 days after 
ingesting 1,840 mg/kg cadmium (Buckler et al. 1986). 
Several studies have found associations between increased mortality and renal dysfunction in residents 
living in cadmium polluted areas.  Significant increases in SMRs were found in residents living in 
cadmium polluted areas of Japan with elevated levels of biomarkers of renal dysfunction (Arisawa et al. 
2001, 2007b; Iwata et al. 1991a, 1991b; Matsuda et al. 2002; Nakagawa et al. 1993; Nishijo et al. 1995, 
2004a, 2006).  Among the studies that examined cause of death, significant increases in deaths from renal 
diseases were found in the residents that were categorized as biomarker-positive (urinary levels of the 
renal biomarker was higher than the cut-off value); the cut-off values used were β2-microglobulin 
≥1,000 μg/g creatinine (Arisawa et al. 2001, 2007b; Iwata et al. 1991a, 1991b; Nakagawa et al. 1993; 
Nishijo et al. 2004a, 2006) or retinol binding protein ≥4 mg/L (Nishijo et al. 1995).  Other studies have 
found that mortality increased in proportion to the renal biomarker level (β2-microglobulin, protein, or 
glucose) (Iwata et al. 1991a, 1991b; Matsuda et al. 2002; Nakagawa et al. 1993; Nishijo et al. 2004a, 
2006).  Increases in mortality from renal diseases have also been observed among populations living in 
cadmium polluted areas of Belgium (Lauwerys and De Wals 1981) and England (Inskip et al. 1982); 
however, statistical analysis was not reported in the Belgium study and the increase in renal disease was 
not statistically significant in the other study.  In a nationwide study in Japan, no significant associations 
between the levels of cadmium in brown rice and deaths from all causes or age-adjusted renal 
insufficiency mortality rate were found (Koizumi et al. 2010). 
Elevated levels of several biomarkers of renal dysfunction and/or associations between cadmium burden 
and these biomarkers have been found in studies of populations living in cadmium nonpolluted areas of 
Japan (Ezaki et al. 2003; Ikeda et al. 1999; Suwazono et al. 2000; Oo et al. 2000; Uno et al. 2005; 
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Yamanaka et al. 1998), South Korea (Hwangbo et al. 2011), Belgium (Buchet et al. 1990; Roels et al. 
1981a), and the United States (Ferraro et al. 2010; Noonan et al. 2002) and in populations living in 
cadmium polluted areas of China (Cai et al. 1990, 1992, 1998; Jin et al. 2002, 2004a, 2004c; Nordberg et 
al. 1997; Wu et al. 2001), Japan (Cai et al. 2001; Hayano et al. 1996; Horiguchi et al. 2010; Ishizaki et al. 
1989; Izuno et al. 2000; Kawada et al. 1992; Kido and Nogawa 1993; Kobayashi et al. 2002b, 2009b; 
Monzawa et al. 1998; Nakadaira and Nishi 2003; Nakashima et al. 1997; Nogawa et al. 1989; Osawa et 
al. 2001; Watanabe et al. 2002), Thailand (Honda et al. 2010; Teeyakasem et al. 2007), Sri Lanka 
(Bandara et al. 2010), Sweden (Järup et al. 2000; Olsson et al. 2002), and Poland (Trzcinka-Ochocka et 
al. 2004).  Most of these studies did not estimate cadmium intake; rather, exposure was characterized 
based on the levels of cadmium in rice, blood, or urine.  The oral route is assumed to be the primary route 
of exposure, although the inhalation route, particularly in smokers, may have contributed to the overall 
cadmium body burden.  The epidemiology data are summarized in Table 3-7 and brief discussions of the 
better designed studies providing valuable dose-response data follows. 
 
 
Buchet et al. (1990) examined 1,699 non-occupationally exposed males and females (aged 20–80 years) 
living in Belgium.  Urinary cadmium levels significantly correlated with urinary β2-microglobulin, retinol 
binding protein, NAG, amino acid, and calcium levels; the partial r2 values were 0.0036, 0.0210, 0.0684, 
0.0160, and 0.0168, respectively.  The probability that individuals would have abnormal values for the 
renal biomarkers (defined as >95th percentile for subjects without diabetes or urinary tract diseases and 
who did not regularly take analgesics) was estimated using logistic regression models with adjustments 
for age, gender, smoking, disease, and use of analgesics.  It was estimated that >10% of 
β2-microglobulin, retinol binding protein, amino acid, and calcium values would be abnormal when 
24-hour urinary cadmium levels were >3.05, 2.87, 2.74, 4.29, or 1.92 μg/24 hour, respectively. 
Järup et al. (2000) examined 1,021 individuals living near a nickel-cadmium battery plant in Sweden for 
at least 5 years (n=799) or employed as battery workers (n=222).  The mean urinary cadmium levels were 
0.81 and 0.65 μg/g creatinine in males and females, respectively.  Urinary cadmium levels were 
significantly associated with urinary human complex-forming glycoprotein (pHC; also referred to as 
α1-microglobulin) levels, after adjustment for age.  The relationship remained statistically significant 
after removal of the cadmium workers from the analysis.  The prevalence of abnormal pHC values 
(defined as exceeding the 95th percentile in a Swedish reference population; >7.1 and 5.3 mg/g creatinine 
for males and females, respectively) was estimated to increase by 10% at urinary cadmium levels of 
1 μg/g creatinine.  The European Chemicals Bureau (2007) recalculated the probability of HC proteinuria 
(using the raw data from Järup and associates) to account for the differences in age of the reference  
CADMIUM  149 
 
3.  HEALTH EFFECTS 
 
 
 
 
 
 
 
 
Table 3-7.  Summary of Human Studies Examining Renal Effects 
 
Mean urinary Effect 
Population studied cadmium level biomarker Results Reference 
General population 1.26 μg/g creat. β2M Significant correlation between Ezaki et al. 
(Japan) 
10,753 females; 35–
 pHC urinary cadmium and effect 
biomarkers; however, no 
2003 
60 years old significant relationship was 
established when age was 
factored into analysis. 
General population 2.1 μg/g creat. β2M Significant correlation between Ikeda et al. 
(Japan) pHC urinary cadmium (not corrected 1999 
470 nonsmoking for creat.) and pHC and β2M. 
females   
General population 1.8 μg/g creat. (M) β2M Significant correlation between Suwazono et 
(Japan) 
1,105 males, 
2.4 μg/g creat. (F) Total protein 
NAG 
urinary cadmium and protein 
and β2M.  Dose-response 
al. 2000 
1,648 females; relationship between urinary 
>50 years old cadmium and prevalence of 
abnormal effect biomarker 
levels. 
General population 2.2–3.4 μg/L (M) total protein Significant correlation (with age Oo et al. 
(Japan) 2.8–3.9 μg/L (F) NAG adjustment) between urinary 2000 
568 males, β2M cadmium and effect 
742 females; biomarkers.  
≥50 years old 
General population 1.3 μg/g creat. (M) β2M Significant correlation between Yamanaka et 
(Japan) 1.3 μg/g creat. (F) total protein urinary cadmium and effect al. 1998 
558 males,  NAG biomarkers (NAG was only 
743 females;  significant in females). 
≥50 years old Dose-response relationship 
between urinary cadmium and 
prevalence of abnormal effect 
biomarker levels. 
General population 0.8 μg/g creat. (M) β2M Significant associations Uno et al. 
(Japan) 
410 males, 
418 females; 40–
1.8 μg/g creat. (F) 
(median levels) 
protein 
NAG 
between urinary cadmium and 
effect biomarkers (protein only 
significant in males). 
2005 
59 years old Dose-response relationship 
between urinary cadmium and 
prevalence of abnormal effect 
biomarker levels. 
General population  Glomerular Significant association between Hwangbo et 
(South Korea) filtration rate elevated blood cadmium levels al. 2011 
955 males, and decreased glomerular 
954 females; filtration rate in females only. 
≥20 years of age 
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Table 3-7.  Summary of Human Studies Examining Renal Effects 
 
Mean urinary Effect 
Population studied cadmium level biomarker Results Reference 
General population 0.040–0.093 μg/hour β2M Dose-response relationship Roels et al. 
(Belgium) protein between urinary cadmium and 1981a 
175 females; mean amino acids urinary protein and amino 
age 81.1–82.3 years albumin acids; significant relationship 
old with β2M and albumin only in 
the two areas with highest 
urinary cadmium levels. 
General population  β2M Significant correlation between Buchet et al. 
(Belgium) protein urinary cadmium and effect 1990 
1,699 males, NAG biomarkers. 
females; 20–80 years amino acids Dose-response relationship 
old calcium between urinary cadmium and 
prevalence of abnormal effect 
biomarker levels.   
General population 0.07 μg/g creat.  β2M No significant associations Noonan et al. 
(United States) (M, child) NAG (after correction for age, sex) 2002 
88 males, 0.08 μg/g creat.  AAP between urinary cadmium and 
71 females; 6–
17 years old;  
71 males, 
80 females; 
≥18 years old 
(F, child) 
0.24 μg/g creat.  
(M, adult) 
0.23 μg/g creat. 
(F, adult) 
albumin effect biomarkers in children. 
Significant association (after 
age and gender adjustment) 
between urinary cadmium and 
NAG and AAP in adults.  Dose-
response relationship between 
urinary cadmium and NAG and 
AAP. 
General population 0.29 µg/g creat. albumin Significant association (after Ferraro et al. 
(United States) age, gender, race/ethnicity, and 2010 
2,644 males, BMI adjustment) between 
2,782 females urinary cadmium >1 µg/g 
≥20 years old (data creatinine and urinary albumin 
from NHANES 1999– to creatinine ratio of >20 mg/g 
2006) (males) or 30 mg/g (females). 
Residents in 11.27 μg/g creat. β2M Significantly higher effect Cai et al. 
cadmium-polluted NAG biomarkers levels. 1990, 1992 
area (China) 
433 males and 
females 
Residents in  β2M Significant dose-response Cai et al. 
cadmium-polluted relationship between urinary 1998 
area (China) cadmium, blood cadmium, and 
219 males and cumulative Cd intake and β2M; 
females prevalence of abnormal values. 
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Table 3-7.  Summary of Human Studies Examining Renal Effects 
 
 
Mean urinary Effect 
Population studied cadmium level biomarker Results Reference 
Residents in High: 11.18 μg/g β2M  Significant correlation between Jin et al. 
cadmium-polluted creat.  RBP urinary cadmium and effect 2002 
area (China) Mod.:  3.55 μg/g albumin biomarkers. 
118 males, creat.    
170 females in high  Dose-response relationship 
exposure group between urinary cadmium and 
80 males, prevalence of abnormal effect 
158 females in biomarker levels. 
moderate exposure 
group  
Residents in  β2M  Dose-response relationship Jin et al. 
cadmium-polluted NAG between urinary cadmium and 2004c 
area (China) NAG-B prevalence of abnormal effect 
118 males, RBP biomarker levels.   
170 females in high albumin 
exposure group 
80 males, 
158 females in 
moderate exposure 
group 
Residents in 9.12 μg/g creat.  β2M  Dose-response relationship Jin et al. 
cadmium-polluted NAG between urinary cadmium and 2004a 
area (China) albumin prevalence of abnormal effect 
66 males, 22 females biomarker levels.   
Residents in High:  9.40 μg/L (M) β2M  Dose-response relationship Nordberg et 
cadmium-polluted 
area (China) 
120 males, 
127 females in high 
 12.13 μg/L (F) 
Mod.:  1.28 μg/L (M) 
 2.05 μg/L (F) 
albumin 
 
 
between urinary cadmium and 
prevalence of abnormal effect 
biomarker levels. 
 
al. 1997 
exposure group 
125 males, 
122 females in 
moderate exposure 
group  
Residents in 6.1 μg/g creat. (M) β2M  Effect biomarkers significantly Wu et al. 
cadmium-polluted 
area (China) 
7.5 μg/g creat. (F) 
 
NAG 
calcium 
higher than controls. 
Dose-response relationship 
2001 
122 males, between urinary cadmium and 
125 females effect biomarkers.   
Residents in 6.8–6.9 μg/g creat. β2M Higher prevalence of abnormal Cai et al. 
cadmium-polluted effect biomarkers compared to 2001 
area (Japan) controls. 
127 males; mean 
age 72.1–73.6 years 
old 
CADMIUM  152 
 
3.  HEALTH EFFECTS 
 
 
 
 
 
 
 
Table 3-7.  Summary of Human Studies Examining Renal Effects 
 
Mean urinary Effect 
Population studied cadmium level biomarker Results Reference 
Residents in 3.16–4.08 μg/g creat. β2M No significant association Horiguchi et 
cadmium-polluted  between urinary cadmium and al. 2004 
area (Japan) effect biomarkers. 
1,178 females 
Residents in  β2M Significant association between Izuno et al. 
cadmium-polluted  cadmium intake and effect 2000 
area (Japan) biomarkers in males only. 
82 males, 56 females 
Residents in  Protein Significant association between Kobayashi et 
cadmium-polluted cadmium intake and increased al. 2002a; 
area (Japan) prevalence of abnormal levels Watanabe et 
634 males, of urinary protein in males. al. 2002 
411 females 
Residents in 4.6 μg/g creat. (M) Potassium Significantly higher urinary Monzawa et 
cadmium-polluted 
area (Japan) 
7.2 μg/g creat. (F) 
 
sodium 
 
potassium levels, compared to 
controls.  Significant correlation 
al. 1998 
1,419 males, between urinary potassium and 
1,745 females urinary cadmium and β2M.  
Urinary sodium not significantly 
different than controls and not 
correlated with urinary 
cadmium. 
Residents in 2.69 μg/g creat. (M) β2M  Significant correlation between Nakadaira 
cadmium-polluted 
area (Japan) 
4.68 μg/g creat. (F) 
 
pHC 
NAG 
urinary cadmium and effect 
biomarkers (except β2M in 
and Nishi 
2003 
44 males, 54 females protein males). 
inorganic 
phosphorus 
Residents in  β2M  Significant correlation between Nakashima 
cadmium-polluted protein cadmium concentration in rice et al. 1997 
area (Japan) amino and effect biomarkers. 
832 males, 
871 females 
nitrogen Dose-response relationship 
between cadmium levels in rice 
and prevalence of abnormal 
β2M (males) and protein 
(females) levels.  
Residents in  Protein Dose response relationship Osawa et al. 
cadmium-polluted between cadmium levels in rice 2001 
area (Japan) and prevalence of abnormal 
826 males, effect biomarker levels. 
641 females 
Residents in  β2M  Dose response relationship Nogawa et 
cadmium-polluted  between cadmium in rice and al. 1989 
area (Japan) effect biomarkers. 
878 males, 
972 females  
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Table 3-7.  Summary of Human Studies Examining Renal Effects 
 
Mean urinary Effect 
Population studied cadmium level biomarker Results Reference 
Residents in 4.56 μg/g creat. (M) β2M  β2M significantly higher than Ishizaki et al. 
cadmium-polluted 7.15 μg/g creat. (F)  controls. 1989 
area (Japan) Dose-response relationship 
1,424 males, between urinary cadmium and 
1,754 females  prevalence of abnormal β2M 
levels.   
Residents in  β2M  Dose response relationship Kido and 
cadmium-polluted  between cadmium in rice and Nogawa 
area (Japan) prevalence of abnormal β2M 1993 
878 males, levels.   
972 females 
Residents in 4.56 μg/g creat. (M) β2M  Dose response relationship Hayano et al. 
cadmium-polluted 
area (Japan) 
7.15 μg/g creat. (F)  between urinary cadmium and 
prevalence of abnormal β2M 
1996 
1,403 males, levels.   
1,716 females; 
≥50 years old 
Residents in 1.78 μg/g creat. (M) NAG Significant correlation between Kawada et 
cadmium-polluted 2.27 μg/g creat. (F) urinary cadmium and NAG. al. 1992 
area (Japan) 
120 males, 
280 females 
Residents in 6.30 µg/g creat. β2M Significant correlation between Horiguchi et 
cadmium-polluted urinary cadmium and β2M. al. 2010 
area (Japan) 
129 females; 34–
74 years of age 
Residents in 12 μg/g creat. β2M  Significant correlation between Teeyakasem 
cadmium-polluted pHC urinary cadmium and effect et al. 2007 
area (Thailand) NAG biomarkers.   
58 males, 70 females protein 
albumin 
Dose-response relationship 
between urinary cadmium and 
prevalence of abnormal β2M 
levels. 
Residents in 5.3 μg/g creat. (M) β2M  Dose-response relationship Honda et al. 
cadmium-polluted 
area (Thailand) 
5.8 µg/g creat. (F) NAG 
 
between urinary cadmium and 
prevalence of abnormal β2M 
2010 
307 males, levels (≥1,000 µg/g creatinine) 
488 females; in females and NAG (≥9 IU/g 
>30 years of age creatinine) in males and 
females. 
Residents in 0.81 μg/g creat. (M) pHC Linear relationship between Järup et al. 
cadmium-polluted 0.66 μg/g creat. (F) urinary cadmium and pHC 2000 
area (includes (relationship remained 
occupationally significant after removal of 
exposed subjects occupationally exposed 
(Sweden) subjects. 
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Table 3-7.  Summary of Human Studies Examining Renal Effects 
 
Population studied 
Mean urinary 
cadmium level 
Effect 
biomarker Results Reference 
Residents in 
cadmium-polluted 
area (Sweden)  
57 males, 48 females 
0.26 μg/g creat.  β2M  
protein HC 
NAG 
albumin 
Significant correlation between 
urinary and blood cadmium and 
effect biomarkers. 
β2M clearance was significantly 
explained by urinary cadmium 
levels. 
Olsson et al. 
2002 
Residents in 
cadmium-polluted 
area (Poland) 
44 males, 
128 females only 
exposed as adults 
72 males, 64 females 
exposed as children  
0.97 μg/g creat. 
(childhood exposure) 
2.23 μg/g creat. 
(adult exposure) 
β2M  
RBP 
NAG 
NAG-A 
NAG-B 
albumin 
In childhood exposure group, 
significant correlations between 
urinary cadmium and β2M, 
RBP, and albumin.  In adult 
exposure group, significant 
correlations between urinary 
cadmium and all effect 
biomarkers. 
Trzcinka-
Ochocka et 
al. 2004 
 
AAP = alanine aminopeptidase; β2M = β2-microglobulin; creat. = creatinine; BMI = body mass index; F = female; 
M = male; Mod. = moderate; NAG = N-acetyl-β-glucosaminidase; NHANES = National Health and Nutrition 
Examination Survey; pHC = human complex-forming glycoprotein, also referred to as α1M; RBP = retinol binding 
protein 
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population (mean of 40 years) and study population (mean of 53 years).  Based on these recalculations, 
the urinary cadmium level associated with a 10% increased probability of abnormal pHC values (20% 
total probability) was 2.62 μg/g creatinine for the total population.  In the environmental exposed 
subgroup, a urinary cadmium level of 0.5 μg/g creatinine was associated with a 13% probability 
(doubling of the probability in reference population) of abnormal pHC values. 
 
 
Noonan et al. (2002) examined residents in Pennsylvania living near a defunct zinc smelting facility 
(geometric mean urinary cadmium level of 0.14 μg/g creatinine) and a reference community located 
10 miles from the facility (geometric mean urinary cadmium levels of 0.12 μg/g creatinine).  The data 
from the two communities were pooled because there were no differences in urinary cadmium levels 
between them.  β2-microglobulin, NAG, alanine aminopeptidase (AAP), and albumin levels were 
measured as biomarkers of renal dysfunction.  The geometric mean urinary cadmium levels were 0.07 and 
0.08 μg/g creatinine in 88 males and 71 females aged 6–17 years and 0.24 and 0.23 μg/g creatinine in 
71 males and 80 females aged ≥18 years.  No significant correlations between urinary cadmium levels 
and renal biomarkers were observed in the children, after adjustment for creatinine, age, and gender.  In 
adults, significant correlations (after adjustment for creatinine, age, gender, smoking, and self-reported 
diabetes or thyroid disease) between urinary cadmium and NAG (partial correlation coefficient of 0.20, 
95% CI of 0.05–0.36) and AAP (partial correlation coefficient of 0.21 and 95% CI of 0.05–0.36) were 
observed.  Significant dose-effect relationships were also found for these two biomarkers.  Urinary 
cadmium levels were not significantly associated with elevated levels of β2-microglobulin or albumin. 
Nogawa et al. (1980) examined 878 males and 972 females aged ≥50 years living in the Kakehashi River 
basin in Japan; the Kakehashi River, cadmium polluted from an upstream mine, was used to irrigate rice 
fields.  β2-Microglobulin measured in morning urine samples was used as a biomarker of renal 
dysfunction and cadmium intake was estimated from rice samples collected in 1974.  Cadmium levels in 
rice were considered to be representative of cadmium intake because over 70% of the total cadmium 
intake has been shown to come from rice.  Cadmium in the rice ranged from 0.10 to 0.69 μg/g.  
β2-Microglobulin levels were significantly higher in the study population compared to a reference 
population of 113 males and 161 females living in a nearby area.  A significant dose-related association 
between total cadmium intake and prevalence of abnormal β2-microglobulin values (defined as 
β2-microglobulin levels of ≥1,000 μg/g creatinine) was found.  The total cadmium intake, which resulted 
in a prevalence of abnormal β2-microglobulin levels equal to the control group, was 1,678 mg in males 
(prevalence in controls was 6.0%) and 1,763 mg in females (prevalence in controls was 5.0%).  A further 
analysis of the exposed subjects (Hochi et al. 1995) found that the prevalence of abnormal 
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β2-microglobulin levels (using a cut-off level of 1,000 μg/g creatinine) exceeded the prevalence in the 
reference population when cadmium intake was ≥2 g and the subjects were divided into subgroups by 
age.  The prevalence of abnormal β2-microglobulin levels at a given cadmium intake increased with age.   
 
 
 
Yamanaka et al. (1998) examined 558 males and 743 females aged ≥50 years living in a cadmium 
nonpolluted area in Japan.  Urinary cadmium level was used as a biomarker of exposure and urinary 
β2-microglobulin, total protein, and NAG as biomarkers of renal dysfunction.  The geometric mean 
urinary cadmium levels were 1.3 and 1.3 μg/g creatinine in males and females, respectively.  Significant 
correlations (after adjustment for age) between urinary cadmium levels and total protein, 
β2-microglobulin, and NAG were found.  Abnormal levels of renal biomarkers were defined as exceeding 
the 84% upper limit value calculated from a referent group of 2,778 non-exposed individuals; the cut-off 
values were 124.8 and 120.8 mg/g creatinine for total protein in males and females, 492 and 403 μg/g 
creatinine for β2-microglobulin, and 8.0 and 8.5 U/g creatinine for NAG.  Dose-response relationships 
between urinary cadmium levels and prevalence of abnormal levels of β2-microglobulin, total protein, 
and NAG were found.  The odds ratios (95% CI) were 6.589 (3.383–12.833), 3.065 (1.700–5.526), and 
1.887 (1.090–3.268) for protein, β2-microglobulin, and NAG in males and 17.486 (7.520–40.660), 
5.625 (3.032–10.435), and 2.313 (1.399–3.824) for protein, β2-microglobulin, and NAG in females. 
Another study of residents living in a cadmium nonpolluted area of Japan examined 346 males and 
529 females from one area (area A) and 222 males and 413 females in another area (area B); all subjects 
were ≥50 years of age and were not occupationally exposed to heavy metals (Oo et al. 2000).  The 
geometric mean urinary cadmium levels were 2.2 and 2.8 μg/L in males and females in area A and 
3.4 and 3.9 μg/L in area B.  Significant correlations (with adjustment for age) were found between urinary 
cadmium and urinary levels of protein, β2-microglobulin (not significant in males in area B) and NAG 
levels.  A significant association between urinary cadmium levels and the prevalence (cut-off levels from 
same referent population as Yamanaka et al. 1998) of abnormal levels of urinary protein (cut-off level of 
113.8 and 96.8 μg/L in males and females), β2-microglobulin (378 and 275 μg/L) (only significant in 
females in area A), and NAG (8.0 and 7.2 μg/L).  The odds ratios (95% CI) for an increase in prevalence 
of abnormal renal biomarkers were 8.810 (3.401–22.819) and 11.282 (3.301–38.362) for protein in males 
in areas A and B, respectively, 8.234 (3.696–18.343) and 23.901 (8.897–64.210) for protein in females in 
areas A and B; 2.558 (1.246–5.248) for β2-microglobulin in females in area A; 47.944 (14.193–161.954) 
and 9.940 (3.153–31.340) for NAG in males in areas A and B; and 72.945 (21.873–243.263) and 
25.374 (9.452–68.117) for NAG in females in areas A and B. 
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In a re-examination of the populations studied by Yamanaka et al. (1998) and Oo et al. (2000), Suwazono 
et al. (2000) measured cadmium levels in blood and urine and urinary levels of total protein, 
β2-microglobulin, and NAG in 1,105 males and 1,648 females over the age of 50 years.  The geometric 
mean concentrations of cadmium in urine were 1.8 and 2.4 μg/g creatinine in males and females, 
respectively, and blood cadmium levels were 2.0 and 1.8 ng/g in males and females.  After adjustment for 
age, significant associations between urinary cadmium levels and urinary protein and β2-microglobulin in 
males and females were found.  Additionally, blood cadmium levels were significantly associated with 
urinary protein and NAG levels in males and urinary protein, β2-microglobulin, and NAG levels in 
females.  Cut-off levels (defined as the 84% upper limit values from 424 male and 1,611 female 
nonsmoking subjects) of 157.4 and 158.5 mg/g creatinine for protein in males and females, respectively, 
507 and 400 μg/g creatinine for β2-microglobulin in males and females, respectively, and 8.2 and 
8.5 μg/g creatinine for NAG in males and females, respectively, were used to evaluate the prevalence of 
abnormal levels of renal biomarkers.  Logistic regression analysis demonstrated significant associations 
between urinary cadmium levels and increased prevalence of abnormal levels of total protein (odds ratio 
of 3.923, 95% CI of 2.2028–7.590) and β2-microglobulin (odds ratio of 2.259, 95% CI of 1.372–3.717) in 
males; in females, significant associations were found for total protein (odds ratio of 7.763; 95% CI of 
4.231–14.243), β2-microglobulin (odds ratio of 2.259, 95% CI of 1.879–4.281), and NAG (odds ratio of 
1.882, 95% CI of 1.311–2.702).  For blood cadmium levels, the only significant association found was for 
an increased prevalence of abnormal total protein levels in females (odds ratio of 3.490, 95% CI of 1.661–
7.331). 
 
 
Jin et al. (2002) examined three populations living various distances from a nonferrous metal smelter.  
The geometric mean levels of urinary cadmium were 11.18 and 12.86 μg/g creatinine in males (n=294) 
and females (n=171) in the highly polluted area, 3.55 and 4.45 μg/g creatinine in males (n=243) and 
females (n=162) in the moderately polluted area, and 1.83 and 1.79 μg/g creatinine in males (n=253) and 
females (n=155) in the control area.  Significant correlations were found between urinary (and blood) 
cadmium levels and renal biomarkers (β2-microglobulin, retinol binding protein, and albumin).  Cut-off 
values for β2-microglobulin, retinol binding protein, and albumin of 300 μg/g creatinine, 300 μg/g 
creatinine, and 15 mg/g creatinine, respectively, were used to assess possible dose-response relationships 
(no additional information was provided); although 300 μg/g creatinine was reported as the cut-off values 
for β2-microglobulin, subsequent analysis of this data set (Jin et al. 2004c) reported a cut-off value of 
800 μg/g creatinine.  Significant dose-response relationships between urinary (and blood) cadmium and 
the prevalence of abnormal levels of renal markers of kidney dysfunction were found. 
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Unlike the studies discussed above, Hellström et al. (2001) used the incidence of renal replacement 
therapy (dialysis or kidney transplantation) as an indicator of renal dysfunction, in particular, end-stage 
renal disease.  Residents of Kalmar County, Sweden were divided into four exposure groups:  high 
exposure (workers at cadmium battery production facility), moderate (residents living within 2 km of the 
cadmium battery facility), low (residents living between 2 and 10 km of the facility), and no exposure 
(residents living at least 10 km from the facility); all subjects were 20–79 years of age.  The Mantel-
Haenszel rate ratio (MH-RR) for renal replacement therapy in the cadmium exposed group was 
1.8 (95% CI 1.3–2.3); among the environmentally exposed group, the MH-RR was 1.7 (95% CI 1.3–2.3).  
The age SRRs were 1.9 (95% CI 1.3–2.5) and 1.9 (95% CI 1.2–2.6) for subjects in the moderate exposure 
group aged 20–79 years or 40–79 years, respectively.  The trend for increasing MH-RR with increasing 
exposure was statistically significant.  The age SRRs were not significantly elevated in the low exposure 
group.  The investigators noted that the causes of end stage renal disease were similar in the cadmium 
exposed and unexposed groups.  When only primary renal diseases (excludes renal failure secondary to 
diabetes or vascular or systemic diseases) were considered, the MH-RR was 1.7 (95% CI 1.1–2.6) for all 
cadmium exposed individuals and 2.1 (95% CI 1.4–3.2) for cadmium exposed individuals aged 40–
79 years.  Although urinary cadmium levels were not assessed in this study, other studies in this area 
found mean urinary cadmium levels of 1.0 and 0.46 μg/g creatinine in residents living within 0.5 and 0.5–
1 km, respectively, of the battery facility (Järup et al. 1995a) and 0.38 and 0.55 μg/g creatinine in men 
and women, respectively, living in the contaminated area (Alfvén et al. 2000).  Ferraro et al. (2011) and 
Swaddiwudhipong et al. (2011) used another approach for evaluating kidney damage by examining the 
association between elevated urinary cadmium levels and kidney stone formation.  Using the NHANES 
survey data from 1988 to 1994, Ferraro et al. (2011) found significantly higher urinary cadmium levels in 
individuals with a history of kidney stone formation, as compared to individuals without a history of 
kidney stone formation.  However, after adjusting for age, race/ethnicity, BMI, smoking habits, region of 
residence, and daily intake of calcium and sodium, a significant association was only found in females; 
the odds ratio of kidney stones was 1,40 (95% CI of 1.06–1.86) among individuals with a urinary 
cadmium level of >1 µg/g.  Swaddiwudhipong et al. (2011) found a significant association between 
urinary cadmium levels and prevalence of urinary stone formation among adults living in cadmium-
contaminated areas of Thailand. 
 
Although there is strong evidence to suggest a relationship between urinary cadmium excretion and 
excretion of renal biomarkers (particularly low molecular weight proteins such as β2-microglobulin, pHC, 
and retinol binding protein), there is less agreement about the significance of the early renal changes and 
the threshold urinary cadmium levels associated with renal damage.  Several studies monitoring 
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populations following a decrease in cadmium exposure have attempted to address the question of the 
reversibility of early renal changes.  In Japan, cadmium-contaminated soil used in rice paddies was 
replaced resulting in decreasing urinary cadmium levels in residents consuming rice grown in these fields 
(Cai et al. 2001; Iwata et al. 1993; Kobayashi et al. 2008b; Sato et al. 2010).  Although, cadmium 
exposure decreased over the same time period, the levels of renal biomarkers increased (Cai et al. 2001; 
Iwata et al. 1993; Kido et al. 1988; Kobayashi et al. 2008b; Sato et al. 2010) and the prevalence of 
abnormal values remained higher compared to the reference population (Cai et al. 2001).  Although 
significant decreases in urinary cadmium levels were observed over time, cadmium burdens still remained 
high; urinary cadmium levels at the later time periods were 6.03–9.6 μg/g creatinine (Cai et al. 2001; 
Iwata et al. 1993; Kido et al. 1988).  Kobayashi et al. (2008b) found significant correlations (after 
adjustment for age) between the amount of time since soil replacement and increases in urinary levels of 
retinol binding protein, total protein, and glucose (males only).  In contrast, a follow-up study of a portion 
of the population examined by Buchet et al. (1990) found small, but statistically significant, decreases in 
urinary cadmium levels and urinary levels of β2-microglobulin, NAG, and retinol binding protein (Hotz 
et al. 1999).  Urinary cadmium levels in this study (0.6–0.9 μg/g creatinine at baseline and 0.5–0.8 μg/g 
creatinine at follow up) were much lower than levels in the Japanese studies.  Wu et al. (2008) examined 
biomarkers of renal dysfunction before (measured in 1995) and after (measured in 1998) remediation in 
148 adults living in an area of China with cadmium pollution.  The subjects were divided into two groups 
based on whether or not they had elevated β2-microglobulin levels in 1995.  Among the subjects with no 
alteration in β2-microglobulin levels in 1995, there were no significant changes in β2-microglobulin 
levels in subjects with urinary cadmium levels of <10 µg/g creatinine in 1995 and significant increases in 
β2-microglobulin levels in the subjects with initial urinary cadmium levels of ≥10 µg/g creatinine.  In the 
subjects with elevated β2-microglobulin levels in 1995, there were significant decreases in 
β2-microglobulin in subjects with urinary cadmium levels of <5 µg/g creatinine, no changes in subjects 
with urinary cadmium levels of 5 µg/g creatinine, and significant increases in β2-microglobulin levels in 
subjects with urinary cadmium levels of ≥10 µg/g creatinine.  A similar pattern was found for urinary 
albumin levels, with significant decreases in urinary albumin levels in subjects previously diagnosed with 
albuminuria and urinary cadmium levels of <5 µg/g creatinine and no changes in urinary albumin levels 
in subjects with urinary cadmium levels of ≥5 µg/g creatinine.  In subjects without albuminuria in 1995, 
there were increases at the higher urinary cadmium levels (5 and 20 µg/g creatinine).  Although the data 
are inconclusive, the results of these studies provide some indication of reversibility of renal damage 
resulting from substantial decreases in cadmium exposure among subjects exposed to low levels of 
cadmium.  However, renal damage may continue to progress in subjects initially exposed to higher levels 
of cadmium.    
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A number of investigators have examined different approaches to establishing a safe cadmium body 
burden (as assessed by urinary cadmium levels).  Several BMD analyses of data from populations living 
in cadmium nonpolluted areas in Sweden (Suwazono et al. 2006) or Japan (Kobayashi et al. 2006, 2008a; 
Suwazono et al. 2011a, 2011b, 2011c; Uno et al. 2005) or cadmium polluted areas in Japan (Shimizu et 
al. 2006) or China (Jin et al. 2004c) have been conducted.  The analyses used urinary cadmium levels as a 
biomarker of cadmium exposure and the prevalence of abnormal levels of β2-microglobulin, pHC, 
protein, NAG, retinol binding protein, albumin, or glomerular filtration rate as biomarkers of renal 
effects.  Two approaches were used for BMD modeling:  dichotomous variable (Jin et al. 2004c; 
Kobayashi et al. 2006; Shimizu et al. 2006; Uno et al. 2005) or hybrid (Kobayashi et al. 2008a; Suwazono 
et al. 2006, 2011a, 2011b, 2011c) approaches.  In the dichotomous variable approach, urinary cadmium 
excretion was divided into categories and the distribution of abnormal values (exceeding the cut-off 
value) was fit to dichotomous BMD models.  As noted by Suwazono et al. (2010), one limitation of this 
approach is that it does not allow for adjustment for potential covariates, particularly age; additionally, the 
results may fluctuate depending on the categorization of exposure, number of categories, or dose 
intervals.  The hybrid approach eliminates the categorization of subjects by exposure (e.g., urinary 
cadmium levels) and is based on a continuous measure of outcome and allows for the adjustment of 
potential covariates such as age and BMI.  As summarized in Table 3-8, the BMDs for urinary cadmium 
levels vary widely between the studies depending on the renal biomarker and the cut-off level used.  For 
example, when NAG is used as the effect biomarker, the BMD0.05 (dose associated with a 5% extra risk) 
values of 0.64, 12.0–10.8, and 6.36–7.74 μg/g creatinine were calculated by Suwazono et al. (2006), 
Kobayashi et al. (2006), and Jin et al. (2004c) when the 95% upper limit cut-off value of 3.6, 16.0–16.6, 
and 15.0 U/g creatinine, respectively, was used.  The results of the two BMD approaches were similar 
when similar cut-off levels were used.  The BMDL (95% confidence bound of the BMD) is typically 
considered a no adverse effect level; the results of these BMD analyses suggest that chronic exposure to 
cadmium resulting in urinary cadmium levels of 0.3–11.31 or 0.6–11.4 μg/g creatinine would be 
associated with a 5 or 10% additional risk of renal dysfunction.   
 
Ikeda and associates used regression analysis to predict a threshold urinary cadmium level.  Plotting 
urinary cadmium levels against β2-microglobulin levels taken from published data from populations 
living in cadmium polluted and non polluted areas of Japan resulted in a distribution shaped like the letter 
“J”.  The threshold level was defined as the point of flexion in the “J” shaped curve.  In the first 
investigation (Ikeda et al. 2003b), the point of flexion was estimated as the point of intersection between 
two regression lines:  one with no elevation in β2-microgloublin from non-exposed populations and the  
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Table 3-8.  Benchmark Dose Estimations of Urinary Cadmium Levels (µg/g 
Creatinine) 
 
Study 
population 
Effect 
biomarker 
Response 
criterion 
BMD 
model 
5% BMR 10% BMR 
Reference BMD BMDL BMD BMDL 
General NAG 3.6 U/g creat. Profile 0.64 0.50 1.08 0.83 Suwazono et 
population (95% cut-off)a likelihood al. 2006 
(Sweden) 
790 females; 
53–64 years old 
pHC 
Estimated 
6.8 mg/g creat. 
(95% cut-off)a 
78.5 
method 0.63 
1.08 
0.49 
0.70 
1.05 
1.80 
0.81 
1.18 
GFR mL/minute 
(95% cut-off)a 
Residents in β2M 507 μg/g creat. Quantal 1.5 (M) 1.2 (M) 3.1 (M) 2.5 (M) Shimizu et 
cadmium- (M) linear 1.4 (F) 1.1 (F) 2.9 (F) 2.3 (F) al. 2006 
polluted  400 μg/g creat. model 
(1,397 males, 
1,706 females) 
(F) 
(84% cut-off)b 
and cadmium 
nonpolluted 
areas (Japan) 
(130 males, 
159 females); 
≥50 years old  
507 μg/g creat. 
(M) 
400 μg/g creat. 
(F) 
(84% cut-off)b 
994 μg/g creat. 
Log-
logistic 
model 
Quantal 
3.7 (M) 
2.6 (F) 
2.3 (M) 
2.9 (M) 
1.5 (F) 
1.8 (M) 
5.1 (M) 
6.3 (F) 
4.7 (M) 
4.2 (M) 
2.7 (F) 
3.7 (M) 
(M) linear 1.7 (F) 1.4 (F) 3.5 (F) 2.9 (F) 
784 μg/g creat. model 
(F) 
(95% cut-off)c 
994 μg/g creat. Log- 4.8 (M) 3.9 (M) 6.3 (M) 5.5 (M) 
(M) logistic 4.4 (F) 3.2 (F) 6.4 (F) 5.1 (F) 
784 μg/g creat. model 
(F) 
(95% cut-off)c 
Residents in β2M 915.5 µg/g Profile 4.0 (M) 3.5 (M)   Suwazono et 
cadmium- creat. (M) likelihood 4.0 (F) (3.7 )F) al. 2011b 
polluted  897.1 µg/g method 
(1,397 males, 
1,706 females)d 
creat. 
(95% cut-off)e 
and cadmium 
nonpolluted 
areas (Japan) 
(520 males, 
700 females); 
≥50 years old 
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Table 3-8.  Benchmark Dose Estimations of Urinary Cadmium Levels (µg/g 
Creatinine) 
 
Study 
population 
Effect 
biomarker 
Response 
criterion 
BMD 
model 
5% BMR 10% BMR 
Reference BMD BMDL BMD BMDL 
General Protein 157 mg/g Log- 3.6 (M) 3.1 (M) 5.6 (M) 4.9 (M) Kobayashi et 
population creat. (M) logistic 4.8 (F) 4.2 (F) 7.5 (F) 6.6 (F) al. 2006 
(Japan) 159 mg/g model 
1,114 males, 
1,664 females  
creat. (F) 
(84% cut-off)f 
309 mg/g  10.6 (M) 6.8 (M) 15.3 (M) 9.6 (M) 
creat. (M) 
311 mg/g 
8.7 (F) 7.3 (F) 12.0 (F) 9.9 (F) 
creat. (F) 
(95% cut-off)g 
β2M 507 μg/g creat.  2.9 (M) 2.4 (M) 5.0 (M) 4.0 (M) 
(M) 3.8 (F) 3.3 (F) 6.6 (F) 5.5 (F) 
400 μg/g creat. 
(F) 
(84% cut-off)f 
994 μg/g creat.  6.4 (M) 4.5 (M) 10.2 (M) 7.1 (M) 
(M) 8.7 (F) 7.3 (F) 12.0 (F) 9.9 (F) 
784 μg/g creat. 
(F) 
(95% cut-off)g 
NAG 8.2 U/g creat.  4.8 (M) 3.3 (M) 8.3 (M) 5.7 (M) 
(M) 4.7 (F) 3.7 (F) 8.3 (F) 6.4 (F) 
8.5 U/g creat. 
(F) 
(84% cut-off)f 
16.0 U/g creat.  12.0 (M) 7.7 (M) 16.4 (M) 10.3 (M) 
(M) 10.8 (F) 8.5 (F) 14.8 (F) 11.4 (F) 
16.6 U/g creat. 
(F) 
(95% cut-off)g 
General β2M 492 µg/g creat. Multiple 3.0 (M) 2.7 (M) 5.0 (M) 4.6 (M) Kobayashi et 
population (M) logistic 3.4 (F) 3.2 (F) 5.7 (F) 5.4 (F) al. 2008a 
(Japan) 407 µg/g creat. model 
1,181 males, 
1,748 females 
(F) 
(84% cut-off)h 
965 µg/g creat. 4.9 (M) 4.5 (M) 7.4 (M) 6.8 (M) 
(M) 5.9 (F) 5.6 (F) 8.6 (F) 8.1 (F) 
798 µg/g creat.  
(F) 
(97.5% cut-off)i 
1,000 µg/g 5.0 (M) 4.6 (M) 7.5 (M) 6.9 (M) 
creat. 6.7 (F) 6.3 (F) 9.4 (F) 8.9 (F) 
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Table 3-8.  Benchmark Dose Estimations of Urinary Cadmium Levels (µg/g 
Creatinine) 
 
Study 
population 
Effect 
biomarker 
Response 
criterion 
BMD 
model 
5% BMR 10% BMR 
Reference BMD BMDL BMD BMDL 
General Protein 159 mg/g Profile 2.6 (M) 2.1 (M)   Suwazono et 
population  creat. (M) likelihood 1.7 (F) 1.5 (M) al. 2011c 
(Japan) 93 mg/g creat. method 
547 males, (F) 
723 females;  (95% cut-off)a
aged ≥50 years β2M 708 µg/g creat.  3.4 (M) 2.6 (M)   
 (M) 1.7 (F) 1.4 (F) 
415 µg/g creat. 
(F) 
 (95% cut-off)e
NAG 10.7 IU/g  6.3 (M) 4.1 (M)   
 creat. (M) 4.3 (F) 3.1 (F) 
11.1 IU/g 
creat. (F) 
 (95% cut-off)j
General Protein 70 mg/g creat. Quantal 0.9 (M) 0.6 (M) 1.9 (M) 1.2 (M) Uno et al. 
population (M) linear 3.2 (F) 1.8 (F) 6.6 (F) 3.6 (F) 2005 
(Japan) 70 mg/g creat. model 
410 males, 
418 females; 
(F) 
(84% cut-off)k 
40–59 years old β2M 233 μg/g creat. 0.5 (M) 0.4 (M) 1.0 (M) 0.7 (M) 
(M) 0.9 (F) 0.8 (F) 1.8 (F) 1.3 (F) 
274 μg/g creat. 
(F) 
(84% cut-off)k 
NAG 2.4 U/g creat. 0.3 (M) 0.3 (M) 0.7 (M) 0.6 (M) 
(M) 0.8 (F) 0.6 (F) 1.6 (F) 1.2 (F) 
2.5 U/g creat. 
(F) 
(84% cut-off)k 
General Protein 67.7 mg/g Profile 1.3 (M) 0.9 (M)   Suwazono et 
population 
 (Japan)l
 creat. (M)
94.6 mg/g 
likelihood 
method 
3.2 (F) 1.9 (F) al. 2011a 
209 males, creat. (F) 
215 females; (95% cut-off)a 
40–49 years old β2M 224.5 µg/g 0.9 (M) 0.7 (M)   
 creat. (M) 2.2 (F) 1.5 (F) 
298.9 µg/g 
creat. (F) 
(95% cut-off)a 
NAG 2.2 IU/g creat. 0.7 (M) 0.6 (M)   
 (M) 1.3 (F) 0.6 (F) 
2.1 IU/g creat. 
(F) 
(95% cut-off)a 
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Table 3-8.  Benchmark Dose Estimations of Urinary Cadmium Levels (µg/g 
Creatinine) 
 
Study 
population 
Effect 
biomarker 
Response 
criterion 
BMD 
model 
5% BMR 10% BMR 
Reference BMD BMDL BMD BMDL 
General 
population 
(Japan)j 
201 males, 
203 females; 
50–59 years 
Protein 94.5 mg/g 
creat. (M) 
92.7 mg/g 
creat. (F) 
(95% cut-off)a 
Profile 
likelihood 
method 
1.6 (M) 
5.7 (F) 
1.1 (M) 
3.4 (F) 
  Suwazono et 
al. 2011a 
β2M 322.1 µg/g 
creat. (M) 
296.7 µg/g 
creat. (F) 
(95% cut-off)a 
1.8 (M) 
2.4 (F) 
1.2 (M) 
1.8 (F) 
  
NAG 2.5 IU/g creat. 
(M) 
3.3 IU/g creat. 
(F) 
(95% cut-off)a 
1.0 (M) 
3.2 (F) 
 
0.8 (M) 
2.3 (F) 
  
Residents in 
cadmium highly 
polluted area 
(China) 
123 males, 
171 females 
Residents in 
cadmium 
moderately 
polluted area 
(China) 
81 males, 
162 females 
NAG 15.0 U/g creat. 
(95% cut-off)m 
Quantal 
linear 
logistic 
regression 
model 
6.36 (M) 
7.74 (F) 
5.83 (M) 
5.46 (F) 
  Jin et al. 
2004c 
NAG-B 4.0 U/g creat. 
(95% cut-off)k 
4.88 (M) 
4.24 (F) 
3.98 (M)  
3.70 (F) 
  
β2M 800 μg/g creat. 
(95% cut-off)m 
5.86 (M) 
9.98 (F) 
4.74 (M) 
8.47 (F) 
  
RBP 0.300 mg/g 
creat. 
(95% cut-off)m 
5.99 (M) 
9.03 (F) 
4.87 (M) 
7.63 (F) 
  
Albumin 25.0 mg/g 
creat. 
(95% cut-off)m 
16.72 
(M) 
14.42 (F) 
11.18 
(M) 
11.31 (F) 
  
 
a95th percentile of effect biomarkers on the “hypothetical” control distribution at a urinary cadmium level of zero. 
b84% upper limit values from a group of 424 males and 1,611 females who did not smoke and lived in three different 
cadmium nonpolluted areas. 
c95% upper limit values from a group of 424 males and 1,611 females who did not smoke and lived in three different 
cadmium nonpolluted areas. 
dSame population of residents living in polluted area as Shimizu et al. (2006). 
e95th percentile calculated by benchmark model at no cadmium exposure (urinary cadmium equal to zero), adjusted 
to mean age. 
f84% upper limit value of the target population of people who have not smoked. 
g95% upper limit value of the target population of people who have not smoked. 
h84th percentile level in subjects from nonpolluted areas. 
i97.5th percentile level in subjects from nonpoulluted areas. 
j95th percentile calculated by benchmark model at no cadmium exposure (urinary cadmium equal to zero), adjusted 
to mean age in females only. 
k84% upper limit value of the target population.   
lSame population as Uno et al. (2005), divided into two age groups. 
m95% upper limit value from a control group 98 males and 155 females living in a cadmium nonpolluted area. 
 
BMD = benchmark dose; BMDL = lower 95% confidence limit on the benchmark dose; BMR = benchmark response; 
β2M = β2-microglobulin; creat. = creatinine; F = female; M = male; NAG = N-acetyl-β-D-glucosaminidase; 
NAG-B = N-acetyl-β-D-glucosaminidase’s isoform B; RBP = retinol binding protein 
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other when β2-microglobulin was >400 or >1,000 μg/g creatinine using data from exposed populations.  
Although no specific data were given for the two populations, the investigators noted that the highest 
urinary cadmium levels in the non-exposed populations were 5.6 and 3.6 μg/g creatinine in females and 
males, respectively.  The points of intersection of the regression lines were 11.0 and 11.7 μg/g creatinine 
in females using the >400 and 1,000 μg/g creatinine criteria, respectively, and 10.0 and 11.0 μg/g 
creatinine in males.  The second investigation also used published data on Japanese populations living in 
polluted and nonpolluted areas (Ikeda et al. 2005b).  The urinary cadmium levels ranged from 0.2 to 
7.8 μg/g creatinine and from 0.8 to 31.6 μg/g creatinine in the nonpolluted and polluted areas, 
respectively, and the data for the two populations were combined.  Plotting urinary cadmium levels 
against β2-microglobulin levels showed that there was a marked increase in β2-microglobulin levels 
(levels exceeded 1,000 μg/g creatinine) when urinary cadmium levels exceeded 4 μg/g creatinine.  The 
urinary cadmium levels at the point of intersection of the regression line for urinary cadmium levels of 
≤2 or ≤5 μg/g creatinine was 6.7 and 6.7 μg/g creatinine using ordinary scales and 3.7 and 3.7 μg/g 
creatinine using double logarithmic scales.  These urinary cadmium levels corresponded to β2-micro-
globluin levels of 139 and 267 μg/g creatinine with the ordinary scales and 118 and 118 μg/g creatinine 
using the double logarithmic scales.  Using these regression equations and a critical β2-microglobulin 
level of 1,000 μg/g creatinine resulted in urinary cadmium levels of 7.6 (ordinary scales) or 8.1 (double 
logarithmic scales) μg/g creatinine.  Based on this analysis, the investigators concluded that at urinary 
cadmium levels of >4 μg/g creatinine, there is a substantial increase in β2-microglobulin levels (Ikeda et 
al. 2005b).  Similarly, Kobayshi et al. (2009a) estimated the threshold level for lifetime cadmium intake 
using BMD modeling in 2607 adults, aged ≥50 years, residing for at least 30 years in an area of Japan 
with known cadmium contamination.  A lifetime cadmium intake of 1.16–2.43 g in males and 0.86–
1.79 g in women would be associated with a 5% additional risk of proteinuria and/or glucosuria.   
 
A third approach used to identify a threshold level was a meta-analysis conducted by Gamo et al. (2006) 
using published data on environmentally exposed populations.  Urinary cadmium was used as a 
biomarker of exposure and the prevalence of abnormal levels of β2-microglobulin as an indicator of renal 
dysfunction.  The investigators estimated maximum permissible geometric mean urinary cadmium levels 
in age- and gender-specific populations that would not result in a significant increase in the prevalence of 
abnormal β2-microglobulin levels.  They concluded that the geometric mean urinary cadmium level for a 
population in a small geographical area should not exceed 3 μg/g creatinine; in a nationwide population, 
the geometric mean should not exceed 2 μg/g creatinine.   
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Numerous studies in rats, mice, and rabbits confirm that oral exposure to cadmium causes kidney damage 
including proteinuria and tubular damage (Andersen et al. 1988; Bernard et al. 1980, 1988a, 1992; 
Bomhard et al. 1984; Borzelleca et al. 1989; Cardenas et al. 1992a, 1992b; Cha 1987; Fingerle et al. 1982; 
Gatta et al. 1989; Gill et al. 1989b; Itokawa et al. 1974; Kawamura et al. 1978; Kotsonis and Klaassen 
1978; Kozlowska et al. 1993; Mangler et al. 1988; Masaoka et al. 1994; Pleasants et al. 1992, 1993; 
Prigge 1978a; Steibert et al. 1984; Stowe et al. 1972; Wilson et al. 1941).  Histopathological findings 
include focal necrosis of proximal tubular epithelial cells and cloudy swelling in renal tubules (Cha 1987).  
Some studies have also shown no effect on renal function (Basinger et al. 1988; Borzelleca et al. 1989; 
Boscolo and Carmignani 1986; Groten et al. 1990; Jamall et al. 1989; Loeser and Lorke 1977a, 1977b). 
 
In acute-duration gavage studies in rats, decreased urine flow (Kotsonis and Klaassen 1977) and 
histopathologic evidence of kidney damage have been reported (Borzelleca et al. 1989) at the very high 
doses of 150 and 138 mg/kg/day, respectively.  No effect on renal function was reported in rats receiving 
13.9 mg/kg/day for 10 days in drinking water (Borzelleca et al. 1989).  Mice treated with a single gavage 
dose showed tubular necrosis at 88.8 mg/kg in one study (Andersen et al. 1988), but no effects on the 
kidney in another study at a dose of 112 mg/kg (Basinger et al. 1988).  Proteinuria is a common finding in 
intermediate-duration oral exposure studies in rats (Bernard et al. 1988a; Cardenas et al. 1992a, 1992b; 
Kotsonis and Klaassen 1978; Prigge 1978a), as are histopathologic changes in the kidney (Gatta et al. 
1989; Itokawa et al. 1974; Kotsonis and Klaassen 1978; Wilson et al. 1941).  Renal clearance was 
decreased in one study (Kawamura et al. 1978).  Both increases (Pleasants et al. 1992, 1993) and 
decreases (Kozlowska et al. 1993) in relative kidney weight have been reported.  These effects occurred 
in rats at doses ranging from 2 to 30 mg/kg/day.  No renal effects were seen in dogs receiving 
0.75 mg/kg/day cadmium for 3 months (Loeser and Lorke 1977b), but interstitial renal fibrosis was 
observed in rabbits exposed to 14.9 mg/kg/day for 200 days (Stowe et al. 1972).  Renal dysfunction has 
been reported in Rhesus monkeys exposed to 1.2 mg/kg/day for 9 years, but not at 0.4 mg/kg/day 
(Masaoka et al. 1994).  Adverse renal effects are common in rats following chronic-duration oral 
exposure to cadmium.  Proteinuria (Bernard et al. 1992; Bomhard et al. 1984) and histopathologic damage 
(Fingerle et al. 1982; Mangler et al. 1988) have been reported at doses ranging from 1.8 to 
12.5 mg/kg/day cadmium. 
 
The hypothesis that a critical concentration of approximately 200 μg/g in the renal cortex must be reached 
before proteinuria develops is generally supported by the animal data (Bhattacharyya et al. 1988c; 
Kotsonis and Klaassen 1978; Mangler et al. 1988; Shaikh et al. 1989; Viau et al. 1984).   
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Endocrine Effects.    Using data from the NHANES 1988–1994, Schwartz et al. (2003) investigated 
possible associations between cadmium exposure (as measured by urinary cadmium levels) and the 
prevalence of impaired fasting glucose and diabetes.  Analysis on 8,722 participants of the survey 
(≥40 years old) showed a dose-related increase in both impaired fasting glucose and diabetes after 
adjusting for age, ethnicity, sex, and BMI.  No other studies were located regarding endocrine effects in 
humans after oral exposure to cadmium.   
 
Studies on the potential toxicity of cadmium to the endocrine system consist of studies conducting 
histopathologic examination of endocrine tissues and studies examining 24-hour variations in hormone 
release.  No adverse effects were seen in parathyroid glands from female Wistar rats exposed to 8 mg 
Cd/kg/day via drinking water for 90 days (Kawamura et al. 1978) or in adrenal gland from male Sprague-
Dawley rats exposed to 8 mg/kg/day via drinking water for 24 weeks (Kotsonis and Klaassen 1978).  
Pituitary, adrenals, thyroid, and thymus were unaffected in Wistar rats exposed to 3 mg/kg/day cadmium 
via feed for 3 months (Loeser and Lorke 1977a).  Wilson et al. (1941) reported pancreatic atrophy and 
pancreatitis in rats from cadmium at 2.79 mg/kg/day via feed for 100 days.  In rabbits exposed to 14.9 mg 
Cd/kg body weight/day via drinking water for 200 days, the pancreas had moderate concentrations of 
cadmium, but no interstitial fibrosis or other pathologic alterations (Stowe et al. 1972).  Alterations in the 
24-hour pattern of plasma adrenocorticotropin hormone and growth hormone levels were observed in rats 
exposed to 0.92 or 1.8 mg Cd/kg/day as cadmium chloride in drinking water for 30 days (Caride et al. 
2010b); significant increases in adenocorticotropin hormone and thyroid stimulating hormone levels were 
also observed.  Cadmium also disrupted the daily pattern of aspartate, glutamate, and glutamine content in 
the anterior and posterior pituitary gland in rats exposed to 0.92 or 1.8 mg Cd/kg/day as cadmium 
chloride in drinking water for 30 days (Caride et al. 2010a). 
 
Dermal Effects.    No studies were located regarding dermal effects in humans after oral exposure to 
cadmium.   
 
Coarse fur was reported in Long-Evans rats receiving 6.13 mg/kg/day cadmium during Gd 6–15 
(Machemer and Lorke 1981).  A ruffled hair coat was reported in Wistar rats receiving 40 mg/kg/day 
cadmium by gavage 5 days/week for 14 weeks (Baranski and Sitarek 1987).  No other reports of dermal 
effects after oral exposure to cadmium were located. 
 
Ocular Effects.    No studies were located regarding ocular effects in humans or animals after oral 
exposure to cadmium. 
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Body Weight Effects.    No studies were located regarding body weight effects in humans after oral 
exposure to cadmium. 
 
Decreased body weight and decreased rates of growth are common findings in studies where experimental 
animals are orally exposed to cadmium.  Sprague-Dawley rats receiving a single gavage dose of 
150 mg/kg cadmium exhibited a 12% decrease in body weight, but 100 mg/kg had no effect (Kotsonis 
and Klaassen 1977).  Daily gavage doses of 15.3 mg/kg over a 10-day period caused a 79% decrease in 
body weight gain in male Sprague-Dawley rats (Borzelleca et al. 1989).  Significant reductions in 
maternal weight gain have also been reported (Baranski 1985; Machemer and Lorke 1981). 
 
Body weight reductions are also seen in intermediate-duration studies.  For example, in a 14-week 
exposure via drinking water in male Long-Evans rats, 2.9 mg/kg/day had no effect on body weight gain; 
however, 5.8 mg/kg/day caused a 6–23% decrease and 11.6 mg/kg/day caused a 47–58% decrease 
(Pleasants et al. 1992, 1993).  In general, intermediate-duration doses in feed or drinking water of 
≤3 mg/kg/day have either no effect or only a small effect (10–20% decrease) on body weight in rats 
(Carmignani and Boscolo 1984; Jamall et al. 1989; Loeser and Lorke 1977a; Muller et al. 1988; Ogoshi et 
al. 1989; Perry et al. 1989; Wilson et al. 1941).  Higher doses (4–14 mg/kg/day) had no effect in some 
studies (Kostial et al. 1993; Kotsonis and Klaassen 1978; Prigge 1978a; Viau et al. 1984) and small 
effects in others (Cha 1987; Kawamura et al. 1978; Kozlowska et al. 1993).  A 29% decrease in maternal 
weight gain was observed in rats exposed to a high dose of 40 mg/kg/day (Baranski and Sitarek 1987).  In 
mice, a dose of 4.8 mg/kg/day had no effect on maternal weight gain, but a dose of 9.6 mg/kg/day caused 
a 14% decrease (Webster 1978).  A high dose of 232 mg/kg/day in mice caused a 29% decrease in body 
weight (Waalkes et al. 1993).  Beagle dogs were unaffected at 0.75 mg/kg/day (Loeser and Lorke 1977b), 
as were rabbits at up to 2.2 mg/kg/day (Boscolo and Carmignani 1986; Tomera and Harakal 1988).  A 
small decrease (11%) was seen in rabbits exposed to 14.9 mg/kg/day for 200 days (Stowe et al. 1972). 
 
A chronic-duration study in Rhesus monkeys reported decreased growth rates at 0.4 mg/kg/day, but no 
effect at 0.12 mg/kg/day (Masaoka et al. 1994).  No effect on body weight was seen in rats at up to 
4.4 mg/kg/day (Decker et al. 1958; Fingerle et al. 1982; Mangler et al. 1988), but a small effect was seen 
at 7 mg/kg/day (Waalkes and Rehm 1992).  Decreased terminal body weight was observed in mice after 
12 months of drinking-water exposure to a high dose of 57 mg/kg/day (Hays and Margaretten 1985). 
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Metabolic Effects.    Hyperthermia and metabolic acidosis were reported in a human male who had 
ingested 25 mg/kg cadmium as cadmium iodide (Wisniewska-Knypl et al. 1971).   
 
No studies were located regarding metabolic effects in animals after oral exposure to cadmium. 
 
3.2.2.3   Immunological and Lymphoreticular Effects  
 
No studies were located regarding immunological effects in humans after oral exposure to cadmium.   
 
Numerous studies in rats, mice, and monkeys have established the capability of cadmium to affect the 
immune system, but the clinical significance of the effects is not clear.  In mice, intermediate-duration 
oral exposure to cadmium has been shown to increase resistance to viral infection (Exon et al. 1986), to 
be without effect on natural or acquired resistance to infection (Bouley et al. 1984), and to increase 
mortality from virally-induced leukemia (Blakley 1986; Malave and de Ruffino 1984).  Oral cadmium 
exposure has also been found to suppress the humoral immune response of mouse splenic cells to sheep 
red blood cell antigen in 6-week-old mice (Blakley 1985), but not in 12-month-old mice (Blakley 1988).  
The author suggests that “natural” age-related immune system dysfunction masked any cadmium 
suppressive effect in the 12-month-old mice, and that immunotoxicological investigations in aged models 
appear to be a poor indicator of immune response in the general population.  Oral cadmium exposure has 
also been found to increase the cell-mediated immune response of monkeys (Chopra et al. 1984), to 
induce anti-nuclear antibodies in mice (Ohsawa et al. 1988), to increase circulating leukocytes in female 
rats (Borzelleca et al. 1989), and to exhibit time-dependent inhibitory and stimulative effects (Cifone et al. 
1989b) or no effect (Stacey et al. 1988a) on natural killer cell activity in rats.  The highest NOAEL values 
and all LOAEL values from each reliable study for immunological effects in each species and duration 
category are recorded in Table 3-6 and plotted in Figure 3-2. 
 
3.2.2.4   Neurological Effects  
 
A few studies have reported an association between environmental cadmium exposure and neuropsycho-
logical functioning.  These studies used hair cadmium as an index of exposure (see Section 3.8.1 for a 
discussion of the limitations of using hair as an indicator of exposure).  End points that were affected 
included verbal IQ in rural Maryland children (Thatcher et al. 1982), acting-out and distractibility in rural 
Wyoming children (Marlowe et al. 1985), and disruptive behavior in Navy recruits (Struempler et al. 
1985).  The usefulness of the data from these studies is limited because of the potential confounding 
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effects of lead exposure; lack of control for other possible confounders including home environment, 
caregiving, and parental IQ levels; and an inadequate quantification of cadmium exposure. 
 
Although cadmium-induced neurotoxicity has not been clearly demonstrated in human studies, it has been 
observed in animal studies.  Both a single oral exposure (Kotsonis and Klaassen 1977) and intermediate-
duration exposure of adult rats to cadmium resulted in significantly decreased motor activity (Kotsonis 
and Klaassen 1978; Nation et al. 1990).  Intermediate-duration oral exposure to cadmium has also been 
reported to cause weakness and muscle atrophy (Sato et al. 1978), induce aggressive behavior (Baranski 
and Sitarek 1987), induce anxiety as manifested by increased passive avoidance behavior (Nation et al. 
1984) and by increased ethanol consumption (Nation et al. 1989), and alter brain biogenic amine content 
and enzyme activities (Murthy et al. 1989).  Doses associated with these effects range from 5 to 
40 mg/kg/day cadmium.  Degenerative changes in the choroid plexus have been reported in mice exposed 
to 1.4 mg/kg/day cadmium in drinking water for 22 weeks (Valois and Webster 1989).  Peripheral 
neuropathy has been reported in rats after a 31-month exposure to cadmium in drinking water (Sato et al. 
1978).  Neurological effects in offspring of animals orally exposed to cadmium during gestation are 
discussed in Section 3.2.2.5.  The highest NOAEL values and all LOAEL values from each reliable study 
for neurological effects in each species and duration category are recorded in Table 3-6 and plotted in 
Figure 3-2. 
 
3.2.2.5   Reproductive Effects  
 
Several studies have examined the possible association between increased cadmium exposure and male 
reproductive toxicity; however, most studies focused on sex steroid hormone levels and the results appear 
to be inconsistent.  Akinloye et al. (2006) found significant associations between increasing blood 
cadmium levels and increasing levels of serum luteinizing hormone, follicle stimulating hormone, 
prolactin, and testosterone among infertile men (sperm counts <20 million/cm3 or no spermatozoa in 
semen).  A significant association between increased blood cadmium levels and increased serum 
testosterone was also found in a group of workers with slight to moderate lead exposure (Telišman et al. 
2000); however, neither study controlled for smoking.  A study by Jurasović et al. (2004) found 
significant associations between blood cadmium levels and increased serum estradiol, follicle stimulating 
hormone, and testosterone levels in infertile men after adjusting for age, smoking, alcohol consumption, 
and biomarkers of lead, copper, zinc, and selenium.  In contrast, a study of Chinese men living in areas 
with high levels of cadmium in rice did not find significant correlations between urinary or blood 
cadmium levels and serum testosterone, follicle stimulating hormone, or luteinizing hormone levels after 
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adjusting for BMI, age, smoking, and alcohol consumption (Zeng et al. 2004a).  However, they did find 
that the prevalence of abnormally elevated serum testosterone levels (>95th percentile for controls) 
increased with exposure to cadmium.  Using NHANES III data, Menke et al. (2008) found significant 
associations between urinary cadmium levels and serum testosterone and estradiol levels, but the 
associations were no longer significant after adjusting from smoking status and serum cotinine levels.  
Differences in study populations (e.g., infertile men, background cadmium exposure, high cadmium 
dietary exposure) and confounding factors (e.g., smoking, lead exposure) limit the interpretation of these 
results. 
 
Four studies examined the possible association between cadmium exposure and sperm quality.  In 
infertile men, increasing serum cadmium levels were significantly associated with abnormal sperm 
morphology and decreased sperm counts, sperm motility, and sperm viability (Akinloye et al. 2006).  
Another study found significant associations between blood cadmium levels and abnormal sperm 
morphology and decreased sperm motility in workers with slight to moderate lead exposure (Telišman et 
al. 2000).  As noted previously, neither study adjusted for smoking.  No significant correlations between 
blood cadmium levels and sperm quality were observed in infertile men with or without adjustment for 
smoking (Jurasović et al. 2004).  Similarly, no significant association between blood cadmium levels and 
abnormal semen parameters were observed in infertile men (Benoff et al. 2009), although seminal plasma 
cadmium levels were significantly negatively correlated with sperm concentration and sperm motility in 
whole semen.  Among men exposed to high levels of environmental cadmium, blood cadmium levels 
were significantly higher in men with abnormal digital rectal examinations of the prostate and trend 
analysis showed a dose-response relationship between cadmium exposure and the prevalence of abnormal 
prostate specific antigen (Zeng et al. 2004b). 
 
Data on possible reproductive toxicity of cadmium in women are limited to two studies examining the 
possible association between cadmium body burden and endometriosis and one study examining 
fecundability.  Among infertile Japanese, no association between urinary cadmium levels and the risk of 
endometriosis was observed (Itoh et al. 2008).  Jackson et al. (2008) found a significant association 
between blood cadmium levels and risk of endometriosis using NHANES 1999–2002 data.  Blood 
cadmium levels were significantly higher among women with endometriosis as compared to women 
without endometriosis.  When comparing participants with the highest tertile of blood cadmium (0.5–
8.5 µg/L) with the lowest tertile (<0.3 µg/L), the multivariate (including lead and mercury blood levels, 
race/ethnicity, smoking status, age) adjusted odds ratio was 3.39 (95% CI of 1.37–8.40).  No association 
between blood cadmium levels and risk of uterine myomas was found.  The possible association between 
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elevated cadmium body burden and time to pregnancy was examined among 400 couples participating in 
the Longitudinal Investigation of Fertility and the Environment (LIFE) Study (Buck Louis et al. 2012).  
After adjusting for several variables (age, BMI, cotinine, parity, and serum lipids), female urine cadmium 
levels were associated with a reduction in the fecundability odds ratio (0.78; 95% CI of 0.63–0.97) (a 
fecundability odds ratio of <1 denotes a longer time to pregnancy). 
 
A number of animal studies have shown adverse reproductive effects to male and female reproductive 
capacity from cadmium exposure.  In male rats and mice, acute oral exposure to near-lethal (60–
100 mg/kg) doses can cause testicular atrophy and necrosis (Andersen et al. 1988; Bomhard et al. 1987; 
Borzelleca et al. 1989), and concomitant decreased fertility (Kotsonis and Klaassen 1978).  Lower-dose 
acute exposures of 25–50 mg/kg did not result in reproductive toxicity in male animals (Andersen et al. 
1988; Bomhard et al. 1987; Dixon et al. 1976).   
 
The following intermediate-duration dosing regimens resulted in neither testicular histopathologic lesions 
nor a decrease in male reproductive success: 0.25 mg Cd/kg/day via gavage for 10 weeks (Bomhard et al. 
1987); 5 mg/kg/day via water for 30–90 days (Dixon et al. 1976); 2.5 mg/kg/day via food for 4 weeks 
(Groten et al. 1990); 8 mg/kg/day via water for 24 weeks (Kotsonis and Klaassen 1978); 3 mg/kg/day via 
food for 12 weeks (Loeser and Lorke 1977a, 1977b); 2.9 mg/kg/day via water for 14 weeks (Pleasants et 
al. 1992); and 4.64 mg/kg/day via water for 70–80 days (Zenick et al. 1982).  Some dosing regimens have 
resulted in adverse reproductive effects.  Male rats exposed to 8.58 mg Cd/kg/day in water for 10 weeks 
developed necrosis and atrophy of seminiferous tubule epithelium (Cha 1987).  Rats exposed to 
5.8 mg/kg/day via water for 14 weeks (Pleasants et al. 1992) or 11.6 mg/kg/day via water for 14 weeks 
(Pleasants et al. 1993) developed increased testes weight.  Rats exposed to 12.9 mg/kg/day in water for 
120 days developed significantly increased relative testis weight, decreased sperm count and motility, 
decreased seminiferous tubular diameter, and seminiferous tubular damage (pyknotic nuclei, 
multinucleated giant cells, interstitial edema, and dilated blood vessels) (Saxena et al. 1989).  In a 
protocol designed to assess the effects of vitamins on cadmium toxicity, Pleasants et al. (1992, 1993) 
reported that vitamins A and D3 reduced the amount of cadmium-related increase in testis weight.  
Bomhard et al. (1987) reported no histopathologic lesions (other than those found in control animals as 
part of aging) in testes of rats receiving 10 weekly doses of 5 mg Cd/kg and followed for up to 30 months. 
 
Higher doses of cadmium were generally needed to elicit a reproductive toxic response in females 
compared to the males.  Although a dose of 65.6 mg Cd/kg/day via gavage for 10 days was sufficient to 
produce testicular atrophy and loss of spermatogenic element in male rats, no effects were seen in female 
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rats up to 138 mg/kg/day (Borzelleca et al. 1989).  Decreased percentage of fertilized females and 
percentage of pregnancies were reported at 61.32 mg Cd/kg/day via gavage for 10 days during gestation 
(Gd 6–15) (Machemer and Lorke 1981).  No effect was seen at doses up to 18.39 mg/kg/day (Machemer 
and Lorke 1981).  Baranski (1987) also reported no treatment related effects on number or percentage of 
females pregnant with 28.8 mg Cd/kg/day via gavage for gestation days (Gds) 1–20.  Baranski and 
Sitarek (1987), however, administered 40 mg/kg by gavage 5 days/week for 14 weeks to female rats and 
observed a significant increased duration (twice as long) of the estrus cycle starting at 7–8 weeks and 
persisting to 14 weeks of exposure and the termination of the experiment.  This adverse effect was not 
seen at 4 mg/kg (Baranski et al. 1983; Baranski and Sitarek 1987).  
 
Petering et al. (1979) exposed female rats to either 2.61 mg/kg/day via drinking water for 60 days prior to 
gestation or during gestation, or 5.23 mg/kg/day via drinking water for 111 days including 90 days prior 
gestation plus 21 days during gestation.  These doses had no significant effects compared with controls 
for the number of pups stillborn.  Pond and Walker (1975) also observed no effects in females from a 
cadmium exposure of 19.7 mg/kg/day via food for 21–25 days, including Gd 1 through lactation day (Ld) 
1, on number of pups born.  No effects from a cadmium exposure on number of pups born to females 
were observed for an exposure of 8.2 mg/kg/day via food for 15 days, including Gd 6–20 (Sorell and 
Graziano 1990). 
 
A dose of 10 mg Cd/kg/day once a day via gavage for 9 weeks (6 weeks prior to gestation and 3 weeks of 
gestation) significantly decreased the number of copulating and pregnant females, and the number of 
implants and live fetuses (Sutou et al. 1980).  No effect was seen at 1 mg/kg/day (Sutou et al. 1980). 
 
Reproductive effects on both male and female rats orally exposed to 2.5 mg/kg/day via drinking water for 
180 days may have resulted in the observed decrease in litter size and increased interval between litters.  
Both males and females were treated over two generations.  Three of five pairs failed to breed in the 
second generations (Schroeder and Mitchener 1971).  No histopathologic lesions were found in testes or 
uteri of dogs given cadmium chloride at 0.75 mg/kg/day via food for 3 months (Loeser and Lorke 1977b).  
 
Male rats were exposed to 0–14 mg Cd/kg/day via food for 77 weeks.  The incidence of prostatic 
hyperplasias was increased above controls (1.8%) from the 3.5 mg Cd/kg/day dose.  The overall incidence 
for prostatic lesions for all cadmium-treated groups was much lower in zinc-deficient rats, possibly 
because of a marked increase in prostatic atrophy that was associated with reduced zinc intake.  
Moreover, there was not a clear dose-response increase in prostatic proliferative lesions.  Testicular 
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tumors (exclusively benign interstitial tumors) increased significantly only at the highest-dose cadmium 
with diets adequate in zinc.  Male Wistar rats exposed to cadmium in the drinking water at 0, 25, 50, 100, 
or 200 ppm developed tumors of the prostate (50 ppm), testes (200 ppm), and hematopoietic system 
(50 ppm), while dietary zinc deficiency has complex, apparently inhibitory effects on cadmium 
carcinogenesis by this route (Waalkes and Rehm 1992). 
 
The highest NOAEL values and all LOAEL values from each reliable study for reproductive effects in 
each species and duration category are recorded in Table 3-6 and plotted in Figure 3-2. 
 
3.2.2.6   Developmental Effects  
 
There are very limited data on the developmental effects of cadmium in humans.  Several studies have 
examined the possible relationship between maternal cadmium levels and newborn size.  No significant 
association between maternal blood cadmium levels and newborn body weight were observed in women 
with mean blood cadmium levels of 0.7 μg/L (Mokhtar et al. 2002), 1.04 μg/L (Nishijo et al. 2004b), 
1.4 μg/L (Galicia-García et al. 1997), or 1.72 μg/L (Zhang et al. 2004) or urinary cadmium levels of 
>2 nmol/mmol creatinine (Nishijo et al. 2002); the Nishijo et al. (2002, 2004b), and Zhang et al. (2004) 
studies used statistical adjustments for maternal age, maternal size, and/or gestation age.  Two studies 
found an association between cord blood cadmium levels and decreasing birthweight (Galicia-García et 
al. 1997; Salpietro et al. 2002); however, the association was only statistically significant in the Salpietro 
et al. (2002) study.  A significant association between newborn height and maternal blood cadmium levels 
was observed in women with a mean blood cadmium level of 9.29 nmol/L (Nishijo et al. 2004b); other 
studies have not found this association (Mokhtar et al. 2002; Nishijo et al. 2002; Zhang et al. 2004).  
Nishijo et al. (2002) found a significant negative correlation between maternal urinary cadmium levels 
and gestation length; Mokhtar et al. (2002) did not find a significant association between maternal blood 
cadmium levels and gestation length. 
 
Urinary cadmium content was measured in women 3 days after giving birth and compared to smoking 
habits and birth weight of offspring.  Among nonsmoking women, when cadmium content was expressed 
as μg/L, cadmium levels were higher in women with infants of below-normal birth weight.  However, 
when cadmium content was expressed as μg/g creatinine, cadmium levels were lower in women with 
infants with below-normal birth weight.  Cadmium levels in smoking women were lower in both μg/L 
and μg/g in women with infants with below-normal birth weight (Cresta et al. 1989).   
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Cao et al. (2009) examined the possible association between postnatal exposure to cadmium (as measured 
by blood cadmium) and neurodevelopment in children participating in the Treatment of Lead-Exposed 
Children trial.  Blood cadmium levels in the children were comparable to levels in the NHANES 2005–
2006 survey, and blood lead levels were between 20 and 44 µg/dL at referral.  No significant associations 
(after adjustment for multiple variables including parent’s education, gender, and concurrent blood lead 
levels) between blood cadmium levels and scores on neuropsychological and behavioral tests were found 
in children evaluated at age 5 and 7 years or IQ evaluated at 2, 5, and 7 years of age.   
 
A number of studies in rats and mice indicate that cadmium can be fetotoxic from oral exposures prior to 
and during gestation.  This fetotoxicity is most often manifested as reduced fetal or pup weights (Ali et al. 
1986; Baranski 1987; Gupta et al. 1993; Kelman et al. 1978; Kostial et al. 1993; Petering et al. 1979; 
Pond and Walker 1975; Sorell and Graziano 1990; Sutou et al. 1980; Webster 1978; Whelton et al. 1988), 
but malformations, primarily of the skeleton, have been found in some studies (Baranski 1985; Machemer 
and Lorke 1981; Schroeder and Mitchener 1971).  Malformations or skeletal effects reported include 
sirenomelia (fused lower limbs), amelia (absence of one or more limbs), and delayed ossification of the 
sternum and ribs (Baranski 1985); dysplasia of facial bones and rear limbs, edema, exenteration, 
cryptorchism, and palatoschisis (Machemer and Lorke 1981); and sharp angulation of the distal third of 
the tail (Schroeder and Mitchener 1971).  Dosing levels were in the 1–20 mg/kg/day range.  
 
The most sensitive indicator of developmental toxicity of cadmium in animals appears to be neuro-
behavioral development.  Offspring of female rats orally exposed to cadmium at a dose of 0.04 mg/kg/day 
prior to and during gestation had reduced exploratory locomotor activity and rotorod performance at age 
2 months (Baranski et al. 1983).  Pups from dams exposed to 0.7 mg/kg/day during gestation had 
significant delays in cliff aversion and swimming behavior.  Locomotor activity was significantly 
increased.  In post-weaning measurements, locomotor activity was significantly decreased in treated 
groups at 60 days of age; conditioned avoidance behavior was also significantly decreased when tested at 
60 and 90 days of age (Ali et al. 1986). 
 
Nagymajtenyi et al. (1997) also reported behavioral and functional neurotoxicological changes caused by 
cadmium in a three-generational study in rats.  Three consecutive generations of Wistar rats were orally 
treated by gavage with 3.5, 7.0, or 14.0 mg Cd/kg bw (as cadmium chloride diluted in distilled water) 
over the period of pregnancy, lactation, and 8 weeks after weaning.  Behavioral (open field behavior) and 
electrophysiological (spontaneous and evoked cortical activity, etc.) parameters of male rats from each 
generation were investigated at the age of 12 weeks.  The main behavioral outcomes were increased 
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vertical exploration activity (rearing) and increased exploration of an open-field center.  The spontaneous 
and evoked electrophysiological variables showed dose- and generation-dependent changes (increased 
frequencies in the electrocorticogram, lengthened latency and duration of evoked potentials, etc.) 
signaling a change in neural functions.  The results indicate that low-level, multigeneration exposure of 
rats to inorganic cadmium can affect nervous system function. 
 
Desi et al. (1998) continued the above studies to further evaluate cadmium associated changes in behavior 
and neurological function in rats following different dosage regimens during pregnancy.  Female Wistar 
rats were given 3.5, 7.0, or 14.0 mg Cd/kg body weight (cadmium chloride dissolved in distilled water) in 
three different treatment regimes:  days 5–15 of pregnancy; days 5–15 of pregnancy + 4 weeks of 
lactation; and days 5–15 of pregnancy + 4 weeks of lactation followed by the same oral treatment of male 
rats of the F1 generation for 8 weeks.  The behavioral (open-field exploration) and electrophysiological 
(electrocorticogram, cortical-evoked potentials, conduction velocity and refractory periods of a peripheral 
nerve) parameters of F1 male rats exposed by various treatments were investigated at the age of 12 weeks.  
The results indicate that cadmium altered the spontaneous and evoked electrophysiological functions 
(e.g., increased the frequency of the electrocorticogram, lengthened the latency and duration of evoked 
potentials, etc.) in a dose- and duration-dependent manner.  Only combining treatment during the prenatal 
development and the 4-week suckling period resulted in a significant dose-dependent decrease of 
horizontal and vertical exploratory activity and a significantly lower exploration frequency of the open-
field center.  The results suggest that low-level pre- and postnatal inorganic cadmium exposure affects the 
electrophysiological and higher order functions of the nervous system.  
 
Neurochemical alterations have also been observed in the offspring of rats administered cadmium acetate 
in drinking water during gestation (1.12 mg Cd/kg/day) and lactation (2.41 mg Cd/kg/day) (Antonio et al. 
2010).  The alterations included decreased serotonin in dorsal hippocampus and dihydroxyphenylacetic 
acid in brain cortex and rostral neostriatum and increased 5-hydroxyindolacetic acid in dorsal 
hippocampus and brain cortex and glutamate in the dorsal hippocampus. 
 
A study by Gupta et al. (1993) examined the developmental profiles of DNA, RNA, proteins, DNA 
synthesis, thymidine kinase activity, and concentrations of zinc and cadmium in the brain of neonates 
from dams exposed to cadmium acetate at 5–6.3 mg/kg/day in drinking water during gestation, and 7–
8 mg/kg/day during a 21-day lactation period.  Pup brain and body weights were significantly decreased 
in the cadmium exposed pups on Ld 7–21.  Cadmium brain accumulation was significantly increased in 
exposed pups on Ld 7 and remained at similar levels on Ld 14 and 21.  DNA and thymidine kinase brain 
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levels were significantly decreased in treated pups compared with controls on Ld 7, 14, and 21.  The 
toxicological significance of changes in DNA incorporation and thymidine kinase activity are uncertain. 
 
Xu et al. (1993b) determined lipid peroxide (LPO) concentrations in rat pups in various organs as an 
index of cadmium toxicity.  Male and female Wistar mice were exposed to cadmium in drinking water at 
0, 5.7, or 14.25 mg/kg/day for 2 months prior to mating.  The pregnant females continued to be exposed 
during gestation and lactation.  Litter size and pup survival rates were unaffected by cadmium.  Body 
weights were not statistically different between the exposed and control groups.  In pups, brain weights 
(at 5.7 and 14.25 mg/kg/day) and liver, kidney, and heart weights (at 14.25 mg/kg/day) were significantly 
decreased.  Although the relative organ weights were lower in the high-dose group, the difference from 
controls was not statistically significant.  LPO concentrations in all organs were significantly increased in 
pups on Ld 7 at 14.25 mg/kg/day except in the kidney; concentrations in the liver, heart, and brain were 
131.5, 156, and 237.4%, respectively, of the concentrations in controls. 
 
In contrast to most of the study results, Saxena et al. (1986) reported no developmental effects from an 
exposure to 21 mg Cd/kg/day via drinking water during gestation (Gd 0–20).  This study evaluated 
simultaneous exposure to lindane (20 mg lindane/kg via gavage on Gd 6–14) and cadmium acetate in 
drinking water at doses that individually did not cause maternal or developmental effects.  Maternal 
toxicity (significantly decreased weight gain) and developmental toxicity were only observed in the 
cadmium plus lindane group.  Fetal body weight was significantly decreased; intrauterine death and the 
rate of skeletal anomalies were significantly increased.  Anomalies consisted of decreased ossification, 
wavy ribs, and scrambled sternebrae.  
 
The highest NOAEL values and all LOAEL values from each reliable study for developmental effects in 
each species and duration category are recorded in Table 3-6 and plotted in Figure 3-2. 
 
3.2.2.7   Cancer  
 
Epidemiology studies have examined the possible association between exposure to elevated levels of 
cadmium and overall cancer rates or specific cancer rates.  Older studies have examined cancer rates 
among residents of cadmium polluted areas but did not estimate cadmium exposure levels.  No significant 
increase in cancer rates was found among residents of a cadmium-polluted village in England (Inskip et 
al. 1982) or in prostate, kidney, or urinary tract cancer among residents of a cadmium-polluted area of 
Belgium (Lauwerys and De Wals 1981).  Another study found that the geographic distribution of elevated 
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rates of prostate cancer incidence paralleled the distribution of elevated cadmium concentrations in water, 
soil, or grain crops in Alberta, Canada (Bako et al. 1982).  In a retrospective mortality study of residents 
of three areas of Japan classified on the basis of rice cadmium content as highly polluted, slightly 
polluted, or nonpolluted, no significant differences were found in mortality from cancer of all sites 
including prostate cancer (Shigematsu 1984).  Inhabitants of cadmium-polluted areas of Japan with 
elevated urinary retinol binding protein excretion had a mortality rate from malignant neoplasms no 
different from expected (Nakagawa et al. 1987).   
 
Three more recent studies of populations living in cadmium-polluted areas have used blood or urine to 
examine dose-response relationships for carcinogenic risk.  Among residents living in a cadmium-
polluted area of China, significantly higher blood cadmium levels were observed in subjects with 
suspected prostate cancer (based on digital rectal examination) as compared to subjects with normal 
digital rectal examination results (Zeng et al. 2004); there were no significant differences in urinary 
cadmium levels.  However, a significant trend was found for the number of cases with positive prostate-
specific antigen levels and urinary cadmium levels.  In a study of residents living in an area of Japan that 
previously had high levels of cadmium contamination, a significant increase in cancer mortality was 
observed among subjects with urinary β2-microglobulin levels of ≥1,000 µg/g creatinine (Arisawa et al. 
2001); however, no increases in cancer incidence were observed in exposed subjects or in subjects with 
elevated urinary β2-microglobulin, urinary cadmium, or blood cadmium levels.  In a follow-up study that 
extended the observation period from 15 to 23 years, no alterations in cancer mortality or cancer 
incidence were observed in the exposed population as compared to referent populations (Arisawa et al. 
2007b).  However, when the subjects were divided into two groups based on urinary β2-microglobulin 
levels, the relative risk of cancer deaths in males and females with β2-microglobulin levels of 
≥1,000 µg/g creatinine was 2.58 (95% CI of 1.25–5.36) compared to residents with urinary 
β2-microglobulin levels of <1,000 µg/g creatinine. 
 
Several case-control studies have examined the possible association between cadmium body burden and 
increased risk of cancer among the general populations.  In a study conducted in Belgium, a significant 
relationship between bladder cancer and blood cadmium levels was reported (Kellen et al. 2007).  After 
adjustment for age, gender, occupational exposure to polyaromatic hydrocarbons or aromatic amines, and 
smoking, the odds ratio was 5.7 (95% CI of 3.3–9.9) when comparing the risk of bladder cancer for 
subjects in the highest blood cadmium tertile to those in the lowest tertile.  Another case-control study 
examined the possible relationship between urinary cadmium levels and breast cancer risk in the United 
States (McElroy et al. 2006).  The breast cancer risk (after adjustment for a number of variables including 
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age, parity, family history of breast cancer and BMI) in women with urinary cadmium levels in the 
highest quartile was 2.29 (95% CI of 1.3–4.2) as compared to women in the lowest quartile; the 
investigators noted that adjusting for smoking status did not change the risk estimate.  Similarly, a 
significant increase in the risk of breast cancer was observed among women living in Long Island, New 
York with urinary cadmium levels >0.60 µg cadmium/g creatinine, as compared to women with urinary 
cadmium levels of <0.22 µg cadmium/g creatinine after controlling for age, menopausal status, smoking 
and alcohol use, and family history (Gallagher et al. 2010).  Another study of residents of the East Nile 
Delta region in Egypt with pancreatic cancer found a significant association between pancreatic cancer 
risk and serum cadmium levels; the odds ratio was 1.12 (95% CI of 1.04–1.23) (Kriegel et al. 2005).  The 
study also found a significant association between farming and risk of pancreatic cancer.  The results of 
this study should be interpreted cautiously since the study did not adjust for smoking status or farming 
occupation. 
 
In a Swedish population-based study of postmenopausal women, an increased risk of endometrial cancer 
was found in women with elevated cadmium intake (Åkesson et al. 2008).  Among women who never 
smoked, did not use postmenopausal hormones, had a BMI of <27 kg/m2, and consistently had a cadmium 
intake above the median intake for the study, the relative risk of endometrial cancer was 2.86 (95% CI of 
1.05–7.79). 
 
One study examined cadmium, zinc, and copper in human kidney tumors and normal kidneys.  Kidneys 
with renal cell carcinoma in cortex from 31 cases (20 men and 11 women) were compared to kidneys of 
patients who had died from causes other than a malignant disease from 17 controls (9 men and 8 women).  
No patients in this study had been occupationally exposed.  Smoking habits for patients were recorded.  
The level of cadmium in tumor tissue did not correlate with cadmium in cortex or medulla in the same 
kidney.  No significant difference was found between cases and controls, although smoking cases had 
higher levels of cadmium.  It was concluded that cadmium was not a risk factor for renal cell carcinoma 
(Hardell et al. 1994). 
 
In rats and mice, earlier studies on chronic oral exposure to cadmium did not report an increased overall 
cancer incidence or the incidence of specific tumor types (Kanisawa and Schroeder 1969; Levy and Clack 
1975; Levy et al. 1975; Löser 1980; Mangler et al. 1988; Schroeder et al. 1964, 1965).  However, 
maximum daily doses tested were only 1 mg/kg/day in mice (Schroeder et al. 1964) and 3.5 mg/kg/day in 
rats (Löser 1980) and, in most of these studies, histopathologic examination was limited compared to 
contemporary standards.  Löser (1980) did perform a relatively thorough histological examination.  A few 
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additional animal studies of noncancer effects of chronic-duration oral cadmium exposure have indicated 
that no dose-related increases in tumors were found at maximum doses of 4.01 mg/kg/day in rats 
(Fingerle et al. 1982) or 8 mg/kg/day in mice (Watanabe et al. 1986). 
 
Waalkes and Rehm (1992) evaluated the effects of chronic dietary zinc deficiency on oral cadmium 
carcinogenesis in male Wistar rats.  Rats were exposed for 77 weeks to cadmium at 0, 1.75, 3.5, 7.0, or 
14.0 mg cadmium/kg/day as cadmium chloride in a diet containing an adequate or a deficient amount of 
zinc.  A significant increase in the incidence of proliferative lesions (hyperplasia and adenomas) was 
observed in the prostate of rats exposed to 1.75 mg cadmium/kg/day in the zinc-adequate (22.7%) or zinc-
deficient (15.4%) groups, as compared to controls (1.9%).  However, the incidences of prostatic lesions 
were not significantly increased in rats exposed to higher cadmium doses.  The incidence of large 
granular lymphocyte leukemia was significantly increased in rats fed the zinc-adequate diet with 3.5 or 
7.0 mg cadmium/kg/day, but not at 14.0 mg cadmium/kg/day; however, an increased incidence was 
observed at 14.0 mg cadmium/kg/day in the zinc-deficient rats.  Exposure to 14.0 mg cadmium/kg/day 
also resulted in a significant increase in interstitial cell tumors of the testes in the group fed a zinc-
adequate diet.  The results of the study suggest that dietary zinc deficiency may inhibit the carcinogenic 
potential of cadmium, but additional research is needed. 
 
A subsequent study by Waalkes et al. (1993) using male B6C3F1 mice evaluated the effects of cadmium 
exposure on tumor incidence at various times after the initiation of the carcinogenic process.  The 
possible role of metallothionein in the susceptibility of transformed cells to cadmium cytotoxicity was 
also evaluated.  At 5 weeks of age, mice received an intraperitoneal injection of N-nitrosodiethylamine 
(NDEA) at 90 mg/kg.  At 2, 4, 8, 16, or 32 weeks post-NDEA injection, mice received water containing 
1,000 ppm cadmium ad libitum for up to 48 weeks of post-NDEA exposure.  Cadmium exposure caused a 
marked "reduction" in liver tumor incidence in NDEA-treated mice even when given as late as 32 weeks 
after the initial NDEA treatment.  Cadmium alone eliminated the spontaneously occurring incidence of 
liver tumors (i.e., 0 of 25 compared with 5 of 25 in the controls).  Liver tumors produced by NDEA were 
typically basophilic adenomas.  Cadmium resulted in a modest reduction in lung tumor incidence, 
statistically significant (28% reduction) only for the 16–48-week cadmium-treated group pretreated with 
NDEA.  Lung tumors were typically adenomas of alveolar cell origin.  Cadmium alone eliminated 
spontaneously occurring lung tumors compared with the controls.  Cadmium significantly reduced the 
multiplicity of tumors induced by NDEA.  NDEA alone typically induced seven tumors per lung, while 
NDEA plus cadmium treatment reduced the number of tumors to 2.5–3.5 (data taken from a graph) with 
some cases showing an 80% reduction in tumor numbers.  Lung tumors found in the cadmium plus 
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NDEA-treatment groups were also smaller in overall size than those found in the NDEA-only treatment 
groups.  Relatively little metallothionein was present in liver carcinomas, liver adenomas, and lung 
adenomas as indicated by immunohistochemistry.  This finding was confirmed biochemically for the liver 
tumors.  The authors concluded that cadmium can effectively “impair” tumor formation in the lungs and 
liver of male B6C3F1 mice and that cadmium appears to be able to selectively destroy existing 
preneoplastic and/or tumor cells (adenomas).  The mechanism may involve a reduced activity and 
responsiveness of the metallothionein system in transformed liver cells.  
 
A two-stage initiation/promotion experiment evaluated the promoting effects of cadmium chloride in the 
drinking water in rats.  Cadmium exposure resulted in the following alterations in tumorigenic outcome: 
in the liver, hepatocellular carcinomas (initiated with diethyl nitrosamine) were decreased; in the stomach, 
tumors (initiated with N-methyl-N’-nitro-nitrosoguanidine plus NaCl at 10% in the diet) were not 
affected; in the kidney, tumors (initiated with N-ethyl-N-hydroxyethyl nitrosamine) showed increased 
dysplastic foci but no increase in renal cell tumors; in the pancreas, tumors (initiated with N-nitrosobis 
[2-oxopropyl] amine) had a nonsignificant increase in adenocarcinomas (female hamster study); and in 
the skin (initiated with 7,12-dimethyl benz(a)anthracene), there was no effect (female SENCAR mouse 
study) (Kurokawa et al. 1989). 
 
3.2.3   Dermal Exposure  
 
3.2.3.1   Death  
 
No studies were located regarding death in humans after dermal exposure to cadmium.   
 
Some guinea pigs died 2 or 6 weeks after being exposed in a skin depot (3.1 cm2) to 2 mL of 0.239 molar 
aqueous of cadmium chloride (0.14 mg/kg body weight) (Wahlberg 1965).  However, it is difficult to 
attribute these deaths to cadmium exposure, due to the low dose compared to oral LD50 values and to the 
fact that no necropsy was done to determine whether the exposed guinea pigs might have died from 
pneumonia (which killed some control guinea pigs) (Wahlberg 1965). 
 
3.2.3.2   Systemic Effects  
 
No studies were located regarding respiratory, cardiovascular, gastrointestinal, hematological, 
musculoskeletal, hepatic, or renal effects in humans or animals after dermal exposure to cadmium. 
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Dermal Effects.    Among eczema patients routinely patch-tested with 2% cadmium chloride, 25 out of 
1,502 showed some reaction (Wahlberg 1977).  Since no reaction was found at lower dilutions in reactive 
patients (Wahlberg 1977), the effect was likely direct irritation of the skin and is indicated as a LOAEL 
value in Table 3-9.   
 
No studies were located regarding dermal effects in animals after dermal exposure to cadmium. 
 
Ocular Effects.    No studies were located regarding ocular effects in humans after dermal exposure to 
cadmium. 
 
Rats exposed to high concentrations of cadmium pigments or cadmium oxide in air had excessive 
lacrimation four hours after exposure (Rusch et al. 1986), possibly due to a direct irritation effect on the 
eyes. 
 
3.2.3.3   Immunological and Lymphoreticular Effects  
 
Dermal exposure to cadmium does not appear to affect the immune system significantly.  One report of 
workers with extensive exposure to cadmium dust reported an increase in complaints of eczema (Friberg 
1950); however, no subsequent studies have confirmed any association.  Routine patch tests among 
dermatitis and eczema patients using up to 2% cadmium chloride solutions have found skin irritation at 
2%, but no evidence of allergic reactions at a dose of 1% among people without known prior cadmium 
exposure (Rudzki et al. 1988; Wahlberg 1977) or among workers occupationally exposed to cadmium 
(Rudzki et al. 1988).  Individuals with yellow tattoos containing cadmium sulfide often experience 
swelling of the surrounding skin on exposure to ultra violet (UV) irradiation (Bjornberg 1963); however, 
this may be the result of dermal damage from the photoconductivity of cadmium sulfide rather than a 
direct immunological reaction.   
 
Guinea pigs showed no contact sensitization following intradermal or topical exposure to cadmium 
chloride at concentrations up to 0.5% (Wahlberg and Boman 1979).  The NOAEL values from each 
reliable study for immunological effects in each species and duration category are recorded in Table 3-9. 
 
Table 3-9  Levels of Significant Exposure to Cadmium  -  Dermal
Species
(Strain)
Exposure/
Duration/
Frequency
(Route)
CommentsSystem NOAEL Less Serious
LOAEL
Serious
Reference
Chemical Form
ACUTE EXPOSURE
Systemic
Human
492
once Dermal 1
Percent (%)
Percent (%)
2 (skin irritation)
Percent (%)
Percent (%)
Wahlberg 1977
CdCl2
492
(Sprague-
Dawley)
Rat
1002
2 hr Ocular 99 (excessive lacrimation)
mg/m³
mg/m³
97 (excessive lacrimation)
mg/m³
mg/m³
112 (eyes closed from
exposure)
mg/m³
mg/m³
Rusch et al. 1986
CdSeS
1002
Immuno/ Lymphoret
Human
hr = hour(s); Immuno/Lymphoret = immunological/lymphoreticular; LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level
493
once
1
Percent (%)
Percent (%)
Rudzki et al. 1988
CdCl2
493
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No studies were located regarding the following health effects in humans or animals after dermal 
exposure to cadmium: 
 
3.2.3.4 Neurological Effects  
3.2.3.5 Reproductive Effects 
3.2.3.6 Developmental Effects  
3.2.3.7   Cancer  
 
3.3   GENOTOXICITY  
 
The genotoxic potential of cadmium has been studied in in vivo studies of cadmium workers, members of 
the general population, and rodents as summarized in Table 3-10.  Although not always consistent, these 
results suggest that cadmium is a clastogenic agent, as judged by the induction of DNA damage, 
micronuclei, sister chromatid exchange (SCE), and chromosomal aberrations.   
 
Palus et al. (2003) examined peripheral lymphocytes from workers occupationally exposed to cadmium 
and found statistically significant increases compared to the control population in micronuclei rates and 
sister chromatid exchanges as well as evidence of an increased incidence of leukocytes with DNA 
fragmentation.  Examination of lymphocytes and leukocytes from workers occupationally exposed to 
cadmium and lead or to cadmium, lead, and zinc showed increased frequency of chromosomal aberrations 
compared to control groups (Abrahim et al. 2011; Bauchinger et al. 1976; Deknudt and Leonard 1975; 
Deknudt et al. 1973), but this effect was not observed in men exposed primarily to cadmium (Bui et al. 
1975; O'Riordan et al. 1978).  Human lymphocytes from individuals inhabiting cadmium-polluted areas 
of China have been found to have increased micronuclei rates and a higher frequency of chromosomal 
aberrations and severe aberration types, in comparison to control populations with either no known 
exposure to cadmium or low-level exposure (Fu et al. 1999; Tang et al. 1990).  Bui et al. (1975) examined 
blood samples from four female Japanese patients with Itai-Itai disease and found no evidence to indicate 
that cadmium is capable of inducing chromosomal damage.  
 
For the most part, cadmium exposure via inhalation (Valverde et al. 2000), oral (Devi et al. 2001; Kasuba 
et al. 2002), and parenteral (Fahmy and Aly 2000; Kasuba et al. 2002; Mukherjee et al. 1988a; Saplakoglu 
et al. 1997; Wronska-Nofer et al. 1999; Zhou et al. 2004b) routes has been shown to be associated with 
DNA damage and induction of micronuclei in rodent cells. 
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Table 3-10.  Genotoxicity of Cadmium In Vivo 
 
Species (test system) End point Results Reference 
Mammalian cells:    
Inhalation exposure:    
Human lymphocytes Chromosomal aberrations + Deknudt et al. 1973 
Human lymphocytes Chromosomal aberrations – Bui et al. 1975 
Human lymphocytes Chromosomal aberrations + Deknudt and Leonard 1975 
Human lymphocytes Chromosomal aberrations + Bauchinger et al. 1976 
Human lymphocytes Chromosomal aberrations – O’Riordan et al. 1978 
Human lymphocytes Chromosomal aberrations + Alessio et al. 1993 
Human lymphocytes Chromosomal aberrations + Abrahim et al. 2011 
Human lymphocytes Sister chromatid exchanges + Abrahim et al. 2011 
Human lymphocytes Sister chromatid exchanges + Palus et al. 2003 
Human lymphocytes Micronuclei + Palus et al. 2003 
Human lymphocytes  DNA damage + Palus et al. 2003 
Mouse bone marrow DNA damage + Valverde et al. 2000 
Mouse brain cells DNA damage + Valverde et al. 2000 
Mouse testicular cells DNA damage + Valverde et al. 2000 
Mouse liver cells DNA damage + Valverde et al. 2000 
Mouse kidney cells DNA damage + Valverde et al. 2000 
Mouse lung cells DNA damage + Valverde et al. 2000 
Mouse nasal epithelial cells DNA damage + Valverde et al. 2000 
Oral exposure:    
Rat bone cells Altered gene expression + Ohba et al. 2007 
Mouse bone marrow Chromosomal aberrations – Deknudt and Gerber 1979 
Mouse bone marrow Chromosomal aberrations + Mukherjee et al. 1988b 
Rat bone marrow Chromosomal aberrations – Desi et al. 2000 
Human leukocytes Chromosomal aberrations + Shiraishi and Yoshida 1972 
Human lymphocytes Chromosomal aberrations – Bui et al. 1975 
Human lymphocytes Chromosomal aberrations + Tang et al. 1990 
Human lymphocytes  Chromosomal aberrations + Fu et al. 1999 
Mouse leukocytes DNA damage + Devi et al. 2001 
Rat lymphocytes DNA damage + Kasuba et al. 2002 
Rat spermatogenesis Dominant lethal mutations – Sutou et al. 1980 
Rat spermatogenesis Dominant lethal mutations – Zenick et al. 1982 
Rat lymphocytes Micronuclei + Kasuba et al. 2002 
  Human lymphocytes Micronuclei + Fu et al. 1999 
Intraperitoneal exposure:    
Mouse oocytes Aneuploidy – Mailhes et al. 1988 
Mouse spermatocytes Chromosomal aberrations + Selypes et al. 1992 
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Table 3-10.  Genotoxicity of Cadmium In Vivo 
 
Species (test system) End point Results Reference 
Mouse bone marrow Chromosomal aberrations + Fahmy and Aly 2000 
Mouse spermatocytes Chromosomal aberrations + Fahmy and Aly 2000 
Mouse bone marrow Chromosomal aberrations – Bruce and Heddle 1979 
Mouse bone marrow Chromosomal aberrations + Mukherjee et al. 1988a 
Mouse spermatocytes Chromosomal translocations – Gilliavod and Leonard 1975 
Rat lung cells  DNA strand breaks + Saplakoglu et al. 1997 
Rat kidney cells DNA strand breaks + Saplakoglu et al. 1997 
Rat liver cells DNA strand breaks – Saplakoglu et al. 1997 
Mouse spermatogenesis Dominant lethal mutations – Epstein et al. 1972 
Mouse spermatogenesis Dominant lethal mutations – Gilliavod and Leonard 1975 
Mouse oocytes Dominant lethal mutations – Suter 1975 
Rat lymphocytes hprt locus Gene mutation ± Jianhua et al. 2006 
Mouse bone marrow Micronuclei ± Mukherjee et al. 1988a 
Mouse bone marrow Micronuclei + Wronska-Nofer et al. 1999 
Mouse bone marrow Micronuclei + Fahmy and Aly 2000 
Mouse bone marrow Sister chromatid exchanges + Mukherjee et al. 1988a 
Mouse bone marrow Sister chromatid exchanges + Fahmy and Aly 2000 
Mouse spermatozoa Sperm morphology – Bruce and Heddle 1979 
Mouse spermatozoa Sperm morphology + Mukherjee et al. 1988a 
Syrian hamster embryo cells Transformation + DiPaulo and Castro 1979 
Subcutaneous exposure:    
Mouse testicular cells Altered gene expression + Zhou et al. 2004b 
Mouse blastocysts Aneuploidy + Watanabe and Endo 1982 
Syrian hamster oocytes Aneuploidy + Watanabe et al. 1979 
Mouse bone marrow Chromosomal aberrations + Karmakar et al. 1998 
Mouse testicular cells DNA damage – Zhou et al. 2004b 
Rat lymphocytes DNA damage + Kasuba et al. 2002 
Rat lymphocytes Micronuclei + Kasuba et al. 2002 
Mouse bone marrow Sister chromatid exchanges – Nayak et al. 1989 
Mouse fetal liver and lung 
cells 
Sister chromatid exchanges – Nayak et al. 1989 
 
– = negative result; + = positive result; ± = weakly positive result; DNA = deoxyribonucleic acid 
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Evidence of the potential for cadmium to induce SCE (Fahmy and Aly 2000; Mukherjee et al. 1988a; 
Nayak et al. 1989) and chromosomal aberrations (Bruce and Heddle 1979; Desi et al. 2000; DiPaulo and 
Castro 1979; Fahmy and Aly 2000; Karmakar et al. 1998; Mukherjee et al. 1988a; Tang et al. 1990; 
Watanabe et al. 1979) is mixed.  Data regarding the aneugenic potential of cadmium are limited and also 
conflicting.  Watanabe and Endo (1982) observed an increased incidence of mouse blastocysts with 
trisomies and triploidies from female mice treated subcutaneously with cadmium compared to control 
mice.  Watanabe et al. (1979) reported that subcutaneous exposure to cadmium induced mutagenicity in 
hamster oocytes, and in particular, induced the production of diploid oocytes.  However, Mailhes et al. 
(1988) did not observe an increased incidence of hyperploid oocytes in female mice treated with cadmium 
via intraperitoneal injection.   
 
 
 
 
No evidence for germ cell mutations (the dominant lethal test) has been observed in male rats orally 
exposed to cadmium (Sutou et al. 1980; Zenick et al. 1982) or in mice exposed to cadmium via inhalation 
(Gilliavod and Leonard 1975; Suter 1975) or intraperitoneal exposure (Epstein et al. 1972).  However, 
chromosomal aberrations in mouse spermatocytes and Syrian hamster oocytes (Fahmy and Aly 2000; 
Selypes et al. 1992; Watanabe et al. 1979) and altered gene expression in mouse testicular cells (Zhou et 
al. 2004b) have been observed following cadmium exposure.   
Data based on in vitro examination of the genotoxic effects of cadmium in microorganisms, yeast, insects, 
and mammalian cells are summarized in Table 3-11.  For the most part, in vitro data support the in vivo 
data suggesting that cadmium has the potential to induce DNA damage, micronuclei, chromosomal 
aberrations, and genetic mutations.   
In vitro studies have shown that cadmium induces genetic mutations in hamster and mouse cells 
(Amacher and Paillet 1980; Filipic and Hei 2004; Honma et al. 1999; Jianhua et al. 2006; Oberly et al. 
1982), transformation in rodent cells (Casto et al. 1979; Terracio and Nachtigal 1988), unscheduled DNA 
synthesis in rat cells (Denizeau and Marion 1989), DNA breaks in human cells (Depault et al. 2006; 
Lopez-Ortal et al. 1999; Mikhailova et al. 1997), DNA lesions in hamster cells (Jianhua et al. 2006), and 
inhibits DNA repair in human and hamster cells (Lutzen et al. 2004; Lynn et al. 1997).  Misra et al. 
(1998) did not observe DNA damage in rat cells following treatment with cadmium, but DNA damage 
has been noted in human cells (Fatur et al. 2002; Rozgaj et al. 2002). 
Chromosomal aberrations following cadmium exposure have been observed in Chinese hamster ovary 
cells (Cai and Arenaz 1998; Deaven and Campbell 1980; Rohr and Bauchinger 1976), but studies on  
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  Results  
With Without 
Species (test system) End point activation activation Reference 
Prokaryotic organisms:     
Bacillus subtilis DNA repair No data ± Nishioka 1975 
B. subtilis DNA repair No data ± Kanematsu et al. 1980 
Salmonella typhimurium Gene mutation – – Bruce and Heddle 1979 
(plate incorporation) 
S. typhimurium Gene mutation – – Milvy and Kay 1978 
(liquid suspension) 
S. typhimurium Gene mutation No data ± Mandel and Ryser 1984 
(liquid suspension) 
S. typhimurium Gene mutation – + Wong 1988 
(plate incorporation) 
Eukaryotic organisms:     
Yeast:     
Saccharomyces cerevisiae Gene mutation No data + Putrament et al. 1977 
S. cerevisiae lntrachromosomal No data + Schiestl et al. 1989 
recombination 
Insects:     
Drosophila melanogaster Dominant lethal No data + Vasudev and Krishnamurthy 
mutations 1979 
D. melanogaster Nondisjunction No data – Ramel and Magnusson 
1979 
D. melanogaster Sex-linked No data – Inoue and Watanabe 1978 
recessive lethal 
mutations 
Mammalian cells:     
Mouse spleen cells Chromosomal No data + Fahmy and Aly 2000 
aberration 
Chinese hamster ovary Hy Chromosomal No data + Rohr and Bauchinger 1976 
cells aberration 
Chinese hamster ovary CHO Chromosomal No data + Deaven and Campbell 1980 
cells aberration 
Chinese hamster ovary CHO Chromosomal No data + Cai and Arenaz 1998 
cells aberration 
Human leukocytes Chromosomal No data + Shiraishi et al. 1972 
aberrations 
Human blood lymphocytes Chromosomal No data – Paton and Allison 1972 
aberration 
Human blood lymphocytes Chromosomal No data + Shiraishi et al. 1972 
aberration 
 
 
 
 
 
 
Table 3-11.  Genotoxicity of Cadmium In Vitro 
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Table 3-11.  Genotoxicity of Cadmium In Vitro 
 
  Results  
With Without 
Species (test system) End point activation activation Reference 
Human blood lymphocytes Chromosomal No data – Deknudt and Deminatti 1978 
aberration 
Human blood lymphocytes Chromosomal No data ± Gasiorek and Bauchinger 
aberration 1981 
Human blood lymphocytes DNA breaks No data + Depault et al. 2006 
Human lymphoblastoid cells DNA breaks No data + Mikhailova et al. 1997 
Human fetal hepatic WRL-68 DNA breaks No data + Lopez-Ortal et al. 1999 
cells 
Chinese hamster ovary DNA damage No data – Misra et al. 1998 
CHO-K1 cells 
Rat L6 myoblast cells DNA damage No data – Misra et al. 1998 
Rat Clone 9 liver cells DNA damage No data – Misra et al. 1998 
Rat TRI 1215 liver cells DNA damage No data – Misra et al. 1998 
Human blood lymphocytes DNA damage No data + Rozgaj et al. 2002 
Human hepatoma cells DNA damage No data + Fatur et al. 2002 
(HepG2) 
V79 Chinese hamster lung DNA lesions No data + Jianhua et al. 2006 
cells  
Chinese hamster ovary DNA repair No data + Lynn et al. 1997 
CHO-K1 cells 
Human 293T-Tet-Off-hMLH1 DNA repair No data + Lutzen et al. 2004 
cells 
V79 Chinese hamster lung Gene mutation No data + Jianhua et al. 2006 
cells hprt locus 
AL human-hamster hybrid Gene mutation No data + Filipic and Hei 2004 
CD59 gene 
Mouse lymphoma L5178Y Gene mutation No data ± Amacher and Paillet 1980 
thymidine kinase locus 
Mouse lymphoma L5178Y Gene mutation No data + Oberly et al. 1982 
thymidine kinase locus 
Mouse lymphoma L5178Y Gene mutation + + Honma et al. 1999 
thymidine kinase locus 
Human blood lymphocytes Micronuclei No data + Migliore et al. 1999 
Human blood lymphocytes Micronuclei No data – Kasuba and Rozgaj 2002 
(G0 phase) 
Human blood lymphocytes Micronuclei No data + Kasuba and Rozgaj 2002 
(S phase) 
Human diploid fibroblasts Micronuclei No data + Seoane and Dulout 2001 
(MRC-5) 
Mouse spleen cells Sister chromatid No data + Fahmy and Aly 2000 
exchanges 
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Table 3-11.  Genotoxicity of Cadmium In Vitro 
 
  Results  
With Without 
Species (test system) End point activation activation Reference 
Human blood lymphocytes Sister chromatid No data – Bassendowska-Karska and 
exchanges Zawadzka-Kos 1987 
Human blood lymphocytes Sister chromatid No data  – Saplakoglu and Iscan 1998 
(G0 phase) exchanges 
Human blood lymphocytes Sister chromatid No data  + Saplakoglu and Iscan 1998 
(S phase) exchanges 
Syrian hamster embryo cells Transformation No data + Casto et al. 1979 
Rat ventral prostate cells Transformation No data + Terracio and Nachtigal 1988 
Rat hepatocytes Unscheduled DNA No data + Denizeau and Marion 1989 
synthesis 
 
C = negative result; + = positive result; ± = weakly positive; CHO = Chinese hamster ovary; DNA = deoxyribonucleic 
acid; NA = not applicable; RNA = ribonucleic acid 
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human cells have shown mixed results (Deknudt and Deminatti 1978; Gasiorek and Bauchinger 1981; 
Paton and Allison 1972; Shiraishi et al. 1972).  For the most part, in vitro studies have not shown 
cadmium to induce SCE in human cells (Bassendowska-Karska and Zawadzka-Kos 1987; Saplakoglu and 
Iscan 1998).  However, a study by Fahmy and Aly (2000) did observe SCE in mouse spleen cells 
following cadmium treatment.  Kasuba and Rozgaj (2002) and Saplakoglu and Iscan (1998) evaluated the 
ability of cadmium to induce micronuclei and SCE in human lymphocytes in vitro respectively, at two 
different stages of the cell cycle, G0 and S phase.  These studies observed that the genotoxicity of 
cadmium may vary depending on the stage of the cell cycle as both micronuclei and SCE were induced in 
cells in S phase, but not in cells in G0 phase.  These observations may in part explain some of the 
contradictory findings regarding cadmium genotoxicity in the literature.   
 
Positive mutagenicity results have been found in some studies using bacterial cells (Kanematsu et al. 
1980; Mandel and Ryser 1984; Nishioka 1975; Wong 1988), in studies using yeast (Putrament et al. 1977; 
Schiestl et al. 1989), and in a single study using Drosophila melanogaster (Vasudev and Krishnamurthy 
1979).  Other studies report negative mutagenicity results in bacterial cells (Bruce and Heddle 1979; 
Milvy and Kay 1978) and in D. melanogaster (Inoue and Watanabe 1978; Ramel and Mangusson 1979). 
 
3.4   TOXICOKINETICS  
 
Cadmium metal and cadmium salts are not well absorbed; approximately 25, 1–10, or <1% of the dose is 
absorbed following inhalation, oral, or dermal exposure.  Several factors can influence inhalation and oral 
absorption efficiency; for example, cadmium in cigarette smoke has a higher absorption efficiency due to 
its small particle size and cadmium absorption from the gastrointestinal tract is increased in individuals 
with poor iron status.  Following absorption from any route of exposure, cadmium widely distributes 
throughout the body, with the highest concentrations found in the liver and kidney.  Cadmium is not 
known to undergo any direct metabolic conversion such as oxidation, reduction, or alkylation.  Absorbed 
cadmium is excreted very slowly, with urinary and fecal excretion being approximately equal.  
Approximately 0.007 and 0.009% of the body burden is excreted in the urine and feces, respectively, per 
day.   
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3.4.1   Absorption  
 
3.4.1.1   Inhalation Exposure  
 
Cadmium metal and cadmium salts have low volatility and exist in air primarily as fine suspended 
particulate matter.  When inhaled, some fraction of this particulate matter is deposited in the airways or 
the lungs, and the rest is exhaled.  Large particles (greater than about 10 μm in diameter) tend to be 
deposited in the upper airway, while small particles (approximately 0.1 μm) tend to penetrate into the 
alveoli.  While some soluble cadmium compounds (cadmium chloride and cadmium sulfate) may undergo 
limited absorption from particles deposited in the respiratory tree, the major site of absorption is the 
alveoli.  Thus, particle size, which controls alveolar deposition, is a key determinant of cadmium 
absorption in the lung (Nordberg et al. 1985). 
 
No direct data are available on cadmium deposition, retention, or absorption in the human lung.  Data 
from animal studies indicate that lung retention is greatest after short-term exposure (5–20% after 
15 minutes to 2 hours) (Barrett et al. 1947; Henderson et al. 1979; Moore et al. 1973; Rusch et al. 1986).  
The initial lung burden declines slowly after exposure ceases (Henderson et al. 1979; Moore et al. 1973; 
Rusch et al. 1986) due to absorption of cadmium and lung clearance of deposited particles.  After longer 
periods of inhalation exposure to cadmium, somewhat lower lung retentions are found (Glaser et al. 
1986).  The absorption of cadmium in lung differs somewhat among chemical forms, but the pattern does 
not correlate with solubility (Glaser et al. 1986; Rusch et al. 1986). 
 
Based on comparison of cadmium body burdens in human smokers and nonsmokers, cadmium absorption 
from cigarettes appears to be higher than absorption of cadmium aerosols measured in animals (Nordberg 
et al. 1985).  The chemical form of cadmium in cigarette smoke is likely to be similar to that produced by 
other combustion processes, primarily cadmium oxide aerosols.  The greater absorption of cadmium from 
cigarette smoke is likely due to the very small size of particles in cigarette smoke and the consequent very 
high alveolar deposition (Nordberg et al. 1985; Takenaka et al. 2004). 
 
Based on the physiology of the human respiratory tree, a comprehensive model has been developed to 
predict the kinetics of inhaled cadmium in humans (Nordberg et al. 1985).  Results of this model suggest 
that only about 5% of particles >10 μm in diameter will be deposited, up to 50% of particles <0.1 μm will 
be deposited, and between 50 and 100% of cadmium deposited in the alveoli will ultimately be absorbed 
(Nordberg et al. 1985). 
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3.4.1.2   Oral Exposure  
 
Most ingested cadmium passes through the gastrointestinal tract without being absorbed (Kjellström et al. 
1978).  Measurement of gastrointestinal absorption is complicated by the fact that not all of a dose 
initially retained in the gastrointestinal system can be considered to be absorbed, because some portion 
may be trapped in the intestinal mucosa without crossing into the blood or lymph (Foulkes 1984).  Thus, 
measures of whole-body cadmium retention may overestimate cadmium absorption (at least in the short-
term).  On the other hand, some absorbed cadmium may be excreted in urine or feces, so that retention 
may underestimate exposure.  However, this underestimate is probably minor because excretion of 
absorbed cadmium is very slow (see Section 3.4.4.2). 
 
Cadmium absorption has been estimated based on the retention of cadmium in the bodies of humans 
following ingestion of radioactive cadmium.  Estimated cadmium absorption ranged from 1.1 to 10.6% 
(Flanagan et al. 1978; McLellan et al. 1978; Newton et al. 1984; Rahola et al. 1973; Shaikh and Smith 
1980; Vanderpool and Reeves 2001).  Although some studies have reported higher absorption levels (25–
42%), this was based on cadmium retention measurements for 3–5 days after exposure that was probably 
too short to accurately measure cadmium transfer from the intestinal mucosa to circulation (Crews et al. 
2000; Rahola et al. 1973).  Using estimated cadmium intakes from national data and measured renal and 
urinary cadmium levels in healthy nonsmokers, cadmium absorption rates of 3–5% have been estimated 
(Ellis et al. 1979; Morgan and Sherlock 1984).  In a balance study of women with high background 
cadmium intakes (mean urinary cadmium levels of 2.7–5.16 μg/g creatinine); the mean absorption rate in 
subjects examined for 7 days was 6.5% (Horiguchi et al. 2004). 
 
The body store of iron influences cadmium absorption; subjects with low iron stores (assessed by serum 
ferritin levels) had an average absorption of 6 and 8.9%, while those with adequate iron stores had an 
average absorption of 2.3 and 2.4% (Flanagan et al. 1978; Shaikh and Smith 1980).  Several 
epidemiology studies have found significant negative correlations between body iron (assessed via serum 
ferritin and/or transferring levels) and cadmium body burden (blood cadmium and/or urinary cadmium 
levels) among men and women (Apinan et al. 2010) and among never-smoking, nonpregnant, non-
menopausal women (Gallagher et al. 2011; Meltzer et al. 2010).  Studies in rats have shown that iron 
deficiency results in the upregulation of divalent metal transporter 1 (DMT1) and metal transporter 
protein 1 (MTP1) in the duodenum, which may facilitate the absorption of cadmium (Kim et al. 2007; 
Ryu et al. 2004).  Other epidemiology studies have found significantly higher cadmium body burdens in 
women with lower iron stores (Kippler et al. 2009).  In contrast, a study of anemic females with high 
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background cadmium levels did not find a significant alteration in cadmium absorption, as compared to 
healthy females; however, cadmium absorption was lower in the anemic group (13.6%) than in healthy 
group (27.4%) (Horiguchi et al. 2004).  It is not known if the differences in the methods used to estimate 
cadmium absorption (kinetic study using radiolabelled cadmium versus a balance study) or the high 
background cadmium intake in the Horiguchi study resulted in the discrepancy between the two studies.  
There is some indication that not all forms of cadmium are equally absorbed.  Some populations with 
high dietary-cadmium exposure from Bluff oysters (McKenzie-Parnell et al. 1988) or seal meat (Hansen 
et al. 1985) have been found not to have elevated blood-cadmium levels, perhaps due to the particular 
form of cadmium in these foods. 
 
 
 
Crews et al. (2000) estimated that 42% of a cadmium dose incorporated into porridge was retained in the 
body 5 days after exposure (as measured by fecal excretion of radiolabelled cadmium); however, the fecal 
collection period was probably too short to accurately measure cadmium absorption.  The investigators 
also attempted to measure cadmium absorption in 12-month-old infants; 18% of the labeled cadmium in 
the porridge was retained in the body after 4 days.  As with the adult data, the collection period may have 
been too short to accurately measure cadmium absorption in the infants.   
Most estimates of cadmium absorption in animals are somewhat lower than the values found from human 
studies, particularly after prolonged exposure.  In mice, 0.27–3.2% of an oral dose of cadmium chloride 
was retained after 3–5 days (Bhattacharyya et al. 1981; Engstrom and Nordberg 1979), and in rats, 2–3% 
of a single oral dose of cadmium chloride was retained (Moore et al. 1973; Schafer et al. 1990).  
Following 30 days of oral exposure, 0.2–0.3% of an administered dose was retained in rats (Muller et al. 
1986).  After 4 weeks of dietary exposure to cadmium, absorption of cadmium was reduced to one-third 
the absorption of rats without pre-exposure to cadmium (Schafer et al. 1990).  Cadmium pigments 
(cadmium sulfide and cadmium sulfoselenide) appear to be absorbed much less than cadmium chloride in 
rats (ILZRO 1977).  Increases in absorption have been observed during gestation and lactation, 0.37 and 
0.35% of cadmium administered via gavage was absorbed in mice on gestation days 8 and 15 and 0.56, 
0.60, and 0.30% on lactation days 10, 17, and 24, as compared to 0.27% in nonpregnant controls; 
absorption was only significantly different from nonpregnant controls on lactation days 10 and 17 
(Bhattacharyya et al. 1981).  Similar findings were observed in mice continuously exposed to cadmium 
during pregnancy and/or lactation (Bhattacharyya et al. 1982, 1986). 
The absorption of cadmium from the gastrointestinal tract has been extensively studied in rats and mice, 
and a number of factors are recognized that influence absorption.  Absorption appears to take place in two 
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phases:  uptake from lumen into mucosa, and transfer into the circulation (Foulkes 1985).  Phase 1 may 
involve sequestering of cadmium by metallothionein (Foulkes 1980), but any protective effect is 
overloaded at moderate doses (Kotsonis and Klaassen 1978).  Uptake behaves like a saturable process 
with fractional absorption decreasing at high concentrations (Foulkes 1980).  There is evidence, however, 
to suggest that this saturation results from charge neutralization at the membrane (Foulkes 1985), so that 
it need not be assumed that there is a specific system for carrying cadmium into the body.  At doses high 
enough to damage gastrointestinal mucosa, fractional absorption is increased (Andersen et al. 1988; Goon 
and Klaassen 1989; Lehman and Klaassen 1986).  Cadmium bound to metallothionein was absorbed by 
rats to a lesser extent than cadmium added to the diet as cadmium chloride, but kidney cadmium content 
was only slightly less (Groten et al. 1990).  
 
 
Maitani et al. (1984) compared the distribution of cadmium after oral administration of either cadmium 
ions or Cd-thionein in male CF-1 mice given 0.5 mg Cd/kg, per os (po), as cadmium chloride in saline, 
cadmium chloride in control rat liver homogenate, cadmium thionein in saline, Cd-TH in liver 
homogenate, or liver homogenate from Cd-treated rats.  In all cases, 85–90% of the cadmium dose was 
present in feces within 24 hours.  However, in groups receiving cadmium chloride, more cadmium was 
found in feces on days 2 and 3, compared to those receiving cadmium-thionein.  In a companion study, 
tissue levels indicated that less cadmium was absorbed when rats received cadmium-thionein in saline 
than cadmium chloride in saline.  Cadmium-thionein added to liver homogenate or liver homogenate 
containing cadmium-thionein increased the absorption of cadmium, resulting in renal cadmium levels 
similar to those in mice receiving cadmium chloride in saline.  The kidney/liver cadmium concentration 
ratio (9) was the same for cadmium-thionein in all three media.  Although Cd-TH gave much higher 
kidney/liver cadmium ratios than cadmium chloride (9 versus 2), renal cadmium concentrations were the 
same or lower than after cadmium chloride treatments.  The authors concluded that the high kidney/liver 
cadmium ratio after cadmium-thionein treatment versus cadmium chloride was due to lower 
concentrations of cadmium in liver rather than marked increases in renal cadmium levels.  While the 
chemical form of cadmium administered affects the absorption and distribution, the amount of cadmium 
reaching the kidney after cadmium-thionein administration is similar to that after cadmium chloride 
administration. 
At moderate doses of cadmium, the presence of divalent and trivalent cations, such as calcium, 
chromium, magnesium, and zinc, may decrease cadmium uptake, probably by a nonspecific effect on the 
charge distribution of the intestinal brush border membrane (Foulkes 1985).  However, the influence of 
cations on cadmium absorption is complex, because zinc can increase the amount of cadmium absorbed 
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from the intestine (Jaeger 1990).  A refined diet high in fat and protein increases cadmium absorption in 
mice, partially due to increased gastrointestinal passage time (Schafer et al. 1986).  Studies in newborn 
rats and pigs also provide evidence that diet constituents influence cadmium absorption; absorption of 
cadmium chloride was higher when administered in water compared to cereal-based infant formula 
(Eklund et al. 2001, 2004).  Diets low in iron increase cadmium absorption (Flanagan et al. 1978; Reeves 
and Chaney 2001, 2002; Schafer et al. 1990); a diet low in calcium will also increase cadmium absorption 
(Reeves and Chaney 2001, 2002).  In contrast, low levels of dietary iron did not increase cadmium 
absorption in suckling piglets; however, iron supplementation did increase cadmium absorption (Öhrvik 
et al. 2007); this difference may be due to the high cadmium dose used in the study.  Zinc deficiency may 
result in an increased accumulation of cadmium in the intestinal wall, but does not affect transport into the 
blood (Foulkes and Voner 1981; Hoadley and Cousins 1985).  The absorption of cadmium in rats depends 
on age, with measured absorption decreasing from 12 to 5 to 0.5% at 2 hours, 24 hours, and 6 weeks after 
birth, respectively (Sasser and Jarboe 1977).  Sasser and Jarboe (1980) also reported that absorption of 
cadmium in the gastrointestinal tract of young guinea pigs was 20-fold higher than in adult guinea pigs.  
Thus, for a given individual, the absorption following oral exposure to cadmium is likely to depend on 
physiologic status (age; body stores of iron, calcium, and zinc; pregnancy history; etc.) and, also, on the 
presence and levels of ions and other dietary components ingested with the cadmium. 
 
 
3.4.1.3   Dermal Exposure  
 
A few measurements of dermal absorption of cadmium in animals have been made, with only one in vitro 
study using human skin to determine the percutaneous absorption of cadmium. 
A study by Wester et al. (1992) evaluated the percutaneous absorption of cadmium from water and soil 
into and through human skin using in vitro skin cells.  Radioactive cadmium (109cadmium chloride) was 
made to a concentration of 116 ppb in water or 13 ppb in filtered soil (26% sand, 26% clay, 48% silt, 
0.9% organic content).  Cadmium chloride was administered either at 5 μL/cm2 or 2 volumes of 
2.5 μL/cm2 (the same amount of cadmium apparently applied).  Human cadaver skin dermatomed at 
500 μm was placed in flow-through skin cells and perfused with human plasma.  Approximately 0.1–
0.6% of the cadmium chloride in water entered the plasma perfusate over the 16-hour perfusion period, 
while 2.4–12.7% of applied dose remained in the skin.  Most of the cadmium (74–93%) remained 
unabsorbed and was recovered from the skin surface.  Total recoveries ranged from 88±20 to 103±3.  
When cadmium-contaminated soil (13 ppb cadmium chloride) was applied to the skin surface, plasma 
levels ranged from 0.02 to 0.07% of the applied dose, while the skin contained 0.06–0.13% of applied 
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dose.  Surface wash ranged from 82 to 102% of applied dose.  Total recoveries were from 83±33 to 
106±2.  The large differences between water and soil absorption into the plasma and retention in the skin 
were attributed to differences in cadmium partition coefficients, measured to be 3.61x101 for stratum 
corneum (powdered):water and 1.03x105 for soil:water.  These measurements indicate that soil has a 
relatively higher affinity for cadmium than does the stratum corneum.  The transfer of cadmium from soil 
to skin depends on the soil’s binding capacity and water retention and variables describing the physical 
contact with the skin.  When cadmium levels in the soil were increased from 6.5 to 65 ppb, skin levels 
correspondingly increased, but plasma receptor fluid levels remained constant.  This suggests that, with in 
vitro perfusion, the surface concentration of cadmium will influence skin cadmium concentration, but that 
absorption into plasma receptor fluid is relatively independent of the skin surface concentration.  The 
authors offer the caveat that in vitro methods can influence results and therefore, the receptor fluid 
accumulation must be interpreted with caution.  The authors calculate that a whole-body exposure to 
cadmium at 116 ppb in water with 0.5% absorption will result in a daily systemic intake of about 10 μg 
cadmium. 
 
 
A few animal studies are available that describe the percutaneous absorption of cadmium as estimated 
from the accumulation of cadmium in the liver and kidneys of mice and rabbits.  Male rabbits (strain not 
specified) dosed with cadmium chloride percutaneously via a 1% aqueous solution (6.1 mg cadmium) or 
2% ointment (12.2 mg cadmium) over a 10-cm2 shaved area (Kimura and Otaki 1972).  Animals were 
treated 5 times over 3 weeks (duration of exposure not reported) and were killed 2 weeks after the last 
application.  Only cadmium contents of liver and kidney were measured, so total absorption through the 
skin may have been greater.  Accumulated amounts of cadmium in the liver and kidneys were found to be 
0.4–0.61% 2 weeks after the end of cadmium exposure.  This percentage was similar for aqueous solution 
or hydrocarbon ointment.  Similarly, male hairless mice (strain not specified) were dosed with cadmium 
chloride percutaneously with a 2% ointment (containing 0.61 mg cadmium) 1 or 5 times in a week 
(duration of exposure not reported) and killed 1 week later (Kimura and Otaki 1972).  Accumulated 
amounts of cadmium in the liver and kidneys were found to be 0.2–0.87%.   
Cadmium was detected in liver, kidneys, and urine following dermal exposure in guinea pigs (Skog and 
Wahlberg 1964).  The disappearance of cadmium from cadmium chloride in water applied to guinea pig 
skin was dependent on concentration, with a peak mean absorption of 1.8% over 5 hours at 0.239 molar 
cadmium (about a 2.7% solution).  Less absorption occurred both at higher and lower concentrations of a 
cadmium chloride solution applied to the skin (Skog and Wahlberg 1964).  
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The results from all of these studies suggest that dermal absorption is slow, and would be of concern only 
in situations where concentrated solutions would be in contact with the skin for several hours or longer. 
 
3.4.2   Distribution  
 
Cadmium is widely distributed in the body, with the major portion of the body burden located in the liver 
and kidney.  Animals and humans appear to have a similar pattern of distribution that is relatively 
independent of route of exposure, but somewhat dependent on duration of exposure.  
 
3.4.2.1   Inhalation Exposure  
 
Cadmium was found in autopsy samples from nearly all organs of a worker extensively exposed to 
cadmium dust, with greatest concentrations in the liver, kidney, pancreas, and vertebrae (Friberg 1950).  
In workers dying from inhalation of cadmium, lung-cadmium concentration was somewhat lower than 
liver or kidney cadmium concentration (Beton et al. 1966; Lucas et al. 1980; Patwardhan and Finckh 
1976).  The concentration of cadmium in the liver of occupationally exposed workers generally increases 
in proportion to intensity and duration of exposure to values up to 100 μg/g (Gompertz et al. 1983; Roels 
et al. 1981b).  The concentration of cadmium in the kidney rises more slowly than in the liver after 
exposure (Gompertz et al. 1983) and begins to decline after the onset of renal damage at a critical 
concentration of 160–285 μg/g (Roels et al. 1981b). 
 
 
In animals acutely exposed to cadmium carbonate aerosols, about 60% of the inhaled dose is found in the 
gastrointestinal tract, transported by mucociliary clearance (Moore et al. 1973).  Following a 2-hour 
inhalation of approximately 100 mg/m3 of cadmium, cadmium concentration in rat liver increased from 
an initial concentration of 0.8 μg/g in males and 1.9 μg/g in females immediately after exposure up to a 
peak of about 2 μg/g in males and 3.8 μg/g in females 1 week postexposure, then declined to 1.7 and 
2.5 μg/g, respectively, by 30 days postexposure.  The kidney concentrations were initially <0.5 μg/g in 
males and females, rising to approximately 8 μg/g in both sexes by 1 week postexposure and to 18 μg/g in 
males and 15 μg/g in females by 30 days postexposure (Rusch et al. 1986). 
3.4.2.2   Oral Exposure  
 
As discussed in Chapter 6, most nonoccupationally exposed people are exposed to cadmium primarily 
through the diet.  Cadmium can be detected in virtually all tissues in adults from industrialized countries, 
with greatest concentrations in the liver and kidney (Chung et al. 1986; Sumino et al. 1975).  Average 
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cadmium concentrations in the kidney are near zero at birth, and rise roughly linearly with age to a peak 
(typically around 40–50 μg/g wet weight) between ages 50 and 60, after which kidney concentrations 
plateau or decline (Chung et al. 1986; Hammer et al. 1973; Lauwerys et al. 1984).  Liver cadmium 
concentrations also begin near zero at birth, increase to typical values of 1–2 μg/g wet weight by age 20–
25, then increase only slightly thereafter (Chung et al. 1986; Hammer et al. 1973; Lauwerys et al. 1984; 
Sumino et al. 1975). 
 
 
 
Distribution of cadmium in animals after oral exposure is similar to that found in humans, with highest 
accumulation in the liver and kidneys, and lower levels spread throughout the rest of the body (Kotsonis 
and Klaassen 1978; Weigel et al. 1984).  Liver and kidney cadmium concentrations are comparable after 
short-term exposure (Andersen et al. 1988; Jonah and Bhattacharyya 1989), but the kidney concentration 
exceeds the liver concentration following prolonged exposure (Kotsonis and Klaassen 1978), except at 
very high exposures (Ando et al. 1998; Bernard et al. 1980; Hiratsuka et al. 1999).  In mice orally 
exposed to cadmium during lactation, 53% of the whole-body cadmium was found in the kidneys as 
compared to 27% in nonpregnant controls (Bhattacharyya et al. 1982). 
Maitani et al. (1984) compared the distribution of cadmium in rats after an acute oral administration of 
either cadmium ions or cadmium bound to metallothionein.  In all cases, 85–90% of the dose was present 
in the feces within 24 hours postexposure.  More of the cadmium-thionein was retained after 2–3 days, 
and less of the cadmium-thionein was distributed to the liver than was the case for the ionic cadmium.  
Kidney levels were comparable.   
The placenta may act as a partial barrier to fetal exposure to cadmium.  Cadmium concentration has been 
found to be approximately half as high in cord blood as in maternal blood in several studies including 
both smoking and nonsmoking women (Kuhnert et al. 1982; Lauwerys et al. 1978; Truska et al. 1989).  
Accumulation of cadmium in the placenta at levels about 10 times higher than maternal blood cadmium 
concentration has been found in studies of women in Belgium (Roels et al. 1978) and the United States 
(Kuhnert et al. 1982); however, in a study in Czechoslovakia, the concentration of cadmium in the 
placenta was found to be less than in either maternal or cord blood (Truska et al. 1989).  In mice orally 
exposed to cadmium during pregnancy, maternal blood, placental, and fetal cadmium concentrations were 
essentially equal among control animals (with environmental cadmium exposure), but placental 
concentration increased with cadmium dose much more rapidly than either maternal blood or fetal 
cadmium concentration (Sorell and Graziano 1990).  Thus, timing and level of cadmium exposure may 
influence the uptake of cadmium by the placenta, perhaps explaining the conflicting human studies.   
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Goyer and Cherian (1992) localized metallothionein in full-term human placenta and in fetal cells in 
human placenta.  Metallothionein was present in trophoblasts (which facilitate transport of substances 
entering the placenta from the maternal blood), Hofbauer cells (motile macrophages capable of 
phagocytosis and protein ingestion), amniotic epithelial cells (fetal derivatives), and decidual cells 
(endometrial stromal cells that have been transformed under hormonal influence into large pale cells, rich 
in glycogen).  The mechanism by which the placenta transports the essential metals, copper and zinc, 
while limiting the transport of cadmium is unknown, but may involve the approximately 1,000-fold 
higher concentration of zinc in the placenta and the higher affinity of cadmium than zinc for 
metallothionein.  
 
Cadmium levels in human milk are 5–10% of levels in blood, possibly due to inhibited transfer from 
blood because of metallothionein binding of cadmium in blood cells (Radisch et al. 1987).  Bhattacharyya 
et al. (1982) examined the maternal transfer of cadmium to pups during gestation and lactation in mice.  
Approximately 3, 11, and 25% of maternal cadmium was transferred to the pups following gestation-only 
exposure, lactation-only exposure, and gestation and lactation exposure, respectively. 
 
3.4.2.3   Dermal Exposure  
 
No studies were located regarding distribution in humans after dermal exposure to cadmium.  Elevated 
levels of cadmium were found in the liver and kidneys of rabbits and mice dermally exposed to cadmium 
(Kimura and Otaki 1972). 
 
3.4.3   Metabolism  
 
Cadmium is not known to undergo any direct metabolic conversion such as oxidation, reduction, or 
alkylation.  The cadmium (+2) ion does bind to anionic groups (especially sulfhydryl groups) in proteins 
(especially albumin and metallothionein) and other molecules (Nordberg et al. 1985).  Plasma cadmium 
circulates primarily bound to metallothionein, and albumin (Foulkes and Blanck 1990; Roberts and Clark 
1988). 
 
3.4.4   Elimination and Excretion  
 
Most cadmium that is ingested or inhaled and transported to the gut via mucociliary clearance is not 
absorbed and is excreted in the feces.  Absorbed cadmium is excreted very slowly, with urinary and fecal 
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excretion being approximately equal (Kjellström and Nordberg 1978).  The half-time for cadmium in the 
whole body in humans was >26 years (Shaikh and Smith 1980) and half-times of several months up to 
several years have been calculated in mice, rats, rabbits, and monkeys (Kjellström and Nordberg 1985).  
Half-times in the slowest phase were from 20 to 50% of the maximum life span of the animal (Kjellström 
and Nordberg 1985).  In the human body, the main portion of the cadmium body burden is found in the 
liver and kidney and in other tissues (particularly muscle, skin, and bone).  After reviewing the literature, 
Kjellström and Nordberg (1985) developed a range of half-times from their kinetic model of 6–38 years 
for the human kidney and 4–19 years for the human liver. 
 
3.4.4.1   Inhalation Exposure  
 
Cadmium excretion in urine of occupationally exposed workers increases proportionally with body 
burden of cadmium, but the amount of cadmium excreted represents only a small fraction of the total 
body burden unless renal damage is present; in this case, urinary cadmium excretion markedly increases 
(Roels et al. 1981b).  Fecal excretion in workers occupationally exposed to cadmium reflects mainly 
cadmium dust swallowed from industrial air and/or incidentally ingested from contaminated hands 
(Adamsson et al. 1979). 
 
In rats, following a 2-hour inhalation exposure to cadmium carbonate, cadmium was primarily eliminated 
in the feces, with a minor component (approximately 1% of fecal excretion) in the urine (Rusch et al. 
1986).  Cadmium excretion by both routes declined with time after exposure, with significantly elevated 
excretion found at 7 days, but not 30 days, after exposure (Rusch et al. 1986).  Most of the cadmium 
initially excreted in the feces was probably not absorbed, but rather represented particles transported from 
the lung to the gastrointestinal tract (Moore et al. 1973). 
 
3.4.4.2   Oral Exposure  
 
Following oral exposure, the major proportion of administered cadmium is found in the feces, because 
absorption is so low (see Section 3.4.1.2) (Kjellström et al. 1978).  Among five healthy adult volunteers, 
fecal excretion of a single dose of radiolabeled cadmium declined with time up to 45 days after ingestion, 
while urinary excretion remained at a low, near-constant level (Rahola et al. 1973).  After about 20 days, 
fecal and urinary excretion appeared to be comparable (Rahola et al. 1973).  In contrast, among 
four healthy adults ingesting cadmium in intrinsically labeled crabmeat, fecal excretion was 30 times 
higher than urinary excretion up to 10 weeks after ingestion of the test meal (Newton et al. 1984).  In rats 
orally exposed to up to 0.35 mg/kg/day of cadmium in the diet for 60 days, no significant increase in 
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urinary cadmium content was found (Weigel et al. 1984).  The overall excretion of absorbed cadmium is 
slow, with biological half-times of 70–270 days in rats or mice orally exposed to cadmium (Engstrom and 
Nordberg 1979; Moore et al. 1973). 
 
 
In a comprehensive model developed for human cadmium toxicokinetics, parameters for urinary and fecal 
excretion were derived by adjustments to empirical data derived from human and animal studies 
(Kjellström and Nordberg 1978, 1985).  Fecal excretion constitutes unabsorbed cadmium plus "true" 
excretion originating from blood via the intestinal wall (a function of cadmium body burden) and from 
bile via the liver (a function of cadmium liver burden) (Kjellström and Nordberg 1985).  Urinary 
excretion depends on blood concentration and kidney concentration, and total excretion is assumed to 
equal daily intake at steady state.  Using these methods and assumptions, daily fecal and urinary excretion 
is estimated to be 0.007 and 0.009% of body burden, respectively (Kjellström and Nordberg 1978, 1985).  
A whole-body retention half-time estimate of >26 years was obtained by Shaikh and Smith (1980) in a 
study using orally ingested radiolabelled cadmium and monitoring a subject for over 2 years. 
Groups of 10 female outbred albino rats were exposed to cadmium in drinking water (as cadmium 
chloride) at 0 or 4.8 mg/kg/day for 10 weeks (at 4 weeks prior to mating, at 3 weeks of gestation, or 
3 weeks into lactation).  After weaning, exposure to cadmium was terminated.  In dams, kidney 
concentrations exceeded liver concentrations, while in pups, the renal and liver concentrations were 
similar at all times during exposure.  In pups, both hepatic and renal cadmium concentrations 
considerably increased only during the second half of the lactation period (Ld 11–21).  The concentrations 
in the dams were several orders higher than in the offspring.  After discontinuation of exposure, organ 
concentration slightly decreased in dams (2% in liver and 12% in kidneys), while in pups, the decrease 
was 84% in the liver and 62% in the kidneys.  These values do not indicate cadmium elimination but 
rather dilution caused by growth (Kostial et al. 1993). 
 
3.4.4.3   Dermal Exposure  
 
No studies were located regarding excretion in humans after dermal exposure to cadmium.  Cadmium was 
reportedly detected in urine in guinea pigs dermally exposed to aqueous cadmium chloride, but no details 
are available (Skog and Wahlberg 1964). 
 
CADMIUM  203 
 
3.  HEALTH EFFECTS 
 
 
 
 
 
 
 
3.4.5   Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models  
 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry 
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of 
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.   
 
 
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between:  (1) the external/exposure concentration and target 
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and 
Krishnan 1994; Andersen et al. 1987a).  These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from 
route to route, between species, and between subpopulations within a species.  The biological basis of 
PBPK models results in more meaningful extrapolations than those generated with the more conventional 
use of uncertainty factors.   
The PBPK model for a chemical substance is developed in four interconnected steps:  (1) model 
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and 
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of 
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters.  The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these 
solutions.   
 
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems.  If the uptake and disposition of the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for 
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many biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty.  The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of 
PBPK models in risk assessment. 
 
 
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the 
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).  
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in 
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species.  
Figure 3-3 shows a conceptualized representation of a PBPK model. 
If PBPK models for cadmium exist, the overall results and individual models are discussed in this section 
in terms of their use in risk assessment, tissue dosimetry, and dose, route, and species extrapolations. 
 
3.4.5.1 Summary of Cadmium PBPK Models 
 
Several models have been reported to describe the kinetics of cadmium in mammalian systems.  Of these 
models, the Nordberg-Kjellström model (Kjellström and Nordberg 1978; Nordberg and Kjellström 1979) 
has been the most widely used for cadmium risk assessment.  Three of the most relevant cadmium models 
will be discussed here. 
 
3.4.5.2   Cadmium PBPK Model Comparison 
 
Although the Nordberg-Kjellström model (Kjellström and Nordberg 1978; Nordberg and Kjellström 
1979) has its limitations, it provides the best overall description of cadmium toxicokinetics and is largely 
based on human data.  The Shank (Shank et al. 1977) and Matsubara-Khan (Matsubara-Khan 1974) 
models are not as useful for human risk assessment applications, but they do provide useful insights into 
the absorption, distribution, and compartmentalization of cadmium in laboratory animals.  These insights 
may have some future use in human risk assessment as PBPK models for cadmium continue to be refined. 
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Figure 3-3.  Conceptual Representation of a Physiologically Based 
Pharmacokinetic (PBPK) Model for a  
Hypothetical Chemical Substance 
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Note:  This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance.  The chemical substance is shown to be absorbed via the skin, by inhalation, or by 
ingestion, metabolized in the liver, and excreted in the urine or by exhalation. 
 
Source:  adapted from Krishnan and Andersen 1994 
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3.4.5.3   Discussion of Cadmium Models 
 
The Nordberg-Kjellström Model 
 
 
 
 
The Nordberg-Kjellström model (Kjellström and Nordberg 1978; Nordberg and Kjellström 1979) is a 
linear multicompartment model that is the most commonly used model for cadmium risk assessment work 
today.  The Nordberg-Kjellström schematic model diagram is shown in Figure 3-4.   
Risk assessment.    The Nordberg-Kjellström model has been demonstrated to be a useful model in 
human risk assessment work.  Frazier (1994), however, noted that the model has two major limitations:  
(1) the linear nature of the model may not adequately allow a good description of known nonlinearities in 
biological responses to cadmium dosing, and (2) the phenomenological approach taken with this model 
does not provide a foundation for incorporating biological variability into the model parameters. 
Description of the Model.    The Nordberg-Kjellström model (see Figure 3-4) is a linear multi-
compartment model that describes the disposition of cadmium via the oral and inhalation routes of 
exposure only.  Dermal exposure and subsequent absorption through the skin were assumed to be 
negligible in this model.  For inhalation exposures, the model accounts for different deposition patterns 
for different size particles in nasopharyngeal, tracheobronchial, and alveolar regions of the respiratory 
tract.  Particles with mass median aerodynamic diameter (MMAD) of 5 μm (i.e., cadmium-laden dust) 
were assumed to distribute mainly to the nasopharyngeal region (75%), with lesser amounts depositing in 
the alveolar (20%) and tracheobronchial (5%) regions.  Particles of 0.05 μm MMAD (i.e., cigarette 
smoke) were assumed to deposit 50% in the alveolar compartment, 10% in the tracheobronchial 
compartment, and none in the nasopharyngeal compartment.  The remaining amounts are exhaled.  For all 
particle sizes initially deposited in the nasopharyngeal and tracheobronchial compartments, mucociliary 
clearance clears some particles from the respiratory tract to enter the oral compartment for absorption or 
out of the body and back to the environment.  Assumed model coefficient values and the available 
physiological parameters are shown in Table 3-12. 
For the oral route of exposure, cadmium may enter the gastrointestinal tract via food or water 
contaminated with cadmium, or as cadmium particles embedded in mucus from the respiratory tract via 
the mucociliary/tracheobronchial escalator.  By either route of exposure, the model assumes that cadmium 
enters into any of three blood compartments (B) (see Figure 3-4).  B1 is the plasma compartment where  
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Figure 3-4.  A Schematic Representation of the Nordberg-Kjellström Model  
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Coefficient or parameter Assumed range Unita 
Values fitting to 
empirical data 
Model parameters 
C1  0.1–0.2 (cigarette smoke)   0.1  
 0.4–0.9 (factory smoke)   0.7  
C2  0.4–0.6 (cigarette smoke)   0.4  
 
C3  
C4  
0.1–0.3 (factory smoke)  
0.01–1.0 
0.1xC3 = 0.001–0.1 
 
-1day  
-1day  
0.13  
0.05  
0.005  
C5  0.03–0.1   0.048  
C6  0.05  -1day  0.05  
C7  0.2–0.4   0.25  
C8  0.5–5.0  μg 1  
C9  0.4–0.8   0.44  
C10  0.00004–0.0002  -1day  0.00014  
C11  0.05–0.5   0.27  
C12  0.1–0.4   0.25 
C13  
C14  
C15  
C16  
0–0.0001  
0.0001–0.0003  
0–0.0001  
0.004–0.015  
-1day  
-1day  
-1day  
-1day  
0.00003  
0.00016  
0.00005  
0.012  
C17  0.8–0.98   0.95  
C18  
C19  
0–0.0001  
0.00002–0.0002  
-1day  
-1day  
0.00001  
0.00014  
CX  0 01–0.05   0.04  
C20  0.05–0.5   0.1  
C21  0–0.000002  -1day  0.0000011  
Physiologic parameters 
Average liver weight  1,500  gram  
Average blood volume  70  mL/kg  
Average blood specific gravity  1.06   
Average daily urine excretion (adult)  1.0 L  
Average daily urine excretion (aged)  0.9  L  
Average daily urine excretion (child)  0.5  L  
 
aBlanks indicate a unitless value. 
 
Source:  Kjellström and Nordberg 1978; Nordberg and Kjellström 1979 
 
 
 
 
 
 
Table 3-12.  Assumed Model Parameters and Some Physiologic Parameters for 
the Nordberg-Kjellström Model 
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cadmium may bind to plasma components (i.e., albumin and other organic constituents).  B2 is the red-
blood cell compartment, which represents the accumulation of cadmium in erythrocytes, while 
B3 represents the binding of cadmium to metallothionein.  The model does not take into account 
induction of metallothionein after cadmium exposure.  From the blood, cadmium is calculated to 
distribute to either the liver, kidney, or "other tissues," the major accumulation sites.  Elimination is either 
via the feces or in the urine.  The transport of cadmium between the compartments is assumed to follow 
first-order exponential functions and is driven on concentration-dependent gradients.  
 
 
 
Validation of the model.    The Nordberg-Kjellström model was validated using several independent 
sets of human data from both Sweden and Japan.  The data set by Friberg et al. (1974) estimated that 
smoking 20 cigarettes a day would result in an inhalation of 2–4 μg/day of cadmium, assuming smoking 
started at 20 years of age and daily cadmium intake from food was 16 μg/day.  Based on the Friberg et al. 
(1974) data, the model predictions of cadmium concentrations in the kidney agreed well with the 
observed data from a study by Elinder et al. (1978); however, the model predicted higher than expected 
values for liver cadmium compared to the observed data from the Elinder study.  The model's urinary 
excretion of cadmium (0.84 μg/24 hours for a 50-year-old person) agreed well with the observed data 
(0.56–0.8 μg/24 hours).  The model predicted blood cadmium levels for Swedish smokers to be about 
2 ng/g which compared well to the actual concentration of 1.6 ng/g. 
The model was also validated against a data set for an average 45-year-old Japanese person living in 
Tokyo whose daily intake of cadmium is 40 μg via food and 2.7 μg via the inhalation route.  Subjects 
were assumed to be smokers averaging 24 cigarettes a day starting at age 20.  Based on these exposure 
conditions, the measured values for cadmium in the kidney, liver, and "other tissues" (in this case, muscle 
only) were reported to be 65, 3.4, and 0.2 μg/g, respectively, with the model predicting 48, 3.2, and 
0.18 μg/g.  For blood and urine, the measured values were 4.5 μg/g for blood and 1.1 μg/L for urine; the 
model predicted 3.4 μg/g and 1.3 μg/24 hours (assuming 1 L of urine output/day, the value would be 
1.3 μg/L). 
Another study of Japanese people reported cadmium concentrations in urine in relation to high cadmium 
concentrations in rice in their daily diet.  For people who consumed rice containing 0.04 μg/g of rice 
(240 μg/day), the observed urinary level of cadmium was 7 μg/L; consumption of rice containing 1.1 μg 
cadmium/g of rice (660 μg/day), resulted in an observed value of 14 μg/L of urine.  After making certain 
assumptions about the average daily consumption of rice containing an assumed amount of cadmium, and 
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assuming an average urine production of 1 L/day, the model calculated urinary levels of 4.8 and 
15.5 μg/L of urine, agreeing well with the observed values. 
 
 
 
 
The model was also validated against a data set with high concentrations of cadmium in air (50 μg/m3) 
(Piscator 1972) and blood cadmium concentrations ranging from 10 to 50 ng/g whole blood.  Calculated 
blood, urine, liver, and kidney levels of cadmium agreed only roughly with the observed values; however, 
the authors concluded that the model predictions may not be accurate based on the observations that 
workers with long exposure histories had most likely experienced higher exposure levels in the past, 
skewing the data set, resulting in poor model predictions.  Another data set by Piscator (1984) involved a 
group of Swedish workers involved in polishing cadmium-plated objects, who were exposed to high 
concentrations of cadmium for ≤2 years.  Cadmium levels were measured in the urine and blood.  When 
this exposure data set was input into the model, the model could not adequately predict blood and urine 
levels for these workers. 
Target tissues.    The Nordberg-Kjellström model assumes that the kidney and liver are the two 
specific target tissues in which cadmium accumulates.  The model also accounts for all other tissue 
accumulation in the "other tissues" compartment (i.e., muscle).  The model assumes a human liver tissue 
half-life (t1/2) of 4–19 years and a kidney t1/2 of 6–38 years.  For the "other tissue" compartments, t1/2 was 
assumed to be 9–47 years.  The Nordberg-Kjellström model does account for the loss of renal tubular 
epithelial cells leading to a loss of tubular reabsorptive capacity.  This loss of cells could conceivably 
result in an increase in the excretion of cadmium from the tubules and an increase in the transport of 
cadmium from the tubules to the blood.  This loss of cells is theorized to account for the large t1/2 range 
for cadmium in the kidney.  The model assumed that no changes in the movement of cadmium from the 
kidney to blood occurred with age and that the loss of cadmium from the kidney to the urine increased 
linearly after the age of 30. 
The Nordberg-Kjellström model also accounted for differences in kidney and liver weights among 
different age groups and between peoples of different ethnic origins.  The model corrected for differences 
in liver, kidney, blood, and "other tissue" weights with relation to age (1 and 79 years of age) and 
ethnicity (Japan and Sweden). 
Species extrapolation.    The Nordberg-Kjellström model was based solely on data collected from 
humans and was intended for human risk assessment applications.  The model did not address any 
potential application for this model of cadmium in laboratory animals. 
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High-low dose extrapolation.    The Nordberg-Kjellström model has been shown to adequately 
predict fluid and tissue concentrations via the oral and inhalation routes of exposure for humans exposed 
to low doses of cadmium.  However, the model has difficulty in adequately predicting fluid and tissue 
concentrations in humans exposed to high concentrations of cadmium, especially for those individuals 
exposed to high concentrations via the inhalation route. 
 
 
 
 
Interroute extrapolation.    The Nordberg-Kjellström model adequately predicted the fate of cadmium 
in target tissues after exposure via the inhalation and oral routes.  The dermal route of exposure was not 
incorporated into the model parameters and was considered an insignificant route of exposure in humans. 
 
The Shank Model 
Risk assessment.    The Shank model (Shank et al. 1977) may have the potential to serve as an 
alternative mathematical model for predicting the retention of cadmium in biological systems.  
Unfortunately, no human data were used to validate the Shank model for use as a risk assessment tool in 
cases of human exposure.  In addition, the Shank model was validated only for the intravenous and 
subcutaneous routes of exposure; no data were presented for the oral, inhalation, or dermal routes of 
exposure. 
Description of the model.    A schematic representation of the Shank model is illustrated in 
Figure 3-5.  The model mathematically represents the dynamic transport of cadmium between 
compartments in a mammalian biological system based on the male adult SW/NIH mouse as the test 
animal species.  The intent was to predict the retention of cadmium in other species of animals (including 
humans) without requiring an adjustment of species-specific rate constants from within the model. 
Male adult mice of the SW/NIH strain were dosed intravenously with 109Cd as 109Cd acetate.  Mice 
received 1–3 intravenous injections spaced 48 hours apart.  Animals in each group were sacrificed at 
2 and 10 minutes and 1, 10, and 48 hours after the last dose.  Tissues (liver, kidney, pancreas, spleen, 
gastrointestinal tract, testes, carcass, and feces) were harvested and the radioactivity recorded.  A nine-
compartment model was derived.  Cadmium kinetics between compartments are described by first-order 
kinetics.  The individual compartment retention values, obtained from the distribution study, were 
incorporated into the model equations and the rate constants derived. 
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Figure 3-5.  A Schematic Representation of the Shank Model 
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Source:  Forrester 1968 
CADMIUM  213 
 
3.  HEALTH EFFECTS 
 
 
 
 
 
 
 
 
Validation of the model.    The Shank model was validated using three independent data sets.  Mann 
(1973) dosed dogs, goats, and sheep with one intravenous injection of 109Cd acetate (30 μCi), and the liver 
and kidneys were examined for cadmium content 8 weeks after administration.  The Shank model's 
predicted values of cadmium retention in liver and kidneys at 8 weeks after a single administration were 
in good agreement with the observed values of the Mann (1973) study in all three species.  Only data 
from the liver and kidneys were available for evaluation.  A data set from a study by Gunn et al. (1968b) 
was used to evaluate the ability of the Shank model to predict the retention of cadmium in liver and 
kidney after a single subcutaneous administration of cadmium chloride.  Animals in that study were 
sacrificed 2 weeks after administration, and the liver and kidneys were examined for cadmium content.  
The model values for the same time period were in very close agreement with observed values.  Again, 
only data from the liver and kidneys were available for evaluation.  Finally, a data set by Shanbaky (1973) 
was used to test the model's validity with multiple injections of cadmium acetate in rats.  Five injections 
of cadmium acetate were administered over a 48-hour period; liver, kidneys, pancreas, spleen, and 
gastrointestinal tract were examined for cadmium content.  The Shank model was found to be in close 
agreement with the arithmetic means of observed values found in the Shanbaky (1973) study. 
 
 
 
 
 
No human data were presented to validate the model's effectiveness in predicting the cadmium retention 
in human target tissues after either a single or multiple dosing regime. 
Target tissues.    The target tissues for this model included the liver, kidney, pancreas, spleen, 
gastrointestinal tract, testes, and carcass of laboratory animals.  No human tissue was used to derive 
cadmium retention in any of these tissues. 
Species extrapolation.    The model used goats, dogs, rats, mice, and sheep with various doses and 
dosing schemes of cadmium acetate and cadmium chloride and was found to serve as a good predictor of 
cadmium retention in the target tissues listed above.  No human data were presented to determine if the 
model could satisfactorily predict the cadmium retention in human target tissues. 
High-low dose extrapolation.    High- and low-dose extrapolation was not specifically addressed by 
the Shank model. 
Interroute extrapolation.    Interroute extrapolations were addressed in a limited fashion by the Shank 
model.  The model appeared to adequately predict the amount of cadmium retention in the target organs 
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of laboratory animals, in particular the liver and kidney, when dosed by either the intravenous or 
subcutaneous routes.  The inhalation and dermal routes of exposure, and other parenteral routes of 
exposure (intramuscular, intraperitoneal, intradermal, etc.) were not addressed by the Shank model.  No 
human data were presented to determine if interroute extrapolations were valid. 
 
 
 
 
 
The Matsubara-Khan Model 
Risk assessment.    The Matsubara-Khan model (Matsubara-Khan 1974) has not been used as a tool 
in risk assessment for humans.  This model does demonstrate that cadmium kinetics and biological half-
lives vary by tissue. 
Description of the model.    The Matsubara-Khan model is a simple model that attempted to fit 
cadmium elimination kinetic parameters into either a one- or two-compartment model.  To obtain the data 
for the model, male and female ICR mice (8 weeks of age) were administered a single subcutaneous 
injection of a known amount of 109cadmium chloride.  Specific groups of mice were sacrificed at 1, 2, 4, 
8, 16, 32, 64, or 128 days after injection.  At the time of sacrifice, blood, liver, kidney, salivary gland, 
stomach wall and stomach contents, small intestine and small intestine contents, and colon wall and colon 
contents were removed and the amount of 109Cd remaining in these tissues was determined. 
An oral study was conducted in conjunction with the subcutaneous study described above.  In the oral 
study, 8-week-old male mice (ddd x BALB/c; F1) were orally administered 
115mcadmium chloride by 
gavage.  Groups of mice were sacrificed at 1, 2, 4, 8, 16, 32, 64, or 128 days after injection.  At the time 
of sacrifice, liver, kidney, salivary gland, stomach wall, gonad, and spleen were removed and the amount 
of 115mCd remaining in these tissues was determined. 
The rate of uptake, rate constants, and biological half-lives determined for the subcutaneous and orally 
dosed mice are summarized in Table 3-13.  Matsubara-Khan found that tissue kinetics in mice dosed 
subcutaneously with 109cadmium chloride fit into either a one- or two-compartment model, depending on 
the tissue.  The data from the digestive tract organs (stomach wall, small intestine, and colon) were best 
fitted into a 1-compartment model, with a strained fit of the data from the digestive tract contents 
(stomach, small intestine, and colon contents) to the one-compartment model.  Data from the blood, liver, 
kidneys, and salivary glands were best fitted to the two-compartment model.  Extremely small second-rate 
constants in the kidneys and salivary glands indicate that the elimination of cadmium from these tissues is 
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Table 3-13.  Estimated Parameters, Rate of Uptake, Rate Constants, and 
Biological Half-Lives in Selected Mouse Organs After Subcutaneous  
and Oral Administrations of 109CdCI2 
 
Rate of uptake  
 (95% CL)  
Rate constants 
(95% CL)  
b and c  Biological half-life  
(days)  
Organ SC  PO  SC  PO  SC  PO  
Liver  
Kidney  
Salivary gland  
Blood  
Stomach wall  
Stomach contents  
Small intestine  
Small intestine contents  
Colon  
Colon contents  
Gonad  
Spleen  
21  
22 
21 
0.15 
1.7 
0.68  
0.95  
2.5 
1.4  
4.1  
NM  
NM  
8.7 
1.4 
0.33 
NM 
0.36  
NM  
NM  
NM 
NM  
NM  
0.37  
0.44  
0.011 
0.57  
0.0007 
0.30 
0.0016 
0.73 
0.024 
0.65 
0.0073  
0.062  
0.01  
0.067 
0.013  
0.15  
NM  
NM  
0.016  
0.91  
0.016 
0.30 
0.0047 
0.78 
NM 
0.017  
NM  
NM  
NM 
NM  
NM  
0.012  
0.0011  
631.2  
9902.3 
4330.95 
291.1 
95  
11  
69  
10 
53  
4.6  
NM  
NM  
430.76  
4332.3 
1500.89 
NM 
41  
NM  
NM  
NM 
NM  
NM  
58  
630  
 
CL = confidence limits; PO = oral; SC = subcutaneous; NM = not measured 
 
Source:  Matsubara-Khan 1974  
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very slow.  For the oral study, similar findings were observed, with data from the gonads and spleen 
fitting the one-compartment model best.  Biological half-lives were invariably longer for the 
subcutaneously dosed animals, while the rate constants were slightly smaller for the subcutaneously dosed 
animals.  Sex-related differences in rate of uptake, rate constants, and biological half-lives were not 
found, except in the kidney data in which females had slightly smaller rate constants. 
 
 
 
 
 
Validation of the model.    No independent data sets were used to validate the Matsubara-Khan 
model. 
Target tissues.    For the subcutaneous injection study, the Matsubara-Khan model used blood, liver, 
kidney, salivary gland, stomach wall and stomach contents, small intestine and small intestine contents, 
and colon wall and colon contents.  For the oral study, the model used liver, kidney, salivary glands, 
stomach wall, gonads, and spleen. 
Species extrapolation.    No species extrapolations were performed in the Matsubara-Khan model. 
High-low dose extrapolation.    No high-low dose extrapolations were performed in the Matsubara-
Khan model. 
Interroute extrapolation.    The Matsubara-Khan model compared the oral and subcutaneous routes 
and reported similar rate constants for many of the tissues examined.  Biological half-lives varied 
considerably for the kidney and salivary gland, but were not much different for liver between the two 
routes of exposure. 
 
3.5   MECHANISMS OF ACTION  
 
3.5.1   Pharmacokinetic Mechanisms  
 
Absorption.    Cadmium can be absorbed by the inhalation, oral, and dermal routes of exposure 
regardless of its chemical form (chloride, carbonate, oxide, sulfide, sulfate, or other forms).  Absorption 
by the dermal route of exposure, however, is relatively insignificant for cadmium, although small 
amounts are absorbed percutaneously over a long period of time (Wester et al. 1992).  Absorption is 
mainly of concern from inhalation and oral exposures. 
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Gastrointestinal tract absorption of cadmium (in any chemical form) is relatively low when compared to 
the total amount of cadmium absorbed via the inhalation route.  In humans, cadmium absorption has been 
reported to be approximately 1–10% ((Flanagan et al. 1978; McLellan et al. 1978; Newton et al. 1984; 
Rahola et al. 1973; Shaikh and Smith 1980; Vanderpool and Reeves 2001).  In other species, 
gastrointestinal tract absorption of cadmium has been determined to be 1–2% in mice and rats (Decker et 
al. 1958; Ragan 1977), 0.5–3.0% in monkeys (Friberg et al. 1974), 2% in goats (Miller et al. 1969), 5% in 
pigs and lambs (Cousins et al. 1973; Doyle et al. 1974), and nearly 16% in cattle (Miller et al. 1967).  
Lehman and Klaassen (1986) investigated the dose-dependence of cadmium absorption and disposition in 
male Sprague-Dawley rats.  Cadmium absorption was estimated to be 0.35 and 1% following oral 
exposure to 1 or 10,000 μg/kg, respectively.  Goon and Klaassen (1989) measured absorption of cadmium 
in rat intestine in situ and reported that the intestinal absorption of cadmium is dosage independent at low 
dosages of cadmium (<10 μg/kg) and dosage dependent at high dosages (>10 μg/kg).  They also 
evaluated the role of metallothionein and concluded that saturation of intestinal metallothionein is not a 
major determinant of the observed dosage-dependent absorption of cadmium.   
 
 
 
Although the mechanism involved in the intestinal absorption of cadmium has not been fully elucidated, 
there is evidence that one or more transporter proteins are involved.  Several studies have found evidence 
that divalent metal transporter I protein plays an important role in the gastrointestinal absorption of 
cadmium (Kim et al. 2007; Park et al. 2002; Ryu et al. 2004).  However, studies in knockout mice suggest 
that other transporter proteins are involved with cadmium absorption (Min et al. 2008; Ryu et al. 2004; 
Suzuki et al. 2007).   
In some cases, cadmium bound to metallothionein (as in food) is not absorbed or distributed from the 
gastrointestinal tract as readily as ionic cadmium.  Mice had lower blood and liver cadmium levels from 
oral exposure to cadmium-metallothionein, compared to levels from cadmium chloride exposure for 
comparable doses, but the cadmium-metallothionein resulted in higher kidney cadmium levels.  Sharma et 
al. (1983) reported that human exposure to very high intakes of cadmium during the consumption of 
oysters resulted in increases in whole blood and urine cadmium levels; however, the increase was not 
proportional to the level of intake. 
A higher fraction of inhaled cadmium than ingested cadmium is absorbed.  The total amount of cadmium 
absorbed by the body via the lungs depends on the particle size.  Larger particles are deposited in the 
nasopharyngeal and tracheobronchial airways via impaction, and are largely cleared by mucociliary 
processes, leading to absorption by the gastrointestinal tract.  Smaller particles reach the smaller airways 
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and alveoli, and depending on the particle's solubility, are absorbed and distributed to the rest of the body.  
Solubility in lung fluids plays a role in absorption from the lung into the body of cadmium salts.  
Theoretically, the highly soluble salts, chloride, nitrate, acetate, and sulfate would be expected to give the 
highest blood levels following inhalation exposure to a given air concentration.  The insoluble cadmium 
salts, the various sulfides, should yield the lowest blood level.  The lung, however, is rich in carbon 
dioxide that is continuously transferred from the blood.  Particles of the various cadmium sulfides within 
the lung can react with this carbon dioxide.  Lung tissue may then absorb and transfer solubilized or 
released cadmium ions to the blood.   
 
 
 
No direct data, however, are available on cadmium deposition, retention, or absorption in the human lung.  
Data from animal studies indicate that lung retention is greatest after short-term exposure, 5–20% after 
15 minutes to 2 hours (Barrett et al. 1947; Henderson et al. 1979; Moore et al. 1973; Rusch et al. 1986).  
The initial lung burden declines slowly after exposure ceases (Henderson et al. 1979; Moore et al. 1973; 
Rusch et al. 1986), due to the absorption of cadmium and the lung clearance of deposited particles.  After 
longer periods of inhalation exposure to cadmium, somewhat lower lung retentions are found (Glaser et 
al. 1986).  The absorption of cadmium in the lung differs somewhat among chemical forms, but the 
pattern apparently does not correlate well with solubility in water (Glaser et al. 1986; Rusch et al. 1986).  
Retention of cadmium has been reported to be >40% in rats (Moore et al. 1973), 40% in canines (Friberg 
et al. 1974), and 10–20% in mice (Potts et al. 1950). 
The cadmium levels in cigarettes range from 0.28 to 3.38 μg (Elinder et al. 1985b; Watanabe et al. 1987); 
the mean in 38 U.S. brands was 1.07 μg (Watanabe et al. 1987).  Approximately 10% of the cadmium in 
cigarettes is inhaled (Elinder et al. 1985b).  Based on comparison of cadmium body burdens in human 
smokers and nonsmokers, cadmium absorption from cigarettes appears to be higher than absorptions of 
cadmium aerosols measured in animals (Nordberg et al. 1985).  The chemical form of cadmium in 
cigarette smoke is likely to be similar to that produced by other combustion processes, primarily cadmium 
oxide aerosols.  The greater absorption of cadmium from cigarette smoke is likely due to the very small 
size of particles in cigarette smoke and the consequent very high alveolar deposition (Nordberg et al. 
1985). 
Distribution and Metabolism.    Absorbed cadmium is distributed throughout the body, with the 
highest concentrations found in the liver and kidneys.  Cadmium is not known to undergo direct 
metabolic conversions.  It has a high affinity for the sulfyhydryl groups of albumin and metallothionein 
(Nordberg et al. 1985).  The interaction between cadmium and metallothionein plays a critical role in the 
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toxicokinetics and toxicity, as discussed in Section 3.5.2, of cadmium.  Metallothionein sequesters a large 
fraction of tissue cadmium (Shaikh 1982) and studies in metallothionein transgenic and metallothionein-
null mice suggest that metallothionein influences tissue retention, but may not affect cadmium 
distribution to the liver, kidney, pancreas, or spleen (Liu and Klaassen 1996; Liu et al. 1996; Wong and 
Klaassen 1980a).  Metallothionein turns over with half-lives of 2.8 days in the rat liver and 5 days in the 
kidney (Shaikh and Smith 1976); however, cadmium is retained in both organs bound mainly to 
metallothionein.  It has a retention half-time of 73 days in the liver and a life-time in the kidneys (Shaikh 
1982). 
 
 
 
 
Shaikh et al. (1993) report that disposition of cadmium in mouse liver, kidney, and testes is different for 
different strains, sex, or age.  Different dose levels (i.e., subcutaneous doses in the 5–30 μmol/kg body 
weight range) also altered the disposition.  Liver cadmium levels and metallothionein levels did not 
always correlate with hepatotoxicity.  The difference in the tissue accumulation of cadmium may relate to 
variations in the hormonal or other intrinsic factors that affect cellular uptake of cadmium, subcellular 
distribution of cadmium, or metallothionein metabolism.  
Excretion.    Since a small fraction of the cadmium presented to the gastrointestinal tract is absorbed, 
most of the oral dose is excreted via the feces.  After inhalation exposure to cadmium, the initial lung 
burden of cadmium-laden particles depositing in the nasopharyngeal or central airways will be cleared via 
the mucociliary mechanisms, possibly undergoing a small amount of absorption by the oral route.  The 
remaining cadmium particles will be absorbed in the lung.  Once absorbed cadmium has distributed 
throughout the body (primarily to the liver and kidney), the amounts of fecal and urinary excretion of 
cadmium are approximately equal.  The amount of cadmium in the urine of occupationally exposed 
workers increases proportionally with body burden of cadmium, but the amount of cadmium excreted 
represents only a small fraction of the total body burden unless renal damage is present; in this case, 
urinary cadmium excretion increases markedly (Roels et al. 1981b). 
Klaassen and Kotsonis (1977) evaluated biliary excretion of an intravenous bolus of cadmium chloride in 
the rat, rabbit, and dog.  Marked species variation in biliary excretion was observed with rabbits at about 
1/6th the rate of the rats, and dogs about 1/300th the rate of the rats.  In the rat, the bile/plasma 
concentration ratio of cadmium was highly dose dependent, increasing with higher dose; at 0.1 mg/kg, the 
bile/plasma ratio was 2.6 and at 3.0 mg/kg, the bile/plasma ratio was 133.  The bile/liver concentration 
ratio of cadmium was equal to or much lower than 1 decreasing to <1% for the low dose regimen.   
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3.5.2   Mechanisms of Toxicity  
 
Cadmium is toxic to a wide range of organs and tissues; however, the primary target organs of cadmium 
toxicity are the kidneys; bone and lung (following inhalation exposure) are also sensitive targets of 
toxicity.  Changes in the kidney due to cadmium toxicity have been well established.  Chronic exposure to 
cadmium by the oral or inhalation routes has produced proximal tubule cell damage, proteinuria (mainly 
low-molecular weight proteins, such as β2-microglobulin), glycosuria, amino aciduria, polyuria, 
decreased absorption of phosphate, and enzymuria in humans and in a number of laboratory animal 
species.  The clinical symptoms result from the degeneration and atrophy of the proximal tubules, or (in 
worse cases) interstitial fibrosis of the kidney (Stowe et al. 1972).  Cadmium has been shown to perturb 
lipid composition and enhance lipid peroxidation (Gill et al. 1989b).  Depletion of antioxidant enzymes, 
specifically glutathione peroxidase and superoxide dismutase, has been proposed as the mechanism of 
cadmium’s cardiotoxic effects (Jamall and Smith 1985a), but subsequent studies showed that cardiotoxic 
mechanisms other than peroxidation are also present (Jamall et al. 1989).  Cadmium has been shown to 
alter zinc, iron and copper metabolism (Petering et al. 1979) as well as selenium (Jamall and Smith 
1985b).  Xu et al. (1995) propose that an initiating step in cadmium-induced toxicity to the testes is 
cadmium interference with zinc-protein complexes that control DNA transcription which subsequently 
leads to apoptosis.  Cadmium sequestration by metallothionein (or a chelator in the case of the Xu et al. 
[1995] study) prevents cadmium from disrupting zinc-dependent transcriptional controls. 
 
 
Cardenas et al. (1992a) investigated a cadmium-induced depletion of glomerular membrane polyanions 
and the resulting increased excretion of high-molecular-weight proteins.  Interference with glomerular 
membrane polyanionic charge may precede the tubular damage as a more sensitive and early response to 
cadmium (Roels et al. 1993).  Acute or chronic doses of cadmium have also been reported to reduce 
hepatic glycogen stores and to increase blood glucose levels.  Intralobular fibrosis, cirrhosis, focal 
mononuclear infiltrates, and proliferation of the smooth endoplasmic reticulum are among the nonspecific 
histopathological indicators of cadmium toxicity. 
Cadmium complexed with metallothionein from the liver can redistribute to the kidney (Dudley et al. 
1985).  When metallothionein-bound cadmium is transported to the kidney, it readily diffuses and is 
filtered at the glomerulus, and may be effectively reabsorbed from the glomerular filtrate by the proximal 
tubule cells (Foulkes 1978).  In the kidneys, exogenous metallothionein is degraded in lysosomes and 
released cadmium is sequestered by the endogenous metallothionein as well as other proteins (Cherian 
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and Shaikh 1975; Squibb et al. 1984; Vestergaard and Shaikh 1994).  This non-metallothionein-bound 
cadmium can then induce new metallothionein synthesis in the proximal tubule (Squibb et al. 1984).   
 
 
 
Early work indicated that metallothionein binding decreased the toxicity of cadmium, and the ability of 
the liver to synthesize metallothionein appeared to be adequate to bind all the accumulated cadmium 
(Goyer et al. 1989; Kotsonis and Klaassen 1978).  The rate of metallothionein synthesis in the kidney is 
lower than in the liver (Sendelbach and Klaassen 1988), and is thought to be insufficient, at some point, to 
bind the intrarenal cadmium (Kotsonis and Klaassen 1978).  Renal damage is believed to occur when the 
localization of cadmium, or an excessive concentration of cadmium, is unbound to metallothionein.  
Acute exposure to low levels of cadmium bound to metallothionein produced an intracellular renal 
damage as described above (Squibb et al. 1984), but damage to brush-border membranes of the renal 
tubule has also been reported from metallothionein-bound cadmium (Suzuki and Cherian 1987) 
suggesting other toxic mechanisms may be present.   
Dorian et al. (1992a) evaluated the intra-renal distribution of 109cadmium-metallothionein injected 
(intravenously) into male Swiss mice at a nonnephrotoxic dose (0.1 mg Cd/kg) and concluded that 
cadmium-metallothionein-induced nephrotoxicity might be due, at least in part, to its preferential uptake 
of cadmium-metallothionein into the S1 and S2 segments of the proximal tubules, the site of cadmium-
induced nephrotoxicity.  In a companion study, Dorian et al. (1992b) reported that this preferential renal 
uptake was also observed after administration of various doses of [35S]cadmium-metallothionein.  In 
contrast to the earlier observed persistency of 109cadmium in the kidney after 109cadmium-metallothionein 
administration, however, 35S disappeared rapidly (with a half-life of approximately 2 hours); 24 hours 
after injection of [35S]cadmium-metallothionein, there was very little 35S left in the kidneys.  These 
observations indicate that the protein portion of cadmium-metallothionein is rapidly degraded after renal 
uptake of cadmium metallothionein and that the released cadmium is retained in the kidney. 
The toxic effects and distribution of cadmium were compared after intravenous injection of 109cadmium-
metallothionein at 0.05–1 mg Cd/kg body w eight and 109cadmium chloride at 0.1–3 mg/kg in male Swiss 
mice (Dorian et al. 1995).  Cadmium-metallothionein increased urinary excretion of glucose, and protein 
indicated renal injury, with dosages as low as 0.2 mg Cd/kg.  In contrast, renal function was unaltered by 
cadmium chloride administration, even at dosages as high as 3 mg Cd/kg.  Cadmium-metallothionein 
distributed almost exclusively to the kidney, whereas cadmium chloride preferentially distributed to the 
liver.  However, a high concentration of cadmium was also found in the kidneys after cadmium chloride 
administration (i.e., the renal cadmium concentration after administration of a high but nonnephrotoxic 
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dose of cadmium chloride was equal to or higher than that obtained after injection of nephrotoxic doses of 
cadmium-metallothionein).  Light microscopic autoradiography studies indicated that cadmium from 
cadmium-metallothionein preferentially distributed to the convoluted segments (S1 and S2) of the 
proximal tubules, whereas cadmium from cadmium chloride distributed equally to the various segments 
(convoluted and straight) of the proximal tubules.  However, the concentration of cadmium at the site of 
nephrotoxicity, the proximal convoluted tubules, was higher after cadmium chloride than after cadmium-
metallothionein administration.  A higher cadmium concentration in both apical and basal parts of the 
proximal cells was found after cadmium chloride than after cadmium-metallothionein administration.  
The authors suggest that cadmium-metallothionein is nephrotoxic, and cadmium chloride is not 
nephrotoxic because of a higher concentration of cadmium in the target cells after cadmium-
metallothionein.  Dorian and Klaassen (1995) evaluated the effects of zinc-metallothionein on 
109cadmium-metallothionein renal uptake and nephrotoxicity and concluded that zinc-metallothionein is 
not only nontoxic to the kidney at a dose as high as 5 μmole metallothionein/kg, but it can also protect 
against the nephrotoxic effect of cadmium-metallothionein without decreasing renal cadmium 
concentration.  
 
 
 
To further test the hypothesis that nephrotoxicity produced from chronic cadmium exposure results from a 
cadmium-metallothionein complex, Liu et al. (1998) exposed metallothionein-null mice to a wide range 
of cadmium chloride doses, 6 times/week for up to 10 weeks.  Renal cadmium burden increased with dose 
and duration up to 140 μg Cd/g kidney in control mice (i.e., metallothionein normal) with a 150-fold 
increase in renal metallothionein levels (800 μg metallothionein/g kidney).  Renal cadmium was much 
lower in metallothionein-null mice (10 μg Cd/g), and metallothionein levels were not detectable.  The 
maximum tolerated dose of cadmium (as indicated by routine urinalysis and histopathology measures) 
was approximately 8 times higher in control mice than in metallothionein-null mice.  Lesions were more 
severe in metallothionein-null mice than in controls.   
The critical concentration of cadmium in the renal cortex that is likely to produce renal dysfunction also 
remains a topic of intense investigation.  Whether the critical concentration of urinary cadmium is closer 
to 5 or 10 μg Cd/g creatinine, corresponding to about 100 and 200 μg cadmium/g kidney, respectively, is 
the current focus of the debate.  In one analysis, the critical concentration producing dysfunction in 10% 
of a susceptible population has been estimated to be approximately 200 μg cadmium/g kidney; 50% of the 
susceptible population would experience dysfunction with a kidney concentration of 300 μg/g (Ellis et al. 
1984, 1985; Roels et al. 1983). 
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Studies in humans and animals have demonstrated that the bone is a sensitive target of cadmium toxicity.  
It is likely that cadmium acts by direct and indirect mechanisms, which can lead to decreased bone 
mineral density and increased fractures (Brzóska and Moniuszko-Jakoniuk 2005c, 2005d).  Studies in 
young animals suggest that cadmium inhibits osteoblastic activity, resulting in a decrease in the synthesis 
of bone organic matrix and mineralization (Brzóska and Moniuszko-Jakoniuk 2005d).  The decreased 
osteoblastic activity may also influence osteoclastic activity leading to increased bone resorption.  During 
intense bone growth, effects on osteoblasts result in decreased bone formation; after skeletal maturity, 
cadmium exposure results in increased bone resorption.  Cadmium-induced renal damage can also result 
in secondary effects on bone (Brzóska and Moniuszko-Jakoniuk 2005c).  Cadmium-induced renal damage 
interferes with the hydroxylation of 25-hydroxy-vitamin D to form 1,25-dihydroxy-vitamin D.  Decreased 
serum concentration of 1,25-dihydroxy-vitamin D, along with impaired kidney resorptive function, result 
in calcium and phosphate deficiency (via decreased gastrointestinal absorption and increased calcium and 
phosphate urinary loss).  To maintain calcium and phosphate homeostasis, parathyroid hormone is 
released, which enhances bone resorption. 
 
3.5.3   Animal-to-Human Extrapolations  
 
The effects of cadmium exposure have been studied in humans and in many laboratory animal species.  
The target organs are similar among species, with the kidneys, bone, and lungs (inhalation only) being the 
primary organs for cadmium induced toxicity.  Absorption, distribution, and excretion of cadmium after 
oral and inhalation exposures are roughly similar among species; however, there are some notable 
differences and caveats.  Most estimates of cadmium absorption in animals are somewhat lower than the 
values found from human studies, particularly after prolonged exposure.  Differences in the breathing 
patterns between rats (obligatory nose breathers) and humans (mouth and nose breathers) may also result 
in radically different lung burden patterns (and hence, different absorption profiles) of cadmium particles 
in the lungs.  Many of the common laboratory animals (in particular the mouse and rat) provide useful 
information on the toxic effects of cadmium; due to their relatively short lifespan, however, they may not 
be as useful from a risk assessment point of view in determining the human lifetime effects from inhaling 
cadmium in air, or ingesting it in food and water.  Rates of synthesis and inducibility of metallothionein 
also differ among species, sex, and target organ.   
 
Even within species there can be significant differences in metallothionein synthesis, and these 
differences correlate to the degree of cadmium toxicity observed (e.g., the mouse) (Shaikh et al. 1993).  
The Shaikh et al. (1993) study employed acute exposures.  Strain differences in carcinogenic effects have 
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also been reported for chronic exposures of subcutaneously administered cadmium chloride in male DBA 
and NFS mice.  DBA mice developed lymphomas, while NFS mice developed hepatocellular adenomas 
and carcinomas, and sarcomas at the injection site.  Both strains developed nonneoplastic testicular 
lesions (fibrosis and mineralization) (Waalkes and Rhem 1992). 
 
Metal-metal interactions are also an important factor in cadmium kinetics and toxicity, and organ specific 
metal concentrations and metabolism can differ among species.  It is thought that further development of 
PBPK/PD models will assist in addressing these differences and in extrapolating the animal data to 
support risk assessments in humans. 
 
3.6   TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS  
 
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine 
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors.  However, appropriate 
terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to 
develop a screening program for “...certain substances [which] may have an effect produced by a 
naturally occurring estrogen, or other such endocrine effect[s]...”.  To meet this mandate, EPA convened a 
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine 
disruptors.  In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents.  The terminology endocrine modulators has also been used to 
convey the fact that effects caused by such chemicals may not necessarily be adverse.  Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to 
the health of humans, aquatic animals, and wildlife.  However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist 
in the natural environment.  Examples of natural hormone mimics are the isoflavinoid phytoestrogens 
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992).  These chemicals are derived from plants and are 
similar in structure and action to endogenous estrogen.  Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial, 
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or 
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997a).  Stated differently, such compounds may cause toxicities that 
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are mediated through the neuroendocrine axis.  As a result, these chemicals may play a role in altering, 
for example, metabolic, sexual, immune, and neurobehavioral function.  Such chemicals are also thought 
to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994; 
Giwercman et al. 1993; Hoel et al. 1992). 
 
 
 
 
 
No studies were located regarding endocrine disruption in humans and/or animals after exposure to 
cadmium. 
No in vitro studies were located regarding endocrine disruption of cadmium. 
3.7   CHILDREN’S SUSCEPTIBILITY  
 
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed.  Potential 
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect 
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed. 
Children are not small adults.  They differ from adults in their exposures and may differ in their 
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the 
extent of their exposure.  Exposures of children are discussed in Section 6.6, Exposures of Children. 
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less 
susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993).  Vulnerability often depends on developmental stage.  There are 
critical periods of structural and functional development during both prenatal and postnatal life, and a 
particular structure or function will be most sensitive to disruption during its critical period(s).  Damage 
may not be evident until a later stage of development.  There are often differences in pharmacokinetics 
and metabolism between children and adults.  For example, absorption may be different in neonates 
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants 
and young children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water, and their brains and livers are 
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proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 
1966; Widdowson and Dickerson 1964).  The infant also has an immature blood-brain barrier (Adinolfi 
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975).  Many 
xenobiotic metabolizing enzymes have distinctive developmental patterns.  At various stages of growth 
and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and 
Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the 
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of 
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient 
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly 
relevant to cancer. 
 
 
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per 
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their 
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar 
absorption (NRC 1993). 
Occupational and environmental exposure studies in adults provide strong evidence that the lung 
(inhalation exposure only) and kidneys are sensitive targets of toxicity; it is likely that these effects would 
also be seen in children.  Because cadmium is a cumulative toxin and has a very long half-time in the 
body, exposures to children in even low amounts may have long-term adverse consequences.  Average 
cadmium concentrations in the kidney are near zero at birth, and rise roughly linearly with age to a peak 
(typically around 40–50 μg/g wet weight) between the ages of 50 and 60 years, after which kidney 
concentrations plateau or decline (Chung et al. 1986; Hammer et al. 1973; Lauwerys et al. 1984).  There 
are limited data on the renal toxicity of cadmium in children.  One study found significant associations 
between urinary and blood cadmium levels with urinary levels of NAG and retinol binding protein (de 
Burbure et al. 2006); however, the investigators cautioned that the early response observed in this group 
of children exposed to elevated levels of cadmium (and other metals) may reflect an early renal response 
that may be adaptive and/or reversible.  Another study (Trzcinka-Ochocka et al. 2004) found higher 
urinary concentrations of β2-microglobulin and retinol binding protein in a population exposed to high 
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levels of cadmium starting in childhood as compared to a group only exposed as adults even though 
urinary cadmium levels were lower (statistical comparisons of urinary cadmium levels were not made 
between the groups).  These data suggest that adults exposed to cadmium as children may be more 
susceptible to the renal toxicity of cadmium than persons only exposed as adults.  This is supported by the 
findings of Jacquillet et al. (2007) of renal damage in mature rats exposed to cadmium via gestation and 
lactation. 
 
 
There are epidemiological data suggesting that the bone is also a sensitive target of cadmium toxicity 
(Åkesson et al. 2005; Alfvén et al. 2000, 2002a, 2004; Aoshima et al. 2003; Jin et al. 2004b; Nordberg et 
al. 2002; Staessen et al. 1999; Wang et al. 2003; Zhu et al. 2004).  Epidemiology studies suggest that the 
elderly may be more susceptible than younger adults; however, no studies examined childhood exposure.  
Animal studies suggest that young animals are more susceptible than adult or elderly animals (Ogoshi et 
al. 1989). 
A potential for cadmium to have adverse neurological effects is an important consideration.  However, 
only a few studies have reported an association between environmental cadmium exposure and 
neuropsychological functioning.  End points that were affected included verbal IQ in rural Maryland 
children (Thatcher et al. 1982), and acting-out and distractibility in rural Wyoming children (Marlowe et 
al. 1985).  The usefulness of the data from these studies is limited, however, because of the potential 
confounding effects of lead exposure; lack of control for other possible confounders including home 
environment, caregiving, and parental IQ levels; and inadequate quantification of cadmium exposure (i.e., 
the studies used hair cadmium as an index of exposure, which has some limitations because of potential 
confounding from exogenous sources).  Several animal studies have reported alterations in performance 
on neurobehavioral tests in rats exposed to cadmium via gestation and lactation (Ali et al. 1986; Baranski 
et al. 1983; Desi et al. 1998; Nagymajtenyi et al. 1997).  Several studies have examined the possible 
association between cadmium exposure and newborn birth weight, and most reliable studies have not 
found a significant association (Galicia-García et al. 1997; Mokhtar et al. 2002; Nishijo et al. 2002, 
2004b; Zhang et al. 2004).  Animal studies have found significant decreases in body weight or skeletal 
anomalies or malformations in the offspring of rats exposed to high doses of cadmium (Ali et al. 1986; 
Baranski 1985, 1987; Gupta et al. 1993; Kelman et al. 1978; Kostial et al. 1993; Machemer and Lorke 
1981; Petering et al. 1979; Pond and Walker 1975; Schroeder and Mitchener 1971; Sorell and Graziano 
1990; Sutou et al. 1980; Webster 1978; Whelton et al. 1988).  
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Oral cadmium exposure has also been reported to suppress the T-lymphocyte and macrophage-dependent 
humoral immune response of 6-week-old mice against sheep red blood cells (Blakley 1985), but not of 
12-month-old mice (Blakley 1988).  The investigators cautioned that “natural” age-related immune 
system dysfunction may have masked any cadmium suppressive effect. 
 
 
 
Children are most likely to be exposed to cadmium in food or water.  Most ingested cadmium passes 
through the gastrointestinal tract without being absorbed.  In adults, only about 1/20 of the total ingested 
cadmium (in food or water) is absorbed (McLellan et al. 1978, Rahola et al. 1973; Shaikh and Smith 
1980).  The retention of cadmium in the gut slowly decreases over a period of 1–3 weeks after ingestion 
in adults (Rahola et al. 1973).  The absorption of cadmium in rats depends on age, with measured 
absorption decreasing from 12 to 5 to 0.5% at 2 hours, 24 hours, and 6 weeks after birth, respectively 
(Sasser and Jarboe 1977).  Sasser and Jarboe (1980) also reported that absorption of cadmium in the 
gastrointestinal tract of young guinea pigs was 20-fold higher than in adult guinea pigs. 
Tissue distribution and retention of cadmium differed between 4- and 70-day-old rats.  Cadmium was 3–
6 times more concentrated in the newborn spleen, bone, brain, testes, and muscle than in the adult rat 
2 hours after an intravenous administration of 1 mg Cd/kg body weight.  Liver concentration of 
metallothionein was 20 times greater in the newborn than in the adult; kidney metallothionein concen-
trations were comparable, but liver cadmium was only 30% higher and kidney cadmium was 50% higher 
in the newborn.  Nineteen days post-cadmium exposure, the retention of cadmium in the liver, kidney, 
and lung was similar in both the newborn and the adult rat (Wong and Klaassen 1980a).  Goering and 
Klaassen (1984b) report that high levels of metallothionein in 10-day-old rats play an important role in 
their resistance to liver damage, presumably by binding and retaining cadmium.  However, the tissue 
distribution data led Wong and Klaassen (1980a) to propose that metallothionein does not play a major 
role in the tissue distribution and retention of cadmium in the young. 
Cadmium can be transferred to offspring in breast milk.  Cadmium levels in human milk are 5–10% of 
levels in blood, possibly due to inhibited transfer from blood because of metallothionein binding of 
cadmium in blood cells (Radisch et al. 1987).  A significant association between urinary cadmium levels 
and cadmium levels in breast milk was found in women environmentally exposed to cadmium (Nishijo et 
al. 2002).  In female outbred albino rats exposed to cadmium in drinking water (as cadmium chloride) at 
0 or 4.8 mg/kg/day for 10 weeks (at 4 weeks prior to mating, 3 weeks of gestation, or 3 weeks into 
lactation), kidney concentrations exceeded liver concentrations, while in their pups, the renal and liver 
concentrations were similar at all times during exposure.  In pups, both hepatic and renal cadmium 
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concentrations considerably increased only during the second half of the lactation period (Ld 11–21).  The 
cadmium tissue concentrations in dams were several orders higher than in offspring.  Another study found 
a positive correlation between cadmium levels in breast milk and cadmium levels in the pups’ kidneys in 
rats receiving an intravenous injection of cadmium on lactation days 3–16 (Petersson Grawé and 
Oskarsson 2000).   
 
 
Although studies on elimination of cadmium from the tissues of children are not available, the results of 
studies in animals provide some insight.  Most cadmium that is ingested or inhaled and transported to the 
gut via mucociliary clearance is excreted in the feces.  Of the cadmium that is absorbed into the body, 
most is excreted very slowly, with urinary and fecal excretion being approximately equal (Kjellström and 
Nordberg 1978).  Half-times for cadmium in the whole body of mice, rats, rabbits, and monkeys have 
been calculated to be from several months up to several years (Kjellström and Nordberg 1985).  Half-
times in the slowest phase were 20–50% of the maximum life span of the animal (Kjellström and 
Nordberg 1985).  In the human body, the main portion of the cadmium body burden is found in the liver 
and kidney and in other tissues (particularly muscle, skin, and bone).  After reviewing the literature, 
Kjellström and Nordberg (1985) developed a range of half-times from their kinetic model of between 
6 and 38 years for the human kidney and between 4 and 19 years for the human liver.  These high values 
indicate the persistence of cadmium in the body and the importance of minimizing exposures in children 
to prevent long-term accumulation and toxicity. 
The placenta may act as a partial barrier to fetal exposure to cadmium.  Cadmium concentration has been 
found to be approximately half as high in cord blood as in maternal blood in several studies including 
both smoking and nonsmoking women (Kuhnert et al. 1982; Lauwerys et al. 1978; Truska et al. 1989).  
Accumulation of cadmium in the placenta at levels about 10 times higher than maternal blood cadmium 
concentration has been found in studies of women in Belgium (Roels et al. 1978) and the United States 
(Kuhnert et al. 1982); however, in another study in Czechoslovakia, the concentration of cadmium in the 
placenta was found to be less than in either maternal or cord blood (Truska et al. 1989).  In mice orally 
exposed to cadmium during pregnancy, maternal blood, placental, and fetal cadmium concentrations were 
essentially equal among control animals (with environmental cadmium exposure), but placental 
concentration increased with cadmium dose much more rapidly than either maternal blood or fetal 
cadmium concentration (Sorell and Graziano 1990).  Thus, timing and level of cadmium exposure may 
influence the uptake of cadmium by the placenta, perhaps explaining the conflicting human studies.   
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Of particular importance to the toxicokinetics and toxicity of cadmium is its interaction with the protein 
metallothionein.  Metallothionein is a low-molecular-weight protein, very rich in cysteine, which is 
capable of binding as many as seven cadmium atoms per molecule and is inducible in most tissues by 
exposure to cadmium, zinc, and other metals (Waalkes and Goering 1990).  Metallothionein binding 
decreases the toxicity of cadmium (Goyer et al. 1989; Kotsonis and Klaassen 1978).  Goyer and Cherian 
(1992) localized metallothionein in full-term human placenta and in fetal cells in human placenta.  
Metallothionein was present in trophoblasts (which facilitate transport of substances entering the placenta 
from the maternal blood), Hofbauer cells (motile macrophages capable of phagocytosis and protein 
ingestion), amniotic epithelial cells (fetal derivatives), and decidual cells (endometrial stromal cells that 
have been transformed under hormonal influence into large pale cells, rich in glycogen).  The mechanism 
by which the placenta transports the essential metals, copper and zinc, while limiting the transport of 
cadmium is unknown, but may involve the approximately 1,000-fold higher concentration of zinc in the 
placenta and the higher affinity of cadmium than zinc for metallothionein.  
 
 
Chan and Cherian (1993) report that pregnancy in Sprague-Dawley rats previously administered cadmium 
chloride (1.0 mg Cd/kg body weight subcutaneously, daily for 8 days) leads to a mobilization of cadmium 
from the liver (40% decrease compared to nonpregnant cadmium treated controls) and an increase in the 
kidneys (60% increase).  A similar pattern is seen for metallothionein.  Plasma cadmium and 
metallothionein also increased in the pregnant group.  Placental cadmium increased in the cadmium-
treated rats compared to the untreated controls.  In this rat model, then, pregnancy resulted in a transfer of 
hepatic cadmium and metallothionein via the blood to the kidney and placenta. 
 
3.8   BIOMARKERS OF EXPOSURE AND EFFECT  
 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples.  They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 
1989).   
The National Report on Human Exposure to Environmental Chemicals provides an ongoing assessment 
of the exposure of the U.S. population to environmental chemicals using biomonitoring.  This report is 
available at http://www.cdc.gov/exposurereport/.  The biomonitoring data for cadmium from this report is 
discussed in Section 6.5.  A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the 
product of an interaction between a xenobiotic agent and some target molecule(s) or cell(s) that is 
measured within a compartment of an organism (NAS/NRC 1989).  The preferred biomarkers of exposure 
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are generally the substance itself, substance-specific metabolites in readily obtainable body fluid(s), or 
excreta.  However, several factors can confound the use and interpretation of biomarkers of exposure.  
The body burden of a substance may be the result of exposures from more than one source.  The 
substance being measured may be a metabolite of another xenobiotic substance (e.g., high urinary levels 
of phenol can result from exposure to several different aromatic compounds).  Depending on the 
properties of the substance (e.g., biologic half-life) and environmental conditions (e.g., duration and route 
of exposure), the substance and all of its metabolites may have left the body by the time samples can be 
taken.  It may be difficult to identify individuals exposed to hazardous substances that are commonly 
found in body tissues and fluids (e.g., essential mineral nutrients such as copper, zinc, and selenium).  
Biomarkers of exposure to cadmium are discussed in Section 3.8.1. 
 
 
 
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989).  This definition encompasses biochemical or cellular signals of 
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial 
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung 
capacity.  Note that these markers are not often substance specific.  They also may not be directly 
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused 
by cadmium are discussed in Section 3.8.2. 
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability 
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or 
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response.  If biomarkers of susceptibility exist, they are 
discussed in Section 3.10, Populations That Are Unusually Susceptible. 
3.8.1   Biomarkers Used to Identify or Quantify Exposure to Cadmium 
 
Cadmium levels in blood, urine, feces, liver, kidney, hair, and other tissues have been used as biological 
indicators of exposure to cadmium.  A discussion of the utility and limitations of each for human 
biomonitoring is provided below. 
 
Blood cadmium levels are principally indicative of recent exposure(s) to cadmium rather than whole-body 
burdens (Ghezzi et al. 1985; Järup et al. 1988; Lauwerys et al. 1994; Roels et al. 1989).  The 50th 
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percentile of blood cadmium concentrations in adults living in the United States was 0.330 μg/L (CDC 
2011).  Environmental exposure can elevate blood cadmium concentration to above 10 μg/L (Kido et al. 
1990a, 1990b; Shiwen et al. 1990).  Workers occupationally exposed to cadmium by inhalation may have 
blood cadmium levels ranging up to 50 μg/L (Roels et al. 1981b).   
 
 
 
Urine cadmium levels primarily reflect total body burden of cadmium, although urine levels do respond 
somewhat to recent exposure (Bernard and Lauwerys 1986).  Use of a biokinetic model, such as the 
Nordberg-Kjellström model, allows estimation of cadmium dietary consumption or airborne cadmium 
levels from urinary cadmium levels; these models are described in greater detail in Section 3.4.5.3.  When 
the critical level for renal damage has been reached, urinary cadmium levels rise sharply because of the 
release of intrarenal cadmium along with decreased renal reabsorption of cadmium (Lauwerys et al. 1994; 
Roels et al. 1981b).  In the U.S. general population, the geometric mean urinary cadmium level in adults 
is 0.232 μg/L (or 0.247 μg/g creatinine) (CDC 2011).  In populations with substantial environmental or 
occupational exposure, values can range up to 50 μg/g creatinine, (Falck et al. 1983; Roels et al. 1981b; 
Tohyama et al. 1988).  In environmentally exposed individuals, Buchet et al. (1990) report that abnormal 
values of various biomarkers are found in 5% of the population with urinary excretion of cadmium above 
the 2–4 μg Cd/24 hour level (approximately 1–3 μg/g creatinine).  Significant correlations between total 
cadmium exposure and urinary cadmium levels have been found in environmentally exposed populations 
(Kido et al. 2004; Kobayashi et al. 2005; Shimbo et al. 2000).  Among environmentally exposed subjects, 
there was good agreement between urinary cadmium levels measured at different times, suggesting that a 
single determination would be an accruement measure (Ikeda et al. 2005a).   
Fecal cadmium may be used as a direct indicator of daily dietary intake of cadmium because dietary 
cadmium is poorly absorbed in the gastrointestinal tract (Kjellström et al. 1978).  In workers exposed by 
inhalation, fecal cadmium has been used to estimate the amount of inhaled cadmium transported to the 
gastrointestinal tract and the amount of dust ingested incidentally at work (Adamsson et al. 1979).  Fecal 
cadmium primarily reflects recently ingested cadmium and, therefore, is not a good indicator of past 
cadmium exposure (Shaikh and Smith 1984). 
Liver and kidney tissues preferentially accumulate cadmium, and concentrations of cadmium in liver and 
kidney may be measured using non-invasive techniques such as in vivo neutron activation analysis or in 
the kidney by X-ray fluorescence analysis (Christoffersson et al. 1987; Scott and Chettle 1986); however, 
the limit of detection is near background levels (Nordberg 2010).  Levels in both tissues increase with age 
and level of cadmium exposure, but kidney cadmium concentration tends to peak around age 50–60, 
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while liver cadmium concentration continues to rise.  Typical values for a 60-year-old North American 
with average environmental cadmium exposure are 25–40 μg/g wet weight in kidney cortex and 1–3 μg/g 
wet weight in liver (Elinder 1985b).  In workers exposed to cadmium by inhalation, values up to 300 μg/g 
wet weight in kidney and 100 μg/g wet weight in liver can be found (Christoffersson et al. 1987; Roels et 
al. 1981b).  Because kidney cadmium content begins to decline after the onset of cadmium-induced renal 
dysfunction, liver cadmium may be a better indicator of cadmium exposure than kidney cadmium, and it 
has been suggested that kidney dysfunction is likely to appear at liver cadmium concentrations between 
30 and 60 μg/g wet weight (Roels et al. 1981b).  In vivo liver and kidney cadmium measurements 
involving neutron activation analysis or X-ray fluorescence require complex and costly equipment and 
may pose a radiation hazard (Shaikh and Smith 1984), and those involving biopsy specimens (Lindqvist 
et al. 1989) require a painful and invasive procedure.  Therefore, these methods for in vivo analysis are 
better suited for monitoring of occupationally exposed workers than environmentally exposed populations 
(Scott and Chettle 1986).  Among cadmium workers, significant correlations of kidney cadmium levels 
with urinary and blood cadmium levels and liver cadmium with urinary cadmium levels were found 
(Börjesson et al. 1997, 2001).  Similar correlations (urinary cadmium with renal cadmium) in an autopsy 
study of subjects without occupational exposure to cadmium; a urinary cadmium level of 1.7 μg/g 
creatinine was equivalent to a renal cadmium level of 50 μg/g (Orlowski et al. 1998). 
 
 
Hair levels of cadmium have been used as a measure of cadmium exposure, although the possibility of 
exogenous contamination has led to substantial controversy concerning the reliability of hair levels as a 
measure of absorbed dose (Frery et al. 1993; Huel et al. 1984; Lauwerys et al. 1994, Shaikh and Smith 
1984; Wilhelm et al. 1990).  Recent evidence has shown a correlation between cadmium levels in the hair 
of newborn infants and their mothers (Huel et al. 1984) and between cadmium levels in scalp and pubic 
hair (Wilhelm et al. 1990), indicating that among environmentally exposed populations, external 
contamination may not be significant for hair samples taken close to the scalp.  Under occupational 
conditions, external contamination may be a more substantial problem (Shaikh and Smith 1984).   
On the other hand, Frery et al. (1993) evaluated hair levels in a male population with a high expected 
exposure to tobacco smoke and in a population of pregnant woman and their newborns; they concluded 
that cadmium hair analysis was a reliable indicator for the subjects with the highest exposure, but was not 
sensitive enough to resolve differences for low level exposures.  Newborn cadmium hair levels were a 
more sensitive indicator than mother’s hair, but the research was not able to determine if this was 
attributable to physiological changes or the lower reliability of the mother’s head hair.  Exogenous 
contamination is not considered a problem for newborn hair.  The authors state that the variability 
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introduced by exogenous contamination can be minimized by using the first 8 cm of hair from the scalp 
and by using careful washing techniques.  There was also no significant difference between hair levels for 
passive or nonsmokers indicating that either the above mentioned precautions worked or that the passive 
smoke source of exposure was not significant.  
 
 
 
Cadmium measurements have been made on a variety of other biological materials, including milk 
(Schulte-Lobbert and Bohn 1977; Sikorski et al. 1989), placenta (Kuhnert et al. 1982; Roels et al. 1978; 
Saaranen et al. 1989), nails (Takagi et al. 1988), teeth (Sharon 1988), and cataractous lenses (Racz and 
Erdohelyi 1988).  Although in some cases it could be established that levels in these tissues were higher 
among smokers than nonsmokers, the significance of cadmium levels as a marker of recent or total 
cadmium exposure has not been established for any of these tissues. 
Studies in cadmium workers suggest that metallothionein levels may also be a biomarker of cadmium 
exposure.  Elevated levels of metallothionein gene expression were observed in peripheral blood 
lymphocytes in highly exposed workers.  The level of metallothionein gene expression was significantly 
correlated with blood and urinary cadmium levels (Lu et al. 2001).  Urinary metallothionein correlates 
with cadmium concentrations in liver, kidney, and urine (Shaikh and Smith 1984; Tohyama et al. 1981).  
Relatively strong correlations have been found between urinary metallothionein and urinary cadmium 
levels in exposed humans (Kawada et al. 1990), and a dose-related increase in urinary metallothionein 
was found in rats exposed to cadmium in drinking water for up to 2 years (Shaikh et al. 1989).  Hochi et 
al. (1995) also found a significant relationship between cadmium intake and urinary metallothionein 
levels among residents consuming cadmium-contaminated rice.   
 
3.8.2   Biomarkers Used to Characterize Effects Caused by Cadmium 
 
Acute inhalation exposure to high levels of cadmium causes respiratory damage and may lead to death.  
No information was located on biomarkers of respiratory effects in humans, but based on animal 
experiments, activity of alkaline phosphatase in the surfactant fraction of BALF has been suggested as a 
sensitive marker of pulmonary damage following acute cadmium inhalation (Boudreau et al. 1989).  Such 
a biomarker of effect is not specific to cadmium exposure and would be most relevant to occupational 
exposures. 
Renal dysfunction, usually first manifested as impaired tubular reabsorption of filtered solutes, is 
generally considered the primary toxic effect of chronic cadmium exposure (see Section 3.2).  Impaired 
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kidney function has been measured by increased levels of solutes (proteins, amino acids, uric acid, 
calcium, copper, phosphorous, etc.) in urine and/or serum.  Excess urinary excretion of low-molecular-
weight proteins and solutes is associated with decreased tubular reabsorption.  Increased excretion of 
high-molecular-weight proteins or decreased serum clearance of creatinine reflect glomerular 
dysfunction, which is generally associated with progressive renal damage (Roels et al. 1989).  A brief 
discussion of the utility and limitations of several measures of tubular damage as biomarkers of effects of 
cadmium exposure is provided below.  These biomarkers are normally found in the urine and elevated 
levels are not specific for cadmium. 
 
 
 
 
Urinary β2-microglobulin, a low molecular weight protein, has been widely used as an indicator of 
tubular renal dysfunction (Arisawa et al. 1997; Piscator 1984; Roels et al. 1981a; Smith et al. 1980).  
However, tubular renal dysfunction can be caused by exposures and diseases other than cadmium, so 
β2-microglobulin is not a specific marker of cadmium-induced effects (Shaikh and Smith 1984).  
Practical considerations in using urinary β2-microglobulin as a marker of tubular renal dysfunction 
include the need to control the pH of samples to prevent the rapid degradation that occurs at pH values 
below 5.5 (Shaikh and Smith 1984), and the fact that urinary β2-microglobulin excretion normally rises 
with age (Roels et al. 1989). 
Urinary retinol-binding protein is also considered to be a sensitive indicator of decreased tubular 
reabsorption, but it also is not specific for cadmium-induced damage in the kidney (Shaikh and Smith 
1984; Topping et al. 1986).  Retinol-binding protein is more stable in urine than β2-microglobulin 
(Bernard and Lauwerys 1981) and appears to be of approximately equal sensitivity and specificity for 
detecting tubular proteinuria in cadmium-exposed populations (Topping et al. 1986).  Levels of both 
proteins fluctuate over time, so regular, repeated sampling may be necessary to establish abnormal levels 
(Ormos et al. 1985). 
Human complex-forming glycoprotein (pHC, also referred to as α1-microglobulin) is another sensitive 
marker of tubular renal dysfunction (Moriguchi et al. 2004, 2005a; Pless-Mulloli et al. 1998; Tohyama et 
al. 1986).  As with retinol binding protein, pHC is more stable in urine than β2-microglobulin at room 
temperature and low urinary pH levels.   
Urinary N-acetyl-β-D-glucosaminidase (NAG), a lysosomal enzyme present in high concentrations in the 
proximal tubule, has been shown to correlate with urinary cadmium levels in occupationally and 
environmentally exposed subjects (Jin et al. 1999; Kalahasthi et al. 2007) and has a better correlation with 
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urinary cadmium levels than does β2-microglobulin at low cadmium exposure levels (urinary cadmium 
<10 μg/g creatinine) (Chia et al. 1989; Kawada et al. 1990; Mueller et al. 1989).  However, increased 
urinary NAG activity can result from effects other than nephrotoxicity (Bernard and Lauwerys 1989).  Jin 
et al. (1999) suggest that measurement of the B isozyme (NAG-B), which is released into the urine 
following tubular cell breakdown, may be a sensitive measure of renal damage. 
 
 
 
Other enzymes, proteins, and amino acids in urine have been suggested as biological markers of incipient 
renal or liver damage resulting from cadmium exposure.  Markers found to be sensitive indicators in 
exposed humans include trehalase (Iwata et al. 1988), alanine aminopeptidase (Mueller et al. 1989), and 
calcium (Buchet et al. 1990).  Changes in urinary alkaline phosphatase, γ-glutamyl transferase, urate, and 
phosphate tend to be significant only after other markers of renal damage are clearly elevated (Mason et 
al. 1988).  Several other enzymatic markers of cadmium-induced renal damage have been suggested 
based on animal studies (Bomhard et al. 1984; Gatta et al. 1989; Girolami et al. 1989).  Aminoaciduria 
has been found to be more sensitive than proteinuria for renal damage in animal studies (Nomiyama et al. 
1975), but less sensitive in humans (Axelsson and Piscator 1966).  Recent work by Prozialeck et al. 
(2007) suggest that kidney injury molecule 1 may be a sensitive marker for renal dysfunction.  At present, 
not enough information is available to determine which, if any, of these parameters provide sensitive and 
specific indicators of cadmium-induced renal damage. 
At the present time, there is no single biological indicator for cadmium toxicity that is entirely adequate 
when considered alone.  Measurement of cadmium levels in various biological materials can provide an 
indication of recent or total cadmium exposure, but the probability of adverse effects cannot be reliably 
predicted except at high exposure levels.  Measurement of a variety of markers of renal dysfunction can 
provide a sensitive measure of early kidney toxicity, but cannot establish whether cadmium exposure was 
the cause. 
There is also considerable controversy as to whether the critical concentration of urinary cadmium is 
closer to 5 or 10 μg Cd/g creatinine, corresponding to about 100 and 200 ppm in the kidney, respectively.  
Roels et al. (1993) correlated a number of markers with cadmium in blood and urine in a study population 
of workers occupationally exposed to cadmium from cadmium smelting operations.  Three main 
groupings of thresholds were identified corresponding with different markers of effects: one around 2 μg 
Cd/g creatinine mainly associated with biochemical alterations (increased urinary 6-keto-prostaglandin 
F1x and urinary sialic acid), a second around 4 μg Cd/g creatinine associated with increased excretion of 
high molecular weight proteins (possibly due to disruption of the glomerular membrane polyanionic 
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charge) and tubular antigens or enzymes (BBA, NAG), and a third around 10 μg Cd/g creatinine 
associated with increased excretion of low molecular weight proteins and other indicators.  The 10 μg 
Cd/g creatinine level had previously been proposed as the biological threshold for cadmium-induced 
nephropathy.  Whether the earlier changes are indicative of irreversible adverse renal effects remains an 
area of continued investigation.  
 
 
 
To further evaluate the reversibility of proteinuria, Roels et al. (1997) studied the progression of 
cadmium-induced renal tubular dysfunction in cadmium workers according to the severity of the 
microproteinuria at the time the exposure was substantially decreased.  A total of 32 cadmium male 
workers were divided into two groups on the basis of historical records of urinary cadmium concentration 
(CdU) covering the period until 1984.  The workers with CdU values of >10 μg Cd/g creatinine were 
subdivided further on the basis of the urinary concentration of β2-microglobulin (β2-MG-U) measured 
during the first observation period (1980–1984).  In each group, the tubular microproteinuria as reflected 
by β2-MG-U and the concentration of retinol-binding protein in urine as well as the internal cadmium 
dose as reflected by the concentration of cadmium in blood and urine were compared between the first 
and second (1990–1992) observation periods.  Increased microproteinuria was often diagnosed in cases 
with CdU values of >10 μg Cd/g creatinine.  The progression of tubular renal function was found to 
depend on the extent of the body burden of cadmium (as reflected by CdU) and the severity of the initial 
microproteinuria at the time high cadmium exposure was reduced or ceased.  When cadmium exposure 
was reduced and β2-MG-U did not exceed the upper reference limit of 300 μg/g creatinine, the risk of 
developing tubular dysfunction at a later stage was likely to be low, even in cases with historical CdU 
values occasionally >10 but always <20 μg Cd/g creatinine.  When the microproteinuria was mild 
(β2-MG-U >300 and ≤1,500 μg/g creatinine) at the time exposure was reduced, and the historical CdU 
values had never exceeded 20 μg Cd/g creatinine, there was indication of a reversible tubulotoxic effect 
of cadmium.  When severe microproteinuria (β2-MG-U >1,500 μg/g creatinine) was diagnosed in 
combination with historical CdU values exceeding 20 μg Cd/g creatinine, Cd-induced tubular dysfunction 
was progressive in spite of reduction or cessation of cadmium exposure. 
For more information on biomarkers for renal and hepatic effects of chemicals see Agency for Toxic 
Substances and Disease Registry Subcommittee Report on Biological Indicators of Organ Damage 
(Agency for Toxic Substances and Disease Registry 1990a).  For information on biomarkers for 
neurological effects see OTA (1990). 
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3.9   INTERACTIONS WITH OTHER CHEMICALS  
 
Cadmium toxicity can be influenced by a wide variety of other chemicals.  In humans, dietary 
deficiencies of calcium, protein, and vitamin D are likely to account for increased susceptibility to bone 
effects following cadmium exposure (Kjellström 1986c).  Iron deficiency has been shown to increase 
gastrointestinal absorption of cadmium in humans (Flanagan et al. 1978), while oral zinc supplementation 
has been demonstrated to decrease the oral absorption of cadmium.  No other information was located 
concerning interaction of cadmium with other chemicals in humans. 
 
 
 
In animals, a few interactions following inhalation exposure have been evaluated.  In rats exposed to 
cadmium chloride by inhalation, simultaneous exposure to zinc oxide prevents fatalities (Oldiges and 
Glaser 1986) and lung cancer (Oldiges et al. 1989).  Exposure to an atmosphere containing 80% oxygen 
aggravated pulmonary damage from cadmium chloride inhalation in mice (Martin and Witschi 1985). 
The toxicity of oral exposure to cadmium in animals has been shown to be influenced by several factors.  
In Japanese quail, cadmium toxicity was intensified by single or combined deficiencies of zinc, copper, 
iron, calcium, and protein (Fox et al. 1979).  A calcium-deficient diet in animals has been shown to 
aggravate cadmium immunotoxicity (Chopra et al. 1984) and fetotoxicity (Pond and Walker 1975).  
Simultaneous exposure to lindane increased the developmental toxicity of cadmium in rats (Saxena et al. 
1986).  Female rats have an increased susceptibility to cadmium-induced bone loss due to multiple rounds 
of gestation and lactation (Bhattacharyya et al. 1988b) or ovariectomy (Bhattacharyya et al. 1988c), 
possibly related to associated effects on trace element status.  Hopf et al. (1990) report that exposure to 
ethanol and cadmium in a liquid diet produced liver damage in rats at doses that were not separately 
hepatotoxic.  In contrast, Kershaw et al. (1990) reported that ethanol pretreatment in male Sprague-
Dawley rats substantially reduced the lethal and hepatotoxic properties of cadmium, possibly due to a 
reduced interaction between cadmium and target sites in liver organelles and cytosolic high-molecular-
weight (HMW) proteins.  Ethanol pretreatment in this study decreased (approximately 60%) the content 
of cadmium in nuclei, mitochondria, and endoplasmic reticulum, and nearly eliminated the association of 
cadmium with cytosolic HMW proteins.  Reduction in the concentration of cadmium in potential target 
sites of intoxication was caused by a metallothionein-promoted sequestration of cadmium to the cytosol. 
When cadmium is co-administered with ethanol in rats, there is a pronounced increase in cadmium 
accumulation in various regions of the brain (e.g., the corpus striatum and cerebral cortex).  The cadmium 
is not bound to metallothionein, and there is a marked increase in lipid peroxidation and inhibition of 
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membrane bound enzymes (Pal et al. 1993a, 1993b).  Rats pretreated with acetaminophen are more 
sensitive to the renal toxicity of cadmium in water (Bernard et al. 1988a).  Co-administration of lead and 
cadmium in the diet of rats had additive effects in reducing body weights, but neurologic toxicity was 
antagonized (Nation et al. 1990). 
 
 
 
Numerous interactions have been demonstrated in animals using parenteral exposure, generally indicating 
that induction of metallothionein by pretreatment with zinc, selenium, or other metals, reduces toxicity of 
parenteral cadmium exposure (Gunn et al. 1968a, 1968b; Naruse and Hayashi 1989; Yamane et al. 1990).  
Zinc, calcium, or magnesium can prevent injection site, testicular, and prostatic cancers induced by 
subcutaneous or intramuscular injection of cadmium, but these interactions have been shown to be a 
complex phenomenon, dependent on dose, route, and target organ (Poirier et al. 1983; Waalkes et al. 
1989).  Mn(II) pretreatment reduces Cd(II)-induced lethality (Goering and Klaassen 1985).  Cadmium has 
been noted to have an inhibitory effect on manganese uptake (Gruden and Matausic 1989).  In addition, 
manganese appears to be capable of increasing the synthesis of the metal-binding protein metallothionein 
(Waalkes and Klaassen 1985).  Data from a study by Goering and Klaasen (1985) suggest that manganese 
pretreatment increases the amount of Cd+2 bound to metallothionein, thereby decreasing hepatotoxicity 
due to unbound Cd+2.  The significance of these observations to humans exposed to cadmium and 
manganese by the oral or inhalation routes is not clear.  
Induction of hepatic metallothionein by cold stress reduced the acute toxicity of cadmium given by 
gavage to mice (Baer and Benson 1987).  In addition to effects on metallothionein induction, substances 
may interact with cadmium by altering the competition among metal ions for enzyme or regulatory 
protein binding sites.  For example, simultaneous administration of garlic (which is high in reduced 
sulfhydryl groups) decreases oral cadmium renal toxicity in rats (Cha 1987). 
Coexposure to selenium reduced the clastogenic effect of cadmium on mouse bone marrow (Mukherjee et 
al. 1988b).  Selenium deficiency enhances cadmium-induced cardiotoxicity possibly mediated via lipid 
peroxidation indicated by a significant reduction in the activities of the selenoenzyme, glutathione 
peroxidase.  Selenium supplements in the diet prevented cadmium’s cardiotoxic effect (Jamall and Smith 
1985a).  Selenium has also been shown to prevent testicular damage in rats (Kar et al. 1960; Omaye and 
Tappel 1975).  In testes, selenium as selenite given before or during cadmium administration was shown 
to divert the binding of cadmium from low molecular proteins to higher molecular weight proteins (Chen 
et al. 1975; Whanger 1992).  In contrast, Jamall and Smith (1985c) report a shift in cadmium binding 
from metallothionein to lower weight proteins in kidney and liver from a diet supplemented with 
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selenium compared to a selenium deficient diet.  The selenium-cadmium interaction thus appears to be 
dependent on the duration and sequence of coexposure and possibly the organ-specific levels of 
selenoenzymes or other essential metals. 
 
3.10   POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE  
 
A susceptible population will exhibit a different or enhanced response to cadmium than will most persons 
exposed to the same level of cadmium in the environment.  Reasons may include genetic makeup, age, 
health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke).  These 
parameters result in increased absorption, reduced detoxification or excretion of cadmium, or 
compromised function of organs affected by cadmium.  Populations who are at greater risk due to their 
unusually high exposure to cadmium are discussed in Section 6.7, Populations with Potentially High 
Exposures. 
 
Differences in individual sensitivity to cadmium have not been systematically studied, but based on what 
is known about cadmium toxicity, some inferences can be made.  Populations with depleted stores of 
calcium, iron, or other dietary components due to multiple pregnancies and/or dietary deficiencies could 
be expected to have increased cadmium absorption from the gastrointestinal tract.  Urinary cadmium 
levels have been shown to be correlated with iron status among pregnant women (Åkesson et al. 2002).  
However, a general population study of women living in Japan (Tsukahara et al. 2003) did not find 
significantly elevated levels of urinary cadmium, β2-microglobulin, or pHC among women with anemia 
or iron deficiency, as compared to healthy women.  Populations with kidney damage from causes 
unrelated to cadmium exposure, including diabetes, some drugs and chemicals, and the natural age-related 
decline in kidney function, could be expected to exhibit nephrotoxicity at lower cadmium exposures than 
those of normal healthy adults (Buchet et al. 1990).  There is also some evidence to suggest that diabetics 
may be more susceptible to the toxicity of cadmium (Åkesson et al. 2005; Buchet et al. 1990; Haswell-
Elkins et al. 2008).  Elevated levels of metallothionein-antibody have been significantly associated with 
excretion of biomarkers of tubular dysfunction among cadmium workers (Chen et al. 2006a), but not with 
urinary or blood cadmium levels.  In a study of diabetics, metallothionein-antibodies were significantly 
associated with urinary levels of β2-microglobulin levels, which were indicative of cadmium toxicity but 
not with urinary albumin levels, which would be indicative of glomerular damage (Chen et al. 2006c).  
However, a significant association between elevated albumin creatinine ratio and urinary cadmium levels 
was found in another study of diabetics (Haswell-Elkins et al. 2008) and the frequency of albuminuria 
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was 64% among diabetics with high urinary cadmium levels of 1–2 µg/g creatinine and 80% among those 
with urinary cadmium levels of >2 µg/g creatinine. 
 
 
A discussion of the susceptibility of children is found in Section 3.7, Children’s Susceptibility. 
3.11   METHODS FOR REDUCING TOXIC EFFECTS  
 
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to cadmium.  However, because some of the treatments discussed may be experimental and 
unproven, this section should not be used as a guide for treatment of exposures to cadmium.  When 
specific exposures have occurred, poison control centers and medical toxicologists should be consulted 
for medical advice.  The following texts provide specific information about treatment following exposures 
to cadmium:   
 
Caravati EM, McGuigan MA, MacGregor Whyte I, et al.  Cadmium fume pneumonitis.  In:  Medical 
toxicology, 3rd ed.  Philadelphia, PA:  Lippincott Williams & Wilkins, 1411-1414. 
 
Leikin JB, Paloucek FP.  2002.  Cadmium.  In:  Poisoning and toxicology handbook.  Hudson, OH:  Lexi-
Comp, Inc., 309-310. 
 
Viccellio P.  1998.  Cadmium, mercury, and arsenic.  In:  Emergency toxicology.  2nd ed.  Philadelphia, 
PA:  Lippincott-Raven Publishers, 379-380. 
 
3.11.1   Reducing Peak Absorption Following Exposure  
 
Inhalation exposure to high concentrations of cadmium can be particularly dangerous because initial 
symptoms are often as mild as those associated with low-level exposure, and exposed individuals who are 
unaware either of the presence of cadmium or of the dangers of inhaling cadmium may allow exposure to 
continue until a harmful or even fatal dose is received (Beton et al. 1966; Lucas et al. 1980).  Severe 
respiratory symptoms that may develop within a few hours of high-dose inhalation exposure include 
tracheobronchitis, pneumonitis, and pulmonary edema, accompanied by additional nonspecific flu-like 
symptoms (sweating, shivering, malaise) (Beton et al. 1966).  Aside from removing a victim to fresh air 
and providing supportive medical care, no effective means have been reported for reducing absorption 
following inhalation exposure to cadmium (Bronstein and Currance 1988; EPA 1989d).  Supportive 
medical care of individuals with inhalation exposure to high levels of cadmium includes monitoring for 
respiratory distress, assisting ventilation as needed, and administering humidified oxygen (Bronstein and 
Currance 1988; EPA 1989d).  If pulmonary edema develops, individuals may be treated with 
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supplemental oxygen, positive-pressure mechanical ventilation, and administration of diuretics, 
intravenous fluids, and steroid medications.  Antibiotic therapy and monitoring fluid balance (due to 
kidney function impairment) may also be required (Beton et al. 1966; Bronstein and Currance 1988; EPA 
1989d; Haddad and Winchester 1990). 
 
 
 
Oral exposure to cadmium is not an immediate threat because high doses are irritating enough to induce 
vomiting.  In fact, the only known acute fatalities from oral exposure to cadmium followed intentional 
ingestion of high doses (Baker and Hafner 1961; Buckler et al. 1986; Frant and Kleeman 1941; Nordberg 
et al. 1973; Shipman 1986; Wisniewska-Knypl et al. 1971).  Although inducing vomiting is sometimes 
recommended following ingestion of cadmium (Ellenhorn and Barceloux 1988; Stutz and Janusz 1988), 
concentrated cadmium solutions may be caustic, and esophageal damage could result from spontaneous or 
induced vomiting.  Administration of water or milk may be indicated for patients able to swallow 
(Bronstein and Currance 1988; EPA 1989d).  Administration of cathartics such as sorbitol or magnesium 
sulfate to enhance elimination from the gastrointestinal tract has been recommended (EPA 1989d; Stutz 
and Janusz 1988); however, the administration of activated charcoal to bind unabsorbed cadmium does 
not appear to be effective (Agency for Toxic Substances and Disease Registry 1990b; Ellenhorn and 
Barceloux 1988). 
The intestinal absorption of cadmium at levels below those leading to gastrointestinal damage is relatively 
low (5–10% of the administered dose) (Flanagan et al. 1978; McLellan et al. 1978; Newton et al. 1984; 
Rahola et al. 1973).  Other polyvalent cations including calcium, magnesium, and zinc can interfere with 
cadmium uptake (Foulkes 1985), but administration of competing cations can in some cases increase 
rather than decrease cadmium absorption (Jaeger 1990), and is therefore not recommended for the 
treatment of cadmium ingestion.  Oral administration of some compounds that chelate cadmium such as 
meso-2,3-dimercaptosuccinic acid has been found in rodent studies to reduce absorption following acute 
oral exposure to cadmium, but other chelators such as dithiocarbamates can increase toxicity (see 
Section 3.4.1.2).  At present, no recommendations for chelation treatment to reduce absorption can be 
made (Jones and Cherian 1990).  Administration of garlic (which is high in reduced sulfhydryl groups) 
has been shown to decrease oral cadmium toxicity in rats (Cha 1987).  Thus, use of garlic could be an 
area of future research. 
Dermal or ocular exposure to high levels of cadmium may cause irritation (Wahlberg 1977) and should be 
treated by removing contaminated clothing, washing the skin, and thoroughly flushing the eyes (EPA 
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1989d; Stutz and Janusz 1988).  These measures will also reduce the relatively small potential for dermal 
absorption of cadmium (see Section 3.4.1.3). 
 
3.11.2   Reducing Body Burden  
 
A variety of chelating agents have been evaluated (Cantilena and Klaassen 1981; Jones et al. 1992, 1994; 
Kostial et al. 1996; Singh et al. 1996).  Some of the more familiar chelators that are beneficial for other 
toxic metals actually increase cadmium toxicity by mobilizing the cadmium and substantially increasing 
the renal concentrations and toxicity (Agency for Toxic Substances and Disease Registry 1990b; 
Goldfrank et al. 1990; Jones and Cherian 1990).  One such agent is the chelating agent dimercaprol (also 
known as BAL, British Anti-Lewisite), commonly used for treating cases of lewisite toxicosis.  BAL is 
widely recognized as harmful in treating cadmium exposures.  Some sources recommend using ethylene-
diamine tetraacetic acid (EDTA) salts (Cantilena and Klaassen 1980, 1981; Ellenhorn and Barceloux 
1988; Stutz and Janusz 1988) or use of EDTA with caution about potential nephrotoxicity (EPA 1989d; 
Haddad and Winchester 1990).  Other chelators that have reduced the cadmium burden in animal studies 
include diethylenetriaminepentaacetic acid (DTPA), 2,3-dimercaptosuccinic acid (DMSA), and various 
dithiocarbamates (Cantilena and Klaassen 1981, 1982b; Kamenosono et al. 2002a; Wang et al. 1999).   
 
Cantilena and Klaassen (1982a) demonstrated the importance of rapid administration of DTPA, EDTA, or 
DMSA following acute cadmium exposure if they are to be effective.  Waalkes et al. (1983) evaluated the 
role of metallothionein in the acute drop in chelator efficacy following cadmium poisoning in male 
Sprague-Dawley rats.  Although the chelator, DTPA, reduced cadmium content in the various organs 
when given immediately after cadmium, it was ineffective at all later times.  Increases in hepatic and 
renal metallothionein did not occur until 2 hours after cadmium, and did not coincide with the earlier drop 
in chelator efficacy.  Blockade of metallothionein synthesis by actinomycin D treatment (1.25 mg/kg, 
1 hour before Cd) failed to prolong the chelators effectiveness.  Furthermore, newborn rats have high 
levels of hepatic metallothionein, which had no effect on the time course of chelator effectiveness since 
DTPA still decreased cadmium organ contents, if given immediately following cadmium, but had no 
effect if given 2 hours after cadmium.  The authors concluded that metallothionein does not have an 
important role in the acute decrease in efficacy of chelation therapy for cadmium poisoning.  The quick 
onset of chelator ineffectiveness may be due to the rapid uptake of cadmium into tissues, which makes it 
relatively unavailable of chelation. 
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Jones et al. (1992, 1994) investigated a series of monoalkyl and monoalkyl esters of meso-2,3-di-
mercaptosuccinic acid.  Monoisoamyl meso-2,3-dimercaptosuccinate (Mi-ADMS) was an effective 
chelating agent for reduction of kidney and liver cadmium when administered either parenterally or orally 
(Jones et al. 1992).  This finding was supported by a study by Eybl et al. (1994), which showed that 
Mi-ADMS, administered orally every 48 hours for 12 days after acute cadmium exposure, was effective 
at reducing cadmium in the kidney and liver, but not in the testes and brain.  Monophenethyl meso-
2,3-dimercaptosuccinic acid, mono(3-phenylpropyl) meso-2,3-dimercaptosuccinic acid, and 
mono(2-phenoxyethyl) meso-2,3-dimercaptosuccinic acid compounds successfully remove “aged” 
cadmium deposits and can be administered via a variety of routes (Jones et al. 1994).   
 
Another area of chelation therapy research is in the use of multiple chelators.  Blaha et al. (1995) 
evaluated the ability of two carbodithioate chelators, sodium N-(4-methylbenzyl)-4-O-(β-D-galacto-
pyranosyl)-D-glucamine-N-carbodithioate (MeBLDTC) and sodium 4-carboxyamidopiperidine-
N-carbothioate (INADTC), singly or in combination to reduce cadmium burden from chronically exposed 
rats.  The combination therapy resulted in a synergistic effect on increased biliary excretion and reduced 
renal cadmium that, in the case of biliary excretion, was more than doubled that expected for a simple 
additive interaction. 
 
3.11.3   Interfering with the Mechanism of Action for Toxic Effects  
 
The toxic effects of cadmium are generally thought to be caused by "free" cadmium ions; that is, 
cadmium not bound to metallothionein or other proteins (Goyer et al. 1989).  However, cadmium bound 
to metallothionein may have the capacity to directly damage renal tubular membranes during uptake 
(Suzuki and Cherian 1987).  Free cadmium ions may have a number of adverse effects, including 
inactivation of metal-dependent enzymes, activation of calmodulin, and initiation of the production of 
active oxygen species (Palmer et al. 1986; Waalkes and Goering 1990). 
 
Respiratory damage caused by acute, high-level inhalation exposure to cadmium can cause impaired lung 
function that can last many years after exposure (Barnhart and Rosenstock 1984; Townshend 1982).  No 
treatments other than supportive care and avoidance of additional risk factors for lung injury are presently 
known. 
 
The kidneys appear to be highly vulnerable to chronic cadmium exposure by either the oral or inhalation 
routes.  The basis for the preferential sensitivity of the kidney is related to the filtering and reabsorption of 
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circulating cadmium-metallothionein complex, which is then thought to be degraded in the tubular cell 
lysosomes and released as free intracellular cadmium.  The toxic effect results from the limited ability of 
the kidney to synthesize new cytosolic metallothionein in response to an increasing cadmium load (Goyer 
et al. 1989).  Cadmium bound to metallothionein, however, may also have nephrotoxic activity (Suzuki 
and Cherian 1987).   
 
 
 
No treatments are currently available that specifically target free cadmium ions in the renal cortex, but 
zinc and calcium can stimulate metallothionein synthesis and may also compete with cadmium for 
enzyme binding sites.  Thus, zinc, and/or calcium supplementation might help reduce renal cadmium 
toxicity, at least in zinc- or calcium-deficient individuals.  It is not known whether administration of these 
compounds would be beneficial in individuals with adequate zinc and calcium intakes, and their clinical 
use is not currently recommended.  Since one of the postulated mechanisms of cadmium toxicity is the 
stimulation and production of active oxygen species, it is possible that increasing the cellular levels of 
antioxidants such as superoxide dismutase, reduced sulfur compounds (particularly glutathione), 
vitamin C, vitamin E, or β-carotene could reduce renal cadmium toxicity by scavenging active oxygen 
species prior to reaction with cellular components.  Several animal studies have examined co-
administration of several antioxidants on cadmium-induced kidney damage.  Beneficial effects were 
found for vitamin E (Shaikh and Tang 1999; Shaikh et al. 1999a), N-acetyl cysteine (Kaplan et al. 2008; 
Shaikh et al. 1999a, 1999b), glycine (Shaikh and Tang 1999), glycyrrhizin (Nomiyama and Nomiyama 
1998), and a drug containing glycyrrhizin, glycine, and cysteine (Shaikh and Tang 1999; Shaikh et al. 
1999a).  However, antioxidants are not currently recommended for the treatment of cadmium-exposed 
humans. 
Treatments for the cadmium-related effects on bone have not been evaluated.  Although the mechanism of 
bone damage has not been fully elucidated, it is likely that calcium loss and altered vitamin D 
metabolism, which result from cadmium-induced kidney damage, play an important role.  Thus, 
treatments that interfere with the renal damage will likely have a beneficial effect on bone.   
Research in chelation therapy is promising for agents that can interfere or possibly reverse the toxic 
effects of cadmium.  Xu et al. (1995, 1996) demonstrated that monoisoamyl meso-2,3-dimercapto-
succinate, when administered within 1 hour after acute exposure, prevents the formation of cadmium-
induced apoptotic DNA fragmentation and associated histopathological injury in the testes of rats.  Perry 
et al. (1989) report a reversal of the cadmium induced hypertension in rats with the chelator d-myo-
inositol-1,2,6-triphosphate. 
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3.12   ADEQUACY OF THE DATABASE  
 
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of cadmium is available.  Where adequate information is not 
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the 
initiation of a program of research designed to determine the health effects (and techniques for developing 
methods to determine such health effects) of cadmium. 
 
 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
 
3.12.1   Existing Information on Health Effects of Cadmium 
 
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
cadmium are summarized in Figure 3-6.  The purpose of this figure is to illustrate the existing information 
concerning the health effects of cadmium.  Each dot in the figure indicates that one or more studies 
provide information associated with that particular effect.  The dot does not necessarily imply anything 
about the quality of the study or studies, nor should missing information in this figure be interpreted as a 
“data need”.  A data need, as defined in ATSDR’s Decision Guide for Identifying Substance-Specific 
Data Needs Related to Toxicological Profiles (Agency for Toxic Substances and Disease Registry 1989), 
is substance-specific information necessary to conduct comprehensive public health assessments.  
Generally, ATSDR defines a data gap more broadly as any substance-specific information missing from 
the scientific literature. 
There is a massive database regarding the health effects of cadmium.  In humans, the majority of studies 
have involved workers exposed by inhalation or residents of cadmium-polluted areas exposed primarily in 
the diet.  Quantitative estimates of exposure levels are not available for many of these studies; however, 
many studies provided information on urinary cadmium levels that would be reflective of the cadmium 
body burden.  Lethality, systemic toxicity, genotoxicity, and cancer have been studied in humans more 
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Figure 3-6.  Existing Information on Health Effects of Cadmium 
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extensively than immunotoxicity or neurotoxicity, with less being known about reproductive or 
developmental toxicity of cadmium in humans following inhalation or oral exposure.  In animals, effects 
following oral exposures have generally been more thoroughly investigated than those following 
inhalation exposure, and few studies of cadmium toxicity following dermal exposure in humans were 
located. 
 
 
3.12.2   Identification of Data Needs  
 
Acute-Duration Exposure.    There are limited data on the acute toxicity of cadmium in humans.  
Although there are numerous reports of respiratory effects in workers exposed to high concentrations of 
cadmium, there are no reliable estimates of levels associated with these effects.  Animal studies provide 
support for identification of the respiratory tract as the most sensitive target of toxicity following 
inhalation exposure.  Acute exposures to high levels of airborne cadmium has resulted in pneumonia, 
emphysema, and edema in laboratory animals (Boudreau et al. 1989; Buckley and Bassett 1987b; Bus et 
al. 1978; Grose et al. 1987; Hart 1986; Henderson et al. 1979; NTP 1995; Palmer et al. 1986) and lower 
concentrations were associated with focal inflammation and minimal fibrosis (NTP 1995).  A decreased 
immune response in mice was observed at similar cadmium concentrations (Graham et al. 1978; 
Krzystyniak et al. 1987).  Other adverse effects observed at higher concentrations include erosions of the 
stomach, decreases in body weight, and reduced activity (Rusch et al. 1986).  The available acute-
duration animal data were considered adequate for derivation of an acute-duration inhalation MRL for 
cadmium.   
There are no reliable human studies on the toxicity of cadmium following acute-duration oral exposure.  
In laboratory animals, acute exposure to high doses of cadmium resulted in a variety of effects, including 
altered hematological parameters, focal necrosis and degeneration of the liver, focal necrosis in renal 
tubular epithelium, necrosis and ulceration in the stomach and intestines, decreased motor activity, and 
testicular atrophy and necrosis (Andersen et al. 1988; Basinger et al. 1988; Bomhard et al. 1987; 
Borzelleca et al. 1989; Dixon et al. 1976; Kotsonis and Klaassen 1977; Machemer and Lorke 1981; 
Sakata et al. 1988; Shimizu and Morita 1990).  There is some indication that developmental effects 
(delays in ossification and increased malformations) may occur at lower cadmium doses (Baranski 1985; 
Machemer and Lorke 1981).  The acute-duration oral database was not considered adequate for derivation 
of an MRL because the results of the study that identified the lowest LOAEL (Baranski 1985) were 
inadequately reported and were inconsistent with a longer-duration study conducted by the same 
investigator.  Although the data suggest that the developing organism is the most sensitive target, 
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additional studies are needed to support this assumption.  Studies characterizing the dose-response 
relationships for the most sensitive effects are needed for derivation of an acute-duration oral MRL.   
 
 
 
 
No reliable information was located regarding toxicity following dermal exposure to cadmium, but based 
on the lack of reported effects in the workers handling cadmium compounds, it seems unlikely that 
dermal exposure could deliver a significant dose of cadmium.   
Intermediate-Duration Exposure.    There are limited data on the toxicity of cadmium in humans 
following intermediate-duration exposure.   
Intermediate-duration inhalation studies in laboratory animals have identified several targets of toxicity 
including the respiratory tract (Glaser et al. 1986; Kutzman et al. 1986; NTP 1995; Prigge 1978a), 
reproductive effects (Baranski and Sitarek 1987; NTP 1995), and developing nervous system (Baranski 
1984, 1985).  At the lowest cadmium concentration tested, alveolar histiocytic infiltration and 
degeneration or metaplasia in the larynx were observed in mice (NTP 1995) and neurodevelopmental 
effects were observed in rats (Baranski 1984, 1985).  These LOAELs were considered for derivation of an 
intermediate-duration inhalation MRL; however, an MRL based on the human equivalent concentration 
of the LOAELs would be lower than the chronic-duration inhalation MRL based on human data.  
Additional studies are needed to identify no-adverse-effect levels in animals for these sensitive targets of 
toxicity. 
A number of studies have been conducted involving intermediate-duration oral exposure to laboratory 
animals.  The results of these studies suggest that the growing bone is the most sensitive target.  The 
skeletal effects observed in young rats include decreases in bone mineral density, impaired mechanical 
strength, increased fractures, and increased bone turnover (Brzóska and Moniuszko-Jakoniuk 2005a, 
2005b, 2005d; Brzóska et al. 2004b, 2005a, 2005b, 2005c; Ogoshi et al. 1989).  Developmental effects, 
including impaired renal function and neurodevelopmental alterations, have been observed at similar dose 
levels (Ali et al. 1986; Baranski et al. 1983; Jacquillet et al. 2007).  At higher doses, observed effects 
included renal damage (proteinuria, tubular necrosis, and decreased renal clearance), liver necrosis, and 
anemia (Cha 1987; Gatta et al. 1989; Groten et al. 1990; Itokawa et al. 1974; Kawamura et al. 1978; 
Kawamura et al. 1978; Kotsonis and Klaassen 1978; Prigge 1978a), altered immune response (Blakley 
1985, 1986; Chopra et al. 1984), decreased motor activity (Kotsonis and Klaassen 1978; Nation et al. 
1990), and necrosis and atrophy of seminiferous tubules and decreased sperm count and motility (Cha 
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1987; Saxena et al. 1989).  The database of intermediate-duration animal studies was considered adequate 
for derivation an intermediate-duration oral MRL based on skeletal effects in growing rats. 
 
 
 
No intermediate-duration dermal data were identified in humans or animals.  Studies of possible toxicity 
in animals following intermediate-duration dermal exposure to cadmium are needed to evaluate potential 
health effects in humans exposed to cadmium primarily by the dermal route. 
Chronic-Duration Exposure and Cancer.    Data on the chronic toxicity of inhaled cadmium in 
humans come from numerous occupational exposure studies; no reliable animal studies examining 
noncancerous end points were identified.  These studies have identified the respiratory tract (emphysema, 
impaired lung function) (Chan et al. 1988; Cortona et al. 1992; Davison et al. 1988; Smith et al. 1976) and 
the kidney (tubular proteinuria, decreased glomerular filtration rate, increased excretion of low molecular 
weight proteins) (Bernard et al. 1990; Chen et al. 2006a, 2006b; Chia et al. 1992; Elinder et al. 1985a; 
Falck et al. 1983; Jakubowski et al. 1987, 1992; Järup and Elinder 1994; Järup et al. 1988; Shaikh et al. 
1987; Toffoletto et al. 1992; Verschoor et al. 1987) as the most sensitive targets of toxicity.  Comparisons 
of the adverse effect levels for these two end points are difficult because the studies on respiratory effects 
typically reported air concentrations (current levels or estimated cumulative exposure) as the exposure 
biomarker and those examining renal effects typically used urinary cadmium levels as the exposure 
biomarker; based on limited data, the kidney appears to be the more sensitive target.  Studies examining 
both end points in occupationally exposed populations would provide valuable information on sensitivity.  
None of the available human studies were considered adequate for derivation of an inhalation MRL 
because cadmium air concentrations were poorly characterized or no data were provided on the 
contribution of dietary cadmium to the cadmium body burden.  However, the similarities on the toxicity 
and toxicokinetics of cadmium following inhalation and oral exposure allow for the use of the oral 
database to derive an inhalation MRL. 
There is an extensive database of studies examining the chronic oral toxicity of cadmium in humans.  
These environmental exposure studies have identified two sensitive targets of cadmium toxicity—the 
skeletal system and the kidney.  The skeletal effects included increased risk of osteoporosis and bone 
fractures and decreases in bone mineral density (Alfvén et al. 2000, 2004; Nordberg et al. 2002; Schutte et 
al. 2008; Staessen et al. 1999; Wang et al. 2003).  Renal effects range from death due to renal failure 
(Arisawa et al. 2001, 2007b; Iwata et al. 1991a, 1991b; Matsuda et al. 2002; Nakagawa et al. 1993; 
Nishijo et al. 1995, 2004a, 2006) to increases in the prevalence of low molecular weight proteinuria 
(Buchet et al. 1990; Cai et al. 1990, 1992, 1998, 2001; Hayano et al. 1996; Ishizaki et al. 1989; Izuno et 
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al. 2000; Järup et al. 2000; Jin et al. 2002, 2004a, 2004c; Kawada et al. 1992; Kido and Nogawa 1993; 
Kobayashi et al. 2002a; Monzawa et al. 1998; Nakashima et al. 1997; Nogawa et al. 1989; Noonan et al. 
2002; Nordberg et al. 1997; Olsson et al. 2002; Oo et al. 2000; Osawa et al. 2001; Roels et al. 1981b; 
Suwazono et al. 2006; Teeyakasem et al. 2007; Trzcinka-Ochocka et al. 2004; Uno et al. 2005; Yamanaka 
et al. 1998; Wu et al. 2001).  Animal studies confirm the identification of the kidney and bone as the most 
sensitive targets of cadmium toxicity (Akahori et al. 1994; Bernard et al. 1992; Bomhard et al. 1984; 
Brzóska and Moniuszko-Jakoniuk 2004a, 2004b; Fingerle et al. 1982; Mangler et al. 1988).  Sufficient 
information from human studies is available to derive a chronic oral MRL.  No information was located 
regarding dermal toxicity of chronic cadmium exposure in humans or animals, and studies of dermal 
toxicity are needed to evaluate risks to populations exposed to cadmium primarily by dermal contact. 
 
 
The evidence of carcinogenicity from human studies is limited, due to uncertainties in cadmium exposure 
estimates and confounding factors including exposure to arsenic, a known human lung carcinogen, and 
smoking.  Occupational exposure studies have found significant increases in lung cancer mortalities 
(Ades and Kazantzis 1988; Järup et al. 1998a; Kazantzis et al. 1988; Stayner et al. 1992a; Sorahan 1987; 
Sorahan and Waterhouse 1983; Thun et al. 1985).  However, lung cancer deaths were often not 
significantly associated with cadmium exposure or duration.  Other studies have not found increases in 
lung cancer deaths (Armstrong and Kazantzis 1983; Elinder et al. 1985c; Lamm et al. 1992, 1994; 
Sorahan and Esmen 2004; Sorahan and Lancashire 1997).  Additional occupational exposure studies 
controlling for these exposures and providing more precise cadmium dose estimates are needed to provide 
more definitive evidence of the carcinogenic potential in humans of inhaled cadmium.  Evidence for the 
carcinogenicity of cadmium by the inhalation route is available from studies in rats (Takenaka et al. 
1983).  Additional studies in animals are needed to evaluate the lack of an observed increase in lung 
cancer in mice and hamsters exposed to cadmium by inhalation (Heinrich et al. 1989).  Cadmium has not 
been shown to be carcinogenic following oral exposure in humans (Bako et al. 1982; Hardell et al. 1994; 
Inskip et al. 1982; Lauwerys and De Wals 1981; Nakagawa et al. 1987; Shigematsu 1984).  In rats, 
however, cadmium increased tumors of the prostate, testes, and hematopoietic system (Waalkes et al. 
1992).  Additional lifetime-exposure studies in rats, mice, and hamsters orally exposed to cadmium at 
sufficiently high doses are needed to further define the carcinogenic potential of cadmium. 
Genotoxicity.    The evidence for the genotoxicity of cadmium is mixed (see Tables 3-10 and 3-11).  In 
vitro studies have provided both positive and negative results (Amacher and Paillet 1980; Bruce and 
Heddle 1979; Casto et al. 1979; Denizeau and Marion 1989; Depault et al. 2006; Fatur et al. 2002; Filipic 
and Hei 2004; Honma et al. 1999; Jianhua et al. 2006; Lopez-Ortal et al. 1999; Lutzen et al. 2004; Lynn et 
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al. 1997; Mikhailova et al. 1997; Oberly et al. 1982; Rozgaj et al. 2002; Shiraishi et al. 1972; Terracio and 
Nachtigal 1988).  Studies of chromosomal aberrations in humans (Bui et al. 1975; Deknudt and Leonard 
1975; Fu et al. 1999; O'Riordan et al. 1978; Tang et al. 1990) and animals (Bruce and Heddle 1979; Desi 
et al. 2000; DiPaulo and Castro 1979; Fahmy and Aly 2000; Karmakar et al. 1998; Mukherjee et al. 
1988a; Tan et al. 1990; Watanabe et al. 1979) exposed to cadmium have also found both positive and 
negative results.  DNA damage has been consistently observed in in vitro studies (Devi et al. 2001; 
Fahmy and Aly 2000; Kasuba et al. 2002; Mukherjee et al. 1988a; Saplakoglu et al. 1997; Valverde et al. 
2000; Wronska-Nofer et al. 1999; Zhou et al. 2004b).  In animals, parenteral, but not inhalation or oral, 
cadmium exposure has been found to cause germ cell mutations (Gilliavod and Leonard 1975; Suter 
1975; Sutou et al. 1980; Watanabe and Endo 1982; Zenick et al. 1982).  Additional studies investigating 
effects in exposed humans using larger populations with quantitative estimates of exposure would be 
useful to evaluate the human genotoxicity of cadmium. 
 
Reproductive Toxicity.    Only limited or conflicting evidence is available to evaluate the potential for 
cadmium exposure to cause reproductive toxicity in humans.  Some studies report no effect on male 
fertility (Gennart et al. 1992), sex hormone levels (Mason 1990; Menke et al. 2008; Zeng et al. 2004a), 
sperm density (Noack-Fuller et al. 1993), or semen quality (Jurasović et al. 2004; Saaranen et al. 1989), 
while others report a reduction in sperm number or viability (Akinloye et al. 2006; Telišman et al. 2000; 
Xu et al. 1993a) or alterations in sex steroid hormone levels (Akinloye et al. 2006; Jurasović et al. 2004; 
Telišman et al. 2000).  In one study, men occupationally exposed to cadmium at levels resulting in renal 
damage had no change in testicular function (Mason 1990).  Adverse effects in animals from inhalation 
exposure have been reported including increased duration of the estrous cycle (Baranski and Sitarek 1987; 
NTP 1995; Tsvetkova 1970), and increased relative testes weight but no loss in reproductive success 
(Kutzman et al. 1986).  Adverse reproductive effects in animals from high-dose, acute, oral cadmium 
exposure have been reported including testicular atrophy and necrosis (Andersen et al. 1988; Bomhard et 
al. 1987; Borzelleca et al. 1989), and decreased fertility (Kotsonis and Klaassen 1978; Machemer and 
Lorke 1981).  At lower doses and intermediate exposures, adverse effects have included necrosis and 
atrophy of seminiferous tubule epithelium (Cha 1987), increased testes weight (Pleasants et al. 1992, 
1993), increased prostatic hyperplasias (Waalkes and Rehm 1992), significantly increased relative testes 
weight, decreased sperm count and motility, decreased seminiferous tubular diameter, seminiferous 
tubular damage (Saxena et al. 1989), and decreased fertility (Sutou et al. 1980).  Other animal studies for 
lower dose intermediate exposures, however, report no adverse effects (Baranski et al. 1983; Bomhard et 
al. 1987; Groten et al. 1990; Kostial et al. 1993; Kotsonis and Klaassen 1978; Loeser and Lorke 1977a; 
Pleasants et al. 1992; Pond and Walker 1975; Zenick et al. 1982).  Additional studies in animals, as well 
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as retrospective, case-matched studies of reproductive success of populations for which occupational or 
environmental exposure to cadmium has been estimated, are needed to further evaluate the potential 
reproductive toxicity of cadmium in humans.  Additional studies would be useful (preferably with larger 
sample sizes) to evaluate the robustness of the association between cadmium and adverse effects on 
sperm. 
 
 
Developmental Toxicity.    The potential for cadmium exposure to cause developmental toxicity from 
pre- or postnatal exposures in humans is not known.  One study in occupationally exposed women 
reported children with lowered birth weights, but with no increase in malformations (Tsvetkova 1970).  
However, no control was made for parity, maternal weight, gestational age, or other factors known to 
influence birth weight.  Many animal studies demonstrate that developmental toxicity may occur 
following cadmium exposure by oral routes with a relatively few studies reporting developmental effects 
following inhalation or oral exposure (Ali et al. 1986; Baranski 1985, 1987; Baranski et al. 1983; Gupta et 
al. 1993; Kelman et al. 1978; Kostial et al. 1993; Machemer and Lorke 1981; Petering et al. 1979; Pond 
and Walker 1975; Schroeder and Mitchener 1971; Sorell and Graziano 1990; Sutou et al. 1980; Webster 
1978; Whelton et al. 1988).  At lower inhalation and oral doses, impaired performance on 
neurobehavioral tests have been observed (Ali et al. 1986; Baranski et al. 1983; Desi et al. 1998; 
Nagymajtenyi et al. 1997).  Retrospective, case-matched studies of developmental toxicity among 
children of women with known occupational or environmental exposure to cadmium are needed to 
evaluate the potential for cadmium exposure to cause human developmental toxicity such as skeletal 
malformations and neurobehavioral effects (as suggested in animal studies).  Studies are also needed to 
follow up on the results of increased susceptibility of young to bone damage (Ogoshi et al. 1989) or 
suppression of the immune response (Blakley 1985) reported in animals.  The difference in the immune 
response (using the same protocol) between young mice (Blakley 1985) and older mice (Blakley 1988) 
should also be further evaluated.  Studies of postnatal cadmium exposure to children, especially for 
children with diets deficient in calcium, protein, or iron, would be useful to evaluate whether increased 
cadmium absorption from the diet leads to developmental effects. 
Immunotoxicity.    A variety of immunologic effects have been found in animals exposed to cadmium 
by the oral or inhalation routes (Blakley 1988; Bouley et al. 1984; Cifone et al. 1989a).  However, the 
biological significance of these effects is not clear, and there is little information available on 
immunotoxicity in humans.  Investigations of immunologic function of populations occupationally or 
environmentally exposed to cadmium, and follow-up mechanistic studies in animals are needed to 
evaluate the potential immunotoxicity of cadmium exposure in humans. 
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Neurotoxicity.    A few studies have suggested an association between cadmium exposure in humans 
and impaired neuropsychologic functioning at levels below those causing nephrotoxicity (Hart et al. 
1989b; Marlowe et al. 1985; Thatcher et al. 1982).  Neurotoxicity has also been found in animal studies 
(Nation et al. 1984; Wong and Klaassen 1982).  Additional studies to investigate neurologic effects in 
populations with known cadmium exposure and studies of possible mechanisms of neurotoxicity in 
animals are needed to evaluate the potential neurotoxicity of cadmium exposure to humans.  In addition, 
studies examining neurobehavioral end points in children would be useful. 
 
Epidemiological and Human Dosimetry Studies.    Cause/effect relationships for renal toxicity of 
cadmium have been derived from studies of workers occupationally exposed to cadmium by inhalation 
(Bernard et al. 1990; Chen et al. 2006a, 2006b; Chia et al. 1992; Elinder et al. 1985b; Falck et al. 1983; 
Jakubowski et al. 1987, 1992; Järup and Elinder 1994; Järup et al. 1988; Kawada et al. 1989; Roels et al. 
1993; Shaikh et al. 1987; Thun et al. 1989; Toffoletto et al. 1992; Verschoor et al. 1987) and of 
populations environmentally exposed to cadmium in the diet (Buchet et al. 1990; Cai et al. 1990, 1992, 
1998, 2001; Hayano et al. 1996; Ishizaki et al. 1989; Izuno et al. 2000; Järup et al. 2000; Jin et al. 2002, 
2004a, 2004c; Kawada et al. 1992; Kido and Nogawa 1993; Kobayashi et al. 2002b; Monzawa et al. 
1998; Nakadaira and Nishi 2003; Nakashima et al. 1997; Nogawa et al. 1989; Noonan et al. 2002; 
Nordberg et al. 1997; Roels et al. 1981a; Olsson et al. 2002; Oo et al. 2000; Osawa et al. 2001; Suwazono 
et al. 2000; Teeyakasem et al. 2007; Trzcinka-Ochocka et al. 2004; Uno et al. 2005; Watanabe et al. 
2002Wu et al. 2001; Yamanaka et al. 1998).  There is also epidemiological evidence that chronic 
environmental exposure to cadmium can result in decreases in bone mineral density and increases in the 
risk of bone fractures and osteoporosis (Åkesson et al. 2005; Alfvén et al. 2000, 2004; Schutte et al. 2008; 
Staessen et al. 1999).  Additional studies are needed to elucidate the mechanisms of these bone effects in 
humans and to determine if the skeletal system is a more sensitive target of cadmium toxicity than the 
kidney effects.  Measurement of additional toxicity end points (reproductive, developmental, 
immunological, and neurological) in these well characterized populations are needed to evaluate whether 
any of these effects may occur at exposure levels below those leading to kidney damage.  Additional 
development of PBPK/PD models is needed to evaluate human exposure scenarios.  In its assessment of 
the U.S. population’s exposure to environmental chemicals, the CDC measured urinary cadmium levels.  
If urinary cadmium levels are monitored in future assessments, it would be useful to also measure 
biomarkers of tubular dysfunction; these data would be useful in examining possible relationships 
between cadmium exposure and renal function in the general population.   
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Biomarkers of Exposure and Effect.     
 
 
 
Exposure.  Cadmium levels can be measured in a variety of tissues and fluids, including blood, urine, 
milk, liver, kidney, hair, and nails (Elinder and Lind 1985; Roels et al. 1981b; Sharma et al. 1982).  Blood 
cadmium is a useful indicator of recent cadmium exposure, and urinary cadmium is a useful indicator of 
total body burden (Shaikh and Smith 1984).  The most important indicator of the potential for 
toxicological injury is generally considered to be the cadmium concentration in the renal cortex, but 
individuals vary in the concentration causing renal effects (the "critical concentration") (Roels et al. 
1981b).  Methods for in vivo measurement of cadmium content in the kidney exist, but they are complex 
and expensive, and involve some exposure to ionizing radiation (Scott and Chettle 1986).  Efforts to 
develop easier, safer, and less costly methods for in vivo analysis are needed, as well as studies to 
determine factors influencing individual variation in critical concentrations.  Although many studies 
correct urinary cadmium levels for creatinine concentration, several investigators (Alessio et al. 1985; 
Ikeda et al. 2003a; Moriguichi et al. 2005b) have questioned the validity of this approach due to wide 
intra- and interindividual variability and age-related decline in levels.  Additional studies are needed to 
further investigate methods to account for dilution in urine spot samples. 
Effect.  A number of sensitive tests are available to detect early stages of renal dysfunction that are 
known to be caused by cadmium exposure.  These include analysis of urinary excretion of 
β2-microglobulin, retinol-binding protein, metallothionein, or enzymes (Shaikh and Smith 1984).  
However, renal damage detected by these tests is not necessarily associated with cadmium exposure.  
Additional studies are needed to evaluate current or potentially new urinary or serum biomarkers in 
cadmium-exposed populations and their association with incipient injury to the kidney caused by 
cadmium.  The bone is a sensitive target of cadmium toxicity, particularly during growth and in the 
elderly; studies are needed to develop sensitive biomarkers to detect early signs of bone damage. 
Absorption, Distribution, Metabolism, and Excretion.    Good information exists on cadmium 
toxicokinetics in humans and animals.  PBPK/PD models have been developed to predict the critical 
organ dose as a function of route, duration, and level of exposure by the inhalation and oral routes 
(Kjellström and Nordberg 1978, 1985).  Although general factors influencing absorption, distribution, 
metabolism, and excretion are known, additional studies are needed to provide information on metal 
metabolism and interactions that support quantitative evaluation of individual variations and resulting 
differences in renal cadmium accumulation.  Very limited information exists on the dermal absorption of 
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cadmium (Skog and Wahlberg 1964; Wester et al. 1992).  Additional studies on the dermal absorption of 
cadmium are needed. 
 
 
 
Comparative Toxicokinetics.    Animal and human studies have generally reported comparable 
toxicokinetics of cadmium (Kjellström and Nordberg 1985; Nordberg et al. 1985), suggesting that rats, 
mice, and rabbits are suitable models for cadmium toxicity in humans.  However, some concerns have 
been raised about the appropriateness of the rat model for cadmium-induced lung tumors in humans 
because of differences in the morphology of the rat respiratory tract and resulting differences in cadmium 
particle deposition patterns and target cell populations.  This is especially of concern because cadmium 
appears to be a contact carcinogen for lung cancer.  Additional studies on the differences between the rat 
and human clearance rates, speciation at the level of the target cell, and protein transporters (as they relate 
to solubility and susceptibility) are needed to evaluate the appropriateness of the rat model for predicting 
cadmium-induced human lung cancers.  Additional studies on differences in species, strain, sex, age, and 
other factors on cadmium kinetics and carcinogenic or other systemic effects are also needed to 
extrapolate the animal data to potential human toxicity.  Additional studies establishing the toxicokinetics 
of cadmium in pregnant animals are needed to assess the relevance of the developmental effects observed 
in animals.   
Methods for Reducing Toxic Effects.    The mechanisms of cadmium absorption across epithelial 
layers are likely to be via nonspecific mechanisms (Foulkes 1989).  No methods are known for 
influencing absorption across the lung, but absorption across the gastrointestinal tract may be influenced 
by dietary status (Flanagan et al. 1978).  Studies to determine whether dietary adjustments might help 
decrease cadmium uptake from food or water are needed.  Studies to determine the effects of dietary 
deficiencies in calcium are needed to further evaluate the risk of cadmium exposure to susceptible 
populations.  Uptake across the skin is probably sufficiently slow that simple washing of exposed areas is 
adequate to prevent excessive absorption (Skog and Wahlberg 1964). 
Once cadmium is absorbed, it tends to accumulate in the kidney, which is the main target tissue for 
chronic low-dose exposure.  The cellular and molecular basis for the preferential accumulation in the 
kidney is only partially understood (Waalkes and Goering 1990), and additional studies to define the rate-
limiting steps in renal uptake and renal clearance of cadmium are needed to design strategies for reducing 
the rate of cadmium accumulation in this tissue.  Additional studies on existing and new chelating agents 
and different treatment regimens are needed to improve the clinical therapies for acute and chronic 
exposures to cadmium. 
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The mechanism of cadmium toxicity in renal cells and other tissues probably involves binding of free 
cadmium ions to key cellular enzymes and proteins (Waalkes and Goering 1990).  Thus, any agent that 
prevents cadmium from binding might help prevent toxicity.  The endogenous cadmium-binding protein 
can serve this function; however, metallothionein-cadmium complexes may have renal toxicity (Suzuki 
and Cherian 1987).  Additional studies on the role of metallothionein in cadmium toxicity would be 
useful.  Additional studies are needed on alternative substrate molecules or drugs that could interact with 
free cadmium and prevent binding to key cellular enzymes, as well as the ability of antioxidants to reduce 
damage from active-oxygen species produced by cadmium in tissues. 
 
 
 
 
The impaired renal function that is the typical adverse effect of excessive cadmium exposure is neither 
clinically treatable nor reversible (Agency for Toxic Substances and Disease Registry 1990b; Roels et al. 
1989).  Studies on potential supportive treatment or remedies for cadmium-induced mild renal impairment 
would be valuable. 
The bone is also a sensitive target of cadmium toxicity; however, methods for the treatment of the 
observed effects, decreased bone mineral density and increased fractures, have not been developed and 
are needed. 
Children’s Susceptibility.    Data needs relating to both prenatal and childhood exposures, and 
developmental effects expressed either prenatally or during childhood, are discussed in detail in the 
Developmental Toxicity subsection above. 
There is limited information on the toxicity of cadmium in children.  Although it is likely that children 
will have similar effects as adults, there is some suggestive evidence that childhood exposure may result 
in increased renal toxicity, as compared to persons only exposed as adults (Trzcinka-Ochocka et al. 2004).  
Additionally, studies in animals suggest that young animals are more susceptible to cadmium-induced 
bone damage than adults (Ogoshi et al. 1989); this has not been investigated in humans.  Studies are 
needed to evaluate whether there are age-specific differences in the toxicity of cadmium in humans.  As 
discussed in the Developmental Toxicity section above, there are limited data on the developmental 
toxicity of cadmium in humans, particularly potential neurodevelopmental effects and additional studies 
are needed. 
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Additional research is needed on the toxicokinetics of cadmium during long-term, low-level exposures to 
determine the potential long-term tissue burdens that are likely to result especially for the susceptible 
tissues of liver, kidney, and bone.  Data in animals suggest that children may absorb more cadmium than 
adults, but there are no human data examining these potential differences in the toxicokinetic properties of 
cadmium.  Additional information is needed on cadmium transport across the blood-brain barrier in the 
developing fetus, and the role of metallothionein in the placenta.  
 
 
 
 
 
Neurological and behavioral studies are needed that use the more sophisticated measures available today 
to evaluate children for in utero, acute, and longer term exposures.  These studies should have the 
appropriate controls for confounding factors such as lead, parental use of ethanol, and living conditions. 
Additional studies are needed to evaluate whether or not biomarkers of cadmium exposure and effects 
that have been developed for adults are also applicable to children.  If not, new biomarkers of exposure 
and effect need to be developed. 
The effects of nutritional status (iron, zinc, and calcium levels) on cadmium absorption and accumulation 
in children need further evaluation.  Improved regimens and choices for chelation therapy are also 
needed. 
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs:  
Exposures of Children. 
3.12.3   Ongoing Studies  
 
A number of research projects are in progress investigating the health effects of cadmium.  These projects 
are summarized in Table 3-14. 
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Table 3-14.  Ongoing Studies on Cadmium 
 
Investigator Study topic Institution Sponsor 
Fadrowski, J 
Nebert, DW 
Thomas, DG 
and Kennedy, 
TS 
Newcomb, PA 
Louie, MC 
Meliker, JR 
Rull, RP 
El Mauayed, M 
Guallar, EO 
Heggland, SJ 
Determination if environmental 
cadmium exposure is 
associated with chronic kidney 
disease in children 
Identify and characterize 
genes responsible for 
interindividual differences in 
the response to cadmium 
Examination of the possible 
association between cadmium 
levels in maternal blood and 
breast milk and cognitive 
development in infants 
Examination of the possible 
association between cadmium 
exposure and risk of breast 
cancer 
Examination of the 
contribution of cadmium to the 
progression of breast cancer  
Examination of possible 
association between cadmium 
exposure and breast cancer 
risk 
Examination of possible 
association between cadmium 
exposure and endometrial 
cancer risk 
Examination of the possible 
association between cadmium 
exposure and diabetes risk in 
carriers of a genetic variation 
of the zinc transporter ZnT8 
Possible association between 
cadmium exposure and 
cardiovascular risk in children 
Mechanisms of cadmium-
induced osteotoxicity 
John Hopkins University National Institute of 
Environmental Health 
Sciences 
University of Cincinnati National Institute of 
Environmental Health 
Sciences 
Oklahoma State National Research Initiative  
University 
Fred Hutchinson Cancer National Institute of 
Research Center Environmental Health 
Sciences 
Dominican University of National Cancer Institute 
California 
State University of New National Institute of 
York, Stony Brook Environmental Health 
Sciences 
Northern California National Institute of 
Cancer  Environmental Health 
Sciences 
Northwestern University National Institute of 
Environmental Health 
Sciences 
Johns Hopkins University National Institute of 
Environmental Health 
Sciences 
Albertson College of National Institute of 
Idaho Environmental Health 
Sciences 
 
Source:  FEDRIP 2012 
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4.  CHEMICAL AND PHYSICAL INFORMATION 
 
4.1   CHEMICAL IDENTITY  
 
Table 4-1 lists the common synonyms, trade names, and other pertinent identification information for 
cadmium and its most important compounds. 
 
4.2   PHYSICAL AND CHEMICAL PROPERTIES  
 
Table 4-2 lists important physical and chemical properties of cadmium and its most important 
compounds. 
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Table 4-1.  Chemical Identity of Cadmium and Compoundsa 
 
Characteristic Information 
Chemical name Cadmium Cadmium carbonate Cadmium chloride 
Synonym(s) Colloidal cadmium  Otaviteb; cadmium 
monocarbonate; 
carbonic acid; cadmium 
salt  
Caddyb; Vi-Cadb; cadmium 
dichloride; dichlorocadmium  
Registered trade name(s) No data No data No data 
Chemical formula Cdb CdCO3
b CdCl2
b 
Chemical structure Cdb CdCO3
b CdCl2
b 
Identification numbers:    
CAS registry 7440-43-9b 513-78-0b 10108-64-2 
NIOSH RTECS No data No data  No data  
EPA hazardous waste D006  D006  D006  
OHM/TADS No data No data  No data  
DOT/UN/NA/IMDG shipping No data No data  NA2570/IMCO 6.1  
HSDB 282  1612  278  
NCI No data No data No data 
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Table 4-1.  Chemical Identity of Cadmium and Compoundsa 
 
Characteristic Information 
Chemical name Cadmium oxide Cadmium sulfate  Cadmium sulfide  
Synonym(s) Aska-Ridb; cadmium 
fume; cadmium 
monoxide  
Cadmium sulphate; 
sulfuric acid; cadmium 
(2+) salt  
Cadmium monosulfide; 
cadmium yellow; cadmium 
orange; cadmopur yellow; 
greenockiteb; capsebonb 
Registered trade name(s) No data  No data  No data  
Chemical formula CdOb CdSO4b CdSb 
Chemical structure CdOb CdSO4b CdSb 
Identification numbers:    
 CAS registry 1306-19-0b 10124-36-4b 1306-23-6b 
 NIOSH RTECS No data No data No data  
 EPA hazardous waste D006  D006  D006  
 OHM/TADS No data  No data No data  
 DOT/UN/NA/IMDG shipping UN2570/IMCO 6.1 No data  No data  
 HSDB 1613  274  1614  
 NCI No data No data  No data  
 
aAll information obtained from HSDB 2008 except where noted. 
bO’Neil et al. 2006. 
 
CAS = Chemical Abstracts Service; DOT/UN/NA/IMDG = Department of Transportation/United Nations/North 
America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency; 
HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for 
Occupational Safety and Health; OHM/TADS = Oil and Hazardous Materials/Technical Assistance Data System; 
RTECS = Registry of Toxic Effects of Chemical Substances 
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Table 4-2.  Physical and Chemical Properties of Cadmium and Compoundsa 
 
Property Cadmium Cadmium carbonate 
Molecular weight 112.41b 172.42b 
Color Silver-whiteb Whitec 
Physical state Lustrous metalb  Powder or rhombohedral leafletsb 
Melting point 321 °Cb Decomposes at 357 °C 
Boiling point 765 °Cb No data 
Density at 20 °C 8.65 g/cm3 at 25 °Cb 4.58 g/cm3f 
Odor Odorless No data 
Odor threshold:   
 Water No data No data 
 Air No data No data 
Solubility:   
 Water at 20 °C Insolubleb Insolublef 
 Organic solvents Acids, NH4NO3
f Acids, especially HNO3, 
concentrated NH4 solution
c 
Partition coefficients:   
 Log Kow No data No data 
 Log Koc No data No data 
Vapor pressure 7.5x10-3 mmHg at 257 °C No data 
Henry's law constant at 25 °C No data No data 
Autoignition temperature 250 °C No data 
Flashpoint No data No data 
Flammability limits No data No data 
Conversion factors No data No data 
Explosive limits No data No data 
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Table 4-2.  Physical and Chemical Properties of Cadmium and Compoundsa 
 
Property Cadmium chloride Cadmium oxide 
Molecular weight 183.32 128.41b 
Color Whitec Dark brownb 
Physical state Rhombohedral crystalsb Infusible powder or cubic crystalsb 
Melting point 568 °Cb Decomposes at 950 ºC 
Boiling point 960 °Cb Decomposes at 950 ºC 
Density at 20 °C 4.047g/cm3 at 25 °Ce Crystals 8.15 g/cm3; amorphous 
powder 6.95 g/cm3c 
Odor Odorlessc Odorless 
Odor threshold:   
 Water No data No data 
 Air No data No data 
Solubility:   
 Water at 20 °C Solubleb Insolubleb 
 Organic solvents Acetone, slightly soluble in MEOH 
and ETOHb 
Dilute acid, slowly soluble in NH4 
saltsb 
Partition coefficients:   
 Log Kow No data No data 
 Log Koc No data No data 
Vapor pressure 10 mmHg at 656 °Ce, 40 mmHg at 
736 °Cd, 760 mmHg at 967 °Cd 
1 mmHg at 1,000 °Ce; 10 mm Hg at 
1149 ºC; 40 mm Hg at 1257 ºC 
Henry's law constant at 25 °C No data No data 
Autoignition temperature No data No data 
Flashpoint No data No data 
Flammability limits No data No data 
Conversion factors No data No data 
Explosive limits No data No data 
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Table 4-2.  Physical and Chemical Properties of Cadmium and Compoundsa 
 
Property Cadmium sulfate Cadmium sulfide 
Molecular weight 208.47b 144.48b 
Color Colorlessc Light yellow or orangeb; brownc 
Physical state Monoclinic crystals (hydrate)b Cubic or hexagonal structureb 
Melting point 1,000 °Cc 1,750 °Cc 
Boiling point No data Sublimes in N2 at 980 °C
c 
Density at 20 °C 4.69 g/cm3b 4.82 g/cm3, hexagonal structureb, 
4.5 g/cm3, cubic structureb 
Odor Odorless No data 
Odor threshold:   
 Water No data No data 
 Air No data No data 
Solubility:   
 Water at 20 °C Solublec Soluble at 1.3 mg/L at 18 °Cb 
 Organic solvents Insoluble in alcoholc, acetone, 
ammoniaf 
Concentrated or warm dilute 
mineral acidsb 
Partition coefficients:   
 Log Kow No data No data 
 Log Koc No data No data 
Vapor pressure at 20 °C No data No data 
Henry's law constant at 25 °C No data No data 
Autoignition temperature No data No data 
Flashpoint No data No data 
Flammability limits No data No data 
Conversion factors No data No data 
Explosive limits No data No data 
 
aAll information from HSDB 2008, except where noted. 
bO’Neil et al. 2006. 
cSax and Lewis 2001. 
dFarnsworth 1980. 
eSax and Lewis 2000. 
fLide 2005. 
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5.1   PRODUCTION 
 
Cadmium is a widely but sparsely distributed element found in the earth's crust at concentrations ranging 
from 0.1 to 5 ppm, primarily as sulfide minerals in association with zinc ores, zinc-bearing lead ores, and 
or complex copper-lead-zinc ores (Morrow 2001).  Approximately 3 kg of cadmium for each ton of zinc 
are produced (OECD 1995).  About 80% of cadmium production is associated with zinc production, 
while the other 20% is associated with lead and copper byproduct production and the recapture of 
cadmium from finished products (Morrow 2001).  Between 2003 and 2006, the annual cadmium refinery 
production in the United States declined from 1,450 to 700 metric tons, dropping 52% between 2005 and 
2006 (USGS 2007, 2008).  Demand for cadmium in the nickel-cadmium (Ni-Cd) battery industry is 
strengthening as demand in other areas, like coatings and pigments, has been decreasing due to 
environmental concerns and regulations.  Despite this demand, primary production of cadmium may 
decrease as zinc prices increase, since producers may choose to discard the cadmium byproduct instead of 
refining it (USGS 2008).  
 
 
 
One company produced primary cadmium in the United States during 2007:  Clarksville (Zinifex Ltd.), 
Clarksville, Tennessee.  The Big River Zinc Corporation (Korea Zinc Co, Ltd), Sauget, Illinois operation 
was closed in 2006, citing mine closures and the increasing price of zinc concentrate (USGS 2008).  In 
June 2006, it was purchased by ZincOx Resources plc, Surrey, United Kingdom (USGS 2007).  A third 
company in Ellwood, Pennsylvania, International Metals Reclamation Co. Inc. (INMETCO), recovers 
cadmium from spent nickel-cadmium batteries, which began reclaiming cadmium in 1995 (USGS 2007).  
In 2005, it was estimated that the total cadmium recovery rate was only 12%, with an estimated 
40,000 tons of cadmium being disposed of in municipal waste or held in household storage or industry 
stockpiles between 1996 and 2005 (USGS 2007).  
The following companies are currently cited as major producers of cadmium compounds:  GFS 
Chemicals Inc., Columbus, Ohio (cadmium chloride, cadmium sulfate); CERAC Inc., Milwaukee, 
Wisconsin (cadmium sulfide); and EP Scientific Products, LLC (cadmium sulfide) (SRI 2007).  BASF 
Catalysts LLC, Louisville, Kentucky was specifically cited as a major producer of cadmium sulfide/
sulfoselenide pigments (SRI 2007). 
Tables 5-1 and 5-2 list the facilities in each state that manufacture or process cadmium and cadmium 
compounds, respectively, the intended use, and the range of maximum amounts stored on site.  The data  
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Table 5-1.  Facilities that Produce, Process, or Use Cadmium 
 
Statea 
Number of 
facilities 
Minimum 
amount on site 
in poundsb 
Maximum 
amount on site 
in poundsb Activities and usesc 
AL 19 0 999,999 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
AR 14 0 999,999 1, 2, 3, 5, 6, 7, 8, 10, 12, 13, 14 
AZ 12 0 999,999 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 13 
CA 41 0 99,999 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
CO 8 1,000 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 12 
CT 5 0 99,999 7, 8, 10, 11 
FL 6 0 99,999 1, 2, 3, 4, 6, 7, 8, 10, 12 
GA 8 0 999,999 1, 3, 6, 8, 13, 14 
IA 9 0 99,999 1, 5, 7, 8, 12, 13 
ID 6 10,000 999,999 1, 3, 5, 12, 13 
IL 25 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14 
IN 10 0 999,999 1, 2, 5, 7, 8, 9, 10, 12 
KS 6 100 99,999 1, 3, 7, 8, 12 
KY 11 0 999,999 1, 2, 3, 5, 6, 7, 8, 11 
LA 7 0 999,999 1, 3, 5, 6, 8, 10, 12, 13 
MA 13 0 99,999 1, 2, 3, 4, 7, 8, 10 
MD 5 100 49,999,999 1, 2, 4, 5, 6, 13 
MI 19 0 99,999 1, 2, 3, 5, 6, 7, 8, 10, 12, 13, 14 
MN 10 0 999,999 1, 3, 4, 7, 8, 9, 10, 11, 12, 13 
MO 7 0 999,999 1, 2, 3, 4, 5, 6, 8, 14 
MS 7 0 9,999 5, 7, 8, 12 
NC 13 0 9,999,999 1, 5, 7, 8, 9, 10, 12, 14 
NE 9 100 99,999 1, 2, 5, 7, 8, 12 
NH 4 0 999 1, 3, 8, 12 
NJ 18 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 
NV 2 10,000 99,999 1, 2, 3, 5, 12, 13 
NY 21 0 9,999,999 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14 
OH 32 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
OK 16 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 13 
OR 7 0 9,999,999 1, 5, 8, 12 
PA 35 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
PR 1 0 99 8 
RI 4 0 9,999 2, 3, 7, 8 
SC 20 0 9,999,999 1, 3, 5, 6, 7, 8, 9, 10, 11, 12 
TN 17 0 9,999,999 1, 2, 3, 4, 5, 7, 8, 9, 11, 12, 13 
TX 28 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 13, 14 
UT 8 0 99,999 1, 5, 6, 7, 8, 12, 13 
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Table 5-1.  Facilities that Produce, Process, or Use Cadmium 
 
Statea 
Number of 
facilities 
Minimum 
amount on site 
in poundsb 
Maximum 
amount on site 
in poundsb Activities and usesc 
VA 12 0 99,999 1, 5, 7, 8, 9, 10, 11, 13 
WA 5 0 9,999 1, 2, 3, 5, 10, 13 
WI 14 0 49,999,999 3, 7, 8, 10, 11, 12 
WV 3 100 99,999 7, 8, 12 
WY 1 0 99 1, 13 
 
aPost office state abbreviations used. 
bAmounts on site reported by facilities in each state. 
cActivities/Uses: 
1.  Produce 
2.  Import 
3.  Onsite use/processing 
4.  Sale/Distribution 
5.  Byproduct 
6.  Impurity 
7.  Reactant 
8.  Formulation Component 
9.  Article Component 
10.  Repackaging 
11.  Chemical Processing Aid 
12.  Manufacturing Aid  
13.  Ancillary/Other Uses 
14.  Process Impurity 
 
Source:  TRI09 2011 (Data are from 2009) 
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Table 5-2.  Facilities that Produce, Process, or Use Cadmium Compounds 
 
Statea 
Number of 
facilities 
Minimum 
amount on site 
in poundsb 
Maximum 
amount on site 
in poundsb Activities and usesc 
AK 14 0 499,999,999 1, 5, 7, 9, 11, 12, 14 
AL 31 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 13, 14 
AR 19 100 999,999 1, 2, 3, 5, 7, 8, 12, 13, 14 
AZ 30 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 12, 13, 14 
CA 28 0 49,999,999 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13 
CO 10 100 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13, 14 
CT 28 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 
DE 2 100 9,999 1, 5 
FL 11 0 999,999 1, 2, 3, 5, 6, 8, 12, 13, 14 
GA 15 0 999,999 1, 2, 3, 5, 6, 7, 8, 13 
IA 5 0 99,999 1, 5, 7, 8, 9, 12 
ID 14 100 9,999,999 1, 5, 6, 7, 11, 12, 13, 14 
IL 46 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 13, 14 
IN 19 0 999,999 1, 5, 7, 8, 13, 14 
KS 7 0 99,999 1, 7, 8, 11, 13 
KY 19 100 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 12, 13 
LA 12 0 999,999 1, 2, 3, 5, 7, 8, 12, 13 
MA 14 0 999,999 1, 3, 4, 5, 6, 7, 8, 12, 13 
MD 9 1,000 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 13 
MI 24 0 99,999,999 1, 3, 5, 6, 7, 8, 10, 11, 12, 13 
MN 10 100 999,999 1, 5, 7, 8, 9, 13 
MO 14 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 13 
MS 9 0 999,999 1, 5, 7, 8, 12 
MT 3 1,000 9,999,999 1, 2, 3, 4, 5, 6, 13 
NC 14 0 49,999,999 1, 7, 8, 13 
NE 8 1,000 999,999 1, 2, 5, 8, 12, 13, 14 
NH 1 1,000 9,999 7, 10 
NJ 35 0 9,999,999 1, 2, 3, 4, 6, 7, 8, 9, 10, 12 
NM 6 1,000 9,999,999 1, 5, 13 
NV 22 100 49,999,999 1, 2, 3, 5, 6, 7, 9, 10, 12, 13, 14 
NY 26 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13, 14 
OH 82 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 
OK 19 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13 
OR 4 100 99,999 1, 5, 8 
PA 67 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13 
PR 1 100 999 8 
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Table 5-2.  Facilities that Produce, Process, or Use Cadmium Compounds 
 
Statea 
Number of 
facilities 
Minimum 
amount on site 
in poundsb 
Maximum 
amount on site 
in poundsb Activities and usesc 
RI 8 100 99,999 2, 3, 7, 8, 11 
SC 18 0 999,999 1, 4, 5, 6, 7, 8, 11, 12, 13, 14 
TN 35 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 11, 12, 13, 14 
TX 36 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13, 14 
UT 15 1,000 49,999,999 1, 5, 6, 7, 8, 12, 13 
VA 11 0 99,999 1, 5, 7, 8, 12, 14 
WA 17 0 999,999 1, 2, 3, 5, 6, 7, 8, 9, 11, 12, 13, 14 
WI 14 100 49,999,999 1, 3, 5, 7, 8, 10, 11, 12 
WV 8 0 999,999 1, 2, 3, 7, 8, 11, 12, 13 
 
aPost office state abbreviations used. 
bAmounts on site reported by facilities in each state. 
cActivities/Uses: 
1.  Produce 
2.  Import 
3.  Onsite use/processing 
4.  Sale/Distribution 
5.  Byproduct 
6.  Impurity 
7.  Reactant 
8.  Formulation Component 
9.  Article Component 
10.  Repackaging 
11.  Chemical Processing Aid 
12.  Manufacturing Aid  
13.  Ancillary/Other Uses 
14.  Process Impurity 
 
Source:  TRI09 2011 (Data are from 2009) 
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listed in Tables 5-1 and 5-2 are derived from the Toxics Release Inventory (TRI) (TRI09 2011).  Because 
only certain types of facilities were required to report, this is not an exhaustive list. 
 
 
 
Cadmium metal is available in purities ranging from 99.5 to 99.999% in the following grades:  technical, 
powder, pure sticks, ingots, slabs, and high-purity crystals (<10 ppm impurities) (HSDB 2008).  
Cadmium (as cadmium oxide) is obtained mainly as a byproduct during the processing of zinc-bearing 
ores (e.g., sphalerites), and also from the refining of lead and copper from sulfide ores (e.g., galena) 
(Morrow 2001).  Cadmium oxide produced during roasting of ores is reduced with coke, and cadmium 
metal is separated by distillation or electrodeposition (Elinder 1985a).  Commercial-grade cadmium oxide 
is available in purities ranging from 99 to 99.9999%; common impurities are lead and thallium (NTP 
2005).  Cadmium chloride is produced by reacting molten cadmium with chlorine gas at 600 °C or by 
dissolving cadmium metal or the oxide, carbonate, sulfide, or hydroxide in hydrochloric acid and 
subsequently vaporizing the solution to produce a hydrated crystal (HSDB 2008; IARC 1993).  In 
preparing the anhydrous cadmium chloride salt, the hydrate is refluxed with thionyl chloride or calcined 
in a hydrogen chloride atmosphere (HSDB 2008).  Commercial cadmium chloride is available as a 
hydrate mixture with a purity range of 95.0–99.999% (NTP 2005). 
The commercial preparation of cadmium sulfate usually involves dissolution of the metal oxide, 
carbonate, or sulfide in sulfuric acid with subsequent cooling or evaporation (HSDB 2008).  Anhydrous 
cadmium sulfate is prepared by oxidation of the sulfide or sulfite at elevated temperatures (Herron 2003); 
or by melting cadmium with ammonium or sodium peroxodisulfate (Schulte-Schrepping and Piscator 
2002).  Cadmium sulfate monohydrate, which is the cadmium compound most often marketed, is 
produced by evaporating a cadmium sulfate solution above 41.5 °C (Schulte-Schrepping and Piscator 
2002).  Cadmium sulfate is available in technical and C.P. (chemically pure) grades (Lewis 2001).  
Cadmium sulfide can be prepared by a direct reaction with hydrogen sulfide and cadmium vapor or 
between sulfur and cadmium metal or cadmium oxide (Herron 2003).  Cadmium sulfide is available in 
technical, N.F. (national formulary grade), and high-purity (single crystals) (Lewis 2001).  Cadmium 
carbonate is produced by heating an acidified solution of cadmium chloride and urea in a sealed tube at 
200 °C, the slow absorption of carbon dioxide to cadmium oxide, or the precipitation of the hemihydrate 
from reaction of ammonium carbonate in cadmium ion solution (Herron 2003).  
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5.2   IMPORT/EXPORT  
 
Imports of cadmium into the United States declined steadily from 1994 through 1998, dropping from 
1,110 metric tons per year to an estimated 650 metric tons in 1998 (USGS 1999).  In 1986, imports of 
cadmium metal for consumption increased significantly to 3,000 metric tons, but continually decreased 
into the 1990s.  From 2003 to 2005, cadmium imports of metal, alloys, and scrap increased from 112 to 
288 tons, 74–207 tons of which were metal-only imports (USGS 2008).  Cadmium imports peaked in 
2005 and then declined through 2007, with 172 tons of cadmium metal only and 174 tons of metal, alloys, 
and scrap imported (USGS 2008).  The principal supplying countries were Australia (41%), Canada 
(20%), China (10%), and Peru (9%) (USGS 2008).  
 
 
 
In the mid-1990s, exports varied widely from 38 metric tons in 1993, to 1,450 metric tons in 1994, to 
550 metric tons in 1997.  In 2003, cadmium exports (reported as metal, alloys, and scraps) were 615 tons, 
with exports decreasing to only 154 tons the following year (USGS 2008).  Exports surged again in 2005 
to 686 tons, but have since been steadily decreasing from 483 tons in 2006 to 304 tons in 2007 (USGS 
2008).  
5.3   USE  
 
Cadmium, its alloys, and its compounds are used in a variety of consumer and industrial materials.  The 
dominant use of cadmium is in active electrode materials in Ni-Cd batteries (83% of total cadmium use) 
(USGS 2008).  Cadmium demand for other uses such as pigments for plastics, ceramics, and glasses; 
stabilizers for polyvinyl chloride (PVC) against heat and light; engineering coatings on steel and some 
nonferrous metals; and components of various specialized alloys have been decreasing. (Elinder 1992; 
IARC 1993; Thornton 1992; USGS 2008).  Cadmium salts have been used in a limited capacity as a 
fungicide for golf courses and home lawns (EPA 2006b).  Cadmium chloride is used in photography, 
photocopying, dyeing, calico printing, vacuum tube manufacture, pigment manufacture, galvanoplasty, 
lubricants, ice-nucleation agents, and in the manufacture of special mirrors (Herron 2003).  However, the 
significance of cadmium chloride as a commercial product is declining (IARC 1993).  
Cadmium-based colorants are used mainly in engineering plastics, ceramics, glasses, and enamels (IARC 
1993; OECD 1995).  Cadmium sulfide is especially important in this industry, especially in glasses and 
plastics; however, environmental and health concerns have contributed to a decrease in its production 
(Herron 2003).  Cadmium sulfide (yellow) and cadmium selenide (red) are combined to create solid 
C.P. toners ranging in color from yellows and oranges to reds and maroons (Herron 2003).  Cadmium 
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sulfide and cadmium telluride are used in solar cells and a variety of electronic devices which depend on 
cadmium’s semiconducting properties (Herron 2003; IARC 1993; OECD 1995).  The photoconductive 
and electroluminescent properties of cadmium sulfide have been applied in manufacturing a variety of 
consumer goods (IARC 1993).  Cadmium sulfate solution is used in standard Weston cells (Herron 2003).  
 
 
 
Though cadmium metal consumption for batteries has grown steadily since the 1980s and currently 
consumes 83% of the cadmium produced, other uses of cadmium began declining in the mid 1990s.  
Pigment, stabilizer, coating, and alloy markets for cadmium are decreasing due to environmental concerns 
(USGS 1997, 2008).  Proposed legislation, particularly in the European Union, restricting cadmium in 
consumer products may have a negative effect on cadmium demand (USGS 2008).  Excessive exports 
from Bulgaria and Russia in 1997 caused a drop in the average price of cadmium from $1.84 per pound in 
1995 to $0.51 per pound in 1997.  Also, Ni-Cd batteries have been replaced in some markets by lithium-
ion and nickel metal hydride batteries (USGS 2008).  As of 2006, Ni-Cd batteries made up 18% of the 
rechargeable battery market, down from 56% in 1996 with global sales decreasing 16% between 2005 and 
2006 (USGS 2008).  Despite this trend, demand for cadmium may increase due to new market 
opportunities for Ni-Cd batteries (USGS 2008).  Regulations by local authorities have forced the 
recycling of cadmium in Ni-Cd batteries, further depressing the demand for primary cadmium metal 
(USGS 1999).  
5.4   DISPOSAL  
 
Cadmium-containing wastes are subject to regulations concerning their treatment, storage, and disposal 
(see Chapter 8) (EPA 1982a; HSDB 2008; U.S. Bureau of Mines 1990).  In many states, the disposal of 
Ni-Cd batteries as municipal waste is prohibited (USGS 2007).  Incineration of municipal wastes, 
particularly from older, poorly controlled facilities, is a potential environmental source of cadmium.  In 
modern incineration plants, about 99.9% of cadmium was captured in boilers and control equipment 
(OECD 1995). 
A range of physicochemical processes is available for treatment of cadmium in liquid waste process 
streams, including ion exchange, electrolysis, cementation, and adsorption.  Both ion exchange and 
sulfide precipitation are used as alternate processes aimed at achieving low cadmium residuals in liquid 
wastes (UN 1985).  Combining processes, for example, conducting the primary precipitation of cadmium 
as hydroxide followed by secondary precipitation of residual cadmium as sulfide, has also been adopted.  
The more general application of the sulfide precipitation technique, however, is constrained due to a 
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tendency for formation of colloidal precipitate, the toxicity and odor of hydrogen sulfide, and the 
necessity to oxidize residual sulfide occurring in emissions prior to discharge (UN 1985). 
 
 
 
 
The most widely used treatment process involves the alkaline precipitation of cadmium as hydroxide or 
basic salts (UN 1985).  Removal of specific metal species during hydroxide precipitation is pH-
dependent, and some components of the waste stream can influence the solubility of cadmium hydroxide.  
After filtration, the sludge formed from the conversion of soluble cadmium compounds to insoluble 
compounds can be deposited in a suitable landfill (UN 1985). 
Various cadmium-bearing wastes are subject to aggressive leaching in refuse media, particularly under 
aerobic conditions (UN 1985).  While liquid wastes are banned from land disposal, the leaching tendency 
is accentuated in the presence of brine solutions.  Also, the mobility of cadmium in landfill conditions 
could be enhanced in the presence of mineral acids, which tend to solubilize cadmium compounds, or 
amine-containing materials, which tend to complex cadmium ions.  Waste containing mineral acids, 
cyanides, organic solvents, and amine-type substances should not be landfilled near cadmium-bearing 
wastes (UN 1985).   
In the laboratory, a recommended method for recovering cadmium from small quantities of cadmium 
oxide wastes uses a minimum amount of concentrated nitric acid to form nitrates.  The solution is 
evaporated in a hood to form a thin paste, and then diluted with water and saturated with hydrogen 
sulfide.  After the filtration, the precipitate is washed, dried, and returned to the supplier (UN 1985).   
Cadmium recovery from scrap metals and batteries is becoming increasingly popular, with the main 
emphasis being on recycling Ni-Cd batteries (Morrow 2001).  Battery recycling is relatively easy and can 
be achieved using pyrometallurgical (high temperature) or hydrometallurgical (wet chemical) processes 
(Morrow 2001).  In these processes, the metallic waste that contains iron, nickel, cadmium, and their 
oxides and hydroxides are separated from the other battery components and then converted back to a 
metal that has a technical purity required for the production of new batteries (Morrow 2001).  Cadmium-
based coatings can be recycled using electric-arc furnace (EAF) dust, which is obtained through the re-
melting of scrap steel that contains cadmium coatings and cadmium impurities (Morrow 2001).  
INMETCO in Ellwood, Pennsylvania recovers cadmium from spent Ni-Cd batteries, and has developed 
several collection programs to help facilitate battery recycling (USGS 2007).  Although participation in 
battery recycling has increased in businesses, communities, and retailers, the total recovery of cadmium in 
2005 was only 12% (USGS 2007). 
CADMIUM  276 
 
5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
 
 
 
 
 
 
 
This page is intentionally blank. 
 
CADMIUM  277 
 
 
 
 
 
 
 
 
 
6.  POTENTIAL FOR HUMAN EXPOSURE 
 
6.1   OVERVIEW  
 
Cadmium has been identified in at least 1,014 of the 1,669 hazardous waste sites that have been proposed 
for inclusion on the EPA National Priorities List (NPL) (HazDat 2007).  Cadmium compounds have been 
identified in at least 3 of the 1,669 hazardous waste sites.  However, the number of sites evaluated for 
cadmium is not known.  The frequency of these sites can be seen in Figures 6-1 and 6-2.  Of the 
1,014 sites where cadmium has been identified, 1,005 are located within the United States, 6 are located 
in the Commonwealth of Puerto Rico (not shown), 2 are located in Guam, and 1 is located in the Virgin 
Islands.  All sites where cadmium compounds were detected are located in the United States.  
 
 
Cadmium occurs in the earth’s crust at an abundance of 0.1–0.5 ppm and is commonly associated with 
zinc, lead, and copper ores.  It is also a natural constituent of ocean water, with average levels between 
<5 and 110 ng/L; with higher levels reported near coastal areas and in marine phosphates and 
phosphorites (Morrow 2001).  Natural emissions of cadmium to the environment can result from volcanic 
eruptions, forest fires, generation of sea salt aerosols, or other natural phenomena (EPA 1985a; Morrow 
2001; Shevchenko et al. 2003).  Cadmium is refined and consumed for use in batteries (83%), pigments 
(8%), coatings and platings (7%), stabilizers for plastics (1.2%), and nonferrous alloys, photovoltaic 
devices, and other (0.8%) (USGS 2008).  Nonferrous metal mining and refining, manufacture and 
application of phosphate fertilizers, fossil fuel combustion, and waste incineration and disposal are the 
main anthropogenic sources of cadmium in the environment.  
Cadmium can be released to the atmosphere through metal production activities, fossil fuel combustion, 
and waste incineration.  The main cadmium compounds found in air are cadmium oxide, chloride, and 
sulfate, and these compounds are expected to undergo minimal transformation in the atmosphere (EPA 
1980d).  The major fate of cadmium in air is through transport and deposition.  Cadmium can travel long 
distances in the atmosphere and then deposit (wet or dry) onto surface soils and water, which can result in 
elevated cadmium levels even in remote locations (Shevchenko et al. 2003).  Results from the 2006 final 
report of EPA’s Urban Air Toxic Monitoring program reported average daily cadmium levels of 
<0.01 μg/m3 at several monitoring sites throughout the United States (EPA 2007).  These sites include:  
Bountiful, Utah; Northbrook, Illinois; Austin, Texas; St. Louis, Missouri; Indianapolis, Indiana; and 
Birmingham, Alabama (EPA 2007).  Atmospheric concentrations of cadmium are generally highest in the 
vicinity of cadmium-emitting industries (Elinder 1985a; Pirrone et al. 1996).  Due to advances in 
pollution control technology, cadmium emissions to air are not expected to increase, even though  
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Figure 6-1.  Frequency of NPL Sites with Cadmium Contamination 
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Figure 6-2.  Frequency of NPL Sites with Cadmium Compounds Contamination 
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cadmium-emitting industries are expected to grow (Herron 2003; Morrow 2010; Schulte-Schrepping and 
Piscator 2002).  Except for those who live near cadmium-emitting industries, inhalation of cadmium in 
the ambient air is not a major source of exposure.  
 
 
 
 
The main sources of cadmium to soil include atmospheric deposition and direct application methods such 
as phosphate fertilizer use and sewage sludge disposal.  Some phosphate fertilizers can contain up to 
300 mg Cd/kg (Alloway and Steinnes 1999).  Wet and dry deposition of cadmium from the atmosphere 
may also contribute sizable amounts of cadmium to soil in the areas surrounding sources of atmospheric 
emissions (EPA 1985a; Mielke et al. 1991).  Cadmium’s mobility in soil depends on several factors 
including the pH of the soil and the availability of organic matter.  Generally, cadmium will bind strongly 
to organic matter and this will, for the most part, immobilize cadmium (Autier and White 2004).  
However, immobilized cadmium is available to plant life and can easily enter the food supply.  Cadmium 
in soil tends to be more available when the soil pH is low (acidic) (Elinder 1992). 
Water sources near cadmium-emitting industries, both with historic and current operations, have shown a 
marked elevation of cadmium in water sediments and aquatic organisms (Angelo et al. 2007; Arnason and 
Fletcher 2003; Brumbaugh et al. 2005; Mason et al. 2000; Paulson 1997).  In surface water and 
groundwater, cadmium can exist as the hydrated ion or as ionic complexes with other inorganic or organic 
substances.  While soluble forms may migrate in water, cadmium is relatively nonmobile in insoluble 
complexes or adsorbed to sediments.  Cadmium is taken up and retained by aquatic and terrestrial plants 
and is concentrated in the liver and kidney of animals that eat the plants (Elinder 1985a).   
For the U.S. population, cadmium exposure through the drinking water supply is of minor concern.  EPA 
requires water suppliers to limit the cadmium concentration in water to <5 μg/L (EPA 2006a).  
In the United States, the largest source of cadmium exposure for nonsmoking adults and children is 
through dietary intake (NTP 2005).  Based on the mean cadmium daily intakes of males and females aged 
6–60 years reported by Choudhury et al. (2001), age-weighted mean cadmium intakes of 0.35 µg/kg/day 
for males and 0.30 µg/kg/day for females were calculated for U.S. nonsmokers.  In general, vegetables, 
particularly leafy vegetables such as lettuce (0.051 mg/kg) and spinach (0.124 mg/kg), have the highest 
concentrations of cadmium; the concentrations of cadmium in all vegetables ranged from 0.001 to 
0.124 mg/kg (FDA 2010; Morrow 2001).  Peanuts, soybeans, and sunflower seeds have naturally high 
levels of cadmium (Morrow 2001); the mean concentration of cadmium in legumes and nuts ranged from 
0.001 to 0.054 mg/kg (FDA 2010).  People who regularly consume shellfish and organ meats (liver and 
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kidney) have an increased risk of cadmium exposure, as these organisms tend to accumulate cadmium 
(Elinder 1985a).   
Tobacco leaves naturally accumulate cadmium (Morrow 2001).  Cadmium levels in cigarettes vary 
greatly depending on the source of production.  Cigarettes produced in Mexico were found to have the 
highest level of cadmium per cigarette (arithmetic mean [AM] ± arithmetic standard deviation [ASD] = 
2.03 µg/cigarette ±0.33), while cigarettes from India were found to have the lowest (arithmetic mean ± 
arithmetic standard deviation = 0.35 µg/cigarette ±0.09).  The arithmetic mean for the United States was 
1.07 µg/cigarette ±0.11 (Watanabe et al. 1987).  Tobacco contains approximately 0.5–2.0 μg cadmium per 
cigarette, and about 10% is inhaled when smoked (Morrow 2010).  The geometric mean blood cadmium 
level for the heavy smoker subgroup in New York City was reported as 1.58 μg/L, compared to the 
geometric mean of 0.77 μg/L for all New York City adults (McKelvey et al. 2007).  
 
6.2   RELEASES TO THE ENVIRONMENT  
 
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of 
facilities are required to report (EPA 2005).  This is not an exhaustive list.  Manufacturing and processing 
facilities are required to report information to the TRI only if they employ 10 or more full-time 
employees; if their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 
1081, and 1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the 
purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust 
coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to 
facilities that combust coal and/or oil for the purpose of generating electricity for distribution in 
commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 
5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities 
primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces, 
imports, or processes ≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI 
chemical in a calendar year (EPA 2005). 
Additional releases of cadmium to the environment occur from natural sources and from processes such 
as combustion of fossil fuel, incineration of municipal or industrial wastes, or land application of sewage 
sludge or fertilizer (EPA 1985a).  Quantitative information on releases of cadmium to specific 
environmental media is discussed below. 
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6.2.1   Air  
 
Estimated releases of 731 pounds (~0.3 metric tons) of cadmium to the atmosphere from 41 domestic 
manufacturing and processing facilities in 2009, accounted for about 0.18% of the estimated total 
environmental releases of cadmium from facilities required to report to the TRI (TRI09 2011).  These 
releases are summarized in Table 6-1.  Estimated releases of 11,567 pounds (~5.2 metric tons) of 
cadmium compounds to the atmosphere from 85 domestic manufacturing and processing facilities in 
2009, accounted for about 0.55% of the estimated total environmental releases of cadmium from facilities 
required to report to the TRI (TRI09 2011).  These releases are summarized in Table 6-2.   
 
 
Cadmium is released to the atmosphere from both natural and anthropogenic sources.  Cadmium is widely 
distributed in the earth's crust (EPA 1985a) with concentrations reported between 0.1 and 0.5 ppm and 
higher levels in sedimentary rocks (Morrow 2001).  Consequently, cadmium may be released to the air 
from entrainment of dust particles, volcanic eruptions, forest fires, or other natural phenomena (EPA 
1985a; Morrow 2001).  Cadmium exists in ocean waters at average levels ranging from <5 to 110 ng/L 
and may transport to the atmosphere through natural processes like generation of sea-salt aerosols 
(Morrow 2001; Shevchenko et al. 2003).  Increased cadmium levels in the air over the Russian Arctic 
have been detected during the summer and autumn seasons and are believed to be attributed to natural 
processes, while the levels detected during the winter and spring seasons were due to anthropogenic 
sources (Shevchenko et al. 2003).   
However, industrial activities are the main sources of cadmium release to air (EPA 1985a), and emissions 
from anthropogenic sources have been found to exceed those of natural origin by an order of magnitude 
(IARC 1993).  Major industrial sources of cadmium emissions include zinc, lead, copper, and cadmium 
smelting operations; coal and oil-fired boiler; other urban and industrial emissions; phosphate fertilizer 
manufacture; road dust; and municipal and sewage sludge incinerators (Alloway and Steinnes 1999; 
Morrow 2001).  Emission of cadmium through nonferrous metal production in 1995 was highest in Asia 
with 1,176 tonnes and North America emitting 191 tonnes.  Estimated emissions of cadmium from 
municipal waste and sewage sludge incineration in North America were 8 and 7 tonnes/year, respectively, 
in the mid-1990s (Pacyna and Pacyna 2001).  Additional sources that contribute negligible amounts of 
cadmium are rubber tire wear, motor oil combustion, cement manufacturing, and fertilizer and fungicide 
application (Wilber et al. 1992).  Average cadmium emission factors for combustion of coal and oil are 
about 0.1 and 0.05 g/ton, respectively.  Cement production releases an estimated 0.01 g/ton cement and  
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Table 6-1.  Releases to the Environment from Facilities that Produce, Process, or 
Use Cadmiuma 
 
 Reported amounts released in pounds per yearb 
Statec RFd Aire Waterf UIg Landh Otheri 
Total release 
On-sitej Off-sitek On- and off-site 
AL 2 13 122 0 36,955 11 37,087 13 37,100 
AR 3 4 7 0 0 100 6 105 111 
AZ 1 0 0 0 16,005 0 16,005 0 16,005 
CA 2 426 169 0 13,992 20 14,263 344 14,607 
FL 1 0 0 0 0 0 0 0 0 
GA 1 26 0 0 5 0 26 5 31 
IA 1 0 0 0 0 0 0 0 0 
IN 1 3 0 0 0 0 3 0 3 
KS 2 0 0 0 0 0 0 0 0 
KY 1 19 0 0 0 0 19 0 19 
LA 2 75 0 0 61 0 136 0 136 
MI 1 0 0 0 5 0 0 5 5 
NC 2 30 0 0 0 0 30 0 30 
NE 1 1 0 0 10,282 0 10,249 34 10,283 
NV 1 2 0 0 40,681 524 40,683 524 41,207 
NY 2 0 11 0 0 8 11 8 19 
OH 4 7 0 104,579 22,337 1 126,586 338 126,924 
OK 1 13 0 0 38,780 0 38,793 0 38,793 
OR 1 1 0 0 13,575 1 13,577 1 13,577 
PA 1 59 3 0 0 0 62 0 62 
TN 2 5 0 0 38,186 2,519 5 40,705 40,710 
TX 3 1 22 37,988 0 26 37,990 47 38,037 
UT 3 11 4 0 22,020 2,849 22,031 2,853 24,884 
VA 1 0 0 0 0 0 0 0 0 
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Table 6-1.  Releases to the Environment from Facilities that Produce, Process, or 
Use Cadmiuma 
 
 
Statec RFd 
Reported amounts released in pounds bper year  
Aire fWater  UIg Landh 
Total release 
i jOther  On-site  kOff-site  On- and off-site 
WI 1 35 0 0 181 0 35 181 216 
Total 41 731 338 142,567 253,065 6,059 357,597 45,164 402,760 
 
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an 
exhaustive list.  Data are rounded to nearest whole number. 
bData in TRI are maximum amounts released by each facility. 
cPost office state abbreviations are used. 
dNumber of reporting facilities. 
eThe sum of fugitive and point source releases are included in releases to air by a given facility. 
fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal 
and metal compounds). 
gClass I wells, Class II-V wells, and underground injection. 
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other onsite landfills, land treatment, surface 
impoundments, other land disposal, other landfills. 
iStorage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for 
disposal, unknown 
jThe sum of all releases of the chemical to air, land, water, and underground injection wells. 
kTotal amount of chemical transferred off-site, including to POTWs. 
 
RF = reporting facilities; UI = underground injection 
 
Source:  TRI09 2011 (Data are from 2009) 
 
CADMIUM  285 
 
6.  POTENTIAL FOR HUMAN EXPOSURE 
 
 
 
 
 
 
 
 
Table 6-2.  Releases to the Environment from Facilities that Produce, Process, or 
Use Cadmium Compoundsa 
 
 Reported amounts released in pounds per yearb 
Statec RFd Aire Waterf UIg Landh Otheri 
Total release 
On-sitej Off-sitek On- and off-site 
AK 3 129 3 0 61,176 0 61,308 0 61,308 
AL 4 221 122 0 698,581 0 698,681 243 698,924 
AR 1 0 0 0 0 131 0 131 131 
AZ 3 611 5 0 63,392 0 63,753 255 64,008 
CA 1 0 0 0 115 0 0 115 115 
CO 1 1 0 0 0 0 1 0 1 
CT 1 0 0 0 0 0 0 0 0 
FL 1 0 0 0 0 0 0 0 0 
GA 3 8 3 0 0 0 9 3 11 
ID 2 6,409 6 0 386,455 0 392,870 0 392,870 
IL 5 59 117 215 33,651 1,553 1,289 34,306 35,595 
IN 3 76 6 0 13,361 41 82 13,402 13,484 
LA 1 0 0 0 0 0 0 0 0 
MA 3 25 251 0 0 1,021 25 1,272 1,297 
MD 1 0 0 0 0 12,400 0 12,400 12,400 
MI 1 0 5 0 250 0 0 255 255 
MO 1 593 265 0 6,178 9 6,987 58 7,045 
NC 1 0 0 0 0 0 0 0 0 
NE 1 250 0 0 250 21,000 250 21,250 21,500 
NJ 2 5 1 0 1,488 140 5 1,629 1,634 
NV 4 40 0 0 165,471 0 165,506 5 165,511 
NY 1 0 21 0 0 0 21 0 21 
OH 10 37 102 0 4,264 15,604 1,471 18,536 20,007 
OK 1 31 0 0 0 0 31 0 31 
PA 8 646 326 0 2,596 9,442 721 12,289 13,010 
SC 1 255 10 0 6,165 0 265 6,165 6,430 
TN 5 1,997 597 0 192,927 428 195,516 433 195,949 
TX 7 30 335 2,118 334,113 2,583 334,650 4,529 339,179 
UT 4 130 133 0 54,954 107 55,217 107 55,324 
WA 1 2 2 0 0 5 4 5 9 
WI 3 10 27 0 1 6,623 10 6,651 6,661 
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Table 6-2.  Releases to the Environment from Facilities that Produce, Process, or 
Use Cadmium Compoundsa 
 
 
Statec RFd 
Reported amounts released in pounds bper year  
Aire fWater  i jUIg Landh Other  On-site  
Total release 
kOff-site  On- and off-site 
WV 1 2 7 0 1,018 0 518 509 1,027 
Total 85 11,567 2,346 2,333 2,026,406 71,087 1,979,190 134,549 2,113,739 
 
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an 
exhaustive list.  Data are rounded to nearest whole number. 
bData in TRI are maximum amounts released by each facility. 
cPost office state abbreviations are used. 
dNumber of reporting facilities. 
eThe sum of fugitive and point source releases are included in releases to air by a given facility. 
fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal 
and metal compounds). 
gClass I wells, Class II-V wells, and underground injection. 
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other onsite landfills, land treatment, surface 
impoundments, other land disposal, other landfills. 
iStorage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for 
disposal, unknown 
jThe sum of all releases of the chemical to air, land, water, and underground injection wells. 
kTotal amount of chemical transferred off-site, including to POTWs. 
 
RF = reporting facilities; UI = underground injection 
 
Source:  TRI09 2011 (Data are from 2009) 
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pig iron and steel production releases an estimated 0.1 g/ton (Pacyna and Pacyna 2001).  Atmospheric 
cadmium exists mainly in the forms of cadmium oxide and cadmium chloride (Morrow 2001). 
 
 
 
Cadmium emissions have decreased dramatically since the 1960s as primary cadmium producers now use 
the electrolytic process and pollution control technologies such as agglomeration, electrostatic 
purification of gas exhaust, and exhaust filtration have been implemented (Herron 2003; Morrow 2001; 
Schulte-Schrepping and Piscator 2002).  Anthropogenic cadmium emissions have decreased by over 90% 
in the last 50 years (Morrow 2010).   
There is a potential for release of cadmium to air from hazardous waste sites.  Cadmium has been 
detected in air samples collected at 50 of the 1,014 NPL hazardous waste sites where cadmium was 
detected in some environmental medium (HazDat 2007).  Cadmium compounds were detected in air 
samples collected at one of three NPL hazardous waste sites where cadmium compounds were detected.  
The HazDat information used includes data from NPL sites only.   
 
6.2.2   Water  
 
Estimated releases of 338 pounds (~0.15 metric tons) of cadmium to surface water from 41 domestic 
manufacturing and processing facilities in 2009, accounted for about 0.084% of the estimated total 
environmental releases from facilities required to report to the TRI.  This estimate includes releases to 
wastewater treatment and publicly owned treatment works (TRI09 2011).  These releases are summarized 
in Table 6-1.  Estimated releases of 2,346 pounds (~1.1 metric tons) of cadmium compounds to surface 
water from 85 domestic manufacturing and processing facilities in 2009, accounted for about 0.11% of 
the estimated total environmental releases from facilities required to report to the TRI.  This is estimate 
includes releases to wastewater treatment and publicly owned treatment works (TRI09 2011).  These 
releases are summarized in Table 6-2.   
Cadmium may be released to water by natural weathering processes, by discharge from industrial 
facilities or sewage treatment plants, atmospheric deposition, by leaching from landfills or soil, or 
phosphate fertilizers (EPA 1981a, 1985a; IJC 1989; Morrow 2001).  Cadmium may also leach into 
drinking water supplies from pipes in the distribution system (Elinder 1985a).  The average level of 
cadmium in ocean water has been reported between <5 and 110 ng/L, with higher levels reported near 
coastal areas and in marine phosphates and phosphorites (Morrow 2001).  
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Smelting of nonferrous metal ores has been estimated to be the largest anthropogenic source of cadmium 
released into the aquatic environment.  Cadmium contamination can result from entry into aquifers of 
mine drainage water, waste water, tailing pond overflow, and rainwater runoff from mine areas (IARC 
1993).  The upper Clark Fork River in Montana is contaminated with large amounts of cadmium from 
past mining activities between 1880 and 1972.  While mining wastes are no longer released into the river, 
an estimated 14.5 million cubic meters of tailings have been incorporated into the river bed, floodplain, 
and reservoir sediments (Canfield et al. 1994).  Other human sources include spent solutions from plating 
operations and phosphate fertilizers.  Cadmium constitutes up to 35 mg/kg of phosphorous pentoxide, a 
component of phosphate-based fertilizers, in the United States (IARC 1993).  Atmospheric fallout of 
cadmium to aquatic systems is another major source of cadmium to the environment (IARC 1993; 
Muntau and Baudo 1992).  
 
 
A large proportion of the cadmium load in the aquatic environment is due to diffuse pollution originating 
from many different sources rather than from point sources.  In the estuarine portion of the Hudson River, 
it has been found that more cadmium was released from agricultural and urban run-off than from 
industrial and municipal sewage treatment plants (Muntau and Baudo 1992).  In an urban environment, 
there are also multiple sources of cadmium to waste water.  In an urban waste water study conducted in 
the United Kingdom, cadmium was detected in the waste water originating from industrial, commercial, 
and private sectors, with the highest average cadmium concentration detected in the waste water of new 
(<5 years old) private housing (0.375 μg/L) (Rule et al. 2006).  
There is also a potential for release of cadmium to water from hazardous waste sites.  Cadmium has been 
detected in surface water samples collected at 354 of the 1,014 NPL hazardous waste sites, and in 
groundwater samples collected at 675 of the 1,014 NPL hazardous waste sites where cadmium has been 
detected in some environmental medium (HazDat 2007).  The HazDat information used includes data 
from NPL sites only. 
 
6.2.3   Soil  
 
Estimated releases of 253,065 pounds (~115 metric tons) of cadmium to soils from 41 domestic 
manufacturing and processing facilities in 2009, accounted for about 63% of the estimated total 
environmental releases of cadmium from facilities required to report to the TRI (TRI09 2011).  An 
additional 142,567 pounds (~65 metric tons), constituting about 35% of the total environmental 
emissions, were released via underground injection and to Class I wells, Class II-V wells (TRI09 2011).  
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These releases are summarized in Table 6-1.  Estimated releases of 2,026,406 pounds (~919 metric tons) 
of cadmium compounds to soils from 85 domestic manufacturing and processing facilities in 2009, 
accounted for about 96% of the estimated total environmental releases from facilities required to report to 
the TRI.  An additional 2,333 pounds (~1 metric tons), constituting about 0.1% of the total environmental 
emissions, were released via underground injection and to Class I wells, Class II-V wells (TRI09 2011).  
These releases are summarized in Table 6-2. 
 
 
 
 
Major sources of cadmium to soil include atmospheric emissions, direct application, and accidental or 
fugitive contamination.  Direct application emissions refer to phosphate fertilizers, phosphogypsum and 
other byproduct gypsums (from the manufacture of phosphoric acid and phosphorite), sewage sludges, 
composted municipal solid waste, and residual ashes from wood, coal, or other types of combustion.  
Contamination sources include industrial site contamination, mine waste dumps, and corrosion of metal 
structures (Alloway and Steinnes 1999).  
Approximately 61% of the 5.6 million dry tons of sewage sludge produced annually in the United States 
is landspread (NRC 2002).  The EPA ceiling limit for the cadmium content of sludge applied to land is 
85 mg/kg in sewage sludge, the cumulative pollution loading rate is 39 kg/ha, and the maximum annual 
cadmium loading of 1.9 kg-ha-1·year-1 (EPA 2011a).   Estimated cadmium concentrations in sewage 
sludge range from 0.21 to >11.8 mg/kg (EPA 2009a).  Sludges from treatment plants that serve cadmium 
industries (i.e., battery manufacturing) tend to have higher levels of cadmium (Alloway and Steinnes 
1999).  
Phosphate fertilizers are a major source of cadmium input to agricultural soils (EPA 1985a).  The natural 
cadmium concentration in phosphates ranges from 3 to 100 μg/g (EPA 1985a; Singh 1994).  Some may 
contain up to 300 mg Cd/kg (Alloway and Steinnes 1999).  It is estimated that over 8 million tons of 
phosphate fertilizer were used in the United States in 2010 (USDA 2012).  Any soil treated with these 
fertilizers will have a cadmium input, but exactly how much will vary (Alloway and Steinnes 1999).  For 
example, continuous fertilization with a high rate of triple super-phosphate (1,175 kg P-ha-1·year-1) for a 
period of 36 years resulted in a 14-fold increase in cadmium content of surface soils (Singh 1994).   
Wet and dry deposition of cadmium from the atmosphere may also contribute sizable amounts of 
cadmium to soil in the areas surrounding sources of atmospheric emissions, such as incinerators and 
vehicular traffic, which may release cadmium from burned fuel and tire wear (EPA 1985a; Mielke et al. 
1991).  High-temperature sources, such as smelters and incinerators, release small particles that are ideal 
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for long-range atmospheric transport.  Also, vapors emitted from high temperature processes will 
preferentially condense onto smaller particles, thus making vapor emissions available for transport 
(Steinnes and Friedland 2006).  Aerosols containing cadmium can be carried very long distances in the 
atmosphere before being deposited to soils.  In the soils in southern Norway, most of the cadmium and 
other heavy metals that are deposited from the atmosphere originate from other parts of Europe (Alloway 
and Steinnes 1999).  Long-range atmospheric deposition is more evident in organic-rich soils as they have 
a tendency to concentrate heavy metals (Steinnes and Friedland 2006).  
 
 
There is also a potential for release of cadmium to soil from hazardous waste sites.  Cadmium has been 
detected in soil samples collected at 606 of the 1,014 NPL hazardous waste sites and in sediment samples 
collected at 392 of the 1,014 NPL hazardous waste sites where cadmium has been detected in some 
environmental medium (HazDat 2007).  The HazDat information used includes data from NPL sites only. 
 
6.3   ENVIRONMENTAL FATE  
 
6.3.1   Transport and Partitioning  
 
Cadmium is expected to partition primarily to soil (80–90%) when released to the environment.  
Although particulate and vapor cadmium may be released to the air, the net flux to soil will be positive as 
cadmium will eventually deposit onto soils (Morrow 2001; Wilber et al. 1992).  
Cadmium and cadmium compounds have negligible vapor pressures (see Table 4-2) but can be released 
to the environment by emissions from municipal waste incinerators, nonferrous metal production, and 
other high-temperature processes (Morrow 2001).  Cadmium emitted to the atmosphere from combustion 
processes condense onto very small particulates that are in the respirable range (<10 μm) and are subject 
to long-range transport (Steinnes and Friedland 2006; Wilber et al. 1992).  These cadmium pollutants may 
be transported from a hundred to a few thousand kilometers and have a typical atmospheric residence 
time of about 1–10 days before deposition occurs (EPA 1980d).  Larger cadmium-containing particles 
from smelters and other pollutant sources are also removed from the atmosphere by gravitational settling, 
with substantial deposition in areas downwind of the pollutant source.  Cadmium-containing particulates 
may dissolve in atmospheric water droplets and be removed from air by wet deposition.   
 
Cadmium is more mobile in aquatic environments than most other heavy metals (e.g., lead).  In most 
natural surface waters, the affinities of complexing ligands for cadmium generally follow the order of 
humic acids > CO3
2– > OH– ≥ Cl– ≥ SO4
2– (EPA 1979).  In unpolluted natural waters, most cadmium 
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transported in the water column will exist in the dissolved state as the hydrated ion Cd(H2O)6
2+.  Minor 
amounts of cadmium are transported with the coarse particulates, and only a small fraction is transported 
with the colloids.  In unpolluted waters, cadmium can be removed from solution by exchange of cadmium 
for calcium in the lattice structure of carbonate minerals (EPA 1979).  In polluted or organic-rich waters, 
adsorption of cadmium by humic substances and other organic complexing agents plays a dominant role 
in transport, partitioning, and remobilization of cadmium (EPA 1979).  Cadmium concentration in water 
is inversely related to the pH and the concentration of organic material in the water (EPA 1979).  Because 
cadmium exists only in the +2 oxidation state in water, aqueous cadmium is not strongly influenced by 
the oxidizing or reducing potential of the water.  However, under reducing conditions, cadmium may 
form cadmium sulfide, which is poorly soluble and tends to precipitate (EPA 1983c; McComish and Ong 
1988).  Free (ionic) cadmium seems to be the toxic form and becomes much more prevalent at low 
salinity (Sprague 1986).  Cadmium has a relatively long residence time in aquatic systems.  In Lake 
Michigan, a mean residence time of 4–10 years was calculated for cadmium compared to 22 years 
calculated for mercury (Wester et al. 1992). 
 
Precipitation and sorption to mineral surfaces, hydrous metal oxides, and organic materials are the most 
important processes for removal of cadmium to bed sediments.  Humic acid is the major component of 
sediment responsible for adsorption.  Sorption increases as the pH increases (EPA 1979).  Sediment 
bacteria may also assist in the partitioning of cadmium from water to sediments (Burke and Pfister 1988).  
Both cadmium-sensitive and cadmium-resistant bacteria reduced the cadmium concentration in the water 
column from 1 ppm to between 0.2 and 0.6 ppm, with a corresponding increase in cadmium concentration 
in the sediments in the simulated environment (Burke and Pfister 1988).  Studies indicate that 
concentrations of cadmium in sediments are at least one order of magnitude higher than in the overlying 
water (EPA 1979).  The mode of sorption of cadmium to sediments is important in determining its 
disposition to remobilize.  Cadmium associated with carbonate minerals, precipitated as stable solid 
compounds or co-precipitated with hydrous iron oxides, is less likely to be mobilized by resuspension of 
sediments or biological activity.  Cadmium that is adsorbed to mineral surfaces such as clay, or to organic 
materials, is more easily bioaccumulated or released in the dissolved state when the sediment is disturbed 
(EPA 1979).  Cadmium may redissolve from sediments under varying ambient conditions of pH, salinity, 
and redox potential (DOI 1985; EPA 1979; Feijtel et al. 1988; Muntau and Baudo 1992).  Cadmium is not 
known to form volatile compounds in the aquatic environment, so partitioning from water to the 
atmosphere does not occur (EPA 1979). 
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Debusk et al. (1996) studied the retention and compartmentalization of lead and cadmium in wetland 
microcosms.  Differences between measured concentrations in inflow and outflow samples indicated that 
approximately half of the added cadmium was retained in the wetland microcosms.  Experiments showed 
that nearly all trace metals were present in the sediments as sulfides, limiting their bioavailability and 
toxicity.  The results of their analyses and a lack of noticeable biological effects suggested that in 
wetlands containing organic sediments, the sediment chemistry dominates cycling of the trace metals. 
 
 
 
In soils, pH, oxidation-reduction reactions, and formation of complexes are important factors affecting the 
mobility of cadmium (Bermond and Bourgeois 1992; Herrero and Martin 1993).  Cadmium can 
participate in exchange reactions on the negatively charged surface of clay minerals.  In acid soils, the 
reaction is reversible.  However, adsorption increases with pH and may become irreversible (Herrero and 
Martin 1993).  Cadmium also may precipitate as insoluble cadmium compounds, or form complexes or 
chelates by interaction with organic matter.  Available data suggest that organic matter is more effective 
than inorganic constituents in keeping cadmium unavailable (McBride 1995).  Examples of cadmium 
compounds found in soil are Cd3(PO4)2, CdCO3, and Cd(OH)2 (Herrero and Martin 1993).  These 
compounds are formed as the pH rises.  It has been found that about 90% of cadmium in soils remains in 
the top 15 cm (Anonymous 1994). 
The mobility and plant availability of cadmium in wetland soils are substantially different from upland 
soils.  Cadmium tends to be retained more strongly in wetland soils and is more available to plants under 
upland conditions (Gambrell 1994).  Debusk et al. (1996) compared heavy metal uptake by cattails and 
duckweed wetland microcosms and found that duckweed, on a whole-plant basis, accumulates cadmium 
more effectively than cattail does.  The potential cadmium removal rate for duckweed is 2–4 mg 
Cd/m2/day.   
Cadmium in soils may leach into water, especially under acidic conditions (Elinder 1985a; EPA 1979).  
Roy et al. (1993) demonstrated that chlorine complexation in the leachate of ash from a municipal solid 
waste incinerator can result in a decrease in cadmium sorption by two common clays, kaolinite and illite.  
They also found that cationic competitive sorption enhances mobility in soils.  Cadmium-containing soil 
particles may also be entrained into the air or eroded into water, resulting in dispersion of cadmium into 
these media (EPA 1985a).  Contamination of soil by cadmium is of concern because the cadmium is taken 
up efficiently by plants and, therefore, enters the food chain for humans and other animals.  A low soil 
pH, which is becoming prevalent in many areas of the world due to acid rain, increases the uptake of 
cadmium by plants (Elinder 1992). 
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Aquatic and terrestrial organisms bioaccumulate cadmium (Handy 1992a, 1992b; Kuroshima 1992; Naqvi 
and Howell 1993; Roseman et al. 1994; Suresh et al. 1993).  Cadmium concentrates in freshwater and 
marine animals to concentrations hundreds to thousands of times higher than in the water (EPA 1979).  
Reported bioconcentration factors (BCFs) range from <200 to 18,000 for invertebrates (van Hattum et al. 
1989), from 3 to 4,190 for fresh water aquatic organisms (ASTER 1995), and from 5 to 3,160 for 
saltwater aquatic organisms (ASTER 1994).  Bioconcentration in fish depends on the pH and the humus 
content of the water (John et al. 1987).  Because of their high ability to accumulate metals, some aquatic 
plants have been suggested for use in pollution control.  For example, it has been suggested that the 
rapidly-growing water hyacinth (Eichhornia crassipes) could be used to remove cadmium from domestic 
and industrial effluents (Ding et al. 1994; Muntau and Baudo 1992). 
The data indicate that cadmium bioaccumulates in all levels of the food chain.  Cadmium accumulation 
has been reported in grasses and food crops, and in earthworms, poultry, cattle, horses, and wildlife 
(Alloway et al. 1990; Beyer et al. 1987; Gochfeld and Burger 1982; Kalac et al. 1996; Munshower 1977; 
Ornes and Sajwan 1993; Rutzke et al. 1993; Sileo and Beyer 1985; Vos et al. 1990).  The metal burden of 
a crop depends on uptake by the root system, direct foliar uptake and translocation within the plant, and 
surface deposition of particulate matter (Nwosu et al. 1995).  In general, cadmium accumulates in the 
leaves of plants and, therefore, is more of a risk in leafy vegetables grown in contaminated soil than in 
seed or root crops (Alloway et al. 1990).  He and Singh (1994) report that, for plants grown in the same 
soil, accumulation of cadmium decreased in this order:  leafy vegetables, root vegetables, and grain crops.  
Alloway et al. (1990) also demonstrated that uptake of cadmium decreased in this order:  lettuces, 
cabbages, radishes, and carrots.  Nwosu et al. (1995) investigated the uptake of cadmium and lead in 
lettuce and radish grown in loam soil spiked with known mixtures of CdCl2 and Pb(NO3)2.  They found 
that the mean uptake of cadmium by lettuce and radish increased as the concentrations of cadmium and 
lead in the soil increased.  Their results supported previous findings that cadmium is absorbed by passive 
diffusion and translocated freely in the soil.  The observed decline in cadmium uptake by lettuce at 
400 mg/kg could be attributed to saturation of the active binding sites on the plant root system or by early 
toxicological responses of the plant root.  The study also supported earlier findings that radish did not 
accumulate as much cadmium as lettuce. 
Some studies have concluded that soil pH is the major factor influencing plant uptake of cadmium from 
soils (Smith 1994).  Amending soil with lime raises the pH, increasing cadmium adsorption to the soil and 
reducing bioavailability (He and Singh 1994; Thornton 1992).  One study found that in peeled potato 
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tubers, potato peelings, oat straw, and ryegrass, cadmium concentrations generally decreased as simple 
linear functions of increasing soil pH over the range of pH values measured (pH 3.9–7.6) (Smith 1994).  
Soil type also affects uptake of cadmium by plants.  For soils with the same total cadmium content, 
cadmium has been found to be more soluble and more plant-available in sandy soil than in clay soil (He 
and Singh 1994).  Similarly, cadmium mobility and bioavailability are higher in noncalcareous than in 
calcareous soils (Thornton 1992).  Oxidation-reduction potential may also have a large effect on soil-to-
plant cadmium transport.  The absorption of cadmium paddy rice is significantly affected by the 
oxidation-reduction potential of the soil.  The oxidation-reduction potential of rice paddy soils shifts 
drastically compared to upland soils due to submerging and draining techniques.  Cadmium to rice ratios 
(cadmium concentration in brown rice/cadmium concentration in soil) were the smallest when the rice 
was grown under submerged conditions during the whole growth period.  The ratios were the largest 
when the soil (coarse Toyama soil) was drained after the tillering stage.  This is due to changes in 
cadmium solubility.  Under flooded conditions, cadmium sulfide formation increases, and thus, cadmium 
solubility decreases (Iimura 1981).  
 
 
Since cadmium accumulates largely in the liver and kidneys of vertebrates and not in the muscle tissue 
(Harrison and Klaverkamp 1990; Sileo and Beyer 1985; Vos et al. 1990), and intestinal absorption of 
cadmium is low, biomagnification through the food chain may not be significant (Sprague 1986).  In a 
study of marine organisms from the Tyrrhenian Sea, no evidence of cadmium biomagnification was found 
along pelagic or benthic food webs (Bargagli 1993).  Although some data indicate increased cadmium 
concentrations in animals at the top of the food chain, comparisons among animals at different trophic 
levels are difficult, and the data available on biomagnification are not conclusive (Beyer 1986; Gochfeld 
and Burger 1982).  Nevertheless, uptake of cadmium from soil by feed crops may result in high levels of 
cadmium in beef and poultry (especially in the liver and kidneys).  This accumulation of cadmium in the 
food chain has important implications for human exposure to cadmium, whether or not significant 
biomagnification occurs. 
Boularbah et al. (1992) isolated sic cadmium-resistant bacterial strains from a soil receiving dredged 
sediments and containing 50 mg Cd/kg.  The isolates tolerated higher cadmium concentrations than the 
control strain and accumulated cadmium at concentrations ranging from 0 to 100 mg/L.  One of the 
isolates, Bacillus brevis, was found to be the most resistant to cadmium, with the ability to accumulate up 
to 70 mg Cd/g of cells dry weight, and may have some use in reclamation of metal-contaminated soils. 
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6.3.2   Transformation and Degradation  
 
6.3.2.1   Air  
 
Little information is available on the atmospheric reaction of cadmium (EPA 1980d).  The common 
cadmium compounds found in air (oxide, sulfate, chloride) are stable and not subject to photochemical 
reactions (EPA 1980d).  Cadmium sulfide may photolyze to cadmium sulfate in aqueous aerosols (Konig 
et al. 1992).  Transformation of cadmium among types of compounds in the atmosphere is mainly by 
dissolution in water or dilute acids (EPA 1980d). 
 
6.3.2.2   Water  
 
In fresh water, cadmium is present primarily as the cadmium(+2) ion and Cd(OH)2 and CdCO3 
complexes, although at high concentrations of organic material, more than half may occur in organic 
complexes (McComish and Ong 1988).  Some cadmium compounds, such as cadmium sulfide, cadmium 
carbonate, and cadmium oxide, are practically insoluble in water.  However, water-insoluble compounds 
can be changed to water-soluble salts by interaction with acids or light and oxygen.  For example, 
aqueous suspensions of cadmium sulfide can gradually photoxidize to soluble cadmium (IARC 1993).  
Cadmium complexation with chloride ion increases with salinity until, in normal seawater, cadmium 
exists almost entirely as chloride species (CdCl+, CdCl2, CdCl3
–) with a minor portion as Cd2+.  In 
reducing environments, cadmium precipitates as cadmium sulfide in the presence of sulfide ions 
(McComish and Ong 1988).  Photolysis is not an important mechanism in the aquatic fate of cadmium 
compounds (EPA 1983c), nor is biological methylation likely to occur (EPA 1979). 
 
6.3.2.3   Sediment and Soil  
 
Transformation processes for cadmium in soil are mediated by sorption from and desorption to water, and 
include precipitation, dissolution, complexation, and ion exchange (McComish and Ong 1988).  
Important factors affecting transformation in soil include the cation exchange capacity, pH, and content of 
clay minerals, carbonate minerals, oxides, organic matter, and oxygen (McComish and Ong 1988). 
 
6.4   LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT  
 
Reliable evaluation of the potential for human exposure to cadmium depends in part on the reliability of 
supporting analytical data from environmental samples and biological specimens.  Concentrations of 
cadmium in unpolluted atmospheres and in pristine surface waters are often so low as to be near the limits 
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of current analytical methods.  In reviewing data on cadmium levels monitored or estimated in the 
environment, it should also be noted that the amount of chemical identified analytically is not necessarily 
equivalent to the amount that is bioavailable.  The analytical methods available for monitoring cadmium 
in a variety of environmental media are detailed in Chapter 7. 
 
6.4.1   Air  
 
Cadmium levels in ambient air generally range from 0.1 to 5 ng/m3 in rural areas, 2–15 ng/m3 in urban 
areas, and 15–150 ng/m3 in industrialized areas.  Remote areas can contain lower levels of cadmium 
(Morrow 2001).  Cadmium can undergo long-range atmospheric transport and deposition causing 
cadmium contamination in areas with no local cadmium inputs.  Smoking can greatly affect indoor air 
concentrations of cadmium.  In nonsmoking environments, there is little difference between indoor and 
outdoor air quality (Morrow 2001).  Monitoring studies conducted for EPA’s 2006 Final Report for the 
Urban Air Toxics Monitoring Program detected cadmium in ambient air at several monitoring sites 
throughout the United States.  At all detection sites in Bountiful, Utah; Northbrook, Illinois; Austin, 
Texas; St. Louis, Missouri; Indianapolis, Indiana; and Birmingham, Alabama average daily cadmium 
levels in ambient air were <0.01 μg/m3.  In Bountiful, Utah average daily cadmium levels were reported 
as 0.0008 μg/m3 (EPA 2007).  
 
 
Emission rates of cadmium from solid waste incinerators have been found to range from 20 to 
2,000 μg/m3 from the stacks of traditional incinerators and from 10 to 40 μg/m3 from advanced 
incinerators.  Advances in pollution control and increased government regulations have resulted in 
decreased cadmium emissions to the environment (EPA 1990a; Herron 2003; Morrow 2001; Schulte-
Schrepping and Piscator 2002).  Although there may be an increase in fossil fuel combustion and waste 
incineration, it does not appear likely that overall cadmium emissions to air will increase substantially in 
the United States.   
Cadmium levels in aerosols over Russian Arctic seas were measured in order to understand the magnitude 
of long-range atmospheric deposition.  Ten-year average monthly mean concentrations ranged from 
0.002 to 0.080 ng/m3 in Franz Josef Land and from 0.0026 to 0.048 ng/m3 in Sevemaya Zemlya.  The 
highest concentrations were reported in the spring season and the lowest concentrations reported in the 
autumn for both sampling sites.  During the winter and spring months, it was estimated that >50% of the 
average air pollutant concentrations in the Russian Arctic are due to atmospheric pollution.  The 
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anthropogenic sources of cadmium to the Russian Arctic are the industrial areas of Northern Europe, Kola 
Peninsula, and the Urals and Norilsk regions (Shevchenko et al. 2003).   
 
 
Atmospheric concentrations of cadmium are generally highest in the vicinity of cadmium-emitting 
industries such as smelters, municipal incinerators, or fossil fuel combustion facilities (Elinder 1985a; 
Pirrone et al. 1996).  The mean annual concentration of airborne cadmium in an area about 1 km from a 
zinc smelter in Colorado was 0.023 μg/m3 (2.3x10-5 mg/m3) (IARC 1993).  Sweet et al. (1993) conducted 
a study of airborne inhalable particulate matter (PM-10) over a 2-year period in two urban/industrial areas 
(southeast Chicago and East St. Louis) and one rural area in Illinois.  There was a significant difference 
between the cadmium levels in the urban areas and the cadmium levels in the rural area.  Cadmium 
concentrations in the East St. Louis area were 5–10 times higher, with a range of <4 to 115 ng/m3 
(average 15[24] ng/m3) for fine particles and a range of <4–97 ng/m3 (average 10[18] ng/m3) for course 
particles.  In the Kikinda region of Serbia and Montenegro, where metal processing and construction 
industries are located, a mean annual atmospheric deposit of 36.0 μg/m2 per day was reported in 1995.  A 
period of decreased industrial production, which decreased atmospheric cadmium deposits by 93%, 
resulted in 17% cadmium reduction in cattle feed and 13% in milk (Vidovic et al. 2005).  Moss studies 
conducted by Hasselbach et al. (2005) in the area of the Red Dog Mine in Alaska reported cadmium 
levels >24 mg/kg dry weight in moss adjacent to the ore haul road.  Ore dust containing heavy metals 
escapes from the ore trucks on the haul road and can be deposited in the nearby area (Hasselbach et al. 
2005).   
Annual average concentrations of atmospheric cadmium over three Great Lakes reflect the influence of 
industrialization and urbanization; Lake Erie’s levels of 0.6 ng/m3 were higher than fine particle 
concentrations of 0.2 ng/m3 over Lake Michigan and <0.2 ng/m3 over Lake Superior (Sweet et al. 1998).  
In the Lake Michigan Urban Air Toxics Study of dry deposition of metals, the flux of cadmium on the 
south side of Chicago was reported at about 0.01 mg/m2/day and levels in rural Michigan and over Lake 
Michigan were far lower (Holsen et al. 1993). 
 
6.4.2   Water  
 
The average level of cadmium in ocean water has been reported between <5 and 110 ng/L, with higher 
levels reported near coastal areas and in marine phosphates and phosphorites (Morrow 2001).  
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Thornton (1992) reports that waters from the vicinity of cadmium-bearing mineral deposits may have 
cadmium concentrations of ≥1,000 μg/L.  The cadmium concentration of natural surface water and 
groundwater is usually <1 μg/L (Elinder 1985a, 1992).  EPA requires water suppliers to limit the 
cadmium concentration in drinking water to <5 μg/L (EPA 2006a). 
 
 
Groundwater in New Jersey has an estimated median level of 1 μg Cd/L with a high level of 405 μg/L.  In 
a survey of groundwater surrounding waste sites, a concentration of 6,000 μg Cd/L was found (NTP 
1994).  The National Urban Runoff Program measured cadmium concentrations in urban storm water 
runoff; concentrations ranged from 0.1 to 14 μg/L in 55% of samples that were positive for cadmium 
(Cole et al. 1984).  Cadmium in highway run-off has been detected at levels of 0.0–0.06 mg/L (0.0–
60 μg/L).   
In the estuarine portion of the Hudson River, more cadmium was released from agricultural and urban 
run-off than from industrial and municipal sewage treatment plants (Muntau and Baudo 1992).  In an 
urban environment, there are also multiple sources of cadmium to waste water, based on an urban waste 
water study conducted in the United Kingdom.  Cadmium was detected in the waste water originating 
from industrial, commercial, and private sectors, with the highest average cadmium concentration 
detected in the foul water of new (<5 years old) private housing (0.375 μg/L) (Rule et al. 2006).  
Cadmium was detected in the contaminated groundwater plume near in the Moon Creek watershed in the 
Couer D’Alene Mining District of Idaho at concentrations of ≤0.077 mg/L.  The cadmium was 
transported to the creek with the plume where it was subsequently diluted (Paulson 1997).  In the Spring 
River Basin of Kansas, Missouri, and Oklahoma, part of the Tri-State Mining District, cadmium was 
detected in surfaces waters at concentrations ranging from <1.0 to 24 μg/L (peak flow) and from <1.0 to 
75.0 μg/L (base flow).  It was detected in the sediment of the sampling sites at concentrations ranging 
from 0.62 to 300 μg/g dry weight in the <250 μm sediment fraction and from 0.89 to 180 μg/g dry weight 
in the <63 μm fraction (Angelo et al. 2007).  
 
6.4.3   Sediment and Soil  
 
Cadmium concentrations in soils not contaminated by anthropogenic sources range from 0.06 to 
1.1 mg/kg, with a minimum of 0.01 mg/kg and a maximum of 2.7 mg/kg (Alloway and Steinnes 1999).  
Cadmium content in marine sediments ranges from 0.1 to 1.0 μg/g (ppm) in the Atlantic and Pacific 
oceans (Thornton 1992).  Average cadmium concentration in agricultural soils of remote locations was 
reported as 0.27 mg/kg (Holmgren et al. 1993).  Soils with parent materials such as black shale (cadmium 
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content up to 24 mg/kg) may have higher concentrations of natural cadmium.  Since the U.S. mandatory 
limit of cadmium in sewage sludge is <20 mg/kg, soils receiving sewage sludge should not have 
heightened cadmium levels (Alloway and Steinnes 1999).  Topsoil concentrations are often more than 
twice as high as subsoil levels as the result of atmospheric fallout and contamination (Pierce et al. 1982).  
Cadmium will partition mostly to soil and sediment when released to the environment.  Atmospheric 
deposition is a major source of surface soil contamination, which allows cadmium to be introduced into 
the food supply (Alloway and Steinnes 1999; Morrow 2001).  
 
Markedly elevated levels may occur in topsoils near sources of contamination.  Moss studies conducted 
by Hasselbach et al. (2005) in the area of the Red Dog Mine in Alaska reported cadmium levels 
>24 mg/kg dry weight in moss (n=151), as a measure atmospheric deposition onto soil surfaces, within 
10 m of the ore haul road.  Ore dust containing heavy metals escapes from the ore trucks during loading 
and unloading at the mine and port site settles on the surfaces of the trucks, which blow off the trucks 
during transport on the haul road and deposited in the nearby area.  The mean cadmium concentrations in 
moss and subsurface soil throughout the entire study were 1.86 and 0.27 mg/kg dry weight, respectively.  
Cadmium concentrations in moss and subsurface soil were 0.08–24.30 and 0.07–0.75 mg/kg dry weight.  
There did not appear to be a connection between the elevated subsurface cadmium levels and the local 
geochemistry.  Geospatial analysis showed that areas as far as 12 km north of the haul road may be 
affected by mining emission depositions (Hasselbach et al. 2005).  In the vicinity of a smelter in Helena, 
Montana, average soil values were 72 ppm within 1 km and 1.4 ppm between 18 and 60 km (EPA 1981a).  
Total cadmium concentrations in soil samples taken from a Superfund site in southeast Kansas ranged 
from 15 to 86 mg/kg (ppm).  In the same study, soil samples were extracted with diethylenetriamine-
pentaacetic acid (DPTA) to approximate the plant-available metal concentrations.  Extractable cadmium 
concentrations ranged from 0.6 to 10 mg/kg (ppm) (Abdel-Saheb et al. 1994).  Soil cadmium levels in 
five Minnesota cities were highest in areas with the most vehicular traffic (>2 ppm in about 10% of inner-
city samples) and also showed a pattern consistent with past deposition from a sewage-sludge incinerator 
(Mielke et al. 1991).  Cadmium levels >750 mg/kg have been found in sites polluted by nonferrous metal 
mining and smelting have been reported (Alloway and Steinnes 1999).  
 
In the Spring River Basin of Kansas, Missouri, and Oklahoma, part of the Tri-State Mining District, 
cadmium was detected in surfaces waters at concentrations of <1.0–24 μg/L (peak flow) and <1.0–
75.0 μg/L (base flow).  Cadmium was detected in the sediment of the sampling sites at concentrations 
ranging from 0.62 to 300 μg/g dry weight in the <250 μm sediment fraction and from 0.89 to 180 μg/g 
dry weight in the <63 μm fraction (Angelo et al. 2007).  A study conducted in 1999 at the Patroon Creek 
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Reservoir in Albany County, New York sampled sediment cores for heavy metals, including cadmium.  
The watershed includes two industrial sites:  one in operation from 1955 to present and the other 
operating from 1958 to 1984.  Sediment samples in the interval of 0–1.68 m showed an average cadmium 
concentration of 1.69 mg/kg.  This concentration is comparable to other stream and reservoir sediments 
impacted by industrial pollution (Arnason and Fletcher 2003).  Sediments of the Sawmill River in 
Yonkers, New York contained the highest cadmium levels (6.9 mg/kg) in the Hudson River Basin during 
a sampling study conducted between 1992 and 1995 (USGS 1998b).  
 
 
 
Surficial sediments collected from 18 locations in three major tributaries to Newark Bay, New Jersey, had 
a mean cadmium concentration of 10±6 mg/kg (ppm) dry weight (Bonnevie et al. 1994).  The highest 
cadmium concentrations were found in the Ironbound section of the Passaic River, a heavily 
industrialized area (29 mg/kg and 14 mg/kg), and in the Arthur Kill on the northwest side of Prall’s Island 
(15 mg/kg).  An investigation of metals distribution in sediments along the Hudson River estuary revealed 
that cadmium concentrations in suspension were higher than in the bottom sediments by a factor of 30 
(Gibbs 1994). 
Soils derived from dredged material in confined disposal facilities in the Great Lakes Region had 
cadmium concentrations (dry weight) of <1.9–32 ppm (Beyer and Stafford 1993).  In an analytical survey 
of sewage sludges from 16 large cities in the United States, cadmium concentrations ranged from 2.72 to 
242 ppm (dry weight).  Besides the sample with a cadmium concentration of 242 ppm, all other sludges 
had cadmium contents ≤14.7 ppm (Gutenmann et al. 1994). 
 
6.4.4   Other Environmental Media  
 
Cadmium levels in food can vary greatly depending on the type of food, agricultural and cultivating 
practices, and amount atmospheric deposition and other anthropogenic contamination.  In general, leafy 
vegetables, such as lettuce and spinach, and staples, such as potatoes and grains, contain relatively high 
values of cadmium.  Peanuts, soybeans, and sunflower seeds have naturally high levels of cadmium.  
Meat and fish container lower amounts of cadmium, with the exception of animal organ meats, such as 
kidney and liver, as these organs concentrate cadmium (Morrow 2001).  
As part of the U.S. Food and Drug Administration (FDA) Total Diet Study, average concentrations of 
cadmium in 14 food groups were analyzed from samples collected in 56 American cities.  Cadmium was 
found in nearly all samples at varying concentrations.  In general, the eggs, milk and cheese, condiments 
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and sweeteners, beverages, and fats and dressings groups contained low concentrations of cadmium 
(≤0.004 mg/kg) (FDA 2010).  Food items that contained high levels of cadmium were dry roasted peanuts 
(0.054 mg/kg), shredded wheat cereal (0.050 mg/kg), boiled spinach (0.124 mg/kg), iceberg lettuce 
(0.051 mg/kg), leaf lettuce (0.064 mg/kg), and potato chips (0.057 mg/kg) (FDA 2010).  Table 6-3 
summarizes the data from this study.   
 
 
Watanabe et al. (1996) measured the cadmium content in rice samples from various areas in the world 
during the period from 1990 to 1995.  Twenty-nine samples collected in the United States had a geometric 
mean of 7.43 ng Cd/g, with a standard deviation of 2.11.  Shellfish, liver, and kidney meats have higher 
concentrations than other fish or meat (up to 1 ppm) (Elinder 1985a; IARC 1993; Schmitt and 
Brumbaugh 1990).  Particularly high concentrations of cadmium of 2–30 mg/kg (ppm) fresh weight have 
been found in the edible brown meat of marine shellfish (Elinder 1992).  Cadmium concentrations up to 
8 μg/g in oysters and 3 μg/g in salmon flesh have been reported (IARC 1993).  Sprague (1986) reviewed 
tissue concentrations of cadmium for marine mollusks and crustaceans.  They found that drills, a type of 
sea snail, were higher in cadmium (average, 26 μg/g dry weight) than almost all other mollusks, although 
scallops and whelks also tended to be high.  Oysters from polluted areas averaged 18 μg/g dry weight, 
which was significantly higher than oysters from clean areas (average concentration 1.4 µg/g dry weight).  
Clams were relatively low in cadmium (average, 0.5–1.0 μg/g dry weight).  The average concentration of 
cadmium in clams from polluted areas was only 2.7 μg/g dry weight, but this was significantly higher 
than levels in clams from clean areas.  In Fiscal Year (FY) 1985/1986, the FDA conducted a survey of 
cadmium, lead, and other elements in fresh clams and oysters collected from U.S. coastal areas used for 
shellfish production (Capar and Yess 1996).  Average cadmium levels (wet weight) were 
0.09±0.06 mg/kg (ppm) (n=75) in hardshell clams, 0.05±0.04 mg/kg (n=59) in softshell clams, 
0.51±0.31 mg/kg (n=104) in Eastern oysters, and 1.1±0.6 mg/kg (n=40) in Pacific oysters.  In FY91, FDA 
analyzed 5 samples of domestic clams and 24 samples of domestic oysters (collected from both coasts) 
for cadmium and found average concentrations of 0.06 and 0.62 mg/kg, respectively (Capar and Yess 
1996).  Although no conclusions can be drawn in light of the small numbers of FY91 samples, these 
results do not appear to be appreciably different from those of the FY85/86 survey.. 
Cadmium is accumulated mainly in the hepatopancreas (digestive gland) of the crab, and cadmium levels 
as high as 30–50 ppm have been detected in this edible part of the animal.  Cadmium levels as high as 
10 ppm also have been measured in some species of wild-growing edible mushrooms (Lind et al. 1995).  
Lind et al. (1995) conducted a feeding study in mice to determine the bioavailability of cadmium from 
crab hepatopancreas and mushroom in relation to organic cadmium.  The cadmium accumulation in the  
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Table 6-3.  Mean Concentrations of Cadmium for FDA’s Total Diet Study Market 
Baskets 2006-1 through 2008-4 
 
Food product Mean concentration range (mg/kg) 
Milk and cheese Not detected–0.002 
Eggs Not detected–0.0003 
Meat, poultry, and fish Not detected–0.069 
Legumes and nuts 0.001–0.054 
Grain products 0.0001–0.028 
Fruit Not detected–0.015 
Vegetables 0.001–0.124 
Mixed dishes and meals 0.003–0.021 
Desserts Not detected–0.028 
Condiments and sweeteners 0.001–0.0002 
Fats and dressings Not detected–0.004 
Beverages Not detected–0.001 
Infant and junior foods 0.0002–0.026 
 
Source:  FDA 2010 
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liver and kidney of the mice was used as an estimate of the intestinal absorption.  The group that was fed 
crab accumulated less cadmium in the liver and kidney than the groups fed mushrooms or inorganic 
cadmium salt.  They concluded from the results of the study that cadmium from boiled crab has a lower 
bioavailability for absorption in the gastrointestinal tract of mice than inorganic cadmium and cadmium 
from dried mushrooms.  Almost all (99%) of the cadmium in the boiled crab hepatopancreas was 
associated with insoluble ligands, probably denatured protein.  In fresh crab hepatopancreas, most of the 
cadmium is in a soluble form bound to metallothionein (Lind et al. 1995).  
 
 
 
Significant concentrations of cadmium have been observed in fish living in stormwater ponds in Florida, 
especially in the redear sunfish, a bottom feeder (Campbell 1994).  The mean cadmium concentration in 
redear sunfish living in stormwater ponds was 1.64 mg/kg wet weight compared to 0.198 mg/kg for 
redear sunfish living in control ponds.  Similarly, the mean cadmium concentration in largemouth bass 
living in stormwater ponds was 3.16 mg/kg wet weight compared to 0.241 mg/kg for largemouth bass 
living in control ponds.  Red drum, flounder, and seatrout collected from South Carolina estuaries during 
the period 1990–1993 had consistently low cadmium levels throughout the sampling area and with 
respect to species (Mathews 1994).  The mean concentration for all fillets and whole fish was 86.2 ppb 
wet weight, with 70.7% (n=164) of the samples having <25 ppb. 
Cadmium and other heavy metals were detected in several of the freshwater invertebrates and fish of two 
Maryland streams.  Due to their remote location and lack of source inputs, it is believed that the cadmium 
contamination was a result of long-range atmospheric deposition.  Samples were taken from the 
Herrington Creek tributary (HCRT) and Blacklick Run (BLK) during October 1997, April 1998, and July 
1998.  Cadmium concentrations in the trout of BLK ranged from about 37 to 90 ng/g wet, with the older 
specimens having the higher cadmium concentrations.  Cadmium concentrations in crayfish ranged from 
about 40 to 160 ng/g wet in BLK, with the younger specimens containing the highest levels of cadmium.  
Crayfish in HRCT ranged from 45 to 155 ng/g, with the highest levels in the middle age group.  In 
crayfish, cadmium strongly accumulates in the gills, while the kidney accumulates cadmium in trout 
(Mason et al. 2000).  
Cadmium concentrations in the fish of the mining-contaminated waters of Oklahoma were reported by 
Brumbaugh et al. (2005).  This area was part of the Tri-State Mining District that was extensively mined 
for lead and zinc from the mid-1800s to the 1950s, and contains nonremediated sites.  Blood and carcass 
cadmium concentrations differed between species and sites, but were generally greatest in carp.  Carcass 
cadmium in catfish were relatively low, with <0.1 μg/g dry weight in 34 of 36 samples.  
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Cadmium concentrations of ≥0.5 ppm have been found in rice grown in cadmium-polluted areas of Japan 
(Nogawa et al. 1989) and China (Shiwen et al. 1990).  Tobacco also concentrates cadmium from the soil, 
and cadmium content of cigarettes typically ranges from 1 to 2 μg/cigarette (Elinder 1985a, 1992).  
Some food crops, including confectionery sunflowers, have a propensity to take up cadmium from the soil 
in which they are grown and deposit it in the kernels.  In a study to determine the cadmium burden of 
persons who report regular consumption of sunflower kernels, Reeves and Vanderpool (1997) analyzed 
19 different lots of sunflower kernels from the 1995 crop grown in the northern Great Plains region of 
North Dakota and Minnesota.  They found a range of 0.33–0.67 μg Cd/g, with a mean±standard deviation 
of 0.48±0.11 μg/g fresh weight.  The study showed that high intakes of sunflower kernels increased the 
intake of cadmium.  However, the amount of cadmium in whole blood or in red blood cells was not 
affected by cadmium intake.  The authors pointed out that an increased intake of sunflowers will increase 
not only the cadmium intake, but also the intake of copper and phytate.  In turn, this could reduce the 
availability of cadmium from this food source. 
DOI (1985) examined the concentrations of cadmium in a variety of aquatic and terrestrial flora and fauna 
and identified six trends:  (1) in general, marine biota contained significantly higher cadmium residues 
than their freshwater or terrestrial counterparts; (2) cadmium tends to concentrate in the viscera of 
vertebrates, especially in the liver and kidneys; (3) cadmium concentrations are higher in older organisms 
than in younger ones, especially in carnivores and marine vertebrates; (4) higher concentrations for 
individuals of a single species collected at various locations are almost always associated with proximity 
to industrial/urban areas or point-source discharges of cadmium-containing wastes; (5) background levels 
of cadmium in crops and other plants are generally <1.0 mg/kg (ppm); and (6) cadmium concentrations in 
biota are dependent upon the species analyzed, the season of collection, ambient cadmium levels, and the 
sex of the organism. 
During a study monitoring cadmium levels in 331 cigarette packs from over 20 areas around the world it 
was found that the mean cadmium level per cigarette was 1.15 µg/cigarette ±0.43 (AM±ASD) or 
1.06 µg/cigarette ±1.539 (geometric mean [GM]±geometric standard deviation[GSD]).  Cigarettes from 
Mexico had the highest mean level of cadmium with an AM±ASD of 2.03 µg/cigarette ±0.33 or a 
GM±GSD of 2.00 µg/cigarette ±1.190.  Cigarettes from India had the lowest mean levels of cadmium 
with an AM±ASD of 0.35 µg/cigarette ±0.09 or a GM±GSD of 0.34 µg/cigarette ±1.284.  The arithmetic 
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mean for the United States was 1.07 µg/cigarette ±0.11 and the GM±GSD was 1.06 µg/cigarette ±1.115 
(Watanabe et al. 1987). 
 
 
 
 
 
The cadmium content of coals varies widely; concentrations of 0.01–180 μg/g (ppm) have been reported 
for the United States (Thornton 1992; Wilber et al. 1992). 
6.5   GENERAL POPULATION AND OCCUPATIONAL EXPOSURE  
 
The general population may be exposed to cadmium through ingestion of food and drinking water, 
inhalation of particulates from ambient air or tobacco smoke, or ingestion of contaminated soil or dust.  
For nonsmokers, food is the major source of cadmium exposure (NTP 2005).  Inhalation of cigarette 
smoke is the major source of cadmium exposure for smokers (CDC 2005).  Cadmium is introduced to the 
food chain through agricultural soils, which may naturally contain cadmium, or from anthropogenic 
sources such as atmospheric deposition or direct application methods such as phosphate fertilizer 
application and municipal waste composting (Alloway and Steinnes 1999; Morrow 2001).  Cadmium-
plated utensils and galvanized equipment used in food processing and preparation; enamel and pottery 
glazes with cadmium-based pigments; and stabilizers used in food-contact plastics are also sources of 
food contamination (Galal-Gorchev 1993).  Cadmium levels in soils are not a direct indicator of the level 
of cadmium in the food supply, with the exception of extreme contamination, as other factors such as the 
type of crop and farming methods are important (Morrow 2001).  
Based on food intake rates and food-cadmium concentrations, the estimated geometric mean daily intake 
of cadmium for the U.S. population is 18.9 μg/day, down from an estimated 30 μg/day in the 1980s 
(Choudhury et al. 2001; Gartrell et al. 1986).  Based on the mean cadmium daily intakes for males and 
females aged 6–60 years reported by Choudhury et al. (2001), age-weighted mean cadmium intakes of 
0.35 µg/kg/day for males and 0.30 µg/kg/day for females were calculated for U.S. nonsmokers.   
In the Fourth National Report on Human Exposures to Environmental Chemicals reported by the CDC 
(2011) results from the National Health and Nutrition Examination Survey (NHANES) 1999–2008 were 
reported.  Cadmium levels in blood (see Table 6-4), urine (creatine corrected) (see Table 6-5), and urine 
(see Table 6-6) was evaluated for a variety age groups and ethnicities.  Blood cadmium reflects both 
recent and cumulative exposures and urinary cadmium reflects cadmium exposure and the concentration 
of cadmium in the kidneys.   
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Table 6-4.  Geometric Mean and Selected Percentile Blood Concentrations (μg/L) 
of Cadmium in the U.S. Population from 1999 to 2008 
 
Geometric Selected percentiles (95% CI) 
Group 
Survey 
years 
amean  (95% 
CI) 50th 75th 90th 95th 
Sample 
size 
Total, age 1 and 1999–2000 0.412 (0.378– 0.300 (0.300– 0.600 (0.500– 1.00 (0.900– 1.30 (1.20– 7,970 
older 0.449) 0.400) 0.600) 1.00) 1.40) 
 2001–2002 Not calculated 0.300 (<LOD– 0.400 (0.400– 0.900 (0.900– 1.30 (1.20– 8,945, 
0.300) 0.500) 1.10) 1.60) 
 2003–2004 0.304 (0.289– 0.300 (0.300– 0.500 (0.500– 1.10 (1.00– 1.60 (1.50– 8,372 
0.320) 0.300) 0.600) 1.20) 1.60) 
 2005–2006 0.310 (0.294– 0.270 (0.250– 0.501 (0.460– 1.02 (0.910– 1.53 (1.34– 8,407 
0.327) 0.280) 0.560) 1.13) 1.75) 
 2007–2008 0.315 (0.300– 0.270 (0.260– 0.500 (0.460– 1.00 (0.900– 1.51 (1.30– 8,266 
0.331) 0.280) 0.560) 1.13) 1.77) 
Age group        
1–5 Years 1999–2000 Not calculated <LOD 0.300 (<LOD– 0.400 (0.300– 0.400 (0.300– 723 
0.300) 0.400) 0.400) 
 2001–2002 Not calculated <LOD <LOD <LOD 0.300 (<LOD– 898 
0.300) 
 2003–2004 Not calculated <LOD <LOD 0.200 (0.200– 0.200 (0.200– 910 
0.300) 0.400) 
 2005–2006 Not calculated <LOD <LOD <LOD 0.230 (0.210– 968 
0.250) 
 2007–2008 Not calculated <LOD <LOD 0.210 (<LOD– 0.240 (0.220– 817 
0.230) 0.260) 
6–11 Years 1999–2000 Not calculated <LOD 0.300 (<LOD– 0.400 (0.300– 0.400 (0.400– 905 
0.300) 0.400) 0.500) 
 2001–2002 Not calculated <LOD <LOD <LOD 0.400 (0.300– 1,044 
0.400) 
 2003–2004 Not calculated <LOD 0.200 (<LOD– 0.300 (0.200– 0.300 (0.300– 856 
0.200) 0.300) 0.300) 
 2005–2006 Not calculated <LOD <LOD 0.220 (0.200– 0.260 (0.230– 934 
0.300) 0.280) 
 2007–2008 Not calculated <LOD <LOD 0.230 (0.210– 0.260 (0.240– 1,011 
0.240) 0.280) 
12–19 Years 1999–2000 0.333 (0.304– 0.300 (<LOD– 0.300 (0.300– 0.800 (0.600– 1.10 (0.900– 2,135 
0.366 0.300) 0.400) 0.900) 1.10) 
 2001–2002 Not calculated <LOD 0.300 (<LOD– 0.400 (0.400– 0.800 (0.600– 2,231 
0.300) 0.500) 1.10) 
 2003–2004 Not calculated 0.200 (<LOD– 0.300 (0.300– 0.600 (0.500– 0.900 (0.800– 2,081 
0.200) 0.300) 0.700) 1.10) 
 2005–2006 Not calculated <LOD 0.250 (0.240– 0.520 (0.500– 0.960 (0.820– 1,996 
0.270) 0.700) 1.08) 
 2007–2008 Not calculated <LOD 0.260 (0.240– 0.520 (0.400– 0.960 (0.730– 1,074 
0.270) 0.670) 1.19) 
CADMIUM  307 
 
6.  POTENTIAL FOR HUMAN EXPOSURE 
 
 
 
 
 
 
 
Table 6-4.  Geometric Mean and Selected Percentile Blood Concentrations (μg/L) 
of Cadmium in the U.S. Population from 1999 to 2008 
 
Geometric Selected percentiles (95% CI) 
Group 
Survey 
years 
amean  (95% 
CI) 50th 75th 90th 95th 
Sample 
size 
≥20 Years 1999–2000 0.468 (0.426– 0.400 (0.300– 0.600 (0.600– 1.00 (1.00– 1.50 (1.40– 4,207 
0.513) 0.400) 0.700) 1.10) 1.60) 
 2001–2002 Not calculated 0.300 (0.300– 0.600 (0.500– 1.10 (0.900– 1.60 (1.30– 4,772 
0.400) 0.600) 1.20) 1.80) 
 2003–2004 0.378 (0.359– 0.400 (0.300– 0.600 (0.600– 1.20 (1.20– 1.80 (1.60– 4,525 
0.398) 0.400) 0.700) 1.30) 1.90) 
 2005–2006 0.373 (0.352– 0.330 (0.310– 0.610 (0.570– 1.17 (1.06– 1.72 (1.53– 4,509 
0.395) 0.350) 0.660) 1.26) 1.95) 
 2007–2008 0.376(0.354– 0.330 (0.310– 0.600 (0.550– 1.16 (1.02– 1.70 (1.50– 5,364 
0.399) 0.350) 0.670) 1.30) 1.96) 
Gender        
Males 1999–2000 0.403 (0.368– 0.400 (0.300– 0.600 (0.500– 1.00 (0.900– 1.30 (1.20– 3,913 
0.441) 0.400) 0.600) 1.10) 1.50) 
 2001–2002 Not calculated 0.300 (<LOD– 0.400 (0.400– 0.900 (0.900– 1.40 (1.20– 4,339 
0.300) 0.500) 1.10) 1.80) 
 2003–2004 0.283 (0.266– 0.300 (0.200– 0.500 (0.500– 1.10 (1.00– 1.60 (1.50– 4,131 
0.300) 0.300) 0.500) 1.20) 1.60) 
 2005–2006 Not calculated 0.240 (0.220– 0.470 (0.420– 1.02 (0.910– 1.53 (1.27– 4,092 
0.260) 0.530) 1.12) 1.86) 
 2007–2008 0.299 (0.283– 0.240 (0.230– 0.470 (0.420– 1.05 (0.930– 1.60 (1.30– 4,147 
0.317) 0.260) 0.540) 1.19) 1.90) 
Females 1999–2000 0.421 (0.386– 0.300 (0.300– 0.600 (0.500– 1.00 (0.800– 1.30 (1.10– 4,057 
0.460) 0.400) 0.600) 1.00) 1.40) 
 2001–2002 Not calculated 0.300 (0.300– 0.500 (0.500– 1.00 (0.900– 1.40 (1.20– 4,606 
0.400) 0.600) 1.10) 1.60) 
 2003–2004 0.326 (0.300– 0.300 (0.300– 0.600 (0.500– 1.10 (1.00– 1.60 (1.50– 4,241 
0.300) 0.300) 0.600) 1.20 ) 1.70) 
 2005–2006 0.329 (0.311– 0.290 (0.280– 0.530 (0.480– 1.02 (0.870– 1.54 (1.33– 4,315 
0.349) 0.310) 0.580) 1.18)_ 1.79) 
 2007–2008 0.331 (0.316– 0.290 (0.280– 0.530 (0.480– 0.980 (0.860– 1.43 (1.29– 4,119 
0.348) 0.310) 0.570) 1.10)_ 1.63) 
Race/ethnicity        
Mexican 1999–2000 0.395 (0.367– 0.400 (0.300– 0.400 (0.400– 0.700 (0.700– 1.10 (0.900– 2,742 
Americans 0.424) 0.400) 0.500) 0.900) 1.30) 
 2001–2002 Not calculated <LOD 0.300 (0.300– 0.600 (0.500– 1.00 (0.700– 2,268 
0.400) 0.700) 1.30) 
 2003–2004 0.235 (0.26– 0.200 (0.200– 0.400 (0.300– 0.600 (0.500– 1.00 (0.800– 2,085 
0.255) 0.300) 0.400) 0.800) 1.50) 
 2005–2006 Not calculated 0.220 (0.200– 0.350 (0.300– 0.580 (0.510– 0.820 (0.710– 2,236 
0.240) 0.400) 0.680) 1.00) 
 2007–2008 Not calculated 0.220 (0.210– 0.350 (0.320– 0.570 (0.510– 0.870 (0.690– 1,712 
0.230) 0.370) 0.660) 1.02) 
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Table 6-4.  Geometric Mean and Selected Percentile Blood Concentrations (μg/L) 
of Cadmium in the U.S. Population from 1999 to 2008 
 
Group 
Survey 
years 
Geometric 
meana (95% 
CI) 
Selected percentiles (95% CI) 
50th 75th 90th 95th 
Sample 
size 
Non-Hispanic 
blacks 
1999–2000 0.393 (0.361–
0.427) 
0.300 (0.300–
0.400) 
0.600 (0.500–
0.600) 
1.00 (0.800–
1.10) 
1.40 (1.10–
1.50) 
1,842 
 2001–2002 Not calculated <LOD 0.400 (0.400–
0.500) 
1.00 (0.900–
1.00) 
1.40 (1.20–
1.50) 
2,219 
 2003–2004 0.304 (0.275–
0.337) 
0.300 (0.300–
0.300) 
0.500 (0.400–
0.600) 
1.00 (0.900–
1.20) 
1.50 (1.30–
1.70) 
2,292 
 2005–2006 0.307 (0.290–
0.326) 
0.260 (0.250–
0.280) 
0.490 (0.440–
0.570) 
1.03 (0.880–
1.21) 
1.50 (1.23–
1.79) 
2,193 
 2007–2008 0.333 (0.316–
0.352) 
0.280 (0.270–
0.300) 
0.550 (0.480–
0.620) 
1.20 (1.02–
1.36) 
1.81 (1.45–
2.13) 
1,746 
Non-Hispanic 
whites 
1999–2000 0.376 (0.470–
0.209) 
0.400 (0.300–
0.400) 
0.500 (0.500–
0.600) 
1.00 (0.900–
1.10) 
1.30 (1.20–
1.40) 
2,716 
 2001–2002 Not calculated <LOD 0.500 (0.500–
0.600) 
0.900 (0.900–
1.10) 
1.40 (1.20–
1.80) 
3,806 
 2003–2004 0.313 (0.296–
0.331) 
0.300 (0.300–
0.300) 
0.600 (0.500–
0.600) 
1.10 (1.00–
1.20) 
1.60 (1.50–
1.70) 
3,478 
 2005–2006 0.321 (0.300–
0.343) 
0.270 (0.250–
0.300) 
0.540 (0.470–
0.610) 
1.08 (0.930–
1.23) 
1.64 (1.40–
1.94) 
3,310 
 2007–2008 0.210 (0.303–
0.341) 
0.270 (0.260–
0.290) 
0.520 (0.470–
0.580) 
1.05 (0.920–
1.20) 
1.55 (1.30–
1.80) 
3,461 
 
aThe proportion of results below the LOD was too high to provide a valid result. 
 
CI = confidence interval; LOD = limit of detection 
 
Source:  CDC 2011 
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Table 6-5.  Geometric Mean and Selected Percentile Urine Concentrations 
(Creatinine Corrected) (μg/g Creatinine) of Cadmium in the 
U.S. Population from 1999 to 2008 
 
Geometric Selected percentiles (95% CI) 
Group 
Survey 
years 
amean  (95% 
CI) 50th 75th 90th 95th 
Sample 
size 
Total, age 6 and 1999–2000 0.181 (0.157– 0.219 (0.199– 0.423 (0.391– 0.712 (0.645– 0.933 (0.826– 2,257 
older 0.209) 0.238) 0.446) 0.757) 1.07) 
 2001–2002 0.199 (0.181– 0.212 (0.194– 0.404 (0.377– 0.690 (0.630– 0.917 (0.813– 2,689 
0.218) 0.232) 0.440) 0.754) 0.998) 
 2003–2004 0.210 (0.201– 0.208 (0.189– 0.412 (0.381– 0.678 (0.650– 0.940 (0.833– 2,543 
0.219) 0.226) 0.438) 0.716) 1.04) 
 2005–2006 0.189 (0.169– 0.180 (0.160– 0.370 (0.310– 0.650 (0.590– 0.910 (0.770– 2,576 
0.210) 0.200) 0.430) 0.720) 1.08) 
 2007–2008 0.193 (0.177– 0.190 (0.180– 0.370 (0.330– 0.660 (0.580– 0.960 (0.850– 2,627 
0.210) 0.210) 0.410) 0.740) 1.06) 
Age group        
6–11 Years 1999–2000 Not calculated 0.085 (0.063– 0.147 (0.123– 0.210 (0.171– 0.300 (0.184– 310 
0.107) 0.182) 0.316) 0.607) 
 2001–2002 0.075 (0.059– 0.100 (0.083– 0.166 (0.136– 0.233 (0.206– 0.291 (0.221– 368 
0.094) 0.112) 0.192) 0.281) 0.440) 
 2003–2004 0.090 (0.078– 0.091 (0.075– 0.126 (0.111– 0.200 (0.147– 0.308 (0.178– 287 
0.104) 0.104) 0.156) 0.350) 0.415) 
 2005–2006 0.081 (0.072– 0.080 (0.070– 0.130 (0.110– 0.170 (0.150– 0.200 (0.180– 355 
0.092) 0.090) 0.140) 0.190) 0.240) 
 2007–2008 0.084 (0.076– 0.080 (0.080– 0.120 (0.110– 0.180 (0.150– 0.260 (0.180– 394 
0.092) 0.090) 0.140) 0.240) 0.430) 
12–19 Years 1999–2000 0.071 (0.051– 0.093 (0.084– 0.147 (0.130– 0.215 (0.204– 0.283 (0.222– 648 
0.098) 0.106) 0.163) 0.240) 0.404) 
 2001–2002 0.078 (0.067– 0.091 (0.085– 0.136 (0.123– 0.191 (0.175– 0.280 (0.234– 762 
0.091) 0.101) 0.143) 0.234) 0.321) 
 2003–2004 0.086 (0.077– 0.084 (0.074– 0.122 (0.113– 0.176 (0.154– 0.234 (0.187– 724 
0.096) 0.097) 0.135) 0.198) 0.274) 
 2005–2006 0.076 (0.071– 0.080 (0.070– 0.120 (0.110– 0.50 (0.140– 0.210 (0.160– 701 
0.081) 0.0990) 0.130) 0.180) 0.240) 
 2007–2008 0.070 (0.062– 0.070 (0.070– 0.110 (0.100– 0.150 (0.130– 0.180 (0.160– 376 
0.079) 0.080) 0.110) 0.160) 0.200) 
≥20 Years 1999–2000 0.267 (0.247– 0.288 (0.261– 0.484 (0.433– 0.769 (0.727– 1.07 (0.927– 1,299 
0.289) 0.304) 0.545) 0.818) 1.17) 
 2001–2002 0.261 (0.236– 0.273 (0.247– 0.481 (0.426– 0.776 (0.691– 0.979 (0.874– 1,559 
0.289) 0.303) 0.518) 0.850) 1.12) 
 2003–2004 0.268 (0.255– 0.270 (0.247– 0.490 (0.444– 0.767 (0.688– 1.02 (0.909– 1,532 
0.281) 0.292) 0.538) 0.830) 1.14) 
 2005–2006 0.240 (0.216– 0.250 (0.200– 0.440 (0.400– 0.730 (0.660– 1.02 (0.850– 1,520 
0.267) 0.260) .0500) 0.820) 1.18) 
 2007–2008 0.247 (0.227– 0.250 (0.220– 0.430 (0.390– 0.740 (0.670– 1.05 (0.930– 1,857 
0.270) 0.270) 0.70) 0.840) 1.16) 
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Table 6-5.  Geometric Mean and Selected Percentile Urine Concentrations 
(Creatinine Corrected) (μg/g Creatinine) of Cadmium in the 
U.S. Population from 1999 to 2008 
 
Geometric Selected percentiles (95% CI) 
Group 
Survey 
years 
amean  (95% 
CI) 50th 75th 90th 95th 
Sample 
size 
Gender        
Males 1999–2000 0.154 (0.131– 0.174 (0.158– 0.329 (0.293– 0.617 (0.537– 0.788 (0.696– 1,121 
0.182) 0.191) 0.382) 0.700) 0.929) 
 2001–2002 0.159 (0.143– 0.168 (0.157– 0.334 (0.304– 0.532 (0.491– 0.757 (0.690– 1,334 
0.177) 0.182) 0.364) 0.653) 0.856) 
 2003–2004 0.173 (0.161– 0.162 (0.143– 0.325 (0.300– 0.591 (0.560– 0.740 (0.678– 1,277 
0.187) 0.185) 0.352) 0.631) 0.795) 
 2005–2006 0.160 (0.145– 0.150 (0.130– 0.300 (0.260– 0.362 (0.560– 0.820 (0.710– 1,271 
0.177) 0.160) 0.340) 0.340) 0.990) 
 2007–2008 0.160 (0.146– 0.160 (0.140– 0.290 (0.260– 0.520 (0.430– 0.740 (0.600– 1,327 
0.175) 0.180) 0.330) 0.650) 0.960) 
Females 1999–2000 0.211 (0.170– 0.267 (0.239– 0.473 (0.423– 0.783 (0.690– 1.09 (0.813– 1,136 
0.261) 0.308) 0.551) 0.917) 1.38) 
 2001–2002 0.245 (0.216– 0.263 (0.228– 0.479 (0.414– 0.792 (0.687– 0.985 (0.876– 1,355 
0.278) 0.297) 0.541) 0.884) 1.16) 
 2003–2004 0.252 (0.238– 0.253 (0.227– 0.487 (0.438– 0.802 (0.716– 1.06 (0.940– 1,266 
0.266) 0.288) 0.533) 0.906) 1.21) 
 2005–2006 0.220 (0.193– 0.220 (0.180– 0.420 (0.370– 0.690 (0.590– 0.990 (0.780– 1,305 
0.252) 0.250) 0.470) 0.850) 1.31) 
 2007–2008 0.231 (0.211– 0.230 (0.200– 0.440 (0.390– 0.770 (0.700– 1.09 (0.970– 1,300 
0.254) 0.270) 0.480) 0.860) 1.17) 
Race/ethnicity        
Mexican 1999–2000 0.175 (0.137– 0.181 (0.144– 0.331 (0.266– 0.612 (0.441– 0.843 (0.674– 780 
Americans 0.223) 0.225) 0.418) 0.828) 1.13) 
 2001–2002 0.156 (0.136– 0.170 (0.150– 0.282 (0.263– 0.501 (0.388– 0.693 (0.507– 682 
0.177) 0.184) 0.340) 0.614) 0.839) 
 2003–2004 0.160 (0.147– 0.159 (0.140– 0.296 (0.256– 0.531 (0.418– 0.718 (0.562– 614 
0.181) 0.183) 0.311) 0.667) 0.950) 
 2005–2006 0162 (0.146– 0.150 (0.140– 0.280 (0.220– 0.480 (0.430– 0.570 (0.520– 652 
0.181) 0.170) 0.340) 0.510) 0.640) 
 2007–2008 0.162 (0.144– 0.160 (0.130– 0.280 (0.220– 0.530 (0.390– 0.720 (0.520– 515 
0.183) 0.180) 0.340) 0.640) 1.07) 
Non-Hispanic 1999–2000 0.183 (0.140– 0.201 (0.168– 0.414 (0.343– 0.658 (0.516– 0.873 (0.722– 546 
blacks 0.240) 0.241) 0.472) 0.827) 0.962) 
 2001–2002 0.190 (0.156– 0.195 (0.174– 0.385 (0.336– 0.676 (0.559– 0.917 (0.725– 667 
0.232) 0.225) 0.449) 0.850) 1.08) 
 2003–2004 0.190 (0.173– 0.185 (0.168– 0.338 (0.288– 0.700 (0.500– 0.865 (0.708– 717 
0.210 ) 0.207) 0.431) 0.818) 1.10) 
 2005–2006 0.171 (0.159– 0.160 (0.140– 0.320 (0.290– 0.550 (0.500– 0.700 (0.610– 692 
0.183) 0.180) 0.370) 0.580) 0.730) 
 2007–2008 0.180 (0.164– 0.170 (0.160– 0.330 (0.290– 0.600 (0.470– 0.770 (0.690– 589 
0.197) 0.190) 0.390) 0.700) 0.900) 
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Table 6-5.  Geometric Mean and Selected Percentile Urine Concentrations 
(Creatinine Corrected) (μg/g Creatinine) of Cadmium in the 
U.S. Population from 1999 to 2008 
 
Group 
Survey 
years 
Geometric 
meana (95% 
CI) 
Selected percentiles (95% CI) 
50th 75th 90th 95th 
Sample 
size 
Non-Hispanic 
whites 
1999–2000 0.175 (0.146–
0.209) 
0.219 (0.191–
0.250) 
0.432 (0.387–
0.470) 
0.729 (0.666–
0.783) 
1.00 (0.826–
1.16) 
760 
 2001–2002 0.205 (0.184–
0.229) 
0.224 (0.208–
0.242) 
0.421 (0.382–
0.470) 
0.719 (0.668–
0.784) 
0.931 (0.806–
1.05) 
1,132 
 2003–2004 0.220 (0.209–
0.235) 
0.221 (0.197–
0.253) 
0.434 (0.398–
0.476) 
0.687 (0.647–
0.767) 
1.00 (0.830–
1.08) 
1,070 
 2005–2006 0.193 (0.169–
0.221) 
0.180 (0.160–
0.220) 
0.390 (0.310–
0.480) 
0.680 (0.630–
0.750) 
0.930 (0.800–
1.07) 
1,041 
 2007–2008 0.199 (0.178–
0.221) 
0.200 (0.180–
0.220) 
0.380 (0.340–
0.440) 
0.700 (0.630–
0.810) 
1.03 (0.880–
1.13) 
1,095 
 
aThe proportion of results below the LOD was too high to provide a valid result. 
 
CI = confidence interval; LOD = limit of detection 
 
Source:  CDC 2011 
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Table 6-6.  Geometric Mean and Selected Percentile Urine Concentrations (μg/L) 
of Cadmium in the U.S. Population from 1999 to 2008 
 
Selected percentiles (95% CI) Geometric 
aSurvey mean  (95% Sampl
Group years CI) 50th 75th 90th 95th size 
Total, age 6 and 1999–2000 0.193 (0.169– 0.232 (0.214– 0.475 (0.436– 0.858 (0.763– 1.20 (1.06– 2,257 
older 0.220) 0.249) 0.519) 0.980) 1.33) 
 2001–2002 0.210 (0.189– 0.229 (0.207– 0.458 (0.423– 0.839 (0.753– 1.20 (1.07– 2,690 
0.235) 0.255) 0.482) 0.919) 1.28) 
 2003–2004 0.211 (0.196– 0.210 (0.200– 0.450 (0.400– 0.800 (0.730– 1.15 (0.980– 2,543 
0.226) 0.230) 0.500) 0.880) 1.26) 
 2005–2006 0.191 (0.170– 0.200 (0.170– 0.400 (0.360– 0.780 (0.700– 1.05 (0.960– 2,576 
0.216) 0.220) 0.460) 0.860) 1.17) 
 2007–2008 0.185 (0.173– 01.80 (0.170– 0.380 (0.360– 0.700 (0.50– 1.00 (0.920– 2,627 
0.198) 0.200) 0.400) 0.770) 1.12) 
Age group        
6–11 Years 1999–2000 Not calculated 0.078 (0.061– 0.141 (0.115– 0.219 (0.178– 0.279 (0.211– 310 
0.101) 0.173) 0.233) 0.507) 
 2001–2002 0.061 (<LOD– 0.077 (0.067– 0.140 (0.112– 0.219 (0.184– 0.282 (0.260– 368 
0.081) 0.092) 0.160) 0.262) 0.326) 
 2003–2004 0.077 (0.065– 0.080 (0.060– 0.120 (0.100– 0.190 (0.160– 0.310 ( 287 
0.090) 0.090) 0.160) 0.310) 0.170–0.610) 
 2005–2006 0.066 (0.056– 0.060 (0.050– 0.110 (0.090– 0.180 ( 0.240 (0.160– 355 
0.078) 0.080) 0.130) 0.130–0.240) 0.290) 
 2007–2008 0.064 (0.058– 0.060 (0.050– 0.110 (0.090– 0.180 (0.140– 0.230 (0.180– 394 
0.071) 0.070) 0.130) 0.210) 0.310) 
12–19 Years 1999–2000 0.092 (0.067– 0.128 (0.107– 0.202 (0.183– 0.329 (0.272– 0.424 (0.366– 648 
0.126) 0.148) 0.232) 0.372) 0.596) 
 2001–2002 0.109 (0.087– 0.135 (0.114– 0.210 (0.189– 0.327 (0.289– 0.442 (0.366– 762 
0.136) 0.157) 0.247) 0.366) 0.480) 
 2003–2004 0.121 (0.190– 0.130 (0.110– 0.200 (0.160– 0.300 (0.260– 0.390 (0.330– 724 
0.134) 0.150) 0.190) 0.360) 0.490) 
 2005–2006 0.099 (0.090– 0.110 (0.100– 0.170 (0.150– 0.240 (0.210– 0.310 (0.250– 701 
0.109) 0.120) 0.190) 0.280) 0.430) 
 2007–2008 0.089 (0.079– 0.080 (0.070– 0.150 (0.140– 0.260 (0.200– 0.330 (0.280– 376 
0.100) 0.110) 0.170) 0.300) 0.410) 
≥20 Years 1999–2000 0.281 (0.253– 0.306 (0.261– 0.551 (0.510– 0.979 (0.836– 1.31 (1.13– 1,299 
0.313) 0.339) 0.621) 1.13) 1.57) 
 2001–2002 0.273 (0.249– 0.280 (0.261– 0.545 (0.493– 0.955 (0.855– 1.28 (1.20– 1,560 
0.299) 0.308) 0.607) 1.06) 1.43) 
 2003–2004 0.260 (0.238– 0.210 (0.210– 0.260 (0.470– 0.890 (0.800– 1.25 (1.09– 1,532 
0.284) 0.300) 0.580) 0.990) 1.46) 
 2005–2006 0.241 (0.213– 0.250 (0.220– 0.490 (0.440– 0.860 (0.790– 1.12 (1.06– 1,520 
0.272) 0.290) 0.560) 0.930) 1.32) 
 2007–2008 0.232 (0.215– 0.240 (0.210– 0.450 (0.410– 0.790 (0.730– 1.13 (0.990– 1,857 
0.251) 0.260) 0.490) 0.870) 1.44) 
e 
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Table 6-6.  Geometric Mean and Selected Percentile Urine Concentrations (μg/L) 
of Cadmium in the U.S. Population from 1999 to 2008 
 
Group 
Survey 
years 
Geometric 
meana (95% 
CI) 
Selected percentiles (95% CI) 
50th 75th 90th 95th 
Sample 
size 
Gender        
Males 1999–2000 0.199 (0.165–
0.241) 
0.227 (0.193–
0.263) 
0.462 (0.381–
0.539) 
0.892 (0.748–
1.15) 
1.41 (0.980–
1.83) 
1,121 
 2001–2002 0.201 (0.177–
0.229) 
0.223 (0.191–
0.257) 
0.445 (0.393–
0.481) 
0.870 (0.741–
1.03) 
1.22 (1.12–
1.38) 
1,335 
 2003–2004 0.206 (0.190–
0.222) 
0.210 (0.190–
0.230)  
0.440 (0.390–
0.490) 
0.790 (0.700–
0.870) 
1.01 (0.890–
1.25) 
1,277 
 2005–2006 0.195 (0.176–
0.217) 
0.210 (0.190–
0.230) 
0.400 (0.360–
0.440) 
0.800 (0.730–
0.890) 
1.17 (1.01–
1.30) 
1,271 
 2007–2008 0.179 (0.162–
0.197) 
0.180 (0.160–
0.200) 
0.360 (0.320–
0.400) 
0.670 (0.540–
0.780) 
0.950 (0.800–
1.14) 
1,327 
Females 1999–2000 0.187 (0.153–
0.229) 
0.239 (0.220–
0.255) 
0.492 (0.456–
0.540) 
0.806 (0.705–
0.980) 
1.10 (1.01–
1.19) 
1,136 
 2001–2002 0.219 (0.192–
0.251) 
0.234 (0.202–
0.265) 
0.466 (0.433–
0.519) 
0.817 (0.733–
0.886) 
1.17 (0.918–
1.36) 
1,355 
 2003–2004 0.216 (0.195–
0.238) 
0.210 (0.200–
0.240)  
0.450 (0.400–
0.530) 
0.820 (0.700–
0.960) 
120 (1.02–
1.37) 
1,266 
 2005–2006 0.188 ( 
0.160–0.221) 
0.190 (0.170–
0.200) 
0.400 (0.350–
0.480) 
0.750 (0.640–
0.860) 
0.980 (0.830–
1.20) 
1,305 
 2007–2008 0.191 (0.177–
0.207) 
0.190 (0.170–
0.200) 
0.400 (0.370–
0.430) 
0.740 (0.670–
0.840) 
1.09 (0.940–
1.38) 
1,300 
Race/ethnicity        
Mexican 
Americans 
1999–2000 0.191 (0.157–
0.233) 
0.202 (0.167–
0.221) 
0.438 (0.351–
0.551) 
0.813 (0.686–
0.977) 
1.12 (0.886–
1.38) 
780 
 2001–2002 0.160 (0.135–
0.189) 
0.181 (0.171–
0.198) 
0.321 (0.285–
0.362) 
0.559 (0.430–
0.733) 
0.766 (0.633–
1.15) 
683 
 2003–2004 0.175 (0.151–
0.203 
0.170 0.150–
0.210) 
0.350 0.290–
0.430) 
0.680 (0.520–
0.820) 
1.04 (0.820–
1.20) 
614 
 2005–2006 0.173 (0.152–
0.193) 
0.180 (0.160–
0.200) 
0.340 (0.300–
0.380) 
0.560 (0.500–
0.630) 
0.780 (0.660–
0.900) 
652 
 2007–2008 0.160 (0.141–
0.182) 
0.170 (0.140–
0.210) 
0.320 (0.290–
0.380) 
0.570 (0.520–
0.640) 
0.730 (0.640–
0.840) 
515 
Non-Hispanic 
blacks 
1999–2000 0.283 (0.208–
0.387) 
0.312 (0.243–
0.412) 
0.633 (0.498–
0.806) 
1.22 (0.892–
1.38) 
1.48 (1.30–
1.72) 
546 
 2001–2002 0.277 (0.229–
0.336) 
0.302 (0.257–
0.354) 
0.580 (0.476–
0.713) 
1.04 (0.843–
1.38) 
1.51 (1.28–
1.74) 
667 
 2003–2004 0.265 (0.237–
0295) 
0.270 (0.220–
0.320) 
0.550 (0.440–
0.640) 
0.960 0.810–
1.17) 
1.52 (1.06–
1.82) 
717 
 2005–2006 0.236 (0.240–
0.210) 
0.240 (0.210–
0.260) 
0.480 (0.420–
0.530) 
0.830 (0.670–
0.930) 
1.04 (0.870–
1.26) 
692 
 2007–2008 0.246 (0.218–
0.277) 
0.260 (0.220–
0.300) 
0.460 (0.420–
0.530) 
0.840 (0.690–
0.980) 
1.40 (0.900–
1.85) 
589 
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Table 6-6.  Geometric Mean and Selected Percentile Urine Concentrations (μg/L) 
of Cadmium in the U.S. Population from 1999 to 2008 
 
Group 
Survey 
years 
Geometric 
meana (95% 
CI) 
Selected percentiles (95% CI) 
50th 75th 90th 95th 
Sample 
size 
Non-Hispanic 
whites 
1999–2000 0.175 (0.148–
0.206) 
0.220 (0.194–
0.246) 
0.455 (0.388–
0.510) 
0.797 (0.714–
1.01) 
1.17 (0.963–
1.47) 
760 
 2001–2002 0.204 (0.179–
0.231) 
0.221 (0.191–
0.255) 
0.445 (0.394–
0.479) 
0.813 (0.717–
0.875) 
1.17 (0.989–
1.24) 
1,132 
 2003–2004 0.209 (0.192–
0.226) 
0.200 (0.190–
0.220) 
0.440 (0.390–
0.500) 
0.790 (0.700–
0.860) 
1.13 (0.940–
1.26) 
1,070 
 2005–2006 0.185 (0.159–
0.216) 
0.200 (0.160–
0.230) 
0.400 (0.330–
0.480) 
0.780 (0.670–
0.920) 
1.05 (0.940–
1.25) 
1,041 
 2007–2008 0.177 (0.161–
0.195) 
0.170 (0.150–
0.190) 
0.370 (0.330–
0.400) 
0.690 (0.620–
0.780) 
1.00 (0.880–
1.12) 
1,095 
 
aThe proportion of results below the LOD was too high to provide a valid result. 
 
CI = confidence interval; LOD = limit of detection 
 
Source:  CDC 2011 
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As a part of the New York City Health and Nutrition Examination Survey (NYC HANES), 2004 blood 
cadmium levels were evaluated in 1,811 New York City adults (age 20 years and older).  The variables 
used in this study were sex, age, race/ethnicity, place of birth, family income, education, and smoking 
status (see Table 6-7 for detailed results of this study).  The geometric mean blood cadmium 
concentration in New York City adults was 0.77 μg/L, slightly higher than the 1999–2000 estimated 
national mean of 0.47 μg/L with heavy smokers having the highest geometric mean blood cadmium level 
of 1.58 μg/L, higher than any other subgroup.  The reason for the elevated blood cadmium levels in 
nonsmoking, New York City adults is not known, although it was speculated that higher shellfish 
consumption may be the cause of elevated blood cadmium levels in Asian subgroup (McKelvey et al. 
2007).   
 
 
 
Vahter et al. (1996) studied the dietary intake and uptake of cadmium in nonsmoking women consuming 
a mixed diet low in shellfish (n=34) or with shellfish once a week or more (n=17).  The shellfish diets, 
with a median of 22 μg Cd/day, contained twice as much cadmium as the mixed diets, which had a 
median of 10.5 μg Cd/day.  In spite of the differences in the daily intake of cadmium, there were no 
statistically significant differences in the blood cadmium concentrations of the shellfish group (0.25 μg/L) 
and the mixed diet group (0.23 μg/L) or in the urinary cadmium concentrations of the shellfish and mixed 
diet groups (0.10 μg/L in both groups).  These results indicate a lower absorption of cadmium in the 
shellfish group than in the mixed diet group or a difference in kinetics.  The authors suggested that a 
higher gastrointestinal absorption of cadmium in the mixed diet group could be explained in part by their 
lower body iron stores as measured by the concentrations of serum ferritin (S-fer).  A median S-fer 
concentration of 18 μg/L was measured for the mixed diet group compared to a median of 31 μg/L for the 
shellfish group.  
Except in the vicinity of cadmium-emitting industries or incinerators, the intake of cadmium from 
drinking water or ambient air is of minor significance (Elinder 1985a).  Cadmium is removed from waste 
water and sewage through precipitation to hydroxide or carbonate compounds and ultimate separation 
(Schulte-Schrepping and Piscator 2002).  EPA requires water suppliers to limit the cadmium 
concentration in water to <5 μg/L (EPA 2006a). 
IARC (1993) reports that the total body burden of non-occupationally exposed adult subjects has been 
estimated to range from 9.5 to 50 mg in the United States and Europe.  People living near sources of 
cadmium pollution may be exposed to higher levels of cadmium.  Ambient air cadmium concentrations in 
industrialized areas was estimated between 15 and 150 ng/m3 (Morrow 2001).  During a study conducted  
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Table 6-7.  Blood Cadmium Concentrations, Geometric Means, Adjusted 
Proportional Change in Means, and 95th Percentiles in  
New York City Adults in Population Subgroups 
 
Results 
Crude weighted 
geometric mean 
blood cadmium 
Adjusted proportional 
change in mean 
blood cadmium 
Crude weighted 
95th percentile 
blood cadmium 
Variable Numbera (μg/L)  (μg/L)b (μg/L) 
Total: 1,811 0.77 — 1.88 
Male 762 0.76 1.00 1.95 
Female 1,049 0.79 1.07 1.83 
20–39 years old 903 0.76 1.00 1.82 
40–59 years old 673 0.84 1.16 2.19 
≥60 years old 235 0.77 1.15 1.52 
White, non-Hispanicc 529 0.73 1.04 1.71 
Black, non-Hispanicc 390 0.80 1.11 1.97 
Asian, non-Hispanicc 231 0.99 1.41 2.36 
Hispanicc 630 0.73 1.00 1.73 
Place of birth:     
United States 882 0.76 1.00 1.95 
Outside the United 
States 923 0.79 1.02 1.73 
Family income ($ U.S.):     
<20,000 610 0.86 1.00 2.33 
20,000–49,999 566 0.77 0.94 1.76 
50,000–74,999 256 0.74 0.92 1.76 
≥75,000 304 0.69 0.91 1.43 
Education:     
<Bachelors 1,252 0.82 1.09 2.02 
Bachelors or greater 551 0.69 1.00 1.43 
Smoking status:     
Never smoked 1,036 0.66 1.00 1.28 
Former smoker 310 0.71 1.07 1.32 
Current smoker 449 1.22 1.88 3.00 
 
aTotals do not all equal 1,811 because of missing data. 
bThe exponential β coefficient from a log-linear multiple regression that includes all covariates in the table.  Sample 
size for adjust analysis is 1,707, after excluding study participants for whom covariate data are missing. 
cExcludes 27 participants who self-classified as “other”.  
 
Source:  McKelvey et al. 2007 
 
 
CADMIUM  317 
 
6.  POTENTIAL FOR HUMAN EXPOSURE 
 
 
 
 
 
 
 
in Germany between March and May 2000, cadmium levels in child-mother pairs, as a function of 
ambient air quality, were compared between populations in the urban, industrialized area of Duisburg and 
the rural area of North Rhine Westphalia.  Cadmium levels in the ambient air of Duisburg-South ranged 
from 1.5 to 31 ng/m3, compared to 0.5 ng/m3 in the rural are of Westphalia.  Cadmium levels in the blood 
and urine of mothers in the industrialized area were higher than in the rural areas.  Cadmium levels in the 
blood and urine of the children did not differ between the two areas.  In the industrialized area, regression 
analysis indicated a significant influence of cadmium in ambient air on cadmium in blood (Wilhelm et al. 
2005).   
 
 
 
It has been estimated that tobacco contains 1.7 μg cadmium per cigarette, and about 10% is inhaled when 
smoked (Morrow 2001; NTP 2005).  Tobacco leaves naturally accumulate large amounts of cadmium 
(Morrow 2001).  During a study monitoring cadmium levels in 331 cigarette packs from over 20 areas 
around the world, it was found that the mean cadmium level per cigarette was 1.15 µg/cigarette 
±0.43 (AM±ASD) or 1.06 µg/cigarette ±1.539 GM±GSD.  Cigarettes from Mexico had the highest mean 
level of cadmium with an AM±ASD of 2.03 µg/cigarette ±0.33 or a GM±GSD of 2.00 µg/cigarette 
±1.190.  Cigarettes from India had the lowest mean levels of cadmium with an AM±ASD of 0.35 
µg/cigarette ±0.09 or a GM±GSD of 0.34 µg/cigarette ±1.284 (Watanabe et al. 1987).  The amount of 
cadmium absorbed from smoking one pack of cigarettes per day is about 1–3 μg/day (Lewis et al. 1972a; 
Nordberg et al. 1985), roughly the same as from the diet.  This large contribution is due to the greater 
absorption of cadmium from the lungs than from the gastrointestinal tract (Elinder 1985a).  Direct 
measurement of cadmium levels in body tissues confirms that smoking roughly doubles cadmium body 
burden in comparison to not smoking, with kidney concentrations averaging 15–20 μg/g wet weight for 
nonsmokers and 30–40 μg/g wet weight for heavy smokers at the age of 50–60 (Ellis et al. 1979; Hammer 
et al. 1973; Lewis et al. 1972a, 1972b).  Ellis et al. (1979) found an increase in kidney cadmium of 
0.11±0.05 mg per pack-year (AM±ASD) of smoking and an increase in liver cadmium concentration of 
0.077±0.065 μg/g per pack-year (AM±ASD).  Because excretion of cadmium is very slow, half-lives of 
cadmium in the body are correspondingly long (17–38 years) (Wester et al. 1992). 
Workers in a variety of occupations may be exposed to cadmium and cadmium compounds.  Occupations 
with potential exposure to cadmium are listed in Table 6-8 (IARC 1993). 
Highest levels of occupational exposure would be expected to occur in operations involving heating 
cadmium-containing products by smelting, welding, soldering, or electroplating, and also in operations 
associated with producing cadmium powders (OSHA 1990).  The primary route of occupational exposure  
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Table 6-8.  Occupations with Potential Exposure to Cadmium and Cadmium 
Compounds 
 
Occupation 
Alloy productiona Phosphorous production 
Battery productiona Pigment production and usea 
Brazing Plastics productiona 
Coating Plating 
Diamond cutting Printing 
Dry color formulation Semiconductor and superconductor production 
Electroplating Sensors production 
Electrical contacts production Smelting and refininga 
Enameling Solar cells production 
Engraving Soldering 
Glasswork Stabilizer production 
Laser cutting Textile printing 
Metallizing Thin film production 
Paint production and use Transistors production 
Pesticide production and use Welding 
 
aActivity with high risk because atmospheric concentrations of cadmium are high and the number of workers 
employed is significant. 
 
Source:  IARC 1993 
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is through inhalation of dust and fumes, and also incidental ingestion of dust from contaminated hands, 
cigarettes, or food (Adamsson et al. 1979).   
 
 
 
 
Concentrations of airborne cadmium found in the workplace vary considerably with the type of industry 
and the specific working conditions.  Processes that involve high temperatures can generate cadmium 
oxide fumes that are absorbed very efficiently through the lungs (IARC 1993).  Deposition and absorption 
of dust containing different compounds depend upon particle size (IARC 1993).  These exposures can be 
controlled through use of personal protective equipment and good industrial hygiene practices, and 
through operating procedures designed to reduce workplace emissions of cadmium (OSHA 1990).   
Data from the National Occupational Exposure Survey (NOES), conducted by NIOSH from 1981 to 
1983, estimated the number of workers potentially exposed to various chemicals in the workplace during 
the same period (NIOSH 1990); these data are summarized in Table 6-9.  The NOES database does not 
contain information on the frequency, level, or duration of exposure of workers to any of the chemicals 
listed.  It provides only estimates of workers potentially exposed to the chemicals.  
 
6.6   EXPOSURES OF CHILDREN  
 
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from 
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility. 
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways.  
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a 
larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults.  
The developing human’s source of nutrition changes with age:  from placental nourishment to breast milk 
or formula to the diet of older children who eat more of certain types of foods than adults.  A child’s 
behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors.  Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993). 
Children are most likely to be exposed to cadmium in from ingestion of food (NTP 2005).  There are no 
data on gastrointestinal absorption of cadmium in children, although very limited evidence exists that 
cadmium absorption from the gut may be greater in young animals.  Oral absorption is discussed in more 
detail in Section 3.4.1.2.  A study performed in Cincinnati, Ohio, investigated cadmium in human milk  
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Table 6-9.  Estimated Number of Workers Potentially Exposed to Various 
Chemicals in the Workplace in 1981–1983 
 
Chemical Number of workers potentially exposed 
Cadmium sulfide 45,562 
Cadmium oxide 15,727 
Cadmium (pure) 335 
Cadmium dust (form unknown) 3,893 
Cadmium powder (form unknown) 486 
Cadmium sulfate 1,313 
1:1 Cadmium salt of carbonic acid 164 
Cadmium (form unknown) 88,968 
Total 153,486 
 
Source:  NIOSH 1990 
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and found a mean concentration of 19 ppb (0.019 ppm) (Jensen 1983).  The NHANES 1999–2008 
reported cadmium levels in blood (see Table 6-4) and urine (see Tables 6-5 and 6-6) for children in 
different age groups (CDC 2011).  The NYC HANES did not test for blood cadmium levels in children, 
although the blood cadmium levels in adults were slightly higher than the national average (McKelvey et 
al. 2007).  Results of the U.S. FDA Total Diet Study (Capar and Cunningham 2000) reported cadmium 
levels in infant and junior foods ranged from no detection to 0.090 mg/kg.  According to the National 
Human Exposure Assessment Survey (NHEXAS), children in EPA Region V (Great Lakes Region) have 
a mean dietary cadmium exposure of 17 (±1.8) μg/kg for minority children and 21 (±2.2) μg/kg for non-
minority children (Pellizzari et al. 1999).  
 
 
Except in the vicinity of cadmium-emitting industries or incinerators, the intake of cadmium from 
drinking water or ambient air is of minor significance (Elinder 1985a).  Ambient air cadmium 
concentrations in industrialized areas has been estimated between 15 and 150 ng/m3 (Morrow 2001).  
Cadmium levels in the ambient air of Duisburg-South, Germany ranged from 1.5 to 31 ng/m3, compared 
to 0.5 ng/m3 in the rural are of Westphalia.  Cadmium levels in the blood and urine of mothers in the 
industrialized area were higher than in the rural areas.  Cadmium levels in the blood and urine of the 
children did not differ between the two areas.  In the industrialized area, regression analysis indicated a 
significant influence of cadmium in ambient air on cadmium in blood (Wilhelm et al. 2005).  Children in 
the homes of parents who smoke also can be exposed to cadmium through the inhalation of environmental 
tobacco smoke.  There is potential for cadmium originating from second-hand smoke to settle onto 
surfaces; thus, there is a possibility that children may ingest cadmium from contaminated surfaces by the 
hand-to-mouth pathway.  Although no data were found, children playing near hazardous waste sites could 
be exposed to cadmium in soil by hand-to-mouth activity and/or soil pica.  No case studies were found on 
accidental poisoning of children by swallowing cadmium-containing batteries or by ingesting cadmium-
containing household pesticides, which also are potential routes of exposure.  No information was found 
concerning differences in the weight-adjusted intakes of cadmium by children.  
In the Workers’ Home Contamination Study conducted under the Workers’ Family Protection Act 
(DHHS 1995), several studies were identified that reported home contamination with cadmium 
originating from parental occupation in a lead smelter.  In a study of 396 children of ages 1–9 years living 
<900 m from a primary lead smelter, 380 children (96%) had blood cadmium (CdB) levels >0.0089 μg/L 
(Carvalho et al. 1986).  The geometric mean and standard deviation were 0.087 µmol/L and 2.5, 
respectively.  No significant relationship was found between parental occupation in the smelter and CdB 
in children, but a significant relationship was found between presence of smelter dross in the house and 
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elevated CdB in children.  Higher CdB was significantly associated with shorter distance from the home 
to the smelter.  In a similar study of 263 children (ages 1–9 years), living <900 m from a primary lead 
smelter, the mean cadmium in hair was significantly higher at 6.0 ppm for children whose fathers worked 
in lead smelters than the concentration of 3.7 ppm for children whose fathers had other jobs (Carvalho et 
al. 1989).  In a study of 9 children from families of lead workers and 195 children (ages 4–17 years) from 
other families, the children from the families of lead workers had significantly higher geometric mean 
urinary cadmium (CdU) (0.34 μg/L ±2.6) than children from other families (0.13 μg/L ±2.2).  The CdB 
levels of children from families of lead workers were higher than those of the children from other 
families, but the difference was not statistically significant (Brockhaus et al. 1988).  Maravelias et al. 
(1989) measured the CdBs of 514 children (ages 5–12) from four schools located within various distances 
(500–1500 m) from a lead smelter.  The geometric mean and geometric standard deviation CdB was 
0.36 μg/L ±1.4, respectively, with a range of 0.1–3.1 μg/L.  Children from the school closest to the 
smelter had higher CdB levels than children from other schools, but no relationship was found between 
childrens’ CdB and parental employment in the smelter.  
 
The placenta may act as a partial barrier to fetal exposure to cadmium.  Cadmium concentration has been 
found to be approximately half as high in cord blood as in maternal blood in several studies including 
both smoking and nonsmoking women (Kuhnert et al. 1982; Lauwerys et al. 1978; Truska et al. 1989).  
Accumulation of cadmium in the placenta at levels about 10 times higher than maternal blood cadmium 
concentration has been found in studies of women in Belgium (Roels et al. 1978) and the United States 
(Kuhnert et al. 1982); however, in a study in Czechoslovakia, the concentration of cadmium in the 
placenta was found to be less than in either maternal or cord blood (Truska et al. 1989).  Baranowska 
(1995) also measured the concentrations of cadmium and lead in human placenta and in maternal and 
neonatal (cord) blood to assess the influence of a strongly polluted environment on the content of metals 
in tissues and on the permeability of the placenta to cadmium and lead.  Samples for the study were 
collected from women living in the industrial district of Upper Silesia, one of the most polluted regions in 
Poland.  The mean (range) concentration of cadmium in the air was 11.3 (2.1–25.4) ng/m3 
(0.0113 [0.0021–0.0254] μg/m3).  The mean concentrations of cadmium were 4.90 ng/mL 
(0.00490 μg/mL) in venous blood, 0.11 μg/g in placenta, and 1.13 ng/mL (0.00113 μg/mL) in cord blood.  
The researcher concluded that the placenta is a better barrier for cadmium than for lead, based upon the 
relative decrease in metal concentrations from placenta to cord blood.  The mechanism by which the 
placenta transports the essential metals, copper and zinc, while limiting the transport of cadmium is 
unknown, but may involve the approximately 1,000-fold higher concentration of zinc in the placenta and 
the higher affinity of cadmium than zinc for metallothionein (Goyer and Cherian 1992).  Timing and level 
CADMIUM  323 
 
6.  POTENTIAL FOR HUMAN EXPOSURE 
 
 
 
 
 
 
 
of cadmium exposure may influence the uptake of cadmium by the placenta, perhaps explaining the 
conflicting human studies.  Galicia-García et al. (1995) performed analyses of cadmium in maternal, cord, 
and newborn blood for 50 births in a Mexico City hospital.  Multiple regression analyses applied to the 
data indicated a significant association between cord and newborn blood and between cord and maternal 
blood, but not among maternal and newborn blood.  Birth weight of the newborns was found to be 
inversely associated with cord blood cadmium levels and smoking habits.  
 
 
 
 
 
The analysis of Weidenberg et al. (2011) on the bioavailability of cadmium present in inexpensive 
jewelry suggests that substantial quantities of cadmium may be released from jewelry that is mouthed or 
swallowed and that the amount released was greatly varied from item to item. 
6.7   POPULATIONS WITH POTENTIALLY HIGH EXPOSURES  
The greatest potential for above-average exposure of the general population to cadmium is from smoking, 
which may double the exposure of a typical individual.  Smokers who are exposed to cadmium in the 
workplace are at highest risk (CDC 2005).  Individuals living near zinc or lead smelting operations, 
municipal incinerators, or other industrial processes emitting cadmium to the air will also have above-
average exposure (Elinder 1985a).  Exposures through inhalation are diminishing due to pollution 
controls at such facilities, but exposure resulting from soil contamination may continue to be significant.  
Persons who have corrosive drinking water and cadmium-containing plumbing, who habitually consume 
cadmium-concentrating foods (kidney, liver, and shellfish), or who ingest grains or vegetables grown in 
soils treated with municipal sludge or phosphate fertilizer all may have increased exposure (Elinder 
1985a).  The 2004 NYC HANES indicated that the New York City Asian population, especially those 
born in China, had higher concentrations of cadmium in blood.  The authors speculate that this might be 
due to higher consumption of fish and shellfish (McKelvey et al. 2007).  
Multiple pathways of exposure may exist for populations at hazardous waste sites contaminated with 
cadmium (ingestion of contaminated drinking water or garden vegetables, inhalation of airborne dust, 
incidental ingestion of contaminated soil). 
Persons who consume large quantities of sunflower kernels can be exposed to higher levels of cadmium.  
Reeves and Vanderpool (1997) identified specific groups of men who were likely to consume sunflower 
kernels.  The groups included baseball and softball players, delivery and long-distance drivers, and line 
workers in sunflower kernel processing plants. 
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Recreational and subsistence fishers that consume appreciably higher amounts of locally caught fish from 
contaminated waterbodies may be exposed to higher levels of cadmium associated with dietary intake 
(EPA 1993a).  Cadmium contamination has triggered the issuance of several human health advisories.  As 
of December 1997, cadmium was identified as the causative pollutant in five fish and shellfish 
consumption advisories in New York and another in New Jersey.  EPA is considering including cadmium 
as a target analyte and has recommended that this metal be monitored in fish and shellfish tissue samples 
collected as part of state toxics monitoring programs.  EPA recommends that residue data obtained from 
these monitoring programs be used by states to conduct risk assessments to determine the need for issuing 
fish and shellfish consumption advisories for the protection of the general public as well as recreational 
and subsistence fishers.  Under the same program, EPA has issued a statewide advisory in Maine for 
cadmium in moose (EPA 1998). 
 
6.8   ADEQUACY OF THE DATABASE  
 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of cadmium is available.  Where adequate information is not 
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research 
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of cadmium. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
6.8.1   Identification of Data Needs  
 
Physical and Chemical Properties.    The chemical and physical properties of cadmium and its salts 
are known well enough to permit estimation of the environmental fate of the compounds (Elinder 1985a, 
1992).  Additional information on properties does not appear to be crucial for evaluating potential fate. 
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Production, Import/Export, Use, Release, and Disposal.    According to the Emergency 
Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required 
to submit substance release and off-site transfer information to the EPA.  The TRI, which contains this 
information for 2009, became available in February of 2011.  This database is updated yearly and should 
provide a list of industrial production facilities and emissions. 
 
 
 
The production volume, producers, import/export quantities, and uses of cadmium in the United States are 
well documented (SRI 2007; USGS 2007, 2008).  Recycling of cadmium from spent batteries is 
increasing, and there are some data to suggest that there is still a large portion of cadmium being disposed 
of as municipal waste (USGS 2007).  More data concerning the amount of municipal disposal would be 
helpful.  Disposal of cadmium-containing wastes is regulated by the federal government, and data are 
available for industrial disposal practices (EPA 1982a; HSDB 2008; U.S. Bureau of Mines 1990).  Most 
releases of cadmium are not from production of the metal or its compounds, but from combustion or 
smelter emissions, land application of sewage sludge and fertilizers, and other sources; estimates of these 
releases have been made (TRI09 2011).   
Environmental Fate.    Cadmium partitioning among media occurs, and this partitioning depends on 
local environmental conditions (Elinder 1985a, 1992).  Cadmium may be subject to long-range transport 
in air and water (EPA 1980d).  Cadmium is persistent in all media, although it may form organic 
complexes in soil and water under certain environmental conditions (EPA 1979).  These processes, which 
are important for determining the environmental fate of cadmium, seem to be relatively well understood.  
Therefore, additional information on environmental fate does not appear to be essential to evaluate 
potential human exposure to cadmium. 
Bioavailability from Environmental Media.    Factors that control the bioavailability of cadmium 
from air, water, soil, and food have been investigated.  Intestinal absorption of cadmium from food is low, 
about 5–10% (McLellan et al. 1978; Newton et al. 1984; Rahola et al. 1973), but the absorption of 
cadmium from soil is not known.  Absorption from the lungs is somewhat greater, averaging about 25% 
(Nordberg et al. 1985).  Estimates of dermal absorption of cadmium from soil and water on human skin 
have been made (Wester et al. 1992).  There is some evidence that bioavailability of cadmium to plants 
and worms from contaminated soil is greater following remediation (Van Gestel et al. 1988).  Additional 
information on the factors influencing bioavailability, particularly from remediated soil, are needed to 
assess residual risk to populations in the vicinity of reclaimed hazardous waste sites. 
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Food Chain Bioaccumulation.    Sufficient data are available to indicate that cadmium is 
concentrated in plants, aquatic organisms, and animals (Alloway et al. 1990; Beyer 1986; Handy 1992a, 
1992b; Kuroshima 1992; Naqvi and Howell 1993; Roseman et al. 1994; Suresh et al. 1993; Vos et al. 
1990).  In vertebrates, cadmium accumulates in the liver and kidneys (Harrison and Klaverkamp 1990; 
Sileo and Beyer 1985; Vos et al. 1990).  There is strong evidence for food chain bioaccumulation, but the 
potential for biomagnification is uncertain.  Additional studies on biomagnification are needed to provide 
data for more accurate evaluation of the environmental impact of cadmium contamination. 
 
 
 
Exposure Levels in Environmental Media.    Reliable monitoring data for the levels of cadmium in 
contaminated media at hazardous waste sites are needed so that the information obtained on levels of 
cadmium in the environment can be used in combination with the known body burden of cadmium to 
assess the potential risk of adverse health effects in populations living in the vicinity of hazardous waste 
sites. 
Current ambient air quality surveys testing for cadmium concentrations in rural and urban locations in the 
United States is lacking.  Since the major source of exposure to cadmium is through dietary intake and 
since cadmium emissions to air are not expected to increase, there may be less interest in these data.  
There are several long-range atmospheric transport studies, but since these were conducted Europe and 
Russia, they only illustrate the potential for cadmium contamination via atmospheric deposition in the 
United States (Reimann et al. 1997; Shevchenko et al. 2003; Vidovic et al. 2005).  There is also minimal 
data on current levels of cadmium in agricultural soils of the United States and the identification of the 
sources of cadmium levels, whether they are native geochemistry, phosphate fertilizers, atmospheric 
deposition, etc. (Xue et al. 2000).  Continuing monitoring efforts in all media would allow more precise 
estimation of current sources and levels of human exposure and would assist in identifying major sources 
contributing to current exposure. 
Exposure Levels in Humans.    Cadmium has been detected in human blood, urine, breast milk, 
liver, kidney, and other tissues, both in occupationally exposed individuals and in the general population 
(CDC 2011; McKelvey et al. 2007; OSHA 1990).  The NHANES and NYC HANES provide current data 
on the levels of cadmium in humans (CDC 2011; McKelvey et al. 2007).  Other large-scale surveys 
concentrating on urban, agricultural, and suburban communities would be beneficial in understanding 
cadmium exposure to the U.S. population.  Also, more information is needed on the specific exposure 
levels for different cadmium salts to determine if cadmium sulfides, for example, are associated with less 
harmful effects than cadmium oxides (Chettle and Ellis 1992). 
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This information is necessary for assessing the need to conduct health studies on these populations. 
Exposures of Children.    Cadmium has been measured in maternal and neonatal (cord) blood and in 
placenta (Baranowska 1995; Galicia-García et al. 1995; Kuhnert et al. 1982; Lauwerys et al. 1978; Roels 
et al. 1978; Truska et al. 1989), but the resulting data are sometimes conflicting with respect to the uptake 
of cadmium by the placenta.  Research on the effects of timing and level of exposure on cadmium uptake 
by the placenta might help to explain these conflicting human studies.  More recent data would be useful, 
both from women and children living in unpolluted areas (for background levels) and in polluted areas 
such as those near existing or former lead smelters.  
There are some current data concerning cadmium exposure in children (Capar and Cunningham 2000; 
CDC 2011; Pellizzari et al. 1999).  The NHANES 1999–2008 reported cadmium levels in blood (see 
Table 6-4) and urine (see Table 6-5) for children in different age groups (CDC 2011).  The NYC HANES 
did not test for blood cadmium levels in children, although the blood cadmium levels in adults were 
slightly higher than the national average (McKelvey et al. 2007).  Results of the U.S. FDA Total Diet 
Study (Capar and Cunningham 2000) reported cadmium levels in infant and junior foods ranged from no 
detection to 0.090 mg/kg.  According to the NHEXAS, children in EPA Region V (Great Lakes Region) 
have a mean dietary cadmium exposure of 17 (±1.8) μg/kg for minority children and 21 (±2.2) μg/kg for 
non-minority children (Pellizzari et al. 1999).  
Some body burden data are available for children living near lead smelters (Lagerkvist and Lundstrom 
2004; Leroyer et al. 2001; Jin et al. 2002).  However, none of the studies took place in the United States.  
Body burden data from children living in polluted and unpolluted regions (for background levels) of the 
United States are needed.  
Current information on whether children are different in their weight-adjusted intake of cadmium via oral, 
inhalation, and dermal exposures was not located.  A study to determine this information would be useful.  
Also, no information was found on childhood specific means to reduce cadmium exposure. 
Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification of Data 
Needs:  Children’s Susceptibility. 
CADMIUM  328 
 
6.  POTENTIAL FOR HUMAN EXPOSURE 
 
 
 
 
 
 
 
Exposure Registries.    The State of New York has established the Heavy Metals Registry for 
surveillance of occupational heavy metals absorption.  Cadmium levels >10 μg/L in blood and 5 μg/L in 
urine are reported to the registry.  The number of adults with reportable levels has varies per year, but 
there have always been <50 adults reported per year.  Between 1995 and 2003, the number of reportable 
adults was <5, and these exposures are due mostly to exposure for people working as jewelers and casting 
machine operators (NYS Dept of Health 2006).  
 
 
 
 
No other exposure registries for cadmium were located.  This substance is not currently one of the 
compounds for which a subregistry has been established in the National Exposure Registry.  The 
substance will be considered in the future when chemical selection is made for subregistries to be 
established.  The information that is amassed in the National Exposure Registry facilitates the 
epidemiological research needed to assess adverse health outcomes that may be related to exposure to this 
substance. 
6.8.2   Ongoing Studies  
 
The Federal Research in Progress (FEDRIP 2008) database provides additional information obtainable 
from a few ongoing studies that may fill in some of the data needs identified in Section 6.8.1.  These 
studies are summarized in Table 6-10. 
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Investigator Affiliation Research description Sponsor 
Birnbaum ER Caldera Biomarkers of response to environmental National Institute of 
Pharmaceuticals, stressors Environmental 
Inc., Los Alamos, Health Sciences 
New Mexico 
Chen Z X-Ray Optical Direct measurement of trace elements in National Center for 
Systems, Inc. body fluids Research 
East Greenbush, Resources 
New York 
Dweik BM Giner, Inc., Field-deployable monitor to assess personal National Institute of 
Newton, exposure to multiple heavy metals Environmental 
Massachusetts Health Sciences 
Fallin MD Johns Hopkins AGE-related epigenetic changes - National Institute of 
University, environmental causes and disease Environmental 
Baltimore, consequences Health Sciences 
Maryland 
Fox MA Johns Hopkins Environmental exposure to metal mixtures National Institute of 
University, and kidney disease Environmental 
Baltimore, Health Sciences 
Maryland 
Larkin PM Ecoarray, Inc. Developing and using sheepshead minnow National Institute of 
Alachua, Florida microarrays for ecotoxicology Environmental 
Health Sciences 
Mo J Kumetrix, Inc, Automatic multi-analyte in-situ bioassay for National Institute of 
Union City, monitoring exposure to toxic metals Environmental 
California Health Sciences 
Polette-Niewold Mayan Pigments, SBIR phase II:  One-step environmentally- National Science 
LA Inc. friendly synthesis of novel organic/inorganic Foundation 
hybrid pigments 
Santra S University of Selective detection of toxic heavy metal ions National Science 
Central Florida using highly sensitive quantum dot probes Foundation 
Basta N; Raun Oklahoma State Chemistry and bioavailability of waste U.S. Department of 
WR University constituents in soils  Agriculture 
Basta NT Oklahoma State Heavy metal and trace element chemistry in U.S. Department of 
University soils:  Chemical speciation and bioavailability  Agriculture 
Basta NT; Lower Ohio State Heavy metal and trace element U.S. Department of 
SK; Lanno R University biogeochemistry in soils:  Chemical Agriculture 
speciation, bioavailability, and toxicity  
Bleam WF; University of Verifying and quantifying the specific U.S. Department of 
Helmke PA Wisconsin complexation of metals to humic substances Agriculture 
Chaney RL Beltsville Characterization and remediation of potential U.S. Department of 
Agricultural trace element and phosphate risks from Agriculture 
Research Center contaminated soils 
Chaney RL Beltsville Risk assessment and remediation of soil and U.S. Department of 
Agricultural amendment trace elements  Agriculture 
Research Center 
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Table 6-10.  Ongoing Studies on Cadmium 
 
Investigator Affiliation Research description Sponsor 
Chaney RL; Virginia Effects of long-term biosolids applications on U.S. Department of 
Daniels WL Polytechnic phytoavailability of soil cadmium and zinc Agriculture 
Institute 
Chang AC; Page University of Chemistry and bioavailability of waste U.S. Department of 
AL California, constituents in soils  Agriculture 
Riverside 
Eick MJ Virginia Trace element and ligand adsorption/ U.S. Department of 
Polytechnic desorption from soil constituent surfaces  Agriculture 
Institute 
Hopkins DG North Dakota Influence of geologic materials and pedogenic U.S. Department of 
State University processes on trace elements in soil Agriculture 
landscapes  
Hunt JR; Lykken University of Whole body counting and radiotracer U.S. Department of 
GI North Dakota methods in research on mineral requirements Agriculture 
in human nutrition  
Kpomblekou- Tuskegee Trace elements in broiler littered soils:  Fate U.S. Department of 
Ademawou K; University and effects on nitrogen transformation  Agriculture 
Ankumah RO 
Martinez CE Pennsylvania Chemical and biogeochemical processes U.S. Department of 
State University involved in trace and toxic element cycling in Agriculture 
soils 
Morrissey MT Oregon State Characterization of the cadmium health risk, U.S. Department of 
University concentrations and ways to minimize Agriculture 
cadmium residues in shellfish 
Schwab AP; Purdue University Chemistry and bioavailability of waste U.S. Department of 
Joern B; Johnston constituents in soils  Agriculture 
C 
Sparks DL University of Rates and mechanisms of metal and U.S. Department of 
Delaware metalloid sorption/surfaces Agriculture 
Thomas, DG; Oklahoma State Maternal dietary nutrients and neurotoxins in U.S. Department of 
Kennedy TS University infant cognitive development Agriculture 
Williams PL University of Environmental health impacts of soil U.S. Department of 
Georgia contamination Agriculture 
 National Risk Biomonitoring of source water quality U.S. Environmental 
Management 
Research 
Protection Agency 
Laboratory 
Petterson L National Efficient monitoring of heterogeneous media U.S. Environmental 
Exposure 
Research Lab 
and electronic wastes  Protection Agency 
Environmental 
Sciences Division 
Characterization 
and Monitoring 
Branch 
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Table 6-10.  Ongoing Studies on Cadmium 
 
Investigator Affiliation Research description Sponsor 
Petterson L 
Nolan P 
Janes D 
National 
Exposure 
Research Lab 
Ecosystems 
Research Division 
Ecosystems 
Assessment 
Branch 
Office of Regional 
Administrator 
Office of 
Environmental 
Measurement and 
Evaluation 
Office of 
Research and 
Development 
National Health 
and 
Environmental 
Effects Research 
Lab Mid-
Continent 
Ecology Division 
Geochemical and interfacial applications for 
assessing ecological toxicant exposures 
Lower Merrimack River fish tissue study  
Risks of heavy metals to aquatic organisms 
from multiple exposure routes  
U.S. Environmental 
Protection Agency 
U.S. Environmental 
Protection Agency 
U.S. Environmental 
Protection Agency 
 
Sources:  FEDRIP 2008; SI/EPA 2007 
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7.  ANALYTICAL METHODS 
 
The purpose of this chapter is to describe the analytical methods that are available for detecting, 
measuring, and/or monitoring cadmium, its metabolites, and other biomarkers of exposure and effect to 
cadmium.  The intent is not to provide an exhaustive list of analytical methods.  Rather, the intention is to 
identify well-established methods that are used as the standard methods of analysis.  Many of the 
analytical methods used for environmental samples are the methods approved by federal agencies and 
organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH).  Other 
methods presented in this chapter are those that are approved by groups such as the Association of 
Official Analytical Chemists (AOAC) and the American Public Health Association (APHA).  
Additionally, analytical methods are included that modify previously used methods to obtain lower 
detection limits and/or to improve accuracy and precision. 
 
7.1   BIOLOGICAL MATERIALS  
 
The most common analytical procedures for measuring cadmium concentrations in biological samples use 
the methods of atomic absorption spectroscopy (AAS) and inductively coupled plasma atomic emission 
spectroscopy (ICP/AES).  These basic methods of analysis are well defined and generally accepted for the 
analysis of cadmium.  
 
Samples are prepared for AAS and ICP/AES methods in a variety of ways.  Digestion with nitric acid is 
most common (Roberts and Clark 1986; Sharma et al. 1982).  Cadmium in blood and plasma measured by 
graphite furnace atomic absorption spectroscopy (GFAAS) facilitated by a wet ashing pretreatment of 
samples resulted in good accuracy and reproducibility.  The sample detection limit using this method was 
0.4 μg/L (Roberts and Clark 1986).  This method was also precise and highly reproducible in determining 
cadmium in whole blood, urine, and hair with 99–99.4% recoveries reported (Sharma et al. 1982).  The 
matrix may also be modified with diammonium hydrogen phosphate or other agents such as palladium 
(Pd)-based modifiers (Moreira et al. 1995).  Detection limits as low as 0.1 μg/L with recoveries ranging 
from 93 to 111% are reported using this technique (Subramanian and Meranger 1981; Subramanian et al. 
1983).  If the concentration of cadmium in the dissolved sample is below the detection limit, 
preconcentration techniques, such as chelation and extraction, may be employed (Gross et al. 1976; 
Sharma et al. 1982).  Various ICP methods have been developed for measuring cadmium levels in 
biological materials.  ICP dynamic reaction cell mass spectrometry (ICP-DRC-MS) has been shown to 
eliminate molybdenum-based polyatomic interferences, resulting in a reduction of observed urine 
cadmium concentrations, as compared to ICP-MS measurements (Jarrett et al. 2008).  Since cadmium is a 
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ubiquitous element, the risk of contamination during sampling, processing, and analysis must be 
minimized by strict laboratory procedures (Elinder and Lind 1985).  In procedures for micro-
determination, all glass and plastic-ware should be acid-washed and subsequently rinsed with double-
distilled water.   
 
 
 
 
Current analytical improvements deal primarily with the methods of sample preparation and sample 
introduction to the analytical systems in order to lower the detection limits or decrease sample analysis 
time.  Various improvements in the methods of extraction, preconcentration, chelation, complexation, and 
sample introduction have been developed for use with biological media.  Detection limits as low as 
0.003 μg/L were reported (Espinosa Almendro et al. 1992; Cordero et al. 1994; Jeng et al. 1994; Katskov 
et al. 1994; Komárek et al. 1991; Ma et al. 1994b; Welz et al. 1991). 
The cadmium concentration in biological samples may also be measured by a number of other methods 
such as radiochemical neutron activation analysis (RNAA).  One RNAA procedure involving a rapid 
two-step solvent extraction was used for determining cadmium in tissue samples (Tandon et al. 1994).  
Another method to determine cadmium in biological materials is based on the ion-exchange scheme 
developed by SAMSAHL where cadmium is trapped on an anion exchange resin.  With this method, 
recovery of 98% and a detection limit of 4 μg/kg were reported.  The accuracy of the method was 
estimated by three different approaches:  analysis using radiotracers in inactive sample solutions; by 
analyzing standards, pipetted on filter paper, and processed as samples; and determination by RNAA 
(Woittiez and Tangonan 1992). 
Cadmium concentration in tissue may be measured both in vivo (Ellis 1985; Scott and Chettle 1986) and 
in vitro (Lieberman and Kramer 1970) by neutron activation analysis (NAA).  Direct in vivo assessment 
of body burden in humans focused on the measurements of cadmium in the kidney and liver by NAA.  
The detection limits reported are approximately 2 mg cadmium for the total kidney and 1.5 μg/g for the 
liver (Ellis 1985); 1.9 mg cadmium for the kidney; and 1.3 μg/g for the liver (Scott and Chettle 1986).   
X-ray fluorescence is also used for in vivo measurement of cadmium in the kidney (Christoffersson et al. 
1987; Nilsson and Skerfving 1993; Scott and Chettle 1986; Skerfving and Nilsson 1992).  The in vivo 
techniques are used for clinical measurements of individuals occupationally exposed to cadmium.  
Additional methods applicable to the analysis of cadmium in biological media include ICP/MS (Stroh 
1993; Vanhoe et al. 1994), ICP/AES (Cordero et al. 1994; Espinosa Almendro et al. 1992), and high 
performance liquid chromatography (HPLC) (Chang and Robinson 1993; Steenkamp and Coetzee 1994).  
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Electrothemal vaporization ICP/MS has been utilized for the analysis of dentin and enamel from teeth 
(Grünke et al. 1996).  Electrochemical methods such as adsorptive cathodic stripping voltametry (ACSV) 
and potentiometric stripping analysis (PSA) have been applied to hair analysis (Zhang et al. 1993), animal 
tissues (LaBar and Lamberts 1994), and body fluids (Ostapczuk 1993).  
 
 
 
 
Table 7-1 summarizes some of the methods used for sample preparation and analysis of cadmium in 
biological samples. 
7.2   ENVIRONMENTAL SAMPLES  
 
Analysis for cadmium in environmental samples is usually accomplished by AAS or AES techniques, 
with samples prepared by digestion with acid, preconcentrated with a chelating resin, or direct aspiration 
with no preparation (APHA 1977a, 1977b; EPA 1983a, 1983b, 1997b; OSHA 2002a, 2004; USGS 1985).  
Since cadmium in air is usually associated with particulate matter, standard methods involve collection of 
air samples on glass fiber or membrane filters, acid extraction of the filters, and subsequent analysis 
(APHA 1977a, 1977b; OSHA 2002a, 2002b).  Inductively-coupled plasma spectrometry (ICP) analysis in 
standard methods is also popular.  ICP analysis for water and air samples can be run in tandem with mass 
spectrometry (MS) or AES (EPA 1996b, 1997b, 2003; NIOSH 2003; OSHA 2002b).  ACSV (Nimmo and 
Fones 1994), differential pulse anodic stripping voltametry (DP-ASV) (Nam et al. 1994), and epithermal 
NAA (Landsberger and Wu 1993) have also been used for air analysis.  The accuracy of the analysis of 
cadmium in acid digested atmospheric samples, measured by ACSV, was evaluated and compared with 
GFAAS and ICP/MS.   
Several methods standardized by EPA (1983a, 1983b, 1994b, 1996a, 1996b, 1997b, 2000, 2003) are used 
for measuring concentrations of cadmium in water.  Techniques to compensate for chemical and matrix 
interferences in all three methods are described by EPA (1983a, 1983b, 1994b, 1996a, 1996b, 1997b, 
2000, 2003).  After soils and solid wastes are extracted or solubilized by acid digestion, they may be 
analyzed for cadmium by the same AAS methods that are used for water (EPA 1986d, 1986e).  Water can 
also be analyzed for cadmium by NAA methods (Saleh et al. 1993), PSA methods (Ostapczuk 1993), and 
anodic stripping voltametry (ASV) (Daih and Huang 1992). 
Sediment and soil samples have been analyzed for cadmium using the methods of GFAAS (Klemm and 
Bombach 1995).  Preparation of the samples is generally accomplished by treatment with HCl and HNO3.   
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Table 7-1.  Analytical Methods for Determining Cadmium in Biological Materials 
 
Sample matrix Preparation method 
Analytical 
method 
Sample 
detection 
limit 
Percent 
recovery Reference 
Blood Digestion with nitric acid; 
chelation with APDC and 
extraction with MIBK 
AAS <1 ng/mLa 99 Sharma et al. 
1982 
Blood Modification of matrix with 
diammonium hydrogen 
phosphate/Triton X-100 
GFAAS 0.1 μg/L 100.8±4.3 Subramanian 
and Meranger 
1981  
Blood/plasma Digestion with nitric acid; wet 
ashed 
GFAAS 0.4 μg/L No data Roberts and 
Clark 1986 
Serum Dilution with ammonia/Triton 
X-100 
ICP/MS 0.01 ng/mL No data Stroh 1993 
Tissue and blood Microwave digestion FAAS/flow 
injection 
system 
0.15 μg/L No data Welz et al. 
1991 
Human milk Dilution with deionized and 
double distilled water  
AAS <0.01 ppba No data Schulte-
Lobbert and 
Bohn 1977 
Hair Digestion with nitric acid AAS 0.07 μg/ga 99 Sharma et al. 
1982 
Kidney None (in vivo) XRF 170.1 μg/g No data Christoffersson 
et al. 1987 
Kidney/liver Chelation and extraction with 
solvent 
AAS/direct 
aspiration 
0.01 ppma 
(liver) 
1.9 mg 
(kidney) 
No data Gross et al. 
1976 
Kidney/liver None (in vivo) NAA 1.3 μg/g 
(liver) 
1.9 mg 
(kidney) 
No data Scott and 
Chettle 1986 
 
Muscle Wet ashed with concentrated 
sulfuric acid 
NAA 50 ppb 50–65 Lieberman and 
Kramer 1970 
Urine Dilution with nitric acid ETAAS 0.045 μg/L 97–101 Komárek et al. 
1991 
Urine Modification of matrix with 
diammonium hydrogen 
phosphate/nitric acid 
GFAAS 0.09 ng/mL 92.7–111.1 Subramanian 
et al. 1983 
Urine Digestion with nitric acid AAS 5.67 ng/mLa 99.4 Sharma et al. 
1982 
Biological 
materials 
Microwave digestion followed 
by extraction with APTH in 
MlBK 
ICP/AES 0.15 ng/mL No data Cordero et al. 
1994 
Biological 
materials 
Extraction with 1,5-bis(di-
2-pyridylmethylene) 
thiocarbonohydrazide in MlBK 
ICP/AES 0.1 ng/mL No data Espinosa 
Almendro et al. 
1992 
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Table 7-1.  Analytical Methods for Determining Cadmium in Biological Materials 
 
Sample matrix Preparation method 
Analytical 
method 
Sample 
detection 
limit 
Percent 
recovery Reference 
Biological 
materials 
Digestion with acid GFAAS/flow 
injection 
system 
0.003 μg/L No data Ma et al. 1994a 
Biological fluids 
(blood, urine) 
Acidification PSA 0.001 μg/kg No data Ostapczuk 
1993 
Biological 
materials 
Dry tissues; irradiation 
followed by acid digestion 
RNAA 4 μg/kg 98 Woittiez et al. 
1992 
Teeth, dentin, 
and enalmel 
Digested in nitric acid, diluted 
with water 
ETV-ICP-MS 
PN-ICP-MS 
No data No data Grünke et al. 
1996 
Whole blood, 
urine 
Modified with palladium 
based modifier 
ETAAS 0.22 μg/L No data Moreira et al. 
1995 
Biological 
materials 
Digested with nitric acid and 
hydrogen peroxide 
B-9001-95; 
ICP-AES 
No data 93 USGS 1996 
 
aLowest concentration found 
 
AAS = atomic absorption spectroscopy; APDC = ammonium pyrrolidenedithiocarbamate; APTH = 1,3-bis-
[1-(2-pyridyl)ethylidene] thiocarbon-hydride; ETAAS = electrothermal atomic absorption spectroscopy; FAAS = flame 
atomic absorption; GFAAS = graphite furnace atomic absorption; ICP/AES = inductively coupled plasma atomic 
emission spectroscopy; ICPIMS = inductively coupled plasma mass spectrometry; MlBK = methyl isobutyl ketone; 
NAA = neutron activation analysis; PSA = potentiometric stripping analysis; RNAA = radio chemical neutron 
activation analysis; XRF = x-ray fluorescence 
 
CADMIUM  338 
 
7.  ANALYTICAL METHODS 
 
 
 
 
 
 
 
The most common method for analysis of cadmium in foods is AAS (Bruhn and Franke 1976; Dabeka 
1979; Muys 1984), with GFAAS being one of the most common AAS methods used (Cabrera et al. 
1995).  The FDA’s Total Diet Study 1991–1996 analyzed cadmium and other element concentrations in 
food by dry ash mineralization and GFAAS (Capar and Cunningham 2000).  RNAA (Greenberg et al. 
1979), differential pulse ASV (Satzger et al. 1982, 1984), and the calorimetric dithizone method (AOAC 
1984) may also be employed.  The AAS techniques appear to be most sensitive, with recoveries ranging 
from 94 to 109% (Bruhn and Franke 1976; Muys 1984).  A method used to isolate cadmium by first 
extracting with bismuth diethyldithiocarbamate (Bi[DDC]3) and then with zinc diethyldithiocarbamate 
(Zn[DDC]2) in chloroform and then measuring by RNAA showed 94–106% recovery (Greenberg et al. 
1979). 
 
 
 
 
 
Table 7-2 summarizes some of the methods used for sample preparation and analysis of cadmium in 
environmental samples. 
7.3   ADEQUACY OF THE DATABASE  
 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of cadmium is available.  Where adequate information is not 
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research 
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of cadmium.  
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
7.3.1   Identification of Data Needs  
 
Methods for Determining Biomarkers of Exposure and Effect.     
Exposure.  Measurements of cadmium in liver and kidney are all useful biological indices for human 
exposure to cadmium (Roels et al. 1981b).  Human milk, human placentas, and maternal and neonatal  
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Table 7-2.  Analytical Methods for Determining Cadmium in Environmental 
Samples 
 
Sample Analytical Sample Percent 
matrix Preparation method method detection limit recovery Reference 
Air Collection on glass fiber Method 30.005 μg/m  90 APHA 1977b 
filter; ashed with 311; AAS 
hydrochloric and nitric 
acids 
Air Collection on membrane Method 0.05 μg per No data NlOSH 1994 
filter; ashed with 7048; AAS sample 
hydrochloric and nitric 
acids 
Air Collection on membrane Method 0.3 ng/mL 99.8– NIOSH 2003 
filter; digestion with nitric 7300; ICP 105.2 
acid and perchloric acid 
Air Collection using filters, Method 0.004 μg/mL 99.5 OSHA 2002a 
wipes, or bulk materials; 121; 
desorbed with water AAS/AES 
extractions and mineral 
acid digestions 
Air Collection on membrane 
filter; digested in nitric 
Method 
125G; 
a 0.14 μg
b0.47 μg  
No data OSHA 2002b 
acid, sulfuric acid, and ICP-AES 
hydrogen peroxide 
Air Collection on membrane 
filter; digested with nitric 
acid and small amounts of 
hydrochloric acid 
Method 
189; AAS/ 
AAS-HGA 
 0.2 μg/m3 (AAS)a 
3  0.70 μg/m (AAS)b
3 0.007μg/m (AAS-
HGA)a 
3 0.025 μg/m
(AAS-HGA)b 
No data OSHA 2004 
Air Collection on membrane 
filter, wipe, or bulk 
Method 
206; ICP-
 0.0062 μg/mLa
0.0205 μg/mLb 
No data OSHA 1991 
material; digest with nitric AES 
and hydrochloric acids 
Air Irradiation UF filters Epithermal 8 ng No data Landsberger et al. 
NAA 1993 
Air Acid digestion with filters ACSV 0.6 ng/mL 100 Nimmo and Fones 
(aerosols) 1994 
Atmospheric Direct analysis ETV-ICP- 3pg/m  range No data Lüdke et al. 1997 
particles MS 
Water Digestion with nitric acid Method 5 μg/L 94±24 EPA 1983a 
213.1; 
AAS/direct 
aspiration 
Water Digestion with nitric acid Method 0.1 μg/L 96–99 EPA 1983b 
213.2; 
AAS/ 
GFAAS 
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Table 7-2.  Analytical Methods for Determining Cadmium in Environmental 
Samples 
 
Sample Analytical Sample Percent 
matrix Preparation method method detection limit recovery Reference 
Water On-line preconcentration GFAAS/ 0.8 ng/L No data Welz et al. 1992 
with ion exchange or flow 
sorbent extraction injection 
columns system 
Water Digestion with nitric acid Method 0.0075 μg/L No data EPA 1996a 
1637; 
chelation 
and 
GFAAS 
Water Digestion with nitric acid Method 0.025 μg/L No data EPA 1996b 
1638; ICP-
MS 
Water Preconcentrated with Method 0.0024 μg/L No data EPA 1997b 
chelating resin 1640; 
Online 
Chelation/ 
ICP-MS 
Water  Digested with hydrochloric Method 0.1 μg/L 98±1.1 EPA 2003 
and nitric acids 200.5; 
AVICP-
AES 
Water and Digestion with acids Method 1 μg/L (aqueous); 82–98 EPA 1994a 
Wastes 200.7; 0.2 mg/kg (solids) 
ICP-AES 
Various Digestion with nitric and Method No data 97 EPA 2000 
hydrochloric acids 6010C;  
ICP-AES 
Water and No preconcentration or I-1135; 10 μg/L No data USGS 1985 
sediments pretreatment AAS 
Water Digested with whole water I-4471-97; 5 μg/L No data USGS 1998a 
ICP-OES 
Various Direct aspiration with no I-5135; 10 μg/L No data USGS 1985 
preconcentration or AAS 
pretreatment 
Soil Digestion with nitric acid Method 0.005 mg/L No data EPA 1986e 
7130; 
AAS/direct 
aspiration 
Soil Digestion with nitric acid Method 0.1 μg/L No data EPA 1986d 
7131; 
GFAAS 
Soil and Ultrasonic slurry in dilute GFAAS No data 100±10 Klemm and Bombach 
sediment nitric acid 1995 
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Table 7-2.  Analytical Methods for Determining Cadmium in Environmental 
Samples 
 
Sample 
matrix Preparation method 
Analytical 
method 
Sample 
detection limit 
Percent 
recovery Reference 
Sediment Digestion with 
hydrochloric and nitric 
acid 
LEAFS 500 fg No data Zhou et al. 1998 
Soil and 
sediment 
Digestion with hydrofluoric 
acid and nitric acid; 
complexation with DDPA 
using on-line sorbent 
extraction system 
GFAAS/ 
flow 
injection 
system 
0.8 μg/L No data Ma et al. 1994b 
Food Dry ashed; oxidization 
with nitric acid 
ASV/ 
differential 
pulse 
1 ng/g 99–108 Satzger et al. 1984 
Food Dry ashed; complexation 
with APCD; extraction 
with isoamyl acetate 
AAS 0.1 ng/g 97.5±2.5 Bruhn and Franke 
1976 
Food Extraction with Bi(DDC)3 
then with Zn(DDC)2 in 
chloroform 
RNAA 0.029 μg/gc 94–106 Greenberg et al. 1979 
Food 
(24 hour 
diet) 
Microwave digestion with 
nitric acid and hydrogen 
peroxide 
GFAAS 0.004 μg/g 94–101 Yang et al. 1995 
Food Dry ashed; complexation 
with NaDDTC; extraction 
with IBMK 
GFAAS 0.1 ppbc 94–109 Muys 1984 
Food Homogenization followed 
by wet ashing 
GFAAS 0.01 ppb 94–108 Zhang et al. 1997 
Fruit Homogenized fruit slurried 
with zirconia 
ETAAS 0.3 ng/g 97.7±0.3 Cabrera et al. 1995 
 
aQualitative detection limit 
bQuantitative detection limit 
cLowest concentration found 
 
AAS = atomic absorption spectroscopy; ACSV = adsorptive cathodic stripping voltametry; APCD = ammonium 
pyrrolidino carbodithioate; ASV = anodic stripping voltametry; AVICP-AES = axially viewed inductively coupled 
plasma-atomic emission spectrometry; Bi(DDC)3 = bismuth diethyldithiocarbamate; DDPA = ammonium 
diethyldithiophosphate; ETV-ICP-MS = electrothermal vaporization inductively coupled plasma mass spectrometry; 
GFAAS = graphite furnace atomic absorption; HGA = heated graphite atomizer; IBMK = isobutyl methyl ketone; 
ICP = inductively coupled plasma; LEAFS = laser-excited atomic fluorescence spectrometry; MS = mass 
spectrometry; NAA = neutron activation analysis; NaDDTC = sodiumdiethyl-dithiocarbomate; OES = optical emission 
spectroscopy; RNAA = radiochemical neutron activation analysis; Zn(DDC)2 = zinc diethyldithiocarbamate 
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blood have been investigated as means to determine exposures of women and infants to cadmium 
(Baranowska 1995; Abadin et al. 1997).  Sensitive and selective methods are available for the detection 
and quantitation of cadmium in these biological materials (Elinder and Lind 1985; Sharma et al. 1982).  
Improved methods for sample preparation and in vivo analysis of liver and kidney content are needed to 
assist in monitoring environmentally exposed populations. 
 
 
 
 
Effect.  Sensitive methods are also available for measuring biological markers of cadmium effect, 
particularly urine or serum concentration of β2-microglobulin, retinol-binding protein, metallothionein, 
and creatinine (Kawada et al. 1990; Roels et al. 1989; Topping et al. 1986).   
Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media.    Cadmium is ubiquitous in the environment and does not degrade.  It is found in air, water, soil, 
sediments, and food.  Analytical methods exist for the analysis of cadmium in all of these environmental 
media, and these methods have the sensitivity to measure background levels and detect elevated 
concentrations due to anthropogenic sources such as hazardous waste sites (EPA 1983a, 1983b, 1994b, 
1996a, 1996b, 1997b, 2000, 2003).  Additional research to reduce chemical and matrix interferences are 
needed to improve the speed and accuracy of the analyses. 
7.3.2   Ongoing Studies  
 
The National Report on Human Health Exposure to Environmental Chemicals is an ongoing 
biomonitoring assessment conducted by CDC.  This survey measures over 200 chemicals in blood and 
urine from random samples collected from participants in the National Health and Nutrition Examination 
Survey (NHANES).   The National Exposure Report was last published in 2009 and an update of 
biomonitoring levels for some of the chemicals, including cadmium, was published in 2012 (CDC 2012). 
The information in Table 7-3 was found as a result of a search of the Federal Research in Progress 
database (FEDRIP 2008). 
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Table 7-3.  Ongoing Analytical Methods Studies on Cadmium 
 
Investigator Affiliation Research description Sponsor 
Parker D University of 
California 
Isotopic dilution methods for probing the 
bioavailability of trace elements in soils and 
sediments  
U.S. Department of 
Agriculture 
Pierzynski G Kansas State 
University 
Chemistry, bioavailability, and toxicity of 
constituents in residuals and residual treated 
soils  
U.S. Department of 
Agriculture 
Schwab AP; Joern B; 
Johnston C 
Purdue 
University 
Chemistry and bioavailability of waste 
constituents in soils  
U.S. Department of 
Agriculture 
Santra S University of 
Central Florida 
Selective detection of toxic heavy metal ions 
using highly sensitive quantum dot probes 
National Science 
Foundation 
Swain G Michigan 
State 
University 
Diamond microelectrode arrays:  New 
materials for the electrochemical detection of 
aqueous analytes 
U.S. Department of 
Agriculture 
 
Source:  FEDRIP 2008 
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MRLs are substance-specific estimates, which are intended to serve as screening levels, are used by 
ATSDR health assessors and other responders to identify contaminants and potential health effects that 
may be of concern at hazardous waste sites.  
ATSDR has derived an acute-duration inhalation MRL of 0.03 μg Cd/m3 for cadmium.  This MRL is 
based on a LOAEL of 0.088 mg Cd/m3 (LOAELHEC of 0.01 mg Cd/m
3) for respiratory effects in rats 
exposed to cadmium oxide 6.2 hours/day, 5 days/week for 2 weeks (NTP 1995) and an uncertainty factor 
of 300 (10 for the use of a LOAEL, 3 for extrapolation from animals to humans with dosimetric 
adjustments, and 10 for human variability). 
ATSDR has derived a chronic-duration inhalation MRL of 0.01 μg Cd/m3 for cadmium.  This MRL is 
based on the 95% lower confidence limit of the urinary cadmium level associated with a 10% extra risk of 
low molecular weight proteinuria (UCDL10) estimated from a meta-analysis of environmental exposure 
data.  An air concentration that would result in this urinary cadmium level (0.5 μg/g creatinine), assuming 
a dietary cadmium intake of 0.3 μg/kg/day, was estimated using biokinetic models.  The estimated air 
concentration of 0.1 μg Cd/m3 was divided by an uncertainty factor of 3 for human variability and a 
modifying factor of 3.    
The EPA has not established a reference concentration (RfC) for cadmium. 
ATSDR has derived an intermediate-duration oral MRL of 0.5 μg Cd/kg/day for cadmium.  This MRL is 
based on a BMDLstd1 of 0.05 mg Cd/kg/day for skeletal effects in young female rats exposed to cadmium 
chloride in drinking water for 6, 9, or 12 months (Brzóska and Moniuszko-Jakoniuk 2005d) and an 
uncertainty factor of 100 (10 for extrapolation from animals to humans and 10 for human variability). 
ATSDR has derived a chronic-duration oral MRL of 0.1 μg Cd/kg/day for cadmium.  This MRL is based 
on the UCDL10 for low molecular weight proteinuria estimated from a meta-analysis of environmental 
exposure data.  A cadmium intake that would result in the UCDL10 (0.5 μg/g creatinine) at age 55 was 
estimated using pharmacokinetic models.  The cadmium intake of 0.33 μg/kg/day was divided by an 
uncertainty factor of 3 for human variability.   
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The EPA has established a reference dose (RfD) of 5x10-4 mg/kg/day in water and 1x10-3 mg/kg/day in 
food (IRIS 2012).  The RfD is based on a chronic intake that would result in a kidney concentration of 
200 μg/g ww.   
 
 
 
 
The international and national regulations, advisories, and guidelines regarding cadmium in air, water, 
and other media are summarized in Table 8-1.   
Cadmium compounds are included on the list of 189 chemicals listed as hazardous air pollutants under 
Section 112 of the Clean Air Act as amended (EPA 2007).  Cadmium also is on the list of chemicals 
appearing in the Emergency Planning and Community Right-To-Know Act of 1986 (EPA 2008g).  Under 
Title III of this statute, owners and operators of facilities that manufacture, import, process, or otherwise 
use the chemicals on this list of report annually their release of those chemicals to any environmental 
media. 
Cadmium and cadmium chloride are designed as hazardous substances under Section 311 of the Clean 
Water Act; any discharge of these chemicals over a specified threshold level into navigable waters is 
subject to reporting requirements (EPA 2008c). 
Cadmium is a hazardous waste under the Resource Conservation and Recovery Act (RCRA) under 
several circumstances.  Groundwater monitoring is required at municipal solid waste landfills (EPA 
2008d) and cadmium is considered a priority persistent, bioaccumulative, and toxic (PBT) chemical under 
RCRA waste minimization chemical listing (EPA 1998). 
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Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Cadmium 
 
Agency Description Information Reference 
INTERNATIONAL    
Guidelines:    
 IARC Carcinogenicity classification  IARC 2008 
  Cadmium and cadmium Group 1a 
compounds 
 WHO Air quality guidelines  WHO 2000 
 b,c Cadmium  35 ng/m  
 Drinking water quality guidelines  WHO 2004 
  Cadmium 0.003 mg/L 
NATIONAL    
Regulations and    
Guidelines: 
a.  Air    
 ACGIH Biological exposure indices  ACGIH 2007 
  Cadmium and inorganic  
compounds 
   Cadmium in urine 5 μg/g creatinine 
   Cadmium in blood 5 μg/L 
 TLV (8-hour TWA)  
  Cadmium 30.01 mg/m  
 Hazardous air pollutant  EPA 2007 
  Cadmium compounds Yes 42 USC 7412 
 NIOSH REL (10-hour TWA)  NIOSH 2005 
 f Cadmium  Potential occupational 
carcinogens 
  Cadmium oxide Potential occupational 
carcinogens 
 IDLH  
  Cadmium (as Cd) 9 mg/m3 
  Cadmium oxide (as Cd) 39 mg/m  
  Category of pesticides  NIOSH 1992b 
  Cadmium carbonate Group II pesticideg 
  Cadmium chloride Group I pesticideh 
  Cadmium sulfate Group II pesticideg 
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Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Cadmium 
 
Agency Description Information Reference 
NATIONAL (cont.)    
 OSHA PEL (8-hour TWA) for general industry  OSHA 2007a 
29 CFR 
1910.1027 
  Cadmium (as Cd) 5 μg/m3 
 PEL (8-hour TWA) for shipyard 
industry 
 OSHA 2007b 
29 CFR 
1915.1027   Cadmium (as Cd) 5 μg/m3 
 PEL (8-hour TWA) for construction 
industry 
 OSHA 2007c 
29 CFR 
1926.1127   Cadmium (as Cd) 5 μg/m3 
b.  Water    
 EPA Designated as hazardous substances 
in accordance with 
Section 311(b)(2)(A) of the Clean 
Water Act 
 EPA 2008b 
40 CFR 116.4 
  Cadmium chloride Yes 
 Drinking water standards and health 
advisories 
 EPA 2011b 
  Cadmium  
   1-day health advisory for a 
10-kg child 
0.04 mg/L 
   10-day health advisory for a 
10-kg child 
0.04 mg/L 
   DWEL 0.02 mg/L 
   Lifetime 0.005 mg/L 
 National primary drinking water 
standards 
 EPA 2009b 
  Cadmium  
   MCL 0.005 mg/L 
   Public health goal 0.005 mg/L 
 Reportable quantities of hazardous 
substances designated pursuant to 
Section 311 of the Clean Water Act 
 EPA 2008c 
40 CFR 117.3 
  Cadmium chloride 10 pounds 
  Toxic pollutants designated pursuant 
to Section 307(a)(1) of the Clean 
Water Act 
 EPA 2008h 
40 CFR 401.15 
  Cadmium and compounds Yes 
c.  Food    
 FDA Bottled drinking water  FDA 2007 
21 CFR 165.110   Cadmium 0.005 mg/L 
 EAFUS No data FDA 2008 
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Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Cadmium 
 
Agency Description Information Reference 
NATIONAL (cont.)    
d.  Other    
 ACGIH Carcinogenicity classification  ACGIH 2007 
  Cadmium A2j  
  Cadmium compounds (as Cd) A2j 
 EPA Carcinogenicity classification  IRIS 2012 
  Cadmium Group B1k 
 Inhalation unit risk  
  Cadmium 1.8x10-3 per μg/m3 
 RfC  
  Cadmium No data 
 RfD  
  Cadmium  
   Food 1x10-3 mg/kg-day 
   Water 5x10-4 mg/kg-day 
 RCRA waste minimization PBT priority 
chemical list 
 EPA 1998 
63 FR 60332 
  Cadmium Yes 
 Standards for owners and operators of 
hazardous waste TSD facilities; 
groundwater monitoring list 
 EPA 2008d 
40 CFR 264, 
Appendix IX 
  Cadmium Yes 
 Superfund, emergency planning, and 
community right-to-know 
  
  Designated CERCLA hazardous 
substance 
 EPA 2008e 
40 CFR 302.4 
   Cadmium Yesl,m 
   Cadmium and compounds Yesn 
   Cadmium chloride Yeso 
  Reportable quantity   
   Cadmium 10 pounds 
   Cadmium and compounds Nonep 
   Cadmium chloride 10 pounds  
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Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Cadmium 
 
Agency Description Information Reference 
NATIONAL (cont.)    
 EPA Superfund, emergency planning, and 
community right-to-know 
  
  Effective date of toxic chemical 
release reporting 
 EPA 2008g 
40 CFR 372.65 
   Cadmium 01/01/1987 
   Cadmium compoundsq 01/01/1987 
  Extremely Hazardous Substances  EPA 2008f 
40 CFR 355, 
Appendix A 
   Cadmium oxide  
    Reportable quantity 100 pounds 
    Threshold planning quantity 100/10,000 pounds 
 NTP Carcinogenicity classification  NTP 2011 
  Cadmium and cadmium 
compounds 
Known to be human 
carcinogens 
 
aGroup 1:  The agent is carcinogenic to humans. 
bThe guideline value is based on the prevention of a further increase of cadmium in agricultural soils, which is 
likely to increase the dietary intake. 
cTWA based on effects other than cancer or odor/annoyance using an averaging time of 1 year. 
dRespriable fraction. 
eHigher current priority chemical for guideline development. 
fREL applies to all cadmium compounds (as Cd). 
gGroup II pesticide:  Contains the pesticides that pose as significant risk of carcinogenic, teratogenic, neurotoxic, or reproductive 
effects 
hGroup I pesticide:  Contains the pesticides that pose as significant risk of adverse acute health effects at low concentrations 
iThe CMC is an estimate of the highest concentration of a material in surface water to which an aquatic community can be 
exposed briefly without resulting in an unacceptable effect.  The CCC is an estimate of the highest concentration of a material in 
surface water to which an aquatic community can be exposed indefinitely without resulting in an unacceptable effect. 
jA2:  Suspected human carcinogen. 
kGroup B1:  Probable human carcinogen based on limited evidence of carcinogenicity in humans. 
lDesignated CERCLA hazardous substance pursuant to Section 307(a) of the Clean Water Act. 
mNo reporting of releases of this hazardous substance is required if the diameter of the pieces of the solid metal released is 
larger than 100 micrometers (0.004 inches). 
nDesignated CERCLA hazardous substance pursuant to Section 307(a) of the Clean Water Act and Section 112 of the Clean Air 
Act. 
oDesignated CERCLA hazardous substance pursuant to Section 311(b)(2) of the Clean Water Act. 
pIndicates that no reportable quantity is being assigned to the generic or broad class. 
qCadmium compounds:  Includes any unique chemical substance that contains cadmium as part of that chemical's 
infrastructure. 
 
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = acute exposure guideline levels; 
CCC = Criterion Continuous Concentration; CERCLA = Comprehensive Environmental Response, Compensation, and Liability 
Act; CFR = Code of Federal Regulations; CMC = Criteria Maximum Concentration; DWEL = drinking water equivalent level; 
EAFUS = Everything Added to Food in the United States; EPA = Environmental Protection Agency; FDA = Food and Drug 
Administration; IARC = International Agency for Research on Cancer; IDLH = immediately dangerous to life or health; 
IRIS = Integrated Risk Information System; MCL = maximum contaminant level; NIOSH = National Institute for Occupational 
Safety and Health; NTP = National Toxicology Program; OSHA = Occupational Safety and Health Administration; 
PBT = persistant, bioaccumulative, and toxic; PEL = permissible exposure limit; RCRA = Resource Conservation and Recovery 
Act; REL = recommended exposure limit; RfC = inhalation reference concentration; RfD = oral reference dose; TLV = threshold 
limit values; TSD = treatment, storage, and disposal; TWA = time-weighted average; USC = United States Code; WHO = World 
Health Organization 
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Absorption—The taking up of liquids by solids, or of gases by solids or liquids. 
 
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the 
Toxicological Profiles. 
 
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact. 
 
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of 
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium. 
 
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase) 
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a 
fixed solid/solution ratio.  It is generally expressed in micrograms of chemical sorbed per gram of soil or 
sediment. 
 
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a 
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the 
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be 
10%.  The BMD is determined by modeling the dose response curve in the region of the dose response 
relationship where biologically observable data are feasible.    
 
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological 
or epidemiological data to calculate a BMD. 
 
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period. 
 
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples.  They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility. 
 
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces 
significant increases in the incidence of cancer (or tumors) between the exposed population and its 
appropriate control. 
 
Carcinogen—A chemical capable of inducing cancer. 
 
Case-Control Study—A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without outcome. 
 
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest 
some potential topics for scientific research, but are not actual research studies. 
 
Case Series—Describes the experience of a small number of individuals with the same disease or 
exposure.  These may suggest potential topics for scientific research, but are not actual research studies. 
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Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously. 
 
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological 
Profiles. 
 
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a 
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are 
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group. 
 
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines 
the relationship between exposure and outcome to a chemical or to chemicals at one point in time. 
 
Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human 
health assessment. 
 
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result 
from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point 
in the life span of the organism. 
 
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a 
toxicant and the incidence of the adverse effects. 
 
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs.  The terms, as used here, include malformations and variations, altered growth, and in utero 
death. 
 
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water 
levels for a chemical substance based on health effects information.  A health advisory is not a legally 
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials. 
 
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of 
disease or other health-related conditions within a defined human population during a specified period.   
 
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of 
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome. 
 
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from 
the body or environmental media. 
 
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or 
irreversible health effects. 
 
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from 
exposure to environmental agents such as chemicals. 
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Immunological Effects—Functional changes in the immune response. 
 
Incidence—The ratio of individuals in a population who develop a specified condition to the total 
number of individuals in that population who could have developed that condition in a specified time 
period.  
 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles. 
 
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube. 
 
In Vivo—Occurring within the living organism. 
 
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been reported 
to have caused death in humans or animals. 
 
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for 
a specific length of time is expected to cause death in 50% of a defined experimental animal population. 
 
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that 
has been reported to have caused death in humans or animals. 
 
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population. 
 
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical 
is expected to cause death in 50% of a defined experimental animal population. 
 
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity 
of adverse effects between the exposed population and its appropriate control. 
 
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus. 
 
Malformations—Permanent structural changes that may adversely affect survival, development, or 
function. 
 
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure. 
 
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk 
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty 
factors.  The default value for a MF is 1. 
 
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population. 
 
Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time. 
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Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA.  Mutations can lead to birth defects, miscarriages, or cancer. 
 
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of 
death or pathological conditions. 
 
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
chemical. 
 
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not 
considered to be adverse. 
 
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical 
in n-octanol and water, in dilute solution. 
 
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence 
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not 
exposed to the risk factor).  An OR of greater than 1 is considered to indicate greater risk of disease in the 
exposed group compared to the unexposed group. 
 
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase. 
 
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) 
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek. 
 
Pesticide—General classification of chemicals specifically developed and produced for use in the control 
of agricultural and public health pests. 
 
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate 
(disposition) of an exogenous substance in an organism.  Utilizing computational techniques, it provides 
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body. 
 
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent 
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models:  data-based 
and physiologically-based.  A data-based model divides the animal system into a series of compartments, 
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the 
physiologically-based model compartments represent real anatomic regions of the body. 
 
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-
response model that quantitatively describes the relationship between target tissue dose and toxic end 
points.  These models advance the importance of physiologically based models in that they clearly 
describe the biological effect (response) produced by the system following exposure to an exogenous 
substance.  
 
Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments 
representing organs or tissue groups with realistic weights and blood flows.  These models require a 
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variety of physiological information:  tissue volumes, blood flow rates to tissues, cardiac output, alveolar 
ventilation rates, and possibly membrane permeabilities.  The models also utilize biochemical 
information, such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also 
called biologically based tissue dosimetry models. 
 
Prevalence—The number of cases of a disease or condition in a population at one point in time.  
 
Prospective Study—A type of cohort study in which the pertinent observations are made on events 
occurring after the start of the study.  A group is followed over time. 
 
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the 
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually μg/L for water, mg/kg/day for food, and 
μg/m3 for air). 
 
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour 
workweek. 
 
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of 
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) 
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.  
The inhalation reference concentration is for continuous inhalation exposures and is appropriately 
expressed in units of mg/m3 or ppm. 
 
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the 
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious 
effects during a lifetime.  The RfD is operationally derived from the no-observed-adverse-effect level 
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect 
various types of data used to estimate RfDs and an additional modifying factor, which is based on a 
professional judgment of the entire database on the chemical.  The RfDs are not applicable to 
nonthreshold effects such as cancer. 
 
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under 
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable 
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act.  Quantities are measured over a 
24-hour period. 
 
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result 
from exposure to a chemical.  The toxicity may be directed to the reproductive organs and/or the related 
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of 
this system. 
 
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is 
undertaken.  Retrospective studies are limited to causal factors that can be ascertained from existing 
records and/or examining survivors of the cohort. 
 
Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical. 
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Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or 
inherited characteristic that is associated with an increased occurrence of disease or other health-related 
event or condition. 
 
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among 
persons without risk factors.  A risk ratio greater than 1 indicates greater risk of disease in the exposed 
group compared to the unexposed group. 
 
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial 
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes 
continually.  No more than four excursions are allowed per day, and there must be at least 60 minutes 
between exposure periods.  The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may 
not be exceeded. 
 
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population. 
 
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical. 
 
Teratogen—A chemical that causes structural defects that affect the development of an organism. 
 
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.  
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit 
(STEL), or as a ceiling limit (CL). 
 
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour 
workday or 40-hour workweek. 
 
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population. 
 
Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism. 
 
Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or 
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data.  UFs are intended to 
account for (1) the variation in sensitivity among the members of the human population, (2) the 
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from 
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data.  
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used; 
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic 
average of 10 and 1. 
 
Xenobiotic—Any chemical that is foreign to the biological system. 
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The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99–
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with 
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most 
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances. 
The toxicological profiles include an examination, summary, and interpretation of available toxicological 
information and epidemiologic evaluations of a hazardous substance.  During the development of 
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure.  An MRL is an estimate of the daily human exposure to a hazardous substance 
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration 
of exposure.  MRLs are based on noncancer health effects only and are not based on a consideration of 
cancer effects.  These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites.  It is important to note that MRLs are not intended to define clean-up or 
action levels. 
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor 
approach.  They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects.  MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure.  MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans.  Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level 
above the MRL does not mean that adverse health effects will occur. 
MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that 
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are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention.  Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking.  In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive.  Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals. 
 
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the 
Division of Toxicology and Human Health Sciences (proposed), expert panel peer reviews, and agency-
wide MRL Workgroup reviews, with participation from other federal agencies and comments from the 
public.  They are subject to change as new information becomes available concomitant with updating the 
toxicological profiles.  Thus, MRLs in the most recent toxicological profiles supersede previously 
published levels.  For additional information regarding MRLs, please contact the Division of Toxicology 
and Human Health Sciences (proposed), Agency for Toxic Substances and Disease Registry, 1600 Clifton 
Road NE, Mailstop F-62, Atlanta, Georgia 30333. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical Name: Cadmium 
CAS Numbers: 7440-43-9 
Date: September, 2012 
Profile Status: Post-Public Comment Draft 2 
Route: [X] Inhalation   [ ] Oral 
Duration: [X] Acute   [ ] Intermediate   [ ] Chronic 
Graph Key: 16 
Species: Rat 
 
Minimal Risk Level:  0.03 [ ] mg/kg/day   [X] μg Cd/m3 
 
Reference:  NTP.  1995.  Cadmium oxide administered by inhalation to F344/N rats and B6C3F1 mice.  
National Toxicology Program, U.S. Department of Health and Human Services, Research Triangle Park, 
NC.   
 
 
Experimental design:  Groups of five male and five female F344 rats were exposed to 0, 0.1, 0.3, 1, 3, or 
10 mg cadmium oxide/m3 (0, 0.088, 0.26, 0.88, 2.6, or 8.8 mg Cd/m3) 6.2 hours/day, 5 days/week for 
2 weeks.  The mean MMAD of the cadmium oxide particles was 1.5 μm with a geometric standard 
deviation of 1.6–1.8.  The animals were observed twice daily and weighed on days 1 and 8, and at 
termination.  Other parameters used to assess toxicity included organ weights (heart, kidney, liver, lungs, 
spleen, testis, and thymus) and histopathological examination (gross lesions, heart, kidney, liver, lungs, 
tracheobronchial lymph nodes, and nasal cavity and turbinates).   
 
Effect noted in study and corresponding doses:  All rats in the 8.8 mg Cd/m3 group died by day 6; no 
other deaths occurred.  A slight decrease in terminal body weights was observed at 2.6 mg Cd/m3; 
however, the body weights were within 10% of control weights.  Significant increases in relative and 
absolute lung weights were observed at 0.26 (males only), 0.88, and 2.6 mg Cd/m3.  Histological 
alterations were limited to the respiratory tract and consisted of alveolar histiocytic infiltrate and focal 
inflammation in alveolar septa in all rats exposed to ≥0.088 mg Cd/m3, necrosis of the epithelium lining 
alveolar ducts in all rats exposed to ≥0.26 mg Cd/m3, tracheobronchiolar lymph node inflammation at 
≥0.88 mg Cd/m3 (incidences in the 0, 0.088, 0.26, 0.88, 2.6, and 8.8 mg Cd/m3 groups were 0/3, 0/5, 5/5, 
5/5, and 3/4 in males and 0/4, 1/5, 1/5, 3/5, 5/5, and 3/5 in females), degeneration of the nasal olfactory 
epithelium at 0.88 mg Cd/m3 (0/5, 0/5, 0/5, 2/5, 5/5, and 5/5 in males and 0/5, 0/5, 0/5, 4/5, 4/5, and 4/4 in 
females) and inflammation (0/5. 0/5. 0/5, 1/5, 5/5, and 3/5 in males and 0/5, 0/5, 0/5, 0/5, 4/5, and 3/4 in 
females) and metaplasia (0/5. 0/5. 0/5, 1/5, 0/5, and 5/5 in males and 0/5, 0/5, 0/5, 0/5, 4/5, and 4/4 in 
females)of the nasal respiratory epithelium at 2.6 mg Cd/m3. 
Dose and end point used for MRL derivation:  The LOAEL of 0.088 mg Cd/m3 was selected as the point 
of departure for derivation of the MRL; benchmark dose analysis was considered; however, the data were 
not suitable for benchmark dose analysis because the incidence data for alveolar histiocytic infiltration do 
not provide sufficient information about the shape of the dose-response relationship below the 100% 
response level.   
 
[ ] NOAEL   [X] LOAEL 
 
Uncertainty Factors used in MRL derivation: 
 
 [X]  10 for use of a LOAEL 
 [X]  3 for extrapolation from animals to humans with dosimetric adjustment 
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 [X]  10 for human variability 
  
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No. 
 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:   
 
The LOAELHEC was calculated using the equations below.   
 
 LOAELHEC = LOAELADJ x RDDR 
 
The duration-adjusted LOAEL (LOAELADJ) was calculated as follows: 
 
 LOAELADJ = 0.088 mg Cd/m
3 x 6.2 hours/24 hours x 5 days/7 days 
 LOAELADJ = 0.016 mg Cd/m
3 
 
The regional deposited dose ratio (RDDR) for the pulmonary region of 0.617 was calculated with EPA’s 
RDDR calculator (EPA 1994a) using the final body weight of 0.194 kg for the male rats exposed 
0.088 mg Cd/m3, the reported MMAD of 1.5 μm and the midpoint of the reported range of geometric 
standard deviations (1.7) 
 
 LOAELHEC = 0.016 mg Cd/m
3 x 0.617 
 LOAELHEC = 0.01 mg Cd/m
3 
 
Was a conversion used from intermittent to continuous exposure?  Yes (see above) 
 
Other additional studies or pertinent information that lend support to this MRL:  The acute toxicity of 
airborne cadmium, particularly cadmium oxide fumes, was first recognized in the early 1920s and there 
have been numerous case reports of cadmium workers dying after brief exposures to presumably high 
concentrations of cadmium fumes (European Chemicals Bureau 2007).  The initial symptoms, similar to 
those observed in metal fume fever, are usually mild but rapidly progress to severe pulmonary edema and 
chemical pneumonitis.  Persistent respiratory effects (often lasting years after the exposure) have been 
reported in workers surviving these initial effects.  There are limited monitoring data for these human 
reports; however, Elinder (1986b) estimated that an 8-hour exposure to 1–5 mg/m3 would be immediately 
dangerous. 
 
Animal studies support the findings in humans that acute exposure to cadmium results in lung damage.  
Single exposures to approximately 1–10 mg Cd/m3 as cadmium chloride or cadmium oxide resulted in 
interstitial pneumonitis, diffuse alveolitis with hemorrhage, focal interstitial thickening, and edema 
(Boudreau et al. 1989; Buckley and Bassett 1987b; Bus et al. 1978; Grose et al. 1987; Hart 1986; 
Henderson et al. 1979; Palmer et al. 1986).  Repeated exposure to 6.1 mg Cd/m3 1 hour/day for 5, 10, or 
15 days resulted in emphysema in rats (Snider et al. 1973).  At lower concentrations of 0.4–0.5 mg Cd/m3 
as cadmium oxide for 2–3 hours (Buckley and Bassett 1987b; Grose et al. 1987) or 0.17 mg Cd/m3 as 
cadmium chloride 6 hours/day for 10 days (Klimisch 1993) resulted in mild hypercellularity and increases 
in lung weight.  Alveolar histiocytic infiltration and focal inflammation and minimal fibrosis in alveolar 
septa were observed in rats exposed to 0.088 mg Cd/m3 as cadmium oxide 6.2 hours/day, 5 days/week for 
2 weeks (NTP 1995); in similarly exposed mice, histiocytic infiltration was observed at 0.088 mg Cd/m3 
(NTP 1995).  At similar concentrations (0.19 or 0.88 mg Cd/m3as cadmium chloride), decreases in 
humoral immune response were observed in mice exposed for 1–2 hours (Graham et al. 1978; 
Krzystyniak et al. 1987).  Other effects that have been reported in animals acutely exposed to cadmium 
include erosion of the stomach, decreased body weight gain, and tremors in rats exposed to 132 mg Cd/m3 
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as cadmium carbonate for 2 hours (Rusch et al. 1986) and weight loss and reduced activity in rats exposed 
to 112 mg Cd/m3 as cadmium oxide for 2 hours (Rusch et al. 1986). 
 
Agency Contact (Chemical Manager):  Obaid Faroon, DVM, Ph.D. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical Name: Cadmium 
CAS Numbers: 7440-43-9 
Date: September, 2012 
Profile Status: Post-Public Comment Draft 2 
Route: [X] Inhalation   [ ] Oral 
Duration: [ ] Acute   [ ] Intermediate   [X] Chronic 
Graph Key: 63 
Species: Human 
 
Minimal Risk Level:  0.01 [ ] mg/kg/day   [X] μg Cd/m3 
 
Reference:  Buchet JP, Lauwerys R, Roels H, et al.  1990.  Renal effects of cadmium body burden of the 
general population.  Lancet 336:699-702. 
 
Järup L, Hellstrom L, Alfven T, et al.  2000.  Low level exposure to cadmium and early kidney damage:  
The OSCAR study.  Occup Environ Med 57(10):668-672. 
 
Suwazono Y, Sand S, Vahter M, et al.  2006.  Benchmark dose for cadmium-induced renal effects in 
humans.  Environ Health Perspect 114:1072-1076. 
 
Experimental design:  As detailed in the chronic oral MRL worksheet, a meta-analysis of select 
environmental exposure dose-response studies examining the relationship between urinary cadmium and 
the prevalence of elevated levels of biomarkers of renal function in environmentally exposed populations 
was conducted; for the inhalation MRL, the meta-analysis also included dose-response data from 
three occupational exposure studies (Chen et al. 2006a, 2006b; Järup and Elinder 1994; Roels et al. 1993).  
The meta-analysis was used to establish a point of departure for the urinary cadmium-response 
relationship and pharmacokinetic models (ICRP 1994; Kjellström and Nordberg 1978) were used to 
predict cadmium air concentrations. 
 
Dose and end point used for MRL derivation:  Analysis of the available environmental exposure studies 
and occupational exposure studies resulted in an estimation of a urinary cadmium level that would result 
in a 10% increase in the prevalence of β2-microglobulin proteinuria (UCD10).  The lowest UCD10 
(1.34 μg/g creatinine) was estimated from the European environmental exposure studies (Buchet et al. 
1990; Järup et al. 2000; Suwazono et al. 2006); the UCD10 values from the occupational exposure studies 
were 7.50 μg/g creatinine for the European cohorts (Järup and Elinder 1994; Roels et al. 1993) and 
4.58 μg/g creatinine for the Chinese cohort (Chen et al. 2006a, 2006b).  The UCD10 from the 
environmental exposure studies was selected as the basis of the MRL.  The 95% lower confidence limit 
on this value (UCDL10) of 0.5 μg/g creatinine was used as the point of departure for the MRL. 
 
[ ] NOAEL   [ ] LOAEL   [X] UCDL10  
 
Deposition and clearance of inhaled cadmium oxide and cadmium sulfide particles were modeled using 
the ICRP Human Respiratory Tract Model (ICRP 1994).  The ICRP model simulates deposition, 
retention, and absorption of inhaled cadmium particles of specific aerodynamic diameters, when specific 
parameters for cadmium clearance are used in the model (ICRP 1980).  Cadmium-specific parameters 
represent categories of solubility and dissolution kinetics in the respiratory tract (e.g., slow, S; moderate, 
M; or fast, F).  Cadmium compounds are classified as follows: oxides and hydroxides, S; sulfides, halides 
and nitrates, M; all other, including chloride salts, F.   
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Inhalation exposures (μg/m3) to cadmium oxide or cadmium sulfide aerosols having particle diameters of 
1, 5, or 10 g (AMAD) were simulated using the ICRP model.  Predicted mass transfers of cadmium 
from the respiratory tract to the gastrointestinal tract (i.e., mucocilliary transport) and to blood (i.e., 
absorption) were used as inputs to the gastrointestinal and blood compartments of the Kjellström-
Nordberg pharmacokinetic model (1978) to simulate the kidney and urinary cadmium levels that 
correspond to a given inhalation exposure.   
 
An airborne cadmium concentration of 1.8–2.4 μg/m3 as cadmium oxide or 1.2–1.4 μg/m3 as cadmium 
sulfide would result in a urinary cadmium level of 0.5 μg/g creatinine, assuming that the air was the only 
source of cadmium.  This assumption is not accurate because the diet is a significant contributor to the 
cadmium body burden.  Thus, inhalation exposures were combined with ingestion intakes to estimate an 
internal dose in terms of urinary cadmium.  The age-weighted average intakes of cadmium in nonsmoking 
males and females in the United States are 0.35 and 0.30 μg Cd/kg/day, respectively (0.32 μg/kg/day for 
males and females combined) (Choudhury et al. 2001).   
 
Based on the relationship predicted between chronic inhalation exposures to cadmium sulfide 
(AMAD=1 μm) and oral intakes that yield the same urinary cadmium level, exposure to an airborne 
cadmium concentration of 0.1 μg/m3 and a dietary intake of 0.3 μg/kg/day would result in a urinary 
cadmium level of 0.5 μg/g creatinine.   
 
Uncertainty Factors and Modifying Factors used in MRL derivation: 
 
 [ ]  10 for use of a LOAEL 
 [ ]  10 for extrapolation from animals to humans with dosimetric adjustment 
 [X]  3 for human variability 
 
The uncertainty factor of 3 for human variability was used to account for the possible increased sensitivity 
of diabetics (Åkesson et al. 2005; Buchet et al. 1990).   
 
[X]  modifying factor of 3  
 
The modifying factor of 3 was used to account for the lack of adequate human data that could be used to 
compare the relative sensitivities of the respiratory tract and kidneys.   
 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No. 
 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:  Not 
applicable. 
 
Was a conversion used from intermittent to continuous exposure?  The pharmacokinetic model assumes 
continuous exposure. 
 
Other additional studies or pertinent information that lend support to this MRL:  Numerous studies 
examining the toxicity of cadmium in workers have identified the respiratory tract and the kidney as 
sensitive targets of toxicity.  A variety of respiratory tract effects have been observed in cadmium workers 
including respiratory symptoms (e.g., dyspnea, coughing, wheezing), emphysema, and impaired lung 
function.  However, many of these studies did not control for smoking, and thus, the role of cadmium in 
the induction of these effects is difficult to determine.  Impaired lung function was reported in several 
studies that controlled for smoking (Chan et al. 1988; Cortona et al. 1992; Davison et al. 1988; Smith et 
al. 1976); other studies have not found significant alterations (Edling et al. 1986).  The observed 
alterations include an increase in residual volume in workers exposed to air concentrations of cadmium 
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fumes ranging from 0.008 (in 1990) to 1.53 mg/m3 (in 1975) (mean urinary cadmium level in the workers 
was 4.3 μg/L) (Cortona et al. 1992); alterations in several lung function parameters (e.g., forced 
expiratory volume, transfer factor, transfer coefficient) in workers exposed to 0.034–0.156 mg/m3 
(Davison et al. 1988); and decreased force vital capacity in workers exposed to >0.2 mg/m3 (Smith et al. 
1976).  Additionally, Chan et al. (1988) found significant improvements in several parameters of lung 
function of workers following reduction or cessation of cadmium exposure. 
 
The renal toxicity of cadmium in workers chronically exposed to high levels of cadmium is well 
established.  Observed effects include tubular proteinuria (increased excretion of low molecular weight 
proteins), decreased resorption of other solutes (increased excretion of enzymes such as N-acetyl-
β-glucosaminidase (NAG), amino acids, glucose, calcium, inorganic phosphate), evidence of increased 
glomerular permeability (increased excretion of albumin), increased kidney stone formation, and 
decreased glomerular filtration rate.  The earliest sign of cadmium-induced kidney damage is an increase 
in urinary levels of low molecular weight proteins (particularly, β2-microglobulin, retinol binding protein, 
and human complex-forming glycoprotein [pHC]) in cadmium workers, as compared to levels found in a 
reference group of workers or the general population (Bernard et al. 1990; Chen et al. 2006a, 2006b; Chia 
et al. 1992; Elinder et al. 1985a; Falck et al. 1983; Jakubowski et al. 1987, 1992; Järup and Elinder 1994; 
Järup et al. 1988; Shaikh et al. 1987; Toffoletto et al. 1992; Verschoor et al. 1987).  Significant alterations 
in the prevalence of low molecular weight proteinuria among cadmium workers has been observed at 
urinary cadmium levels of 1.5 μg/g creatinine and higher (Chen et al. 2006a; Elinder et al. 1985a; 
Jakubowski et al. 1987; Järup and Elinder 1994). 
 
Agency Contact (Chemical Manager):  Obaid Faroon, DVM, Ph.D. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical Name: Cadmium 
CAS Numbers: 7440-43-9 
Date: September, 2012 
Profile Status: Post-Public Comment Draft 2 
Route: [ ] Inhalation   [X] Oral 
Duration: [ ] Acute   [X] Intermediate   [ ] Chronic 
Graph Key: 33 
Species: Rat 
 
Minimal Risk Level:  0.5  [X]  μg Cd/kg/day   [ ] ppm 
 
Reference:  Brzóska MM, Moniuszko-Jakoniuk J.  2005d.  Disorders in bone metabolism of female rats 
chronically exposed to cadmium.  Toxicol Appl Pharmacol 202(1):68-83. 
 
Brzóska MM, Majewska K, Moniuszko-Jakoniuk J.  2005a.  Bone mineral density, chemical composition 
and biomechanical properties of the tibia of female rats exposed to cadmium since weaning up to skeletal 
maturity.  Food Chem Toxicol 43(10):1507-1519. 
 
Brzóska MM, Majewska K, Moniuszko-Jakoniuk J.  2005c.  Weakness in the mechanical properties of 
the femur of growing female rats exposed to cadmium.  Arch Toxicol 79(5):277-288. 
 
Experimental design:  Groups of 40 3-week-old female Wistar rats were exposed to 0, 1, 5, or 50 mg 
Cd/L as cadmium chloride in drinking water for 12 months.  The investigators noted that cadmium 
intakes were 0.059–0.219, 0.236–1.005, and 2.247–9.649 mg Cd/kg/day in the 1, 5, and 50 mg/L groups, 
respectively.  Using cadmium intake data presented in a figure, cadmium intakes of 0.2, 0.5, and 4 mg 
Cd/kg/day were estimated.  Bone mineral density, bone mineral concentration, and mineralization area of 
the lumbar spine, femur and total skeleton (bone mineral density only) were assessed after 3, 6, 9, or 
12 months of exposure.  The mechanical properties of the femur and tibia were evaluated after 12 months 
of exposure.  Markers for bone resorption (urinary and serum levels of C-terminal cross-linking 
telopeptide of type I collagen [CTX]) and bone formation (serum osteocalcin, total alkaline phosphatase, 
and cortical bone and trabecular bone alkaline phosphatase), and serum and urinary levels of calcium 
were also measured at 3, 6, 9, and 12 months.   
 
Effect noted in study and corresponding doses:  No significant alterations in body weight gain or food and 
water consumption were observed.  Significant decreases in total skeletal bone mineral density was 
observed at ≥0.2 mg Cd/kg/day; the decrease was significant after 3 months in the 4 mg Cd/kg/day group, 
after 6 months in the 0.5 mg Cd/kg/day group, and after 9 months in the 0.2 mg Cd/kg/day group.  
Significant decreases in whole tibia and diaphysis bone mineral density were observed at ≥0.2 mg 
Cd/kg/day after 12 months of exposure.  At 0.2 mg Cd/kg/day, bone mineral density was decreased at the 
proximal and distal ends of the femur after 6 months of exposure; diaphysis bone mineral density was not 
affected.  At 0.5 mg Cd/kg/day, bone mineral density was decreased at the femur proximal and distal ends 
after 3 months of exposure and diaphysis bone mineral density after 6 months of exposure.  At 4 mg 
Cd/kg/day decreases in femoral proximal, distal, and diaphysis bone mineral density were decreased after 
3 months of exposure.  Similarly, bone mineral density was significantly decreased in the lumbar spine in 
the 0.2 and 0.5 mg Cd/kg/day groups beginning at 6 months and at 3 months in the 4 mg Cd/kg/day 
group.  Significant decreases in the mineralization area were observed in the femur and lumbar spine of 
rats exposed to 4 mg Cd/kg/day; lumbar spine bone mineral area was also affected at 0.5 mg Cd/kg/day.  
Significant decreases in tibia weight and length were observed at 4 mg Cd/kg/day.  In tests of the 
mechanical properties of the tibia diaphysis, significant alterations in ultimate load, yield load, and 
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displacement at load were observed at ≥0.2 mg Cd/kg/day; work to fracture was also significantly altered 
at 4 mg Cd/kg/day.  In the mechanical properties compression tests of the tibia, significant alterations 
were observed in ultimate load, ultimate load, and stiffness at 0.2 mg Cd/kg/day; displacement at yield 
and work to fracture at ≥0.5 mg Cd/kg/day; and displacement at ultimate at 4 mg Cd/kg/day.  Multiple 
regression analysis showed that the cadmium-induced weakness in bone mechanical properties of the tibia 
was primarily due to its effects on bone composition, particularly the non-organic components, organic 
components, and the ratio of the ash weight to organic weight.  The mechanical properties of the femur 
were strongly influenced by the bone mineral density (at the whole bone and diaphysis).  A significant 
decrease in femur length was observed at 6 months of exposure to ≥0.2 mg Cd/kg/day; however, 
decreases in length were not observed at other time points in the 0.2 or 0.5 mg Cd/kg/day groups.  Femur 
weight was significantly decreased at 4 mg Cd/kg/day.  In tests of mechanical properties of the femoral 
neck and distal, decreases in yield load, ultimate load, displacement at ultimate, work to fracture (neck 
only), and stiffness (distal only) were observed at ≥0.2 mg Cd/kg/day.  For the femoral diaphysis, 
significant alterations were observed for yield load, displacement at yield, and stiffness at ≥0.2 mg 
Cd/kg/day.  Significant decreases in osteocalcin concentrations were observed in all cadmium groups 
during the first 6 months of exposure, but not during the last 6 months.  Decreases in total alkaline 
phosphatase levels at 4 mg Cd/kg/day, trabecular bone alkaline phosphatase at 0.2 mg Cd/kg/day, and 
cortical bone alkaline phosphatase at 4 mg Cd/kg/day were observed.  CTX was decreased at ≥0.2 mg 
Cd/kg/day.  Total urinary calcium and fractional excretion of calcium were increased at ≥0.2 mg 
Cd/kg/day. 
 
Dose and end point used for MRL derivation:   
 
[ ] NOAEL   [ ] LOAEL   [X] BMDLsd1 
 
At the lowest dose tested, 0.2 mg Cd/kg/day, a number of skeletal alterations were observed including 
decreases in bone mineral density in the lumbar spine, femur, and tibia, alterations in the mechanical 
properties of the femur and tibia, decreases in osteocalcin levels, decreases in trabecular bone alkaline 
phosphatase, and decreases in CTX.  Of these skeletal end points, the decrease in bone mineral density 
was selected as the critical effect because Brzóska et al. (2005a, 2005c) demonstrated that the bone 
mineral density was a stronger predictor of femur and tibia strength and the risk of fractures. 
 
Available continuous models in the EPA Benchmark Dose Software (version 1.4.1c) were fit to data 
(Table A-1) for changes in bone mineral density of the femur and lumbar spine in female rats resulting 
from exposure to cadmium in the drinking water for 6, 9, or 12 months (Brzóska and Moniuszko-
Jakoniuk 2005d).  The BMD and the 95% lower confidence limit (BMDL) is an estimate of the doses 
associated with a change of 1 standard deviation from the control.  The model-fitting procedure for 
continuous data is as follows.  The simplest model (linear) is applied to the data while assuming constant 
variance.  If the data are consistent with the assumption of constant variance (p≥0.1), then the other 
continuous models (polynomial, power, and Hill models) are applied to the data.  Among the models 
providing adequate fits to the means (p≥0.1), the one with the lowest Akaike’s information criterion 
(AIC) for the fitted model is selected for BMD derivation.  If the test for constant variance is negative, the 
linear model is run again while applying the power model integrated into the benchmark dose software 
(BMDS) to account for nonhomogenous variance.  If the nonhomogenous variance model provides an 
adequate fit (p≥0.1) to the variance data, then the other continuous models are applied to the data.  
Among the models providing adequate fits to the means (p≥0.1), the one with the lowest AIC for the 
fitted model is selected for BMD derivation.  If the tests for both constant and non-constant variance are 
negative, then the data set is considered not to be suitable for BMD modeling.   
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Table A-1.  Data Sets for Changes in Mineral Bone Density of the Femur and 
Lumbar Spine in Female Rats Exposed to Cadmium in  
Drinking Water for 6, 9, or 12 Months 
 
Dataseta 
Dose (mg Cd/kg/day) 
0 0.2 0.5 4 
Femurb 
6 month 329.7±3.6 317.6±2.7c 308.5±3.4d 303.4±3.4e 
9 month 343.8±3.1 328.2±2.9d 322.8±3.0e 310.4±3.4e 
12 month 354.3±3.7 338.0±1.9d 330.9±3.1d 318.7±3.4e 
Lumbar spineb 
6 month 272.0±2.4 263.4±2.6c 258.3±2.7d 249.5±2.9e 
9 month 282.4±2.3 271.8±1.6d 267.8±1.8e 259.5±2.7e 
12 month 286.1±2.3 275.5±1.9d 269.1±1.9e 257.1±3.0e 
 
an=10. 
bmean±SE; standard errors were transformed to standard deviations for benchmark dose modeling via a function in 
the BMD software. 
cSignificantly different (p≤0.05) from the control group.  
dSignificantly different (p≤0.01) from the control group.  
eSignificantly different (p≤0.001) from the control group. 
 
Source:  Brzóska and Moniuszko-Jakoniuk 2005d 
 
The potential points of departures derived from the best fitting models for each dataset are summarized in 
Table A-2. 
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Table A-2.  Summary of BMDs and BMDLs From the Best Fitting Models 
Predicting Changes in Bone Mineral Density in Female Rats After  
Cadmium Exposure From Drinking Water 
 
Exposure 
Period 
(months) Best-fitting model 
Number of 
doses 
BMDsd1a  
(mg Cd/kg/day) 
BMDLsd1a  
(mg Cd/kg/day) 
Femur 
6 Linear 3 0.24 0.17 
9 Hill 4 0.11 0.05 
12 Hill 4 0.09 0.05 
Lumbar spine  
6 Hill 4 0.19 0.08 
9 Hill 4 0.11 0.05 
12 Hill 4 0.12 0.07 
 
aBMDs and BMDLs from continuous data are associated with a 1 standard deviation change from the control. 
 
The BMDLsd1 of 0.05 mg Cd/kg/day estimated from the 9-month lumbar spine data set was selected as the 
point of departure for the MRL.  In young female rats, the process of intense bone formation occurs 
during the first 7 months of life (the first 6 months of exposure in this study); thereafter, the increase in 
bone mineral density slows.  In the lumbar spine of the control group, the changes in bone mineral density 
at 3–6 months, 6–9 months, and 9–12 months were 15, 4, and 1%, respectively.  Thus, the 9-month data 
may best reflect the effect of cadmium on bone mineral density during the period of rapid skeletal growth.  
The lumbar spine data was selected over the femur data set because trabecular bone, which is abundant in 
the spine, appears to be more susceptible to cadmium toxicity than cortical bone. 
 
For the 9-month lumbar spine data set, the simplest model (linear) was applied to the data first to test for a 
fit for constant variance.  The constant variance model did provide an adequate fit (as assessed by the 
p-value for variance) to the data.  The polynomial, power, and Hill models were then fit to the data with 
constant variance assumed.  The Hill model was the only model that provided an adequate fit to the data 
(as assessed by the p-value for the means) (Table A-3).  Using the constant-variance Hill model, the 
BMDsd1 and BMDLsd1 are 0.11 mg/kg and 0.05 mg Cd/kg/day, respectively (Figure A-1). 
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Table A-3.  Model Predictions for Changes in Bone Mineral Density of the Lumbar 
Spine in Female Rats Exposed to Cd in Drinking Water for 9 Months 
 
Modela 
Variance 
p-valueb 
p-Value for 
the meansb AIC 
BMDsd1  
(mg Cd/kg/day) 
BMDLsd1 
(mg Cd/kg/day) 
Linearc 0.36 0.00 211.92 1.93 1.42 
Polynomial (1-degree)c 0.36 0.00 211.92 1.93 1.42 
Polynomial (2-degree)c 0.36 0.00 211.92 1.93 1.42 
Polynomial (3-degree)c 0.36 0.00 211.92 1.93 1.42 
Power 0.36 0.00 211.92 1.93 1.42 
Hill 0.36 0.60 197.21 0.11 0.05 
 
aConstant variance assumed for all models. 
bValues <0.1 fail to meet conventional goodness-of-fit criteria. 
cRestriction = non-positive. 
 
AIC = Akaike’s Information Criteria; BMD = benchmark dose; BMDL = lower confidence limit (95%) on the 
benchmark dose; p = p value from the Chi-squared test; Std1 = a 1 standard deviation change from the control. 
 
Source:  Brzóska and Moniuszko-Jakoniuk 2005d 
 
Figure A-1.  Predicted and Observed Incidence of Changes in Lumbar Spine Bone 
Mineral Density in Female Rats Exposed to Cadmium in Drinking Water for 
9 Months (Brzóska and Moniuszko-Jakoniuk 2005d)* 
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*BMDs and BMDLs indicated are associated with a 1 standard deviation change from the control, and are in units of  
mg Cd/kg/day. 
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Uncertainty Factors used in MRL derivation: 
 
 [  ]   10 for use of a LOAEL 
 [X]  10 for extrapolation from animals to humans 
 [X]  10 for human variability 
 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Investigators 
estimated doses based on body weight and water consumption. 
 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:  Not 
applicable. 
 
Was a conversion used from intermittent to continuous exposure?  Not applicable. 
 
Other additional studies or pertinent information that lend support to this MRL:  There are limited data on 
the toxicity of cadmium in humans following intermediate-duration exposure.  Numerous animal studies 
have examined the systemic, immunological, neurological, reproductive, and developmental toxicity of 
cadmium.  The most sensitive systemic effect following intermediate-duration oral exposure to cadmium 
appears to be damage to growing bone.  Exposure to 0.2 mg Cd/kg/day as cadmium chloride in drinking 
water for 3–12 months resulted decreases in bone mineral density, impaired mechanical strength of the 
lumbar spine, tibia, and femur bones, increased bone turnover, and increased incidence of deformed or 
fractured lumbar spine bone in young female rats (3 weeks of age at study initiation) (Brzóska and 
Moniuszko-Jakoniuk 2005d; Brzóska et al. 2004b, 2005a, 2005b, 2005c, 2010); similar findings were 
observed in young male rats exposed to 0.5 mg Cd/kg/day for up to 12 months (Brzóska and Moniuszko-
Jakoniuk 2005a, 2005b).  Decreases in bone strength were also observed in young rats exposed to 0.8 mg 
Cd/kg/day as cadmium chloride in drinking water for 4 weeks (Ogoshi et al. 1989); however, no skeletal 
effects were observed in adult or elderly female rats exposed to doses >20 mg Cd/kg/day for 4 weeks 
(Ogoshi et al. 1989).   
 
Renal effects have been observed at higher doses than the skeletal effects.  Vesiculation of the proximal 
tubules was observed in rats exposed to 1.18 mg Cd/kg/day as cadmium chloride in drinking water for 
40 weeks (Gatta et al. 1989).  At approximately 3–8 mg Cd/kg/day, proteinuria, tubular necrosis, and 
decreased renal clearance were observed in rats (Cha 1987; Itokawa et al. 1974; Kawamura et al. 1978; 
Kotsonis and Klaassen 1978; Prigge 1978a).  Liver necrosis and anemia (Cha 1987; Groten et al. 1990; 
Kawamura et al. 1978) were observed at similar cadmium doses. 
 
A number of developmental effects have been observed in the offspring of rats exposed to cadmium 
during gestation and lactation.  Decreases in glomerular filtration rates and increases in urinary fractional 
excretion of phosphate, magnesium, potassium, sodium, and calcium were observed in 60-day-old 
offspring of rats administered via gavage 0.5 mg Cd/kg/day on gestation days 1–21 (Jacquillet et al. 
2007).  Neurodevelopmental alterations have also been observed at the low maternal doses.  Delays in the 
development of sensory motor coordination reflexes and increased motor activity were observed at 
0.706 mg Cd/kg/day (gestation days 1–21) (Ali et al. 1986), decreased motor activity at 0.04 mg 
Cd/kg/day (5–8 weeks of pre-gestation exposure, gestation days 1–21) (Baranski et al. 1983), decreased 
ambulation and rearing activity and altered ECG at 14 mg Cd/kg/day (gestation days 5–15, lactation 
days 2–28, postnatal days 1–56) (Desi et al. 1998) or 7 mg Cd/kg/day (F2 and F3 generations) 
(Nagymajtenyi et al. 1997) have been observed.  Decreases in pup body weight were observed at ≥5 mg 
Cd/kg/day (Baranski 1987; Gupta et al. 1993; Kostial et al. 1993; Pond and Walker 1975) and decreases 
in fetal body weight or birth weight were observed at ≥2.4 mg Cd/kg/day (Petering et al. 1979; Sorell and 
Graziano 1990; Webster 1978; Sutou et al. 1980).  Another commonly reported developmental effect was 
alterations in hematocrit levels or anemia in the offspring of animals exposed to ≥1.5 mg Cd/kg/day 
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(Kelman et al. 1978; Baranski 1987; Webster 1978).  Increases in the occurrence of malformations or 
anomalies is limited to a study by Sutou et al. (1980), which reported a significant delay in ossification in 
rats exposed to 10 mg Cd/kg/day. 
 
The animal studies identify several sensitive targets of toxicity following intermediate-duration exposure 
to cadmium; these include skeletal mineralization in young female rats exposed for at least 3 months to 
0.2 mg Cd/kg/day (Brzóska and Moniuszko-Jakoniuk 2005d; Brzóska et al. 2004b, 2005a, 2005b, 2005c), 
decreased glomerular filtration in young rats exposed during gestation to maternal doses of 0.5 mg 
Cd/kg/day (Jacquillet et al. 2007), and neurodevelopmental effects following gestational exposure to 
0.04 mg Cd/kg/day (Baranski et al. 1983).  Although the Baranski et al. (1983) study reported the lowest 
LOAEL, it was not selected as the principal study for derivation of an intermediate-duration MRL.  For 
locomotor activity, a significant decrease in activity was observed in female offspring exposed to 0.04, 
0.4, and 4 mg Cd/kg/day, as compared to controls; however, no significant differences were found 
between the cadmium groups despite the 100-fold difference in doses.  Locomotor activity was also 
decreased in males exposed to 0.4 or 4 mg Cd/kg/day.  For the rotorod test, a significant decrease in the 
length of time the rat stayed on the rotorod was observed in males exposed to 0.04 and 0.4 mg Cd/kg/day, 
but not to 4 mg Cd/kg/day and in females exposed to 0.4 and 4 mg Cd/kg/day; no differences between the 
cadmium groups were observed in the males and females.  The results were poorly reported and the 
investigators did not explain the lack of dose-response of the effects or the discrepancy between genders. 
 
Agency Contact (Chemical Manager):  Obaid Faroon, DVM, Ph.D. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical Name: Cadmium 
CAS Numbers: 7440-43-9 
Date: September, 2012 
Profile Status: Post-Public Comment Draft 2 
Route: [ ] Inhalation   [X] Oral 
Duration: [ ] Acute   [ ] Intermediate   [X] Chronic 
Graph Key: 106 
Species: Human 
 
Minimal Risk Level:  0.1 [X] μg Cd/kg/day   [ ]  μg Cd/m3 
 
Reference:  Buchet JP, Lauwerys R, Roels H, et al.  1990.  Renal effects of cadmium body burden of the 
general population.  Lancet 336:699-702. 
 
Järup L, Hellstrom L, Alfven T, et al.  2000.  Low level exposure to cadmium and early kidney damage:  
The OSCAR study.  Occup Environ Med 57(10):668-672. 
 
Suwazono Y, Sand S, Vahter M, et al.  2006.  Benchmark dose for cadmium-induced renal effects in 
humans.  Environ Health Perspect 114:1072-1076. 
 
Experimental design:  ATSDR conducted a meta-analysis of select environmental exposure dose-response 
studies examining the relationship between urinary cadmium and the prevalence of elevated levels of 
biomarkers of renal function (Buchet et al. 1990; Järup et al. 2000; Jin et al. 2004c; Kobayashi et al. 2006; 
Shimizu et al. 2006; Suwazono et al. 2006; Wu et al. 2001).  The studies were selected based on the 
following qualitative criteria:  (1) the study measured an urinary cadmium as indicator of internal dose; 
(2) the study measured reliable indicators of low molecular weight (LMW) proteinuria; (3) a dose-
response relationship was reported in sufficient detail so that the dose-response function could be 
reproduced independently; (4) the study was of reasonable size to have provided statistical strength to the 
estimates of dose-response model parameters (i.e., most studies selected included several hundred to 
several thousand subjects); and (5) major co-variables that might affect the dose-response relationship 
(e.g., age, gender) were measured or constrained by design and included in the dose-response analysis.  
No attempt was made to weight selected studies for quality, statistical power, or statistical uncertainty in 
dose-response parameters.  Studies using a cut-off value for β2-microglobulin of ≥1,000 μg/g creatinine 
were eliminated from the analysis based on the conclusions of Bernard et al. (1997) that urinary 
β2-microglobulin levels of 1,000–10,000 μg/g creatinine were indicative of irreversible tubular 
proteinuria, which may lead to an age-related decline in glomerular filtration rate.  Additionally, an 
attempt was made to avoid using multiple analyses of the same study population.  
 
The individual dose-response functions from each study were implemented to arrive at estimates of the 
internal dose (urinary cadmium expressed as μg/g creatinine) corresponding to probabilities of 10% 
excess risk of low molecular weight proteinuria (urinary cadmium dose, UCD10).  Estimates were derived 
from the seven environmental exposure studies listed above.  When available, male and female data were 
treated separately; thus, 11 dose-response relationships were analyzed.  For studies that did not report the 
UCD10, the value was estimated by iteration of the reported dose response relationship for varying values 
of urinary cadmium, until an excess risk of 10% was achieved.  For studies that reported the dose-
response relationship graphically, but did not report the actual dose-response function, a function was 
derived by least squares fitting based on data from a digitization of the graphic 
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Dose and end point used for MRL derivation:  Aggregate UCD10 estimates and the estimates stratified by 
location (i.e., Europe, Japan, China) are presented in Table A-4.  The lowest UCD10 (1.34 μg/g creatinine) 
was estimated from the European database; and the 95% lower confidence limit on this UCD10 (UCDL10) 
of 0.5 μg/g creatinine was considered as the point of departure for the MRL.   
 
Table A-4.  Estimates of the UCD10 and Cadmium Intake from Environmental 
Exposure Dose-Response Studies  
 
 
UCD10a 
(μg Cd/g creatinine) 
Cadmium intakeb 
(μg/kg/day) 
 Females Males 
Europe (n=4)c    
Mean 1.34 0.97 2.24 
Median — — — 
95% CI 0.50, 2.18 0.33, 1.75 0.70, 3.94 
Japan (n=4)d    
Mean 5.23 4.59 10.1 
Median — — — 
95% CI 4.24, 6.21 3.67, 5.49 8.07, 12.0 
China (n=3)e    
Mean 9.55 8.60 18.8 
Median — — — 
95% CI 2.96, 16.1 2.48, 14.7 5.51, 31.9 
All (n=11)    
Mean 4.99 4.37 9.58 
Median 4.20 3.63 7.99 
95% CI 1.44, 6.60 1.06, 5.86 2.45, 12.8 
 
aEstimates of urinary cadmium level corresponding to probabilities of 10% excess risk of low molecular weight 
proteinuria (UCD10). 
bUCD was transformed into estimates of chronic cadmium intake that would result in the UCD at age 55 using a 
modification (Choudhury et al. 2001; Diamond et al. 2003) of the Kjellström and Nordberg (1978) model. 
cDose-response function data from Buchet et al. (1990), Suwazono et al. (2006), and Järup et al. (2000); dose 
response data from males and females in the Buchet et al. (1990) study were treated separately. 
dDose-response function data from Kobayashi et al. (2006) and Shimizu et al. (2006); dose response data from 
males and females were treated separately. 
eDose-response function data from Jin et al. (2004c) and Wu et al. (2001); dose response data from males and 
females in the Jin et al. (2004c) study were treated separately. 
 
UCD = urinary cadmium dose 
 
 [ ] NOAEL   [ ] LOAEL   [X] UCDL10 
 
The UCDL10 of 0.5 μg/g creatinine was transformed into estimates of chronic cadmium intake (expressed 
as μg/kg/day) that would result in the UCDL10 at age 55 (approximate age of peak cadmium concentration 
in the renal cortex associated with a constant chronic intake).  The dose transformations were achieved by 
simulation using a modification of the Kjellström and Nordberg (1978) model.  The following 
modifications (Choudhury et al. 2001; Diamond et al. 2003) were made to the model:  (1) the equations 
describing intercompartmental transfers of cadmium were implemented as differential equations in 
Advanced Computer Simulation Language (acslXtreme, version 2.4.0.9); (2) growth algorithms for males 
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and females and corresponding organ weights (O’Flaherty 1993) were used to calculate age-specific 
cadmium concentrations from tissue cadmium masses; (3) the cadmium concentration in renal cortex 
(RC, μg/g) was calculated as follows:  
 
KW
KRC ⋅= 5.1       
 
where K is the age-specific renal cadmium burden (μg) and KW is the age-specific kidney wet 
weight (g) (Friberg et al. 1974) 
 
(4) the rate of creatinine excretion (e.g., Crur, g creatinine/day) was calculated from the relationship 
between lean body mass (LBM) and Crur); and (5) absorption of ingested cadmium was assumed to be 5% 
in males and 10% in females.  The rate of creatinine excretion (e.g., Crur, g creatinine/day) was estimated 
from the relationship between LBM (kg) and Crur: 
   
58.82.27 +⋅= urCrLBM     
 
where the constants 27.2 and 8.58 are the sample size-weighted arithmetic mean of estimates of 
these variables from eight studies reported in (Forbes and Bruining 1976).  Lean body mass was 
estimated as follows (ICRP 1981): 
 
LBM
LBM
 
femalesadultBW ,85.0⋅=     
malesadultBW ,88.0⋅=      
where the central tendency for adult body weight for males and females were assumed to be 
70 and 58 kg for adult European/American males and females, respectively. 
 
Dose units expressed as cadmium intake (μg/kg/day), urinary cadmium excretion (μg/g creatinine), or 
kidney tissue cadmium (μg/g cortex) were interconverted by iterative pharmacokinetic model simulations 
of constant intakes for the life-time to age 55 years, the age at which renal cortex cadmium concentrations 
are predicted to reach their peak when the rate of intake (μg/kg/day) is constant.  
 
The dietary cadmium intakes which would result in urinary cadmium levels of 1.34 and 0.5 μg/g 
creatinine (UCD10 and UCDL10) are 0.97 and 0.33 μg/kg/day in females and 2.24 and 0.70 μg/kg/day in 
males.   
 
Uncertainty Factors used in MRL derivation: 
 
 [ ]  10 for use of a LOAEL 
 [ ]  10 for extrapolation from animals to humans  
 [X]  3 for human variability 
 
The UCD is based on several large-scale environmental exposure studies that likely included sensitive 
subpopulations; however, there is concern that individuals with diabetes may be especially sensitive to the 
renal toxicity of cadmium (Åkesson et al. 2005; Buchet et al. 1990) and diabetics were excluded from a 
number of human studies, and thus, an uncertainty factor of 3 was used.   
 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No. 
 
CADMIUM  A-19 
 
APPENDIX A 
 
 
 
 
 
 
 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:  Not 
applicable. 
 
Was a conversion used from intermittent to continuous exposure?  No. 
 
Other additional studies or pertinent information that lend support to this MRL:  The results of numerous 
studies of environmentally exposed populations provide strong evidence that the kidney, and possibly 
bone, is the most sensitive target of toxicity following chronic exposure to cadmium.  Most of the studies 
have focused on subclinical alterations of kidney function, as measured by the urinary excretion of several 
biomarkers including low molecular weight proteins (β2-microglobulin, pHC, retinol binding protein), 
intracellular tubular enzymes (NAG), amino acids, high molecular weight proteins (albumin), and 
electrolytes (potassium, sodium, calcium).  Significant associations between urinary cadmium levels and 
an increased prevalence of abnormal levels of these biomarkers have been found in populations living in 
areas with moderate or high cadmium pollution or low cadmium pollution (Bandara et al. 2010; Buchet et 
al. 1990; Cai et al. 1990, 1992, 1998, 2001; Ferraro et al. 2010; Hayano et al. 1996; Honda et al. 2010; 
Horiguchi et al. 2004, 2010; Hwangbo et al. 2011; Ishizaki et al. 1989; Izuno et al. 2000; Järup et al. 
2000; Jin et al. 2002, 2004a, 2004c; Kawada et al. 1992; Kido and Nogawa 1993; Kobayashi et al. 2002a, 
2009b; Monzawa et al. 1998; Nakashima et al. 1997; Nogawa et al. 1989; Noonan et al. 2002; Nordberg 
et al. 1997; Olsson et al. 2002; Oo et al. 2000; Osawa et al. 2001; Roels et al. 1981b; Suwazono et al. 
2006; Teeyakasem et al. 2007; Trzcinka-Ochocka et al. 2004; Uno et al. 2005; Yamanaka et al. 1998; Wu 
et al. 2001).  Increases in the prevalence of abnormal biomarker levels appear to be the most sensitive 
indicator of cadmium toxicity and alterations have been observed at urinary cadmium levels ranging from 
1 μg/g creatinine (Järup et al. 2000) to 9.51 μg/g creatinine (Jin et al. 2004a). 
 
Several studies have examined the possible association between exposure to cadmium and bone effects.  
Significant associations between urinary cadmium levels and an increased risk of bone fractures at urinary 
cadmium levels of ≥0.7 μg/g creatinine (Alfvén et al. 2004; Staessen et al. 1999; Wang et al. 2003), 
increased risk of osteoporosis at urinary cadmium levels of ≥1.5 μg/g creatinine (Alfvén et al. 2000; Jin et 
al. 2004b; Wang et al. 2003), and decreased bone mineral density at urinary cadmium levels of ≥0.6 μg/g 
creatinine (Engström et al. 2009; Nordberg et al. 2002; Schutte et al. 2008; Trzcinka-Ochocka et al. 
2010).   
 
The adverse effect levels for renal effects were similar to those observed for skeletal effects.  Because the 
renal effects database is stronger, it was used for derivation of a chronic-duration oral MRL for cadmium.  
Three approaches were considered for derivation of the MRL:  (1) NOAEL/LOAEL approach using a 
single environmental exposure study finding an increased prevalence of abnormal renal effect biomarker 
levels, (2) selection of a point of departure from a published benchmark dose analysis, or (3) selection of 
a point of departure on an analysis of the dose-response functions from a number of environmental 
exposure studies. 
 
In the first approach, all studies in which individual internal doses for subjects were estimated based on 
urinary cadmium were considered.  The Järup et al. (2000) study identified the lowest adverse effect 
level; the investigators estimated that a urinary cadmium level of 1 μg/g creatinine would be associated 
with a 10% increase in the prevalence of abnormal pHC levels above background prevalence 
(approximately a 10% added risk).  The European Chemicals Bureau (2007) recalculated the probability 
of HC proteinuria because the reference population and the study population were not matched for age 
(40 versus 53 years, respectively).  They estimated that the probability of HC proteinuria (13%) would be 
twice as high as the reference population at a urinary cadmium concentration of 0.5 μg/g creatinine.  For 
the second approach, eight published benchmark dose analyses were evaluated (Jin et al. 2004b; 
Kobayashi et al. 2006, 2008a; Shimizu et al. 2006; Suwazono et al. 2006, 2011b, 2011c; Uno et al. 2005).  
The lower 95% confidence interval of the benchmark dose (BMDL) for low molecular weight proteinuria 
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ranged from 0.7 μg/g creatinine (Uno et al. 2005) to 9.9 μg/g creatinine (Kobayashi et al. 2006).  The 
third approach involved a meta-analysis of selected environmental exposure dose-response studies.  Using 
individual dose-response functions from each study, estimates of the internal cadmium dose 
corresponding to probabilities of 10% excess risk of low molecular weight proteinuria were calculated.  
The lowest UCD10 (1.34 μg/g creatinine) was estimated from the European database; and the 95% lower 
confidence limit on this UCD10 (UCDL10) of 0.5 μg/g creatinine was considered as a potential point of 
departure for the MRL.   
 
The points of departure selected using the three different approaches are similar:  0.5 μg/g creatinine from 
the Järup et al. (2000) study (using the European Chemicals Bureau 2007 recalculation), 0.7 μg/g 
creatinine from the Uno et al. (2005) benchmark dose analysis, and 0.5 μg/g creatinine from the dose-
response analysis.  The third approach was selected for the derivation of the MRL because it uses the 
whole dose-response curves from several studies rather than data from a single study.   
 
Agency Contact (Chemical Manager):  Obaid Faroon, DVM, Ph.D. 
 
 
CADMIUM  B-1 
 
 
 
 
 
 
 
 
 
APPENDIX B.  USER'S GUIDE 
 
Chapter 1 
 
 
 
 
 
 
 
 
 
Public Health Statement 
This chapter of the profile is a health effects summary written in non-technical language.  Its intended 
audience is the general public, especially people living in the vicinity of a hazardous waste site or 
chemical release.  If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the chemical. 
The major headings in the Public Health Statement are useful to find specific topics of concern.  The 
topics are written in a question and answer format.  The answer to each question includes a sentence that 
will direct the reader to chapters in the profile that will provide more information on the given topic. 
Chapter 2 
Relevance to Public Health 
This chapter provides a health effects summary based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight-
of-evidence discussions for human health end points by addressing the following questions: 
 
 1. What effects are known to occur in humans? 
 
 2. What effects observed in animals are likely to be of concern to humans? 
 
 3. What exposure conditions are likely to be of concern to humans, especially around hazardous 
waste sites? 
 
The chapter covers end points in the same order that they appear within the Discussion of Health Effects 
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect.  Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter.   
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer 
potency or perform cancer risk assessments.  Minimal Risk Levels (MRLs) for noncancer end points (if 
derived) and the end points from which they were derived are indicated and discussed. 
 
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section. 
Interpretation of Minimal Risk Levels 
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral 
routes of entry at each duration of exposure (acute, intermediate, and chronic).  These MRLs are not 
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans. 
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MRLs should help physicians and public health officials determine the safety of a community living near 
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water.  
MRLs are based largely on toxicological studies in animals and on reports of human occupational 
exposure. 
 
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are 
Unusually Susceptible" provide important supplemental information. 
 
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a 
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.   
 
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable 
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect 
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor 
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In 
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study.  Uncertainty factors used 
in developing a substance-specific MRL are provided in the footnotes of the levels of significant exposure 
(LSE) tables. 
 
Chapter 3 
 
Health Effects 
 
Tables and Figures for Levels of Significant Exposure (LSE) 
 
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects.  These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end 
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in 
10,000 to 1 in 10,000,000.  Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario.  The LSE tables and figures should always be used in 
conjunction with the text.  All entries in these tables and figures represent studies that provide reliable, 
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs). 
 
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends 
correspond to the numbers in the example table and figure. 
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LEGEND 
See Sample LSE Table 3-1 (page B-6) 
 
(1) Route of Exposure.  One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure.  Typically 
when sufficient data exist, three LSE tables and two LSE figures are presented in the document.  
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes.  Not all substances will have data on each 
route of exposure and will not, therefore, have all five of the tables and figures. 
 
(2) Exposure Period.  Three exposure periods—acute (less than 15 days), intermediate (15–
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.  
In this example, an inhalation study of intermediate exposure duration is reported.  For quick 
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure. 
 
(3) Health Effect.  The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.  
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.  
Systemic effects are further defined in the "System" column of the LSE table (see key number 
18). 
 
(4) Key to Figure.  Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure.  In this example, the study 
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL 
(also see the two "18r" data points in sample Figure 3-1). 
 
(5) Species.  The test species, whether animal or human, are identified in this column.  Chapter 2, 
"Relevance to Public Health," covers the relevance of animal data to human toxicity and 
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.  
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent 
human doses to derive an MRL. 
 
(6) Exposure Frequency/Duration.  The duration of the study and the weekly and daily exposure 
regimens are provided in this column.  This permits comparison of NOAELs and LOAELs from 
different studies.  In this case (key number 18), rats were exposed to “Chemical x” via inhalation 
for 6 hours/day, 5 days/week, for 13 weeks.  For a more complete review of the dosing regimen, 
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 
1981). 
 
(7) System.  This column further defines the systemic effects.  These systems include respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular.  "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered 
in these systems.  In the example of key number 18, one systemic effect (respiratory) was 
investigated. 
 
(8) NOAEL.  A NOAEL is the highest exposure level at which no harmful effects were seen in the 
organ system studied.  Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 
which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b"). 
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(9) LOAEL.  A LOAEL is the lowest dose used in the study that caused a harmful health effect.  
LOAELs have been classified into "Less Serious" and "Serious" effects.  These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the 
gradation of effects with increasing dose.  A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL.  The respiratory effect reported in key 
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm.  MRLs are not derived from 
Serious LOAELs. 
 
(10) Reference.  The complete reference citation is given in Chapter 9 of the profile. 
 
(11) CEL.  A CEL is the lowest exposure level associated with the onset of carcinogenesis in 
experimental or epidemiologic studies.  CELs are always considered serious effects.  The LSE 
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing 
measurable cancer increases. 
 
(12) Footnotes.  Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm. 
 
 
LEGEND 
See Sample Figure 3-1 (page B-7) 
 
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the 
reader quickly compare health effects according to exposure concentrations for particular exposure 
periods. 
 
(13) Exposure Period.  The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated. 
 
(14) Health Effect.  These are the categories of health effects for which reliable quantitative data 
exists.  The same health effects appear in the LSE table. 
 
(15) Levels of Exposure.  Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log 
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day. 
 
(16) NOAEL.  In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 18 
corresponds to the entry in the LSE table.  The dashed descending arrow indicates the 
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of 
0.005 ppm (see footnote "b" in the LSE table). 
 
(17) CEL.  Key number 38m is one of three studies for which CELs were derived.  The diamond 
symbol refers to a CEL for the test species-mouse.  The number 38 corresponds to the entry in the 
LSE table. 
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(18) Estimated Upper-Bound Human Cancer Risk Levels.  This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the 
cancer dose response curve at low dose levels (q1*). 
 
(19) Key to LSE Figure.  The Key explains the abbreviations and symbols used in the figure. 
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Table 3-1.  Levels of Significant Exposure to [Chemical x] – Inhalation 
 
Reference 
INTERMEDIATE EXPOSURE 
 
   ↓ 
Nitschke et al. 1981 
 
CHRONIC EXPOSURE 
 
Wong et al. 1982 
NTP 1982 
NTP 1982 
a The number corresponds to entries in Figure 3-1. 
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of  5x10-3 ppm; dose adjusted for intermittent exposure and divided 
by an uncertainty factor of 100 (10 for extrapolation from animal to humans, 10 for human variability). 
10 
LOAEL (effect) 
Serious (ppm) 
 
 
 
 
(CEL, multiple 
organs) 
(CEL, lung tumors, 
nasal tumors) 
(CEL, lung tumors, 
hemangiosarcomas) 
Less serious 
(ppm) 
 
  ↓ 
10 (hyperplasia) 
 
 
11 
↓ 
20 
10 
10 
 
 
 
 
 
SAMPLE 
9 
NOAEL 
(ppm) 
 
↓ 
3b 
 
 
 
 
 
 
 
8 
System 
 
↓ 
Resp 
 
 
 
 
 
 
7 
Exposure 
frequency/ 
duration 
 
↓ 
13 wk 
5 d/wk 
6 hr/d 
 
18 mo 
5 d/wk 
7 hr/d 
89–104 wk 
5 d/wk 
6 hr/d 
79–103 wk 
5 d/wk 
6 hr/d 
6 
Species 
 
  ↓ 
Rat 
 
 
 
Rat 
Rat 
Mouse 
5 
Key to 
figurea 
 
Systemic 
18 
 
 
Cancer 
38 
39 
40 
→ 
 
→ 
 
→ 
→ 
 
 
 
 
 
→ 
1 
2 
 
3 
 
4 
 
 
 
 
 
12 
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APPENDIX C.  ACRONYMS, ABBREVIATIONS, AND SYMBOLS 
 
ACGIH American Conference of Governmental Industrial Hygienists 
ACOEM American College of Occupational and Environmental Medicine 
ADI acceptable daily intake 
ADME absorption, distribution, metabolism, and excretion 
AED atomic emission detection 
AFID alkali flame ionization detector 
AFOSH Air Force Office of Safety and Health 
ALT alanine aminotransferase 
AML acute myeloid leukemia 
AOAC Association of Official Analytical Chemists 
AOEC Association of Occupational and Environmental Clinics 
AP alkaline phosphatase 
APHA American Public Health Association 
AST aspartate aminotransferase 
atm atmosphere 
ATSDR Agency for Toxic Substances and Disease Registry 
AWQC Ambient Water Quality Criteria 
BAT best available technology 
BCF bioconcentration factor 
BEI Biological Exposure Index 
BMD/C benchmark dose or benchmark concentration 
BMDX dose that produces a X% change in response rate of an adverse effect 
BMDLX 95% lower confidence limit on the BMDX 
BMDS Benchmark Dose Software   
BMR benchmark response 
BSC Board of Scientific Counselors 
C centigrade 
CAA Clean Air Act 
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency 
CAS Chemical Abstract Services 
CDC Centers for Disease Control and Prevention 
CEL cancer effect level 
CELDS Computer-Environmental Legislative Data System 
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act 
CFR Code of Federal Regulations 
Ci curie 
CI confidence interval 
CL ceiling limit value 
CLP Contract Laboratory Program 
cm centimeter 
CML chronic myeloid leukemia 
CPSC Consumer Products Safety Commission 
CWA Clean Water Act 
DHEW Department of Health, Education, and Welfare 
DHHS Department of Health and Human Services 
DNA deoxyribonucleic acid 
DOD Department of Defense 
DOE Department of Energy 
DOL Department of Labor 
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DOT Department of Transportation 
DOT/UN/ Department of Transportation/United Nations/ 
    NA/IMDG     North America/Intergovernmental Maritime Dangerous Goods Code 
DWEL drinking water exposure level 
ECD electron capture detection 
ECG/EKG electrocardiogram 
EEG electroencephalogram 
EEGL Emergency Exposure Guidance Level 
EPA Environmental Protection Agency 
F Fahrenheit 
F1 first-filial generation 
FAO Food and Agricultural Organization of the United Nations 
FDA Food and Drug Administration 
FEMA Federal Emergency Management Agency 
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act 
FPD flame photometric detection 
fpm feet per minute 
FR Federal Register 
FSH follicle stimulating hormone 
g gram 
GC gas chromatography 
gd gestational day 
GLC gas liquid chromatography 
GPC gel permeation chromatography 
HPLC high-performance liquid chromatography 
HRGC high resolution gas chromatography 
HSDB Hazardous Substance Data Bank  
IARC International Agency for Research on Cancer 
IDLH immediately dangerous to life and health 
ILO International Labor Organization 
IRIS Integrated Risk Information System   
Kd adsorption ratio 
kg kilogram 
kkg metric ton 
Koc organic carbon partition coefficient 
Kow octanol-water partition coefficient 
L liter 
LC liquid chromatography 
LC50 lethal concentration, 50% kill 
LCLo lethal concentration, low 
LD50 lethal dose, 50% kill 
LDLo lethal dose, low 
LDH lactic dehydrogenase 
LH luteinizing hormone 
LOAEL lowest-observed-adverse-effect level 
LSE Levels of Significant Exposure 
LT50 lethal time, 50% kill 
m meter 
MA trans,trans-muconic acid 
MAL maximum allowable level 
mCi millicurie 
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MCL maximum contaminant level 
MCLG maximum contaminant level goal 
MF modifying factor 
MFO mixed function oxidase 
mg milligram 
mL milliliter 
mm millimeter 
mmHg millimeters of mercury 
mmol millimole 
mppcf millions of particles per cubic foot 
MRL Minimal Risk Level 
MS mass spectrometry 
NAAQS National Ambient Air Quality Standard 
NAS National Academy of Science 
NATICH National Air Toxics Information Clearinghouse 
NATO North Atlantic Treaty Organization 
NCE normochromatic erythrocytes 
NCEH National Center for Environmental Health 
NCI National Cancer Institute 
ND not detected 
NFPA National Fire Protection Association 
ng nanogram 
NHANES National Health and Nutrition Examination Survey 
NIEHS National Institute of Environmental Health Sciences 
NIOSH National Institute for Occupational Safety and Health 
NIOSHTIC NIOSH's Computerized Information Retrieval System 
NLM National Library of Medicine 
nm nanometer 
nmol nanomole 
NOAEL no-observed-adverse-effect level 
NOES National Occupational Exposure Survey 
NOHS National Occupational Hazard Survey 
NPD nitrogen phosphorus detection 
NPDES National Pollutant Discharge Elimination System 
NPL National Priorities List 
NR not reported 
NRC National Research Council 
NS not specified 
NSPS New Source Performance Standards 
NTIS National Technical Information Service 
NTP National Toxicology Program 
ODW Office of Drinking Water, EPA 
OERR Office of Emergency and Remedial Response, EPA 
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System 
OPP Office of Pesticide Programs, EPA 
OPPT Office of Pollution Prevention and Toxics, EPA 
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA 
OR odds ratio 
OSHA Occupational Safety and Health Administration 
OSW Office of Solid Waste, EPA 
OTS Office of Toxic Substances 
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OW Office of Water 
OWRS Office of Water Regulations and Standards, EPA 
PAH polycyclic aromatic hydrocarbon 
PBPD physiologically based pharmacodynamic  
PBPK physiologically based pharmacokinetic  
PCE polychromatic erythrocytes 
PEL permissible exposure limit 
pg picogram 
PHS Public Health Service 
PID photo ionization detector 
pmol picomole 
PMR proportionate mortality ratio 
ppb parts per billion 
ppm parts per million 
ppt parts per trillion 
PSNS pretreatment standards for new sources 
RBC red blood cell 
REL recommended exposure level/limit 
RfC reference concentration 
RfD reference dose 
RNA ribonucleic acid 
RQ reportable quantity 
RTECS Registry of Toxic Effects of Chemical Substances 
SARA Superfund Amendments and Reauthorization Act 
SCE sister chromatid exchange 
SGOT serum glutamic oxaloacetic transaminase 
SGPT serum glutamic pyruvic transaminase 
SIC standard industrial classification 
SIM selected ion monitoring 
SMCL secondary maximum contaminant level 
SMR standardized mortality ratio 
SNARL suggested no adverse response level 
SPEGL Short-Term Public Emergency Guidance Level 
STEL short term exposure limit 
STORET Storage and Retrieval 
TD50 toxic dose, 50% specific toxic effect 
TLV threshold limit value 
TOC total organic carbon 
TPQ threshold planning quantity 
TRI Toxics Release Inventory 
TSCA Toxic Substances Control Act 
TWA time-weighted average 
UF uncertainty factor 
U.S. United States 
USDA United States Department of Agriculture 
USGS United States Geological Survey 
VOC volatile organic compound 
WBC white blood cell 
WHO World Health Organization 
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> greater than 
≥ greater than or equal to 
= equal to 
< less than 
≤ less than or equal to 
% percent 
α alpha 
β beta 
γ gamma 
δ delta 
μm micrometer 
μg microgram 
q1
* cancer slope factor 
– negative 
+ positive 
(+) weakly positive result 
(–) weakly negative result 
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absorbed dose .................................................................................................................................... 231, 233 
adenocarcinoma ........................................................................................................................................ 103 
adenocarcinomas ....................................................................................................................... 103, 104, 181 
adrenal gland ............................................................................................................................................. 167 
adrenals ..................................................................................................................................................... 167 
adsorbed ............................................................................................................................................ 280, 291 
adsorption .................................................................................................................. 274, 291, 292, 293, 330 
aerobic ....................................................................................................................................................... 275 
alanine aminotransferase (see ALT) ................................................................................................... 85, 145 
ALT (see alanine aminotransferase) ......................................................................................................... 146 
ambient air .......................................................................................... 11, 280, 296, 305, 315, 317, 321, 326 
anemia ....................................................................................................... 25, 26, 27, 84, 138, 139, 240, 249 
aspartate aminotransferase (see AST) ....................................................................................................... 145 
AST (see aspartate aminotransferase) ....................................................................................................... 146 
bioaccumulation ........................................................................................................................................ 326 
bioavailability ........................................................................... 292, 293, 301, 303, 323, 325, 329, 330, 343 
bioconcentration factor ............................................................................................................................. 293 
biokinetic .......................................................................................................................................... 232, 345 
biological half-time ................................................................................................................................... 202 
biomarker ..................... 13, 16, 21, 31, 32, 33, 35, 36, 37, 39, 86, 88, 89, 90, 136, 141, 143, 145, 147, 148,  
  149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 160, 161, 164, 165,  
  170, 230, 231, 232, 234, 235, 237, 240, 250, 254, 255, 258, 333 
blood cell count ........................................................................................................................................... 84 
body weight effects ............................................................................................................................. 93, 168 
breast milk ..................................................................................................................... 6, 228, 259, 319, 326 
cancer ........................................ 5, 15, 46, 100, 101, 102, 104, 177, 178, 179, 226, 238, 246, 251, 256, 350 
carcinogen ......................................................................................... 5, 13, 15, 100, 102, 104, 251, 256, 350 
carcinogenic ................................................ 5, 15, 45, 46, 101, 102, 103, 104, 178, 180, 223, 251, 256, 350 
carcinogenicity .......................................................................................................... 100, 102, 104, 251, 350 
carcinoma ............................................................................................................ 73, 103, 104, 179, 181, 224 
cardiovascular ....................................................................................................................... 82, 83, 136, 181 
cardiovascular effects .......................................................................................................................... 82, 136 
chromosomal aberrations .......................................................................................................... 184, 187, 252 
clearance ........................................... 22, 26, 47, 49, 154, 166, 192, 198, 200, 206, 218, 229, 235, 249, 256 
crustaceans ................................................................................................................................................ 301 
death ........................................................ 4, 5, 45, 46, 47, 48, 49, 81, 89, 105, 136, 147, 177, 181, 234, 250 
deoxyribonucleic acid (see DNA) ..................................................................................................... 186, 190 
dermal effects .............................................................................................................................. 93, 167, 182 
developmental effects ................................................. 14, 19, 25, 27, 99, 174, 177, 184, 248, 253, 256, 257 
DNA (see deoxyribonucleic acid) ....... 81, 176, 184, 185, 186, 187, 188, 189, 190, 220, 231, 245, 252, 259 
elimination half-time ................................................................................................................................... 16 
endocrine ............................................................................................................................. 97, 167, 224, 225 
endocrine effects ....................................................................................................................................... 167 
fetus ................................................................................................................................................... 225, 258 
follicle stimulating hormone ..................................................................................................................... 170 
fractional absorption ......................................................................................................................... 105, 195 
gastrointestinal effects ........................................................................................................................ 83, 139 
general population ............................... 13, 16, 20, 30, 47, 143, 169, 178, 184, 232, 240, 254, 305, 323, 326 
genotoxic ..................................................................................................................................... 45, 184, 187 
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genotoxicity............................................................................................................................... 191, 246, 251 
groundwater ................................................................................................................ 11, 280, 288, 298, 349 
half-life .............................................................................................................................. 210, 215, 221, 231 
hematological effects .................................................................................................................... 13, 84, 139 
hematopoietic .................................................................................................................................... 174, 251 
hepatic effects ....................................................................................................... 13, 85, 145, 146, 147, 237 
hydrolysis .................................................................................................................................................. 146 
immune system ......................................................................................................................... 169, 182, 228 
immunological ............................................................................................ 13, 26, 45, 94, 95, 169, 182, 254 
immunological effects ..................................................................................................... 13, 94, 95, 169, 182 
Kow ............................................................................................................................................ 264, 265, 266 
LD50 ................................................................................................................................................... 105, 181 
leukemia .............................................................................................................................. 27, 106, 169, 180 
menstrual ..................................................................................................................................................... 98 
metabolic effects ....................................................................................................................................... 169 
micronuclei ............................................................................................................................... 184, 187, 191 
milk ................................................................................... 200, 228, 234, 242, 255, 297, 300, 319, 336, 338 
mucociliary ..................................................................................... 23, 47, 49, 198, 200, 206, 217, 219, 229 
musculoskeletal effects ................................................................................................................. 84, 85, 140 
neonatal ..................................................................................................................................... 322, 327, 338 
neurobehavioral............................................................................... 14, 19, 99, 100, 175, 225, 227, 253, 254 
neurodevelopmental .............................................................................................................. 19, 27, 249, 257 
neurological effects ....................................................................................... 95, 96, 169, 170, 184, 227, 237 
nuclear ....................................................................................................................................................... 169 
ocular effects ............................................................................................................................... 93, 167, 182 
odds ratio ................................................................................................... 137, 143, 156, 157, 158, 171, 178 
partition coefficients ................................................................................................................................. 197 
pharmacodynamic ..................................................................................................................................... 203 
pharmacokinetic .......................................................................... 16, 22, 23, 43, 81, 203, 204, 205, 225, 345 
photolysis .................................................................................................................................................. 103 
placenta ............................................................................................. 199, 200, 229, 230, 234, 258, 322, 327 
pulmonary fibrosis ...................................................................................................................................... 50 
rate constant .............................................................................................................................. 211, 214, 216 
renal effects ......................................................... 22, 31, 32, 85, 87, 147, 149, 160, 166, 181, 237, 250, 255 
reproductive effects ................................................................. 97, 98, 99, 170, 172, 174, 184, 249, 252, 350 
respiratory effects ............................................................ 17, 21, 50, 73, 77, 79, 93, 106, 234, 248, 250, 345 
retention .................................................... 22, 48, 49, 50, 192, 193, 197, 202, 211, 213, 218, 219, 228, 292 
salivation ................................................................................................................................................... 139 
sequestered ................................................................................................................................................ 220 
solubility ..................................................................................... 12, 22, 45, 49, 50, 192, 218, 256, 275, 294 
spermatozoa ...................................................................................................................................... 170, 186 
systemic effects ............................................................................................................. 50, 94, 106, 181, 256 
T3 ................................................................................................................................................ 51, 107, 183 
thyroid ............................................................................................................................................... 155, 167 
thyroid stimulating hormone ..................................................................................................................... 167 
toxicokinetic .................................................................... 12, 16, 45, 202, 204, 219, 230, 250, 255, 256, 258 
tremors .................................................................................................................................................. 17, 96 
tumors ............................................................................................... 103, 104, 174, 179, 180, 181, 251, 256 
vapor pressure ........................................................................................................................................... 290 
volatility .................................................................................................................................................... 192 
 
 
 
 
 
 
 
 
 
 
 
 
 
